<SEC-DOCUMENT>0001047469-12-002276.txt : 20120308
<SEC-HEADER>0001047469-12-002276.hdr.sgml : 20120308
<ACCEPTANCE-DATETIME>20120308124633
ACCESSION NUMBER:		0001047469-12-002276
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20111231
FILED AS OF DATE:		20120308
DATE AS OF CHANGE:		20120308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		12676593

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a2207736z10-k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg46501_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM 10-K  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>(Mark&nbsp;one)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> For the fiscal year ended December&nbsp;31, 2011</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> or</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Commission File Number&nbsp;000-15006  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Delaware</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 13-3191702</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>119 Fourth Avenue, Needham, Massachusetts 02494</B></FONT><FONT SIZE=2><BR>
(Address of principal executive offices) (Zip Code) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Registrant's
telephone number, including area code: </FONT><FONT SIZE=2><B>(781)&nbsp;433-0771</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Securities
registered pursuant to Section&nbsp;12(b) of the Act: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title of Class: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Name of Each Exchange on Which Registered: </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Common Stock, par value $.001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>NASDAQ Global Market</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Securities
registered pursuant to Section&nbsp;12(g) of the Act: </FONT><FONT SIZE=2><B>None</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the
past 90&nbsp;days.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the
registrant was required to submit and post such files).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;229.405 of this Chapter)
is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this
Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="133pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="144pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="163pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Large&nbsp;accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Smaller Reporting Company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate market value of the registrant's common stock held by non-affiliates as of June&nbsp;30, 2011 was $156.1&nbsp;million. Exclusion of
shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the actions of the management or policies of the registrant,
or that such person is controlled by or under common control with the registrant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of common stock outstanding at February&nbsp;29, 2012 was 57,160,636 shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>DOCUMENTS INCORPORATED BY REFERENCE</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Portions
of the definitive Proxy Statement for our 2012 Annual Meeting of Stockholders are incorporated by reference into Part&nbsp;III of this Report. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=975978,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]BA46501A.;10',USER='CDESORM',CD=';2-MAR-2012;16:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg46501_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="BG46501A_main_toc"></A> </FONT> <FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>
ANNUAL REPORT ON FORM 10-K<BR>
YEAR ENDED DECEMBER 31, 2011  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="bg46501_table_of_contents"> </A>
  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG46501_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#PartI"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;I</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dc46501_item_1._business"><FONT SIZE=2>Item&nbsp;1.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dc46501_item_1._business"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc46501_item_1._business"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#di46501_item_1a._risk_factors"><FONT SIZE=2>Item&nbsp;1A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#di46501_item_1a._risk_factors"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di46501_item_1a._risk_factors"><FONT SIZE=2>23</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_1b._unresolved_staff_comments"><FONT SIZE=2>Item&nbsp;1B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_1b._unresolved_staff_comments"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unresolved Staff Comments</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk46501_item_1b._unresolved_staff_comments"><FONT SIZE=2>39</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_2._properties"><FONT SIZE=2>Item&nbsp;2.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_2._properties"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Properties</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk46501_item_2._properties"><FONT SIZE=2>39</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_3._legal_proceedings"><FONT SIZE=2>Item&nbsp;3.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_3._legal_proceedings"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Proceedings</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk46501_item_3._legal_proceedings"><FONT SIZE=2>39</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_4._mine_safety_disclosures"><FONT SIZE=2>Item&nbsp;4.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk46501_item_4._mine_safety_disclosures"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mine Safety Disclosures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk46501_item_4._mine_safety_disclosures"><FONT SIZE=2>39</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#PartII"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;II</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm46501_item_5._market_for_registrant___ite04666"><FONT SIZE=2>Item&nbsp;5.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm46501_item_5._market_for_registrant___ite04666"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market for Registrant's Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm46501_item_5._market_for_registrant___ite04666"><FONT SIZE=2>40</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm46501_item_6._selected_financial_data"><FONT SIZE=2>Item&nbsp;6.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm46501_item_6._selected_financial_data"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm46501_item_6._selected_financial_data"><FONT SIZE=2>41</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do46501_item_7._management_s_discussio__ite03668"><FONT SIZE=2>Item&nbsp;7.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do46501_item_7._management_s_discussio__ite03668"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do46501_item_7._management_s_discussio__ite03668"><FONT SIZE=2>43</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds46501_item_7a._quantitative_and_qual__ite02669"><FONT SIZE=2>Item&nbsp;7A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds46501_item_7a._quantitative_and_qual__ite02669"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds46501_item_7a._quantitative_and_qual__ite02669"><FONT SIZE=2>64</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fa46501_item_8._financial_statements_and_supplementary_data"><FONT SIZE=2>Item&nbsp;8.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fa46501_item_8._financial_statements_and_supplementary_data"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Statements and Supplementary Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fa46501_item_8._financial_statements_and_supplementary_data"><FONT SIZE=2>65</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9._changes_in_and_disagre__ite03576"><FONT SIZE=2>Item&nbsp;9.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9._changes_in_and_disagre__ite03576"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in and Disagreements With Accountants on Accounting and Financial
Disclosure</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_9._changes_in_and_disagre__ite03576"><FONT SIZE=2>97</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9a._controls_and_procedures"><FONT SIZE=2>Item&nbsp;9A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9a._controls_and_procedures"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Controls and Procedures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_9a._controls_and_procedures"><FONT SIZE=2>97</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9b._other_information"><FONT SIZE=2>Item&nbsp;9B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_9b._other_information"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_9b._other_information"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#PartIII"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;III</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_10._directors,_executive___ite02336"><FONT SIZE=2>Item&nbsp;10.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_10._directors,_executive___ite02336"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors, Executive Officers and Corporate Governance</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_10._directors,_executive___ite02336"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_11._executive_compensation"><FONT SIZE=2>Item&nbsp;11.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_11._executive_compensation"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_11._executive_compensation"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_12._security_ownership_of__ite04004"><FONT SIZE=2>Item&nbsp;12.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_12._security_ownership_of__ite04004"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_12._security_ownership_of__ite04004"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_13._certain_relationships__ite03067"><FONT SIZE=2>Item&nbsp;13.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fu46501_item_13._certain_relationships__ite03067"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Transactions, and Director
Independence</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fu46501_item_13._certain_relationships__ite03067"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#it14"><FONT SIZE=2>Item&nbsp;14.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#it14"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Accountant Fees and Services</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#it14"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#partiv"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;IV</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fw46501_item_15._exhibits,_financial_statement_schedules"><FONT SIZE=2>Item&nbsp;15.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fw46501_item_15._exhibits,_financial_statement_schedules"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exhibits, Financial Statement Schedules</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fw46501_item_15._exhibits,_financial_statement_schedules"><FONT SIZE=2>99</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><A HREF="#jc46501_signatures"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Signatures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#jc46501_signatures"><FONT SIZE=2>105</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=191244,FOLIO='i',FILE='DISK104:[12ZAA1.12ZAA46501]BG46501A.;9',USER='CHE106815',CD=';8-MAR-2012;08:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da46501_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K contains
forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations,
assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual
results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than
statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "can,"
"anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target,"
"potential" and other similar words and expressions of the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include,
but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to raise sufficient capital to fund our clinical studies to meet our long-term liquidity needs, on
terms acceptable to us, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to successfully complete research and further development, including animal, preclinical and clinical studies,
and commercialization of rindopepimut, CDX-011, CDX-1127, and other drug candidates and the growth of the markets for those drug candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development,
including our Phase&nbsp;3 trial for rindopepimut; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the cost, timing, scope and results of ongoing safety and efficacy trials of rindopepimut, CDX-011,
CDX-1127 and other preclinical and clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to fund and complete the development and commercialization of rindopepimut for North America internally and to
find a strategic partner to commercialize rindopepimut outside of North America; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the ability to negotiate strategic partnerships, where appropriate, for our lead programs, including CDX-011
and CDX-1127, as well as for our non-core programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the strategies and business plans of our partners, such as GlaxoSmithKline's plans with respect to Rotarix&reg;
and Vaccine Technologies' plans concerning the CholeraGarde&reg; (Peru-15) and ETEC E. coli vaccines, which are not within our control, and our ability to maintain strong, mutually
beneficial relationships with these partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to adapt our APC Targeting Technology&#153; to develop new, safe and effective vaccines against
oncology and infectious disease indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to develop technological capabilities and expand our focus to broader markets for vaccines; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing
facility or supplied by contract manufacturers and partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the availability, cost, delivery and quality of clinical management services provided by our clinical research
organization partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the timing, cost and uncertainty of obtaining regulatory approvals for our drug candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=638682,FOLIO='ii',FILE='DISK104:[12ZAA1.12ZAA46501]DA46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_da46501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our ability to develop and commercialize products before competitors that are superior to the alternatives developed by
such competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the validity of our patents and our ability to avoid intellectual property litigation, which can be costly and divert
management time and attention; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the factors listed under "Risk Factors" in this Annual Report on Form&nbsp;10-K. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or
correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we
believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=735717,FOLIO='iii',FILE='DISK104:[12ZAA1.12ZAA46501]DA46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc46501_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="PartI"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc46501_part_i"> </A>
<A NAME="toc_dc46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART I    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dc46501_item_1._business"> </A>
<A NAME="toc_dc46501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc., which we refer to as "Celldex," "we," "us," "our" or the "Company," is a biopharmaceutical company
focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III
(EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth.
EGFRvIII has been shown by polymerase chain reaction (PCR) analysis to be expressed in approximately 31% of glioblastoma (GB) tumors, also referred to as glioblastoma multiforme (GBM), the most common
and aggressive form of brain cancer. Based on results from three prior Phase&nbsp;2 trials, in December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3
study of rindopepimut in patients with surgically resected EGFRvIII-positive GB. In December 2011, we also initiated ReACT, a Phase&nbsp;2 study of rindopepimut in combination with
Avastin&reg; in patients with recurrent EGFRvIII-positive GB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
other lead drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human
monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a
variety of human cancers including breast cancer. In December 2011, we completed enrollment of EMERGE, a randomized Phase&nbsp;2b study of CDX-011 in patients with heavily
pre-treated, advanced,&nbsp;GPNMB-positive breast cancer and expect to present results at an appropriate scientific conference in the first half of 2012. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1127
is a fully human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain
lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target
and eliminate cancerous cells in tumor bearing mice and to directly kill or inhibit the growth of CD27 expressing lymphomas and leukemias </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT
SIZE=2>. In November 2011, we initiated an open label, dose-escalating Phase&nbsp;1 study of CDX-1127 in patients with
selected malignant solid tumors or hematologic cancers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&#153; program, CDX-301, an immune cell mobilizing
agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally
our strategy is to develop and demonstrate proof-of-concept for our drug candidates before leveraging their value through partnerships or, in
appropriate situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a drug candidate generally involves bringing
it through Phase&nbsp;1 clinical trials and one or more Phase&nbsp;2 clinical trials so that we are able to demonstrate, based on human trials, good safety data for the drug candidate and some
data indicating its effectiveness. We thus leverage the value of our technology portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to
maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Our current collaborations include the commercialization
of an oral human rotavirus vaccine. We are exploring potential development and commercialization collaborations for certain drug candidates such as CDX-011 and CDX-1127.
Furthermore, while we plan to retain the rights to develop and commercialize rindopepimut in North America, we are exploring potential partnership opportunities to commercialize rindopepimut outside </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=839916,FOLIO='1',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
North America. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are
using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other
diseases that modify undesirable activity by the body's own proteins or cells. A number of our immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of
clinical trials. We expect that a large percentage of our research and development expenses will be incurred in support of our current and future clinical trial programs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are material to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="158pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110<BR>
(rindopepimut)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Front-line Glioblastoma</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110<BR>
(rindopepimut)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Recurrent Glioblastoma</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-011<BR>
(glembatumumab vedotin)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic breast cancer and melanoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Lymphoma/leukemia and solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cancer, autoimmune disease and transplant</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PRECLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ovarian and renal cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>MARKETED PRODUCTS</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rotarix</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Rotavirus infection</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlaxoSmithKline</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Marketed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
our expertise in immunology, we are building business franchises in major disease areas including oncology. We have pursued some of these opportunities independently in a highly
focused manner. In other cases, we have leveraged the financial support and development capabilities of corporate and public sector partners to bring our development projects to fruition. The research
we have pursued over the past several years has matured into what we believe is an exciting and diverse portfolio of drug candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
success has depended and will continue to depend upon many factors, including our ability, and that of our licensees and collaborators, to successfully develop, obtain regulatory
approval for and commercialize our drug candidates. Commercial sales are currently generated by GlaxoSmithKline, which is marketing Rotarix. We have had no commercial revenues from sales of our human
therapeutic or other human vaccine products and we have had a history of operating losses. It is possible that we may not be able to successfully develop, obtain regulatory approval for or
commercialize our drug candidates, and we are subject to a number of risks that you should be aware of before investing in us. These risks are described more fully in "Item&nbsp;1A. Risk Factors." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a Delaware corporation organized in 1983. Our website is located at </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com.</I></FONT><FONT SIZE=2> On our website, investors
can obtain, free of charge, a copy of our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=196479,FOLIO='2',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>other
reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act of 1934, as amended, as soon as reasonably practicable after we file such material electronically with,
or furnish it to, the Securities and Exchange Commission (SEC). None of the information posted on our website is incorporated by reference into this Annual Report. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rindopepimut  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead clinical development program, rindopepimut, is a peptide-based immunotherapy that targets the tumor specific molecule called
EGFRvIII, a functional variant of the naturally expressed EGFR, a protein which has been well validated as a target for cancer therapy. Unlike EGFR, EGFRvIII is not present in normal tissues and has
been shown to be a transforming oncogene that can directly contribute to cancer cell growth. EGFRvIII is commonly present in glioblastoma or GB, also commonly referred to as glioblastoma multiforme or
GBM, the most common and aggressive form of brain cancer. The rindopepimut vaccine is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin (KLH) and
administered together with the adjuvant GM-CSF. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation for rindopepimut
for the treatment of EGFRvIII expressing GB and the FDA has also granted Fast Track designation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2008, we and Pfizer&nbsp;Inc. (Pfizer) entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide license
to rindopepimut. The Pfizer Agreement provided for reimbursement by Pfizer of all costs incurred by us in connection with the collaboration since the effective date. In November 2010, the Pfizer
Agreement was terminated (the "Pfizer Termination") and all rights to rindopepimut were returned to us. Pfizer did not provide a reason for termination. Effective with the Pfizer Termination, Pfizer
is no longer funding the development of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;1 (VICTORI) and Phase&nbsp;2a (ACTIVATE) studies of EGFRvIII immunotherapy were led by collaborating investigators at the Brain Center at Duke Comprehensive Cancer
Center in Durham, North Carolina and at M.D. Anderson Cancer Center in Houston, Texas and enrolled 14 and 18
evaluable GB patients, respectively. An extension of the Phase&nbsp;2a study (ACT II)&nbsp;at the same two institutions evaluated 22 additional GB patients treated in combination with maintenance
temozolomide (TMZ) (the current standard of care). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
initiated a Phase&nbsp;2b/3 randomized study (ACT III)&nbsp;of rindopepimut combined with standard of care, TMZ, versus standard of care alone in patients with GB in over 30 sites
throughout the United States. In December 2008, we announced an amendment to convert the ACT III study to a single-arm Phase&nbsp;2 clinical trial in which all patients were to receive
rindopepimut in combination with temozolomide. The decision, which followed the recommendation of the Independent Data Monitoring Committee, was based on the observation that the majority of patients
randomized to the control (standard of care) arm withdrew from this open-label study after being randomized to the control arm. Patients participating in the control arm of the study were
offered the option to receive treatment with rindopepimut. Under this amendment, the ACT III study provided for a multi-center, non-randomized dataset for rindopepimut in patients with
newly diagnosed GB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2010, we announced complete data for the primary endpoint of the 65 patients enrolled to receive rindopepimut in combination with maintenance TMZ in the ACT III study. The
data showed that 43 of 65 patients (66%) were progression-free at 5.5&nbsp;months after entry into the study. Taking into account the 3 to 3.5&nbsp;months required to complete
pre-study chemoradiation and enter into the study, the 5.5&nbsp;month time point in ACT III corresponds to approximately 8.5&nbsp;months after diagnosis. The ACTIVATE and ACT II
trials, which were conducted in two leading centers, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=598729,FOLIO='3',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reported
progression-free rates at 8.5&nbsp;months after diagnosis of 70% and 80%, respectively, and similar results were seen in the ACT III trial, which enrolled patients in over 25
centers in the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the progression free survival (PFS) and overall survival (OS) rates from clinical trials of rindopepimut as compared to matched historical controls and the
standard of care (SOC). </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median PFS from<BR>
diagnosis (months) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median OS from<BR>
diagnosis (months) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS at 24&nbsp;months </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACT III (n=65)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACT II (n=22)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACTIVATE (n=18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matched historical control (n=17)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Standard of care radiation/TMZ (n=287)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Change
in median PFS not statistically significant from ACTIVATE and ACT II.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Sampson,
et al. J. Clin. Oncol. 2010&nbsp;Nov 1, 28(31), 4722-9. Historical controls were treated at M.D. Anderson and matched for eligibility
(EGFRvIII-positive, karnofsky performance status (KPS) greater-than or equal to 80%, complete resection, radiation/temozolomide (TMZ) and without progression through ~ 3&nbsp;months
post-diagnosis).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Stupp,
et al. N. Engl. J. Med. 2005, 352, 987-96. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Importantly,
rindopepimut showed a similar benefit in patients whether or not they expressed an active DNA repair gene (MGMT) that has been shown to limit the benefit from TMZ treatment.
In ACT III, the number of patients who were expected to be resistant to the TMZ chemotherapy appeared to do better with vaccination than the numbers observed in the historical data. Patients who have
an active DNA repair gene, MGMT (unmethylated), generally have a worse outcome, presumably because they do not gain much benefit from TMZ as reported in the literature. Patients with a methylated MGMT
promoter in their tumor do not express MGMT and have a more favorable outcome to TMZ treatment. Patients with methylated tumors (n=25) that were treated with the rindopepimut regimen experienced a
median PFS of 17.5&nbsp;months, which compares favorably with the published data from the SOC of radiation plus TMZ (R+TMZ) of 10.3&nbsp;months. Those with unmethylated tumors (n=40) treated with
the rindopepimut regimen experienced a PFS of 11.2&nbsp;months, which compared favorably to the PFS with SOC of 5.3&nbsp;months in this patient population. Thus, rindopepimut would appear to
benefit both methylated and unmethylated MGMT patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3 study of rindopepimut in patients with surgically resected, EGFRvIII-positive GB.
Patients will be randomized after the completion of surgery and standard chemoradiation. The treatment regime includes a vaccine priming phase post-radiation followed by an adjuvant
temozolomide phase and a vaccine maintenance therapy phase. Patients will be treated until disease progression or intolerance to therapy. The primary objective of the study is to determine whether
rindopepimut plus adjuvant GM-CSF improves the overall survival of patients with newly diagnosed EGFRvIII-positive GB after Gross Total Resection (GTR) when compared to treatment with TMZ
and a control injection of KLH. KLH is a component of rindopepimut and was selected due to its ability to generate a similar injection site reaction to that observed with the rindopepimut vaccine. ACT
IV will enroll up to 440 patients at over 150 centers worldwide to recruit approximately 374 patients with GTR to be included in the primary analysis. Our targeted patient accrual is 24&nbsp;months
and another 18 to
24&nbsp;months of follow-up. We expect it will cost over $50&nbsp;million to complete this Phase&nbsp;3 study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we also initiated ReACT, a Phase&nbsp;2 study of rindopepimut in combination with Avastin&reg; in patients with recurrent EGFRvIII-positive GB. ReACT will
enroll approximately 95 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=752078,FOLIO='4',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>patients
in a first or second relapse of GB following receipt of standard therapy and will be conducted at approximately 20 sites across the United States. Approximately 70 patients who have yet to
receive Avastin will be randomized to receive either rindopepimut and Avastin or a control injection of KLH and Avastin in a blinded fashion. Another 25 patients who are refractory to Avastin having
received Avastin in either the frontline or recurrent setting with subsequent progression will receive rindopepimut plus Avastin in a single treatment arm. We expect preliminary data from this study
to be available in mid-2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, researchers at Stanford University are conducting a pilot trial of rindopepimut in pediatric patients with pontine glioma in an investigator sponsored trial. Patient
screening is ongoing for this trial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Glembatumumab Vedotin (CDX-011)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked
to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including
breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics,&nbsp;Inc. The ADC is designed to be stable
in the bloodstream. Following intravenous administration, CDX-011 targets and binds to&nbsp;GPNMB and upon internalization into the targeted cell, CDX-011 is designed to
release MMAE from CR011 to produce a cell-killing effect. The FDA has granted Fast Track designation to CDX-011 for the treatment of advanced,
refractory/resistant&nbsp;GPNMB-expressing breast cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Breast Cancer:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In June 2008, an open-label, multi-center Phase&nbsp;1/2 study was initiated of CDX-011
administered intravenously once every three weeks to patients with locally advanced or metastatic breast cancer who had received prior therapy (median of seven prior regimens). The study began with a
bridging phase to confirm the maximum tolerated dose (MTD) and then expanded into a Phase&nbsp;2 open-label, multi-center study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
study confirmed the safety of CDX-011 at the pre-defined maximum dose level (1.88 mg/kg) in 6 patients. An additional 28 patients were enrolled as an expanded
Phase&nbsp;2 cohort (for a total of 34 treated patients at 1.88 mg/kg, the Phase&nbsp;2 dose) to evaluate the PFS rate at 12&nbsp;weeks. As previously seen in melanoma patients, the 1.88 mg/kg
dose was well tolerated in this patient population with the most common adverse events of rash, alopecia, and fatigue. The primary activity endpoint, which called for at least 5 of 25 (20%) patients
in the Phase&nbsp;2 study portion to be progression-free at 12&nbsp;weeks, was met as 9 of 26 (35%) evaluable patients were progression-free at 12&nbsp;weeks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all patients treated at the maximum dose level, tumor shrinkage was seen in 62% (16/26) and median PFS was 9.1&nbsp;weeks. A subset of 10 patients had "triple negative disease," a
more aggressive breast cancer subtype that carries a high risk of relapse and reduced survival as well as limited therapeutic options due to lack of over-expression of HER2/neu, estrogen
and progesterone receptors. In these patients, 78% (7/9) had some tumor shrinkage, 12-week PFS rate was 70% (7/10), and median PFS was 17.9&nbsp;weeks. Tumor samples from a subset of
patients across all dose groups were analyzed for&nbsp;GPNMB expression. The tumor samples from most patients showed evidence of stromal and/or tumor cell expression of&nbsp;GPNMB. The most common
treatment-related toxicities were fatigue, rash, nausea, alopecia (hair loss), neutropenia and vomiting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we completed enrollment of EMERGE, a randomized, multi-center Phase&nbsp;2b study of CDX-011 in patients with heavily pre-treated,
advanced,&nbsp;GPNMB-positive breast cancer. Patients were randomized (2:1) to receive either CDX-011 or single-agent "Investigator's Choice" chemotherapy. Patients randomized to receive
Investigator's Choice are allowed to cross over to CDX-011 following disease progression. Activity endpoints include response rate (RR) and PFS. We expect that a significant portion of the
enrolled patients will have triple-negative disease, since&nbsp;GPNMB </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=30240,FOLIO='5',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>is
frequently expressed in this patient population. We expect to present results at the 2012 American Society of Clinical Oncology (ASCO) meeting in June 2012. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2009, Formatech,&nbsp;Inc., a third party contract manufacturer ("Formatech") was engaged by us for the aseptic filling of one lot of our CDX-011 product candidate being
used in our ongoing Phase&nbsp;2b study. The CDX-011 lot from Formatech has passed all of the sterility testing performed during drug release and in subsequent stability studies. At the
end of January 2012, we were notified by the FDA that because significant Good Manufacturing Practice (GMP) violations were uncovered during inspection of Formatech, our Phase&nbsp;2b study for
CDX-011 was being placed on partial clinical hold. The FDA uncovered these findings during their inspections of the Formatech facility between August to October 2010 and July to August
2011. These inspections began approximately one year after the CDX-011 drug product was filled at Formatech. Specifically, the FDA requested that no new patients be treated with
CDX-011. However, patients already undergoing treatment with CDX-011 could continue treatment using vials of CDX-011 from the lot filled by Formatech, after such
patients were informed of the potential risk and reconsented to continued participation in the study. Since the Phase&nbsp;2b trial completed accrual of patients in December 2011 and there are
currently no other ongoing open studies with CDX-011, the only patients that are affected by the partial hold are in the Investigator's Choice (control arm) of the study who currently are
not receiving CDX-011 and may be eligible to cross over at the time of progression and receive CDX-011 under the study protocol. Currently there are eight patients remaining on
the control arm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have initiated discussions with the FDA regarding our proposal to utilize vials of CDX-011 that were filled by a different contract manufacturer. Although the FDA has
stated that no new patients may receive CDX-011 and that no patients may cross over to receive CDX-011, we have asked the FDA to reconsider allowing patients currently on the
control arm to cross over to CDX-011 after stability testing and confirmation that the product filled by the other contract manufacturer is acceptable for continued use. If the FDA agrees
to our proposal concerning use of the alternative CDX-011 for the eligible cross-over patients, we believe that we should have sufficient clinical supply of CDX-011
to treat these cross-over patients. If we are not able to treat the eight remaining cross-over patients with CDX-011, patients may withdraw from the control arm
study upon learning that they will not be allowed to cross over to CDX-011 following disease progression. However, the primary analyses for the study are entirely based upon the primary
randomization and do not include the cross over results. Based on our discussions with our clinical investigators, we do not believe that a high proportion of patients will withdraw from the control
arm prior to progression. We do not believe that this partial hold will significantly impact analysis of the Phase&nbsp;2b data for purposes of determining next steps in our future development of
CDX-011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the FDA has agreed in concept that we could reprocess the remaining available vials of CDX-011 manufactured at Formatech at another cGMP contract manufacturer.
The FDA's final decision regarding the acceptability of this reprocessing will be made upon review of data concerning the stability and sterility of the reprocessed vials of CDX-011. If we
are unsuccessful at reprocessing the available drug product or if FDA does not approve the use of these reprocessed vials, we will need to manufacture new drug product for subsequent clinical studies
for CDX-011, which may cause a delay in the initiation of a subsequent trial with CDX-011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Metastatic Melanoma:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2009, we completed enrollment of 117 patients in a Phase&nbsp;1/2 open-label, multi-center, dose
escalation study to evaluate the safety, tolerability and pharmacokinetics of CDX-011 for patients with un-resectable Stage&nbsp;III or Stage&nbsp;IV melanoma who had
failed no more than one prior line of cytotoxic therapy. The MTD was determined to be 1.88 mg/kg administered intravenously (IV)&nbsp;once every three weeks. The study achieved its primary activity
objective with an ORR in the Phase&nbsp;2 cohort of 15% (5/34). Median PFS was 3.9&nbsp;months. CDX-011 was generally well tolerated, with the most frequent treatment-related adverse
events being rash, fatigue, alopecia (hair loss), pruritus, diarrhea and neuropathy. In the subset of patients with tumor </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=212662,FOLIO='6',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>biopsies,
high levels of tumor expression of&nbsp;GPNMB appeared to correlate with favorable outcome. In the seven patients whose tumors were found to express high amounts of&nbsp;GPNMB, and who
were treated at the maximum tolerated doses across all dosing schedules, median PFS was 4.9&nbsp;months. The development of rash, which may be associated with the presence of&nbsp;GPNMB in the
skin also seemed to correlate with greater PFS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to initially focus our resources on advancing CDX-011 in breast cancer while pursuing further development of CDX-011 in melanoma through collaborations
and investigator sponsored studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1127  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1127 is a human monoclonal antibody that targets CD27, a member of the tumor necrosis factor (TNF) receptor
superfamily. We have entered into license agreements with the University of Southampton, UK for intellectual property related to uses of anti-CD27 antibodies and with Medarex for access to
the UltiMab technology to develop and commercialize human antibodies to CD27. CD27 acts downstream from CD40 and may provide a novel way to regulate the immune responses. CD27 is a
co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential
therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target and eliminate cancerous cells in tumor bearing mice and to directly kill or inhibit the growth of
CD27 expressing lymphomas and leukemias </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>. Both mechanisms have been seen even at low
doses in appropriate preclinical models. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2011, we initiated an open label, dose-escalating Phase&nbsp;1 study of CDX-1127 in patients with selected malignant solid tumors or hematologic
cancers at multiple clinical sites in the United States. The Phase&nbsp;1 study is designed to test five escalating doses of CDX-1127 to determine a Phase&nbsp;2 dose for further
development based on safety, tolerability, potential activity and immunogenicity. The study will accrue approximately 30 patients in each of the two arms, either selected refractory/relapsed solid
tumors or lymphomas/leukemias known to express CD27. Patients will have received all appropriate prior therapies for their specific disease. The trial design incorporates both single dosing and
multiple dosing regimens at each dose level. We expect to complete enrollment in this study by the end of 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401, developed from our APC Targeting Technology, is a fusion protein consisting of a fully human monoclonal antibody
with specificity for the dendritic cell receptor, DEC-205, linked to the NY-ESO-1 tumor antigen. In humans, NY-ESO-1 has been detected in
20&nbsp;&#150;&nbsp;30% of all melanoma, lung, esophageal, liver, gastric, prostate, ovarian and bladder cancers, thus representing a broad opportunity. This product is intended to
selectively deliver the NY-ESO-1 antigen to dendritic cells for generating robust immune responses against cancer cells expressing NY-ESO-1. We are
developing CDX-1401 for the treatment of malignant melanoma and a variety of solid tumors which express the proprietary cancer antigen NY-ESO-1, which we licensed
from the Ludwig Institute for Cancer Research in 2006. Preclinical studies have shown that CDX-1401 is effective for activation of human T&nbsp;cell responses against
NY-ESO-1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2009, we initiated enrollment in a dose-escalating, multi-center, Phase&nbsp;1/2 study aimed at determining the optimal dose for further development based on
the safety, tolerability, and immunogenicity of the CDX-1401 vaccine. The trial will evaluate three different doses of the vaccine in combination with TLR agonists poly-ICLC or
Hiltonol&#153; and/or R848 or resiquimod. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2010, we announced interim data for the first 20 patients enrolled in the study, 35% of whom had confirmed NY-ESO-1 expression. The interim data showed
that six patients maintained stable disease and were eligible for multiple cycles of the treatment regimen, including 4 patients who </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=375489,FOLIO='7',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<A NAME="page_dc46501_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>have
received 3 or more cycles (6&nbsp;weeks of treatment followed by a 6&nbsp;week rest), with stable disease of up to 11.5+ months. The treatment was well tolerated and there were no
dose-limiting toxicities. Robust anti-NY-ESO-1 immunity was induced with the majority of the patients developing
anti-NY-ESO-1 antibody responses and 39% of the patients having increases in NY-ESO-1 specific T&nbsp;cell responses, including both CD4
and CD8 responses. Importantly, the T cell responses were directed against multiple regions of the NY-ESO-1 antigen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2012, we completed enrollment in the Phase&nbsp;1 portion of the study and expect to report data at an appropriate scientific conference in the second half of 2012. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301 is a FMS-like tyrosine kinase 3 ligand (Flt3L) stem cell mobilizer and dendritic cell growth factor. We
licensed CDX-301 from Amgen in March 2009. CDX-301 is a potent hematopoietic cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem
cells. CDX-301 has demonstrated a unique capacity to increase the number of circulating dendritic cells in both laboratory and clinical studies. In addition, CDX-301 has shown
impressive results in models of cancer, infectious diseases and inflammatory/autoimmune diseases. We believe CDX-301 may hold significant opportunity for synergistic development in
combination with other proprietary molecules in our portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2012, we initiated a dose-escalating Phase&nbsp;1 study of CDX-301 in approximately 30 healthy subjects in collaboration with Rockefeller University.
The Phase&nbsp;1 study will evaluate seven different dosing regimens of CDX-301 to determine the appropriate dose for further development based on safety, tolerability, and biological
activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Preclinical Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1135  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135 is a molecule that inhibits a part of the human immune system called the complement system. The complement system
is a series of proteins that are important initiators of the body's acute inflammatory response against disease, infection and injury. Excessive complement activation also plays a role in some
persistent inflammatory conditions. CDX-1135 is a soluble form of naturally occurring Complement Receptor 1 that has been shown to inhibit the activation of the complement cascade in
animal models and in human clinical trials. In preclinical studies, CDX-1135 has been shown to inhibit both the classical and alternative pathways of complement activation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dense
Deposit Disease (DDD) is a rare and devastating disease that is caused by uncontrolled activation of the alternative pathway of complement and leads to progressive kidney damage in
children. There is currently no treatment for patients with DDD and about half progress to end-stage renal disease within 10&nbsp;years. Because DDD recurs in virtually all patients who
receive a kidney transplant, transplantation is not a viable option for these patients. In animal models of DDD, CDX-1135 treatment showed evidence of reversal of kidney damage. We believe
that regulating the complement system could have therapeutic and prophylactic applications in DDD and several other acute and chronic conditions, including organ transplantation, multiple sclerosis,
rheumatoid arthritis, age-related macular degeneration (AMD), atypical Hemolytic Uremic Syndrome (aHUS), Paroxysmal Nocturnal Hemaglobinuria (PNH), and myasthenia gravis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=425955,FOLIO='8',FILE='DISK104:[12ZAA1.12ZAA46501]DC46501A.;9',USER='LPALLES',CD=';5-MAR-2012;15:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de46501_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135 is currently being studied in DDD under an investigator sponsored IND and initial experience indicates that CDX-1135 limits
complement abnormalities. In 2011, we completed process development activities and manufactured GMP clinical drug product. Based on discussion to date with the FDA, we are currently planning to
initiate a Phase&nbsp;2 pilot study of CDX-1135 in a small number of DDD patients to determine the appropriate dose and regimen for further clinical development based on safety,
tolerability and biological activity in 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 is a fully-human monoclonal ADC that targets TIM-1, a molecule that is highly expressed on renal and
ovarian cancers with minimal expression in normal tissues. The antibody, CDX-014, is linked to a potent chemotherapeutic, monomethyl auristatin E (MMAE), using Seattle Genetics'
proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells, resulting in a targeted
cell-killing effect. CDX-014 has shown potent activity in preclinical models of ovarian and renal cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Development Strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Precision Targeted Immunotherapy Platform:  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g337285.jpg" ALT="GRAPHIC" WIDTH="547" HEIGHT="415">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe there is tremendous untapped potential in immunotherapy that can be exploited through the right combination of therapeutic agents. Immunotherapy approaches have encountered
difficulties when following standard drug development. The mechanisms of action are complex, activity is generally not dependent on highest tolerated dose and patient response is highly variable. Our
understanding of the immune system, cancer's effect on immune mediated mechanisms, and the impact of conventional therapies on the immune system provides a new rationale for combining therapies that
may lead to significant clinical responses. The concept of Precision Targeted Immunotherapy is to exploit this knowledge and the availability of good, tested products that may not be sufficiently
effective </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=900206,FOLIO='9',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>to
be commercialized as a monotherapy, but which we believe may be very effective in combination approaches. Our goal is to develop products that maximize the efficacy of immunotherapy regimens
through combinations of therapeutic agents. These therapeutic agents include: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therapeutic Antibodies:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;These programs are based on the well validated approach to using antibodies that target cancer and other
diseases directly,
or interfere with critical interactions between the patient and the disease. Our antibody programs include antibody-drug conjugates (ADCs) that are designed to deliver potent cytotoxic
molecules to cancer cells, and traditional unmodified antibody approaches. Our current programs are based on fully human sequence antibodies to minimize patient reactivity against the drug. In
addition, we have access through a Research and Commercialization Agreement with Medarex (now a subsidiary of Bristol-Myers Squibb) to the UltiMAb&reg; Technology for generating fully human
monoclonal antibodies. Under this agreement, we can exercise up to ten separate licenses to develop and commercialize therapeutic antibody products, either alone or through collaboration with our
licensing partners. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our APC Targeting Technology&#153;:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This is a new class of vaccines based on our proprietary antibody-targeted vaccine technology that
is used
to generate an immune response against cancer or other diseases. Our APC Targeting Technology&#153; uses human monoclonal antibodies linked to disease associated antigens to efficiently deliver
the attached antigens to immune cells known as antigen presenting cells, or APCs. This technology has been designed to allow us to take advantage of many important characteristics of human monoclonal
antibodies, including their long circulating half-life, well known safety profile, and standardized manufacturing procedures. We believe that our APC Targeting Technology&#153;
provides significant manufacturing, regulatory and other practical advantages over patient specific and other immune-based treatments and can substantially reduce the dosage and cost currently
required in conventional immunotherapies. Preclinical studies have demonstrated that APC Targeting Technology&#153; is more effective than conventional non-targeted vaccines. We
have developed several proprietary monoclonal antibodies that can independently be developed to generate new product opportunities. Our CDX-1401 program is in clinical development
utilizing the APC technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immune System Modulators:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Immune system modulators include drugs that activate or suppress specific parts of the immune system.
Currently we are
combining our APC technology drug candidates with molecules known as Toll-Like Receptor (TLR) agonists that can activate patients' innate and adaptive immunity. We are also developing an
immune cell growth factor called FMS-like tyrosine kinase 3 ligand (FLT3-L or CDX-301) designed to expand immune cells and stem cells. In addition, we are
investigating the activity of a complement inhibitor (CDX-1135) that suppresses inflammatory reactions. These agents further support our Precision Targeted Immunotherapy Platform. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Antibody-Drug Conjugates (ADC):</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;ADCs are monoclonal antibodies that are linked to potent cell-killing drugs. Our ADCs utilize
fully-human monoclonal antibodies that internalize within target cells after binding to their cell-surface receptors. Enzymes present inside the cell cause the cell-killing
drug to be released from the monoclonal antibody, allowing it to have the desired activity. A key component of our ADCs is the linker that
attaches the drug to the monoclonal antibody. When the ADC is internalized within the target cell, the drug is released, thereby minimizing toxicity to normal tissues. Our CDX-011 program
is in clinical development with the ADC technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
strategy is to utilize our expertise to design and develop targeted immunotherapeutics that have significant and growing market potential; to establish governmental and corporate
alliances to fund development; and to commercialize our products either through corporate partners or, in appropriate circumstances, through our own direct selling efforts. Our goal is to demonstrate
clinical proof-of-concept for each product, and then seek partners to help see those products which we cannot develop ourselves through to commercialization. This approach
allows us to maximize the overall value of our technology and product portfolios while best ensuring the expeditious development of each individual product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=276912,FOLIO='10',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that may significantly harm our commercial success, and ultimately the market price of our common stock, include but are not limited to, announcements of technological
innovations or new commercial products by our competitors, disclosure of unsuccessful results of clinical testing or regulatory proceedings and governmental approvals, adverse developments in patent
or other proprietary rights, public concern about the safety of products developed by us and general economic and market conditions. See "Item&nbsp;1A. Risk Factors." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Partnerships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy is to develop and demonstrate proof-of-concept for our drug candidates before leveraging their
value through partnerships or, in appropriate situations, continuing late stage development through commercialization ourselves. We are exploring potential development and commercialization
collaborations for certain product candidates such as CDX-011 and CDX-1127. Furthermore, while we plan to retain the rights to develop and commercialize rindopepimut in North
America, we are exploring potential partnership opportunities to commercialize rindopepimut outside of North America. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into collaborative partnership agreements with pharmaceutical and other companies and organizations that provide financial and other resources, including capabilities in
research, development, manufacturing, and sales and marketing, to support our research and development programs. We depend on these relationships and may enter into more of them in the future. Some of
our partners have substantial responsibility to commercialize a product and to make decisions about the amount and timing of resources that are devoted to developing and commercializing a product. As
a result, we do not have complete control over how resources are used toward some of our products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partnership
agreements may terminate without benefit to us if the underlying products are not fully developed. If we fail to meet our obligations under these agreements, they could
terminate and we might need to enter into relationships with other collaborators and to spend additional time, money, and other valuable resources in the process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot predict whether our collaborators will continue their development efforts or, if they do, whether their efforts will achieve success. Many of our collaborators face the same
kinds of risks and uncertainties in their business that we face. A delay or setback to a partner will, at a minimum, delay the commercialization of any affected products, and may ultimately prevent
it. Moreover, any partner could breach its agreement with us or otherwise not use best efforts to promote our products. A partner may choose to pursue alternative technologies or products that compete
with our technologies or products. In either case, if a partner failed to successfully develop one of our products, we would need to find another partner. Our ability to do so would depend upon our
legal right to do so at the time and whether the product remained commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> GlaxoSmithKline&nbsp;plc (Glaxo)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rotavirus is a major cause of diarrhea and vomiting in infants and children. In 1997, we licensed our oral rotavirus strain to Glaxo
and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. Glaxo gained approval for its rotavirus vaccine, Rotarix, in Mexico in July 2004, which
represented the first in a series of worldwide approvals and commercial launches for the product leading up to the approval in Europe in 2006 and in the U.S. in 2008. We licensed-in our
rotavirus strain in 1995 and owe a license fee of 30% to Cincinnati Children's Hospital Medical Center (CCH) on net royalties received from Glaxo. We are obligated to maintain a license with CCH with
respect to the Glaxo agreement. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=627613,FOLIO='11',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>90&nbsp;days
prior written notice. The last relevant patent is scheduled to expire in December 2012. No additional milestone payments are due from Glaxo under the agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund II,&nbsp;L.P. (PRF) purchased a 70% interest in the milestone payments and net royalties that we
will receive on the development and worldwide sales of Rotarix. We have received a total of $60&nbsp;million in milestone payments under the PRF agreement. No additional milestone payments are due
from PRF under the agreement. The PRF agreement terminates in December 2012, unless otherwise extended. We would retain approximately 65% of the royalties on worldwide sales of Rotarix if PRF receives
2.45 times the aggregate cash payments of $60&nbsp;million it made to us prior to December 2012. We do not expect this to occur. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Vaccine Technologies,&nbsp;Inc. (VTI)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2009, we entered into a license agreement with VTI under which we granted a worldwide exclusive license to VTI to develop
and commercialize our CholeraGarde and ETEC vaccine programs. We may receive milestones payments of up to $0.8&nbsp;million and royalties in the low to mid teens with respect to development and
commercialization of the technology licensed to VTI. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> TopoTarget A/S (TopoTarget)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our April 2008 agreement (TopoTarget Agreement) with TopoTarget, we could receive up to $6&nbsp;million in either potential
commercial milestone payments related to future net sales of Belinostat or 10% of any sublicense income received by TopoTarget (TopoTarget Payments). We have no financial and operational
responsibility for the clinical development of Belinostat under the TopoTarget Agreement. In February 2010, TopoTarget entered into a co-development and commercialization agreement for
Belinostat with Spectrum Pharmaceuticals,&nbsp;Inc. resulting in our receipt of $3&nbsp;million of the TopoTarget Payments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Research Collaboration and License Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into license agreements whereby we have received licenses or options to license technology, specified patents and/or
patent applications. These license and collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing
patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain development, regulatory and/or commercial milestones. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Medarex,&nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and Medarex, a former related party, have entered into the following agreements, each of which was approved by a majority of its
independent directors who did not have an interest in the transaction. These agreements include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>An Assignment and License Agreement, as amended, (Assignment and License Agreement) that provides for the assignment of
certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#153; and an anti-mannose
receptor product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A Research and Commercialization Agreement, as amended, (Research and Commercialization Agreement) that provides us with
certain rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform for generating antibodies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Assignment and License Agreement, we may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing
Product or Anti-Mannose </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=917404,FOLIO='12',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Product
to Medarex until the later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product.
Under the terms of the Research and Commercialization Agreement, we may be required to pay milestones of up to $7.0&nbsp;million upon obtaining first approval for commercial sale in a first
indication of a product containing a licensed antibody and royalty payments in the low- to mid-single digits on any net product sales to Medarex with respect to the development
of any products containing such licensed antibodies until the later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial
sale of such licensed product. In September 2010, we exercised an option under our Research and Commercialization
Agreement, whereby we licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including CDX-1127. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2005, we and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205
receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205
receptor patent rights for educational and research purposes. We may be required to pay milestones of up to $3.9&nbsp;million upon obtaining first approval for commercial sale in a first indication
of a product targeting the licensed receptor and royalty payments in the low- to mid-single digits on any net product sales to Rockefeller with respect to development and
commercialization of the human DEC-205 receptor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Duke University Brain Tumor Cancer Center (Duke)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2006, we and Duke entered into a license agreement that gave us access and reference to the clinical data generated by
Duke and its collaborators in order for us to generate our own filing with the FDA relating to rindopepimut. We may be required to pay milestones of up to $1.0&nbsp;million upon obtaining first
approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Duke with respect to development and commercialization of
rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Ludwig Institute for Cancer Research (Ludwig)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2006, we and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in
combination with our APC Targeting Technology. The term of the agreement is for ten years. We may be required to pay milestones of up to $1.0&nbsp;million upon obtaining first approval for
commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Ludwig with respect to development and commercialization of the technology
licensed from Ludwig. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Alteris Therapeutics,&nbsp;Inc. (Alteris)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2005, we completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. We may be required to pay
Alteris up to $5.0&nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including rindopepimut. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Thomas Jefferson University (TJU)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of the assets of Alteris, we obtained the rights to two exclusive license agreements with TJU dated
February 2003 related to the EGFRvIII tumor antigen. Under these licenses, we may be required to pay milestones of up to $3.0&nbsp;million upon obtaining first approval for commercial sale in a
first indication and royalty payments in the low-single digits on any net product sales to TJU with respect to development and commercialization of rindopepimut. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=157578,FOLIO='13',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> 3M Company  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2008, we and 3M Company entered into a license agreement for the exclusive worldwide rights to access 3M Company's proprietary
Immune Response Modifier, Resiquimod&#153;, (and additional Toll-Like Receptor 7/8 agonists (TLR)) for clinical study with our proprietary APC Targeting Technology, for use as
vaccine adjuvants, with the right to sublicense the technology. We may be required to pay milestones of up to $3.8&nbsp;million upon obtaining first approval for commercial sale of each product
using this vaccine adjuvant and royalty payments in the low-single digits on any net product sales to 3M Company with respect to development and commercialization of the technology
licensed from 3M Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> University of Southampton, UK (Southampton)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2008, we entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially
important target for immunotherapy of various cancers. We may be required to pay milestones of up to approximately $1.4&nbsp;million upon obtaining first approval for commercial sale in a first
indication and royalty payments in the low-single digits on any net product sales to Southampton with respect to development and commercialization of CDX-1127. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Amgen&nbsp;Inc. (Amgen)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2009, we entered into a license agreement with Amgen to expand our Precision Targeted Immunotherapy Platform by acquiring
exclusive rights to FMS-like tyrosine kinase 3 ligand (Flt3L or CDX-301) and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase
the numbers and activity of immune cells that control immune responses. We may be required to pay milestones of up to $1.3&nbsp;million upon obtaining first approval for commercial sale in a first
indication and royalty payments in the low-single digits on any net product sales to Amgen with respect to development and commercialization of the technology licensed from Amgen,
including CDX-301. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Amgen Fremont (formerly Abgenix)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of CuraGen Corporation (CuraGen) in 2009, we assumed the license agreement between CuraGen and Amgen
Fremont (successor in-interest to Abgenix) to develop fully-human monoclonal antibody therapeutics. In May 2009, an amendment to the license agreement (Amgen Amendment) was entered into
related to CuraGen's exclusive rights to develop and commercialize CDX-011, CDX-014 and 10 other licensed antigens. Under the Amgen Amendment, CuraGen and Amgen Fremont agreed
to modify the terms of their existing cross-license of antigens whereby our amended license would be fully paid-up and royalty-free (except for any potentially required
payments to the original licensor of CDX-011). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Seattle Genetics,&nbsp;Inc. (Seattle Genetics)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of CuraGen, we assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen
acquired the rights to proprietary ADC technology for use with its proprietary antibodies for the potential treatment of cancer. We may be required to pay milestones of up to $7.5&nbsp;million upon
obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales to Seattle Genetics with respect to development
and commercialization of the ADC technology, including CDX-011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Competition  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
Many of the products that we are attempting to develop and commercialize will be competing with existing therapies. In addition, a number of companies are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=746111,FOLIO='14',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>pursuing
the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies both in the United
States and abroad. Our competitors may utilize discovery technologies and techniques or partner with collaborators in order to develop products more rapidly or successfully than us or our
collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources than we do. In addition,
academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies
and may establish exclusive collaborative or licensing relationships with our competitors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies,
firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research institutions. The competitors for
which we are aware have initiated a Phase&nbsp;3 study or have obtained marketing approval for a potentially competitive drug include Alexion, Agenus, Baxter, BMS, Dendreon, Eli Lilly,
GlaxoSmithKline, ImmunoGen, Merck, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Takeda.
Many other companies are developing or commercializing products in areas that we have targeted for product development. Some of these products use therapeutic approaches that may compete directly with
our drug candidates. Most of our competitors possess substantially greater financial, technical and human resources than we possess. In addition, many of our competitors have significantly greater
experience than we have in conducting preclinical and nonclinical testing and human clinical trials of drug candidates, scaling up manufacturing operations and obtaining regulatory approvals of drugs
and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for drugs more rapidly than we do. If we obtain regulatory approval and launch commercial sales
of our drug candidates, we also will compete with respect to manufacturing efficiency and sales and marketing capabilities, areas in which we currently have limited experience. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also face competition from pharmaceutical and biotechnology companies, academic institutions, government agencies and private research organizations in recruiting and retaining highly
qualified scientific personnel and consultants and in the development and acquisition of technologies. Moreover, technology controlled by third parties that may be advantageous to our business may be
acquired or licensed by our competitors, thereby preventing us from obtaining technology on commercially reasonable terms, if at all. We will also compete for the services of third parties that may
have already developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies to target the diseases on which we have focused both in
the U.S. and outside of the U.S. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
competitive position will also depend upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes and
secure sufficient capital resources for the often lengthy period between technological conception and commercial sales. We will require substantial capital resources to complete development of some or
all of our products, obtain the necessary regulatory approvals and successfully manufacture and market our products. In order to secure capital resources, we anticipate having to sell additional
capital stock, which would dilute existing stockholders. We may also attempt to obtain funds through research grants and agreements with commercial collaborators. However, these types of fundings are
uncertain because they are at the discretion of the organizations and companies that control the funds. As a result, we may not receive any funds from grants or collaborations. Alternatively, we may
borrow funds from commercial lenders, likely at high interest rates, which would increase the risk of any investment in us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1030664,FOLIO='15',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_de46501_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in large scale manufacturing and we have relied upon collaborators or contractors to manufacture some of our
proposed products for both
clinical and commercial purposes to date. We have established our own manufacturing facility in Fall River, Massachusetts, to produce antibodies, vaccines and other products that we may develop at
scale for clinical trials. In 2010, we completed renovations at our Fall River, MA manufacturing facility which increased our capacity by installing a 1000L bioreactor and made improvement to the
facility to be able to manufacture in compliance with European Medicines Agency (EMEA) regulations. Implementing EMEA requirements along with FDA Good Manufacturing Practices (GMP) will allow us to
distribute potential products to clinical sites in both the US and EU. In order for us to establish a commercial manufacturing facility, we will require substantial additional funds and will be
required to hire and retain significant additional personnel and comply with the extensive GMP regulations applicable to such facility. The commercial manufacturing facility would also need to be
licensed for the production of antibodies, vaccines and other products by the FDA. We intend to establish manufacturing arrangements with contract manufacturers that comply with the FDA's requirements
and other regulatory standards, although there can be no assurance that we will be able to do so. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we believe that there is currently sufficient capacity worldwide for the production of our potential products by our collaborators or through contract manufacturers, establishing
long-term relationships with contract manufacturers and securing multiple sources for the necessary quantities of clinical and commercial materials required can be a challenge. Qualifying
the initial source of clinical and ultimately commercial material is a time consuming and expensive process due to the highly regulated nature of the pharmaceutical/biotech industry. These costs are
hopefully mitigated in the economies of scale realized in commercial manufacture and product sale. The key difficulty in qualifying more than one source for each product is the duplicated time and
expense in doing so without the potential to mitigate these costs if the secondary source is never utilized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use rindopepimut drug product that was manufactured by Pfizer in the ACT IV and ReACT clinical studies. We plan to establish a relationship with a contract manufacturer to support
future clinical trials and for the commercial manufacturing of rindopepimut. To date, we have utilized contract manufacturers for the manufacture of clinical trial supplies of CDX-011. We
manufacture clinical materials of CDX-1127, CDX-1401, CDX-1135 and CDX-301 in our Fall River facility for our current and planned Phase&nbsp;1 and
Phase&nbsp;2 clinical trials. Manufacture of the rotavirus vaccine is the responsibility of Glaxo, which has received from us a worldwide exclusive license to commercialize this vaccine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
manufacturing processes for our other vaccine and immunotherapeutic delivery systems and vaccines utilize known technologies. We believe that the products we currently have under
development can be scaled up to permit manufacture in commercial quantities. However, there can be no assurance that we will not encounter difficulties in scaling up the manufacturing processes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of third party manufacturers limits our control over and ability to monitor the manufacturing process. As a result, we may not be able to detect a variety of problems that may arise
and may face additional costs in the process of interfacing with and monitoring the progress of our contract manufacturers. If third party manufacturers fail to meet our manufacturing needs in an
acceptable manner, we would face delays and additional costs while we develop internal manufacturing capabilities or find alternative third party manufacturers. It may not be possible to have multiple
third party manufacturers ready to supply us with needed material at all or without incurring significant costs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=120681,FOLIO='16',FILE='DISK104:[12ZAA1.12ZAA46501]DE46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg46501_1_17"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Marketing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of existing and future partnership agreements, we rely and expect to continue to rely on the efforts of our
collaborators, including Glaxo, for the sale and marketing of our products. There can be no assurance that our collaborators will develop and market vaccine products incorporating our technologies,
or, if marketed, that such efforts will be successful. The failure of our collaborators to successfully market products would harm our business. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have retained, and in the future intend to retain, marketing rights to some of our drug candidates, including vaccine and immunotherapeutic delivery systems and vaccine candidates, in
selected geographic areas and for specified indications. We intend to seek marketing and distribution agreements and/or co-promotion agreements for the distribution of our products in
these geographic areas and for these indications. We believe that these arrangements could enable us to generate greater financial return than might be obtained from early stage licensing and
collaboration agreements. We currently have no marketing and sales staff and limited experience relating to marketing and distribution of commercial products, including vaccines. If we determine in
the future to engage in direct marketing of our products, we will be required to recruit an experienced marketing group, develop a supporting distribution capability and incur significant additional
expenditures. There can be no assurance that we will be able to establish a successful marketing force. We may choose or
find it necessary to enter into strategic partnerships on uncertain, but potentially unfavorable, terms to sell, market and distribute our products. Any delay in the marketing or distribution of our
products, whether it results from problems with internal capabilities or with a collaborative relationship, could harm the value of an investment in us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Patents, Licenses and Proprietary Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, our intellectual property strategy is to protect our technology by filing patent applications and obtaining patent rights
covering our own technology, both in the United States and in foreign countries that we consider important to our business. In addition, we have acquired and will seek to acquire as needed or desired,
exclusive rights of others through assignment or license to complement our portfolio of patent rights. We also rely on trade secrets, unpatented know-how and technological expertise and
innovation to develop and maintain our competitive position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Patents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful development and marketing of products by us will depend in part on our ability to create and maintain intellectual
property, including patent rights. We are the owner or exclusive licensee to proprietary patent positions in the areas of vaccine technologies, antibody technologies and complement inhibitor
technology. Although we continue to pursue patent protection for our products, no assurance can be given that any pending application will issue as a patent, that any issued patent will have a scope
that will be of commercial benefit, or that we will be able to successfully enforce our patent position against infringers. We routinely review our patent portfolio and adjust our strategies for
prosecution and maintenance of individual cases according to a number of factors including program priorities, stage of development, and patent term. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
own or license rights under more than 400 granted patents and national and regional patent applications around the world covering inventions relating to our business. The key patents
and patent applications owned by us or licensed to us that we consider important to our business include the following (the indicated and estimated patent expiry dates do not include any possible
Patent Term Extensions or Supplementary Protection Certificates, if these may be secured in due course):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Patents for the technology used in rindopepimut have expiration dates through 2014 in the United States and through 2015
in the United Kingdom, Germany and France. We also have rights under patent applications around the world relating to uses of rindopepimut which are </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=282676,FOLIO='17',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_dg46501_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>currently
pending. If issued and maintained to full term in a form which covers commercial use of rindopepimut, the latter filings could potentially provide additional patent protection for the
relevant use in the relevant territories to 2026. We also have rights to an international patent application relating to methods of manufacture and formulation of rindopepimut, which, if issued in the
main designated territories in a form which covers manufacture and/or formulation rindopepimut and maintained to full term in due course, would have estimated patent expiry dates in 2030. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our patent portfolio for CDX-011 includes an issued patent in Europe and pending patent applications in the
U.S. and Japan. If issued and maintained to full term in due course, these would have estimated patent expiry dates in 2025. In addition, patent rights relating to the toxin and conjugation technology
used in CDX-011 have been licensed from Seattle Genetics. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We have licensed pending patent applications in the U.S., Europe and Japan relating to the technology used in
CDX-1127. If issued and maintained to full term in due course, these would have estimated patent expiry dates in 2027. U.S. and international patent applications have also been filed
which, if issued in the main designated territories and maintained to full term in due course, would have estimated patent expiry dates in 2031. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We have pending patent application relating to the technology used in CDX-1401 which, if issued and maintained
to full term in due course, would have estimated patent expiry dates in 2028. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Patents for the technology used in CDX-1135 have expiration dates that range from 2013 to 2016. Further patent
applications are also pending. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Patents for the technology used in CDX-301 have current expiration dates that range from 2016 in the major
European territories to 2020 in the US. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our patent portfolio for CDX-014 includes pending patent applications in the U.S., Europe and Japan. If issued
and maintained to full term in due course, these would have estimated patent expiry dates in 2024. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Patents for the technology used in the cholera and typhoid vaccines expire between 2013 and 2016. Our patent portfolio for
ETEC includes pending patent applications around the world which, if issued and maintained to full term in due course, would have estimated patent expiry dates in 2028. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A U.S. patent for our rotavirus strain that we licensed to Glaxo has an expiration date in December 2012. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that patent applications owned by or licensed to us will result in granted patents or that, if granted, the resultant patents will afford protection against
competitors with similar technology. It is also possible that third parties may obtain patents or other proprietary rights that may be necessary or useful to us. In cases where third parties are first
to invent a particular product or technology, it is possible that those parties will obtain patents that will be sufficiently broad to prevent us from using important technology or from further
developing or commercializing important vaccine and immunotherapeutic systems and vaccine candidates. If licenses from third parties are necessary but cannot be obtained, commercialization of the
covered products might be delayed or prevented. Even if these licenses can be obtained, they would probably require us to pay ongoing royalties and other costs, which could be substantial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
a patent has a statutory presumption of validity in the United States, the issuance of a patent is not conclusive as to validity or as to the enforceable scope of the patent
claims. The validity or enforceability of a patent after its issuance by the Patent and Trademark Office can be challenged in litigation. As a business that uses a substantial amount of intellectual
property, we face a heightened </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=22,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=599401,FOLIO='18',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_dg46501_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>risk
of intellectual property litigation. If the outcome of the litigation is adverse to the owner of the patent, third parties may then be able to use the invention covered by the patent without
authorization or payment. There can be no assurance that our issued patents or any patents subsequently issued to or licensed by us will not be successfully challenged in the future. In addition,
there can be no assurance that our patents will not be infringed or that the coverage of our patents will not be successfully avoided by competitors through design innovation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are aware that others, including universities and companies, have filed patent applications and have been granted patents in the United States and other countries which claim subject
matter potentially useful or necessary to the commercialization of our products. The ultimate scope and validity of existing or future patents which have been or may be granted to third parties, and
the availability and cost of acquiring rights in those patents necessary to the manufacture, use or sale of our products presently cannot be determined by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
parties may have or may obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>certain patents and applications in the United States and Europe owned by Sanofi-Aventis, which relate to antibody-antigen
conjugates and methods of their use for eliciting an immune response against the antigen; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>certain patents and applications in the United States and foreign countries covering particular antigens and antigenic
fragments targeted by our current vaccine drug candidates, including CDX-1401; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>certain patents and pending applications related to particular receptors and other molecules on dendritic cells and
macrophages that may be useful for generating monoclonal antibodies and can be employed in our APC Targeting Technology; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>two United States patents and related foreign patents and applications covering methods of diagnosing gliomas by detecting
the presence of the EGFRvIII (tumor specific splice variant) protein; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a United States patent relating to certain uses of GM-CSF; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a United States patent owned by Genentech,&nbsp;Inc., relating to the production of recombinant antibodies in host
cells; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a United States patent owned by GlaxoSmithKline&nbsp;plc related to methods of culturing cells under certain conditions;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>certain patents held by third parties relating to antibody expression in particular types of host cells. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the patents referred to in the previous paragraphs, there may be other patent applications and issued patents belonging to competitors that may require us to alter our
vaccine candidates and vaccine and immunotherapeutic delivery systems, pay licensing fees or cease some of our activities. If our drug candidates conflict with patents that have been or may be granted
to competitors, universities or others, the patent owners could bring legal action against us claiming damages and seeking to enjoin manufacturing and marketing of the patented products. If any of
these actions is successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected products. There can
be no assurance that we would prevail in any such action or that any license required under any such third party patent would be made available on acceptable terms or at all. We believe that there may
be significant litigation in the biotechnology and vaccine industries regarding patent and other intellectual property rights. If we become involved in that litigation, we could consume substantial
resources. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=23,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=666138,FOLIO='19',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_dg46501_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Licenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into several significant license agreements relating to technology that is being developed by us and/or our
collaborators. In general, these institutions have granted us an exclusive worldwide license (with right to sublicense) to make, use and sell products embodying the licensed technology, subject to the
reservation by the licensor of a non-exclusive right to use the technologies for non-commercial research purposes. Generally, the term of each license is through the expiration
of the last of the patents issued with respect to the technologies covered by the license. We have generally agreed to use reasonable efforts to develop and commercialize licensed products and to
achieve specified milestones and pay license fees, milestone payments and royalties based on the net sales of the licensed products or to pay a percentage of sublicense income. If we breach our
obligations, the licensor has the right to terminate the license, and, in some cases, convert the license to a non-exclusive license. Generally, we control and are responsible for the cost
of defending the patent rights of the technologies that we license. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Proprietary Rights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also rely on unpatented technology, trade secrets and confidential information, and no assurance can be given that others will not
independently develop substantially equivalent information and techniques or otherwise gain access to our know-how and information, or that we can meaningfully protect our rights in such
unpatented technology, trade secrets and information. We require each of our employees, consultants and advisors to execute a confidentiality agreement at the commencement of an employment or
consulting relationship with us. The agreements generally provide that all inventions conceived by the individual in the course of employment or in providing services to us and all confidential
information developed by, or made known to, the individual during the term of the relationship shall be the exclusive property of us and shall be kept confidential and not disclosed to third parties
except in limited specified circumstances. There can be no assurance, however, that these agreements will provide meaningful protection for our information in the event of unauthorized use or
disclosure of such confidential information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Government Regulation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our activities and products are significantly regulated by a number of governmental entities, including the FDA in the United States
and by comparable authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of our
products. We must obtain regulatory approval for a product in all of these areas before we can commercialize the product. Product development within this
regulatory framework takes a number of years and involves the expenditure of substantial resources. Many products that initially appear promising ultimately do not reach the market because they are
found to be unsafe or ineffective when tested. Our inability to commercialize a product would impair our ability to earn future revenues. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> FDA Approval Process  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, vaccines and immunotherapeutics for human use are subject to FDA approval as "biologics" under the Public Health
Service Act and "drugs" under the Federal Food, Drug and Cosmetic Act. The steps required before a new product can be commercialized include: preclinical studies in animals, clinical trials in humans
to determine safety and efficacy and FDA approval of the product for commercial sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data
obtained at any stage of testing is susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Moreover, during the regulatory process, new or
changed drug approval policies may cause unanticipated delays or rejection of our product. We may not obtain </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=24,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=168223,FOLIO='20',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_dg46501_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>necessary
regulatory approvals within a reasonable period of time, if at all, or avoid delays or other problems in testing our products. Moreover, even if we received regulatory approval for a
product, the approval may require limitations on use, which could restrict the size of the potential market for the product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA provides that human clinical trials may begin thirty (30)&nbsp;days after receipt and review of an IND application, unless the FDA requests additional information or changes to
the study protocol within that period. An IND must be sponsored and filed for each of our proposed products. Authorization to conduct a clinical trial in no way assures that the FDA will ultimately
approve the product. Clinical trials are usually conducted in three sequential phases. In a Phase&nbsp;1 trial, the product is given to a small number of healthy volunteers to test for safety
(adverse effects). Phase&nbsp;2 trials are conducted on a limited group of the target patient population; safety, optimal dosage and efficacy are studied. A Phase&nbsp;3 trial is performed in a
large patient population over a wide geographic area to provide evidence for the safety of the product and to prove and confirm efficacy. The FDA has ongoing oversight over all these trials and can
order a temporary or permanent discontinuation if warranted. Such an action could materially harm us. Clinical tests are critical to the success of our products but are subject to unforeseen and
uncontrollable delay, including delay in enrollment of patients. Any delay in clinical trials could delay our commercialization of a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
product's safety and effectiveness in one test is not necessarily indicative of its safety and effectiveness in another test. Moreover, we may not discover all potential problems with
a product even after completing testing on it. Some of our products and technologies have undergone only preclinical testing. As a result, we do not know whether they are safe or effective for humans.
Also, regulatory authorities may decide, contrary to our findings, that a product is unsafe or not as effective in actual use as its test results indicated. This could prevent the product's widespread
use, require its withdrawal from the market or expose us to liability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of the clinical trials and all supporting data are submitted to the FDA for approval. A Biologics License Application (BLA) is submitted for a biologic product; a New Drug
Application (NDA) for a drug product. The interval between IND filing and BLA/NDA filing is usually at least several years due to the length of the clinical trials, and the BLA/NDA review process can
take over a year. During this time the FDA may request further testing or additional trials or may turn down the application. Even with approval, the FDA frequently requires post-marketing
safety studies (known as Phase&nbsp;4 trials) to be performed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA requires that the manufacturing facility that produces a licensed product meet specified standards, undergo an inspection and obtain an establishment license prior to commercial
marketing. Subsequent discovery of previously unknown problems with a product or its manufacturing process may result in restrictions on the product or the manufacturer, including withdrawal of the
product from the market. Failure to comply with the applicable regulatory requirements can result in fines, suspensions of regulatory approvals, product recalls, operating restrictions and criminal
prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Expedited Review and Approval  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has various programs, including fast track, priority review, and accelerated approval, that are intended to expedite or
simplify the process for reviewing drugs, and/or provide for approval on the basis of surrogate endpoints. Generally, drugs that may be eligible for these programs are those for serious or
life-threatening conditions, those with the potential to address unmet medical needs, and those that offer meaningful benefits over existing treatments, however, these programs do not
affect the standards for approval. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. As a condition of approval, the FDA may
require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=25,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1027154,FOLIO='21',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_dg46501_1_22"> </A>


<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Orphan Drug  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is
generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable
expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. If a
product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which
means that the FDA may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In
addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further
marketing of a product based on the results of these post-marketing programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Foreign Regulation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and
commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign
countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and the time may be longer or shorter than that
required for FDA approval. Approval by the FDA does not ensure approval by the regulatory bodies of other countries. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
European Union regulatory systems, we may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is
compulsory for medicines produced by biotechnology and optional for those which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union
member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under the decentralized procedure, the holder of a national marketing authorization may
submit an application to the remaining member states. Within 90&nbsp;days of receiving the applications and assessments report each member state must decide whether to recognize approval. If a
member state does not recognize the
marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. As in the United States, we may apply for designation
of our products as orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. Orphan drugs in Europe enjoy economic and
marketing benefits, including a 10-year market exclusivity period for the approved indication, but not for the same drug, unless another applicant can show that its product is safer, more
effective or otherwise clinically superior to the orphan-designated product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
collaborators are also subject to all of the above-described regulations in connection with the commercialization of products utilizing our technology. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=26,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=441731,FOLIO='22',FILE='DISK104:[12ZAA1.12ZAA46501]DG46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di46501_1_23"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Other Regulatory Processes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws
relating to the oversight activities of the SEC and the regulations of the NASDAQ Global Market, on which our shares are traded. We are also subject to regulation under other federal laws and
regulation under state and local laws, including laws relating to occupational safety, laboratory practices, environmental regulations, and hazardous substance control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Employees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2011, we employed 103 employees, 14 of whom have Ph.D. and/or M.D. degrees. Of these employees, 86 were
engaged in or directly support research and development activities. We believe that our employee relations are good. We believe that our future
success will depend in large part on our ability to attract and retain experienced and skilled employees.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="di46501_item_1a._risk_factors"> </A>
<A NAME="toc_di46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should consider carefully these risk factors together with all of the information included or incorporated by reference in this
Annual Report in addition to our financial statements and the notes to our financial statements. This section includes forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a discussion of the risk factors that we believe are material to us at this time. These risks and uncertainties are not the only ones facing us and there may be
additional matters that we are unaware of or that we currently consider immaterial. All of these could adversely affect our business, results of operations, financial condition and cash flows. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Risks Related to our Business  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We expect to incur future losses and we may never become profitable.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred operating losses of $43.4&nbsp;million, $6.5&nbsp;million and $36.9&nbsp;million during 2011, 2010 and 2009,
respectively, and expect to incur an operating loss in 2012. We believe that operating losses will continue beyond 2012 because we are planning to incur significant costs associated with the clinical
development and manufacturing commercial supply of rindopepimut to prepare for the potential launch of rindopepimut. In addition, we are planning to incur significant costs in the clinical development
of CDX-011, CDX-1127, CDX-1401, CDX-301 and CDX-1135. Our net losses have had and will continue to have an adverse effect on, among other
things, our stockholders' equity, total assets and working capital. We expect that losses will fluctuate from quarter to quarter and year to year, and that such fluctuations may be substantial. We
cannot predict when we will become profitable, if at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our long term success depends heavily on our ability to fund and complete research and development activities for, and to commercialize, our lead drug candidate,
rindopepimut, which we are developing internally.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While in the past we have typically focused on developing and demonstrating proof-of-concept for our product
candidates by bringing such candidates through Phase&nbsp;1 and one or more Phase&nbsp;2 clincial trials, and then leveraging their value through partnerships, we have decided to fund and complete
the research and development activities for rindopepimut ourselves. We plan to commercialize rindopepimut ourselves in North America and to find a partner to commercialize rindopepimut outside of
North America. Therefore, we must allocate a significant portion of our time, personnel and financial resources to the development of rindopepimut. We initiated ACT IV, our pivotal Phase&nbsp;3
clinical trial of rindopepimut, in December 2011. While we are targeting two years for patient accrual, it could take up to three years to enroll all the patients, and another 18 to 24&nbsp;months
of follow-up, at a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=787420,FOLIO='23',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>cost
of over $50&nbsp;million to complete this Phase&nbsp;3 study. Our management team lacks significant experience in completing Phase&nbsp;3 clinical trials and bringing a drug through
commercialization. If we face delays, difficulties or unanticipated costs in completing the development of rindopepimut, we will need substantial additional financing. Further, even if we complete the
development of rindopepimut and gain marketing approvals from the FDA and comparable foreign regulatory authorities in a timely manner, we cannot be sure that rindopepimut will be commercially
successful in the pharmaceutical market. If the results of clinical trials of rindopepimut, the anticipated or actual timing of marketing approvals for rindopepimut, or the market acceptance of
rindopepimut, if approved, do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We may be unable to manage one Phase&nbsp;3 clinical trial or multiple late stage clinical trials for a variety of product candidates simultaneously.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue
developing all of our current products. Our management team does not have significant experience in completing late stage clinical trials and the management of late stage clinical trials is more
complex and time consuming than early stage trials. Typically, early stage trials involve several hundred patients in no more than 10-30 clinical sites. Late stage (Phase&nbsp;3) trials
may involve up to several thousand patients in up to several hundred clinical sites and may require facilities in several countries. Therefore, the project management required to supervise and control
such an extensive program is substantially larger than early stage programs. As the need for these resources is not known until some months before the trials begin, it is
necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this team to be recruited quickly, the sponsor is faced with a decision to
delay the program or to initiate it with inadequate management resources. This may result in recruitment of inappropriate patients, inadequate monitoring of clinical investigators and inappropriate
handling of data or data analysis. Consequently it is possible that conclusions of efficacy or safety may not be acceptable to permit filing of a BLA or NDA for any one of the above reasons or a
combination of several. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We will need additional capital to fund our operations, including the development, manufacture and potential commercialization of our drug candidates. If we do not have or
cannot raise additional capital when needed, we will be unable to develop and ultimately commercialize our drug candidates successfully.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to incur significant costs as we develop our drug candidates. In particular, the continuing development and commercialization
of rindopepimut requires additional capital beyond our current resources. As of December&nbsp;31, 2011, we had cash, cash equivalents and marketable securities of $53.3&nbsp;million, which, at
that time, we believed would support expected operations for more than 12&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the next twelve months, we may take further steps to raise additional capital to fund our long-term liquidity needs. Our capital raising activities may include, but
may not be limited to, one or more of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>licensing of drug candidates with existing or new collaborative partners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>possible business combinations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>issuance of debt; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>issuance of common stock or other securities via private placements or public offerings. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we may continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating
position in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=223709,FOLIO='24',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>capital-raising
efforts may worsen as existing resources are used. There is also no assurance that we will be able to enter into further collaborative relationships. Additional equity financing may be
dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; and licensing or
strategic collaborations may result in royalties or other terms which reduce our economic potential from products under development. If we are unable to raise the funds necessary to meet our
long-term liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license
out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2011, we entered into a financing facility with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., providing for the sale of up to 5&nbsp;million shares of our common stock from time to
time into the open market at prevailing prices. During the year ended December&nbsp;31, 2011, we sold 575,000 shares of common stock under the Cantor Agreement and raised $2.2&nbsp;million in net
proceeds, after deducting commission and offering expenses. As of December&nbsp;31, 2011, we had 4,425,000 shares available to be sold under the Cantor Agreement. In January 2012, we sold 2,450,000
shares of common stock under the Cantor Agreement and raised $8.5&nbsp;million in net proceeds. Under the terms of the Cantor Agreement, we will have the ability to sell up to 1,975,000 shares of
our common stock upon the expiration or earlier waiver of our 90-day lock-up with the underwriters of our recent offering in February 2012. We may or may not sell additional
shares under this facility, depending on the volume and price of our common stock, as well as our capital needs and potential alternative sources of capital. If we actively sell shares under this
facility, a significant number of shares of common stock could be issued in a short period of time, although we would attempt to structure the volume and price thresholds in a way that minimizes
market impact. Notwithstanding these control efforts, these sales, or the perceived risk of dilution from potential sales of stock through this facility, may depress our stock price, cause holders of
our common stock to sell their shares, or encourage short selling by market participants, which could contribute to a decline in our stock price. A decline in our stock price might impede our ability
to raise capital through the issuance of additional shares of common stock or other equity securities, and may cause our stockholders to lose part or all of the value of their investment in our stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2012, we issued 10,500,000 shares of our common stock in an underwritten public offering. The net proceeds to us were $37.7&nbsp;million, after deducting underwriting fees
and estimated offering expenses. We have granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if
any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product development.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. If any of these third parties fails to perform as we expect
or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third parties who we currently rely on for clinical development activities include Novella Clinical&nbsp;Inc. (Novella) for ACT IV. If Novella is unable to perform in a
quality and timely manner, and at a feasible cost, ACT IV will face delays. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=200693,FOLIO='25',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We may enter into collaboration agreements for the licensing, development and ultimate commercialization of some of our drug candidates including, where appropriate, for our
lead drug candidates. In such cases, we will depend greatly on our third party collaborators to license, develop and commercialize such drug candidates, and they may not meet our expectations.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exploring potential co-development and commercialization partnerships for certain products, including rindopepimut
for commercialization outside of North America, CDX-011 and CDX-1127. The process of identifying collaborators and negotiating collaboration agreements for the licensing,
development and ultimate commercialization of some of our drug candidates may cause delays and increased costs. We may not be able to enter into collaboration agreements on terms favorable to us.
Furthermore some of those agreements may give substantial responsibility over our drug candidates to the collaborator. Some collaborators may be unable or unwilling to devote sufficient resources to
develop our drug candidates as their agreements require. They often face business risks similar to ours, and this could interfere with their efforts. Also, collaborators may choose to devote their
resources to products that compete with ours. If a collaborator does not successfully develop any one of our products, we will need to find another collaborator to do so. The success of our search for
a new collaborator will depend on our legal right to do so at the time and whether the product remains commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into collaboration agreements for one or more of our lead drug candidates, the success of such drug candidates will depend in great part upon our and our collaborators'
success in promoting them as superior to other treatment alternatives. We believe that our drug candidates can be proven to offer disease prevention and treatment with notable advantages over drugs in
terms of patient compliance and effectiveness. However, there can be no assurance that we will be able to prove these advantages or that the advantages will be sufficient to support the successful
commercialization of our drug candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We may face delays, difficulties or unanticipated costs in establishing sales, distribution and manufacturing capabilities for our commercially ready products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our current plan is to retain, rather than license to a third party, all rights to rindopepimut in North America (and to explore
partnership opportunities to commercialize rindopepimut outside of North America) and our APC Targeting Technology programs. As a result, we will have full responsibility for commercialization of
these products if and when they are approved for sale. We currently lack the marketing, sales and distribution capabilities that we will need to carry out this strategy. To market any of our products
directly, we must develop a substantial marketing and sales force with technical expertise and a supporting distribution capability. We have little expertise in this area, and we may not succeed. We
may find it necessary to enter into strategic partnerships on uncertain but potentially unfavorable terms to sell, market and distribute our products when they are approved for sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our products are difficult to manufacture, especially in large quantities, and we have not yet developed commercial scale manufacturing processes for any of our products. We do
not currently plan to develop internal manufacturing capabilities to produce any of our products at commercial scale if they are approved for sale. To the extent that we choose to market and
distribute these products ourselves, this strategy will make us dependent on other companies to produce our products in adequate quantities, in compliance with regulatory requirements, and at a
competitive cost. We may not find third parties capable of meeting those manufacturing needs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our drug candidates are subject to extensive regulatory scrutiny.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our drug candidates are at various stages of development and commercialization and our activities and drug candidates are
significantly regulated by a number of governmental entities, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=271053,FOLIO='26',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>including
the FDA in the United States and by comparable authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety, effectiveness, labeling,
documentation, advertising and sale of drugs and drug candidates. We or our partners must obtain regulatory approval for a drug candidate in all of these areas before we can commercialize the drug
candidate. Product development within this regulatory framework takes a number of years and involves the expenditure of substantial resources. This process typically requires extensive preclinical and
clinical testing, which may take longer or cost more than we anticipate, and may prove unsuccessful due to numerous factors. Many drug candidates that initially appear promising ultimately do not
reach the market because they are found to be unsafe or ineffective when tested. Companies in the pharmaceutical, biotechnology and vaccines industries have suffered significant setbacks in advanced
clinical trials, even after obtaining promising results in earlier trials. Our inability to commercialize a drug candidate would impair our ability to earn future revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> If our products do not pass required tests for safety and effectiveness, we will not be able to derive commercial revenue from them.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to succeed, we will need to derive commercial revenue from the products we have under development. The FDA has not approved
our rindopepimut, CDX-011 or CDX-1127 drug candidates or any of our other products for sale to date. Our drug candidates are in various stages of preclinical and clinical
testing. Preclinical tests are performed at an early stage of a product's development and provide information about a product's safety and effectiveness on laboratory animals. Preclinical tests can
last years. If a product passes its preclinical tests satisfactorily, and we determine that further development is warranted, we would file an IND application for the product with the FDA, and if the
FDA gives its approval we would begin Phase&nbsp;1 clinical tests. Phase&nbsp;1 testing generally lasts between 6 and 24&nbsp;months. If Phase&nbsp;1 test results are satisfactory and the FDA
gives its approval, we can begin Phase&nbsp;2 clinical tests. Phase&nbsp;2 testing generally lasts between 6 and 36&nbsp;months. If Phase&nbsp;2 test results are satisfactory and the FDA gives
its approval, we can begin Phase&nbsp;3 pivotal studies. Phase&nbsp;3 studies generally last between 12 and 48&nbsp;months. Once clinical testing is completed and a new drug application is filed
with the FDA, it may take more than a year to receive FDA approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases we must show that a pharmaceutical product is both safe and effective before the FDA, or drug approval agencies of other countries where we intend to sell the product, will
approve it for sale. Our research and testing programs must comply with drug approval requirements both in the United States and in other countries, since we are developing our lead products with the
intention to, or could later decide to, commercialize them both in the U.S. and abroad. A product may fail for safety or effectiveness at any stage of the testing process. A major risk we face is the
possibility that none of our products under development will come through the testing process to final approval for sale, with the result that we cannot derive any commercial revenue from them after
investing significant amounts of capital in multiple stages of preclinical and clinical testing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Product testing is critical to the success of our products but subject to delay or cancellation if we have difficulty enrolling patients.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our portfolio of potential products moves from preclinical testing to clinical testing, and then through progressively larger and
more complex clinical trials, we will need to enroll an increasing number of patients with the appropriate characteristics. At times we have experienced difficulty enrolling patients and we may
experience more difficulty as the scale of our clinical testing program increases. The factors that affect our ability to enroll patients are largely uncontrollable and include principally the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the nature of the clinical test; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the size of the patient population; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=494083,FOLIO='27',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>patients' willingness to receive a placebo or less effective treatment on the control arm of a clinical study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the distance between patients and clinical test sites; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the eligibility criteria for the trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot enroll patients as needed, our costs may increase or it could force us to delay or terminate testing for a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We may have delays in completing our clinical trials and we may not complete them at all.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not completed the clinical trials necessary to obtain FDA approval to market rindopepimut, CDX-011 or any of our
other products in development. We initiated a Phase&nbsp;3 study of rindopepimut in December 2011 but we have not initiated Phase&nbsp;3 studies for CDX-011 or any of our other
products in development. Our management lacks significant experience in completing Phase&nbsp;3 trials and bringing a drug through commercialization. Our rindopepimut Phase&nbsp;3 trial,
CDX-011 Phase&nbsp;2b studies and planned clinical trials for other products in development may be delayed or terminated as a result of many factors, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>difficulty in enrolling patients in our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>failure by regulators to authorize us to commence a clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>suspension or termination by regulators of clinical research for many reasons, including concerns about patient safety or
failure of our contract manufacturers to comply with cGMP requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>delays or failure of the FDA to remove the partial clinical hold on our CDX-011 studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>treatment candidates demonstrating a lack of efficacy during clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>inability to continue to fund clinical trials or to find a partner to fund the clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>competition with ongoing clinical trials and scheduling conflicts with participating clinicians; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>delays in completing data collection and analysis for clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay or failure to complete clinical trials and obtain FDA approval for our drug candidates could have a material adverse effect on our cost to develop and commercialize, and our
ability to generate revenue from, a particular drug candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn future revenues.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that none of the drug candidates that we develop will obtain the regulatory approvals necessary for us to begin
commercializing them. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the nature of the drug
candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval.
Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular drug candidate including, but not limited to, loss of
patent term during the approval period. Furthermore, if we, or our partners, do not reach the market with our products before our competitors offer products for the same or similar uses, or if </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=13054,FOLIO='28',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>we,
or our partners, are not effective in marketing our products, our revenues from product sales, if any, will be reduced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies,
firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research institutions. The competitors for
which we are aware have initiated a Phase&nbsp;3 study or have obtained marketing approval for a potentially competitive drug include Alexion, Agenus, Baxter, BMS, Dendreon, Eli Lilly,
GlaxoSmithKline, ImmunoGen, Merck, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Takeda. Most of our competitors have substantially greater resources, more extensive experience in conducting
preclinical studies and clinical testing and obtaining regulatory approvals for their products, greater operating experience, greater research and development and marketing capabilities and greater
production capabilities than those of ours. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products, especially if we
experience any delay in obtaining required regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Failure to comply with applicable regulatory requirements would adversely impact our operations.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even after receiving regulatory approval, our products would be subject to extensive regulatory requirements, and our failure to comply
with applicable regulatory requirements will adversely impact our operations. In the United States, the FDA requires that the manufacturing facility that produces a product meet specified standards,
undergo an inspection and obtain an establishment license prior to commercial marketing. Subsequent discovery of previously unknown problems with a product or its manufacturing process may result in
restrictions on the product or the manufacturer, including withdrawal of the product from the market. Failure to comply with the applicable regulatory requirements can result in fines, suspensions of
regulatory approvals, product recalls, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We depend greatly on the intellectual capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our
products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of Anthony S. Marucci, our President and Chief Executive Officer, or other key members of our staff, including Avery W.
Catlin, our Chief Financial Officer, Dr.&nbsp;Thomas Davis, our Chief Medical Officer, Dr.&nbsp;Tibor Keler, our Chief Scientific Officer or Ronald
Pepin, our Chief Business Officer, could harm us. We entered into employment agreements with Messrs.&nbsp;Marucci, Catlin, Davis, Keler and Pepin although an employment agreement as a practical
matter does not guarantee retention of an employee. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to
us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial and marketing personnel, particularly as we
expand our activities in clinical trials, the regulatory approval process and sales and manufacturing. We routinely enter into consulting agreements with our scientific and clinical collaborators and
advisors, key opinion leaders and heads of academic departments in the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who recruit patients
into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for this type of personnel from other companies,
research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=33,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=345456,FOLIO='29',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<A NAME="page_di46501_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> We rely on contract manufacturers over whom we have limited control. Should the cost, delivery and quality of clinical and commercial grade materials supplied by contract
manufacturers vary to our disadvantage, our business operations could suffer significant harm.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in large scale manufacturing at our Fall River facility. We rely on sourcing from third-party manufacturers
for suitable quantities of some of our clinical and commercial grade materials and certain filling and packaging essential to preclinical and clinical studies currently underway and to planned
clinical trials in addition to those currently being conducted by third parties or us. The inability to have suitable quality and quantities of these essential materials produced in a timely manner
would result in significant delays in the clinical development and commercialization of products, which could adversely affect our business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, one lot of our CDX-011 product candidate being used in our on-going Phase&nbsp;2b study was aseptically filled in 2009 by Formatech, a third party
contract manufacturer. The CDX-011 lot from Formatech has passed all of the sterility testing performed during drug release and in subsequent stability studies. At the end of January 2012,
we were notified by the FDA that because significant Good Manufacturing Practice (GMP) violations were uncovered during inspection of Formatech, our Phase&nbsp;2b study for CDX-011 was
being placed on partial clinical hold. The FDA uncovered these findings during their inspections of the Formatech facility between August to October 2010 and July to August 2011. These inspections
began approximately one year after the CDX-011 drug product was filled at Formatech. Specifically, the FDA requested that no new patients be treated with CDX-011. However,
patients already undergoing treatment with CDX-011 could continue treatment using vials of CDX-011 from the lot filled by Formatech, after such patients
were informed of the potential risk and reconsented to continued participation in the study. Since the Phase&nbsp;2b trial completed accrual of patients in December 2011 and there are currently no
other ongoing open studies with CDX-011, the only patients that are affected by the partial hold are the eight patients remaining in the control arm of the study, who currently are not
receiving CDX-011, and may be eligible to cross-over at the time of progression and receive CDX-011 under the study protocol. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have initiated discussions with the FDA regarding our proposal to utilize vials of CDX-011 that were filled by a different contract manufacturer. Although the FDA has
stated that no new patients may receive CDX-011 and that no patients may cross-over to receive CDX-011, we have asked the FDA to reconsider allowing patients
currently on the control arm to cross-over to CDX-011 after stability testing and confirmation that the product filled by the other contract manufacturer is acceptable for
continued use. If the FDA agrees to our proposal concerning use of the alternative CDX-011 for the eligible cross-over patients, we believe that we should have sufficient
clinical supply of CDX-011 to treat these cross-over patients. If we are not able to treat the eight remaining cross-over patients with CDX-011,
patients may withdraw from the control arm study upon learning that they will not be allowed to cross-over to CDX-011 following disease progression. However, the primary
analyses for the study are entirely based upon the primary randomization and do not include the cross-over results. Based on our discussions with our clinical investigators, we do not
believe that a high proportion of patients will withdraw from the control arm prior to progression. We do not believe that this partial hold will significantly impact analysis of the Phase&nbsp;2b
data for purposes of determining next steps in our future development of CDX-011. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=34,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=351049,FOLIO='30',FILE='DISK104:[12ZAA1.12ZAA46501]DI46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk46501_1_31"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the FDA has agreed in concept that we could reprocess the remaining available vials of CDX-011 manufactured at Formatech at another cGMP
contract manufacturer. The FDA's final decision regarding the acceptability of this reprocessing will be made upon review of data concerning the stability and sterility of the reprocessed vials of
CDX-011. If we are unsuccessful at reprocessing the available drug product or if FDA does not approve the use of these reprocessed vials, we will need to manufacture new drug product for
subsequent clinical studies for CDX-011, which may cause a delay in the initiation of a subsequent trial with CDX-011. We also rely on collaborators and contract manufacturers
to manufacture proposed products in both clinical and commercial quantities in the future. Our leading vaccine candidates require specialized manufacturing capabilities and processes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may face difficulty in securing commitments from U.S. and foreign contract manufacturers as these manufacturers could be unwilling or unable to accommodate our needs. Relying on
foreign manufacturers involves peculiar and increased risks, including the risk relating to the difficulty foreign manufacturers may face in complying with GMP requirements as a result of language
barriers, lack of familiarity with GMP or the FDA regulatory process or other causes, economic or political instability in or affecting the home countries of our foreign manufacturers, shipping
delays, potential changes in foreign regulatory laws governing the sales of our product supplies, fluctuations in foreign currency exchange rates and the imposition or application of trade
restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurances that we will be able to enter into long-term arrangements with third party manufacturers on acceptable terms, or at all. Further, contract
manufacturers must also be able to meet our timetable and requirements, and must operate in compliance with GMP; failure to do so could result in, among other things, the disruption of product
supplies. As noted above, non-U.S. contract manufacturers may face special challenges in complying with GMP requirements, and although we are not currently dependent on
non-U.S. collaborators or contract manufacturers, we may choose or be required to rely on non-U.S. sources in the future as we seek to develop stable supplies of increasing
quantities of materials for ongoing clinical trials of larger scale. Our dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to
develop and deliver products on a timely and competitive basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third parties who we currently rely on for sourcing of suitable quantities of some of our clinical and commercial grade materials include Biosyn, Bayer and Sanofi for our
rindopepimut drug candidate. If we or our third-party manufacturers are unable to produce drug material in suitable quantities of appropriate quality, in a timely manner, and at a feasible cost, our
clinical tests will face delays. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Certain factors could negatively affect the demand for and sales of Rotarix&reg;, which would have a material adverse affect on our revenues.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have licensed a rotavirus strain to Glaxo for the purposes of Glaxo developing and commercializing their Rotarix&reg;
vaccine worldwide. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon
90&nbsp;days prior written notice. The last relevant patent is scheduled to expire in December 2012. Glaxo gained approval for Rotarix&reg; in Mexico in July 2004, in the European Union in
February 2006 and in the United States in April 2008. In May 2005, we entered into an agreement whereby an affiliate of PRF purchased a 70% interest in the net royalties we receive on worldwide sales
of Rotarix&reg;. In addition, we retain upside participation in the worldwide net royalties from Rotarix&reg; once, and if, PRF receives an agreed upon return on capital invested (2.45
times PRF's aggregate cash payments to us of $60&nbsp;million). The PRF agreement terminates in December 2012, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=19983,FOLIO='31',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>unless
otherwise extended. The following are potential factors, among others, that may negatively affect the demand for Rotarix&reg;:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>competitors in the pharmaceuticals, biotechnology and vaccines market have greater financial and management resources, and
significantly more experience in bringing products to market, and may develop, manufacture and market products that are more effective or less expensive than Rotarix&reg;; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Rotarix&reg; could be replaced by a novel product and may become obsolete; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Glaxo may be unable to prevent third parties from infringing upon their proprietary rights related to
Rotarix&reg;; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>users may not accept such a recently approved product without years of proven history; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>we are dependent on Glaxo for the manufacturing, testing, acquisition of regulatory approvals, marketing, distribution and
commercialization of Rotarix&reg;. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on the sales of Rotarix&reg; and our revenues. However, any decline in revenue would not impact our net income because
any royalty revenue we receive from sales of Rotarix&reg; is offset by a corresponding royalty expense that we pay to PRF. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Other factors could affect the demand for and sales of Rotarix and any other products that we may commercialize in the future.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, other factors that could affect the demand for and sales and profitability of our products include, but are not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the timing of regulatory approval, if any, of competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our, Glaxo's, or any other of our partners' pricing decisions, as applicable, including a decision to increase or decrease
the price of a product, and the pricing decisions of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>government and third-party payer reimbursement and coverage decisions that affect the utilization of our products and
competing products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>negative safety or efficacy data from new clinical studies conducted either in the U.S. or internationally by any party
could cause the sales of our products to decrease or a product to be recalled; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the degree of patent protection afforded our products by patents granted to or licensed by us and by the outcome of
litigation involving our or any of our licensor's patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the outcome of litigation involving patents of other companies concerning our products or processes related to production
and formulation of those products or uses of those products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the increasing use and development of alternate therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the rate of market penetration by competing products; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the termination of, or change in, existing arrangements with our partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on Glaxo's sales of Rotarix and on the sales of any other products that we may commercialize in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=476784,FOLIO='32',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We face the risk of product liability claims, which could exceed our insurance coverage, and produce recalls, each of which could deplete our cash resources.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a participant in the pharmaceutical, biotechnology and vaccines industries, we are exposed to the risk of product liability claims
alleging that use of our drug candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our drug candidates and may be
made directly by patients involved in clinical trials of our products, by consumers or healthcare providers or by individuals, organizations or companies selling our products. Product liability claims
can be expensive to defend, even if the drug or drug candidate did not actually cause the alleged injury or harm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
covering product liability claims becomes increasingly expensive as a drug candidate moves through the development pipeline to commercialization. Under our license agreements,
we are required to maintain clinical trial liability insurance coverage up to $14&nbsp;million. However, there can be no assurance that such insurance coverage is or will continue to be adequate or
available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be able to
secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability for damages resulting from a product liability claim could exceed
the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material adverse effect on our business, financial condition and results of
operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business and inhibit or prevent commercialization of other products and drug
candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If we cannot maintain acceptable amounts
of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material
adverse impact on our operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of our collaborators,
advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in
advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively
by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets under the terms of
research and development partnership or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor's
discovery of our trade secrets would impair our competitive position. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=962790,FOLIO='33',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We may not be able to successfully integrate newly-acquired technology with our existing technology or to modify our technologies to create new vaccines.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our acquisition of technology assets from entities such as 3M Company and Amgen, we have acquired access to
Resiquimod&#153; (a TLR 7/8 agonist) and Flt3L, which may improve the immunogenicity of our vaccines. If we are able to integrate these licensed assets with our vaccine technologies, we believe
these assets will give our vaccines a competitive advantage. However, if we are unable to successfully integrate licensed assets, or other technologies which we have acquired or may acquire in the
future, with our existing technologies and potential products currently under development, we may be unable to realize any benefit from our acquisition of these assets, or other technologies which we
have acquired or may acquire in the future and may face the loss of our investment of financial resources and time in the integration process. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our vaccine technology portfolio may offer opportunities to develop vaccines that treat a variety of oncology, inflammatory and infectious diseases by stimulating a
patient's immune system against those disease organisms. If our vaccine technology portfolio cannot be used to create effective
vaccines against a variety of disease organisms, we may lose all or portions of our investment in development efforts for new vaccine candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We license technology from other companies to develop products, and those companies could influence research and development or restrict our use of it.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Companies that license technologies to us that we use in our research and development programs may require us to achieve milestones or
devote minimum amounts of resources to develop products using those technologies. They may also require us to make significant royalty and milestone payments, including a percentage of any
sublicensing income, as well as payments to reimburse them for patent costs. The number and variety of our research and development programs require us to establish priorities and to allocate
available resources among competing programs. From time to time we may choose to slow down or cease our efforts on particular products. If in doing so we fail to fully perform our obligations under a
license, the licensor can terminate the licenses or permit our competitors to use the technology. Moreover, we may lose our right to market and sell any products based on the licensed technology. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> We have many competitors in our field and they may develop technologies that make ours obsolete.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology, pharmaceuticals and therapeutics are rapidly evolving fields in which scientific and technological developments are
expected to continue at a rapid pace. We have many competitors in the U.S. and abroad. The competitors for which we are aware have initiated a Phase&nbsp;3 study or have obtained marketing approval
for a potentially competitive drug include Alexion, Agenus, Baxter, BMS, Dendreon, Eli Lilly, GlaxoSmithKline, ImmunoGen, Merck, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Takeda. Our
success depends upon our ability to develop and maintain a competitive position in the product categories and technologies on which we focus. Many of our competitors have greater capabilities,
experience and financial resources than we do. Competition is intense and is expected to increase as new products enter the market and new technologies become available. Our competitors
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>develop technologies and products that are more effective than ours, making ours obsolete or otherwise noncompetitive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain regulatory approval for products more rapidly or effectively than us; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain patent protection or other intellectual property rights that would block our ability to develop competitive
products. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=777455,FOLIO='34',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> We rely on patents, patent applications and other intellectual property protections to protect our technology and trade secrets; which are expensive and may not provide
sufficient protection.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to obtain and maintain patent protection for technologies that we use. Biotechnology patents
involve complex legal, scientific and factual questions and are highly uncertain. To date, there is no consistent policy regarding the breadth of claims allowed in biotechnology patents, particularly
in regard to patents for technologies for human uses like those we use in our business. We cannot predict whether the patents we seek will issue. If they do issue, a competitor may challenge them and
limit their scope. Moreover, our patents may not afford effective protection against competitors with similar technology. A successful challenge to any one of our patents could result in a third
party's ability to use the technology covered by the patent. We also face the risk that others will infringe, avoid or circumvent our patents. Technology that we license from others is subject to
similar risks and this could harm our ability to use that technology. If we, or a company that licenses technology to us, were not the first creator of an invention that we use, our use of the
underlying product or technology will face restrictions, including elimination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we must defend against suits brought against us or prosecute suits against others involving intellectual property rights, we will incur substantial costs. In addition to any potential
liability for significant monetary damages, a decision against us may require us to obtain licenses to patents or other intellectual property rights of others on potentially unfavorable terms. If
those licenses from third parties are necessary but we cannot acquire them, we would attempt to design around the relevant technology, which would cause higher development costs and delays, and may
ultimately prove impracticable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our business requires us to use hazardous materials, which increases our exposure to dangerous and costly accidents.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development activities involve the use of hazardous chemicals, biological materials and radioactive compounds.
Although we believe that our safety
procedures for handling and disposing of hazardous materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. In the event of an accident, an injured party will likely sue us for any resulting damages with potentially significant liability. The ongoing cost of
complying with environmental laws and regulations is significant and may increase in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Health care reform and restrictions on reimbursement may limit our returns on potential products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our strategy ultimately depends on the commercial success of our products, we assume, among other things, that end users of our
products will be able to pay for them. In the United States and other countries, in most cases, the volume of sales of products like those we are developing depends on the availability of
reimbursement from third-party payors, including national health care agencies, private health insurance plans and health maintenance organizations. Third-party payors increasingly challenge the
prices charged for medical products and services. Accordingly, if we succeed in bringing products to market, and reimbursement is not available or is insufficient, we could be prevented from
successfully commercializing our potential products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
health care industry in the United States and in Europe is undergoing fundamental changes as a result of political, economic and regulatory influences. Reforms proposed from time to
time include mandated basic health care benefits, controls on health care spending, the establishment of governmental controls over the cost of therapies, creation of large medical services and
products purchasing groups and fundamental changes to the health care delivery system. We anticipate ongoing review and assessment of health care delivery systems and methods of payment in the United
States and other countries. We cannot predict whether any particular reform initiatives will result or, if </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=204630,FOLIO='35',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>adopted,
what their impact on us will be. However, we expect that adoption of any reform proposed will impair our ability to market products at acceptable prices and that uncertainty concerning future
government regulation of consumer healthcare purchasing and insurance may result in difficulties for drug development companies, like Celldex, in raising capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Changes in laws affecting the health care industry could adversely affect our business.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., there have been numerous proposals considered at the federal and state levels for comprehensive reforms of health care and
its cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. Congress has considered legislation to reform the U.S.
health care system by expanding health insurance coverage, reducing health care costs and making other changes. While health care reform may increase the number of patients who have insurance coverage
for our products, it may also include cost containment measures that adversely affect reimbursement for our products. Congress has also considered legislation to change the Medicare reimbursement
system for outpatient drugs, increase the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs and facilitate the importation of lower-cost
prescription drugs that are marketed outside the U.S. Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting
manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations
continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed
care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on
prices and reimbursement for our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our collaborators and partners operate in a highly regulated industry. As a result, governmental actions may adversely affect our business, operations or financial condition,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to
health care availability, method of delivery and payment for health care products and services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and
result in lost market opportunity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on
product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of
approved products, or otherwise adversely affect the market for our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations and judicial decisions affecting pricing or marketing practices; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the tax laws relating to our operations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment in the U.S. of health care reform, possible legislation which could ease the entry of competing follow-on biologics in the marketplace, new legislation or
implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of
previously enacted and possible future changes in laws that could adversely affect our business. In addition, the Food and Drug Administration Amendments Act of 2007 included new authorization for the
FDA to require post-market safety monitoring, along with an expanded clinical trials registry and clinical trials results database, and expanded authority for the FDA to impose civil
monetary penalties on companies that fail to meet certain commitments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=104006,FOLIO='36',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> If physicians, patients and third-party payors do not accept any future drugs that we may develop, we may be unable to generate significant revenue, if any.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if our drug candidates as well as any drug candidates that we may develop or acquire in the future obtain regulatory approval,
they may not gain market acceptance among physicians, patients and health care payors. Physicians may elect not to recommend these drugs for a variety of reasons
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>timing of market introduction of competitive drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lower demonstrated clinical safety and efficacy compared to other drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of cost-effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of availability of reimbursement from third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>convenience and ease of administration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>prevalence and severity of adverse side effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>other potential advantages of alternative treatment methods; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ineffective marketing and distribution support. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any drugs that we develop fail to achieve market acceptance, we would not be able to generate sufficient revenue from product sales to maintain or grow our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Risks Related to our Capital Stock  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our history of losses and uncertainty of future profitability make our common stock a highly speculative investment.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have had no commercial revenue to date from sales of our human therapeutic or vaccine products and cannot predict when we will have
commercial revenue from such sales. We had an accumulated deficit of $205&nbsp;million as of December&nbsp;31, 2011. We expect to spend substantial funds to continue the research and development
testing of our products that we have in the preclinical and clinical testing stages of development that have not been partnered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities.
These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the regulatory approval process. As a
result, we may continue to lose money for several years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
common stock, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our share price has been and could remain volatile.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January
2011 through December 2011, the market price of our common stock has fluctuated from a high of $4.46 per share in the second quarter of 2011, to a low of $2.11 per share in the fourth quarter of 2011.
Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price
of our common stock to fluctuate substantially with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=601377,FOLIO='37',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>significant
market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a short period of time, those sales could adversely affect
the market price of our common stock and could impair our ability to raise capital. In addition, in recent
years, the stock market has experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their
operating performance and may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our
stock, which could result in substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> The restrictive covenants contained in our credit agreement may limit our activities.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;30, 2010, we entered into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial,&nbsp;LLC
(MidCap) pursuant to which we borrowed $10&nbsp;million (the "Term Loan") from MidCap. In March 2011, we amended the Loan Agreement and borrowed an additional $5&nbsp;million from General Electric
Capital Corporation (GECC) (collectively with MidCap, the "Lenders") to increase the amount owed under the Term Loan to $15&nbsp;million. Our obligations under the Term Loan are secured by a first
priority lien upon and security interest in substantially all of our existing and after-acquired assets, excluding our intellectual property assets (the "Collateral"). Under the Term Loan, we are
subject to specified affirmative covenants customary for loans of this type, including but not limited to the obligations to maintain good standing, provide various notices to the Lenders, deliver
financial statements to the Lenders, maintain adequate insurance, promptly discharge all taxes, protect our intellectual property and protect the Collateral. We are also subject to certain negative
covenants customary for loans of this type, including but not limited to prohibitions against certain mergers and consolidations, certain management and ownership changes constituting a "change of
control," and the imposition of additional liens on Collateral or other of our assets, as well as prohibitions against additional indebtedness, certain dispositions of property, changes in our
business, name or location, payment of dividends, prepayment of certain other indebtedness, certain investments or acquisitions, and certain transactions with affiliates, in each case subject to
certain customary exceptions, including exceptions that allow us to enter into non-exclusive and/or exclusive licenses and similar agreements providing for the use of our intellectual
property in collaboration with third parties provided certain conditions are met. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Failure
to comply with the restrictive covenants in our Term Loan could accelerate the repayment of any debt outstanding under the Term Loan. Additionally, as a result of these
restrictive covenants, we may be at a disadvantage compared to our competitors that have greater operating and financing flexibility than we do. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Our ability to use our net operating loss carryforwards will be subject to limitation and, under certain circumstances, may be eliminated.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization of our net operating loss (NOL) and research and development credit (R&amp;D credit) carryforwards may be subject to
substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future provided
by Section&nbsp;382 of the Internal Revenue Code of 1986 (Section&nbsp;382), as well as similar state provisions. In general, an ownership change, as defined by Section&nbsp;382, results from
transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2007, June 2009 and in December 2009, we experienced a change in ownership as defined by Section&nbsp;382 of the Internal Revenue Code. Historically, we have raised capital
through the issuance of capital stock on several occasions which, combined with shareholders' subsequent disposition of those shares, has resulted in three changes of control, as defined by
Section&nbsp;382. As a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=262230,FOLIO='38',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dk46501_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>result
of the ownership change in October 2007, utilization of its Federal NOLs is subject to an annual limitation. Any unused annual limitation may be carried over to later years, and the amount of
the limitation may, under certain circumstances, be subject to adjustment if the fair value of the our net assets are determined to be below or in excess of the tax basis of such assets at the time of
the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. Subsequent ownership changes, as defined in Section&nbsp;382,
could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future taxable income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not undertaken a study to assess whether an ownership change or multiple ownership changes has occurred for (i)&nbsp;AVANT or CuraGen prior to our acquisitions, (ii)&nbsp;the
Company on the state level, (iii)&nbsp;the Company since December 2009, or (iv)&nbsp;R&amp;D credits. If there has been an ownership change at any time since its formation, utilization of NOL or tax
credit carryforwards would be subject to an annual limitation under Section&nbsp;382. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Refer
to Note&nbsp;15, "Income Taxes," in the accompanying notes to the consolidated financial statements for additional discussion on income taxes.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk46501_item_1b._unresolved_staff_comments"> </A>
<A NAME="toc_dk46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;UNRESOLVED STAFF COMMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk46501_item_2._properties"> </A>
<A NAME="toc_dk46501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;PROPERTIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our significant leased properties are described below. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:64pt;"><FONT SIZE=1><B>Property Location

<!-- COMMAND=ADD_SCROPPEDRULE,64pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Approximate Square Feet </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Use </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Lease Expiration Date </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Needham, Massachusetts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Office Headquarters and Laboratory</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>April 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Fall River, Massachusetts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Manufacturing Facility</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>December 2017(1)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Phillipsburg, New Jersey</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Office and Laboratory</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August 2016(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>New Haven, Connecticut</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January 2013(3)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes two renewal options of five years each. Lease also includes provision for early termination in December 2015 upon prior notice of one year.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes one renewal option of five years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes one renewal option of three years.  </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk46501_item_3._legal_proceedings"> </A>
<A NAME="toc_dk46501_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material legal proceedings.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk46501_item_4._mine_safety_disclosures"> </A>
<A NAME="toc_dk46501_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=43,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1044268,FOLIO='39',FILE='DISK104:[12ZAA1.12ZAA46501]DK46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm46501_1_40"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="PartII"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm46501_part_ii"> </A>
<A NAME="toc_dm46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dm46501_item_5._market_for_registrant___ite04666"> </A>
<A NAME="toc_dm46501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock currently trades on the Nasdaq Global Market (NASDAQ) under the symbol "CLDX". The following table sets forth for the
periods indicated the high and low sale prices per share for our common stock, as reported by NASDAQ. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:46pt;"><FONT SIZE=1><B>Fiscal Period

<!-- COMMAND=ADD_SCROPPEDRULE,46pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2010</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2011</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of February&nbsp;29, 2012, there were approximately 562 shareholders of record of our common stock. On February&nbsp;29, 2012 the closing price of our common stock, as reported by
NASDAQ, was $3.79 per share. We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2011 regarding shares of our common stock that may be issued under
our existing equity compensation plans, including our 2008 Stock Option and Incentive Plan (the "2008 Plan") and our 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"). </FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="166pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon exercise<BR>
of outstanding options<BR>
and rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under equity<BR>
compensation plan<BR>
(excluding securities<BR>
referenced in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,459,034</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.08</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>997,493</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan, 2004 ESPP Plan, Celldex Research's 2005 Equity Incentive Plan and CuraGen's 2007 Stock Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not
be determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 ESPP Plan. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=44,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=983618,FOLIO='40',FILE='DISK104:[12ZAA1.12ZAA46501]DM46501A.;8',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dm46501_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm46501_celldex_theapeutics,_inc.,_nas__cel02591"> </A>
<A NAME="toc_dm46501_3"> </A>
<BR></FONT><FONT SIZE=2><B>  CELLDEX THEAPEUTICS,&nbsp;INC., NASDAQ MARKET INDEX&#151;U.S. AND<BR>  PEER GROUP INDICES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The graph below compares the cumulative total stockholder return on the common stock for the period from December&nbsp;31, 2006
through December&nbsp;31, 2011, with the cumulative return on (i)&nbsp;NASDAQ Market Index&#151;U.S. Companies and (ii)&nbsp;NASDAQ Pharmaceutical Index. The comparison assumes investment
of $100 on December&nbsp;31, 2006 in our common stock and in each of the indices and, in each case, assumes reinvestment of all dividends. The points on the graph are as of December&nbsp;31 of the
year indicated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g477545.jpg" ALT="GRAPHIC" WIDTH="546" HEIGHT="301">
  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2006 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Celldex Therapeutics,&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Stock Market (U.S.) Index</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>114</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Pharmaceutical Stock Index</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>128</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="dm46501_item_6._selected_financial_data"> </A>
<A NAME="toc_dm46501_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following selected consolidated financial data are derived from our financial statements. The consolidated statement of operations
data for the years ended December&nbsp;31, 2011, 2010 and 2009 and the consolidated balance sheet data as of December&nbsp;31, 2011 and 2010 have been derived from our audited consolidated
financial statements included elsewhere in this Annual Report on Form&nbsp;10-K. This data should be read in conjunction with our audited consolidated financial statements and related
notes which are included elsewhere in this Annual Report on Form&nbsp;10-K, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in
Item&nbsp;7 below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;1, 2009, our acquisition of CuraGen became effective. The CuraGen acquisition was accounted for using the acquisition method of accounting and was treated as our
acquisition of CuraGen. Accordingly, the financial information presented below for periods prior to October&nbsp;1, 2009 reflects the financial position and the results of operations of us alone,
and for periods from October&nbsp;1, 2009 forward the combined financial position and combined results of operations of us and CuraGen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;7, 2008, the AVANT merger became effective. The AVANT merger was accounted for using the purchase method of accounting and was treated as our acquisition of AVANT.
Accordingly, the financial information presented below for periods prior to March&nbsp;8, 2008 reflects the financial position and the results of operations of us alone, and for periods from
March&nbsp;8, 2008 forward the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=45,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=918605,FOLIO='41',FILE='DISK104:[12ZAA1.12ZAA46501]DM46501A.;8',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dm46501_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>combined
financial position and combined results of operations of us and AVANT. All amounts are in thousands except per share data. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED STATEMENTS OF OPERATIONS DATA  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>REVENUE:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,716</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>220</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>940</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,386</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,716</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,180</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,406</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OPERATING EXPENSE:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,892</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charge for In-Process Research and Development(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,521</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,464</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,022</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,664</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,030</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,914</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,508</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,259</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>435</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,796</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,337</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(156</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss Before Income Taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income Tax Benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and Diluted Net Loss Per Common Share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.08</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.81</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Used in Calculating Basic and Diluted Net Loss Per Common Share(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Weighted
average common shares outstanding for 2007 have been adjusted to reflect the AVANT merger and a reverse stock split of
1-for-12 effective March&nbsp;7, 2008.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2008 amount arose as a result of the merger between AVANT and us. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED BALANCE SHEET DATA  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working Capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,739</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,569</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,994</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>109,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140,364</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long Term Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,480</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,190</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,558</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>370</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(205,006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(160,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(157,674</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(121,149</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(73,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Stockholders' Equity (Deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,255</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>73,767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,132</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=46,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=425957,FOLIO='42',FILE='DISK104:[12ZAA1.12ZAA46501]DM46501A.;8',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do46501_1_43"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do46501_item_7._management_s_discussio__ite03668"> </A>
<A NAME="toc_do46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the
treatment of cancer and other difficult-to-treat diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III
(EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth.
EGFRvIII has been shown by polymerase chain reaction (PCR) analysis to be expressed in approximately 31% of glioblastoma (GB) tumors, also referred to as glioblastoma multiforme (GBM), the most common
and aggressive form of brain cancer. Based on results from three prior Phase&nbsp;2 trials, in December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3
study of rindopepimut in patients with surgically resected EGFRvIII-positive GB. In December 2011, we also initiated ReACT, a Phase&nbsp;2 study of rindopepimut in combination with
Avastin&reg; in patients with recurrent EGFRvIII-positive GB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
other lead drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human
monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a
variety of human cancers including breast cancer. In December 2011, we completed enrollment of EMERGE, a randomized Phase&nbsp;2b study of CDX-011 in patients with heavily
pre-treated, advanced,&nbsp;GPNMB-positive breast cancer and expect to present results at an appropriate scientific conference in the first half of 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1127
is a fully human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain
lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target
and eliminate cancerous cells in tumor bearing mice and to directly kill or inhibit the growth of CD27 expressing lymphomas and leukemias </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT
SIZE=2>. In November 2011, we initiated an open label, dose-escalating Phase&nbsp;1 study of CDX-1127 in patients with
selected malignant solid tumors or hematologic cancers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&#153; program, CDX-301, an immune cell mobilizing
agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally
our strategy is to develop and demonstrate proof-of-concept for our drug candidates before leveraging their value through partnerships or, in
appropriate situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a drug candidate generally involves bringing
it through Phase&nbsp;1 clinical trials and one or more Phase&nbsp;2 clinical trials so that we are able to demonstrate, based on human trials, good safety data for the drug candidate and some
data indicating its effectiveness. We thus leverage the value of our technology portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to
maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Our current collaborations include the commercialization
of an oral human rotavirus vaccine. We are exploring potential development and commercialization collaborations for
certain drug candidates such as CDX-011 and CDX-1127. Furthermore, while we plan to retain the rights to develop and commercialize rindopepimut in North America, we are
exploring potential partnership opportunities to commercialize rindopepimut outside of North America. Our drug candidates address market opportunities for which we believe current therapies are
inadequate or non-existent. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=606619,FOLIO='43',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are
using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other
diseases that modify undesirable activity by the body's own proteins or cells. A number of our immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of
clinical trials. We expect that a large percentage of our research and development expenses will be incurred in support of our current and future clinical trial programs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are material to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="158pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110<BR>
(rindopepimut)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Front-line Glioblastoma</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110<BR>
(rindopepimut)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Recurrent Glioblastoma</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-011<BR>
(glembatumumab vedotin)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic breast cancer and melanoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Lymphoma/leukemia and solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cancer, autoimmune disease and transplant</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PRECLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ovarian and renal cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>MARKETED PRODUCTS</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rotarix</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Rotavirus infection</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlaxoSmithKline</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Marketed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
expenditures that will be necessary to execute our business plan are subject to numerous uncertainties. Completion of clinical trials may take several years or more, and the length
of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate. It is not unusual for the clinical development of these types of product
candidates to each take five years or more, and for total development costs to exceed $100&nbsp;million for each product candidate. Our estimates that clinical trials of the type we generally
conduct are typically completed over the following timelines: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:51pt;"><FONT SIZE=1><B>Clinical Phase

<!-- COMMAND=ADD_SCROPPEDRULE,51pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated<BR>
Completion<BR>
Period </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;2 Years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;5 Years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;5 Years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among
others, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of patients that ultimately participate in the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the duration of patient follow-up that seems appropriate in view of results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of clinical sites included in the trials; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=214372,FOLIO='44',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the length of time required to enroll suitable patient subjects; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the efficacy and safety profile of the product candidate. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
test potential product candidates in numerous preclinical studies for safety, toxicology and immunogenicity. We may then conduct multiple clinical trials for each product candidate.
As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain product candidates in order to focus our resources on more promising product candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
element of our business strategy is to pursue the research and development of a broad portfolio of product candidates. This is intended to allow us to diversify the risks associated
with our research and development expenditures. As a result, we believe our future capital requirements and our future financial success are not substantially dependent on any one product candidate.
To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product candidates increases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
approval is required before we can market our product candidates as therapeutic or vaccine products. In order to proceed to subsequent clinical trial stages and to ultimately
achieve regulatory approval, the regulatory agency must conclude that our clinical data is safe and effective. Historically, the results from preclinical testing and early clinical trials (through
Phase&nbsp;2) have often not been predictive of results obtained in later clinical trials. A number of new drugs, biologics and vaccines have shown promising results in early clinical trials, but
subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
our business strategy includes the option of entering into collaborative arrangements with third parties to complete the development and commercialization of our product
candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under control of that third party
rather than us. We cannot forecast with any degree of certainty which proprietary products, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements
would affect our development plan or capital requirements. Our programs may also benefit from subsidies, grants, contracts or government or agency-sponsored studies that could reduce our development
costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the uncertainties discussed above, among others, it is difficult to accurately estimate the duration and completion costs of our research and development projects or when,
if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our
failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to
seek additional, external
sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize
the future success of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the past five years through December&nbsp;31, 2011, we incurred an aggregate of $118.8&nbsp;million in research and development expenses. The following table indicates the
amount incurred for each of our significant research programs and for other identified research and development activities during the years ended December&nbsp;31, 2011, 2010 and 2009. The amounts
disclosed in the following table </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=48378,FOLIO='45',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_46"> </A>


<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reflect
direct research and development costs, license fees associated with the underlying technology and an allocation of indirect research and development costs to each program. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rindopepimut</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,366</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,718</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,098</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,967</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,464</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,899</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,112</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,345</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,424</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>839</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>473</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Programs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,170</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,581</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total R&amp;D Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rindopepimut  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead clinical development program, rindopepimut, is a peptide-based immunotherapy that targets the tumor specific molecule called
EGFRvIII, a functional variant of the naturally EGFR, a protein which has been well validated as a target for cancer therapy. Unlike EGFR, EGFRvIII is not present in normal tissues and has been shown
to be a transforming oncogene that can directly contribute to cancer cell growth. EGFRvIII is commonly present in glioblastoma or GB, also commonly referred to as glioblastoma multiforme or GBM, the
most common and aggressive form of brain cancer. The rindopepimut vaccine is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin (KLH) and administered
together with the adjuvant GM-CSF. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation for rindopepimut for the
treatment of EGFRvIII expressing GB and the FDA has also granted Fast Track designation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2008, we and Pfizer&nbsp;Inc. (Pfizer) entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide license
to rindopepimut. The Pfizer Agreement provided for reimbursement by Pfizer of all costs incurred by us in connection with the collaboration since the effective date. In November 2010, the Pfizer
Agreement was terminated (the "Pfizer Termination") and all rights to rindopepimut were returned to us. Pfizer did not provide a reason for termination. Effective with the Pfizer Termination, Pfizer
is no longer funding the development of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;1 (VICTORI) and Phase&nbsp;2a (ACTIVATE) studies of EGFRvIII immunotherapy were led by collaborating investigators at the Brain Center at Duke Comprehensive Cancer
Center in Durham, North Carolina and at M.D. Anderson Cancer Center in Houston, Texas and enrolled 14 and 18 evaluable GB patients, respectively. An extension of the Phase&nbsp;2a study (ACT
II)&nbsp;at the same two institutions evaluated 22 additional GB patients treated in combination with maintenance temozolomide (TMZ) (the current standard of care). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
initiated a Phase&nbsp;2b/3 randomized study (ACT III)&nbsp;of rindopepimut combined with standard of care, TMZ, versus standard of care alone in patients with GB in over 30 sites
throughout the United States. In December 2008, we announced an amendment to convert the ACT III study to a single-arm Phase&nbsp;2 clinical trial in which all patients were to receive
rindopepimut in combination with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=647578,FOLIO='46',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>temozolomide.
The decision, which followed the recommendation of the Independent Data Monitoring Committee, was based on the observation that the majority of patients randomized to the control
(standard of care) arm withdrew from this open-label study after being randomized to the control arm. Patients participating in the control arm of the study were offered the option to
receive treatment with rindopepimut. Under this amendment, the ACT III study provided for a multi-center, non-randomized dataset for rindopepimut in patients with newly diagnosed GB. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2010, we announced complete data for the primary endpoint of the 65 patients enrolled to receive rindopepimut in combination with maintenance TMZ in the ACT III study. The
data showed that 43 of 65 patients (66%) were progression-free at 5.5&nbsp;months after entry into the study. Taking into account the 3 to 3.5&nbsp;months required to complete
pre-study chemoradiation and enter into the study, the 5.5&nbsp;month time point in ACT III corresponds to approximately 8.5&nbsp;months after diagnosis. The ACTIVATE and ACT II
trials, which were conducted in two leading centers, reported progression-free rates at 8.5&nbsp;months after diagnosis of 70% and 80%, respectively, and similar results were seen in the
ACT III trial, which enrolled patients in over 25 centers in the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the progression free survival (PFS) and overall survival (OS) rates from clinical trials of rindopepimut as compared to matched historical controls and the
standard of care (SOC). </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median PFS from<BR>
diagnosis (months) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median OS from<BR>
diagnosis (months) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS at 24&nbsp;months </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACT III (n=65)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACT II (n=22)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ACTIVATE (n=18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matched historical control (n=17)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Standard of care radiation/TMZ (n=287)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Change
in median PFS not statistically significant from ACTIVATE and ACT II.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Sampson,
et al. J. Clin. Oncol. 2010&nbsp;Nov 1, 28(31), 4722-9. Historical controls were treated at M.D. Anderson and matched for eligibility
(EGFRvIII-positive, karnofsky performance status (KPS) greater-than or equal to 80%, complete resection, radiation/ temozolomide (TMZ) and without progression through ~ 3&nbsp;months
post-diagnosis).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Stupp,
et al. N. Engl. J. Med. 2005, 352, 987-96. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Importantly,
rindopepimut showed a similar benefit in patients whether or not they expressed an active DNA repair gene (MGMT) that has been shown to limit the benefit from TMZ treatment.
In ACT III, the number of patients who were expected to be resistant to the TMZ chemotherapy appeared to do better with vaccination than the numbers observed in the historical data. Patients who have
an active DNA repair gene, MGMT (unmethylated), generally have a worse outcome, presumably because they do not gain much benefit from TMZ as reported in the literature. Patients with a methylated MGMT
promoter in their tumor do not express MGMT and have a more favorable outcome to TMZ treatment. Patients with methylated tumors (n=25) that were treated with the rindopepimut regimen experienced a
median PFS of 17.5&nbsp;months, which compares favorably with the published data from the SOC of radiation plus TMZ (R+TMZ) of 10.3&nbsp;months. Those with unmethylated tumors (n=40) treated with
the rindopepimut regimen experienced a PFS of 11.2&nbsp;months, which compared favorably to the PFS with SOC of 5.3&nbsp;months in this patient population. Thus, rindopepimut would appear to
benefit both methylated and unmethylated MGMT patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3 study of rindopepimut in patients with surgically resected, EGFRvIII-positive GB.
Patients will be randomized after the completion of surgery and standard chemoradiation. The treatment regime </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=757872,FOLIO='47',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>includes
a vaccine priming phase post-radiation followed by an adjuvant temozolomide phase and a vaccine maintenance therapy phase. Patients will be treated until disease progression or
intolerance to therapy. The primary objective of the study is to determine whether rindopepimut plus adjuvant GM-CSF improves the overall survival of patients with newly diagnosed
EGFRvIII-positive GB after Gross Total Resection (GTR) when compared to treatment with TMZ and a control injection of KLH. KLH is a component of rindopepimut and was selected due to its ability to
generate a similar injection site reaction to that observed with the rindopepimut vaccine. ACT IV will enroll up to 440 patients at over 150 centers worldwide to recruit approximately 374 patients
with GTR to be included in the primary analysis. Our targeted patient accrual is 24&nbsp;months and another 18 to 24&nbsp;months of follow-up. We expect it will cost over
$50&nbsp;million to complete this Phase&nbsp;3 study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we also initiated ReACT, a Phase&nbsp;2 study of rindopepimut in combination with Avastin&reg; in patients with recurrent EGFRvIII-positive GB. ReACT will
enroll approximately 95 patients in a first or second relapse of GB following receipt of standard therapy and will be conducted at approximately 20 sites across the United States. Approximately 70
patients who have yet to receive Avastin will be randomized to receive either rindopepimut and Avastin or a control injection of KLH and Avastin in a blinded fashion. Another 25 patients who are
refractory to Avastin having received Avastin in either the frontline or recurrent setting with subsequent progression will receive rindopepimut plus Avastin in a single treatment arm. We expect
preliminary data from this study to be available in mid-2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, researchers at Stanford University are conducting a pilot trial of rindopepimut in pediatric patients with pontine glioma in an investigator sponsored trial. Patient
screening is ongoing for this trial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Glembatumumab Vedotin (CDX-011)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully- human monoclonal antibody, CR011, linked
to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including
breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics,&nbsp;Inc. The ADC is designed to be stable
in the bloodstream. Following intravenous administration, CDX-011 targets and binds to&nbsp;GPNMB and upon internalization into the targeted cell, CDX-011 is designed to
release MMAE from CR011 to produce a cell-killing effect. The FDA has granted Fast Track designation to CDX-011 for the treatment of advanced,
refractory/resistant&nbsp;GPNMB-expressing breast cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Breast Cancer:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In June 2008, an open-label, multi-center Phase&nbsp;1/2 study was initiated of CDX-011
administered intravenously once every three weeks to patients with locally advanced or metastatic breast cancer who had received prior therapy (median of seven prior regimens). The study began with a
bridging phase to confirm the maximum tolerated dose (MTD) and then expanded into a Phase&nbsp;2 open-label, multi-center study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
study confirmed the safety of CDX-011 at the pre-defined maximum dose level (1.88 mg/kg) in 6 patients. An additional 28 patients were enrolled as an expanded
Phase&nbsp;2 cohort (for a total of 34 treated patients at 1.88 mg/kg, the Phase&nbsp;2 dose) to evaluate the PFS rate at 12&nbsp;weeks. As previously seen in melanoma patients, the 1.88 mg/kg
dose was well tolerated in this patient population with the most common adverse events of rash, alopecia, and fatigue. The primary activity endpoint, which called for at least 5 of 25 (20%) patients
in the Phase&nbsp;2 study portion to be progression-free at 12&nbsp;weeks, was met as 9 of 26 (35%) evaluable patients were progression-free at 12&nbsp;weeks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all patients treated at the maximum dose level, tumor shrinkage was seen in 62% (16/26) and median PFS was 9.1&nbsp;weeks. A subset of 10 patients had "triple negative disease," a
more aggressive breast cancer subtype that carries a high risk of relapse and reduced survival as well as limited </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=202514,FOLIO='48',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>therapeutic
options due to lack of over-expression of HER2/neu, estrogen and progesterone receptors. In these patients, 78% (7/9) had some tumor shrinkage, 12-week PFS rate was
70% (7/10), and median PFS was 17.9&nbsp;weeks. Tumor samples from a subset of patients across all dose groups were analyzed for&nbsp;GPNMB expression. The tumor samples from most patients showed
evidence of stromal and/or tumor cell expression of&nbsp;GPNMB. The most common treatment-related toxicities were fatigue, rash, nausea, alopecia (hair loss), neutropenia and vomiting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we completed enrollment of EMERGE, a randomized, multi-center Phase&nbsp;2b study of CDX-011 in patients with heavily pre-treated,
advanced,&nbsp;GPNMB-positive breast cancer. Patients were randomized (2:1) to receive either CDX-011 or single-agent "Investigator's Choice" chemotherapy. Patients randomized to receive
Investigator's Choice are allowed to cross-over to CDX-011 following disease progression. Activity endpoints include response rate (RR) and PFS. We expect that a significant
portion of the enrolled patients will have triple-negative disease, since&nbsp;GPNMB is frequently expressed in this patient population. We expect to present results at the 2012 American Society of
Clinical Oncology (ASCO) meeting in June 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2009, Formatech,&nbsp;Inc., a third party contract manufacturer ("Formatech") was engaged by us for the aseptic filling of one lot of our CDX-011 product candidate being
used in our ongoing Phase&nbsp;2b study. The CDX-011 lot from Formatech has passed all of the sterility testing performed during drug release and in subsequent stability studies. At the
end of January 2012, we were notified by the FDA that because significant Good Manufacturing Practice (GMP) violations were uncovered during inspection of Formatech, our Phase&nbsp;2b study for
CDX-011 was being placed on partial clinical hold. The FDA uncovered these findings during their inspections of the Formatech facility between August to October 2010 and July to August
2011. These inspections began approximately one year after the CDX-011 drug product was filled at Formatech.
Specifically, the FDA requested that no new patients be treated with CDX-011. However, patients already undergoing treatment with CDX-011 could continue treatment using vials
of CDX-011 from the lot filled by Formatech, after such patients were informed of the potential risk and reconsented to continued participation in the study. Since the Phase&nbsp;2b
trial completed accrual of patients in December 2011 and there are currently no other ongoing open studies with CDX-011, the only patients that are affected by the partial hold are in the
Investigator's Choice (control arm) of the study who currently are not receiving CDX-011 and may be eligible to cross over at the time of progression and receive CDX-011 under
the study protocol. Currently there are eight patients remaining on the control arm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have initiated discussions with the FDA regarding our proposal to utilize vials of CDX-011 that were filled by a different contract manufacturer. Although the FDA has
stated that no new patients may receive CDX-011 and that no patients may cross over to receive CDX-011, we have asked the FDA to reconsider allowing patients currently on the
control arm to cross over to CDX-011 after stability testing and confirmation that the product filled by the other contract manufacturer is acceptable for continued use. If the FDA agrees
to our proposal concerning use of the alternative CDX-011 for the eligible cross-over patients, we believe that we should have sufficient clinical supply of CDX-011
to treat these cross-over patients. If we are not able to treat the eight remaining cross-over patients with CDX-011, patients may withdraw from the control arm
study upon learning that they will not be allowed to cross over to CDX-011 following disease progression. However, the primary analyses for the study are entirely based upon the primary
randomization and do not include the cross over results. Based on our discussions with our clinical investigators, we do not believe that a high proportion of patients will withdraw from the control
arm prior to progression. We do not believe that this partial hold will significantly impact analysis of the Phase&nbsp;2b data for purposes of determining next steps in our future development of
CDX-011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the FDA has agreed in concept that we could reprocess the remaining available vials of CDX-011 manufactured at Formatech at another cGMP contract manufacturer.
The FDA's final decision regarding the acceptability of this reprocessing will be made upon review of data concerning </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=53,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=304770,FOLIO='49',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
stability and sterility of the reprocessed vials of CDX-011. If we are unsuccessful at reprocessing the available drug product or if FDA does not approve the use of these reprocessed
vials, we will need to manufacture new drug product for subsequent clinical studies for CDX-011, which may cause a delay in the initiation of a subsequent trial with CDX-011. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Metastatic Melanoma:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2009, we completed enrollment of 117 patients in a Phase&nbsp;1/2 open-label, multi-center, dose
escalation study to evaluate the safety, tolerability and pharmacokinetics of CDX-011 for patients with un-resectable Stage&nbsp;III or Stage&nbsp;IV melanoma who had
failed no more than one prior line of cytotoxic therapy. The MTD was determined to be 1.88 mg/kg administered intravenously (IV)&nbsp;once every three weeks. The study achieved its primary activity
objective with an ORR in the Phase&nbsp;2 cohort of 15% (5/34). Median PFS was 3.9&nbsp;months. CDX-011 was generally well tolerated, with the most frequent treatment-related adverse
events being rash, fatigue, alopecia (hair loss), pruritus, diarrhea and neuropathy. In the subset of patients with tumor biopsies, high levels of tumor expression of&nbsp;GPNMB appeared to
correlate with favorable outcome. In the seven patients whose tumors were found to express high amounts of&nbsp;GPNMB, and who were treated at the maximum tolerated doses across all dosing
schedules, median PFS was 4.9&nbsp;months. The development of rash, which may be associated with the presence of&nbsp;GPNMB in the skin also seemed to correlate with greater PFS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to initially focus our resources on advancing CDX-011 in breast cancer while pursuing further development of CDX-011 in melanoma through collaborations
and investigator sponsored studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1127  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1127 is a human monoclonal antibody that targets CD27, a member of the tumor necrosis factor (TNF) receptor
superfamily. We have entered into license agreements with the University of Southampton, UK for intellectual property related to uses of anti-CD27 antibodies and with Medarex for access to
the UltiMab technology to develop and commercialize human antibodies to CD27. CD27 acts downstream from CD40 and may provide a novel way to regulate the immune responses. CD27 is a
co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential
therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target and eliminate cancerous cells in tumor bearing mice and to directly kill or inhibit the growth of
CD27 expressing lymphomas and leukemias </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>. Both mechanisms have been seen even at low
doses in appropriate preclinical models. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2011, we initiated an open label, dose-escalating Phase&nbsp;1 study of CDX-1127 in patients with selected malignant solid tumors or hematologic
cancers at multiple clinical sites in the United States. The Phase&nbsp;1 study is designed to test five escalating doses of CDX-1127 to determine a Phase&nbsp;2 dose for further
development based on safety, tolerability, potential activity and immunogenicity. The study will accrue approximately 30 patients in each of the two arms, either selected refractory/relapsed solid
tumors or lymphomas/leukemias known to express CD27. Patients will have received all appropriate prior therapies for their specific disease. The trial design incorporates both single dosing and
multiple dosing regimens at each dose level. We expect to complete enrollment in this study by the end of 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401, developed from our APC Targeting Technology, is a fusion protein consisting of a fully human monoclonal antibody
with specificity for the dendritic cell receptor, DEC-205, linked to the NY-ESO-1 tumor antigen. In humans, NY-ESO-1 has been detected in
20&nbsp;&#150;&nbsp;30% of all melanoma, lung, esophageal, liver, gastric, prostate, ovarian and bladder cancers, thus representing a broad opportunity. This product is intended to
selectively deliver the NY-ESO-1 antigen to dendritic cells for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=54,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=756614,FOLIO='50',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<A NAME="page_do46501_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>generating
robust immune responses against cancer cells expressing NY-ESO-1. We are developing CDX-1401 for the treatment of malignant melanoma and a variety of
solid tumors which express the proprietary cancer antigen NY-ESO-1, which we licensed from the Ludwig Institute for Cancer Research in 2006. Preclinical studies have shown that
CDX-1401 is effective for activation of human T&nbsp;cell responses against NY-ESO-1. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2009, we initiated enrollment in a dose-escalating, multi-center, Phase&nbsp;1/2 study aimed at determining the optimal dose for further development based on
the safety, tolerability, and immunogenicity of the CDX-1401 vaccine. The trial will evaluate three different doses of the vaccine in combination with TLR agonists poly-ICLC or
Hiltonol&#153; and/or R848 or resiquimod. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2010, we announced interim data for the first 20 patients enrolled in the study, 35% of whom had confirmed NY-ESO-1 expression. The interim data showed
that six patients maintained stable disease and were eligible for multiple cycles of the treatment regimen, including 4 patients who have received 3 or more cycles (6&nbsp;weeks of treatment
followed by a 6&nbsp;week rest), with stable disease of up to 11.5+ months. The treatment was well tolerated and there were no dose-limiting toxicities. Robust
anti-NY-ESO-1 immunity was induced with the majority of the patients developing anti-NY-ESO-1 antibody responses and 39% of the
patients having increases in NY-ESO-1 specific T&nbsp;cell responses, including both CD4 and CD8 responses. Importantly, the T cell responses were directed against multiple
regions of the NY-ESO-1 antigen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2012, we completed enrollment in the Phase&nbsp;1 portion of the study and expect to report data at an appropriate scientific conference in the second half of 2012. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301 is a FMS-like tyrosine kinase 3 ligand (Flt3L) stem cell mobilizer and dendritic cell growth factor. We
licensed CDX-301 from Amgen in March 2009. CDX-301 is a potent hematopoietic cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem
cells. CDX-301 has demonstrated a unique capacity to increase the number of circulating dendritic cells in both laboratory and clinical studies. In addition, CDX-301 has shown
impressive results in models of cancer, infectious diseases and inflammatory/autoimmune diseases. We believe CDX-301 may hold significant opportunity for synergistic development in
combination with other proprietary molecules in our portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2012, we initiated a dose-escalating Phase&nbsp;1 study of CDX-301 in approximately 30 healthy subjects in collaboration with Rockefeller University.
The Phase&nbsp;1 study will evaluate seven different dosing regimens of CDX-301 to determine the appropriate dose for further development based on safety, tolerability, and biological
activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Preclinical Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1135  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135 is a molecule that inhibits a part of the human immune system called the complement system. The complement system
is a series of proteins that are important initiators of the body's acute inflammatory response against disease, infection and injury. Excessive complement activation also plays a role in some
persistent inflammatory conditions. CDX-1135 is a soluble form of naturally occurring Complement Receptor 1 that has been shown to inhibit the activation of the complement cascade in
animal models and in human clinical trials. In preclinical studies, CDX-1135 has been shown to inhibit both the classical and alternative pathways of complement activation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=55,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=441533,FOLIO='51',FILE='DISK104:[12ZAA1.12ZAA46501]DO46501A.;9',USER='LPALLES',CD=';5-MAR-2012;16:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq46501_1_52"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dense Deposit Disease (DDD) is a rare and devastating disease that is caused by uncontrolled activation of the alternative pathway of complement and leads to
progressive kidney damage in children. There is currently no treatment for patients with DDD and about half progress to end-stage renal disease within 10&nbsp;years. Because DDD recurs
in virtually all patients who receive a kidney transplant, transplantation is not a viable option for these patients. In animal models of DDD, CDX-1135 treatment showed evidence of
reversal of kidney damage. We believe that regulating the complement system could have therapeutic and prophylactic applications in DDD and several other acute and chronic conditions, including organ
transplantation, multiple sclerosis, rheumatoid arthritis, age-related macular degeneration (AMD), atypical Hemolytic Uremic Syndrome (aHUS), Paroxysmal Nocturnal Hemaglobinuria (PNH), and
myasthenia gravis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135
is currently being studied in DDD under an investigator sponsored IND and initial experience indicates that CDX-1135 limits complement abnormalities. In
2011, we completed process development activities and manufactured GMP clinical drug product. Based on discussion to date with the FDA, we are currently planning to initiate a Phase&nbsp;2 pilot
study of CDX-1135 in a small number of DDD patients to determine the appropriate dose and regimen for further clinical development based on safety, tolerability and biological activity in
2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 is a fully-human monoclonal ADC that targets TIM-1, a molecule that is highly expressed on renal and
ovarian cancers with minimal expression in normal tissues. The antibody, CDX-014, is linked to a potent chemotherapeutic, monomethyl auristatin E (MMAE), using Seattle Genetics'
proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells, resulting in a targeted
cell-killing effect. CDX-014 has shown potent activity in preclinical models of ovarian and renal cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Marketed Products  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rotavirus Vaccine  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rotavirus is a major cause of diarrhea and vomiting in infants and children. In 1997, we licensed our oral rotavirus strain to Glaxo
and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. Glaxo gained approval for its rotavirus vaccine, Rotarix, in Mexico in July 2004, which
represented the first in a series of worldwide approvals and commercial launches for the product leading up to the approval in Europe in 2006 and in the U.S. in 2008. We licensed-in our
rotavirus strain in 1995 and owe a license fee of 30% to Cincinnati Children's Hospital Medical Center (CCH) on net royalties received from Glaxo. We are obligated to maintain a license with CCH with
respect to the Glaxo agreement. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon
90&nbsp;days prior written notice. The last relevant patent is scheduled to expire in December 2012. No additional milestone payments are due from Glaxo under the agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2005, we entered into an agreement whereby an affiliate of PRF purchased a 70% interest in the milestone payments and net royalties that we will receive on the development and
worldwide sales of Rotarix. We have received a total of $60&nbsp;million in milestone payments under the PRF agreement. No additional milestone payments are due from PRF under the agreement. The PRF
agreement terminates in December 2012, unless otherwise extended. We would retain approximately 65% of the royalties on worldwide sales of Rotarix if PRF receives 2.45 times the aggregate cash
payments of $60&nbsp;million it made to us prior to December 2012. We do not expect this to occur. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=56,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=611301,FOLIO='52',FILE='DISK104:[12ZAA1.12ZAA46501]DQ46501A.;9',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dq46501_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> CRITICAL ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our significant accounting policies are described in Note&nbsp;2 to the consolidated financial statements included in Item&nbsp;8
of this Form&nbsp;10-K. We believe our most critical accounting policies include accounting for business combinations, revenue recognition, impairment of long-lived assets,
research and development expenses and stock-based compensation expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results we report in our consolidated financial statements.
We evaluate our estimates and judgments on an on-going basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances.
Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what
we anticipate and different assumptions or estimates about the future could materially change our reported results. We believe the following accounting policies are the most critical to us in that
they are important to the portrayal of our financial statements and they require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Business Combinations  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We account for business combinations under the acquisition method of accounting. We record the fair value of the consideration
transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the
fair value of assets, including intangible assets such as IPR&amp;D, using a variety of methods including present-value models. Each asset is measured at fair value from the perspective of a market
participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset,
including a market participant's assumptions regarding the probability of completing IPR&amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a
market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D projects; a market participant's estimates of future cash
flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D
assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are maintained on our
consolidated balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is
amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related
intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs. IPR&amp;D assets are tested for impairment on an annual basis during the
third quarter, or earlier if impairment indicators are present. We performed an annual impairment test of the IPR&amp;D assets as of July&nbsp;1, 2011 and concluded that the IPR&amp;D assets were not
impaired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a
straight-line basis over their estimated useful life. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is recorded to goodwill. Goodwill is evaluated for
impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. We performed an annual impairment test of the goodwill asset as of July&nbsp;1, 2011 and
concluded that the goodwill asset was not impaired. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=57,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=959999,FOLIO='53',FILE='DISK104:[12ZAA1.12ZAA46501]DQ46501A.;9',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dq46501_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Revenue Recognition  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred
or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug
products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for
research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the
deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, we allocate revenue to the various elements based on their
fair value. The fair value of a revenue generating element can be based on current selling prices offered by us or another party for current products or the our best estimate of a selling price for
future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of
the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of our involvement in achieving the milestones and whether the amount of the payment is
commensurate to our performance. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is
recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or our contractual partner. Payments received in advance that are
related to future performance are deferred and recognized as revenue when the research projects are performed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize our licensed technologies and are recognized when the
amount of and basis for such royalty payments are reported to us in accurate and appropriate form and in accordance with the related license agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Impairment of Long-Lived Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We evaluate the recoverability of our long-lived assets, including property and equipment, and intangible assets when
circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and
its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated
fair values. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development
expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other studies, personnel costs, depreciation, license fees and funding of outside research. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trial expenses include expenses associated with clinical research organizations (CRO). The invoicing from CROs for services rendered can lag several months. We accrue the cost
of services rendered in connection with CRO activities based on our estimate of site management, monitoring </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=58,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=868634,FOLIO='54',FILE='DISK104:[12ZAA1.12ZAA46501]DQ46501A.;9',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_dq46501_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>costs,
and project management costs. We maintain regular communication with our CROs to gauge the reasonableness of our estimates. Differences between actual clinical trial expenses and estimated
clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Stock-Based Compensation Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We record stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair
values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and
directors is recognized using the straight-line method over the term of vesting or performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
record stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the
vesting term resulting in periodic adjustments to stock-based compensation expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> RESULTS OF OPERATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Year Ended December&nbsp;31, 2011 compared with Year Ended December&nbsp;31, 2010  </I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
$ </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,187</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(40,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,733</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(37,528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expense:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gain on Sale of Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,428</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,913</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,664</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(43,399</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,944</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>572</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,863</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,337</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,266</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,669</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> Net Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $42.3&nbsp;million increase in net loss for the year ended December&nbsp;31, 2011 compared to the year ended
December&nbsp;31, 2010 was primarily the result of a decrease in product development and licensing agreement revenue. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=59,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=512007,FOLIO='55',FILE='DISK104:[12ZAA1.12ZAA46501]DQ46501A.;9',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds46501_1_56"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Revenue  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $40.1&nbsp;million decrease in product development and licensing agreement revenue for the year ended December&nbsp;31, 2011
compared to the year ended December&nbsp;31, 2010 was primarily due to the termination of the Pfizer Agreement which resulted in us recognizing the remaining deferred revenue of $35.6&nbsp;million
during the year ended December&nbsp;31, 2010. The $0.2&nbsp;million decrease in contracts and grants revenue for the year ended December&nbsp;31, 2011 compared to the year ended
December&nbsp;31, 2010 was due to a decrease in revenue related to our vaccine development work on Rockefeller's DCVax-001 (CDX-2401) program. The $2.7&nbsp;million
increase in product royalty revenue for the year ended December&nbsp;31, 2011 compared to the year ended December&nbsp;31, 2010 was related to our retained interests in Rotarix net royalties which
were not sold to PRF and which is equal to the amount payable to CCH and recognized in royalty expense by us. We expect that royalty revenue related to the Glaxo agreement will end during the year
ended December&nbsp;31, 2013 as the term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement and the last relevant patent is scheduled to
expire in December 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Research and Development Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of (i)&nbsp;personnel expenses, (ii)&nbsp;laboratory supply expenses relating
to the development of our technology, (iii)&nbsp;facility expenses, and (iv)&nbsp;product development expenses associated with our drug candidates as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
$ </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>511</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Supplies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,920</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,674</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,044</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personnel
expenses primarily include salary, benefits, stock-based compensation and payroll taxes. The $0.5&nbsp;million increase in personnel expenses for the year ended
December&nbsp;31, 2011 compared to the year ended December&nbsp;31, 2010 was due to higher headcount. We expect personnel expenses to increase over the next twelve months as we plan to continue to
increase our headcount, primarily in clinical research personnel, to support our Phase&nbsp;3 study of rindopepimut. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Laboratory
supply expenses include laboratory materials and supplies, services, and other related expenses incurred in the development of our technology. The $0.1&nbsp;million increase
in laboratory supply expenses for the year ended December&nbsp;31, 2011 compared to the year ended December&nbsp;31, 2010 was primarily due to the renovations completed during the year ended
December&nbsp;31, 2010 at our Fall River, MA manufacturing facility during which manufacturing activities ceased. We expect supply expenses to increase over the next twelve months as a result of
increased research and development activities, although there may be fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facility
expenses include depreciation, amortization, utilities, rent, maintenance, and other related expenses incurred at our facilities. The $0.3&nbsp;million decrease in facility
expenses for the year ended December&nbsp;31, 2011 compared to the year ended December&nbsp;31, 2010 was primarily due to lower depreciation and amortization expenses. We expect facility expenses
to remain relatively consistent over the next twelve months, although there may be fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product
manufacturing. The $4.2&nbsp;million increase in product development expenses for the year ended December&nbsp;31, 2011 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=829762,FOLIO='56',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compared
to the year ended December&nbsp;31, 2010 was primarily due to an increase in clinical trial costs of $4.6&nbsp;million primarily due to our rindopepimut and CDX-011 programs.
We expect product development expenses to increase over the next twelve months primarily due to the increase in clinical trial expenses related to rindopepimut, although there may be fluctuations on a
quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Royalty Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty expenses include product royalty and sublicense royalty fees on our out-licensed programs. The $3.0&nbsp;million
decrease in royalty expenses for the year ended December&nbsp;31, 2011 compared to the year ended December&nbsp;31, 2010 was primarily due to the
termination of the Pfizer Agreement which resulted in us recognizing the remaining deferred sublicense fees of $5.1&nbsp;million, partially offset by an increase in Rotarix related royalty fees. Our
retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. We
expect royalty expense related to the Glaxo agreement will end during the year ended December&nbsp;31, 2013 as the term of the Glaxo agreement is through the expiration of the last of the relevant
patents covered by the agreement and the last relevant patent is scheduled to expire in December 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> General and Administrative Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $1.2&nbsp;million decrease in general and administrative expenses for the year ended December&nbsp;31, 2011 compared to the
year ended December&nbsp;31, 2010 was primarily due a decrease in legal, patent and other professional services. We expect general and administrative expense to remain relatively consistent over the
next twelve months, although there may be fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Amortization Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $1.2&nbsp;million decrease in amortization expenses for the year ended December&nbsp;31, 2011 compared to the year ended
December&nbsp;31, 2010 was primarily due to the TopoTarget intangible asset becoming fully amortized during the year ended December&nbsp;31, 2011. We recorded amortization expense related to the
TopoTarget Agreement of $0.3&nbsp;million and $1.7&nbsp;million for the years ended December&nbsp;31, 2011 and 2010, respectively. We expect amortization expense of acquired intangible assets to
decrease over the next twelve months as a result of intangible assets becoming fully amortized during 2011. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Investment and Other Income, Net  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $4.9&nbsp;million decrease in investment and other income, net for the year ended December&nbsp;31, 2011 compared to the year
ended December&nbsp;31, 2010 was primarily due to $3.0&nbsp;million received in connection with the TopoTarget Agreement and $1.7&nbsp;million received related to the IRS Qualifying Therapeutic
Discovery Grants during the year ended December&nbsp;31, 2010. We anticipate investment income to increase over the next twelve months due to higher cash and investment balances resulting from
fundraising efforts in January and February 2012. In January 2012, we sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&nbsp;million in net proceeds. In February 2012,
we issued 10,500,000 shares of our common stock in an underwritten
public offering. The net proceeds to us were $37.7&nbsp;million, after deducting underwriting fees and estimated offering expenses. We have granted the underwriters a 30-day option to
purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Interest Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.5&nbsp;million increase in interest expense for the year ended December&nbsp;31, 2011 compared to the year ended
December&nbsp;31, 2010 was primarily due to our Term Loan. On December&nbsp;30, 2010, we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=343963,FOLIO='57',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>entered
into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial,&nbsp;LLC (MidCap) pursuant to which we borrowed $10&nbsp;million (the "Term Loan") from MidCap. In March
2011, we amended the Loan Agreement and borrowed an additional $5&nbsp;million from General Electric Capital Corporation (GECC) (collectively with MidCap, the "Lenders") to increase the amount owed
under the Term Loan to $15&nbsp;million. The Term Loan accrues interest at a fixed annual interest rate equal to the greater of (i)&nbsp;the sum of (A)&nbsp;the LIBOR Rate (as defined in the
Loan Agreement) plus (B)&nbsp;6.25%; or (ii)&nbsp;a minimum rate of 9.50%. We anticipate interest expense to remain relatively consistent over the next twelve months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Year Ended December&nbsp;31, 2010 compared with Year Ended December&nbsp;31, 2009  </I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
$ </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,187</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,662</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>610</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,716</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expense:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,397</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,680</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gain on Sale of Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(604</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>554</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,428</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,691</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>231</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(30,395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,337</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(452</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>196</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss Before Income Taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(37,054</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(34,521</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income Tax Benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>529</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(529</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(33,992</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> Net Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $34.0&nbsp;million decrease in net loss for the year ended December&nbsp;31, 2010 compared to the year ended
December&nbsp;31, 2009 was primarily the result of an increase in product development and licensing agreement revenue and other income and a decrease in general and administrative expense. This
impact was partially offset by a decrease in contracts and grants and product royalty revenue and increased research and development, royalty and amortization expense on acquired intangible assets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Revenue  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $34.5&nbsp;million increase in product development and licensing agreement revenue for the year ended December&nbsp;31, 2010
was primarily due to the Pfizer Termination which resulted in us recognizing the remaining deferred revenue of $35.6&nbsp;million related to the Pfizer Agreement. The $1.6&nbsp;million decrease in
contracts and grants revenue for the year ended December&nbsp;31, 2010 was due to a decrease in revenue related to our vaccine development work on Rockefeller's DCVax-001
(CDX-2401) program. The $1.3&nbsp;million decrease in product royalty revenue for the year ended December&nbsp;31, 2010 was </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=62,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=329655,FOLIO='58',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>related
to our retained interests in Rotarix net royalties which were not sold to PRF and which is equal to the amount payable to CCH and recognized in royalty expense by us. In late March 2010, the
FDA temporarily suspended the use of Rotarix in the United States as a precautionary measure following the discovery of PCV-1 DNA material in the vaccine. In May 2010, the FDA determined
that healthcare practitioners could resume the use of Rotarix. Our royalties from sales of Rotarix were negatively impacted during the year ended December&nbsp;31, 2010 by the FDA's decision to
temporarily suspend the use of Rotarix from March 2010 through May 2010 and that negative impact from the temporary suspension may extend into the future as well. However, our net loss and cash
position were not impacted even though our royalty revenue was impacted because there was an offsetting impact on our royalty expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Research and Development Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of (i)&nbsp;personnel expenses, (ii)&nbsp;laboratory supply expenses relating
to the development of our technology, (iii)&nbsp;facility expenses, and (iv)&nbsp;product development expenses associated with our drug candidates as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
$ </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease)<BR>
% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,096</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Supplies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,782</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,758</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personnel
expenses primarily include salary, benefits, stock-based compensation and payroll taxes. The $1.1&nbsp;million increase in personnel expenses for the year ended
December&nbsp;31, 2010 was due to higher headcount, partially offset by $0.9&nbsp;million in severance expense during the year ended December&nbsp;31, 2009 related to the CuraGen acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Laboratory
supply expenses include laboratory materials and supplies, services, and other related expenses incurred in the development of our technology. The $0.7&nbsp;million decrease
in laboratory supply expenses was primarily due to the renovations completed during the year ended December&nbsp;31, 2010 at our Fall River, MA manufacturing facility during which manufacturing
activities ceased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facility
expenses include depreciation, amortization, utilities, rent, maintenance, and other related expenses incurred at our facilities. The $0.2&nbsp;million increase in facility
expenses for the year ended December&nbsp;31, 2010 was primarily due to higher depreciation and amortization expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product
manufacturing. The $0.1&nbsp;million increase in product development expenses for the year ended December&nbsp;31, 2010 was primarily due to an increase in product development costs related to our
CDX-011 program. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Royalty Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty expenses include product royalty and sublicense royalty fees on our out-licensed programs. The $3.7&nbsp;million
increase in royalty expenses for the year ended December&nbsp;31, 2010 was primarily due to the Pfizer Termination which resulted in us recognizing the remaining deferred sublicense fees related to
the Pfizer Agreement of $5.1&nbsp;million, partially offset by a decrease in Rotarix related royalty fees. Our retained interests in Rotarix net royalties which were not sold to PRF are recorded as
product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=63,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=942527,FOLIO='59',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> General and Administrative Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $6.7&nbsp;million decrease in general and administrative expenses for the year ended December&nbsp;31, 2010 was primarily due
to $3.3&nbsp;million in severance expense incurred during the year ended December&nbsp;31, 2009 related to the CuraGen acquisition and a decrease of $2.1&nbsp;million in consultant and legal
expense primarily related to costs incurred in connection with the CuraGen acquisition in 2009. The decrease was also a result of $0.7&nbsp;million in severance expense, including related
non-cash stock-based compensation expense, incurred during the year ended December&nbsp;31, 2009 related to our former SVP, Business Development. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Amortization Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $2.2&nbsp;million increase in amortization expenses for the year ended December&nbsp;31, 2010 was primarily due to intangible
assets acquired in connection with the CuraGen acquisition including the TopoTarget Agreement. In February 2010, TopoTarget entered into a co-development and commercialization agreement
for Belinostat with Spectrum Pharmaceuticals,&nbsp;Inc. which resulted in our receipt of $3.0&nbsp;million which we recorded as Other Income for the year ended December&nbsp;31, 2010. We
recorded amortization expense related to the TopoTarget Agreement of $1.7&nbsp;million for the year ended December&nbsp;31, 2010. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Investment and Other Income, Net  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $5.0&nbsp;million increase in investment and other income, net for the year ended December&nbsp;31, 2010 was primarily due to
$3.0&nbsp;million received in connection with the TopoTarget Agreement and $1.7&nbsp;million in other income related to the receipt of IRS Qualifying Therapeutic Discovery Grants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Interest Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.9&nbsp;million increase in interest expense for the year ended December&nbsp;31, 2010 was primarily due to the CuraGen Debt
we assumed in connection with the CuraGen acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Income Tax Benefit  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.5&nbsp;million decrease in income tax benefit for the year ended December&nbsp;31, 2010 was due to non-cash tax
consequences as a result of the CuraGen acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> LIQUIDITY AND CAPITAL RESOURCES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2011, our principal sources of liquidity consisted of cash, cash equivalents and marketable securities of
$53.3&nbsp;million. Our working capital at December&nbsp;31, 2011 was $40.4&nbsp;million. At December&nbsp;31, 2011, our Term Loan balance was $15.1&nbsp;million. We incurred a loss of
$44.8&nbsp;million for the year ended December&nbsp;31, 2011. Net cash used in operations for the year ended December&nbsp;31, 2011 was $35.7&nbsp;million. In January 2012, we sold 2,450,000
shares of common stock under the Cantor Agreement and raised $8.5&nbsp;million in net proceeds. In February 2012, we issued 10,500,000 shares of our common stock in an underwritten public offering.
The net proceeds to us were $37.7&nbsp;million, after deducting underwriting fees and estimated offering expenses. We have granted the underwriters a 30-day option to purchase up to an
aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. We believe that the cash, cash equivalents and marketable securities at December&nbsp;31, 2011, the
$8.5&nbsp;million raised under the Cantor Agreement in January 2012, the $37.7&nbsp;million raised in the underwritten offering in February and interest income on invested funds, are sufficient to
meet estimated working capital requirements and fund planned operations for at least the next twelve months. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=64,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=904699,FOLIO='60',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
cash equivalents are highly liquid investments with a maturity of three months or less at the date of purchase and consist primarily of investments in money market mutual funds with
commercial banks and financial institutions. We maintain cash balances with financial institutions in excess of insured limits. We do not anticipate any losses with respect to such cash balances. We
invest our excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds that meet high credit
quality standards, as specified in our investment policy. Our investment policy seeks to manage these assets to achieve our goals of preserving principal and maintaining adequate liquidity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
use of our cash flows for operations has primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices, laboratories and
manufacturing facility, fees paid in connection with preclinical studies, clinical studies, contract manufacturing, laboratory supplies and services, consulting, legal and other professional fees. To
date, the primary sources of cash flows from operations have been payments received from our collaborative partners and from government entities. The timing of any new collaboration agreements,
government contracts or grants and any payments under these agreements, contracts or grants cannot be easily predicted and may vary significantly from quarter to quarter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
raised net proceeds of $35.9&nbsp;million during the year ended December&nbsp;31, 2011 and $46.2&nbsp;million during the two months ended February&nbsp;29, 2012 from the sale
of our common stock. During the next twelve months, we may take further steps to raise additional capital to fund our long-term liquidity needs. Our capital raising activities may include,
but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the
issuance of common stock or other securities via private placements or public offerings. While we may continue to seek capital through a number of means, there can be no assurance that additional
financing will be available on acceptable terms, if at all, and our negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that we will
be able to enter into further collaborative relationships. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment
obligations and covenants that restrict our ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce our economic potential from
products under development. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of one or more
programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at
all, or sell all or part of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Operating Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities was $35.7&nbsp;million for the year ended December&nbsp;31, 2011 compared to
$30.4&nbsp;million for the year ended December&nbsp;31, 2010. The increase in net cash used in operating activities was primarily due to changes in working capital and decreases during the year
ended December&nbsp;31, 2011 in other income and the related amortization of intangible assets resulting from the $3.0&nbsp;million received in connection with the TopoTarget Agreement during the
year ended December&nbsp;31, 2010. We expect that cash used in operating activities will increase over the next twelve months primarily related to costs incurred on our rindopepimut program. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have incurred and will continue to incur significant costs in the area of research and development, including preclinical and clinical trials, as our drug candidates are developed. We
plan to spend significant amounts to progress our current drug candidates through the clinical trial and commercialization process as well as to develop additional drug candidates. As our drug
candidates progress through the clinical trial process, we may be obligated to make significant milestone payments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=65,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1005084,FOLIO='61',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Investing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities was $2.2&nbsp;million for the year ended December&nbsp;31, 2011 compared to
$16.2&nbsp;million for the year ended December&nbsp;31, 2010. The decrease in net cash used in investing activities was primarily due to net purchases of marketable securities for the year ended
December&nbsp;31, 2011 of $1.7&nbsp;million as compared to $14.1&nbsp;million for the year ended December&nbsp;31, 2010. We expect that cash provided by investing activities will increase over
the next twelve months as we fund our operations through the net proceeds from the sale and maturity of marketable securities, cash provided by financing activities and/or new partnerships. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Financing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $28.4&nbsp;million for the year ended December&nbsp;31, 2011 compared to
$10.8&nbsp;million for the year ended December&nbsp;31, 2010. The increase in net cash provided by financing activities was primarily due to the $35.9&nbsp;million in net proceeds we received
through the sale of 11,500,000 shares of our common stock in an underwritten public offering in May 2011 and the sale of 575,000 shares of common stock under the Cantor Agreement during the year ended
December&nbsp;31, 2011. In February 2011, we paid $12.5&nbsp;million to satisfy all outstanding principal related to the CuraGen Debt. In March 2011, we amended the Loan Agreement and borrowed an
additional $5&nbsp;million from GECC to increase the amount owed under the Term Loan to $15&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Equity Offerings  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2010, we filed a shelf registration statement with the Securities and Exchange Commission to register for sale any combination
of the types of securities described in the shelf registration statement up to a dollar amount of $150&nbsp;million. The shelf registration became effective on April&nbsp;22, 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
January&nbsp;6, 2011, we entered into a controlled equity offering sales agreement (the "Cantor Agreement") with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. (Cantor) pursuant to which we
may issue and sell up to 5,000,000 shares of our common stock from time to time through Cantor, acting as agent. We agreed to pay Cantor a commission of up to 5% of the gross proceeds from each sale
and to reimburse Cantor for certain expenses incurred in connection with entering into the Cantor Agreement. The Cantor Agreement terminates upon the sale of all 5,000,000 shares or upon ten day
notice by either Cantor or us. During the year ended December&nbsp;31, 2011, we sold 575,000 shares of common stock under the Cantor Agreement and raised $2.2&nbsp;million in net proceeds, after
deducting commission and offering expenses. In January 2012, we sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&nbsp;million in net proceeds. Under the terms of the
Cantor Agreement, we will have the ability to sell up to 1,975,000 shares of our common stock upon the expiration or earlier waiver of our 90-day lock-up with the underwriters
of our recent offering in February 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2011, we issued 11,500,000 shares of our common stock in an underwritten public offering, including the underwriter's exercise of their full over-allotment option to
purchase an additional 1,500,000 shares of common stock. The net proceeds to us were $33.7&nbsp;million, after deducting underwriting fees and offering expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2012, we issued 10,500,000 shares of our common stock in an underwritten public offering. The net proceeds to us were $37.7&nbsp;million, after deducting underwriting fees
and estimated offering expenses. We have granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if
any. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=66,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1047203,FOLIO='62',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Term Loan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;30, 2010, we entered the Loan Agreement with MidCap pursuant to which we borrowed $10&nbsp;million from MidCap. In
March 2011, we amended the Loan Agreement and borrowed an additional $5&nbsp;million from GECC to increase the amount owed under the Term Loan to $15&nbsp;million. No additional advances are
available under the Loan Agreement. The Term Loan accrues interest at a fixed annual interest rate equal to the greater of (i)&nbsp;the sum of (A)&nbsp;the LIBOR Rate (as defined in the Loan
Agreement) plus (B)&nbsp;6.25%; or (ii)&nbsp;a minimum rate of 9.50%. In September 2011, we exercised an option to extend the interest-only period by 6&nbsp;months from
October&nbsp;1, 2011 to April&nbsp;1, 2012. In March 2012, we amended the Loan Agreement to extend the maturity date from December 2013 to December 2014 in return for an upfront fee of $25,000 and
an additional fee of $37,500 due upon repayment of the Term Loan in full. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
on the Term Loan is payable monthly and principal is due, as amended, in 34 equal consecutive monthly installments commencing on April&nbsp;1, 2012. All unpaid principal and
accrued interest with respect to the Term Loan is due and payable on the earlier of (A)&nbsp;December&nbsp;30, 2014 or (B)&nbsp;the date that the Term Loan otherwise becomes due and payable
under the terms of the Loan Agreement. We may prepay all, but not less than all, of the Term Loan subject to a prepayment premium of 1% in year three and 2% in year two of the original principal
amount of the Term Loan. There is no prepayment premium if the loan is paid off early in year four. We are also obligated to make a payment of $0.5&nbsp;million (Payment Fee) upon the earlier of
(A)&nbsp;December&nbsp;30, 2013 or (B)&nbsp;upon repayment of the Term Loan in full prior to December&nbsp;30, 2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
obligations under the Loan Agreement are secured by a first priority lien upon and security interest in substantially all of our existing and after-acquired assets, excluding our
intellectual property assets. Under the Loan Agreement, we are subject to specified affirmative and negative covenants customary for financings of this type. The Loan Agreement provides that, upon the
occurrence of certain specified events of default customary for financings of this type, our obligations under the Loan Agreement may be automatically accelerated, whereupon our obligations under the
Loan Agreement shall be immediately due and payable. At December&nbsp;31, 2011, we believe we are in compliance with the Loan Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> AGGREGATE CONTRACTUAL OBLIGATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into license agreements whereby we have received licenses or options to license technology, specified patents and/or
patent applications. These license and collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing
patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain development, regulatory and/or commercial milestones. Because the achievement of these
milestones had not occurred as of December&nbsp;31, 2011, such contingencies have not been recorded in our financial statements. We expect to incur approximately $0.7&nbsp;million of milestone
payments in 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our contractual obligations (not including contingent royalty and milestone payments as described above) at December&nbsp;31, 2011 and the effect such
obligations and commercial commitments are expected to have on our liquidity and cash flow in future years. These </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=67,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=691574,FOLIO='63',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<A NAME="page_ds46501_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>obligations,
commitments and supporting arrangements represent expected payments based on current operating forecasts, which are subject to change: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013&nbsp;-&nbsp;2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015&nbsp;-&nbsp;2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Thereafter </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual obligations:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,181</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,405</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,859</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,903</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other contractual obligations(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other long-term liabilities(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>527</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term Loan(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,971</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,479</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total contractual obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,032</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Such
amounts primarily consist of payments for our facility leases and do not assume the exercise of renewal terms or early termination provisions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Such
amounts primarily consist of research and development commitments with third parties. Our obligation to pay certain of these amounts may increase or be
reduced based on certain future events.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Such
amounts include the outstanding balance on a loan payable which accrues interest at 5.5% and is payable monthly.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Such
amounts include the outstanding balance at December&nbsp;31, 2011 on the Term Loan along with the Payment Fee. The Term Loan accrues interest at a
fixed annual interest rate equal to the greater of (i)&nbsp;the sum of (A)&nbsp;the LIBOR Rate (as defined in the Loan Agreement) plus (B)&nbsp;6.25%; or (ii)&nbsp;a minimum rate of 9.50%. As
described above, we amended our Term Loan in March 2012 and currently all amounts borrowed under the Term Loan mature in December 2014. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2><B> RECENT ACCOUNTING PRONOUNCEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Refer to Note&nbsp;2, "Summary of Significant Accounting Policies," in the accompanying notes to the consolidated financial
statements for a discussion of recent accounting pronouncements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> OFF-BALANCE SHEET ARRANGEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds46501_item_7a._quantitative_and_qual__ite02669"> </A>
<A NAME="toc_ds46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We own financial instruments that are sensitive to market risk as part of our investment portfolio. Our investment portfolio is used to
preserve our capital until it is used to fund operations, including our research and development activities. None of these market-risk sensitive instruments are held for trading purposes.
We invest our cash primarily in money market mutual funds. These investments are evaluated quarterly to determine the fair value of the portfolio. From time to time, we invest our excess cash balances
in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds that meet high credit quality standards, as specified in our
investment policy. Our investment policy seeks to manage these assets to achieve our goals of preserving principal and maintaining adequate liquidity. Because of the short-term nature of
these investments, we do not believe we have material exposure due to market risk. The impact to our financial position and results of operations from likely changes in interest rates is not material. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not utilize derivative financial instruments. The carrying amounts reflected in the consolidated balance sheet of cash and cash equivalents, accounts receivables and accounts
payable approximates fair value at December&nbsp;31, 2011 due to the short-term maturities of these instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=68,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=985838,FOLIO='64',FILE='DISK104:[12ZAA1.12ZAA46501]DS46501A.;11',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fa46501_1_65"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fa46501_item_8._financial_statements_and_supplementary_data"> </A>
<A NAME="toc_fa46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fa46501_report_of_independent___fa402278"> </A>
<A NAME="toc_fa46501_2"> </A></FONT> <FONT SIZE=2><B>  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
the Board of Directors and Stockholders of Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and comprehensive loss, of stockholders' equity, and of cash flows,
present fairly, in all material respects, the financial position of Celldex Therapeutics,&nbsp;Inc. and its subsidiaries at December&nbsp;31, 2011 and December&nbsp;31, 2010, and the results of
their operations and their cash flows for each of the three years in the period ended December&nbsp;31, 2011 in conformity with accounting principles generally accepted in the United States of
America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2011, based on criteria established in </FONT> <FONT SIZE=2><I>Internal
Control&#151;Integrated Framework</I></FONT><FONT SIZE=2> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's
management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item&nbsp;9A. Our responsibility is to express opinions on these financial
statements and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and
whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation.
Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing
and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audits provide a reasonable basis for our opinions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures
that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or
timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Boston,
Massachusetts<BR>
March&nbsp;8, 2012 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=234482,FOLIO='65',FILE='DISK104:[12ZAA1.12ZAA46501]FA46501A.;8',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fe46501_1_66"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fe46501_celldex_therapeutics,_inc._con__cel03928"> </A>
<A NAME="toc_fe46501_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED BALANCE SHEETS    <BR>    <BR>    (In thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,899</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,413</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,811</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts and Other Receivables</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>324</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and Other Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,202</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>54,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,947</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and Equipment, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,093</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,832</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intangible Assets, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,836</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>97,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>LIABILITIES AND STOCKHOLDERS' EQUITY</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts Payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>935</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,936</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Portion of Long-Term Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Portion of Term Loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible Subordinated Debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Current Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term Loan, less Current Portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,889</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Long-Term Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,966</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,591</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,272</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and Contingent Liabilities (Notes&nbsp;14 and 16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' Equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December&nbsp;31, 2011 and 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 44,210,636 and 32,055,382 Shares Issued and Outstanding at December&nbsp;31, 2011 and 2010,
respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional Paid-In Capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>271,032</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>232,679</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Other Comprehensive Income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,652</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(205,006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(160,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Stockholders' Equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>68,722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75,255</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Liabilities and Stockholders' Equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>97,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=70,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=143192,FOLIO='66',FILE='DISK104:[12ZAA1.12ZAA46501]FE46501A.;8',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fg46501_1_67"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fg46501_celldex_therapeutics,_inc._con__cel04980"> </A>
<A NAME="toc_fg46501_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    <BR>    <BR>    (In thousands, except per share amounts)    <BR>
</B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>REVENUE:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>220</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,386</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,716</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,180</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>OPERATING EXPENSE:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gain on Sale of Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(604</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,913</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,143</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,664</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,030</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,259</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,796</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,337</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss Before Income Taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income Tax Benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and Diluted Net Loss Per Common Share (See Note&nbsp;2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.08</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Used in Calculating Basic and Diluted Net Loss per Share (See Note&nbsp;2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>COMPREHENSIVE LOSS:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Comprehensive (Loss) Income:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized (Loss) Gain on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,585</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=71,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=937042,FOLIO='67',FILE='DISK104:[12ZAA1.12ZAA46501]FG46501A.;8',USER='CDESORM',CD=';2-MAR-2012;16:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fi46501_1_68"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share amounts)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common<BR>
Stock<BR>
Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common<BR>
Stock Par<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-In<BR>
Capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Other<BR>
Comprehensive<BR>
Income </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2008 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>15,789,756</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>16</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>136,661</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,606</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(121,149</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>18,134</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>172,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>917</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>917</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Connection with the CuraGen acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,722,713</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>88,227</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>88,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Losses on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2009 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>31,685,061</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>32</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>228,863</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,546</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(157,674</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>73,767</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>370,321</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Gains on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2010 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>32,055,382</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>32</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>232,679</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,751</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(160,207</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>75,255</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80,254</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Connection with Cantor Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>575,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,154</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Underwritten Offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,500,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Losses on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2011 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>44,210,636</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>44</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>271,032</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,652</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(205,006</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2><B>$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>68,722</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The accompanying notes are an integral part of the consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=72,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=741139,FOLIO='68',FILE='DISK104:[12ZAA1.12ZAA46501]FI46501A.;20',USER='CDESORM',CD=';2-MAR-2012;16:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fk46501_1_69"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fk46501_celldex_therapeutics,_inc._con__cel02991"> </A>
<A NAME="toc_fk46501_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF CASH FLOWS    <BR>    <BR>    (In thousands)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Operating Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to Reconcile Net Loss to Cash Used in Operating Activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and Amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,718</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,583</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,913</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,143</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and Premium of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Realized Loss (Gain) on Sales and Maturities of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>(Gain) Loss on Sale or Disposal of Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-Based Compensation Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Cash Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>728</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Cash Tax Benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in Operating Assets and Liabilities, Net of Acquisitions:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts and Other Receivables</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>220</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,283</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and Other Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>241</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(546</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>743</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts Payable and Accrued Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,076</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,193</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,463</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(39,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,865</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,699</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash Used in Operating Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,372</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,869</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Investing Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Acquired in the CuraGen acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales and Maturities of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>42,383</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(52,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(56,522</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,559</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquisition of Property and Equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from Sale or Disposal of Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash (Used in) Provided by Investing Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Financing Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Proceeds from Stock Issuances</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,023</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>668</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related Party Loan Due to Medarex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Term Loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of Convertible Subordinated Debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,503</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of Other Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(176</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash Provided by (Used in) Financing Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,434</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,817</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,465</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of Exchange Rate Changes on Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net (Decrease) Increase in Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,388</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35,715</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,745</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents at Beginning of Period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,257</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents at End of Period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,899</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Supplemental Disclosure of Non-Cash Flow Information</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued to Executive Officers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Supplemental Disclosure of Cash Flow Information</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Paid for Interest</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>604</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>157</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the consolidated financial statements.</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=73,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=840519,FOLIO='69',FILE='DISK104:[12ZAA1.12ZAA46501]FK46501A.;8',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fm46501_1_70"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fm46501_celldex_therapeutics,_inc._not__cel02700"> </A>
<A NAME="toc_fm46501_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (1) NATURE OF BUSINESS AND OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for
the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a
pivotal Phase&nbsp;3 study for the treatment of glioblastoma, CDX-011, an antibody-drug conjugate in a randomized Phase&nbsp;2b study for the treatment of advanced breast
cancer and CDX-1127, a therapeutic human antibody in a Phase&nbsp;1 study for cancer indications. The Company has additional clinical and preclinical programs, including
CDX-1401, an APC Targeting Technology&#153; program, CDX-301, an immune cell mobilizing agent, and CDX-1135, a molecule that inhibits a part of the immune
system called the complement system. The Company's collaboration with GlaxoSmithKline (Glaxo) resulted in the commercialization of Rotarix, an oral human rotavirus vaccine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2011, the Company had cash, cash equivalents and marketable securities of $53.3&nbsp;million; working capital of $40.4&nbsp;million; and a Term Loan balance of
$15.1&nbsp;million. The Company incurred a loss of $44.8&nbsp;million for the year ended December&nbsp;31, 2011. Net cash used in operations for the year ended December&nbsp;31, 2011 was
$35.7&nbsp;million. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&nbsp;million in net proceeds. In February 2012, the Company issued
10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&nbsp;million, after deducting underwriting fees and estimated offering expenses.
The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. The Company believes
that the cash, cash equivalents and marketable securities at December&nbsp;31, 2011, the $8.5&nbsp;million raised under the Cantor Agreement in January and the $37.7&nbsp;million raised in the
underwritten public offering in February and interest income on invested funds, will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next
twelve months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company raised net proceeds of $35.9&nbsp;million during the year ended December&nbsp;31, 2011 and $46.2&nbsp;million during the two months ended February&nbsp;29, 2012 from
the sale of its common stock. During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising
activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations,
issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no
assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There
is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company's stockholders; debt financing, if
available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in
royalties or other terms that reduce the Company's economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity
needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than
expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=74,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=876424,FOLIO='70',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Basis of Presentation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. All
intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel
therapeutics for human health care. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Use of Estimates  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (U.S.&nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and
liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Cash and Cash Equivalents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&nbsp;days or less at the date of purchase to
be cash equivalents. Cash equivalents consist principally of money market funds and debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Marketable Securities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency
securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the consolidated balance sheets because they are
available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of
accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in
the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated
statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Concentration of Credit Risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash
equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major
financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a
high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
from Glaxo and Pfizer represented 98% and none for the year ended December&nbsp;31, 2011, 14% and 85% for the year ended December&nbsp;31, 2010 and 52% and 34% for the year
ended December&nbsp;31, 2009 of total Company revenue, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=75,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=873640,FOLIO='71',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Fair Value Measurements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to
maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market
participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair
value hierarchy as defined by U.S.&nbsp;GAAP: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1:
Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2:
Observable inputs other than Level&nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or
liabilities in markets that are not active. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3:
Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Property and Equipment  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the
straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing
equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease,
including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the
asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized.
Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's consolidated statements of
operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction
and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For
manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation
costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Business Combinations  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable
intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=76,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=78835,FOLIO='72',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>intangible
assets such as in-process research and development (IPR&amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective
of a market participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate
an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug
candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D projects; a market participant's estimates of future cash flows from potential product
sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Intangible Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible
assets. These assets are maintained on the Company's consolidated balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the
carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or
is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs. IPR&amp;D assets will be
tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a
straight-line basis over their estimated useful life. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Goodwill  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is
allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Impairment of Long-Lived Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets
when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset
and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their
estimated fair values. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Revenue Recognition  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has
occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=77,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=431283,FOLIO='73',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic
drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product
sales derived from collaborations. These multiple element arrangements are analyzed to determine
whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various
elements based on their fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's
best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of
the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment
is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is
recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that
are related to future performance are deferred and recognized as revenue when the research projects are performed. During the year ended December&nbsp;31, 2010, the Company recorded
$1.7&nbsp;million to other income related to IRS Qualifying Therapeutic Discovery Grants because the grant arrangement was not part of the Company's on-going operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized
when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development
expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other studies, personnel costs, depreciation, license fees and funding of outside research. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trial expenses include expenses associated with clinical research organizations (CRO). The invoicing from CROs for services rendered can lag several months. We accrue the cost
of services rendered in connection with CRO activities based on our estimate of site management, monitoring costs, and project management costs. We maintain regular communication with our CROs to
gauge the reasonableness of our estimates. Differences between actual clinical trial expenses and estimated
clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=78,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=723063,FOLIO='74',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Patent Costs  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners.
Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Stock-Based Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated
fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and
directors is recognized using the straight-line method over the term of vesting or performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured
over the vesting term resulting in periodic adjustments to stock-based compensation expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Foreign Currency Translation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At
December&nbsp;31, 2011 and December&nbsp;31, 2010,
accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&nbsp;million. In 2011, the Company's foreign subsidiary voluntarily liquidated
in order to consolidate the Company's foreign operations into Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Income Taxes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and
deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its
deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation
allowances from period to period are included in the Company's tax provision in the period of change. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the
taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Comprehensive Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company
includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. In December 2011, the Company adopted a new U.S.&nbsp;GAAP
accounting standard which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous
statement of comprehensive income, or in two separate but consecutive statements. This new standard eliminates the option to present components of other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=79,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=995884,FOLIO='75',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fm46501_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>comprehensive
income as part of the statement of equity. The adoption of this new standard did not have a material effect on the Company's operating results or financial position. The consolidated
statements of operations and comprehensive loss reflect total comprehensive loss for the years ended
December&nbsp;31, 2011, 2010 and 2009. There were no significant reclasses to income during the years ended December&nbsp;31, 2011, 2010 and 2009. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Net Loss Per Share  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding
restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional
weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per
common share calculations because the effect would have been anti-dilutive are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,459,034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,019,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,576,159</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible debt</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>353,563</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>353,563</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,465,034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,382,883</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,945,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> Recent Accounting Pronouncements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard
setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet
effective will not have a material impact on the Company's financial position or results of operations upon adoption. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2011, the FASB amended the guidance on the annual testing of goodwill for impairment. The amended guidance will allow companies to assess qualitative factors to determine if
it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under
current accounting standards. This guidance will be effective for the Company's fiscal year ending December&nbsp;30, 2012. The Company does not expect the adoption of this new standard to have a
material effect on its operating results or financial position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2011, the FASB issued a new accounting standard which clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value
measurements that are estimated using significant unobservable (Level&nbsp;3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or
after December&nbsp;15, 2011. The adoption of this standard is not expected to have a material impact on the Company's operating results or financial position. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=80,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=99788,FOLIO='76',FILE='DISK104:[12ZAA1.12ZAA46501]FM46501A.;7',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fo46501_1_77"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (3) BUSINESS COMBINATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Acquisition of CuraGen Corporation (CuraGen)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;1, 2009, the Company acquired CuraGen, a former publicly-traded company. Following the CuraGen acquisition, the
financial statements reflect the financial position, results of operation and cash flows of the combined companies. In connection with the CuraGen acquisition, effective October&nbsp;1, 2009, the
Company (i)&nbsp;issued 15,722,713 shares of common stock of the Company, or 0.2739 shares, in exchange for each share of outstanding CuraGen common stock, plus cash in lieu of fractional shares
(the "CuraGen Exchange Ratio"), (ii)&nbsp;assumed the obligations under CuraGen's 2007 Stock Plan (the "CuraGen 2007 Plan") and each outstanding option to purchase common stock (a "CuraGen Stock
Option") granted under the CuraGen 2007 Plan and (iii)&nbsp;assumed the $12.5&nbsp;million in 4% convertible subordinated debt due February&nbsp;15, 2011 (the "CuraGen Debt"). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transaction was accounted for under the acquisition method of accounting. The acquisition-date fair value of the consideration transferred consisted of the fair value of
the Company's common stock issued of $85.4&nbsp;million and fair value of CuraGen Stock Options that were attributed to precombination service of $2.9&nbsp;million. Of the CuraGen Stock Options
assumed, all but 1%, were immediately vested upon closing in accordance with the terms of the stock option agreements and employment agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recorded the fair value of acquired assets and liabilities to net tangible assets, intangible assets, goodwill and a severance obligation. The difference between the
aggregate consideration transferred and the fair value of assets acquired and liabilities assumed was recorded to goodwill. This goodwill relates to synergies from the CuraGen acquisition and a
deferred tax liability related to acquired IPR&amp;D intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The following table summarizes the fair values of the
assets acquired and liabilities assumed at the acquisition date (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,638</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Identifiable intangible assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPR&amp;D</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amgen Amendment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TopoTarget Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current and long-term assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CuraGen Debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,503</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,190</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assumed liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,778</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>88,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
values assigned to the intangible assets acquired, including the IPR&amp;D, were determined based on fair market value using a risk adjusted discounted cash flow approach. The values
assigned to IPR&amp;D related to the development of CDX-011. At the date of acquisition, CDX-011 had not yet reached technological feasibility nor did it have any alternative
future use. In December 2011, the Company completed enrollment in a randomized Phase&nbsp;2b controlled
study for CDX-011 in patients with heavily pre-treated, advanced breast cancer. The Company expects to incur approximately </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=81,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=382971,FOLIO='77',FILE='DISK104:[12ZAA1.12ZAA46501]FO46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fo46501_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (3) BUSINESS COMBINATIONS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>$1.4&nbsp;million
in 2012 on the Phase&nbsp;2b study. Estimated revenues from CDX-011 are expected to be generated by 2016. The remaining acquired intangible assets arising from the
acquisition are being amortized on a straight line basis over their estimated lives. The net deferred tax liability primarily relates to the temporary differences associated with the IPR&amp;D intangible
assets, which are not deductible for tax purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the CuraGen acquisition, effective October&nbsp;1, 2009, the Company, CuraGen, and The Bank of New York Mellon (the "Trustee") amended the CuraGen Debt to provide
that the CuraGen Debt shall be convertible into 353,563 shares of the Company's common stock at the rate of 28.27823 shares of the Company's common stock per $1,000 principal amount of notes, or
$35.36 per share. The initial carrying value of the CuraGen Debt was accreted ratably, over the term of the CuraGen Debt, to $12.5&nbsp;million due at maturity. Interest expense on the CuraGen Debt
was $0.2&nbsp;million, $1.2&nbsp;million and $0.3&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009 and included $0.1&nbsp;million, $0.7&nbsp;million and
$0.2&nbsp;million in discount accretion, respectively. In February 2011, the Company paid the Trustee $12.8&nbsp;million to satisfy all outstanding principal and accrued interest related to the
CuraGen Debt. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CuraGen
employees who did not receive offers of employment were terminated upon the consummation of the CuraGen acquisition. These employees were eligible for severance payments upon
termination of employment under certain circumstances, including following the CuraGen acquisition. U.S.&nbsp;GAAP requires severance obligations that are incurred by the acquiree for the benefit of
the acquirer to be recognized as an expense in the post-combination period. Because the offer of employment was at the option of the Company, the Company has deemed the CuraGen Severance
to be at its benefit. Accordingly, the Company recorded $3.3&nbsp;million and $0.9&nbsp;million in CuraGen severance expenses to general and administrative and research and development,
respectively, in the consolidated statements of operations for the year ended December&nbsp;31, 2009. In addition, the Company incurred $2.9&nbsp;million in acquisition-related expenses including
investment banking, legal, accounting, and valuation services in the consolidated statements of operations for the year ended December&nbsp;31, 2009. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (4) FAIR VALUE MEASUREMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables set forth the Company's financial assets subject to fair value measurements: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,451</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=82,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=334591,FOLIO='78',FILE='DISK104:[12ZAA1.12ZAA46501]FO46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fo46501_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (4) FAIR VALUE MEASUREMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,786</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents,
marketable securities, short-term accounts receivable, accounts payable and debt obligations. The Company values its marketable securities utilizing independent pricing services which
normally drive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date,
observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable
are reflected in the accompanying consolidated financial statements at cost, which approximates fair value due to the short-term nature of these instruments. Based on current market
interest rates available to the Company for long-term liabilities with similar terms and maturities, the Company believes the fair value approximates the carrying value of the principal
portion of the Term Loan and note payable at December&nbsp;31, 2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (5) MARKETABLE SECURITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of marketable securities is shown below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2011</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. government and municipal obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,808</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,924</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total U.S. government and municipal obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,801</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,817</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,816</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,547</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,476</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,348</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=83,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=800167,FOLIO='79',FILE='DISK104:[12ZAA1.12ZAA46501]FO46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fo46501_1_80"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (5) MARKETABLE SECURITIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2010</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. government and municipal obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,836</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,871</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,428</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,531</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total U.S. government and municipal obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>138</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,402</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,798</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,594</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,595</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,656</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be
other-than-temporarily impaired as of December&nbsp;31, 2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (6) PROPERTY AND EQUIPMENT, NET  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,942</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Manufacturing Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,418</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Office Furniture and Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,314</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,299</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold Improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,244</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Construction in Progress</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>240</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Property and Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,606</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less Accumulated Depreciation and Amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,370</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,774</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
and amortization expense related to property and equipment was $2.2&nbsp;million, $2.7&nbsp;million and $2.6&nbsp;million for the years ended December&nbsp;31, 2011,
2010 and 2009, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=84,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=648391,FOLIO='80',FILE='DISK104:[12ZAA1.12ZAA46501]FO46501A.;6',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fq46501_1_81"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (7) INTANGIBLE ASSETS AND GOODWILL  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net of accumulated amortization, and goodwill are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=10 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated<BR>
Life </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Amortization </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Net </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Amortization </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Net </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intangible Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPR&amp;D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Indefinite</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amgen Amendment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,482</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,121</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,379</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TopoTarget Agreement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,057</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Core Technology</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.5&nbsp;&#150;&nbsp;11&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,040</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>908</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Strategic Partner Agreement</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Intangible Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,923</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,836</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Indefinite</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
estimated fair value attributed to the April 2008 agreement (TopoTarget Agreement) between the Company (as a successor to CuraGen) and TopoTarget A/S (TopoTarget) relates to the
Company's rights under the TopoTarget Agreement to receive up to $6&nbsp;million in either potential commercial milestone payments related to future net sales of Belinostat or 10% of any sublicense
income received by TopoTarget (TopoTarget Payments). In February 2010, TopoTarget entered into a co-development and commercialization agreement for Belinostat with Spectrum
Pharmaceuticals,&nbsp;Inc. which resulted in the Company's receipt of $3.0&nbsp;million of the TopoTarget Payments. The Company recorded this cash receipt as Other Income for the year ended
December&nbsp;31, 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2011, the Company recorded an impairment loss of $0.3&nbsp;million in Strategic Partnership Agreement to amortization of intangible asset
expense due to the Company's termination of rights to intellectual property underlying that Strategic Partnership Agreement. During the year ended December&nbsp;31, 2010, the Company
wrote-off $0.2&nbsp;million in Core Technology to amortization of intangible asset expense. In January 2009, the Company entered into a purchase agreement with Lohmann Animal Health
International ("LAHI") to sell its poultry vaccines assets to LAHI. Under the purchase agreement, LAHI paid an upfront fee of $0.8&nbsp;million and agreed to pay potential milestone payments. During
the year ended December&nbsp;31, 2009, the Company recorded a gain of $0.6&nbsp;million related to the LAHI Agreement based on the upfront fee less the net book value of the related asset. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization
expense for intangible assets was $1.9&nbsp;million, $3.1&nbsp;million and $0.9&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009, respectively.
The estimated future amortization expense of intangible assets as of December&nbsp;31, 2011, for the next five years is as follows (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,089</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=85,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=30447,FOLIO='81',FILE='DISK104:[12ZAA1.12ZAA46501]FQ46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<A NAME="page_fq46501_1_82"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (8) ACCRUED EXPENSES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Royalty and License Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,179</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>826</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Payroll and Employee Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,925</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Research and Development Contract Costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,035</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Professional Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Accrued Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>352</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>518</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> (9) OTHER LONG-TERM LIABILITIES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Rent</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Severance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>685</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Deferred Tax Liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Income from Sale of Tax Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loan Payable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>527</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>581</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less Current Portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-Term Portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,966</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,591</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> Sale of Tax Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to sell New Jersey tax
benefits worth $0.6&nbsp;million (consisting of R&amp;D tax credits) to an independent third party for $0.5&nbsp;million. Under the agreement, the Company must maintain a base of operations in New
Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. The Company is recognizing the $0.5 million over five years starting
in 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Loan Payable  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2003, the Company entered into a lease with the Massachusetts Development Finance Agency whereby the Company received a
loan to finance the build-out of its manufacturing facility in Fall River, Massachusetts. Principal and interest payments on the loan are due monthly using </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=86,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=521580,FOLIO='82',FILE='DISK104:[12ZAA1.12ZAA46501]FQ46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<A NAME="page_fq46501_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (9) OTHER LONG-TERM LIABILITIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>an
amortization period of 15&nbsp;years and interest accrues at a rate of 5.5% per annum. The Company is obligated to repay the following principal amounts for the loan as follows (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>527</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> (10) TERM LOAN  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2010, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial,&nbsp;LLC (MidCap) pursuant to which the Company borrowed
$10&nbsp;million (the "Term Loan") from MidCap. In March 2011, as the Company had anticipated, the Company amended the Loan Agreement and borrowed an additional $5&nbsp;million from General
Electric Capital Corporation (GECC) (collectively with MidCap, the "Lenders") to increase the amount owed under the Term Loan to $15&nbsp;million. No additional advances are available under the Loan
Agreement. The Term Loan accrues interest at a fixed annual interest rate equal to the greater of (i)&nbsp;the sum of (A)&nbsp;the LIBOR Rate (as defined in the Loan Agreement) plus
(B)&nbsp;6.25%; or (ii)&nbsp;a minimum rate of 9.50%. In September 2011, the Company exercised an option to extend the interest-only period by 6&nbsp;months from October&nbsp;1,
2011 to April&nbsp;1, 2012. In March 2012, the Company amended the Loan Agreement to extend the maturity date from December 2013 to December 2014 in return for an upfront fee of $25,000 and an
additional fee of $37,500 due upon repayment of the Term Loan in full. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
on the Term Loan is payable monthly and principal is due, as amended, in 34 equal consecutive monthly installments commencing on April&nbsp;1, 2012. All unpaid principal and
accrued interest with respect to the Term Loan is due and payable on the earlier of (A)&nbsp;December&nbsp;30, 2014 or (B)&nbsp;the date that the Term Loan otherwise becomes due and payable
under the terms of the Loan Agreement. The Company may prepay all, but not less than all, of the Term Loan subject to a prepayment premium of 1% in year three and 2% in year two of the original
principal amount of the Term Loan. There is no prepayment premium if the loan is paid off early in year four. The Company is also obligated to make a payment fee of $0.5&nbsp;million (the "Payment
Fee") upon the earlier of (A)&nbsp;December&nbsp;30, 2013 or (B)&nbsp;upon repayment of the Term Loan in full prior to December&nbsp;30, 2013. The Company is accreting the Payment Fee ratably
over the original term of the Term Loan to interest expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company under the Loan Agreement are secured by a first priority lien upon and security interest in substantially all of the Company's existing and after-acquired
assets, excluding its intellectual property assets. Under the Loan Agreement, the Company is subject to specified affirmative and negative covenants customary for financings of this type. The Loan
Agreement provides that, upon the occurrence of certain specified events of default customary for financings of this type, the Company's obligations under the Loan Agreement may be automatically
accelerated, whereupon the Company's obligations under the Loan Agreement shall be immediately due and payable. At December&nbsp;31, 2011, the Company believes it is in compliance with the Loan
Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=87,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=375235,FOLIO='83',FILE='DISK104:[12ZAA1.12ZAA46501]FQ46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<A NAME="page_fq46501_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (10) TERM LOAN (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2011 and 2010, the Company had $0.2&nbsp;million in capitalized deferred financing costs incurred in connection with the Term Loan and is amortizing these costs
over the original term of the Term Loan to interest expense. Interest expense on the Term Loan including the accretion of the Payment Fee and amortization of the deferred financing costs was
$1.6&nbsp;million for the year ended December&nbsp;31, 2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is obligated to repay the following principal amounts for the Term Loan (including Payment Fee) as follows (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,735</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> (11) STOCKHOLDERS' EQUITY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Common Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2010, the Company filed a shelf registration statement with the Securities and Exchange Commission to register for sale any
combination of the types of securities described in the shelf registration statement up to a dollar amount of $150&nbsp;million. The shelf registration became effective on April&nbsp;22, 2010. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2011, the Company entered into a controlled equity offering sales agreement (the "Cantor Agreement") with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. (Cantor) pursuant to which the
Company may issue and sell up to 5,000,000 shares of its common stock from time to time through Cantor, acting as agent. The Company agreed to pay Cantor a commission of up to 5% of the gross proceeds
from each sale and to reimburse Cantor for certain expenses incurred in connection with entering into the Cantor Agreement. The Cantor Agreement terminates upon the sale of all 5,000,000 shares or
upon ten day notice by either Cantor or the Company. During the year ended December&nbsp;31, 2011, the Company sold 575,000 shares of common stock under the Cantor Agreement and raised
$2.2&nbsp;million in net proceeds, after deducting commission and offering expenses. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised
$8.5&nbsp;million in net proceeds. Under the terms of the Cantor Agreement, the Company will have the ability to sell up to 1,975,000 shares of its common stock upon the expiration or earlier waiver
of the 90-day lock-up with the underwriters of the Company's recent offering in February 2012. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2011, the Company issued 11,500,000 shares of its common stock in an underwritten public offering, including the underwriter's exercise of their full over-allotment
option to purchase an additional 1,500,000 shares of common stock. The net proceeds to the Company were $33.7&nbsp;million, after deducting underwriting fees and offering expenses. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=88,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=224691,FOLIO='84',FILE='DISK104:[12ZAA1.12ZAA46501]FQ46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<A NAME="page_fq46501_1_85"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (11) STOCKHOLDERS' EQUITY (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&nbsp;million, after deducting
underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to
cover overallotments, if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Convertible Preferred Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2011, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated
Class&nbsp;C Preferred Stock including 350,000 shares which have been designated Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock (the
"Series&nbsp;C-1 Preferred Stock"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Shareholder Rights Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Board has adopted a Shareholder Rights Plan, as set forth in the Shareholder Rights Agreement, as amended, between the
Company and Computershare Trust Company, N.A., as Rights Agent (the "Rights Agreement"). Pursuant to the terms of the Rights Agreement, the Board declared a dividend distribution of one Preferred
Stock Purchase Right (a "Right") for each outstanding share of the Company's common stock. Each Right, which expires in November 2014, entitles their holder to purchase from the Company one
ten-thousandth of a share (a "Unit") of Series&nbsp;C-1 Preferred Stock at a cash exercise price of $35.00 per Unit, subject to adjustment. The Rights will trade separately
from the common stock and will become exercisable only when a person or group has acquired 15% or more of the outstanding common stock or upon the commencement by a person or group of a tender offer
that would result in such person or group acquiring 15% or more of the outstanding common stock other than as a result of repurchases of stock by the Company or certain inadvertent actions by a
shareholder. In the event a person or group acquires 15% or more of the outstanding common stock each holder of a Right (except for any such person or group) would be entitled to receive upon exercise
sufficient Units of Series&nbsp;C-1 Preferred Stock to equal a value of two times the exercise price of the Right. In the event the Company is acquired in a merger or other business
combination transaction or if 50% or more of the Company's assets or earning power is sold, each holder of a Right (except for any such person or
group described above) would receive upon exercise common stock of the acquiring company with a value equal to two times the exercise price of the Right. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=89,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=324937,FOLIO='85',FILE='DISK104:[12ZAA1.12ZAA46501]FQ46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fs46501_1_86"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (12) STOCK-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan"),
Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan") and the CuraGen 2007 Plan. There are no shares available for future grant under the Celldex Research 2005 Plan and
CuraGen 2007 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Employee Stock Purchase Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2011, a total of 62,500 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the
2004 ESPP Plan, each participating employee may purchase up to 250 shares of common stock per year, through payroll deductions, at a purchase price equal to 85% of the lower of the fair market value
of the common stock at either the beginning of the offering period or the applicable exercise date. During the years ended December&nbsp;31, 2011 and 2010, the Company issued 6,627 and 5,897 shares
under the 2004 ESPP Plan, respectively. At December&nbsp;31, 2011, 44,382 shares were available for issuance under the 2004 ESPP Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Employee Stock Option and Incentive Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&nbsp;422A of the Internal
Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash
bonuses to employees, consultants and non-employee directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2011, the 2008 Plan allowed for a maximum of 3,900,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to
March&nbsp;7, 2018 and grants of Incentive Stock Options made prior to October&nbsp;20, 2017. The Company's board of directors determines the term of each option, option price, and number of
shares for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five
years for options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the
date of grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee
director stock option awards is accelerated upon a change in control as defined in the 2008 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=90,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=682522,FOLIO='86',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (12) STOCK-BASED COMPENSATION (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of stock option activity for the year ended December&nbsp;31, 2011 is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term (In Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Outstanding at December&nbsp;31, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,019,982</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>942,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(61,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canceled</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(442,205</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Outstanding at December&nbsp;31, 2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,459,034</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.08</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Vested and Expected to Vest at December&nbsp;31, 2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,412,254</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Exercisable at December&nbsp;31, 2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,818,895</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Available for Grant under the 2008 Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>953,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
total intrinsic value of stock options exercised during the years ended December&nbsp;31, 2011, 2010 and 2009 was $0.03&nbsp;million, $1.0&nbsp;million and $0.3&nbsp;million,
respectively. The weighted average grant-date fair value of stock options granted during the years ended December&nbsp;31, 2011, 2010 and 2009 was $1.83, $2.82 and $5.29, respectively.
The total fair value of stock options vested during the years ended December&nbsp;31, 2011, 2010 and 2009 was $2.6&nbsp;million, $2.5&nbsp;million and $2.6&nbsp;million, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value of stock options outstanding at December&nbsp;31, 2011 was $0.03&nbsp;million. The aggregate intrinsic value of stock options vested and expected to
vest at December&nbsp;31, 2011 was $0.03&nbsp;million. As of December&nbsp;31, 2011, total compensation cost related to non-vested employee and non-employee director
stock options not yet recognized was approximately $3.3&nbsp;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.5&nbsp;years. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Restricted Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of restricted stock activity under the 2008 Plan for the year ended December&nbsp;31, 2011 is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Grant Date<BR>
Fair Value<BR>
(per share) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding and unvested at December&nbsp;31, 2010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canceled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding and unvested at December&nbsp;31, 2011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=91,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=566189,FOLIO='87',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_88"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (12) STOCK-BASED COMPENSATION (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Valuation and Expenses Information  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense for the years ended December&nbsp;31, 2011, 2010 and 2009 was recorded as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,383</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,177</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair values of employee and non-employee director stock options granted during the years ended December&nbsp;31, 2011, 2010 and 2009 were valued using the Black-Scholes
option-pricing model with the following assumptions: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected stock price volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68&nbsp;&#150;&nbsp;70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65&nbsp;&#150;&nbsp;67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65&nbsp;&#150;&nbsp;68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected option term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0 Years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.2 Years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.5&nbsp;&#150;&nbsp;6.3 Years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.4&nbsp;&#150;&nbsp;2.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.8&nbsp;&#150;&nbsp;3.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.8&nbsp;&#150;&nbsp;3.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> (13) SIGNIFICANT REVENUE ARRANGEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the Company's significant revenue contracts and arrangements follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> GlaxoSmithKline&nbsp;plc (Glaxo) and Paul Royalty Fund II,&nbsp;L.P. (PRF)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company entered into an agreement with Glaxo to collaborate on the development and commercialization of the Company's oral
rotavirus strain and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. The Company's licensed-in the rotavirus strain that was used to
develop Glaxo's Rotarix rotavirus vaccine in 1995 and owes a license fee of 30% to Cincinnati Children's Hospital Medical Center (CCH) on net royalties received from Glaxo. The Company is obligated to
maintain a license with CCH with respect to the Glaxo agreement. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo
may terminate the agreement upon 90&nbsp;days prior written notice. The last relevant patent is scheduled to expire in December 2012. No additional milestone payments are due from Glaxo under the
agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2005, the Company entered into an agreement whereby an affiliate of PRF purchased a 70% interest in the milestone payments and net royalties the Company will receive on worldwide
sales of Rotarix. We have received a total of $60&nbsp;million in milestone payments under the PRF agreement. No additional milestone payments are due from PRF under the agreement. The PRF agreement
terminates in December 2012, unless otherwise extended. The Company's retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding
amount that is payable to CCH is recorded as royalty expense. Product royalty revenue and royalty expense related to the Company's retained interest in Rotarix was $9.1&nbsp;million,
$6.4&nbsp;million and $7.7&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=92,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=569661,FOLIO='88',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_89"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (13) SIGNIFICANT REVENUE ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Pfizer Inc. (Pfizer)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2008, the Company and Pfizer entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was
granted an exclusive worldwide license to rindopepimut. Under the Pfizer Agreement, Pfizer made an upfront payment to the Company of $40&nbsp;million and made a $10&nbsp;million equity investment
in the Company. The Pfizer Agreement also provided for reimbursement by Pfizer of all costs incurred by the Company in connection with the collaboration since the effective date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company had determined that its performance obligations under this collaboration should be accounted for as a single unit of accounting. The Company's deliverables under this
collaboration primarily included an exclusive license to rindopepimut, research and development services as required under the collaboration and participation in the joint clinical development
committee. The Company had estimated that its expected performance period under the collaboration would be 9.5&nbsp;years based on an assessment of the period over which the Company would have met
its performance obligations under the collaboration. The $40&nbsp;million up-front payment and research and development reimbursements were initially recorded as deferred revenue and
recognized as revenue over this 9.5&nbsp;year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2010, the Pfizer Agreement was terminated (the "Pfizer Termination") and all rights to rindopepimut were returned to the Company. Pfizer did not provide a reason for
termination. As a result of the Pfizer Termination, the Company recognized the remaining deferred revenue related to the Pfizer Agreement to product development and licensing agreement revenue during
the year ended December&nbsp;31, 2010. The Company recorded $39.9&nbsp;million and $5.2&nbsp;million in product development and licensing agreement revenue under the Pfizer Agreement during the
years ended December&nbsp;31, 2010 and 2009, respectively. The Company incurred and invoiced Pfizer reimbursable costs related to the Pfizer collaboration of $0.8&nbsp;million and
$3.2&nbsp;million for the years ended December&nbsp;31, 2010 and 2009, respectively. Effective with the Pfizer Termination, Pfizer is no longer funding the development of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Pfizer Agreement, the Company paid a total of $6.9&nbsp;million in sublicense fees to Duke University and Thomas Jefferson University. The Company recorded these
deferred sublicense fees to other assets in the consolidated balance sheets and was amortizing them to royalty expense over the 9.5-year performance period. As a result of the Pfizer
Termination, the Company recognized the remaining deferred costs related to the Pfizer Agreement to royalty expense during year ended December&nbsp;31, 2010. The Company recorded $5.7&nbsp;million
and $0.7&nbsp;million in royalty expense
related to these deferred sublicense fees during the years ended December&nbsp;31, 2010 and 2009, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has provided research and development support to Rockefeller on the development of their vaccine, DCVax-001,
which the Company refers to as CDX-2401, aimed at providing protection from infection with HIV, the virus known to cause AIDS. Payments to the Company are made on a time and materials
basis. The Company recorded grant revenue from Rockefeller of $0.2&nbsp;million and $1.8&nbsp;million for the years ended December&nbsp;31, 2010 and 2009, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=93,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=309609,FOLIO='89',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_90"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (14) COLLABORATION AGREEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's
licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent
prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense was
$1.4&nbsp;million, $1.0&nbsp;million and $0.7&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Medarex,&nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medarex, a former related party, and the Company have entered into the following agreements, each of which was approved by a majority
of its independent directors who did not have an interest in the transaction. These agreements include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>An Assignment and License Agreement, as amended, (Assignment and License Agreement) that provides for the assignment of
certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#153; and an anti-mannose
receptor product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A Research and Commercialization Agreement, as amended, (Research and Commercialization Agreement) that provides the
Company with certain rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform for
generating antibodies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Assignment and License Agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed
Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the
first commercial sale of such licensed product. Under the terms of the Research and Commercialization Agreement, the Company may be required to pay milestones of up to $7.0&nbsp;million upon
obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low- to mid-single digits on any net
product sales to Medarex with respect to the development of any products containing such licensed antibodies until the later of (i)&nbsp;the expiration of the last to expire applicable patent and
(ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, the Company exercised an option under the Research and Commercialization Agreement, whereby
it licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including CDX-1127. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human
DEC-205 receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human
DEC-205 receptor patent rights for educational and research purposes. The Company may be required to pay milestones of up to $3.9&nbsp;million upon obtaining first approval for
commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low- to mid-single digits on any net product sales to Rockefeller
with respect to development and commercialization of the human DEC-205 receptor. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=94,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=255026,FOLIO='90',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (14) COLLABORATION AGREEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Duke University Brain Tumor Cancer Center (Duke)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical
data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to rindopepimut. The Company may be required to pay milestone of up to
$1.0&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Duke with respect to
development and commercialization of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Ludwig Institute for Cancer Research (Ludwig)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use
in combination with the Company's APC Targeting Technology. The term of the agreement is for ten years. The Company may be required to pay milestones of up to $1.0&nbsp;million upon obtaining first
approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Ludwig with respect to development and commercialization of the
technology licensed from Ludwig. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Alteris Therapeutics,&nbsp;Inc. (Alteris)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be
required to pay Alteris up to $5.0&nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including rindopepimut. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Thomas Jefferson University (TJU)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of the assets of Alteris, the Company obtained the rights to two exclusive license agreements with
TJU dated February 2003 related to the EGFRvIII tumor antigen. Under Under these licenses, the Company may be required to pay milestones of up to $3.0&nbsp;million upon obtaining first approval for
commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to TJU with respect to development and commercialization of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> 3M Company  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2008, the Company and 3M Company entered into a license agreement for the exclusive worldwide rights to access 3M Company's
proprietary Immune Response Modifier, Resiquimod&#153;, (and additional Toll-Like Receptor 7/8 agonists (TLR)) for clinical study with the Company's proprietary APC Targeting
Technology, for use as vaccine adjuvants, with the right to sublicense the technology. The Company may be required to pay milestones of up to $3.8&nbsp;million upon obtaining first approval for
commercial sale of each product using this vaccine adjuvant and royalty payments in the low-single digits on any net product sales to 3M Company with respect to development and
commercialization of the technology licensed from 3M Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> University of Southampton, UK (Southampton)  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially
important target for immunotherapy of various cancers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=95,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=484075,FOLIO='91',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (14) COLLABORATION AGREEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Company may be required to pay milestones of up to approximately $1.4&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the
low-single digits on any net product sales to Southampton with respect to development and commercialization of CDX-1127 </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Amgen&nbsp;Inc. (Amgen)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2009, the Company entered into a license agreement with Amgen to expand its Precision Targeted Immunotherapy Platform by
acquiring exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that
control immune responses. The Company may be required to pay milestones of up to $1.3&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the
low-single digits on any net product sales to Amgen with respect to development and commercialization of the technology licensed from Amgen, including CDX-301. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Seattle Genetics,&nbsp;Inc. (Seattle Genetics)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the CuraGen acquisition, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby
CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may
be required to pay milestones of up to $7.5&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net
product sales to Seattle
Genetics with respect to development and commercialization of the ADC technology, including CDX-011. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (15) INCOME TAXES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of income tax expense attributable to continuing operations consist of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax benefit (provision):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,204</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,512</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,924</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax valuation allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included
in the state tax provision above for the year ended December&nbsp;31, 2009 is the effect of a rate decrease on the deferred tax asset and liabilities offset by a
$0.5&nbsp;million tax benefit due to non-cash tax consequences of the CuraGen acquisition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=96,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=688544,FOLIO='92',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (15) INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pre-tax book income (loss)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss at Statutory Rates</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,213</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,498</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State Taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>661</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,924</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in Valuation Allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax (benefit) provision</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted
rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal components of the deferred tax assets and liabilities at December&nbsp;31, 2011 and 2010, respectively, are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross Deferred Tax Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Operating Loss Carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Credit Carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,285</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,998</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,705</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based Compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,066</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fixed Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,957</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Expenses and Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,499</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross Deferred Tax Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Acquired Intangibles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5,615</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPR&amp;D Intangibles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred License Costs and Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,539</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Deferred Tax Assets and Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105,960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>86,952</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Tax Assets Valuation Allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(110,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(91,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Deferred Tax Asset (Liability)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=97,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=34228,FOLIO='93',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (15) INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net deferred tax liability of $4.7&nbsp;million at December&nbsp;31, 2011 and 2010 relates to the temporary differences associated with the IPR&amp;D intangible assets acquired in
the CuraGen acquisition, which are not deductible for tax purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2011, the Company had the following federal net operating loss (NOL) carryforwards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Prior to the merger of the Company and AVANT, $33.0&nbsp;million was generated by the Company which expire at various
dates starting in 2023 and going through 2028; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Prior to the merger of the Company and AVANT, $132.4&nbsp;million, net of expirations and utilization, was generated by
AVANT which expire at various dates starting in 2012 and going through 2028. NOLs of $0.8&nbsp;million were utilized in 2009. $13.0&nbsp;million and $12.1&nbsp;million in NOLs expired in 2011
and 2010, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Following the merger of the Company and AVANT, $73.9&nbsp;million was generated by the combined company which expire at
various dates starting in 2028 and going through 2031; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Prior to its acquisition by the Company, $518.3&nbsp;million was generated by CuraGen. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, an ownership change, as defined by Section&nbsp;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public
groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOL carryforwards that
may be utilized in future periods. The Company currently expects that it is not more likely than not that the CuraGen loss carryforwards may be utilized and, as such, no related asset has been
recorded for such losses. The Company has not completed an analysis of losses generated by AVANT, however, the Company believes it is remote that $92&nbsp;million of the AVANT loss carryforwards may
be utilized in future periods and there may be substantial limitations on the Company's ability to use the remaining losses of $40.4&nbsp;million. Following the merger of the Company and AVANT, the
Company experienced changes in ownership as defined by Section&nbsp;382 in June 2009 and December 2009. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change
in ownership in October 2007. As a result of the ownership change in October 2007, utilization of the Company's NOLs prior to October 2007 is subject to an annual limitation of $4.5&nbsp;million on
$28.3&nbsp;million of NOLs generated before that date. As a result of the ownership changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&nbsp;million on
$67.7&nbsp;million NOLs. Any unused annual limitation may be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair
value of the Company's net assets are determined to be below or in excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the
five-year period after the ownership change. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development credits ("R&amp;D credit")
of $20.8&nbsp;million and $14.4&nbsp;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOL carryforwards of approximately
$88.7&nbsp;million and the remaining federal and state R&amp;D credit carryforwards of approximately $14.0&nbsp;million and $9.2&nbsp;million, respectively, may be substantially limited. These state
NOLs and federal and state credits expire at various dates starting in 2012 going through 2031. The Company has not yet completed a study of these </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=98,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=526707,FOLIO='94',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_95"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (15) INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>credits
to substantiate the amounts. Until a study is completed, no amounts are being presented as an uncertain tax position. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
ownership changes, as defined in Section&nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be
utilized annually to offset future taxable income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position
of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income
tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of
being realized upon the ultimate settlement with the relevant taxing authority. At December&nbsp;31, 2011 and 2010, we had no unrecognized tax benefits. A full valuation allowance has been provided
against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the
consolidated balance sheet or statement of operations if an adjustment were required. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Massachusetts,
New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company completed an examination by
the Internal Revenue Service with respect to 2008 which resulted in no change to our 2008 tax return. The Company is not currently under examination by any other jurisdictions for any tax year. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss
carryforwards, capitalized R&amp;D expenditures and R&amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state
deferred tax assets and, as a result, a full valuation allowance was maintained at December&nbsp;31, 2011 against the Company's net deferred tax assets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (16) COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has facility and equipment leases that expire at various dates through 2017. Certain of these facility leases contain renewal options, early termination provisions, and
provisions that escalate the base rent payments and require the Company to pay common area maintenance costs (CAM) during the lease term. The Company entered into a letter of credit facility with a
national U.S. financial institution which is collateralized by a security deposit for the leased facility in Phillipsburg, New Jersey. The Company recorded restricted cash related to this security
deposit of $0.2&nbsp;million to other assets in the consolidated balance sheets at December&nbsp;31, 2011 and December&nbsp;31, 2010. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=99,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=928757,FOLIO='95',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<A NAME="page_fs46501_1_96"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (16) COMMITMENTS AND CONTINGENCIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&nbsp;31, 2011 do not include the exercise of
renewal terms or early termination provisions (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,445</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,503</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total minimum lease payments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,181</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's total rent and CAM expense for all facility leases was $2.5&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> (17) RETIREMENT SAVINGS PLAN  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their
compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was
$0.2&nbsp;million, $0.2&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2011, 2010 and 2009, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> (18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>2011

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q1 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q2 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q3 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q4 2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands, except per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,952</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,363</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,059</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,772</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>2010

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q1 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q2 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q3 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q4 2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands, except per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,713</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,951</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,408</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,721</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net (loss) income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,087</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic net (loss) income per common share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Diluted net (loss) income per common share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=100,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=408535,FOLIO='96',FILE='DISK104:[12ZAA1.12ZAA46501]FS46501A.;13',USER='DPERRY',CD=';2-MAR-2012;17:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fu46501_1_97"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_9._changes_in_and_disagre__ite03576"> </A>
<A NAME="toc_fu46501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_9a._controls_and_procedures"> </A>
<A NAME="toc_fu46501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Evaluation of Disclosure Controls and Procedures  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2011, we evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the
effectiveness of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange
Act")). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
December&nbsp;31, 2011. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the
Exchange Act is recorded, processed, summarized and reported within time periods specified by the SEC's rules and forms, and that such information is accumulated and communicated to our management,
including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Management's Annual Report on Internal Control Over Financial Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control
over financial reporting is defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act as the process designed by, or under the supervision of, our Chief Executive
Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and
the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of assets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition
of assets that could have a material effect on our financial statements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of
our internal control over financial reporting based on the framework provided in </FONT><FONT SIZE=2><I>Internal Control&#151;Integrated Framework</I></FONT><FONT SIZE=2> issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of
December&nbsp;31, 2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effectiveness of our internal control over financial reporting as of December&nbsp;31, 2011 has been audited by PricewaterhouseCoopers&nbsp;LLP, an independent registered public
accounting firm, as stated in their report, which is included herein. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=147697,FOLIO='97',FILE='DISK104:[12ZAA1.12ZAA46501]FU46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<A NAME="page_fu46501_1_98"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Changes in Internal Control Over Financial Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were no changes in our internal control over financial reporting during the three months ended December&nbsp;31, 2011 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_9b._other_information"> </A>
<A NAME="toc_fu46501_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. <A NAME="PartIII"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_part_iii"> </A>
<A NAME="toc_fu46501_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PART III    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_10._directors,_executive___ite02336"> </A>
<A NAME="toc_fu46501_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;10 will be included in the definitive Proxy Statement for our 2012 Annual Meeting of
Stockholders, or the 2012 Proxy Statement, under "Information Regarding the Current Directors and Executive Officers of Celldex Therapeutic,&nbsp;Inc.," "Section&nbsp;16(a) Beneficial Ownership
Reporting Compliance," "Code of Business Conduct and Ethics" and "The Board of Directors and Its Committees" and is incorporated herein by reference. If the 2012 Proxy Statement is not filed with the
SEC within 120&nbsp;days after the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_11._executive_compensation"> </A>
<A NAME="toc_fu46501_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;11 will be included in the 2012 Proxy Statement under "Executive Compensation," and
"Compensation Committee Interlocks and Insider Participation," and is incorporated herein by reference. If the 2012 Proxy Statement is not filed with the SEC within 120&nbsp;days after the end of
our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_12._security_ownership_of__ite04004"> </A>
<A NAME="toc_fu46501_7"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;12 will be included in the 2012 Proxy Statement under "Security Ownership of Certain
Beneficial Owners and Management" and "Equity Compensation Plan Information" and is incorporated herein by reference. If the 2012 Proxy Statement is not filed with the SEC within 120&nbsp;days after
the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_13._certain_relationships__ite03067"> </A>
<A NAME="toc_fu46501_8"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;13 will be included in the 2012 Proxy Statement under "Election of Directors" and
"Approval of Related Person Transactions and Transactions with Related Persons" and is incorporated herein by reference. If the 2012 Proxy Statement is not filed with the SEC within 120&nbsp;days
after the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K.
<A NAME="it14"></A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fu46501_item_14._principal_accounting_fees_and_services"> </A>
<A NAME="toc_fu46501_9"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;PRINCIPAL ACCOUNTING FEES AND SERVICES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;14 will be included in the 2012 Proxy Statement under "Independent Registered Public
Accounting Firm" and is incorporated herein by reference. If the 2012 Proxy Statement is not filed with the SEC within 120&nbsp;days after the end of our most recent fiscal year, we will provide
such information by means of an amendment to this Annual Report on Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=102,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=345276,FOLIO='98',FILE='DISK104:[12ZAA1.12ZAA46501]FU46501A.;10',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fw46501_1_99"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="partiv"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fw46501_part_iv"> </A>
<A NAME="toc_fw46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART IV    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="fw46501_item_15._exhibits,_financial_statement_schedules"> </A>
<A NAME="toc_fw46501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS, FINANCIAL STATEMENT SCHEDULES    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
following documents are filed as part of this Form&nbsp;10-K:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Financial Statements:</I></FONT></DD></DL>
</DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Financial Statements and Supplementary Data are included in Part&nbsp;II Item&nbsp;8 of this report.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(2)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Financial Statement Schedules:</I></FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedules
are omitted since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required
is included in the Consolidated Financial Statements or Notes thereto.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(3)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Exhibits:</I></FONT></DD></DL>
</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><FONT SIZE=2><I>Plan of Acquisition, Reorganization, Arrangement, Liquidation or Succession</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of October&nbsp;19, 2007, by and among AVANT, Celldex Merger Corporation, and Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/22/07</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>2.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex Therapeutics,&nbsp;Inc., CuraGen Corporation and Cottrell Merger Sub,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/29/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><BR><FONT SIZE=2><I>Articles of Incorporation and By-Laws</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/10/02</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fourth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/11/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fifth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/11/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amended and Restated By-Laws as of March&nbsp;14, 2007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><BR><FONT SIZE=2><I>Instruments Defining the Rights of Security Holders</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen of Common Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/5/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Shareholder Rights Agreement dated November&nbsp;5, 2004</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/8/04</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=183748,FOLIO='99',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<A NAME="page_fw46501_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;1 to Shareholder Rights Agreement dated October&nbsp;19, 2007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-A/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/22/07</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment No.&nbsp;2 to Shareholder Rights Agreement dated March&nbsp;7, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-A/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/7/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Designations, Preferences and Rights of a Series of Preferred Stock classifying and designating the Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/8/04</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><BR><FONT SIZE=2><I>Material Contracts&#151;Leases</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Commercial Lease Agreement of May&nbsp;1, 1996 between the Company and Fourth Avenue Ventures Limited Partnership</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/23/96</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Extension of Lease Agreement of May&nbsp;1, 1997 between the Company and DIV Needham 53&nbsp;LLC (successor in interest to Fourth Avenue Ventures Limited Partnership) dated as of August&nbsp;23, 2001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/27/02</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>First Amendment to Lease by and between the Company and DIV Needham 53&nbsp;LLC dated November&nbsp;29, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/16/06</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Lease Agreement, by and between the Company and the Massachusetts Development Finance Agency, dated as of December&nbsp;22, 2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>4/30/04</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>First Amendment to Lease between Massachusetts Development Finance Agency and the Company dated March&nbsp;17, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Amendment to Lease by and between the Company and the Massachusetts Development Finance Agency dated as of November&nbsp;4, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/16/06</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Amendment to Lease between Massachusetts Development Finance Agency and the Company dated December&nbsp;20, 2006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fifth Amendment to Lease between Massachusetts Development Finance Agency and the Company dated October&nbsp;3, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Sixth Amendment to Lease between Massachusetts Development Finance Agency and the Company dated August&nbsp;20, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Seventh Amendment to Lease by and between the Company and the Massachusetts Development Finance Agency dated as of June&nbsp;22, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8/5/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Lease Agreement dated as of October&nbsp;21, 2005 by and between Phillipsburg Associates,&nbsp;L.P. and the Company.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=104,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=705292,FOLIO='100',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<A NAME="page_fw46501_1_101"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>First Amendment to Lease between Phillipsburg Associates,&nbsp;L.P. and the Company dated October&nbsp;11, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Subordination, Non-Disturbance and Attornment Agreement between Bank of America and the Company dated October&nbsp;11, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><BR><FONT SIZE=2><I>Material Contracts&#151;License, Collaboration, Supply and Distribution Agreements</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement between the Company and SmithKline Beecham&nbsp;PLC dated as of December&nbsp;1, 1997</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/28/00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment Agreement, dated January&nbsp;9, 2003, between the Company and SmithKline Beecham&nbsp;PLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>9/12/03</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License and Clinical Trials Agreement, effective as of February&nbsp;27, 1995, between the Company and the James&nbsp;N. Gamble Institute of Medical Research</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>9/12/03</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment Agreement between Cincinnati Children's Hospital Medical Center and the Company dated November&nbsp;17, 2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement, dated as of November&nbsp;25, 1988, by and among The Johns Hopkins University, Brigham and Women's Hospital and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>9/12/03</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Purchase Agreement, dated as of May&nbsp;16, 2005, by and between the Company and PRF Vaccine Holdings&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/18/05</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment Agreement to Purchase Agreement between the Company and PRF Vaccine Holdings&nbsp;LLC, dated as of March&nbsp;14, 2006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/15/06</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exclusive License Agreement dated February&nbsp;1, 2003 by and between Thomas Jefferson University and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to License Agreement between Thomas Jefferson University and the Company dated March&nbsp;27, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement dated as of November&nbsp;1, 2005 by and between The Rockefeller University and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement dated September&nbsp;1, 2006 by and between Duke University and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to License Agreement between Duke University and the Company dated April&nbsp;2, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement between Duke University, The Johns Hopkins University and the Company dated December&nbsp;31, 2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=105,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1017148,FOLIO='101',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<A NAME="page_fw46501_1_102"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*10.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to License Agreement between Duke University, The Johns Hopkins University and the Company dated April&nbsp;2, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Assignment and License Agreement, as amended, dated April&nbsp;6, 2004 by and among Medarex,&nbsp;Inc., GenPharm International,&nbsp;Inc. and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Research and Commercialization Agreement, as amended, dated as of April&nbsp;6, 2004 by and among Medarex,&nbsp;Inc., GenPharm International,&nbsp;Inc. and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Supply Agreement dated August&nbsp;18, 2006 by and between the Company and Biosyn</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Research Collaboration and Commercialization Agreement effective October&nbsp;20, 2006 between the Company and the Ludwig Institute for Cancer Research</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/2/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Vaccine Adjuvant License and Collaboration Agreement dated on May&nbsp;30, 2008 between the Company and 3M Innovation Properties Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/2/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exclusive Patent and Know-How License Agreement dated as of November&nbsp;5, 2008 between the Company and the University of Southampton</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/2/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License and Assignment Agreement, between Amgen&nbsp;Inc. and the Company dated March&nbsp;16, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Collaboration Agreement dated June&nbsp;18, 2004 between Seattle Genetics and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Restated Collaboration Agreement dated April&nbsp;12, 2004 and amended October&nbsp;19, 2004 between Abgenix&nbsp;Inc. and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amgen Letter Agreement, by and between CuraGen and Amgen Fremont,&nbsp;Inc. dated May&nbsp;2, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Transfer and Termination Agreement, dated as of April&nbsp;21, 2008 by and between TopoTarget A/S and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement between Medarex and Company dated September&nbsp;17, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Master Services Agreement dated March&nbsp;29, 2010 by and between the Company and Prologue Research International,&nbsp;Inc. (Prologue)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/3/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to Master Services Agreement dated July&nbsp;6, 2011 by and between the Company and Novella Clinical&nbsp;Inc. (formerly known as Prologue)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/3/11</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=106,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=366356,FOLIO='102',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<A NAME="page_fw46501_1_103"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><FONT SIZE=2><I>Material Contracts&#151;Stock Purchase, Financing and Credit Agreements</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Loan and Security Agreement, dated as of December&nbsp;30, 2010, by and among Celldex Therapeutics,&nbsp;Inc., Celldex Research Corporation and MidCap Financial,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1/6/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Promissory Note issued by Celldex Therapeutics,&nbsp;Inc. and Celldex Research Corporation to MidCap Financial,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/6/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Joinder and First Loan Modification Agreement, dated as of March&nbsp;7, 2011, by and among Celldex Therapeutics,&nbsp;Inc., Celldex Research Corporation, MidCap Funding V,&nbsp;LLC and General Electric Capital
Corporation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/9/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Promissory Note issued by Celldex Therapeutics,&nbsp;Inc. and Celldex Research Corporation to General Electric Capital Corporation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/9/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Loan Modification Agreement, dated as of March&nbsp;2, 2012, by and among Celldex Therapeutics,&nbsp;Inc., Celldex Research Corporation, MidCap Funding V,&nbsp;LLC and General Electric Capital
Corporation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/7/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Sales Agreement, dated January&nbsp;6, 2011, between Celldex Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp;&nbsp;Co.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/6/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7 style="font-family:times;"><BR><FONT SIZE=2><I>Material Contracts&#151;Management Contracts and Compensatory Plans</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>2008 Stock Option and Incentive Plan, as amended and restated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2><B>&#134;</B></FONT><FONT SIZE=2>10.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>2004 Employee Stock Purchase Plan, as amended and restated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated January&nbsp;6, 2009, by and between the Company and Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/8/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated January&nbsp;6, 2009, by and between the Company and Thomas Davis, MD</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/8/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated January&nbsp;6, 2009, by and between the Company and Tibor Keler, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/8/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amended and Restated Employment Agreement, dated January&nbsp;6, 2009, by and between the Company and Anthony S. Marucci.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/8/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amended and Restated Employment Agreement, dated July&nbsp;1, 2011, by and between the Company and Ronald&nbsp;A. Pepin, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>7/6/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Stock Option Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/25/10</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=107,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=449458,FOLIO='103',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<A NAME="page_fw46501_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bG46501A_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#134;10.56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>CuraGen 2007 Stock Incentive Plan, amended and restated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Restricted Stock Award</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>21.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>List of Subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of PricewaterhouseCoopers&nbsp;LLP, an Independent Registered Public Accounting Firm</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of President and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of Senior Vice President and Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Section&nbsp;1350 Certifications</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Furnished herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Instance Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Schema Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+103</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Label Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Confidential
treatment has been requested for certain provisions of this Exhibit pursuant to Rule&nbsp;24b-2 promulgated under the Securities
Exchange Act of 1934, as amended.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
a management contract or compensation plan, contract or arrangement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
XBRL information is being furnished and not filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and is not
incorporated by reference into any registration statement under the Securities Act of 1933, as amended. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=108,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=399821,FOLIO='104',FILE='DISK104:[12ZAA1.12ZAA46501]FW46501A.;19',USER='DPERRY',CD=';2-MAR-2012;17:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc46501_1_105"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bG46501A_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc46501_signatures"> </A>
<A NAME="toc_jc46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> CELLDEX THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p align=center style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Date</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the
dates indicated. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer, and Director<BR>
(Principal Executive Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Senior Vice President, Chief Financial Officer and Treasurer<BR>
(Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LARRY ELLBERGER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Larry Ellberger</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director, Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HERBERT J. CONRAD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Herbert J. Conrad</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;GEORGE O. ELSTON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> George O. Elston</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HARRY H. PENNER, JR.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Harry H. Penner, Jr.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;TIMOTHY M. SHANNON, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Timothy M. Shannon, M.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;KAREN L. SHOOS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Karen L. Shoos</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;8, 2012</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=109,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=161189,FOLIO='105',FILE='DISK104:[12ZAA1.12ZAA46501]JC46501A.;14',USER='MALTRI',CD=';6-MAR-2012;20:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.0
<SEQUENCE>2
<FILENAME>a2207736zex-21_0.htm
<DESCRIPTION>EX-21.0
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#12ZAA46501_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lm46501_exhibit_21.0"> </A>
<A NAME="toc_lm46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;21.0    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> LIST OF SUBSIDIARIES  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>State of Incorporation </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Celldex Research Corporation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Delaware</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=1047496,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]LM46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="12ZAA46501_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lm46501_1">Exhibit 21.0</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>a2207736zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#12ZAA46501_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lr46501_exhibit_23.1"> </A>
<A NAME="toc_lr46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in the Registration Statements on Form&nbsp;S-8
(Nos.&nbsp;333-151728, 333-117602 and 333-162423) and on Form&nbsp;S-3 (No.&nbsp;333-165899) of Celldex Therapeutics,&nbsp;Inc. of
our report dated March&nbsp;8, 2012 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Boston,
Massachusetts<BR>
March&nbsp;8, 2012 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=364795,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]LR46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="12ZAA46501_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lr46501_1">Exhibit 23.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a2207736zex-31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#12ZAA46501_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lv46501_exhibit_31.1"> </A>
<A NAME="toc_lv46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CERTIFICATION  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>I,
Anthony S. Marucci, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc.; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:67%;text-align:l;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: March&nbsp;8, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="4",CHK=167903,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]LV46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="12ZAA46501_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lv46501_1">Exhibit 31.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a2207736zex-31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#12ZAA46501_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lx46501_exhibit_31.2"> </A>
<A NAME="toc_lx46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CERTIFICATION  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>I,
Avery W. Catlin, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc.; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:67%;text-align:l;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: March&nbsp;8, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Avery W. Catlin</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Senior Vice President and<BR>
Chief Financial Officer</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="5",CHK=117528,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]LX46501A.;3',USER='AKOSMIN',CD=';2-MAR-2012;15:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="12ZAA46501_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lx46501_1">Exhibit 31.2</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>a2207736zex-32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#12ZAA46501_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lz46501_exhibit_32"> </A>
<A NAME="toc_lz46501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;32    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND<BR>
CHIEF FINANCIAL OFFICER PURSUANT TO<BR>
18 U.S.C. SECTION&nbsp;1350, AS ADOPTED PURSUANT TO<BR>
SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF&nbsp;2002  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, in his capacity as an officer of Celldex Therapeutics,&nbsp;Inc. (the "Company"), that, to his knowledge, the Annual Report of the Company on Form&nbsp;10-K
for the period ended December&nbsp;31, 2011 (the "Form&nbsp;10-K"), fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 (15
U.S.C. &sect;78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This
written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Form&nbsp;10-K. A signed original of this statement has been provided to the Company
and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;text-align:l;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: March&nbsp;8, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Date: March&nbsp;8, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Avery W. Catlin</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Senior Vice President and<BR>
Chief Financial Officer</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
certification shall be not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange
Act. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="6",CHK=408175,FOLIO='blank',FILE='DISK104:[12ZAA1.12ZAA46501]LZ46501A.;6',USER='DPERRY',CD=';2-MAR-2012;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="12ZAA46501_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lz46501_1">Exhibit 32</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2207736",CP="CELLDEX THERAPEUTICS, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>cldx-20111231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<!-- Generated by IRIS Proton Version 2.0.2.3-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cldx="http://www.celldextherapeutics.com/20111231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="cldx-20111231.xsd" />
  <xbrli:context id="D2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011PF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2009_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744218</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements id="TAG1" decimals="-3" contextRef="D2010" unitRef="USD">40187000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG2" decimals="-3" contextRef="D2009" unitRef="Shares">19823000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG3" decimals="-3" contextRef="D2010" unitRef="Shares">31868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="TAG5" decimals="-3" contextRef="D2009" unitRef="USD">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG6" decimals="-3" contextRef="D2009" unitRef="USD">-36525000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG7" decimals="-3" contextRef="D2009" unitRef="Shares">19823000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:AmortizationOfIntangibleAssets id="TAG8" decimals="-3" contextRef="D2010" unitRef="USD">3143000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="TAG9" decimals="-3" contextRef="D2009" unitRef="USD">949000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="TAG10" decimals="-3" contextRef="D2010" unitRef="USD">14000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:MarketableSecuritiesGainLoss id="TAG11" decimals="-3" contextRef="D2010" unitRef="USD">4000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:MarketableSecuritiesGainLoss id="TAG12" decimals="-3" contextRef="D2009" unitRef="USD">-24000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="TAG13" decimals="-3" contextRef="D2010" unitRef="USD">38000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="TAG14" decimals="-3" contextRef="D2009" unitRef="USD">556000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation id="TAG15" decimals="-3" contextRef="D2010" unitRef="USD">2802000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="TAG16" decimals="-3" contextRef="D2009" unitRef="USD">3058000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium id="TAG17" decimals="-3" contextRef="D2010" unitRef="USD">728000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium id="TAG18" decimals="-3" contextRef="D2009" unitRef="USD">181000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="TAG20" decimals="-3" contextRef="D2010" unitRef="USD">-220000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="TAG21" decimals="-3" contextRef="D2009" unitRef="USD">-1283000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="TAG22" decimals="-3" contextRef="D2010" unitRef="USD">546000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="TAG23" decimals="-3" contextRef="D2009" unitRef="USD">-743000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:PreferredStockValue id="TAG24" xsi:nil="true" contextRef="I2010" unitRef="USD" />
  <us-gaap:StockholdersEquity id="TAG25" decimals="-3" contextRef="I2010" unitRef="USD">75255000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="TAG26" decimals="-3" contextRef="I2010" unitRef="USD">-160207000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="TAG27" decimals="-3" contextRef="I2010" unitRef="USD">2751000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CommonStockSharesOutstanding id="TAG28" decimals="INF" contextRef="I2010" unitRef="Shares">32055382</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued id="TAG29" decimals="INF" contextRef="I2010" unitRef="Shares">32055382</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized id="TAG30" decimals="INF" contextRef="I2010" unitRef="Shares">297000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="TAG31" decimals="INF" contextRef="I2010" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesOutstanding id="TAG32" decimals="INF" contextRef="I2010" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="TAG33" decimals="INF" contextRef="I2010" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized id="TAG34" decimals="INF" contextRef="I2010" unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding id="TAG35" decimals="INF" contextRef="I2011" unitRef="Shares">44210636</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued id="TAG36" decimals="INF" contextRef="I2011" unitRef="Shares">44210636</us-gaap:CommonStockSharesIssued>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="TAG37" decimals="-3" contextRef="I2010" unitRef="USD">232679000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CommonStockSharesAuthorized id="TAG38" decimals="INF" contextRef="I2011" unitRef="Shares">297000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="TAG39" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <dei:EntityRegistrantName id="TAG40" contextRef="D2011">Celldex Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="TAG41" contextRef="D2011">0000744218</dei:EntityCentralIndexKey>
  <dei:DocumentType id="TAG42" contextRef="D2011">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="TAG43" contextRef="D2011">2011-12-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="TAG44" contextRef="D2011">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="TAG45" contextRef="D2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="TAG46" contextRef="D2011">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="TAG47" contextRef="D2011">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="TAG48" contextRef="D2011">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="TAG49" contextRef="D2011">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat id="TAG50" decimals="-5" contextRef="I2011PF" unitRef="USD">156100000</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="TAG51" decimals="INF" contextRef="I2011SO" unitRef="Shares">57160636</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="TAG52" contextRef="D2011">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="TAG53" contextRef="D2011">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:EarningsPerShareBasicAndDiluted id="TAG54" decimals="2" contextRef="D2009" unitRef="USDPerShare">-1.84</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:IncomeTaxExpenseBenefit id="TAG55" decimals="-3" contextRef="D2009" unitRef="USD">-529000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:PreferredStockSharesOutstanding id="TAG56" decimals="INF" contextRef="I2011" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="TAG57" decimals="INF" contextRef="I2011" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesAuthorized id="TAG58" decimals="INF" contextRef="I2011" unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="TAG59" decimals="INF" contextRef="I2010" unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="TAG60" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG61" decimals="-3" contextRef="D2010" unitRef="USD">-2533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG62" decimals="-3" contextRef="D2010" unitRef="Shares">31868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="TAG63" decimals="2" contextRef="D2010" unitRef="USDPerShare">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG64" decimals="-3" contextRef="D2010" unitRef="USD">-2533000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InterestExpense id="TAG65" decimals="-3" contextRef="D2010" unitRef="USD">1337000</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense id="TAG66" decimals="-3" contextRef="D2010" unitRef="USD">5259000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss id="TAG67" decimals="-3" contextRef="D2010" unitRef="USD">-6455000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CostsAndExpenses id="TAG68" decimals="-3" contextRef="D2010" unitRef="USD">53248000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense id="TAG69" decimals="-3" contextRef="D2010" unitRef="USD">10428000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GainLossOnDispositionOfAssets id="TAG70" decimals="-3" contextRef="D2010" unitRef="USD">50000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:RoyaltyExpense id="TAG71" decimals="-3" contextRef="D2010" unitRef="USD">12077000</us-gaap:RoyaltyExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="TAG72" decimals="-3" contextRef="D2010" unitRef="USD">27650000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="TAG73" decimals="-3" contextRef="D2010" unitRef="USD">46793000</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue id="TAG74" decimals="-3" contextRef="D2010" unitRef="USD">6386000</us-gaap:RoyaltyRevenue>
  <cldx:RevenueFromContractsAndGrants id="TAG75" decimals="-3" contextRef="D2010" unitRef="USD">220000</cldx:RevenueFromContractsAndGrants>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG76" decimals="-3" contextRef="D2011" unitRef="USD">-44799000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG77" decimals="-3" contextRef="D2011" unitRef="USD">-44799000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:CostsAndExpenses id="TAG78" decimals="-3" contextRef="D2011" unitRef="USD">52664000</us-gaap:CostsAndExpenses>
  <us-gaap:ComprehensiveIncomeNetOfTax id="TAG79" decimals="-3" contextRef="D2009" unitRef="USD">-36585000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="TAG80" decimals="-3" contextRef="D2010" unitRef="USD">-5592000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="TAG81" decimals="-3" contextRef="D2009" unitRef="USD">-722000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="TAG82" decimals="-3" contextRef="D2010" unitRef="USD">-1193000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="TAG83" decimals="-3" contextRef="D2009" unitRef="USD">-2463000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:Revenues id="TAG84" decimals="-3" contextRef="D2011" unitRef="USD">9265000</us-gaap:Revenues>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements id="TAG85" decimals="-3" contextRef="D2009" unitRef="USD">5662000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <us-gaap:CommonStockValue id="TAG86" decimals="-3" contextRef="I2010" unitRef="USD">32000</us-gaap:CommonStockValue>
  <us-gaap:Liabilities id="TAG87" decimals="-3" contextRef="I2010" unitRef="USD">34688000</us-gaap:Liabilities>
  <us-gaap:OtherLiabilitiesNoncurrent id="TAG88" decimals="-3" contextRef="I2010" unitRef="USD">5591000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity id="TAG89" decimals="-3" contextRef="I2011" unitRef="USD">68722000</us-gaap:StockholdersEquity>
  <us-gaap:Liabilities id="TAG90" decimals="-3" contextRef="I2011" unitRef="USD">29272000</us-gaap:Liabilities>
  <us-gaap:Assets id="TAG92" decimals="-3" contextRef="I2011" unitRef="USD">97994000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="TAG93" decimals="-3" contextRef="I2011" unitRef="USD">54684000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG94" decimals="-3" contextRef="I2010" unitRef="USD">21287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG95" decimals="-3" contextRef="I2011" unitRef="USD">11899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies id="TAG96" xsi:nil="true" contextRef="I2010" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies id="TAG97" xsi:nil="true" contextRef="I2011" unitRef="USD" />
  <us-gaap:LiabilitiesAndStockholdersEquity id="TAG98" decimals="-3" contextRef="I2010" unitRef="USD">109943000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG99" decimals="-3" contextRef="D2009" unitRef="USD">-37054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InterestExpense id="TAG100" decimals="-3" contextRef="D2009" unitRef="USD">452000</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense id="TAG101" decimals="-3" contextRef="D2009" unitRef="USD">248000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss id="TAG102" decimals="-3" contextRef="D2009" unitRef="USD">-36850000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CostsAndExpenses id="TAG103" decimals="-3" contextRef="D2009" unitRef="USD">52030000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense id="TAG104" decimals="-3" contextRef="D2009" unitRef="USD">17119000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GainLossOnDispositionOfAssets id="TAG105" decimals="-3" contextRef="D2009" unitRef="USD">604000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:RoyaltyExpense id="TAG106" decimals="-3" contextRef="D2009" unitRef="USD">8397000</us-gaap:RoyaltyExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="TAG107" decimals="-3" contextRef="D2009" unitRef="USD">26169000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="TAG108" decimals="-3" contextRef="D2009" unitRef="USD">15180000</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue id="TAG109" decimals="-3" contextRef="D2009" unitRef="USD">7716000</us-gaap:RoyaltyRevenue>
  <cldx:RevenueFromContractsAndGrants id="TAG110" decimals="-3" contextRef="D2009" unitRef="USD">1802000</cldx:RevenueFromContractsAndGrants>
  <us-gaap:ComprehensiveIncomeNetOfTax id="TAG111" decimals="-3" contextRef="D2010" unitRef="USD">-2328000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="TAG113" decimals="-3" contextRef="D2010" unitRef="USD">2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="TAG114" decimals="-3" contextRef="D2010" unitRef="USD">-39382000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="TAG115" decimals="-3" contextRef="D2009" unitRef="USD">-2038000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="TAG116" decimals="-3" contextRef="D2010" unitRef="USD">-1865000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="TAG117" decimals="-3" contextRef="D2009" unitRef="USD">2699000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="TAG118" decimals="-3" contextRef="D2011" unitRef="USD">-35658000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="TAG119" decimals="-3" contextRef="D2010" unitRef="USD">-30372000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="TAG120" decimals="-3" contextRef="D2009" unitRef="USD">-29869000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CashAcquiredFromAcquisition id="TAG121" decimals="-3" contextRef="D2009" unitRef="USD">51654000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="TAG122" decimals="-3" contextRef="D2010" unitRef="USD">42383000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="TAG123" decimals="-3" contextRef="D2009" unitRef="USD">2674000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="TAG124" decimals="-3" contextRef="D2010" unitRef="USD">56522000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="TAG125" decimals="-3" contextRef="D2009" unitRef="USD">9559000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG126" decimals="-3" contextRef="D2011_RetainedEarningsMember" unitRef="USD">-44799000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="TAG129" decimals="-3" contextRef="D2011_AdditionalPaidInCapitalMember" unitRef="USD">2342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockholdersEquity id="TAG133" decimals="-3" contextRef="I2008_CommonStockMember" unitRef="USD">16000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG134" decimals="-3" contextRef="I2008_AdditionalPaidInCapitalMember" unitRef="USD">136661000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG135" decimals="-3" contextRef="I2008_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2606000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG136" decimals="-3" contextRef="I2008_RetainedEarningsMember" unitRef="USD">-121149000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG137" decimals="-3" contextRef="I2008" unitRef="USD">18134000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="TAG138" decimals="-3" contextRef="D2009_AdditionalPaidInCapitalMember" unitRef="USD">917000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="TAG139" decimals="-3" contextRef="D2009" unitRef="USD">917000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="TAG140" decimals="-3" contextRef="D2009_CommonStockMember" unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="TAG141" decimals="-3" contextRef="D2010" unitRef="USD">2100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="TAG142" decimals="-3" contextRef="D2009_AdditionalPaidInCapitalMember" unitRef="USD">88227000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="TAG143" decimals="-3" contextRef="D2009" unitRef="USD">528000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfProductiveAssets id="TAG144" decimals="-3" contextRef="D2010" unitRef="USD">77000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:ProceedsFromSaleOfProductiveAssets id="TAG145" decimals="-3" contextRef="D2009" unitRef="USD">850000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="TAG146" decimals="-3" contextRef="D2011" unitRef="USD">-2155000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="TAG147" decimals="-3" contextRef="D2010" unitRef="USD">-16162000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="TAG148" decimals="-3" contextRef="D2009" unitRef="USD">45091000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="TAG149" decimals="-3" contextRef="D2010" unitRef="USD">1014000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="TAG150" decimals="-3" contextRef="D2009" unitRef="USD">668000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SecuredLongTermDebt id="TAG151" decimals="-3" contextRef="I2010" unitRef="USD">8889000</us-gaap:SecuredLongTermDebt>
  <us-gaap:LiabilitiesCurrent id="TAG152" decimals="-3" contextRef="I2010" unitRef="USD">20208000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleSubordinatedDebtCurrent id="TAG153" decimals="-3" contextRef="I2010" unitRef="USD">12412000</us-gaap:ConvertibleSubordinatedDebtCurrent>
  <us-gaap:PreferredStockValue id="TAG154" xsi:nil="true" contextRef="I2011" unitRef="USD" />
  <us-gaap:SecuredDebtCurrent id="TAG155" decimals="-3" contextRef="I2010" unitRef="USD">1111000</us-gaap:SecuredDebtCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="TAG156" decimals="-3" contextRef="I2010" unitRef="USD">818000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="TAG157" decimals="-3" contextRef="I2010" unitRef="USD">4936000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent id="TAG158" decimals="-3" contextRef="I2010" unitRef="USD">931000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Assets id="TAG159" decimals="-3" contextRef="I2010" unitRef="USD">109943000</us-gaap:Assets>
  <us-gaap:Goodwill id="TAG160" decimals="-3" contextRef="I2010" unitRef="USD">8965000</us-gaap:Goodwill>
  <us-gaap:OtherAssetsNoncurrent id="TAG161" decimals="-3" contextRef="I2010" unitRef="USD">363000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="TAG162" decimals="-3" contextRef="I2010" unitRef="USD">26836000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:PropertyPlantAndEquipmentNet id="TAG163" decimals="-3" contextRef="I2010" unitRef="USD">10832000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AssetsCurrent id="TAG164" decimals="-3" contextRef="I2010" unitRef="USD">62947000</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="TAG165" decimals="-3" contextRef="I2010" unitRef="USD">1525000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent id="TAG166" decimals="-3" contextRef="I2010" unitRef="USD">324000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:MarketableSecuritiesCurrent id="TAG167" decimals="-3" contextRef="I2010" unitRef="USD">39811000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity id="TAG168" decimals="-3" contextRef="I2011" unitRef="USD">97994000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG169" decimals="-3" contextRef="I2009" unitRef="USD">57002000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG170" decimals="-3" contextRef="I2008" unitRef="USD">44257000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation id="TAG171" decimals="-3" contextRef="D2009" unitRef="USD">250000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="TAG174" decimals="-3" contextRef="D2010" unitRef="USD">2718000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="TAG175" decimals="-3" contextRef="D2009" unitRef="USD">2583000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="TAG176" decimals="-3" contextRef="D2009" unitRef="USD">88243000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="TAG177" decimals="-3" contextRef="D2009_AdditionalPaidInCapitalMember" unitRef="USD">3058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="TAG178" decimals="-3" contextRef="D2009" unitRef="USD">3058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG183" decimals="-3" contextRef="D2009_RetainedEarningsMember" unitRef="USD">-36525000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:StockholdersEquity id="TAG184" decimals="-3" contextRef="I2009_CommonStockMember" unitRef="USD">32000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG185" decimals="-3" contextRef="I2009_AdditionalPaidInCapitalMember" unitRef="USD">228863000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG186" decimals="-3" contextRef="I2009_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2546000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG187" decimals="-3" contextRef="I2009_RetainedEarningsMember" unitRef="USD">-157674000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG188" decimals="-3" contextRef="I2009" unitRef="USD">73767000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="TAG189" decimals="-3" contextRef="D2010_AdditionalPaidInCapitalMember" unitRef="USD">1014000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockholdersEquity id="TAG190" decimals="-3" contextRef="I2011_RetainedEarningsMember" unitRef="USD">-205006000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG191" decimals="-3" contextRef="I2011_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2652000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG192" decimals="-3" contextRef="I2011_AdditionalPaidInCapitalMember" unitRef="USD">271032000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG193" decimals="-3" contextRef="I2011_CommonStockMember" unitRef="USD">44000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="TAG195" decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">172592</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="TAG196" decimals="INF" contextRef="D2009_CommonStockMember" unitRef="Shares">15722713</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="TAG198" decimals="INF" contextRef="D2010_CommonStockMember" unitRef="Shares">370321</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:BasisOfAccounting id="TAG200" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(1) NATURE OF BUSINESS AND OVERVIEW &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Celldex Therapeutics,&amp;#160;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase&amp;#160;3 study for the treatment of glioblastoma, CDX-011, an antibody-drug conjugate in a randomized Phase&amp;#160;2b study for the treatment of advanced breast cancer and CDX-1127, a therapeutic human antibody in a Phase&amp;#160;1 study for cancer indications. The Company has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&amp;#8482; program, CDX-301, an immune cell mobilizing agent, and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's collaboration with GlaxoSmithKline (Glaxo) resulted in the commercialization of Rotarix, an oral human rotavirus vaccine. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2011, the Company had cash, cash equivalents and marketable securities of $53.3&amp;#160;million; working capital of $40.4&amp;#160;million; and a Term Loan balance of $15.1&amp;#160;million. The Company incurred a loss of $44.8&amp;#160;million for the year ended December&amp;#160;31, 2011. Net cash used in operations for the year ended December&amp;#160;31, 2011 was $35.7&amp;#160;million. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&amp;#160;million in net proceeds. In February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&amp;#160;million, after deducting underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. The Company believes that the cash, cash equivalents and marketable securities at December&amp;#160;31, 2011, the $8.5&amp;#160;million raised under the Cantor Agreement in January and the $37.7&amp;#160;million raised in the underwritten public offering in February and interest income on invested funds, will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company raised net proceeds of $35.9&amp;#160;million during the year ended December&amp;#160;31, 2011 and $46.2&amp;#160;million during the two months ended February&amp;#160;29, 2012 from the sale of its common stock. During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms that reduce the Company's economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:BasisOfAccounting>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="TAG202" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(3) BUSINESS COMBINATIONS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Acquisition of CuraGen Corporation (CuraGen) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October&amp;#160;1, 2009, the Company acquired CuraGen, a former publicly-traded company. Following the CuraGen acquisition, the financial statements reflect the financial position, results of operation and cash flows of the combined companies. In connection with the CuraGen acquisition, effective October&amp;#160;1, 2009, the Company (i)&amp;#160;issued 15,722,713 shares of common stock of the Company, or 0.2739 shares, in exchange for each share of outstanding CuraGen common stock, plus cash in lieu of fractional shares (the "CuraGen Exchange Ratio"), (ii)&amp;#160;assumed the obligations under CuraGen's 2007 Stock Plan (the "CuraGen 2007 Plan") and each outstanding option to purchase common stock (a "CuraGen Stock Option") granted under the CuraGen 2007 Plan and (iii)&amp;#160;assumed the $12.5&amp;#160;million in 4% convertible subordinated debt due February&amp;#160;15, 2011 (the "CuraGen Debt"). &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The transaction was accounted for under the acquisition method of accounting. The acquisition-date fair value of the consideration transferred consisted of the fair value of the Company's common stock issued of $85.4&amp;#160;million and fair value of CuraGen Stock Options that were attributed to precombination service of $2.9&amp;#160;million. Of the CuraGen Stock Options assumed, all but 1%, were immediately vested upon closing in accordance with the terms of the stock option agreements and employment agreements. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company recorded the fair value of acquired assets and liabilities to net tangible assets, intangible assets, goodwill and a severance obligation. The difference between the aggregate consideration transferred and the fair value of assets acquired and liabilities assumed was recorded to goodwill. This goodwill relates to synergies from the CuraGen acquisition and a deferred tax liability related to acquired IPR&amp;amp;D intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;51,654&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;18,638&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;11,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Amgen Amendment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;14,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;TopoTarget Agreement&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other current and long-term assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;756&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;8,965&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;CuraGen Debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(11,503&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net deferred tax liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(5,190&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other assumed liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(3,778&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;88,242&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The values assigned to the intangible assets acquired, including the IPR&amp;amp;D, were determined based on fair market value using a risk adjusted discounted cash flow approach. The values assigned to IPR&amp;amp;D related to the development of CDX-011. At the date of acquisition, CDX-011 had not yet reached technological feasibility nor did it have any alternative future use. In December 2011, the Company completed enrollment in a randomized Phase&amp;#160;2b controlled study for CDX-011 in patients with heavily pre-treated, advanced breast cancer. The Company expects to incur approximately $1.4&amp;#160;million in 2012 on the Phase&amp;#160;2b study. Estimated revenues from CDX-011 are expected to be generated by 2016. The remaining acquired intangible assets arising from the acquisition are being amortized on a straight line basis over their estimated lives. The net deferred tax liability primarily relates to the temporary differences associated with the IPR&amp;amp;D intangible assets, which are not deductible for tax purposes. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In connection with the CuraGen acquisition, effective October&amp;#160;1, 2009, the Company, CuraGen, and The Bank of New York Mellon (the "Trustee") amended the CuraGen Debt to provide that the CuraGen Debt shall be convertible into 353,563 shares of the Company's common stock at the rate of 28.27823 shares of the Company's common stock per $1,000 principal amount of notes, or $35.36 per share. The initial carrying value of the CuraGen Debt was accreted ratably, over the term of the CuraGen Debt, to $12.5&amp;#160;million due at maturity. Interest expense on the CuraGen Debt was $0.2&amp;#160;million, $1.2&amp;#160;million and $0.3&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009 and included $0.1&amp;#160;million, $0.7&amp;#160;million and $0.2&amp;#160;million in discount accretion, respectively. In February 2011, the Company paid the Trustee $12.8&amp;#160;million to satisfy all outstanding principal and accrued interest related to the CuraGen Debt. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;CuraGen employees who did not receive offers of employment were terminated upon the consummation of the CuraGen acquisition. These employees were eligible for severance payments upon termination of employment under certain circumstances, including following the CuraGen acquisition. U.S.&amp;#160;GAAP requires severance obligations that are incurred by the acquiree for the benefit of the acquirer to be recognized as an expense in the post-combination period. Because the offer of employment was at the option of the Company, the Company has deemed the CuraGen Severance to be at its benefit. Accordingly, the Company recorded $3.3&amp;#160;million and $0.9&amp;#160;million in CuraGen severance expenses to general and administrative and research and development, respectively, in the consolidated statements of operations for the year ended December&amp;#160;31, 2009. In addition, the Company incurred $2.9&amp;#160;million in acquisition-related expenses including investment banking, legal, accounting, and valuation services in the consolidated statements of operations for the year ended December&amp;#160;31, 2009. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="TAG203" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(4) FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables set forth the Company's financial assets subject to fair value measurements: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="114"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="36"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31, 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;1 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;2 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;3 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,038&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,038&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;41,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;41,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;52,451&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,038&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;41,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="88"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="36"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31, 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;1 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;2 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Level&amp;#160;3 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,975&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,975&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;39,811&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;39,811&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,786&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,975&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;39,811&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;There have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents, marketable securities, short-term accounts receivable, accounts payable and debt obligations. The Company values its marketable securities utilizing independent pricing services which normally drive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable are reflected in the accompanying consolidated financial statements at cost, which approximates fair value due to the short-term nature of these instruments. Based on current market interest rates available to the Company for long-term liabilities with similar terms and maturities, the Company believes the fair value approximates the carrying value of the principal portion of the Term Loan and note payable at December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:MarketableSecuritiesTextBlock id="TAG204" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(5) MARKETABLE SECURITIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of marketable securities is shown below: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;
Cost &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Gross&lt;br /&gt;
Unrealized&lt;br /&gt;
Gains &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Gross&lt;br /&gt;
Unrealized&lt;br /&gt;
Losses &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fair&lt;br /&gt;
Value &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;December&amp;#160;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;19,993&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;20&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;20,013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing after one year through three years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,808&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;122&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,924&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,801&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;142&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;30,937&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,817&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,816&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing after one year through three years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,660&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,547&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;76&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,476&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;41,348&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;147&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;82&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;41,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Amortized&lt;br /&gt;
Cost &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Gross&lt;br /&gt;
Unrealized&lt;br /&gt;
Gains &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Gross&lt;br /&gt;
Unrealized&lt;br /&gt;
Losses &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Fair&lt;br /&gt;
Value &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;December&amp;#160;31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,836&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;35&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,871&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing after one year through three years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,428&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;103&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,531&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26,264&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;138&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26,402&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,798&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,814&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Maturing after one year through three years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,594&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,595&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13,392&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;19&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13,409&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;39,656&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;157&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;39,811&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be other-than-temporarily impaired as of December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:MarketableSecuritiesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="TAG205" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(6) PROPERTY AND EQUIPMENT, NET &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment include the following: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="5"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Laboratory Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,630&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,942&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Manufacturing Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,999&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,418&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Office Furniture and Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,314&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,299&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Leasehold Improvements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13,280&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13,244&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Construction in Progress&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;240&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;703&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total Property and Equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;19,463&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;19,606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Less Accumulated Depreciation and Amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,370&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(8,774&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,093&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,832&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Depreciation and amortization expense related to property and equipment was $2.2&amp;#160;million, $2.7&amp;#160;million and $2.6&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock id="TAG206" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(7) INTANGIBLE ASSETS AND GOODWILL &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible assets, net of accumulated amortization, and goodwill are as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 63.44%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 371px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"150%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="150%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="left" width="79"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="10"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center"&gt;&lt;font size="1"&gt;&lt;b&gt;Estimated&lt;br /&gt;
Life &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Cost &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Accumulated&lt;br /&gt;
Amortization &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Net &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Cost &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Accumulated&lt;br /&gt;
Amortization &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Net &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="17"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Intangible Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;Indefinite&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;11,800&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Amgen Amendment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;16&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(2,018&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12,482&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;14,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,121&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;13,379&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;TopoTarget Agreement&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(2,057&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;343&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Core Technology&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;4.5&amp;#160;&amp;#8211;&amp;#160;11&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,948&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,307&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,948&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,040&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;908&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Strategic Partner Agreement&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="center"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;630&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(630&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;630&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(224&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;406&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total Intangible Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31,278&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,355&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;24,923&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31,278&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,442&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26,836&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;Indefinite&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,965&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,965&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,965&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,965&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The estimated fair value attributed to the April 2008 agreement (TopoTarget Agreement) between the Company (as a successor to CuraGen) and TopoTarget A/S (TopoTarget) relates to the Company's rights under the TopoTarget Agreement to receive up to $6&amp;#160;million in either potential commercial milestone payments related to future net sales of Belinostat or 10% of any sublicense income received by TopoTarget (TopoTarget Payments). In February 2010, TopoTarget entered into a co-development and commercialization agreement for Belinostat with Spectrum Pharmaceuticals,&amp;#160;Inc. which resulted in the Company's receipt of $3.0&amp;#160;million of the TopoTarget Payments. The Company recorded this cash receipt as Other Income for the year ended December&amp;#160;31, 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the year ended December&amp;#160;31, 2011, the Company recorded an impairment loss of $0.3&amp;#160;million in Strategic Partnership Agreement to amortization of intangible asset expense due to the Company's termination of rights to intellectual property underlying that Strategic Partnership Agreement. During the year ended December&amp;#160;31, 2010, the Company wrote-off $0.2&amp;#160;million in Core Technology to amortization of intangible asset expense. In January 2009, the Company entered into a purchase agreement with Lohmann Animal Health International ("LAHI") to sell its poultry vaccines assets to LAHI. Under the purchase agreement, LAHI paid an upfront fee of $0.8&amp;#160;million and agreed to pay potential milestone payments. During the year ended December&amp;#160;31, 2009, the Company recorded a gain of $0.6&amp;#160;million related to the LAHI Agreement based on the upfront fee less the net book value of the related asset. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Amortization expense for intangible assets was $1.9&amp;#160;million, $3.1&amp;#160;million and $0.9&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. The estimated future amortization expense of intangible assets as of December&amp;#160;31, 2011, for the next five years is as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,089&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;994&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesDisclosureTextBlock id="TAG208" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(9) OTHER LONG-TERM LIABILITIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other long-term liabilities include the following: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31, 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="5"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred Rent&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;435&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;450&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Severance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net Deferred Tax Liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred Income from Sale of Tax Benefits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;510&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loan Payable&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;581&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;52&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;32&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,185&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,409&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Less Current Portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(219&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(818&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Long-Term Portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,966&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5,591&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Sale of Tax Benefits &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to sell New Jersey tax benefits worth $0.6&amp;#160;million (consisting of R&amp;amp;D tax credits) to an independent third party for $0.5&amp;#160;million. Under the agreement, the Company must maintain a base of operations in New Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. The Company is recognizing the $0.5 million over five years starting in 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Loan Payable &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In December 2003, the Company entered into a lease with the Massachusetts Development Finance Agency whereby the Company received a loan to finance the build-out of its manufacturing facility in Fall River, Massachusetts. Principal and interest payments on the loan are due monthly using an amortization period of 15&amp;#160;years and interest accrues at a rate of 5.5% per annum. The Company is obligated to repay the following principal amounts for the loan as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="30"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;51&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;58&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;60&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;66&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;229&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <us-gaap:LongTermDebtTextBlock id="TAG209" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(10) TERM LOAN &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In December 2010, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial,&amp;#160;LLC (MidCap) pursuant to which the Company borrowed $10&amp;#160;million (the "Term Loan") from MidCap. In March 2011, as the Company had anticipated, the Company amended the Loan Agreement and borrowed an additional $5&amp;#160;million from General Electric Capital Corporation (GECC) (collectively with MidCap, the "Lenders") to increase the amount owed under the Term Loan to $15&amp;#160;million. No additional advances are available under the Loan Agreement. The Term Loan accrues interest at a fixed annual interest rate equal to the greater of (i)&amp;#160;the sum of (A)&amp;#160;the LIBOR Rate (as defined in the Loan Agreement) plus (B)&amp;#160;6.25%; or (ii)&amp;#160;a minimum rate of 9.50%. In September 2011, the Company exercised an option to extend the interest-only period by 6&amp;#160;months from October&amp;#160;1, 2011 to April&amp;#160;1, 2012. In March 2012, the Company amended the Loan Agreement to extend the maturity date from December 2013 to December 2014 in return for an upfront fee of $25,000 and an additional fee of $37,500 due upon repayment of the Term Loan in full. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Interest on the Term Loan is payable monthly and principal is due, as amended, in 34 equal consecutive monthly installments commencing on April&amp;#160;1, 2012. All unpaid principal and accrued interest with respect to the Term Loan is due and payable on the earlier of (A)&amp;#160;December&amp;#160;30, 2014 or (B)&amp;#160;the date that the Term Loan otherwise becomes due and payable under the terms of the Loan Agreement. The Company may prepay all, but not less than all, of the Term Loan subject to a prepayment premium of 1% in year three and 2% in year two of the original principal amount of the Term Loan. There is no prepayment premium if the loan is paid off early in year four. The Company is also obligated to make a payment fee of $0.5&amp;#160;million (the "Payment Fee") upon the earlier of (A)&amp;#160;December&amp;#160;30, 2013 or (B)&amp;#160;upon repayment of the Term Loan in full prior to December&amp;#160;30, 2013. The Company is accreting the Payment Fee ratably over the original term of the Term Loan to interest expense. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The obligations of the Company under the Loan Agreement are secured by a first priority lien upon and security interest in substantially all of the Company's existing and after-acquired assets, excluding its intellectual property assets. Under the Loan Agreement, the Company is subject to specified affirmative and negative covenants customary for financings of this type. The Loan Agreement provides that, upon the occurrence of certain specified events of default customary for financings of this type, the Company's obligations under the Loan Agreement may be automatically accelerated, whereupon the Company's obligations under the Loan Agreement shall be immediately due and payable. At December&amp;#160;31, 2011, the Company believes it is in compliance with the Loan Agreement. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2011 and 2010, the Company had $0.2&amp;#160;million in capitalized deferred financing costs incurred in connection with the Term Loan and is amortizing these costs over the original term of the Term Loan to interest expense. Interest expense on the Term Loan including the accretion of the Payment Fee and amortization of the deferred financing costs was $1.6&amp;#160;million for the year ended December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company is obligated to repay the following principal amounts for the Term Loan (including Payment Fee) as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;3,971&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;5,744&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;5,735&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;15,450&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:LongTermDebtTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="TAG210" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(11) STOCKHOLDERS' EQUITY &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Common Stock &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In April 2010, the Company filed a shelf registration statement with the Securities and Exchange Commission to register for sale any combination of the types of securities described in the shelf registration statement up to a dollar amount of $150&amp;#160;million. The shelf registration became effective on April&amp;#160;22, 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In January 2011, the Company entered into a controlled equity offering sales agreement (the "Cantor Agreement") with Cantor Fitzgerald&amp;#160;&amp;amp;&amp;#160;Co. (Cantor) pursuant to which the Company may issue and sell up to 5,000,000 shares of its common stock from time to time through Cantor, acting as agent. The Company agreed to pay Cantor a commission of up to 5% of the gross proceeds from each sale and to reimburse Cantor for certain expenses incurred in connection with entering into the Cantor Agreement. The Cantor Agreement terminates upon the sale of all 5,000,000 shares or upon ten day notice by either Cantor or the Company. During the year ended December&amp;#160;31, 2011, the Company sold 575,000 shares of common stock under the Cantor Agreement and raised $2.2&amp;#160;million in net proceeds, after deducting commission and offering expenses. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&amp;#160;million in net proceeds. Under the terms of the Cantor Agreement, the Company will have the ability to sell up to 1,975,000 shares of its common stock upon the expiration or earlier waiver of the 90-day lock-up with the underwriters of the Company's recent offering in February 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May 2011, the Company issued 11,500,000 shares of its common stock in an underwritten public offering, including the underwriter's exercise of their full over-allotment option to purchase an additional 1,500,000 shares of common stock. The net proceeds to the Company were $33.7&amp;#160;million, after deducting underwriting fees and offering expenses. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&amp;#160;million, after deducting underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Convertible Preferred Stock &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2011, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated Class&amp;#160;C Preferred Stock including 350,000 shares which have been designated Series&amp;#160;C-1&amp;#160;Junior Participating Cumulative Preferred Stock (the "Series&amp;#160;C-1 Preferred Stock"). &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Shareholder Rights Plan &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's Board has adopted a Shareholder Rights Plan, as set forth in the Shareholder Rights Agreement, as amended, between the Company and Computershare Trust Company, N.A., as Rights Agent (the "Rights Agreement"). Pursuant to the terms of the Rights Agreement, the Board declared a dividend distribution of one Preferred Stock Purchase Right (a "Right") for each outstanding share of the Company's common stock. Each Right, which expires in November 2014, entitles their holder to purchase from the Company one ten-thousandth of a share (a "Unit") of Series&amp;#160;C-1 Preferred Stock at a cash exercise price of $35.00 per Unit, subject to adjustment. The Rights will trade separately from the common stock and will become exercisable only when a person or group has acquired 15% or more of the outstanding common stock or upon the commencement by a person or group of a tender offer that would result in such person or group acquiring 15% or more of the outstanding common stock other than as a result of repurchases of stock by the Company or certain inadvertent actions by a shareholder. In the event a person or group acquires 15% or more of the outstanding common stock each holder of a Right (except for any such person or group) would be entitled to receive upon exercise sufficient Units of Series&amp;#160;C-1 Preferred Stock to equal a value of two times the exercise price of the Right. In the event the Company is acquired in a merger or other business combination transaction or if 50% or more of the Company's assets or earning power is sold, each holder of a Right (except for any such person or group described above) would receive upon exercise common stock of the acquiring company with a value equal to two times the exercise price of the Right. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="TAG211" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(12) STOCK-BASED COMPENSATION &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan"), Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan") and the CuraGen 2007 Plan. There are no shares available for future grant under the Celldex Research 2005 Plan and CuraGen 2007 Plan. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Employee Stock Purchase Plan &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2011, a total of 62,500 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the 2004 ESPP Plan, each participating employee may purchase up to 250 shares of common stock per year, through payroll deductions, at a purchase price equal to 85% of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date. During the years ended December&amp;#160;31, 2011 and 2010, the Company issued 6,627 and 5,897 shares under the 2004 ESPP Plan, respectively. At December&amp;#160;31, 2011, 44,382 shares were available for issuance under the 2004 ESPP Plan. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Employee Stock Option and Incentive Plan &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&amp;#160;422A of the Internal Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash bonuses to employees, consultants and non-employee directors. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;At December&amp;#160;31, 2011, the 2008 Plan allowed for a maximum of 3,900,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to March&amp;#160;7, 2018 and grants of Incentive Stock Options made prior to October&amp;#160;20, 2017. The Company's board of directors determines the term of each option, option price, and number of shares for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five years for options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the date of grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee director stock option awards is accelerated upon a change in control as defined in the 2008 Plan. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of stock option activity for the year ended December&amp;#160;31, 2011 is as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="47"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="74"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Shares &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;br /&gt;
Per Share &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
Term (In Years) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Options Outstanding at December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;4,019,982&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.93&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;942,884&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2.90&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(61,627&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Canceled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(442,205&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;7.51&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Options Outstanding at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;4,459,034&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Options Vested and Expected to Vest at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;4,412,254&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Options Exercisable at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,818,895&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;7.16&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;5.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Shares Available for Grant under the 2008 Plan&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;953,111&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The total intrinsic value of stock options exercised during the years ended December&amp;#160;31, 2011, 2010 and 2009 was $0.03&amp;#160;million, $1.0&amp;#160;million and $0.3&amp;#160;million, respectively. The weighted average grant-date fair value of stock options granted during the years ended December&amp;#160;31, 2011, 2010 and 2009 was $1.83, $2.82 and $5.29, respectively. The total fair value of stock options vested during the years ended December&amp;#160;31, 2011, 2010 and 2009 was $2.6&amp;#160;million, $2.5&amp;#160;million and $2.6&amp;#160;million, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The aggregate intrinsic value of stock options outstanding at December&amp;#160;31, 2011 was $0.03&amp;#160;million. The aggregate intrinsic value of stock options vested and expected to vest at December&amp;#160;31, 2011 was $0.03&amp;#160;million. As of December&amp;#160;31, 2011, total compensation cost related to non-vested employee and non-employee director stock options not yet recognized was approximately $3.3&amp;#160;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.5&amp;#160;years. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Restricted Stock &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of restricted stock activity under the 2008 Plan for the year ended December&amp;#160;31, 2011 is as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="54"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Shares &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Grant Date&lt;br /&gt;
Fair Value&lt;br /&gt;
(per share) &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding and unvested at December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,338&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.96&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(15,338&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.68&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Canceled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Outstanding and unvested at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Valuation and Expenses Information &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock-based compensation expense for the years ended December&amp;#160;31, 2011, 2010 and 2009 was recorded as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,412&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,625&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,383&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;930&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,177&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,675&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,342&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,802&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,058&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The fair values of employee and non-employee director stock options granted during the years ended December&amp;#160;31, 2011, 2010 and 2009 were valued using the Black-Scholes option-pricing model with the following assumptions: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 78.11%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 228px"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="88"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="88"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="88"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Year Ended&lt;br /&gt;
December&amp;#160;31, 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Year Ended&lt;br /&gt;
December&amp;#160;31, 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Year Ended&lt;br /&gt;
December&amp;#160;31, 2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;68&amp;#160;&amp;#8211;&amp;#160;70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65&amp;#160;&amp;#8211;&amp;#160;67&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;65&amp;#160;&amp;#8211;&amp;#160;68&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected option term&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.0 Years&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.2 Years&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.5&amp;#160;&amp;#8211;&amp;#160;6.3 Years&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.4&amp;#160;&amp;#8211;&amp;#160;2.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.8&amp;#160;&amp;#8211;&amp;#160;3.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.8&amp;#160;&amp;#8211;&amp;#160;3.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="TAG214" decimals="-3" contextRef="D2010" unitRef="USD">1014000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="TAG215" decimals="-3" contextRef="D2010_AdditionalPaidInCapitalMember" unitRef="USD">2802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="TAG216" decimals="-3" contextRef="D2010" unitRef="USD">2802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG221" decimals="-3" contextRef="D2010_RetainedEarningsMember" unitRef="USD">-2533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:StockholdersEquity id="TAG222" decimals="-3" contextRef="I2010_CommonStockMember" unitRef="USD">32000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG223" decimals="-3" contextRef="I2010_AdditionalPaidInCapitalMember" unitRef="USD">232679000</us-gaap:StockholdersEquity>
  <us-gaap:RepaymentsOfSubordinatedDebt id="TAG224" decimals="-3" contextRef="D2009" unitRef="USD">2957000</us-gaap:RepaymentsOfSubordinatedDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="TAG225" decimals="-3" contextRef="D2011" unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="TAG226" decimals="-3" contextRef="D2010" unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:RepaymentsOfOtherLongTermDebt id="TAG227" decimals="-3" contextRef="D2010" unitRef="USD">197000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:RepaymentsOfOtherLongTermDebt id="TAG228" decimals="-3" contextRef="D2009" unitRef="USD">176000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="TAG229" decimals="-3" contextRef="D2010" unitRef="USD">10817000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="TAG230" decimals="-3" contextRef="D2009" unitRef="USD">-2465000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations id="TAG231" decimals="-3" contextRef="D2010" unitRef="USD">2000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations id="TAG232" decimals="-3" contextRef="D2009" unitRef="USD">-12000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="TAG233" decimals="-3" contextRef="D2010" unitRef="USD">-35715000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="TAG234" decimals="-3" contextRef="D2009" unitRef="USD">12745000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:StockholdersEquity id="TAG235" decimals="-3" contextRef="I2010_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2751000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="TAG236" decimals="-3" contextRef="I2010_RetainedEarningsMember" unitRef="USD">-160207000</us-gaap:StockholdersEquity>
  <us-gaap:IncomeTaxDisclosureTextBlock id="TAG237" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(15) INCOME TAXES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The components of income tax expense attributable to continuing operations consist of the following: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;Year Ended December&amp;#160;31, &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Income tax benefit (provision):&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;16,204&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,512&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;12,750&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;State&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;3,131&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;779&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(1,757&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Foreign&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;84&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;107&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;126&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expiration of Net Operating Losses and Research&amp;#160;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(411&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(13,924&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(3,992&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19,008&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(11,526&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;7,127&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred tax valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(19,008&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;11,526&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(6,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;529&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Included in the state tax provision above for the year ended December&amp;#160;31, 2009 is the effect of a rate decrease on the deferred tax asset and liabilities offset by a $0.5&amp;#160;million tax benefit due to non-cash tax consequences of the CuraGen acquisition. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Pre-tax book income (loss)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(44,799&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(2,533&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(37,054&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Loss at Statutory Rates&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(15,213&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(838&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(12,571&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Research and Development Credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(1,736&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(1,498&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(1,456&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;State Taxes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(3,131&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(779&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,757&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;717&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,151&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Expiration of Net Operating Losses and Research&amp;#160;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;411&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;13,924&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;3,992&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;19,008&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(11,526&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;6,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Income tax (benefit) provision&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;(529&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The principal components of the deferred tax assets and liabilities at December&amp;#160;31, 2011 and 2010, respectively, are as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="5"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Gross Deferred Tax Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net Operating Loss Carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;58,802&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;50,228&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Tax Credit Carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;20,285&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;17,998&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred Expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31,002&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;23,705&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Stock-based Compensation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,184&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,066&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Fixed Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,957&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;197&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;311&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;115,499&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;97,265&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Gross Deferred Tax Liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other Acquired Intangibles&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,878&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(5,615&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;IPR&amp;amp;D Intangibles&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred License Costs and Other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(37&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(9,539&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,313&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;105,960&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;86,952&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Deferred Tax Assets Valuation Allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(110,621&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(91,613&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net Deferred Tax Asset (Liability)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The net deferred tax liability of $4.7&amp;#160;million at December&amp;#160;31, 2011 and 2010 relates to the temporary differences associated with the IPR&amp;amp;D intangible assets acquired in the CuraGen acquisition, which are not deductible for tax purposes. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As of December&amp;#160;31, 2011, the Company had the following federal net operating loss (NOL) carryforwards:&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Prior to the merger of the Company and AVANT, $33.0&amp;#160;million was generated by the Company which expire at various dates starting in 2023 and going through 2028; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Prior to the merger of the Company and AVANT, $132.4&amp;#160;million, net of expirations and utilization, was generated by AVANT which expire at various dates starting in 2012 and going through 2028. NOLs of $0.8&amp;#160;million were utilized in 2009. $13.0&amp;#160;million and $12.1&amp;#160;million in NOLs expired in 2011 and 2010, respectively; &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Following the merger of the Company and AVANT, $73.9&amp;#160;million was generated by the combined company which expire at various dates starting in 2028 and going through 2031; and &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Prior to its acquisition by the Company, $518.3&amp;#160;million was generated by CuraGen. &lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In general, an ownership change, as defined by Section&amp;#160;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&amp;#160;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOL carryforwards that may be utilized in future periods. The Company currently expects that it is not more likely than not that the CuraGen loss carryforwards may be utilized and, as such, no related asset has been recorded for such losses. The Company has not completed an analysis of losses generated by AVANT, however, the Company believes it is remote that $92&amp;#160;million of the AVANT loss carryforwards may be utilized in future periods and there may be substantial limitations on the Company's ability to use the remaining losses of $40.4&amp;#160;million. Following the merger of the Company and AVANT, the Company experienced changes in ownership as defined by Section&amp;#160;382 in June 2009 and December 2009. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change in ownership in October 2007. As a result of the ownership change in October 2007, utilization of the Company's NOLs prior to October 2007 is subject to an annual limitation of $4.5&amp;#160;million on $28.3&amp;#160;million of NOLs generated before that date. As a result of the ownership changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&amp;#160;million on $67.7&amp;#160;million NOLs. Any unused annual limitation may be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the Company's net assets are determined to be below or in excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Similar to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development credits ("R&amp;amp;D credit") of $20.8&amp;#160;million and $14.4&amp;#160;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOL carryforwards of approximately $88.7&amp;#160;million and the remaining federal and state R&amp;amp;D credit carryforwards of approximately $14.0&amp;#160;million and $9.2&amp;#160;million, respectively, may be substantially limited. These state NOLs and federal and state credits expire at various dates starting in 2012 going through 2031. The Company has not yet completed a study of these credits to substantiate the amounts. Until a study is completed, no amounts are being presented as an uncertain tax position. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent ownership changes, as defined in Section&amp;#160;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future taxable income. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of being realized upon the ultimate settlement with the relevant taxing authority. At December&amp;#160;31, 2011 and 2010, we had no unrecognized tax benefits. A full valuation allowance has been provided against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Massachusetts, New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company completed an examination by the Internal Revenue Service with respect to 2008 which resulted in no change to our 2008 tax return. The Company is not currently under examination by any other jurisdictions for any tax year. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss carryforwards, capitalized R&amp;amp;D expenditures and R&amp;amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance was maintained at December&amp;#160;31, 2011 against the Company's net deferred tax assets. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="TAG238" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(16) COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has facility and equipment leases that expire at various dates through 2017. Certain of these facility leases contain renewal options, early termination provisions, and provisions that escalate the base rent payments and require the Company to pay common area maintenance costs (CAM) during the lease term. The Company entered into a letter of credit facility with a national U.S. financial institution which is collateralized by a security deposit for the leased facility in Phillipsburg, New Jersey. The Company recorded restricted cash related to this security deposit of $0.2&amp;#160;million to other assets in the consolidated balance sheets at December&amp;#160;31, 2011 and December&amp;#160;31, 2010. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&amp;#160;31, 2011 do not include the exercise of renewal terms or early termination provisions (in thousands): &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,405&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,414&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,445&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,503&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;1,014&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right"&gt;&lt;font size="2"&gt;13,181&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company's total rent and CAM expense for all facility leases was $2.5&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="TAG239" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(17) RETIREMENT SAVINGS PLAN &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was $0.2&amp;#160;million, $0.2&amp;#160;million and $0.1&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="TAG240" contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited) &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="50"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 17pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;!-- COMMAND=ADD_SCROPPEDRULE,17pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q1 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q2 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q3 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q4 2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands, except per share amounts)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,516&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,952&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,363&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,433&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,059&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(10,236&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(11,772&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(12,732&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.27&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.27&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="44"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="45"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 17pt; BORDER-BOTTOM: #000000 1pt solid"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;!-- COMMAND=ADD_SCROPPEDRULE,17pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q1 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q2 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q3 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;Q4 2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="11"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands, except per share amounts)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,713&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,951&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,408&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;37,721&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Net (loss) income&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,582&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(9,525&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(9,087&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;22,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Basic net (loss) income per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.30&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.71&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Diluted net (loss) income per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.30&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.70&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:LiabilitiesCurrent decimals="-3" contextRef="I2011" unitRef="USD">14298000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingIncomeLoss decimals="-3" contextRef="D2011" unitRef="USD">-43399000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax decimals="-3" contextRef="D2011" unitRef="USD">-44898000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations decimals="-3" contextRef="D2011" unitRef="USD">-9000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="-3" contextRef="D2011" unitRef="USD">-9388000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2010" unitRef="USD">203000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2009" unitRef="USD">-48000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2008_CommonStockMember" unitRef="Shares">15789756</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2009_CommonStockMember" unitRef="Shares">31685061</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2010_CommonStockMember" unitRef="Shares">32055382</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="-3" contextRef="D2011_CommonStockMember" unitRef="USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent decimals="-3" contextRef="D2011_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent decimals="-3" contextRef="D2009_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent decimals="-3" contextRef="D2010_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2011_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2009_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">-48000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2010_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD">203000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherNoncashIncomeTaxExpense decimals="-3" contextRef="D2009" unitRef="USD">-529000</us-gaap:OtherNoncashIncomeTaxExpense>
  <us-gaap:InterestPaid decimals="-3" contextRef="D2010" unitRef="USD">604000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid decimals="-3" contextRef="D2009" unitRef="USD">157000</us-gaap:InterestPaid>
  <us-gaap:StockIssuedDuringPeriodValueOther decimals="-3" contextRef="D2011_CommonStockMember" unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodSharesOther decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">575000</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(8) ACCRUED EXPENSES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued expenses include the following: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="64"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times" align="center" colspan="5"&gt;&lt;font size="1"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accrued Royalty and License Fees&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,179&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;826&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accrued Payroll and Employee Benefits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,145&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,925&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accrued Research and Development Contract Costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,035&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,218&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Accrued Professional Fees&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;297&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;449&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Other Accrued Expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;352&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;518&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7,008&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,936&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(14) COLLABORATION AGREEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense was $1.4&amp;#160;million, $1.0&amp;#160;million and $0.7&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Medarex,&amp;#160;Inc., a subsidiary of Bristol-Myers Squibb (Medarex) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Medarex, a former related party, and the Company have entered into the following agreements, each of which was approved by a majority of its independent directors who did not have an interest in the transaction. These agreements include:&lt;/font&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style="list-style: none"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;An Assignment and License Agreement, as amended, (Assignment and License Agreement) that provides for the assignment of certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&amp;#8482; and an anti-mannose receptor product; and &lt;/font&gt;&lt;font size="2"&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#8226;&lt;/font&gt; &lt;/dt&gt;
&lt;dd style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;A Research and Commercialization Agreement, as amended, (Research and Commercialization Agreement) that provides the Company with certain rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform for generating antibodies. &lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/li&gt;&lt;/ul&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Under the terms of the Assignment and License Agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of (i)&amp;#160;the expiration of the last to expire applicable patent and (ii)&amp;#160;the tenth anniversary of the first commercial sale of such licensed product. Under the terms of the Research and Commercialization Agreement, the Company may be required to pay milestones of up to $7.0&amp;#160;million upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low- to mid-single digits on any net product sales to Medarex with respect to the development of any products containing such licensed antibodies until the later of (i)&amp;#160;the expiration of the last to expire applicable patent and (ii)&amp;#160;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, the Company exercised an option under the Research and Commercialization Agreement, whereby it licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including CDX-1127. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Rockefeller University (Rockefeller) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205 receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for educational and research purposes. The Company may be required to pay milestones of up to $3.9&amp;#160;million upon obtaining first approval for commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low- to mid-single digits on any net product sales to Rockefeller with respect to development and commercialization of the human DEC-205 receptor. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Duke University Brain Tumor Cancer Center (Duke) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to rindopepimut. The Company may be required to pay milestone of up to $1.0&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Duke with respect to development and commercialization of rindopepimut. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Ludwig Institute for Cancer Research (Ludwig) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in combination with the Company's APC Targeting Technology. The term of the agreement is for ten years. The Company may be required to pay milestones of up to $1.0&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Ludwig with respect to development and commercialization of the technology licensed from Ludwig. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Alteris Therapeutics,&amp;#160;Inc. (Alteris) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be required to pay Alteris up to $5.0&amp;#160;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including rindopepimut. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Thomas Jefferson University (TJU) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In connection with our acquisition of the assets of Alteris, the Company obtained the rights to two exclusive license agreements with TJU dated February 2003 related to the EGFRvIII tumor antigen. Under Under these licenses, the Company may be required to pay milestones of up to $3.0&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to TJU with respect to development and commercialization of rindopepimut. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;3M Company &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In June 2008, the Company and 3M Company entered into a license agreement for the exclusive worldwide rights to access 3M Company's proprietary Immune Response Modifier, Resiquimod&amp;#8482;, (and additional Toll-Like Receptor 7/8 agonists (TLR)) for clinical study with the Company's proprietary APC Targeting Technology, for use as vaccine adjuvants, with the right to sublicense the technology. The Company may be required to pay milestones of up to $3.8&amp;#160;million upon obtaining first approval for commercial sale of each product using this vaccine adjuvant and royalty payments in the low-single digits on any net product sales to 3M Company with respect to development and commercialization of the technology licensed from 3M Company. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;University of Southampton, UK (Southampton) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. The Company may be required to pay milestones of up to approximately $1.4&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Southampton with respect to development and commercialization of CDX-1127 &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Amgen&amp;#160;Inc. (Amgen) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In March 2009, the Company entered into a license agreement with Amgen to expand its Precision Targeted Immunotherapy Platform by acquiring exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. The Company may be required to pay milestones of up to $1.3&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Amgen with respect to development and commercialization of the technology licensed from Amgen, including CDX-301. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Seattle Genetics,&amp;#160;Inc. (Seattle Genetics) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In connection with the CuraGen acquisition, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may be required to pay milestones of up to $7.5&amp;#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales to Seattle Genetics with respect to development and commercialization of the ADC technology, including CDX-011. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans decimals="INF" contextRef="D2011_CommonStockMember" unitRef="Shares">80254</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&amp;#160;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company considers all highly liquid investments purchased with a maturity date of 90&amp;#160;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Marketable Securities &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the consolidated balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Concentration of Credit Risk &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Revenue from Glaxo and Pfizer represented 98% and none for the year ended December&amp;#160;31, 2011, 14% and 85% for the year ended December&amp;#160;31, 2010 and 52% and 34% for the year ended December&amp;#160;31, 2009 of total Company revenue, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&amp;#160;GAAP: &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2: Observable inputs other than Level&amp;#160;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Property and Equipment &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's consolidated statements of operations. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Business Combinations &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Intangible Assets &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;IPR&amp;amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are maintained on the Company's consolidated balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs. IPR&amp;amp;D assets will be tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Goodwill &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Impairment of Long-Lived Assets &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. During the year ended December&amp;#160;31, 2010, the Company recorded $1.7&amp;#160;million to other income related to IRS Qualifying Therapeutic Discovery Grants because the grant arrangement was not part of the Company's on-going operations. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Research and Development Expenses &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other studies, personnel costs, depreciation, license fees and funding of outside research. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Clinical trial expenses include expenses associated with clinical research organizations (CRO). The invoicing from CROs for services rendered can lag several months. We accrue the cost of services rendered in connection with CRO activities based on our estimate of site management, monitoring costs, and project management costs. We maintain regular communication with our CROs to gauge the reasonableness of our estimates. Differences between actual clinical trial expenses and estimated clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Patent Costs &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the vesting term resulting in periodic adjustments to stock-based compensation expense. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Foreign Currency Translation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&amp;#160;31, 2011 and December&amp;#160;31, 2010, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&amp;#160;million. In 2011, the Company's foreign subsidiary voluntarily liquidated in order to consolidate the Company's foreign operations into Celldex Therapeutics,&amp;#160;Inc. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Income Taxes &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Comprehensive Loss &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. In December 2011, the Company adopted a new U.S.&amp;#160;GAAP accounting standard which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements. This new standard eliminates the option to present components of other comprehensive income as part of the statement of equity. The adoption of this new standard did not have a material effect on the Company's operating results or financial position. The consolidated statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&amp;#160;31, 2011, 2010 and 2009. There were no significant reclasses to income during the years ended December&amp;#160;31, 2011, 2010 and 2009. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Net Loss Per Share &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows: &lt;/font&gt;&lt;/p&gt;
&lt;div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative"&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: times" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" align="right" width="7"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"&gt;&lt;font size="1"&gt;&lt;b&gt;Year Ended December&amp;#160;31, &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: times" align="left"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2011 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2010 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"&gt;&lt;font size="1"&gt;&lt;b&gt;2009 &lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: times"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,459,034&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,019,982&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,576,159&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Convertible debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;353,563&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;353,563&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&lt;font size="2"&gt;Restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;9,338&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;16,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px" valign="top" bgcolor="white"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;
&lt;p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,465,034&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,382,883&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,945,722&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top"&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="FONT-FAMILY: times" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Recent Accounting Pronouncements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In September 2011, the FASB amended the guidance on the annual testing of goodwill for impairment. The amended guidance will allow companies to assess qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. This guidance will be effective for the Company's fiscal year ending December&amp;#160;30, 2012. The Company does not expect the adoption of this new standard to have a material effect on its operating results or financial position. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May 2011, the FASB issued a new accounting standard which clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level&amp;#160;3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after December&amp;#160;15, 2011. The adoption of this standard is not expected to have a material impact on the Company's operating results or financial position. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:MarketableSecuritiesCurrent decimals="-3" contextRef="I2011" unitRef="USD">41413000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent decimals="-3" contextRef="I2011" unitRef="USD">170000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent decimals="-3" contextRef="I2011" unitRef="USD">1202000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet decimals="-3" contextRef="I2011" unitRef="USD">9093000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill decimals="-3" contextRef="I2011" unitRef="USD">24923000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent decimals="-3" contextRef="I2011" unitRef="USD">329000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Goodwill decimals="-3" contextRef="I2011" unitRef="USD">8965000</us-gaap:Goodwill>
  <us-gaap:AccountsPayableCurrent decimals="-3" contextRef="I2011" unitRef="USD">935000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent decimals="-3" contextRef="I2011" unitRef="USD">7008000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent decimals="-3" contextRef="I2011" unitRef="USD">219000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:SecuredDebtCurrent decimals="-3" contextRef="I2011" unitRef="USD">6136000</us-gaap:SecuredDebtCurrent>
  <us-gaap:SecuredLongTermDebt decimals="-3" contextRef="I2011" unitRef="USD">9008000</us-gaap:SecuredLongTermDebt>
  <us-gaap:OtherLiabilitiesNoncurrent decimals="-3" contextRef="I2011" unitRef="USD">5966000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:CommonStockValue decimals="-3" contextRef="I2011" unitRef="USD">44000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock decimals="-3" contextRef="I2011" unitRef="USD">271032000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax decimals="-3" contextRef="I2011" unitRef="USD">2652000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit decimals="-3" contextRef="I2011" unitRef="USD">-205006000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements decimals="-3" contextRef="D2011" unitRef="USD">110000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:RevenueFromContractsAndGrants decimals="-3" contextRef="D2011" unitRef="USD">36000</cldx:RevenueFromContractsAndGrants>
  <us-gaap:RoyaltyRevenue decimals="-3" contextRef="D2011" unitRef="USD">9119000</us-gaap:RoyaltyRevenue>
  <us-gaap:ResearchAndDevelopmentExpense decimals="-3" contextRef="D2011" unitRef="USD">32439000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RoyaltyExpense decimals="-3" contextRef="D2011" unitRef="USD">9119000</us-gaap:RoyaltyExpense>
  <us-gaap:GainLossOnDispositionOfAssets decimals="-3" contextRef="D2011" unitRef="USD">50000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:GeneralAndAdministrativeExpense decimals="-3" contextRef="D2011" unitRef="USD">9243000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AmortizationOfIntangibleAssets decimals="-3" contextRef="D2011" unitRef="USD">1913000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:NonoperatingIncomeExpense decimals="-3" contextRef="D2011" unitRef="USD">396000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:InterestExpense decimals="-3" contextRef="D2011" unitRef="USD">1796000</us-gaap:InterestExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2011" unitRef="USDPerShare">-1.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="-3" contextRef="D2011" unitRef="Shares">39501000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent decimals="-3" contextRef="D2011" unitRef="USD">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax decimals="-3" contextRef="D2011" unitRef="USD">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:DepreciationDepletionAndAmortization decimals="-3" contextRef="D2011" unitRef="USD">2248000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments decimals="-3" contextRef="D2011" unitRef="USD">-17000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:MarketableSecuritiesGainLoss decimals="-3" contextRef="D2011" unitRef="USD">-5000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment decimals="-3" contextRef="D2011" unitRef="USD">58000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation decimals="-3" contextRef="D2011" unitRef="USD">2342000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium decimals="-3" contextRef="D2011" unitRef="USD">307000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals="-3" contextRef="D2011" unitRef="USD">-154000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets decimals="-3" contextRef="D2011" unitRef="USD">-241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets decimals="-3" contextRef="D2011" unitRef="USD">-34000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities decimals="-3" contextRef="D2011" unitRef="USD">2076000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities decimals="-3" contextRef="D2011" unitRef="USD">-138000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities decimals="-3" contextRef="D2011" unitRef="USD">51003000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities decimals="-3" contextRef="D2011" unitRef="USD">52717000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals="-3" contextRef="D2011" unitRef="USD">509000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfProductiveAssets decimals="-3" contextRef="D2011" unitRef="USD">68000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:ProceedsFromIssuanceOfCommonStock decimals="-3" contextRef="D2011" unitRef="USD">36023000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:RepaymentsOfConvertibleDebt decimals="-3" contextRef="D2011" unitRef="USD">12503000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RepaymentsOfOtherLongTermDebt decimals="-3" contextRef="D2011" unitRef="USD">86000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="-3" contextRef="D2011" unitRef="USD">28434000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:InterestPaid decimals="-3" contextRef="D2011" unitRef="USD">1560000</us-gaap:InterestPaid>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan decimals="-3" contextRef="D2011_AdditionalPaidInCapitalMember" unitRef="USD">173000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan decimals="-3" contextRef="D2011" unitRef="USD">173000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueOther decimals="-3" contextRef="D2011_AdditionalPaidInCapitalMember" unitRef="USD">2154000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther decimals="-3" contextRef="D2011" unitRef="USD">2155000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="-3" contextRef="D2011_AdditionalPaidInCapitalMember" unitRef="USD">33684000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues decimals="-3" contextRef="D2011" unitRef="USD">33695000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue decimals="-3" contextRef="D2011" unitRef="USD">2342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares">44210636</us-gaap:CommonStockSharesIssued>
  <cldx:SignificantRevenueArrangementsDisclosureTextBlock contextRef="D2011">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;b&gt;(13) SIGNIFICANT REVENUE ARRANGEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;A summary of the Company's significant revenue contracts and arrangements follows: &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;GlaxoSmithKline&amp;#160;plc (Glaxo) and Paul Royalty Fund II,&amp;#160;L.P. (PRF) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In 1997, the Company entered into an agreement with Glaxo to collaborate on the development and commercialization of the Company's oral rotavirus strain and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. The Company's licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine in 1995 and owes a license fee of 30% to Cincinnati Children's Hospital Medical Center (CCH) on net royalties received from Glaxo. The Company is obligated to maintain a license with CCH with respect to the Glaxo agreement. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon 90&amp;#160;days prior written notice. The last relevant patent is scheduled to expire in December 2012. No additional milestone payments are due from Glaxo under the agreement. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In May 2005, the Company entered into an agreement whereby an affiliate of PRF purchased a 70% interest in the milestone payments and net royalties the Company will receive on worldwide sales of Rotarix. We have received a total of $60&amp;#160;million in milestone payments under the PRF agreement. No additional milestone payments are due from PRF under the agreement. The PRF agreement terminates in December 2012, unless otherwise extended. The Company's retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. Product royalty revenue and royalty expense related to the Company's retained interest in Rotarix was $9.1&amp;#160;million, $6.4&amp;#160;million and $7.7&amp;#160;million for the years ended December&amp;#160;31, 2011, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Pfizer Inc. (Pfizer) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In April 2008, the Company and Pfizer entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide license to rindopepimut. Under the Pfizer Agreement, Pfizer made an upfront payment to the Company of $40&amp;#160;million and made a $10&amp;#160;million equity investment in the Company. The Pfizer Agreement also provided for reimbursement by Pfizer of all costs incurred by the Company in connection with the collaboration since the effective date. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company had determined that its performance obligations under this collaboration should be accounted for as a single unit of accounting. The Company's deliverables under this collaboration primarily included an exclusive license to rindopepimut, research and development services as required under the collaboration and participation in the joint clinical development committee. The Company had estimated that its expected performance period under the collaboration would be 9.5&amp;#160;years based on an assessment of the period over which the Company would have met its performance obligations under the collaboration. The $40&amp;#160;million up-front payment and research and development reimbursements were initially recorded as deferred revenue and recognized as revenue over this 9.5&amp;#160;year period. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In November 2010, the Pfizer Agreement was terminated (the "Pfizer Termination") and all rights to rindopepimut were returned to the Company. Pfizer did not provide a reason for termination. As a result of the Pfizer Termination, the Company recognized the remaining deferred revenue related to the Pfizer Agreement to product development and licensing agreement revenue during the year ended December&amp;#160;31, 2010. The Company recorded $39.9&amp;#160;million and $5.2&amp;#160;million in product development and licensing agreement revenue under the Pfizer Agreement during the years ended December&amp;#160;31, 2010 and 2009, respectively. The Company incurred and invoiced Pfizer reimbursable costs related to the Pfizer collaboration of $0.8&amp;#160;million and $3.2&amp;#160;million for the years ended December&amp;#160;31, 2010 and 2009, respectively. Effective with the Pfizer Termination, Pfizer is no longer funding the development of rindopepimut. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In connection with the Pfizer Agreement, the Company paid a total of $6.9&amp;#160;million in sublicense fees to Duke University and Thomas Jefferson University. The Company recorded these deferred sublicense fees to other assets in the consolidated balance sheets and was amortizing them to royalty expense over the 9.5-year performance period. As a result of the Pfizer Termination, the Company recognized the remaining deferred costs related to the Pfizer Agreement to royalty expense during year ended December&amp;#160;31, 2010. The Company recorded $5.7&amp;#160;million and $0.7&amp;#160;million in royalty expense related to these deferred sublicense fees during the years ended December&amp;#160;31, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&lt;i&gt;Rockefeller University (Rockefeller) &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: times"&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company has provided research and development support to Rockefeller on the development of their vaccine, DCVax-001, which the Company refers to as CDX-2401, aimed at providing protection from infection with HIV, the virus known to cause AIDS. Payments to the Company are made on a time and materials basis. The Company recorded grant revenue from Rockefeller of $0.2&amp;#160;million and $1.8&amp;#160;million for the years ended December&amp;#160;31, 2010 and 2009, respectively. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</cldx:SignificantRevenueArrangementsDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="-3" contextRef="D2011" unitRef="Shares">39501000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cldx-20111231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<xsd:schema targetNamespace="http://www.celldextherapeutics.com/20111231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cldx="http://www.celldextherapeutics.com/20111231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20111231_pre.xml" xlink:title="Presentation Linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20111231_cal.xml" xlink:title="Calculation Linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20111231_def.xml" xlink:title="Definition Linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20111231_lab.xml" xlink:title="Label Linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/CashFlows" id="CashFlows">
        <link:definition>0040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" id="DisclosureNatureOfBusinessAndOverview">
        <link:definition>1010 - Disclosure - NATURE OF BUSINESS AND OVERVIEW</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>1020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss" id="DisclosureComprehensiveLoss">
        <link:definition>8010 - Disclosure - Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>8000 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1040 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>1050 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill" id="DisclosureIntangibleAssetsAndGoodwill">
        <link:definition>1070 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoan" id="DisclosureTermLoan">
        <link:definition>1100 - Disclosure - TERM LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" id="DisclosureOtherLongTermLiabilities">
        <link:definition>1090 - Disclosure - OTHER LONG-TERM LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>1110 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>1120 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>1150 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureBusinessCombinations" id="DisclosureBusinessCombinations">
        <link:definition>1030 - Disclosure - BUSINESS COMBINATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantRevenueArrangements" id="DisclosureSignificantRevenueArrangements">
        <link:definition>1130 - Disclosure - SIGNIFICANT REVENUE ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
        <link:definition>0030 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialData" id="DisclosureSelectedQuarterlyFinancialData">
        <link:definition>1180 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" id="DisclosureRetirementSavingsPlan">
        <link:definition>1170 - Disclosure - RETIREMENT SAVINGS PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>1160 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" id="DisclosureCollaborationAgreements">
        <link:definition>1140 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>1080 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>1060 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementOfIncomeCalc2" id="StatementOfIncomeCalc2">
        <link:definition>0021 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS CALC 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <xsd:element name="RevenueFromProductDevelopmentAndLicensingAgreements" id="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RevenueFromContractsAndGrants" id="cldx_RevenueFromContractsAndGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SignificantRevenueArrangementsDisclosureTextBlock" id="cldx_SignificantRevenueArrangementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantRevenueArrangementsDisclosureAbstract" id="cldx_SignificantRevenueArrangementsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="cldx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementDisclosureAbstract" id="cldx_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cldx-20111231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="cldx-20111231.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="cldx-20111231.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfIncomeCalc2" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfIncomeCalc2" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfIncomeCalc2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: ComprehensiveIncomeNetOfTax to NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="MarketableSecuritiesCurrent" xlink:title="MarketableSecuritiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="MarketableSecuritiesCurrent" xlink:title="calculation: AssetsCurrent to MarketableSecuritiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="AccountsAndOtherReceivablesNetCurrent" xlink:title="AccountsAndOtherReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsAndOtherReceivablesNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsAndOtherReceivablesNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="SecuredDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to SecuredDebtCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="ConvertibleSubordinatedDebtCurrent" xlink:title="ConvertibleSubordinatedDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ConvertibleSubordinatedDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to ConvertibleSubordinatedDebtCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SecuredLongTermDebt" xlink:title="calculation: Liabilities to SecuredLongTermDebt" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapitalCommonStock" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="Revenues" xlink:title="calculation: OperatingIncomeLoss to Revenues" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="calculation: Revenues to RevenueFromProductDevelopmentAndLicensingAgreements" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="RevenueFromContractsAndGrants" xlink:title="RevenueFromContractsAndGrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="RevenueFromContractsAndGrants" xlink:title="calculation: Revenues to RevenueFromContractsAndGrants" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="RoyaltyRevenue" xlink:title="calculation: Revenues to RoyaltyRevenue" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="CostsAndExpenses" xlink:title="calculation: OperatingIncomeLoss to CostsAndExpenses" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: CostsAndExpenses to ResearchAndDevelopmentExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="RoyaltyExpense" xlink:title="RoyaltyExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="RoyaltyExpense" xlink:title="calculation: CostsAndExpenses to RoyaltyExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: CostsAndExpenses to GeneralAndAdministrativeExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="GainLossOnDispositionOfAssets" xlink:title="calculation: CostsAndExpenses to GainLossOnDispositionOfAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: CostsAndExpenses to AmortizationOfIntangibleAssets" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestExpense" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeTaxExpenseBenefit" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DepreciationDepletionAndAmortization" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfIntangibleAssets" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="MarketableSecuritiesGainLoss" xlink:title="MarketableSecuritiesGainLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="MarketableSecuritiesGainLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to MarketableSecuritiesGainLoss" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnSaleOfPropertyPlantEquipment" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDebtDiscountPremium" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsAndOtherReceivables" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInOtherOperatingAssets" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInDeferredRevenue" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInOtherOperatingLiabilities" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeTaxExpense" xlink:label="OtherNoncashIncomeTaxExpense" xlink:title="OtherNoncashIncomeTaxExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="OtherNoncashIncomeTaxExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to OtherNoncashIncomeTaxExpense" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="CashAcquiredFromAcquisition" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to CashAcquiredFromAcquisition" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquireMarketableSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquireMarketableSecurities" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfProductiveAssets" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStock" use="optional" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="RepaymentsOfSubordinatedDebt" xlink:title="RepaymentsOfSubordinatedDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfSubordinatedDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfSubordinatedDebt" use="optional" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfLongTermDebt" use="optional" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfConvertibleDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfConvertibleDebt" use="optional" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="RepaymentsOfOtherLongTermDebt" xlink:title="RepaymentsOfOtherLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfOtherLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfOtherLongTermDebt" use="optional" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" use="optional" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodValueAcquisitions" use="optional" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodValueNewIssues" use="optional" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodValueOther" xlink:title="calculation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodValueOther" use="optional" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="calculation: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" use="optional" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="calculation: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesAcquisitions" use="optional" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="calculation: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesOther" xlink:title="calculation: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesOther" use="optional" order="2.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cldx-20111231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromProductDevelopmentAndLicensingAgreements" xml:lang="en-US" id="label_RevenueFromProductDevelopmentAndLicensingAgreements">Product Development and Licensing Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:to="label_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="label: RevenueFromProductDevelopmentAndLicensingAgreements to label_RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromProductDevelopmentAndLicensingAgreements_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromProductDevelopmentAndLicensingAgreements" xml:lang="en-US" id="label_RevenueFromProductDevelopmentAndLicensingAgreements_2">Revenue from Product Development and Licensing Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:to="label_RevenueFromProductDevelopmentAndLicensingAgreements_2" xlink:title="label: RevenueFromProductDevelopmentAndLicensingAgreements to label_RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromProductDevelopmentAndLicensingAgreements_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RevenueFromProductDevelopmentAndLicensingAgreements" xml:lang="en-US" id="label_RevenueFromProductDevelopmentAndLicensingAgreements_3">This element represents revenue from product development and licensing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:to="label_RevenueFromProductDevelopmentAndLicensingAgreements_3" xlink:title="label: RevenueFromProductDevelopmentAndLicensingAgreements to label_RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="RevenueFromContractsAndGrants" xlink:title="RevenueFromContractsAndGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromContractsAndGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromContractsAndGrants" xml:lang="en-US" id="label_RevenueFromContractsAndGrants">Contracts and Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsAndGrants" xlink:to="label_RevenueFromContractsAndGrants" xlink:title="label: RevenueFromContractsAndGrants to label_RevenueFromContractsAndGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromContractsAndGrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromContractsAndGrants" xml:lang="en-US" id="label_RevenueFromContractsAndGrants_2">Revenue from Contracts and Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsAndGrants" xlink:to="label_RevenueFromContractsAndGrants_2" xlink:title="label: RevenueFromContractsAndGrants to label_RevenueFromContractsAndGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromContractsAndGrants_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RevenueFromContractsAndGrants" xml:lang="en-US" id="label_RevenueFromContractsAndGrants_3">This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsAndGrants" xlink:to="label_RevenueFromContractsAndGrants_3" xlink:title="label: RevenueFromContractsAndGrants to label_RevenueFromContractsAndGrants" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:label="SignificantRevenueArrangementsDisclosureAbstract" xlink:title="SignificantRevenueArrangementsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SignificantRevenueArrangementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantRevenueArrangementsDisclosureAbstract" xml:lang="en-US" id="label_SignificantRevenueArrangementsDisclosureAbstract">SIGNIFICANT REVENUE ARRANGEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRevenueArrangementsDisclosureAbstract" xlink:to="label_SignificantRevenueArrangementsDisclosureAbstract" xlink:title="label: SignificantRevenueArrangementsDisclosureAbstract to label_SignificantRevenueArrangementsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_SignificantRevenueArrangementsDisclosureTextBlock" xlink:label="SignificantRevenueArrangementsDisclosureTextBlock" xlink:title="SignificantRevenueArrangementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantRevenueArrangementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantRevenueArrangementsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantRevenueArrangementsDisclosureTextBlock">Significant Revenue Arrangements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRevenueArrangementsDisclosureTextBlock" xlink:to="label_SignificantRevenueArrangementsDisclosureTextBlock" xlink:title="label: SignificantRevenueArrangementsDisclosureTextBlock to label_SignificantRevenueArrangementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantRevenueArrangementsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SignificantRevenueArrangementsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantRevenueArrangementsDisclosureTextBlock_2">This element may be used to capture the complete disclosure pertaining to an entity's significant revenue contracts and arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRevenueArrangementsDisclosureTextBlock" xlink:to="label_SignificantRevenueArrangementsDisclosureTextBlock_2" xlink:title="label: SignificantRevenueArrangementsDisclosureTextBlock to label_SignificantRevenueArrangementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantRevenueArrangementsDisclosureTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantRevenueArrangementsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantRevenueArrangementsDisclosureTextBlock_3">SIGNIFICANT REVENUE ARRANGEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRevenueArrangementsDisclosureTextBlock" xlink:to="label_SignificantRevenueArrangementsDisclosureTextBlock_3" xlink:title="label: SignificantRevenueArrangementsDisclosureTextBlock to label_SignificantRevenueArrangementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label: DocumentAndEntityInformationAbstract to label_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to label_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label: StatementTable to label_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Statement, Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to label_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to label_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label: StatementLineItems to label_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems_2">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems_2" xlink:title="label: StatementLineItems to label_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label: AssetsAbstract to label_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract_2">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_2" xlink:title="label: AssetsAbstract to label_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract_2">Current Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_2" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">Cash and Cash Equivalents at Beginning of Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_4">Cash and Cash Equivalents at End of Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="MarketableSecuritiesCurrent" xlink:title="MarketableSecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MarketableSecuritiesCurrent" xml:lang="en-US" id="label_MarketableSecuritiesCurrent">Marketable Securities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesCurrent" xlink:to="label_MarketableSecuritiesCurrent" xlink:title="label: MarketableSecuritiesCurrent to label_MarketableSecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MarketableSecuritiesCurrent" xml:lang="en-US" id="label_MarketableSecuritiesCurrent_2">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesCurrent" xlink:to="label_MarketableSecuritiesCurrent_2" xlink:title="label: MarketableSecuritiesCurrent to label_MarketableSecuritiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="AccountsAndOtherReceivablesNetCurrent" xlink:title="AccountsAndOtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US" id="label_AccountsAndOtherReceivablesNetCurrent">Accounts and Other Receivables, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsAndOtherReceivablesNetCurrent" xlink:to="label_AccountsAndOtherReceivablesNetCurrent" xlink:title="label: AccountsAndOtherReceivablesNetCurrent to label_AccountsAndOtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsAndOtherReceivablesNetCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US" id="label_AccountsAndOtherReceivablesNetCurrent_2">Accounts and Other Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsAndOtherReceivablesNetCurrent" xlink:to="label_AccountsAndOtherReceivablesNetCurrent_2" xlink:title="label: AccountsAndOtherReceivablesNetCurrent to label_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Prepaid and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label: AssetsCurrent to label_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent_2">Total Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_2" xlink:title="label: AssetsCurrent to label_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwill">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="label_IntangibleAssetsNetExcludingGoodwill" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to label_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwill_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwill_2">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="label_IntangibleAssetsNetExcludingGoodwill_2" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to label_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent" xlink:title="label: OtherAssetsNoncurrent to label_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent_2">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent_2" xlink:title="label: OtherAssetsNoncurrent to label_OtherAssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="label_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Goodwill" xml:lang="en-US" id="label_Goodwill">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="label_Goodwill" xlink:title="label: Goodwill to label_Goodwill" />
    <link:label xlink:type="resource" xlink:label="label_Goodwill_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Goodwill" xml:lang="en-US" id="label_Goodwill_2">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="label_Goodwill_2" xlink:title="label: Goodwill to label_Goodwill" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label: Assets to label_Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets_2">Total Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_2" xlink:title="label: Assets to label_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_2">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract">Supplemental Disclosure of Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract_2">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract_2" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_2">Current Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_2" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent_2">Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent_2" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to label_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_2">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_2" xlink:title="label: AccruedLiabilitiesCurrent to label_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherLiabilitiesCurrent" xml:lang="en-US" id="label_OtherLiabilitiesCurrent">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="label_OtherLiabilitiesCurrent" xlink:title="label: OtherLiabilitiesCurrent to label_OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherLiabilitiesCurrent" xml:lang="en-US" id="label_OtherLiabilitiesCurrent_2">Current Portion of Long-Term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="label_OtherLiabilitiesCurrent_2" xlink:title="label: OtherLiabilitiesCurrent to label_OtherLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SecuredDebtCurrent" xml:lang="en-US" id="label_SecuredDebtCurrent">Current Portion of Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="label_SecuredDebtCurrent" xlink:title="label: SecuredDebtCurrent to label_SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SecuredDebtCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SecuredDebtCurrent" xml:lang="en-US" id="label_SecuredDebtCurrent_2">Secured Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="label_SecuredDebtCurrent_2" xlink:title="label: SecuredDebtCurrent to label_SecuredDebtCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="ConvertibleSubordinatedDebtCurrent" xlink:title="ConvertibleSubordinatedDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleSubordinatedDebtCurrent" xml:lang="en-US" id="label_ConvertibleSubordinatedDebtCurrent">Convertible Subordinated Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedDebtCurrent" xlink:to="label_ConvertibleSubordinatedDebtCurrent" xlink:title="label: ConvertibleSubordinatedDebtCurrent to label_ConvertibleSubordinatedDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedDebtCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleSubordinatedDebtCurrent" xml:lang="en-US" id="label_ConvertibleSubordinatedDebtCurrent_2">Convertible Subordinated Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedDebtCurrent" xlink:to="label_ConvertibleSubordinatedDebtCurrent_2" xlink:title="label: ConvertibleSubordinatedDebtCurrent to label_ConvertibleSubordinatedDebtCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent_2">Total Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_2" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRevenueCurrent" xml:lang="en-US" id="label_DeferredRevenueCurrent">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="label_DeferredRevenueCurrent" xlink:title="label: DeferredRevenueCurrent to label_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRevenueCurrent" xml:lang="en-US" id="label_DeferredRevenueCurrent_2">Current Portion of Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="label_DeferredRevenueCurrent_2" xlink:title="label: DeferredRevenueCurrent to label_DeferredRevenueCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SecuredLongTermDebt" xml:lang="en-US" id="label_SecuredLongTermDebt">Term Loan, less Current Portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredLongTermDebt" xlink:to="label_SecuredLongTermDebt" xlink:title="label: SecuredLongTermDebt to label_SecuredLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_SecuredLongTermDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SecuredLongTermDebt" xml:lang="en-US" id="label_SecuredLongTermDebt_2">Secured Long-term Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredLongTermDebt" xlink:to="label_SecuredLongTermDebt_2" xlink:title="label: SecuredLongTermDebt to label_SecuredLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="label_OtherLiabilitiesNoncurrent">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="label_OtherLiabilitiesNoncurrent" xlink:title="label: OtherLiabilitiesNoncurrent to label_OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="label_OtherLiabilitiesNoncurrent_2">Other Long-Term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="label_OtherLiabilitiesNoncurrent_2" xlink:title="label: OtherLiabilitiesNoncurrent to label_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities" xlink:title="label: Liabilities to label_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities_2">Total Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities_2" xlink:title="label: Liabilities to label_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies_2">Commitments and Contingent Liabilities (Notes 14 and 16)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_2" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' Equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract_2">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_2" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue" xlink:title="label: PreferredStockValue to label_PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue_2">Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December 31, 2011 and 2010</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue_2" xlink:title="label: PreferredStockValue to label_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label: CommonStockValue to label_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue_2">Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 44,210,636 and 32,055,382 Shares Issued and Outstanding at December 31, 2011 and 2010, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_2" xlink:title="label: CommonStockValue to label_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalCommonStock" xml:lang="en-US" id="label_AdditionalPaidInCapitalCommonStock">Additional Paid in Capital, Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalCommonStock" xlink:to="label_AdditionalPaidInCapitalCommonStock" xlink:title="label: AdditionalPaidInCapitalCommonStock to label_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalCommonStock" xml:lang="en-US" id="label_AdditionalPaidInCapitalCommonStock_2">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalCommonStock" xlink:to="label_AdditionalPaidInCapitalCommonStock_2" xlink:title="label: AdditionalPaidInCapitalCommonStock to label_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_2">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_2" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label: StockholdersEquity to label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_2">Total Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label: StockholdersEquity to label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_3">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_3" xlink:title="label: StockholdersEquity to label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_4">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_4" xlink:title="label: StockholdersEquity to label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_5">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_5" xlink:title="label: StockholdersEquity to label_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_2">Total Liabilities and Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_2" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRevenueNoncurrent" xml:lang="en-US" id="label_DeferredRevenueNoncurrent">Deferred Revenue, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="label_DeferredRevenueNoncurrent" xlink:title="label: DeferredRevenueNoncurrent to label_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRevenueNoncurrent" xml:lang="en-US" id="label_DeferredRevenueNoncurrent_2">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="label_DeferredRevenueNoncurrent_2" xlink:title="label: DeferredRevenueNoncurrent to label_DeferredRevenueNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="ConvertibleSubordinatedDebtNoncurrent" xlink:title="ConvertibleSubordinatedDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleSubordinatedDebtNoncurrent" xml:lang="en-US" id="label_ConvertibleSubordinatedDebtNoncurrent">Convertible Subordinated Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedDebtNoncurrent" xlink:to="label_ConvertibleSubordinatedDebtNoncurrent" xlink:title="label: ConvertibleSubordinatedDebtNoncurrent to label_ConvertibleSubordinatedDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSubordinatedDebtNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleSubordinatedDebtNoncurrent" xml:lang="en-US" id="label_ConvertibleSubordinatedDebtNoncurrent_2">Convertible Subordinated Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSubordinatedDebtNoncurrent" xlink:to="label_ConvertibleSubordinatedDebtNoncurrent_2" xlink:title="label: ConvertibleSubordinatedDebtNoncurrent to label_ConvertibleSubordinatedDebtNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_2">Convertible Preferred Stock, Par Value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_2" xlink:title="label: PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_2">Convertible Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_2" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to label_PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued_2">Convertible Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_2" xlink:title="label: PreferredStockSharesIssued to label_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_2">Convertible Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_2" xlink:title="label: PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Common Stock, Par Value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_2">Common Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_2" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_3">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_3" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_4">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_4" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract_2">REVENUE:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract_2" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RoyaltyRevenue" xml:lang="en-US" id="label_RoyaltyRevenue">Royalty Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="label_RoyaltyRevenue" xlink:title="label: RoyaltyRevenue to label_RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyRevenue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RoyaltyRevenue" xml:lang="en-US" id="label_RoyaltyRevenue_2">Product Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="label_RoyaltyRevenue_2" xlink:title="label: RoyaltyRevenue to label_RoyaltyRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="label_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Revenues" xml:lang="en-US" id="label_Revenues">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues" xlink:title="label: Revenues to label_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_Revenues_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Revenues" xml:lang="en-US" id="label_Revenues_2">Total Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues_2" xlink:title="label: Revenues to label_Revenues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract">Costs and Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract_2">OPERATING EXPENSE:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract_2" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_2">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_2" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="RoyaltyExpense" xlink:title="RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RoyaltyExpense" xml:lang="en-US" id="label_RoyaltyExpense">Royalty Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyExpense" xlink:to="label_RoyaltyExpense" xlink:title="label: RoyaltyExpense to label_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RoyaltyExpense" xml:lang="en-US" id="label_RoyaltyExpense_2">Royalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyExpense" xlink:to="label_RoyaltyExpense_2" xlink:title="label: RoyaltyExpense to label_RoyaltyExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_2">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_2" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnDispositionOfAssets" xml:lang="en-US" id="label_GainLossOnDispositionOfAssets">Gain (Loss) on Disposition of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="label_GainLossOnDispositionOfAssets" xlink:title="label: GainLossOnDispositionOfAssets to label_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDispositionOfAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnDispositionOfAssets" xml:lang="en-US" id="label_GainLossOnDispositionOfAssets_2">Gain on Sale of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="label_GainLossOnDispositionOfAssets_2" xlink:title="label: GainLossOnDispositionOfAssets to label_GainLossOnDispositionOfAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets" xlink:title="label: AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets_2">Amortization of Acquired Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets_2" xlink:title="label: AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets_3">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets_3" xlink:title="label: AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses">Costs and Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses_2">Total Operating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses_2" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss_2">Operating Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_2" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to label_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense_2">Investment and Other Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense_2" xlink:title="label: NonoperatingIncomeExpense to label_NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense" xlink:title="label: InterestExpense to label_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense_2">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_2" xlink:title="label: InterestExpense to label_InterestExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_2">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_3">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_3" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Basic and Diluted Net Loss Per Common Share (See Note 2) (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic_2">Shares Used in Calculating Basic Net Loss per Share (See Note 2) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding_2">Shares Used in Calculating Diluted Net Loss per Share (See Note 2) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to label_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Cash Flows From Operating Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2">Adjustments to Reconcile Net Loss to Cash Used in Operating Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization_2">Depreciation and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization_2" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xlink:type="resource" xlink:label="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US" id="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="label: AccretionAmortizationOfDiscountsAndPremiumsInvestments to label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xlink:type="resource" xlink:label="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US" id="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2">Amortization and Premium of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="label_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2" xlink:title="label: AccretionAmortizationOfDiscountsAndPremiumsInvestments to label_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="MarketableSecuritiesGainLoss" xlink:title="MarketableSecuritiesGainLoss" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MarketableSecuritiesGainLoss" xml:lang="en-US" id="label_MarketableSecuritiesGainLoss">Marketable Securities, Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesGainLoss" xlink:to="label_MarketableSecuritiesGainLoss" xlink:title="label: MarketableSecuritiesGainLoss to label_MarketableSecuritiesGainLoss" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesGainLoss_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_MarketableSecuritiesGainLoss" xml:lang="en-US" id="label_MarketableSecuritiesGainLoss_2">Realized Loss (Gain) on Sales and Maturities of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesGainLoss" xlink:to="label_MarketableSecuritiesGainLoss_2" xlink:title="label: MarketableSecuritiesGainLoss to label_MarketableSecuritiesGainLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment_2">(Gain) Loss on Sale or Disposal of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation_2">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_2" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to label_AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium_2">Non-Cash Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium_2" xlink:title="label: AmortizationOfDebtDiscountPremium to label_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_2">Changes in Operating Assets and Liabilities, Net of Acquisitions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsAndOtherReceivables">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="label_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="label: IncreaseDecreaseInAccountsAndOtherReceivables to label_IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsAndOtherReceivables_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsAndOtherReceivables_2">Accounts and Other Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="label_IncreaseDecreaseInAccountsAndOtherReceivables_2" xlink:title="label: IncreaseDecreaseInAccountsAndOtherReceivables to label_IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2">Prepaid and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets">Increase (Decrease) in Other Operating Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets" xlink:title="label: IncreaseDecreaseInOtherOperatingAssets to label_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingAssets_2">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="label_IncreaseDecreaseInOtherOperatingAssets_2" xlink:title="label: IncreaseDecreaseInOtherOperatingAssets to label_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2">Accounts Payable and Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_IncreaseDecreaseInDeferredRevenue">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRevenue" xlink:to="label_IncreaseDecreaseInDeferredRevenue" xlink:title="label: IncreaseDecreaseInDeferredRevenue to label_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInDeferredRevenue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_IncreaseDecreaseInDeferredRevenue_2">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRevenue" xlink:to="label_IncreaseDecreaseInDeferredRevenue_2" xlink:title="label: IncreaseDecreaseInDeferredRevenue to label_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingLiabilities">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="label_IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to label_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherOperatingLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInOtherOperatingLiabilities_2">Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="label_IncreaseDecreaseInOtherOperatingLiabilities_2" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to label_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Used in Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Cash Flows From Investing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US" id="label_ProceedsFromSaleAndMaturityOfMarketableSecurities">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="label_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="label: ProceedsFromSaleAndMaturityOfMarketableSecurities to label_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleAndMaturityOfMarketableSecurities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US" id="label_ProceedsFromSaleAndMaturityOfMarketableSecurities_2">Sales and Maturities of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="label_ProceedsFromSaleAndMaturityOfMarketableSecurities_2" xlink:title="label: ProceedsFromSaleAndMaturityOfMarketableSecurities to label_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireMarketableSecurities" xml:lang="en-US" id="label_PaymentsToAcquireMarketableSecurities">Payments to Acquire Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireMarketableSecurities" xlink:to="label_PaymentsToAcquireMarketableSecurities" xlink:title="label: PaymentsToAcquireMarketableSecurities to label_PaymentsToAcquireMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireMarketableSecurities_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireMarketableSecurities" xml:lang="en-US" id="label_PaymentsToAcquireMarketableSecurities_2">Purchases of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireMarketableSecurities" xlink:to="label_PaymentsToAcquireMarketableSecurities_2" xlink:title="label: PaymentsToAcquireMarketableSecurities to label_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_2">Acquisition of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US" id="label_ProceedsFromSaleOfProductiveAssets">Proceeds from Sale of Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="label_ProceedsFromSaleOfProductiveAssets" xlink:title="label: ProceedsFromSaleOfProductiveAssets to label_ProceedsFromSaleOfProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfProductiveAssets_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US" id="label_ProceedsFromSaleOfProductiveAssets_2">Proceeds from Sale or Disposal of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="label_ProceedsFromSaleOfProductiveAssets_2" xlink:title="label: ProceedsFromSaleOfProductiveAssets to label_ProceedsFromSaleOfProductiveAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash (Used in) Provided by Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Cash Flows From Financing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock_2">Net Proceeds from Stock Issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock_2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt">Proceeds from Issuance of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt" xlink:title="label: ProceedsFromIssuanceOfLongTermDebt to label_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt_2">Issuance of Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt_2" xlink:title="label: ProceedsFromIssuanceOfLongTermDebt to label_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="RepaymentsOfSubordinatedDebt" xlink:title="RepaymentsOfSubordinatedDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfSubordinatedDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfSubordinatedDebt" xml:lang="en-US" id="label_RepaymentsOfSubordinatedDebt">Repayments of Subordinated Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfSubordinatedDebt" xlink:to="label_RepaymentsOfSubordinatedDebt" xlink:title="label: RepaymentsOfSubordinatedDebt to label_RepaymentsOfSubordinatedDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfSubordinatedDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfSubordinatedDebt" xml:lang="en-US" id="label_RepaymentsOfSubordinatedDebt_2">Related Party Loan Due to Medarex</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfSubordinatedDebt" xlink:to="label_RepaymentsOfSubordinatedDebt_2" xlink:title="label: RepaymentsOfSubordinatedDebt to label_RepaymentsOfSubordinatedDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="RepaymentsOfOtherLongTermDebt" xlink:title="RepaymentsOfOtherLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfOtherLongTermDebt" xml:lang="en-US" id="label_RepaymentsOfOtherLongTermDebt">Repayments of Other Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfOtherLongTermDebt" xlink:to="label_RepaymentsOfOtherLongTermDebt" xlink:title="label: RepaymentsOfOtherLongTermDebt to label_RepaymentsOfOtherLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfOtherLongTermDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfOtherLongTermDebt" xml:lang="en-US" id="label_RepaymentsOfOtherLongTermDebt_2">Payment of Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfOtherLongTermDebt" xlink:to="label_RepaymentsOfOtherLongTermDebt_2" xlink:title="label: RepaymentsOfOtherLongTermDebt to label_RepaymentsOfOtherLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations to label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2">Effect of Exchange Rate Changes on Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations to label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations_2">Net (Decrease) Increase in Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2">Supplemental Disclosure of Non-Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockGrantedDuringPeriodValueSharebasedCompensation" xml:lang="en-US" id="label_StockGrantedDuringPeriodValueSharebasedCompensation">Stock Granted During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="label_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="label: StockGrantedDuringPeriodValueSharebasedCompensation to label_StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_StockGrantedDuringPeriodValueSharebasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockGrantedDuringPeriodValueSharebasedCompensation" xml:lang="en-US" id="label_StockGrantedDuringPeriodValueSharebasedCompensation_2">Shares Issued to Executive Officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="label_StockGrantedDuringPeriodValueSharebasedCompensation_2" xlink:title="label: StockGrantedDuringPeriodValueSharebasedCompensation to label_StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to label_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">NATURE OF BUSINESS AND OVERVIEW</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BasisOfAccounting" xml:lang="en-US" id="label_BasisOfAccounting">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="label_BasisOfAccounting" xlink:title="label: BasisOfAccounting to label_BasisOfAccounting" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccounting_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BasisOfAccounting" xml:lang="en-US" id="label_BasisOfAccounting_2">NATURE OF BUSINESS AND OVERVIEW</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="label_BasisOfAccounting_2" xlink:title="label: BasisOfAccounting to label_BasisOfAccounting" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to label_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAbstract">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAbstract_2">COMPREHENSIVE LOSS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_ComprehensiveIncomeNetOfTaxAbstract_2" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="ComprehensiveIncomeNoteTextBlock" xlink:title="ComprehensiveIncomeNoteTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNoteTextBlock" xml:lang="en-US" id="label_ComprehensiveIncomeNoteTextBlock">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNoteTextBlock" xlink:to="label_ComprehensiveIncomeNoteTextBlock" xlink:title="label: ComprehensiveIncomeNoteTextBlock to label_ComprehensiveIncomeNoteTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNoteTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeNoteTextBlock" xml:lang="en-US" id="label_ComprehensiveIncomeNoteTextBlock_2">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNoteTextBlock" xlink:to="label_ComprehensiveIncomeNoteTextBlock_2" xlink:title="label: ComprehensiveIncomeNoteTextBlock to label_ComprehensiveIncomeNoteTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to label_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareTextBlock" xml:lang="en-US" id="label_EarningsPerShareTextBlock">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock" xlink:title="label: EarningsPerShareTextBlock to label_EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareTextBlock" xml:lang="en-US" id="label_EarningsPerShareTextBlock_2">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock_2" xlink:title="label: EarningsPerShareTextBlock to label_EarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to label_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_2">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_2" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US" id="label_InvestmentsDebtAndEquitySecuritiesAbstract">MARKETABLE SECURITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="label_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="label: InvestmentsDebtAndEquitySecuritiesAbstract to label_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="MarketableSecuritiesTextBlock" xlink:title="MarketableSecuritiesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MarketableSecuritiesTextBlock" xml:lang="en-US" id="label_MarketableSecuritiesTextBlock">Marketable Securities [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesTextBlock" xlink:to="label_MarketableSecuritiesTextBlock" xlink:title="label: MarketableSecuritiesTextBlock to label_MarketableSecuritiesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_MarketableSecuritiesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MarketableSecuritiesTextBlock" xml:lang="en-US" id="label_MarketableSecuritiesTextBlock_2">MARKETABLE SECURITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesTextBlock" xlink:to="label_MarketableSecuritiesTextBlock_2" xlink:title="label: MarketableSecuritiesTextBlock to label_MarketableSecuritiesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetsDisclosureAbstract">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="label_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to label_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetsDisclosureTextBlock">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="label_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to label_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetsDisclosureTextBlock_2">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="label_GoodwillAndIntangibleAssetsDisclosureTextBlock_2" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to label_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureAbstract" xml:lang="en-US" id="label_DebtDisclosureAbstract">TERM LOAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="label_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to label_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtTextBlock" xml:lang="en-US" id="label_LongTermDebtTextBlock">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="label_LongTermDebtTextBlock" xlink:title="label: LongTermDebtTextBlock to label_LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtTextBlock" xml:lang="en-US" id="label_LongTermDebtTextBlock_2">TERM LOAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="label_LongTermDebtTextBlock_2" xlink:title="label: LongTermDebtTextBlock to label_LongTermDebtTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="OtherLiabilitiesDisclosureAbstract" xlink:title="OtherLiabilitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherLiabilitiesDisclosureAbstract" xml:lang="en-US" id="label_OtherLiabilitiesDisclosureAbstract">OTHER LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesDisclosureAbstract" xlink:to="label_OtherLiabilitiesDisclosureAbstract" xlink:title="label: OtherLiabilitiesDisclosureAbstract to label_OtherLiabilitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="OtherLiabilitiesDisclosureTextBlock" xlink:title="OtherLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_OtherLiabilitiesDisclosureTextBlock">Other Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesDisclosureTextBlock" xlink:to="label_OtherLiabilitiesDisclosureTextBlock" xlink:title="label: OtherLiabilitiesDisclosureTextBlock to label_OtherLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_OtherLiabilitiesDisclosureTextBlock_2">OTHER LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesDisclosureTextBlock" xlink:to="label_OtherLiabilitiesDisclosureTextBlock_2" xlink:title="label: OtherLiabilitiesDisclosureTextBlock to label_OtherLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to label_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock_2">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to label_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_2">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_2" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationsAbstract" xml:lang="en-US" id="label_BusinessCombinationsAbstract">BUSINESS COMBINATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="label_BusinessCombinationsAbstract" xlink:title="label: BusinessCombinationsAbstract to label_BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationDisclosureTextBlock" xml:lang="en-US" id="label_BusinessCombinationDisclosureTextBlock">Business Combination Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="label_BusinessCombinationDisclosureTextBlock" xlink:title="label: BusinessCombinationDisclosureTextBlock to label_BusinessCombinationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessCombinationDisclosureTextBlock" xml:lang="en-US" id="label_BusinessCombinationDisclosureTextBlock_2">BUSINESS COMBINATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="label_BusinessCombinationDisclosureTextBlock_2" xlink:title="label: BusinessCombinationDisclosureTextBlock to label_BusinessCombinationDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label: EntityRegistrantName to label_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to label_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label: DocumentType to label_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label: AmendmentFlag to label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label: AmendmentDescription to label_AmendmentDescription" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to label_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to label_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to label_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label: EntityFilerCategory to label_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label: EntityPublicFloat to label_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to label_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to label_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to label_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_2">Income Tax Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_2" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2">Net Loss Before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax_2">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax_2" xlink:title="label: ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2">Foreign Currency Translation Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">Other Comprehensive (Loss) Income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition">Cash Acquired from Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition_2">Cash Acquired in the CuraGen acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition_2" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="label: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2">Shares Issued under Stock Option and Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2" xlink:title="label: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to label_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueAcquisitions">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="label_StockIssuedDuringPeriodValueAcquisitions" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to label_StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueAcquisitions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueAcquisitions_2">Shares Issued in Connection with the CuraGen acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="label_StockIssuedDuringPeriodValueAcquisitions_2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to label_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to label_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesAcquisitions">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to label_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesAcquisitions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesAcquisitions_2">Shares Issued in Connection with the CuraGen acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_StockIssuedDuringPeriodSharesAcquisitions_2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to label_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to label_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Statement, Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to label_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label: EquityComponentDomain to label_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label: CommonStockMember to label_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember_2">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_2" xlink:title="label: CommonStockMember to label_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember_2">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember_2" xlink:title="label: AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember_2">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember_2" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember_2">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember_2" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward_2">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockholdersEquityPeriodIncreaseDecrease">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="label_StockholdersEquityPeriodIncreaseDecrease" xlink:title="label: StockholdersEquityPeriodIncreaseDecrease to label_StockholdersEquityPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPeriodIncreaseDecrease_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockholdersEquityPeriodIncreaseDecrease_2">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="label_StockholdersEquityPeriodIncreaseDecrease_2" xlink:title="label: StockholdersEquityPeriodIncreaseDecrease to label_StockholdersEquityPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="label: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_2">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_2" xlink:title="label: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementDisclosureAbstract" xml:lang="en-US" id="label_CollaborativeArrangementDisclosureAbstract">COLLABORATION AGREEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="label_CollaborativeArrangementDisclosureAbstract" xlink:title="label: CollaborativeArrangementDisclosureAbstract to label_CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="label_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to label_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock_2">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PayablesAndAccrualsAbstract" xml:lang="en-US" id="label_PayablesAndAccrualsAbstract">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="label_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to label_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to label_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock_2">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock_2" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="label_CompensationAndRetirementDisclosureAbstract">RETIREMENT SAVINGS PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="label_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to label_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">RETIREMENT SAVINGS PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US" id="label_QuarterlyFinancialInformationDisclosureAbstract">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="label: QuarterlyFinancialInformationDisclosureAbstract to label_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock_2">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock_2" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2">Unrealized (Loss) Gain on Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues_2">Shares Issued in Underwritten Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Shares Issued in Underwritten Offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_2">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeTaxExpense" xlink:label="OtherNoncashIncomeTaxExpense" xlink:title="OtherNoncashIncomeTaxExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNoncashIncomeTaxExpense" xml:lang="en-US" id="label_OtherNoncashIncomeTaxExpense">Non-Cash Tax Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeTaxExpense" xlink:to="label_OtherNoncashIncomeTaxExpense" xlink:title="label: OtherNoncashIncomeTaxExpense to label_OtherNoncashIncomeTaxExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashIncomeTaxExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNoncashIncomeTaxExpense" xml:lang="en-US" id="label_OtherNoncashIncomeTaxExpense_2">Other Noncash Income Tax Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeTaxExpense" xlink:to="label_OtherNoncashIncomeTaxExpense_2" xlink:title="label: OtherNoncashIncomeTaxExpense to label_OtherNoncashIncomeTaxExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid">Cash Paid for Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid" xlink:title="label: InterestPaid to label_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid_2">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid_2" xlink:title="label: InterestPaid to label_InterestPaid" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueOther" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueOther">Shares Issued in Connection with Cantor Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="label_StockIssuedDuringPeriodValueOther" xlink:title="label: StockIssuedDuringPeriodValueOther to label_StockIssuedDuringPeriodValueOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueOther_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueOther" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueOther_2">Stock Issued During Period, Value, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="label_StockIssuedDuringPeriodValueOther_2" xlink:title="label: StockIssuedDuringPeriodValueOther to label_StockIssuedDuringPeriodValueOther" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesOther" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOther">Shares Issued in Connection with Cantor Agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="label_StockIssuedDuringPeriodSharesOther" xlink:title="label: StockIssuedDuringPeriodSharesOther to label_StockIssuedDuringPeriodSharesOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOther_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesOther" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOther_2">Stock Issued During Period, Shares, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="label_StockIssuedDuringPeriodSharesOther_2" xlink:title="label: StockIssuedDuringPeriodSharesOther to label_StockIssuedDuringPeriodSharesOther" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US" id="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="label: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock to label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US" id="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2" xlink:title="label: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock to label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US" id="label_CollaborativeArrangementDisclosureTextBlock">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="label_CollaborativeArrangementDisclosureTextBlock" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to label_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US" id="label_CollaborativeArrangementDisclosureTextBlock_2">COLLABORATION AGREEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="label_CollaborativeArrangementDisclosureTextBlock_2" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to label_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock_2">Significant Accounting Policies Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock_2" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfConvertibleDebt">Payment of Convertible Subordinated Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfConvertibleDebt" xlink:to="label_RepaymentsOfConvertibleDebt" xlink:title="label: RepaymentsOfConvertibleDebt to label_RepaymentsOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfConvertibleDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfConvertibleDebt_2">Repayments of Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfConvertibleDebt" xlink:to="label_RepaymentsOfConvertibleDebt_2" xlink:title="label: RepaymentsOfConvertibleDebt to label_RepaymentsOfConvertibleDebt" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cldx-20111231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="cldx-20111231.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="cldx-20111231.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="cldx-20111231.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureNatureOfBusinessAndOverview" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureComprehensiveLoss" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureNetLossPerShare" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureFairValueMeasurements" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureMarketableSecurities" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureIntangibleAssetsAndGoodwill" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoan" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureTermLoan" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureOtherLongTermLiabilities" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureBusinessCombinations" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureBusinessCombinations" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantRevenueArrangements" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureSignificantRevenueArrangements" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cldx-20111231.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureSelectedQuarterlyFinancialData" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureRetirementSavingsPlan" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureCollaborationAgreements" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosureAccruedExpenses" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="simple" xlink:href="cldx-20111231.xsd#DisclosurePropertyAndEquipmentNet" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="MarketableSecuritiesCurrent" xlink:title="MarketableSecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="MarketableSecuritiesCurrent" xlink:title="presentation: AssetsCurrentAbstract to MarketableSecuritiesCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="AccountsAndOtherReceivablesNetCurrent" xlink:title="AccountsAndOtherReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsAndOtherReceivablesNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsAndOtherReceivablesNetCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SecuredDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to SecuredDebtCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="ConvertibleSubordinatedDebtCurrent" xlink:title="ConvertibleSubordinatedDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleSubordinatedDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ConvertibleSubordinatedDebtCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SecuredLongTermDebt" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to SecuredLongTermDebt" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapitalCommonStock" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="ConvertibleSubordinatedDebtNoncurrent" xlink:title="ConvertibleSubordinatedDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleSubordinatedDebtNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleSubordinatedDebtNoncurrent" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockParOrStatedValuePerShare" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesAuthorized" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesIssued" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesOutstanding" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockParOrStatedValuePerShare" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesAuthorized" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesIssued" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesOutstanding" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="presentation: StatementLineItems to RevenuesAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="presentation: RevenuesAbstract to RevenueFromProductDevelopmentAndLicensingAgreements" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="RevenueFromContractsAndGrants" xlink:title="RevenueFromContractsAndGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromContractsAndGrants" xlink:title="presentation: RevenuesAbstract to RevenueFromContractsAndGrants" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: RevenuesAbstract to RoyaltyRevenue" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="Revenues" xlink:title="presentation: RevenuesAbstract to Revenues" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="RoyaltyExpense" xlink:title="RoyaltyExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="RoyaltyExpense" xlink:title="presentation: CostsAndExpensesAbstract to RoyaltyExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to GeneralAndAdministrativeExpense" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="presentation: CostsAndExpensesAbstract to GainLossOnDispositionOfAssets" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="presentation: StatementLineItems to OperatingIncomeLoss" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: StatementLineItems to NonoperatingIncomeExpense" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="presentation: StatementLineItems to InterestExpense" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: StatementLineItems to IncomeTaxExpenseBenefit" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: StatementLineItems to EarningsPerShareBasicAndDiluted" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="presentation: StatementLineItems to ComprehensiveIncomeNetOfTaxAbstract" use="optional" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to ComprehensiveIncomeNetOfTax" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="MarketableSecuritiesGainLoss" xlink:title="MarketableSecuritiesGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="MarketableSecuritiesGainLoss" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to MarketableSecuritiesGainLoss" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingAssets" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRevenue" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeTaxExpense" xlink:label="OtherNoncashIncomeTaxExpense" xlink:title="OtherNoncashIncomeTaxExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeTaxExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeTaxExpense" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireMarketableSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireMarketableSecurities" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfProductiveAssets" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="RepaymentsOfSubordinatedDebt" xlink:title="RepaymentsOfSubordinatedDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfSubordinatedDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfSubordinatedDebt" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfLongTermDebt" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="RepaymentsOfOtherLongTermDebt" xlink:title="RepaymentsOfOtherLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfOtherLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfOtherLongTermDebt" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfConvertibleDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfConvertibleDebt" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="presentation: StatementLineItems to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementLineItems to SupplementalCashFlowInformationAbstract" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaid" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockGrantedDuringPeriodValueSharebasedCompensation" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BasisOfAccounting" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BasisOfAccounting" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="ComprehensiveIncomeNoteTextBlock" xlink:title="ComprehensiveIncomeNoteTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="ComprehensiveIncomeNoteTextBlock" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to ComprehensiveIncomeNoteTextBlock" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="MarketableSecuritiesTextBlock" xlink:title="MarketableSecuritiesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="MarketableSecuritiesTextBlock" xlink:title="presentation: InvestmentsDebtAndEquitySecuritiesAbstract to MarketableSecuritiesTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to GoodwillAndIntangibleAssetsDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureTermLoan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="OtherLiabilitiesDisclosureAbstract" xlink:title="OtherLiabilitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="OtherLiabilitiesDisclosureTextBlock" xlink:title="OtherLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherLiabilitiesDisclosureAbstract" xlink:to="OtherLiabilitiesDisclosureTextBlock" xlink:title="presentation: OtherLiabilitiesDisclosureAbstract to OtherLiabilitiesDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureBusinessCombinations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessCombinationDisclosureTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to BusinessCombinationDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureSignificantRevenueArrangements">
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:label="SignificantRevenueArrangementsDisclosureAbstract" xlink:title="SignificantRevenueArrangementsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_SignificantRevenueArrangementsDisclosureTextBlock" xlink:label="SignificantRevenueArrangementsDisclosureTextBlock" xlink:title="SignificantRevenueArrangementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantRevenueArrangementsDisclosureAbstract" xlink:to="SignificantRevenueArrangementsDisclosureTextBlock" xlink:title="presentation: SignificantRevenueArrangementsDisclosureAbstract to SignificantRevenueArrangementsDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentDescription" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentDescription" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" use="optional" order="150.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="presentation: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: StockIssuedDuringPeriodValueAcquisitions to StockIssuedDuringPeriodSharesAcquisitions" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="presentation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssued" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued_2" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssued_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssued" priority="1" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: StockIssuedDuringPeriodValueNewIssues to StockIssuedDuringPeriodSharesNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueOther" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueOther" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="StockIssuedDuringPeriodSharesOther" xlink:title="presentation: StockIssuedDuringPeriodValueOther to StockIssuedDuringPeriodSharesOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: EquityComponentDomain to AdditionalPaidInCapitalMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="presentation: EquityComponentDomain to RetainedEarningsMember" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialData">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="QuarterlyFinancialInformationTextBlock" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to QuarterlyFinancialInformationTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements">
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: CollaborativeArrangementDisclosureAbstract to CollaborativeArrangementDisclosureTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cldx-20111231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0160 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="cldx-20111231.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="cldx-20111231.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cldx-20111231.xsd#StatementOfStockholdersEquity" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract_2" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract_2" xlink:title="definition: StatementLineItems to AssetsAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="definition: AssetsAbstract to AssetsCurrentAbstract" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="MarketableSecuritiesCurrent" xlink:title="MarketableSecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="MarketableSecuritiesCurrent" xlink:title="definition: AssetsCurrentAbstract to MarketableSecuritiesCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="AccountsAndOtherReceivablesNetCurrent" xlink:title="AccountsAndOtherReceivablesNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsAndOtherReceivablesNetCurrent" xlink:title="definition: AssetsCurrentAbstract to AccountsAndOtherReceivablesNetCurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to AssetsCurrent" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsAbstract to PropertyPlantAndEquipmentNet" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="definition: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="definition: AssetsAbstract to Goodwill" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="definition: AssetsAbstract to Assets" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SecuredDebtCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to SecuredDebtCurrent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="ConvertibleSubordinatedDebtCurrent" xlink:title="ConvertibleSubordinatedDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleSubordinatedDebtCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to ConvertibleSubordinatedDebtCurrent" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SecuredLongTermDebt" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to SecuredLongTermDebt" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract_2" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract_2" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="definition: StockholdersEquityAbstract to PreferredStockValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="definition: StockholdersEquityAbstract to CommonStockValue" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="definition: StockholdersEquityAbstract to AdditionalPaidInCapitalCommonStock" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="definition: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="definition: StockholdersEquityAbstract to StockholdersEquity" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="ConvertibleSubordinatedDebtNoncurrent" xlink:title="ConvertibleSubordinatedDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleSubordinatedDebtNoncurrent" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to ConvertibleSubordinatedDebtNoncurrent" order="8010.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="definition: StatementLineItems to RevenuesAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="RevenueFromProductDevelopmentAndLicensingAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="RevenueFromProductDevelopmentAndLicensingAgreements" xlink:title="definition: RevenuesAbstract to RevenueFromProductDevelopmentAndLicensingAgreements" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cldx-20111231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="RevenueFromContractsAndGrants" xlink:title="RevenueFromContractsAndGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="RevenueFromContractsAndGrants" xlink:title="definition: RevenuesAbstract to RevenueFromContractsAndGrants" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="RoyaltyRevenue" xlink:title="definition: RevenuesAbstract to RoyaltyRevenue" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="Revenues" xlink:title="definition: RevenuesAbstract to Revenues" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="definition: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="RoyaltyExpense" xlink:title="RoyaltyExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="RoyaltyExpense" xlink:title="definition: CostsAndExpensesAbstract to RoyaltyExpense" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="definition: CostsAndExpensesAbstract to GainLossOnDispositionOfAssets" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: CostsAndExpensesAbstract to GeneralAndAdministrativeExpense" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="definition: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: StatementLineItems to OperatingIncomeLoss" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpense" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="definition: StatementLineItems to InterestExpense" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="definition: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: StatementLineItems to IncomeTaxExpenseBenefit" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareBasicAndDiluted" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="definition: StatementLineItems to ComprehensiveIncomeNetOfTaxAbstract" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:title="definition: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="definition: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="definition: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="definition: ComprehensiveIncomeNetOfTaxAbstract to ComprehensiveIncomeNetOfTax" use="optional" order="20.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="MarketableSecuritiesGainLoss" xlink:title="MarketableSecuritiesGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="MarketableSecuritiesGainLoss" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to MarketableSecuritiesGainLoss" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="IncreaseDecreaseInAccountsAndOtherReceivables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsAndOtherReceivables" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingAssets" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRevenue" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeTaxExpense" xlink:label="OtherNoncashIncomeTaxExpense" xlink:title="OtherNoncashIncomeTaxExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeTaxExpense" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeTaxExpense" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireMarketableSecurities" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireMarketableSecurities" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfProductiveAssets" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSubordinatedDebt" xlink:label="RepaymentsOfSubordinatedDebt" xlink:title="RepaymentsOfSubordinatedDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfSubordinatedDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfSubordinatedDebt" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfLongTermDebt" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfConvertibleDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfConvertibleDebt" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="RepaymentsOfOtherLongTermDebt" xlink:title="RepaymentsOfOtherLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfOtherLongTermDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfOtherLongTermDebt" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="definition: StatementLineItems to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="definition: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="definition: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockGrantedDuringPeriodValueSharebasedCompensation" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="definition: StatementLineItems to SupplementalCashFlowInformationAbstract" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="definition: SupplementalCashFlowInformationAbstract to InterestPaid" order="10.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="definition: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StockIssuedDuringPeriodValueAcquisitions to StockIssuedDuringPeriodSharesAcquisitions" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StockIssuedDuringPeriodValueNewIssues to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssued" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssued" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="definition: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="StockIssuedDuringPeriodValueOther" xlink:title="StockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueOther" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueOther" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueOther" xlink:to="StockIssuedDuringPeriodSharesOther" xlink:title="definition: StockIssuedDuringPeriodValueOther to StockIssuedDuringPeriodSharesOther" use="optional" order="10.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g337285.jpg
<DESCRIPTION>G337285.JPG
<TEXT>
begin 644 g337285.jpg
M_]C_X``02D9)1@`!`0$!60%9``#__@`_1$E32S$P-#I;,3):04$Q+C$R6D%!
M-#8U,#$N3U544%5473$Q-C5?,5]!4$-?5$5#2%]+7U!(3U1/+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`9\"(P$!$0#_Q``?``$``@("`P$!
M````````````"`D&!P4*`0($`PO_Q`!G$```!@("``0"!`@&"0T,!PD!`@,$
M!08`!P@1"1(3(10Q%2)!40H6(S(X87&!%T)U=Y&T&"0S-C=2H;6W)3178G)T
M=I*QN,'1\!DF0T535'F3HK*SMB=6E9;2U?$U1&-E<X*#H^'_V@`(`0$``#\`
M[_&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*L>;?+.\QUQ<\7>/$HG";35
MKC2QW_81R,EE->P,HFHO%PM<;2"#EJI=IYD0'XR3UJNSK,*X9O&Z+F7DV2D9
MU_(C?W*?@%R!9[YC;-?=KTR0<BTWWJ2R6&0ET-CU9=VLO(SD(I+G>_0^RJZH
MX7FJY+,S-$9-P1:&F?6BY%T0.WQHS=^M.1VJ:7NC4-F9VV@7R&0F8*6:&`JA
M2G[3>1<HS$PKQ4]"OB.(J?A'A4WT/+-'<>\2(L@;O;.,8QF%[%V+2-24>T;*
MV19XFFT6EPSR?L]FFW`-HV(BF)/.NX7/T9150YA3;M&;9-9[(/5VT>P;N'KI
MN@IU,-S<D-[<^-SNKS&3-YUKJ2`75CM,ZZC91[`2$;$@X`?QVNP0ST/BMC6D
M2(.7C?XQ=A3XI.-K4847S:;E9>Z3P]=][<-8K'QKY#W,;Q<8FL--@:MNDH5M
M^-%BI!'1(FQU^UOVI&[::G:=)+Q*K*9.V)+R\)+&++G?OH1U*O+7\8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8'VRC_`)<>(/O)Z\G83A^R
MK+2J5.4>0LQN*RUX;>C8[%%++MY*-I4"J^811JXP=)&:+V:04=J3CE)<(-LS
MCDF\O)5'57D;;=U7ZV[JL[-C"<H]?0\2XY(T.%2481&P=?UYLWK$+R4TU#+N
MI&37KD=#LXJ%WO11=/W.O9!)G=&9E*=*2)H>:=MK=3Y"4`)B,*V7?G9@*B9!
M(<XF%/S>41#L1[[[0/W]8O11[,`=P6XH<H[OX5V]Y-*PEEYCAYM.P)*[=J#=
M)T_/JNQ.E"-"[JI$8FITB1$@-T=D03!`ZMA@FR;]JW5FXB.(KW*ZS98"Y5V"
MMM5F(ZPUFSQ$;/UZ>AW:+^)FH289HR$7*QCYN8Z#QA(,G"#IHY1,9-9!4ARC
M[]!SF,9\C]\RBV3N2D7;9A'L&R[U\^>N$FK-FT:I'7<NG;I<Z:#9LV0347<.
M%CD1013.JJ<B9#&#J=<V.6\[XA.UV6O]9.GZ'%+7-@2=5XQ`=-?X;;E%K'(E
MLN7:J)-U@I4,L90FL()ZF<CU0H[%D$P>.ZNA![MIE9J.A*$K:+$9JS%DR,L0
M%C)I>7TTA4'ZQP+Y1`"B=10>BI)@)S="(9@]GWLZX;13+E1;(1M9N7>^ZS+U
M/AUQ[DU%TAKM%ECM0G-X[>8M7K25AJ2#1HR+'LB':O7+55&#;"$]87ZM4DIQ
M,\1+E!64F,CR^3KU[UM(KH%L&RZG2TJ9,Z\6D#`"4@YK\.NYC9ZEL%3`5\F5
M!*SQ,8!I,7M@4;K-%K_VCMJ_:MGS%RW>LGC=%TT>-%TW+5TU<)E6;N6SA$QT
MEVZZ)R+(K)',FJD<BA#"4P"/T8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,^*18IR4>]CECK)HOFCEFJHW4])<B;I!1NH=!7HWIK%(H8R2GE-
MY%`*?RCUT/6_#7T]Q`ORW&_99OI*FRZ;I_JN\JHIHQETK29D6YSJ(E.JG'V.
M(,JW86N&%3U&KSX:79`I$2;%8T,N5''6TUBQ5[=>E9U[2MCT:3-9*+=(=)-5
MQ$2)D%D'<?(M#D.TFZS8(U=U"6JM22;B(LU>?OHR1:N&KA1,>/T3O>/4:/MG
MTV`0ID9$S477.0NCF9W*C?0-]GU3DCI2J`Y\[E[QPV<[`ZVI;(NJNK3YLSO5
M5E<)R+"N.IJ5.[M2UC=E)5L$*@V>?&,SF72*0B@G`Z?2@'(`"`F#S"54HAT8
MHB8/JB/6FO#5YQS?`79D=Q+W_+JEXJ7ZRJ,]2W>9<'^%X_7FP2!S?BI,/54S
M?":FN4LZ%1H_>.4V5$L+@ZZ@H0,G)*QW;D(<JA2G(8#%,`&*8H@)3%$.P$!`
M1`0$!`0,`B!@$!`1`0'/;/`B`!V/R_[````>XB(^P`'N(^P>^=9SQ->;C[DK
M;9KAQH*6,OJ2!E5(;?\`?H=P11MLB>CG/D>:AKCYLHHFO1H%ZF*.SI)$Q/QD
MGV@T9LJ>#C+226X'2.IJ]JRJ!9I]-!F@Q:@N`JE*3\PG8"!1Z]S"'E23`H>8
MP@4`\I3#G$W#:-)I%*3YC<@X=Q8-;Q\XI`<2^/:*R19SD_N%BLH:+?F8&5!0
M-6U"1:EDK%-/&2T0X2;+2[PCR*81D7:(SZ+U1M3D7MFU<F^1\R-IVC?WB3Z<
M?`5P$%5H-NLLK`Z]HK)V=8T/2JJW7.RB(\A_5>+"YF)-5U*/WCM:;T]!6/>%
MHB^+>DF*"\G,MP5MLT)//!TFHMG"+66M-B.F=,RC%@98B;9@FJ1Y89E1G#L/
MKJG6;]AK6-'::RUQ0=<,'[R48T&F5BF,Y.0\@/I!K6(5E"H/7A4ND2.723(J
MZR:(`BF<XII`"92AF<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9\KMZT8
M-EGCUTW9M&Z9E5W3I9)LV13*'9E%7"YTT4R%#W$QSE``[$1Z`>HJW_G3Q+UJ
MJLULN\Z.K((><%(NL/E[M*%4('8HG95!M-*(J_Q?*X%$`-V!C!T/42+;XQG&
MF&,JE5JOM:[*D\X$7;5^)K<<J8"G$G2UEFV4@!3G`@"88H?*0XG\AA()!T'-
M^-FGVJ6M<=G!B@8H(KV'93=N<Q05'S"JTB*D_*03H>42@1ZIY%A,4143*4Y]
M>+>-3M0RRID-&Z]30%0XHIK7"TJK$2$P^F155.*1(HH4O0'.1%(IC`(E3(`@
M4/S_`.[4;9_V$-<__>VU_P#Y=G,Q/C77E(Q0G-`U-X3URB<8C8,W'G!KT`'3
M(#ZL211<";L2JF.5(`$"F2$0$P[@KGC6:Z<BF6VZ,OL-WY2JJUVRU>RIE'\F
M!S)IR(59<Y0[5$H"`&,!"`(>=003DO3/%6X=6L2)R5SLE#74$"@E=Z7.,T2G
M^J'2DG!(V")(7L>O4.](3ZHB(@'63/H6ZM1;12(KKG9E%NWJ)BMZ-9M,-+O$
MTP]C&78-'9W[?RC^<5=LF8/M`!'K-G`(#]OO\^OD/[P'W#]X9YS1'(KCY2>2
M6MI+7UQ(LS5%0DK5;3'D+]-TNULTU2Q5EACB9/S+M#*'1?1ZBA6<U%K/(B0`
MS5V<249QQ;5KRWS_`!JWZS;H6Z"2+]$2X`<(6ZUIR=9"'ME:<.1%1>'E?06*
MB541=Q$F@^@Y,I'K)4#5Y<B](7C2&PFF\]--XI6R1T?)PLM`SK/XRD[4UY."
MD%NU+LF-*F;Z4I=M:(%1<`7RR%>ET8VT0#IC.1$<^;[4X][UK<=%P5LI[F;<
MZ4NDRO5OH>T.3O;CIC93!B20L&BMEO%$&A7MKKK,YI:FW!)LC%;6U\9G;HSR
M2;>T1,/G'*KCA5]KT^0E&,<TE(N88JE=-_3(LBHDY3'S%$O1@\AQ$1#YBDH7
M_&*`CNSPCO$*L-%L]?\`#^Y3V)TYDT^X7BUMJR.Q,I<(ED3III.W2SUR*B]X
M@6A00U\_6_OF@&J=<44&:C8L)GLK]AUWV'77??V=?/O]G643>*;S[F()W)<-
M^.$XZ:[3GF2+;=6QX)PLB[U)4YIHFLG4*U(-C$,UVG=(IT57Z1;*BYU[5E_I
MKRHV.<K"C6#?&3CY"4BOM)21:-X^-C&A!*4X`DBFDW3`WE`3AWZ:90[,8QA,
M;W$XG4,(FSVW6[7]FKESW9O&5D:GPQT?(-XZS'BT7`V+?.PU54D8/1>MV+=5
MJ[FI:Q.E46D\M%K`,8R4-&F=QPJR\O`0TIT-M;G#O,.1&ZHAM76S*,;U?46J
M(P2GINA=3L11"'HM91(W;-QDEF[=LZN,ZDW14FI@H(()MH=A%Q[.P.P/Y6/>
M5;0ND80;%LVY+A$PT6S,1($`*EYY"7E78=DC(>'8@M)SLJOVC%QJ!S=*N3HH
M+71<3N+U;XQ:^-"-W1+'?[.LA-;,OJJ!T7=JL1413(FU26465CJS")J*,JW"
M@J)&;8RSUUZLO)23MQ*?&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SP)@+[B
M/70=C^H`^8C]P!]H_(/M'(-[U\1'C%HA9Y$2=S&]7!H)DU:=KA)O9Y)JX`@B
M5&6E$W3>M09P/Y2JHR<RD]3`3&*R4$HDRH;<7C!;XN"CIAJ6M5G4D,<3%0DW
MB:=XN8D$#%%3XN20;UB.4.40-Z2-?DS('[\CY7H#96KL'<6V-KN3.]F;)NUZ
M4,83@C9;')2$<D(B80!M#"NG"M"E\P@0C2.0(0/8I0#VS6Y0`I0(0`(0/8"$
M`"%`/N`I0`H?/[`QC&,8SR`B'R$0_9[9[MUEFCI)\T55:/D#E40?-%5&KU!0
MH^8JB#QN9)TB<I@`2G25(<H@`@("`9,+5'/KE?J`[=*"VU-V6&0](GXM[&[O
M<.9!(W8-TEYE4;"P3'W#_4R>9"`==!T``%J&EO&7IDM\+%[YUU)TYZ8Q4U;9
M0#+6>M&$QRAZ[RNO#(V>+2(41$Y8]:S"``(AT'1<MQUGN'5^Y8(MDU=>JU>(
M<0)ZSFOR:#Q5B=3S^1"48=DDHAT/D,(M)1FS<E\H]I=!WFE.7'%>O\FZ*BS1
M=MZQL^HF=2VL;Z"`F5@YHZ/2D3,&0(+M[3;`8B+>QQ:8B;I-K+L2EEHMDIE-
M%>DW]B/9](;F@E*ULZF.E(2>A9'HRH.")]M9"/<&*0LG%R;0R4E"R[<OPDU$
MN&[Q`>S"1.L?<VL;9QAV+/;(J%7/=*3<(YK7MV:G3>)Q33;5"8OBR3(8B9.B
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M8YMT:0FI^<F':LI,S<W)KCZTC-3,BX</Y-\N/G<.5E%>B)`4A)/V:4B]BGN,
M*I<4-6<<]+08VSD?NY<3I1M,J34HJA!0:Y6SLDG>[,!/@:O"-T';TZBPRH,7
MARQL=)U_NY>S<^-ITB8:4QUK+BYI=)>"XN:)4()4*M`J&.F]VC=4SI^=[M.^
M)>>1DG#Y5XO7&#LT:1XYDW4W*REAT[*QVF*W"T:CP[FP[`LSEE!5FN0C7XN9
MFYR1$&\>Q8,TQ!19RY6'RMB&$B:9"J/')TFR*RJ=M7"OB,GQ^@']VOJK.P[Y
MV`U1/=I])3XUE6XT5C.VE"J;A0@'2A8Y0R:DU()`FK:)Q'Z1<=1[.%9L)TXQ
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC`B`?/_M^K]OZL@ER?\0?17&GX^`=2
M)]@[-;$$I-=U%TV5>1[@P&%,+=-G!:,J2(B7ZZ#L'<Z*9R*MH-RF8#YU\N0W
M/OD5R(6?1\Q:U:/17)EB):_H+EY"Q*K10/("%@ETU23MI.9+HK@DB[1AU3^<
MZ$&T`WIA"@I2E*!2%*0A>_*0A0*0O8]CY2E`"AV/N/0![YYQC&,8QC&,8S)J
M?=+?KZ?:6JBV>>I]E8G*=K.5N4=Q$DF!?_!'<,U4_BFQ@$2J,WA7#-8@F36;
MJ)F,4;FN-/B_V&(495?DU"#8XOI-NGLVFQJ+>P-/8Q?7M%1;"BPF4N_3%9_6
M0C7J9"G,$!(*&[R;W)+1U"YHT"#WWQIME7E=L51HH%.M<1(-T(N[1C4YG+K6
MEU=^A\7&J`JHJK!*2R+9_4IY?MRBC$R,NBI6*-OJNUJ7.US8"2=4NE9"3C+#
M#V=+Z)DX>8B#*-I2/D6KH"*MG;9RD9)VW,`]'\KA`RB!RJ&C_J/BA)U/B3S7
MWY(Q$G$:\F)K45MTHU??&-&SC8]<M9Z];=P5!HJ9(S5G8:A9V-%?2S=,(J\L
MX]0RQ9!"#C'A-Z7155?C8@HLH=9060@*BAA.<0*5<``3&$1'H/8/NRG;4(!_
M88<DAZ]Q\4C0P"/V]!I[870=_<'8]!]G8_?EQNM%%&6@)QTU.9%<D.=0AR#Y
M1*<$B`(AU\O,41`W^,`CW\QSF^3G%:<V;X9_$":H$"[?4ZL6"O[ZWW3*ZW>.
M7U]D['5GZ*6PK`Q9$6>VO\2+`^;3+MFY(["-BDFTBV0*RJS9%OBM3M.MM-:L
MC9:&>QDM+2\<@>/;1!BR+ERNY\B+1L@BS]9=RLNX4210;MR*+OG2B3=L14QB
M@>TW@SQ&F*:N/(G>D=ZNZK8R4&LUN1(FX_@CJTFD4PQY$U4A%M?IEL?TK6]1
M4,:(9B%58J%(69<2=FV,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S$KS?*=K2
MK2]UOMCB:I58%L+N5FYEV1HR:)`(%(03F[47<N%!*@S9-DUWKYR=-JS;KN%"
M)&Z['+WQ4;QL\\E1./BLOKB@&,JT>W8PBQV!;6X@9,_T=T'J4:&<`/9"ME#6
MIRF!#K/H3SK1QJA3G.J=150YU%55%%E55#F45665,)U5EE5!,HLLJ<1.JLJ8
MZJIQ$ZAS'$1'UQC&,8QC&,8QC&,W!I??.UN/UK)<-4VY_6Y$YD0E8\!%Y7;*
MU1$?+'V>`6.#"9:>4QRIJ*E2D6/F%6,D&#@"K!=UQTV9P:YQ;)C[3N#3E0KO
M*`6<8B]BYZ0DUJEL9>&031:2,(P4DT*];Y%BW;)D)"VR(>6>/C4T6R2LY&L"
MO4IC>),@@VX,;V;MDDD&Z%>JB*"**9$DDD4K]3TTDDDDRE(FFD0I2)ID*4B9
M"@0A2E*`!3G;_P!&EO\`[S/_`,B^4]:A_0OY)?\`I2=#_P"A[867%:^_1XGO
MY$4_^&GEY'!@`'A[QL`?]ANC?J_\3H_(0]P_=GVM>%O%]AM5ANEAIVK,-B1D
MFI.,95B$DTBD)]3S"%B+4F[].HC84E5%'+>;&#^D6STWQZ"Z;XI7!918QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC-!\BN2&L^,E"<7K8TJ*7K&79UJML!26L
M=PFTT#+DAH!BHHF"JOE`IWK]R=&+B&Y@=2;MND*8*]5'E)RYVIRKMOTQ<WPQ
M%1BW*IZ?KF*=+&K=:1'S$([6`P)&G;*LB(_'V*02]?S**M8I"+C/(R"+.,8Q
MC&,8QC&,8QC&,_1%99NLBX;K+-W#=9)PW<-U5$'#9R@H55!RV<(F(LW<MU2E
M50<(*)K(*E*JDH10I3!9#*>(?:MA\0]K<==U@^LEGEH"O,*#LA,GKR,JI'W.
ML/\`Z$O:90+ZSXL>S<BQMJ)0,]^'3;3Z!Y!7Z7>9=;A[XT-Q#Y"R,(?O!?*>
M]0_H7\DO_2DZ'_T/;"RXK7WZ/$]_(BG_`,-/+R>#'Z'O&S^9NC?YG1R5V,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8R.?)_DQ0N+>LW]_N:H/I!85(^G4]JZ0
M0FKG8C)@9&+C@5\WH-&Q3`\G)<Z2C:&C"*.5"+.#LV;OJ0;VWULGD7?Y#86S
M)H\C).!6;P\0V,JG7ZE"G6%9"O5F/4.8&4:@/D,NL<3OY5V4TC*.'+M3S$TU
MC&,8QC&,8QC&,8QC&,^&1_UN3_?D=_G%KEL%L_1G:_[Q'_W5\I\U#^A?R2_]
M*3H?_0]L++BM??H\3W\B*?\`PT\O)X,?H>\;/YFZ-_F=')78QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QFK]R;?I&B=<V79VP9,(VN5MGZZA4@(K(RC]8P(QD'
M"M#'3%]-3#PR;*.:%,4#K*>JL=)LBNLGT_>2?(J]\G-FR>QKNN*"7Y:.J590
M6]6,IM7!R==G!,!`J8.'!A,5S-2QTRN)F3\[E0$VR3%HTT#C&,8QC&,8QC&,
M8QC&,9\,C_K<G^_([_.+7+8+9^C.U_WB/_NKY19JS:,8QTMO?33E@["4L?/W
M3VQXF52$BC(R-=H6PH*9BGB8^51LL5%PQ?L')?63=>9VV5(V.@BHYO:U]^CQ
M/?R(I_\`#3R\G@Q^A[QL_F;HW^9T<E=C&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC/R761;(JN'"J:"""9UEEECE21123*)U%55#B!$TDR%,=10X@0A"F.80*`B
M'4_\0SF$XY.;/&`JCY0--ZY?/F-/32.<B-LF0$[.4OSM(1#U$WJ8*,*L14OF
M:5\3NP*DYG'J2=>F,8QC,XUMKBX[<O-=UQK^(&<M]J>*L8:-^(09I*JMV;F0
M<JN7KHQ&S)HU8LW+IT[<'(BBDB83&[$I3;(BN+VZYG>DAQO959H&WHP\B1W7
MG<]%,V10BX5*PN5DIY=8(M=NI#KHO6BZ:PD=D4*1(14[*'-;=X>\AM'0<59M
M@T1-&N3,TWKC"=K-CK]RC3V!X8Z;*%7/7'[YRTD'JR9VS))RU33>.P!FW54=
MF*@;*[5P&Y74NDRE^G]7"C#04*G8I^.8VBK2UM@80Z)G*LC+U*-E7,RV19MB
M'<2!$D7+AB@FLJNB!6[D4=9Z/XU;<Y%*SZ.J8F`EU:T>'3E$IFWU^KJ>>>%\
M$61@2;=MC29EQCG0'!D"HHB"(*`'Q"7F^_>/%?=''-E$2&VH6NP;:<E'<,P+
M%W2N6-R$BR9!(.$7K6'>.%H\I6IBF*J[*F4ZAB)%^N<H&CIZB?D%3U4O3`1`
MRGJ$],H@(`(&/YO(`@(@'0B`]B`?,0S9>N=37C:[:_/*/'L9-MK*C2NQKDJX
MF(^.+'5*$$I9)^W^+5($@X;B8.H]J)G2G\0GWZR]=#R`IZZ()B)2@<5DP)YC
M`!BE\XF\OG$!`0+WYA#WZSV!1(Q1,55(Q2AV8Q5""4@==]G,!A`@=>_9A`.O
M?Y>^9CKRC6/:=VK.O*2W:2=KM\JE"P3%>0:L&[B171<.$TG#]R<&S,AD6RQ_
M57,4GU``.Q,`#CDNR6@Y23AI0R#:1B)&0BGZ(N$3%2>Q;Y>.>D(J!_(LFD[;
M+)E73$4E`*!R&$I@SX3J)I]>HJFGW[AZBA""(=]=@!C`(AW[=A[=^WSSP59$
MX]$61./E\_1%4SCY.^O/T4PCY.PZ\_YO?MWGL0Y%"@=,Y%"#\CIG*<@]#T/1
MB")1Z'L!Z$>A`0'W#/;&,^&1_P!;D_WY'?YQ:Y<W%ZQV#M303"N:[J,U;IE9
MJFE\+$MR&30.MZI4Q?/W2K:-CTQ$Q1%1\\;E`O9^_*`B%:54\%_Q"8QY991[
MJBH)$E=]Q-Y:,@VW1%)`:RSKTZ@N_5(G(&9I+`ZD&[0K#XXSTRWJ']$K4GQ)
MK/%=3['U'I*R5_8]/F*I)I1+A$"OTD5F3DZ92%/\!*QZ[R*?E[^0M'JIA#H1
M*`9<-P8_0]XV?S-T;_,Z.2NQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE/GBP\
MJCZWU^VT!2I0S>[;1CU7%Q=,G`INJ_K85%&KAF8Z?1V[R[NDEXA'HY5`@6D\
M?H@N&B@];+]0```'L``````'L```>P``>P`'L`>P8QC&,9:+X<]?JU+A]^<F
M]@7)#6D!0Z<.K:;?G,3(3PUZ_P"SDRLAG&$%%%-(S3V"9J0Q2,&GD.L2:7*9
M=!$CE=&PZIP%5MO,OA[R<H-M;;`K6R]2;'UY9[VWC'L&:Q7W6M,DHTTY(0LD
MFD_AWDVP2DDC1[T!7;)P*:7J+)`@NI`FK<NM`4::H^I-;:MM&O\`73OE13MH
M[?M&P[BE=%CEJ=N:*>M"1R`*MHUB@_C8^7>+@*!D(]@LG\*[<+G=(9QN#C)R
M6@MZ<F^1:6X&&I-534?:[@QW>VMK9ZPO-)G3MG==UW&1T++A+/W"[%!G"M(U
MP@6-!6-8!$B_^DF9#UN<7"IAR3X\'43(3T]SZO,`*`3\@`6V($2@(]E(*?0%
M$2B`!Y0Z'H`RU#6<3093Q.N6X6=FP?6]K%WY]J1HXC:[+NW&P6T74_24@(FT
MN&5?EK>TB1>K5QG+O&K,50>G7=-42+.$=^GKU.EMV0$@]UM&H\IT.)NR9JE1
M>V*[J"`FKYLED^@3TBPS]`H=JFJW&7)%H><:$2D1CEBQ02!XU0C&+<FBL.HL
MIMBEW+<ESW+5-&PVZV7`2U6>RP5/CDG+I^ZBYUDY@5MV5=ND2GA8G:R#E'Z/
MKSY_'OXI-=FHX!BA&I%^_7$I%WZR\9]V7*H4":O5UX+[YM-S5/485I"V::J<
MS0#1#F3@FZ)6`BW(YDFY123341:/';-NHBT`B".-ZRE:-NY+P\-O[NKVKG5Y
MNS'D-#B[>5R#K58LELK!P;ZTA)>+:IIQ:R3%9`QX-@X3,0LL*1H],'CI-%?*
MHR.O1YCAK/<I:G1*ARB4Y9OHVJHUAA68F=E=1$J5C,_--M*LNY9+1#*8!NG%
M+J.53%3^@UU2-Y24D@<<1I*$N@Z[U0YXU4?6-N0L7)?;C'F/(6:+JDO.,X4N
MSI5)*.FC6%5-XQK2=-%PY:?18.WA`)"'8LA1E)11Q]6O:[%HU?8[3AC5=)VY
M-?FG+1&WF\XG3IAJRT.FHB86B/XRNDDR48@&7+"J11G(%:G=*5E)TY!T8G*E
MU]KC>N^>47'2<BJM!FU3R!TQOV`<$AHICY]?,H>BM]G5L':#9)1.+7;HN3.&
M9S"S%>S`LJ7ZO0T9[_V(RVQNK9FPHJ/9Q4'9+;*+UN,CVK5DT8UABH6*K:"3
M9F@V;D,>%8,G+@Q$2"JZ<+JG\QSF,.H,8R8O"CB4_P"6VUR5E\Z>P^NJB2-L
MNQIYB42O"Q9)`@Q]:AW!@%%O.V=PU7:MW:@F&*C6TG+E0<+,VS9Q9GXA'BV:
M!\,J*8\>-+:\8;,W?%P;%9MK6+?G@:/K:.D&95X:5V?:$F[Z14E9AN))-K7(
ME"1MLNU4)+S3R#8R+"3>=?9U^$A>).M:1FVU=XS,X$%CF+2PU?;G,=\.9VBN
M5%2>5V86P'63;IG8@[(X0(9-=1P=D+@B)D[Y_#Q\9O2/B'JGXW<@M;Q.IMRV
MJ,=LF%4>2@V75^W$TFBSB294R8D&K*5B;*V:(+/R5*P(A)G;H&>5BP3;IHY3
M9W@ZSU[7M44&I:WJ17I*S2H-C78%.0=F?O48F-3%%B@X>G*51T=NAY$0<+`*
MRI2%.L=143J&SG,6N5YI>NX->SWZVUBDUMJLV;N9^W6"(K,(W7>*@BT17EIQ
MXPCT572P@DW34<E.NJ()I%.<0+F0,WC20:-7[%TW>LGK=!VS>-%TG+5VU<I$
M7;.6SA$YT5T%T5"*HK)'.FJD<JB9C$,`C[K.$&Y/476213\Q2>=50B9!.8>B
ME\QS%+YC#[%+WV(^P`(YAT/LO7-AN=NUQ`7^E3>PJ`WA'=[HD1:X&3N5*:V5
ML9[77-MJ[*07G*VA/LR'=PJTRP9)RK8IEV!G"11/F;]A]X9X[#Y]AU]_>><8
MQC&,8QC&,8QC&,8QC&,8QC&8AL"\5[6E)M>P+8[%C6Z;`2ECFG)2@=4D=$M%
M';@K=,3I^LZ6*F#=H@4Y3+NE442CYCAG2RW;MJQ[SVM>-K6DZH2ERG'$@DR4
M6.LG"0Z736OUYJ8YC>5K`PR+.-3*4?(=1%=ST*CA0QM5XQC&,9[><_E\GG/Y
M/-YO)YS^3S==>;R>;R>;KV\WE\W7MWUGL594@`!%52`41,`$55(`&-[&,4"G
M`"F,'L8Q0`1#L!$0$0'\_P#+^WW']X_;GT'=O%&J+%1X\48-C`=LP4>.5&#8
MX>;H[9B=4S1N</.<0.BBF8/.?H0\YN_P`1*(&*(E$![`2B)1`0^0@)1`0$/L
M$!`0^P<]O4/Z@*^=3U2J%5*KZA_6(J00,14BOF]4BI#`!B*E."A#`!BF`0`<
M_4SQX=U\>H\>*/\`U"+?2"CQRI(>LD4")+?'G5,\]9(H`5);U_43*`%(8I0`
M`]5'#A559=9PX67<")G"ZSA=5=P80`!,X744,JX,(%*`F6.H(@``/8``!Z@L
MJ`%`%50`I3$+TJH'E(;KS$+T<`*0>@\Q"]%-U]8!SU$QC$*0QC&(0>RD,8QB
M%'L![*0PB0@]@`]E*`]@`C[@`Y^Z[QXZ6*Y=/'KMR4A$RN7;QTZ=%33[]-(K
MEPLJN5)/L?33*H!$^Q\A2]CWX1=NVY7!&[MVV([3])X1L[<MR/$OK?D7A$%4
MRNT?K&_).053^L;ZOUC=R9TORJL^F*L:G(ZTTKLB%;6=O<X#^%&A_C!)5:S-
M?(="1@Y:-E(5^!$7"2;ULRD5GS5F\!19F5N"ZJ9N0C>96VHX^^9?X&CO+YR'
M2?L;GLYS75BWJ&@91@VC)*L4J1;R2+2OU]RQ9M$BL5&;\4%&K1TFJ9VU07)$
MT``H`4H`4I0`I2A[`4I0`"E`/L`````/L``#/.,9V2?#>3C-(<"-A;Q/&%=/
M7*FV]GROG$6RDC':VBW\9%1H.%@13!MZ-7=`D<%!1*M(.E!6`3*$)TB;TE:=
MIW2V;,O<@O.W385BE[I:Y=WV9Q(6"RO59637/[`4A"KN!;MD2%(DU9H-FB)$
MT$$TR8I_!Z7_`,B7_BCG+U^O3U2GH2U5.1=P%IK$Q&6*LSL<H=N_A+%!O49.
M$EV2Y?K).HV3:MG:)P[#S)>4X&(8Q3?THN-.T'.ZN/>D]MOD1;R.Q]6T:Y2C
M<42MRH2T]78]]+))I$^H5$DFJ[!N!0*44?3\I2@(`&8N5MG@X<`TC:,9L"RP
M-3.)B?37,W!0WH&7(E#J)D6,EY!5(F<Y"G$Q2',4`,/4(_"?-T:\W?O3A#X8
MNP+3L6N:RLB%[Y7<EI?4%#NNU[?`0%:J=PHNB&P4/7==M-EEHN9V.>Q?20JQ
M1VL:F,+,N2(E31<IQ?TMXJ?-.U^$AX0U`XR;S-HOD@IXA]%\+3?ENM>O*KL=
M:/90]>E8JGGL=4V-7Y!^*K6AR6MYZ132^@)Y_-P<M$+3#9/Z0($=/$LWMSVV
M]Q(YY\7.0W+_`/A:D>`?BE\5-=L]M):(U90Y[<59VPQFE*8C9:]4&49`5574
MUMK2%UACUXJBUD=2\G!6AU(PR,-]%R2Y2<T>47A^\@?'=M]!V'0ISD7KVH>#
M_I4W)RP:;UM7'SZT;-U_'P%]WM>*]!P1H!VY,5O+/X*LR99&E4Q_+1[:.BG,
M1%)P[[WY&^++XG?`JZ>)CK&2YWZZYSNN,G#'C?<]6;,C=%Z6I,'7=B\A=^:;
MJ+^_6F#UXPD8Z1F:15=G2#&!BWM@7IDM'JT*:G:^+]S*)2/PW?Q8?&)X\<5?
M$<_A)V5LUU;-1Z(XO[LT)N_?6A.'NJ=VTJQ7+D'I'7FPZC8]'Z6O.WZ3(:SO
M=3V#,O==7.T1QI-PS:@Z0>LY%^T1;W&>'1R<Y]5;Q4MC\"N8'**'Y8UBS>'Y
MKGFO4+4VTAKW2Z^MK+9-A0=4G->PC*B-4EYJJ)%GWJ3!]:7\Q-*M(F$<*+M7
MQY@9#LFXQC&,8QC&,8QC&,8QC&,8QC&4I>,9OI2O46F<?8-Z=&1O[D+C=B(J
M'(<*;77GI0D8X*`^4R$]:4P>&(/7G2JZB9@,DL8H]=S&,8QC&,8QC&,8QC&,
M8QC&=D7POY:#W)PLV)HI^[%!S#2.PZ--II'`[E*M[3C7TC'RA""IYR$,:9G&
M:0^5-,R\2N5,PF*?KJW;!T%9M3W>T:TN42K&V>CS+NMS#50@^4R\<8$T'K<X
M?56CY9E\-+1CI,12=QSUJX2,)%`',._$0/\`S<?^*.<]5M.6&[V2!IM2A7,Q
M:+3+L8"O1;1%15=],2BY6K)$I4RF,"953^NZ6$/(U9HN':PD005.7MY<D=C+
M<`^%FG*C3I%NM;JB.F]<UM)-0@#/(T<T1+78XM7!`55C)F!KTQ'O/(5(4"S[
M8H*('.F.6)T6XPFPZ95;W6G)7E?N-?B++#.`$@BI'33%"0:@H!#'*1=-)<$G
M"?F$R2Z:B9NC%$`TW`\2..U9Y+WOF)":RC&7)396O8/55SVM]+65S-RFO:XO
M%N8FK-XYY-N*["QR+F$B7#D8&%BW4DLP;JR;AX<@F'09O"H\/\UZE-DAQPK9
M+G-<I(#FK(RJ-IV,BBOR@K!9HL+MPD.C<R0;:<:C8IE5:,:1J%9?N'IW4C!.
MW"3=5'[;_P"%OP&VG$<F(+87&VGVV*YA7FG;+Y%M9B8NRX;$O=`342IUH,L2
MTIN:G*P*:SDC-:C+5@A@=O/B$U_C'7K1VY">#]H:7X\<B]<<0:CJ/0&T]_ZN
MT+J.RVW9&N7'(O7-IUSQL9P4%J[7UYU=LVP3,*[A8>FP3:LQ5G@4XVZ5U^E$
MW1"1EK!!MP<0L\-W\']JW&79'*'87)B)XH7&I\B]!U7C2MQHX^Z9N53T`TUY
M$RT79+/.V=+;]WV+>[=>;=8H.'DU9>1L"CF'?-W+^/DB@->CZK892O!/\+37
M>E=Q<>J7PXUM7]3;_)5$-Q0#.4OQY>^,Z/9(ZX5.,E[RZN+B_)P\#:8IA/Q\
M+'6AC$I2J(O#LU%EES*2_@.(_':L<A3\K(+647'\@%-*Q7'8VR$Y6RJR0Z9A
M)MM8XNC!%.)M:N%8M9IFU?!(%A@G%3H)I+RBK<OI#([&,8QC&,8QC&,8QC&,
M8QC&,9X$>@'[/U]=]?K']0?,?U9TT.9NXAWKR6VI?6SH[J`_&!6K5`1'\F2I
MT\#0,4H@0!,5-.35:OIT0*(@9674.(B8PCD7\8QC&,8QC&,8QC&,8QC&,9*7
MB)R@LO%/;+.]Q3929K$JW3@=@54JI4AGZT=R5QZC`ZBB;=O881QYI"!=N!!$
M%3.XUR9-E*.E4[^-C:(XG>)-38K9U,M*+6XMHQNR1NE7!D%JA"F*JHE5MD5)
MV(*KA'+F7]*/E?@9%H(*F@ILL>X,=S!53P9=E!)BBCMW6QX7XD"!(*0=H2E/
M@Q-T*XQ!3+-/B2E]P;?3?HF'YNR`/83BU'Q:XM^'G7GVX]BW)C(6]HP<M?X0
MK@DT8K,RK(F*[A=<51J=TZ3D)9(Q6RB3$\Y9I%(1:%>I,%7#8U&'-7EI-\LM
MI%L1&SR$U[4TGD/KBLO!2*]9QCM9%60G9PC=9PV"QV%5LU4?)-UUVT:R:1\6
MW66,W=.G=SGA`;B-=-!3VJY)[ZTQI^S*-XU%10GJEI-O]>:A`3((^J=!A-DL
MD80WUB(((M$`\I03+EMV,8QC&,8QC&,8QC&,8QC&,8QC&,8QD9>9&T3:<XR;
MDOC=7TI1C37\1`&!0$U2V2TF2J\`HE[E$QVTG+MW8E+V;R-CF`!\HYTR"E`A
M2I@83`F4J8&,/9C`0H%`QA^8F$`[$1]Q$1'/.?2S9O)%P5I'M'4@[.(%*U8-
MEWKDQA'H`!NU356$1'_:9N*#XZ[GGP(=O19*.14Z$KBP+L8%'RC_`!A)(N4W
M?E]P_-:&-^KO-KQ7"_8CH2&E[)4(<@]><J*LK,KE#W[`"MV+-N8WL'0?$^41
M'\X.A$<\9<(6X`49+9#@PCY/,6.JZ)`[`P^H!3O9A0>A)T!#"GV!^Q,4Q0`H
M\S_81U3_`&0+3_\`8T%_^/']A'5/]D"T_P#V-!?_`(\^![PAB3%_U-V-+)&Z
M#_\`:-<CW!>^S>;W9R30P`(>4"AY1Z'S"(F`0*&$R7"BYHD,:)NM6D3``"5%
MZRF(DQA\O8AZI22:1?K=@`F]A`.Q$HCY0U=-<7]U0P*'+5$II)/L?4KTQ&21
MCE`.^R-5%V;XP]=_4!J)Q^0%[Z[TK,P$[75Q:V"%EH-P41**4O'/(TW8#UT4
M7B*)5/<!Z%,QP'[!'.(_Z?</V??C&,8QC/)2F.;RD*8YO\4A1.;_`(I0$?\`
M)G*HP<LN`"1DH0HB'1EQ*@'O]O2ABFZZ]_8H_P!.<DG4WYO[JNU1_4`J*C_[
M)"E]OM^L/ZL^TE0#V]20']?IM@#OW^\ZH]>WV]?/[!#/U_%!M_Y\X_\`4I?]
M>/Q0;?\`GSC_`-2E_P!>>AJ@E_$?JA^H[<@A^OW*H7]WMGR*5%V7W2>-E/U'
M(JD(_J[`%`_>/7[,Y2LR6Q]>2Y+#1K%8ZG.)%*F29IUA?PDF*1#@<B2CF,=,
MW#AN4X`<&SD%FXF]S(C[]R$4YZ\T&K`T4OOV_(HG*8HJKLZP62`#'`P^264K
M7TB4P"'13D=`8A.R$,!1$!C-<KW=]BS)K%?[A9[M/&+Y/I>USDC.OR)]=>DW
M6D7"_P`(AU[?#LRMT`#V!/,4RRCPI]GFH'+&$KCER",3MFM3E&=%4'\D,PS1
M_&FLJ"'0_EOBX9]'(&^J/<L<OFZ/Y1[5`#V'8?(?<,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC*</&7O"\;IG5VMF7J'=[`V0>46;M_,HX=QM'AEW(-RMDP,JN4T
MY.PBA2$*8PK-T_*4PAUE*-&XK[1MY4'DFT;4J)6*14KJQ^H$DJD<`,4[>`:^
M:0^L4>R#(&C2B/79@`>\ES4.(^K:\"2\\63NSXGE,89A<641YPZ[\D-&'2*H
MGV'92O7KWL.@.!O?N1T+`0=<;%95Z&BH)H0OE*WAX]K&I]=`'1OA$DC*"(`'
M9E3*&'KL3"/OG+=!WWU[C\Q^W&,8QC'0#\P[S\'35J_0,U?-FSYJ<!`[5\W1
M>-C`/L(&;N2*HF`0]A`2"'7MFA[;QEU#:P55)7C5A^IYA^.J:_T6'G$1'SJQ
M:A',.L/8^X?`I&'Y></LB=>>'=WA/6>4J297)B03&*P7].%L)$_F!2HN%313
M]0`]@^'?-5#C^:U`>@R*4Q"R]>D5HB>BY"&E&XB"T?)M%F3M,/\`&%%<A#&3
M'YE63\Z)P]R*&#WSC,9Y`!$0``$1$>@``$1$?N``]Q']0>^<ZSKDBZZ,H0K1
M(??SN.P.(?8)42]J>_\`M_3#]>9.UK$<AT9?U'9P^?J&]-+_`-4F("(?J,<W
M?V]_+.?111;E`B"2:!0]O*D0J8?O\H!W^T>QS],8QC&,9X,4IRB0Y2G(/S(<
MH'*/[2F`0']X9PSJOQ;H!$$/AE!_\(U$$O?]:?1DC??^8`]_;F-/*J[1[.T5
M([('OY#=(KA^XPBD?]QR#]Q<Y;6=O?ZOV=KZ_(D4;O*-=ZM:BD4*9,3)0<VR
M?NTS>P#Z:[)%R@<0[*8BI@'S%$0'O%-7"+MN@Z;*%6;N4DW#=4@]D507(55%
M0@_:4Z1RF*/W"&?OC&,8QC&,8QC&,8QC&,8QC&,8QC&8A,7!A'B=!J`/W1>P
M$$S@#=(WN`@HL'F\QBC\R)%./\4QDQRN#E1)%L-YJ;F1;LUY"#KKXT>X%H@9
M:,)-27;E-BN<IUVOQ)(MM\0=-4JRY44BJG,F0A0C;]_ZQ[']8C\Q']>,8QC&
M,8QC&,QBUTNJ7B.-%6V!CIUGY1*D#U`!<M!'Y*,'R8IOF"I1'S%.S<(CYO<W
MF#L!@OL[AY)1X.);6#]289E`RIZO,N$4I=$H>8PEBY8X(-),H!T5-L^!F],(
M^4CEV?H!B8-*G64@ZC9Y@^K[Q@L*#Z/E&:[*5:KE`!%%>.<D2<-E/*('+\01
M,#D$JB8*$,4PY2RBF,>';=$`4ZZ%=0?46'[^CB'U`'W]DP(7WZZSD<8QC&,8
MQC&,9\KQDU?HG;NT2+)*$.F(&#HQ2J%$IA3.'1TS=&'HQ!`>^N^_EG8'XM^(
M361J-,I>XV!Z\K&U^$AF=ZC0<R$.\2C8YM'(K61C^7DHMXH5L!W<@S"0CE%C
M'662C$^REM:B)>*GXUE,PDDQEXF1;D=1\G&.D'S!ZV4_,7:.VQU$'"1O?HZ1
MS%[`0'H0$`Y'&,8QC&,8QC&,8QC&,8QC&,8QGQ/Y%G&(&</5BI)AV!0'W45/
MUV":1`^LH<?N`.@^9A*4!$-33=J?2HG10$[-B/MZ)#?E5B^_NX4+T(@8/FB0
M?3`/8PJ_G9BN03WRX,OL>13$Q3%:1<(V3Z$!$I?@OB3%-]QO4<G$P?K*/7OF
MF\8QC&,8QC&,9D56J=BNLPA!5B+<2LFOT;TD0`J3=#S`0SM\Y/T@Q9IF$`4<
MN#D3`>B$]142)FL>U+QEK%&!I-6<$+3:TO*L0ZR7G@XA<``0^C&*Q/[:<(F[
M`DF_(9;S`"K1LP-[#^7(SB%J'DG&'-:XD8:Y-VPHPVP8!)!M98_RE$$4'ICD
M%O/Q1#>7SQ4N19,I//\``KL%S`X+UT^1W%/:G&B>!G<8X).JOW)T*Y?H=)92
MNS0?6,DU7$WF5@YL$@$5H:2,54YB*J1SB1:D^(R-&,8QC&,8QC&,9O.GJBK7
M8X>_=,'"/V]_DG*P%^8C\BB4/;H/;H```R3VDN1VS=#R?KU"5!W`.5@5EJ9,
MF6<UR2$1#U%DT"G*K$21BA]64BS(+F$"@\2?(%^'&\O0/)K7F_XD3P+D8:VL
MD"JSE*E%TOI>/#V*=VQ.4$TYJ'%0?*G)LB`"?F(G(-F#DX(#(S/'F*(]`8O?
MO[=AW[?/V^?M]N><8QC&,\"(!\Q`._8.QZ['Y]?T`(_NSR`@(=@("`_(0]P'
M]^,8QC&,8QC&,8QC.!G)]I"(]GZ6=J%$6[4I@`QOF'J*C[^FB`AT)Q`3&$!*
MF4Q@'K3<C).Y1R9R\5%0X]@0H>R:).^P32)V($*'V_,QQ^L<QC"(Y\./EE?^
MYU"J[-M`E`0]-:.1-WT'9THEB4PAT(_5[^0CT(@'N`9J_&,8QC&,8QC-K:JU
M#9MK2XM(HGP,*S53+-6)RD8[..(8"G%!!/LHOY11,0.@P3.4"E$JSM9LW$IS
MVH:_UU5];0B<)6F)4"CY%'\@MY5)*6=%`0%U(N@*4RRGN8$4B@1LT3'T6J*2
M8>4<ZQF.VNI5J]5Z5J=P@XVQUR<:*,96'EFJ;MB];*?Q%$E`'RJ)G\JK=PD9
M-PU7(FX;*HKID4+UW.:'`>>T(:0V+K<)"S:>,KZL@FL(NY[7IG"H$30ES%`5
M92MBH<J;2Q>F55AYDVDX'F]*3>5N8QC&,8QC&,8S=5'-YJ\@'77D=/"_M[5\
M_?ZOS^OW=_;F79RL'.S-9EX^?KTJ_A)N)<E=QLK%N5&;]DX)[`JW<)"!B^8O
M9%4S>9%=(3(KIJHG.F:Q0WB=VM'7D?1HJF,K#R4G#A&UA58AT:.ZCTRF(]O=
MA:M%47308LP)H'K+)9(L]**IBQ?1T:22&-J;V#S*\1#CCN"%WD_VQ<-LQT/)
M"&PM&6)2,9:ZNU164#Z6BZU!QD:S8TJTLVWG<U.PPWI'2?HH(3?TS&J.6J_:
M5XU\CM4\L--4S>6FK"2?I=R8>NF18$V\U79EJ8&\[4;5&$56/#6NL2158N>B
ME%#@@[1]9LLZ8.&;MQO;&,8SU.<J9#'.8"D(43&,80*!2E`1$1,80*4``!$3
M&$"E`!$P@`".=8GF1XC&V.1NWCZRXA[%L5#TEKR0=,Y+:-"?&BYW<MP;G^$>
M+0-A32%ZQU=6ER.&$6M&';&O\P5S-BZ7J;.$+,3?X"\I>0:6P(C0G*"=9W%"
M\UR3F=-[*D&S**M[^9KA2O)^@VT(Y)I%SZZT`=6>K$VC'Q\QZ$/-,)LTPHK'
M/R7,XQC&,8QC&,8QC,=L,^C"M^B>15^L4?AVXB/0!\A76`/<J1![Z#L!5,'D
M(/L<Q-,.7*[Q=5TZ5,LNL;S**&^W[`*4`]BD*'12$*`%(4`*4``,_#&,@!NA
M,J>S+.!>_P`HK'+&['OZZD2Q$_7RZ#L.P#[/EFKL8QC&,8QC&;ETUI^7VQ/>
M@47$?6(XY#3TX1(H^D40`Y(V/%4HHK2KLH]D`Q54F*`B\=)G`4$'-K=6JT'3
M8-C7:ZP2CXN/2]-%!/LQSG,/F6<N5C=J.7;E3M5RY6,9594PF.;Y`&08QC/Q
M<MF[QNNU=H(N6SE%5NX;N$B+(+H+$,FL@LBJ4Z:J*J9C)JI*%,FH0QB'*8HB
M`]>OGMP7/J%Q([AU+&JJZM>+F<VBN-2F5/KMXZ7`H.V9``5!ICQ94"D[\WXN
M.#`V5/\`1BK4S:K'&,8QC&,8QC-UT@OEKS<>^_.Y>&']72PDZ_\`8[_?F6YK
M^U6"V"G(,=>0+>?EHLI?IF0?E=GA*\99,#MT'9&1T5GTFJ4Y%?@".VB;9$2&
M=N"J+)(#$BB;TM7\+13W>+8UW;5'9+G-'P?QZ<1>Z$P>.'HVZF-GRSQTWEJN
M9PY+=JLJ]=N$HLY)R/.X9-7I$K;)%E4N1FO2R+'X5>2.R(*A2"F<3F,GV``)
M?84U.Q%$P"/7YG?7E'*_-!;\V-X5_(>3O3-A-V/C3L>5:(\@]8QQ5G"S`J9A
M9MMP46/^NDG<JJV4\TY%M4DQNU=04B7!ROVT,^C>Y?0+]3-ITJK[&UY9(NWT
M>ZP<=9*M9H5P#J+FX25;D=,)!HKT4WD61.'G25(FX;+%5:ND472"R*>7XQC.
MNEXI/.F5V78+!PCX[SB@1*:BL!R5V-`.RCYR*D*5]HNKRC45/*[<HJ&1VW+,
MG"+B&9F"@-5RRTC9Q@])\?-(U_7%80GIENU8,(UF10I3I)HI$3;IE*4I4R`4
MI$DRE*FDD0H%``(DF4I0$`R5'9U/IKQ'GINI_)5[0O'JPO8W2U:C!)^-_(C>
MB\=+1,)K_7S`YB'=MDW2SDTO-`F>/4=,G#=9=""KMG?,=S\8O%IY%6F5;S_(
MW2%&@]8RRZCATOJH;:]LNL(9PL`,W4Z:9D)5ML%"(;>7\8G,+'U=\H(N'<+%
M//AT8MS?O`SL/9X6)L=>DV,U!3L<REX:7C'*3R.DXN1;INV+]B[1,9)RT=ME
M4UVZR9A*HF<I@^?0<MC&,8QC&,8QG$34NA#,CN5>CJF[(V0[Z,LL(>P?>!"_
MG*G_`(I`]NS"4HZ/=NW#YRJ[=*"JNL;S'./L'L'12E*'L4A"@!2$#V*4`#[Q
M'YL8QD%=]-`;;&?*]`'Q\3"O/8`#LP-3LSB(![]^9IT(G^L/7^+Y<TSC&,8Q
MC&,9L/6.N9G9]J:5R*`R#<`*ZF94R8J(1$650"K.CA^:HY4'\A'M1$/BG1BE
M,)4$W"J=O-2J4%2("/K==9E91D>D)4R=^=9=8X^=P\=K"'F</':PF6<KG]SJ
M&Z*!4RID)DF,8QC/F>,VD@T<L'[9N]9/6Z[1XS=H)N6CMHY3,BY:NFRQ3HN&
MSA$YTET%2'353.8ARB41#.M;SUX=K<?+:-YHT>N?3MQD3E8))$45)1)]QYUC
M59TKT;RP[L`46JKE8WG]%-:%7.HY9ME7E>6,8QC&,8QC-Z5%+TJ[&A\O4(LL
M/[57"Q@^T?XOE]_;]@#WF2@/0@/7?0@/0_(>A[Z'Y^P_(?;Y9^.BK@CJZU3M
M$M_D5@[U+2,Q%3"I/,W?'>.U7"S9R8XF%.18?$^@Z;'.?U6P(OF_:1NDM><S
M.*"=E:-KS1W3F$L$*]2L55LT,/DDJ[.M@%9H^:JIB`*I&#\FY:J>=I),5%FC
ME-1-0Q0CAQAY(355G'[:;:MZ]8ZZX;M]FTIOTA'1YGK@J#:^5)J901'7%I<*
M)IB@F`C3+`LI"NA3CW40H-FVU==U;>U&//PR;=RX79F,LF0J9SB)DQ,<I@#O
MM0O8]]^RI.Q$/SPR+G`+F=/^&EMP^C]R/W9^&.S;.I\#*O#'.CQNO\\_-ZEB
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M`I+7>X+J-(E)K&^N^BF\HS^'15L$U`-7$%RO[_X@.YZQLVRU)36^D=9QA:GQ
MBT$@0B$+J+7**:39.6F6K5=6/>[*M3%NV<6>8#U1BF96E:C7!V4=ZSF?5O<M
MJ%`P^HM<PCBR;#O2K>K0%>AT2+2<K)20"@FB4H@!&Z0$]1=P[=F3914<BZE7
MZR#5LLNG>3Q$TU/:`XZZRU/:)EO.V&KQ4B>9>,16-&-I">GI6R.8:(.X`JZL
M/`*2YH6+<*IH&=,V*;H&C(JY6B$D<8QC&,8QC&?DNNDV15<+G*FBB0RBAS#T
M!2%#L1_6/V``=B(]``"(@&:*FI968?J.CB8J0=IM41'V10`?8.OEZBGL=4?M
M-T7L2D)UQ.,8QD0.24>9.?K4KT/E>0[I@8??H%(]\*Q0^8@`BE(`/0="/78A
M]N1NQC&,8QC&??%QC^:DF$1%-57TE)NT&+!FB':KETY.":*1>_8H"8>SG-T1
M),IU5!*F0Q@MZT[K!AJRH-89(47,R\\C^QR:9.A?2ATP*8B1S`"GP#`@BTCT
MS==(E,N8H+N5A-M?&,8QC&8=L"AU?9U-L-#N<8E+UJSQJ\7*,E.BF,BL`"FX
M;*]"9L^9+E3>1[M/I5H\01<)"!TPSJ?<C=#V?CIM.<UW806=,TC#)U.P'1]%
M"SU1TLJ2,ET@*)DR.B>FHPF&I#F^#EFKI,.T#MSJ:)QC&,8QC&!'H!'[@[R1
M$2W%K%QS80Z%%DV(8!^8&](HG`?V&$P?\OOG(9PL_`L+'&JQK\%"D$Y%VKI`
MP$=QS]#S"TD6*H_W-VU.83$$?R:J9E&ZY3H+*$-M#2>U%3J+:AV<=%5^FAY(
MF25^JUFXLYS)-WK83F,)"J&+Y%T#&%6.>@=NIV3TU5(?<Q>+,W!S3+:FL%4H
MJW5XSMU"2)FYEXV19NB^25JMF9$$I96L6!H)V$S&+")#I*E<H"FNFFH'Q\0^
M4*<:*+9VB[BXD9)*NV>I2CDR\G0+4*0JJ5IZHLH9P]AW:1%)"CV=4H)6"&`S
M98PS$;(I#,'DGH6L;>ISN<C&;2192;%;XI`$2*I*I+IB"A3I]"`D-YA*H3YD
M-\OX@YRGA0\_)[CI=J[P(Y/3KE;7\P^3@>*VUI]RJHI`OUUQ*ST+<Y1T<YSL
MECK`GJN<>J$(T!,*0X6%!2N)L^TB`@(=A_U?T@/N`A]H#[@/L.5M>(USQC>(
M.OV=7I`1MDY'[/9OFFK:@X$7+2OLDS`SDMIW9LB!SH4ZKKJE*P8K>@K=[,5K
M5HU9)$)R3AJ%^-FAYNQ34K?K[)REHM=IFGULN5OL*H.YNR629<?%RTU*N?(0
MBCU\N(`5%NFDS8M$FL;&MVD8Q9M&\O9M5ULJ;DM24:QQ5!H5)@E[7O;<\PNB
MRJ6I]=1A%5YF:E91QY8XLJY:-7J5=C7BJ9)*0;K.W1DX6*DG"5>%TNIN<]RH
MFN=15V8HW!O1TH=32M%?I+M9K;EM!0Q)3D/MM,%"_35@L+D[MY36$J@"L*Q?
MNIIVW;S4PY0:6#NW-7XZ41LQ8-?C;,_(W81D:P;G>24E)NSD:LF3%DW(HY>.
M'+Q5)LS:()G6?/%$D4R'$2E&S_@]Q"?:L1<[OW,V2D=^79@=,&3@R#UOJBLO
MC`J>HPSE(RJ*T_)D(V6NDV@82K.$DJ_&J#$L%G,M8UC&,8QC&,8QFL+O,^JJ
M6';G_)HB55Z)1]C*]`9)`1#Y@F`@HH'?YXD`>A3$,U]C&,8S0/(F),\IT=*$
M*(FA9M(5!Z[\K:50.S.(C]A2N2,Q'Y^Y@R%N,8QC&,8R?/$G50(H*;1FFX>L
MZ(X85))4@@9)H)A0D9LH&+['>&*>/8G`0$&A'BH`)':9@G/C&,8QC&,A!SNX
MS)\A]1N5X!DFILR@D>3](6(4"KRI/2*:9J*BGVH3[5`@LP,`E1FVD:MV0@KB
M;J[F*8AC%.4Y#E,8IR*$,FHF<HB4Z:B9@`R:B9@$BB9@`Q#E,4P`("&>,8QC
M&,8S[8UJ9[(,6A0[%PZ02']1#*%]0?V%3`QA_4`Y(OV^P.@^P/N#[`QC,;LU
M<2L+1$$W)HZ7C5A>P4PD!C+1<@!0*"@E(8IEV3@H%1D&0F\KE#HQ/(Y1;JI[
MXT_LQGL>(?:QV*W2:6N,1(S607,4_P`204Q!H\9K&]G#9TD`+L'!>@72'TE`
M*L11,E;G*_C?:=37%;:^M8Y)Y($9G8V"NJ**M(;8E0%P1VXK,NLW)ZK9VBLD
M1]6IM'I[7YQ!JZ0/Y`43/(/A_P`H8F3BXN&?R+J1JLZ+AI'N9=$K>5C7[$4V
M\Q6K&R`OEC[37G"@-9AC]1)^V.SG(WU(N2:'+DO,?BQ7MB5:1?M&2;N-D6PK
M`=O[*-U>@7;N&RZ72B+A!4"N&3E,Q5$EB%,40,4V3`\/_P`5"U1'#'E4VY%J
M.K[MS@56HPY)\ZHH2^Z*=9F;N.U$M//`(*"5R>69D2CV>7(03O2#&6)5!S*/
M)'U("ZGI^RN2.S[!OG<\P-IV+?7Z4E8)(I52Q$.S;"H$54:JT657&'I-1;+*
M1E9B"JG%-N#B3?*/)N5EI![.R:5GG<O`<?=),VC[8EG15^+?.%10AZ=7VA4@
MGKE:WR8A]&5VOM5BNI1UV"QO.UBV!%I61:H*5W[FV#%\@W"7#;C%(/Y#BC3+
M622W;MT@F0FN9NY8EZ8DC)O'K-3T'6BJC)M4D*E")BK&6%S',%T3.H*(BW+^
M=U6KU*XT:X-+RH,VKMNP$P%/Z:7E,FCYA3`?;R%(``*QB^Q"@"1/<>LGYP8X
MIS4Q-,.56^XE8EM?I_':<H4LB)?Q!A'K=0B%TF69E!*2Z3T:Y$L1'.4"K4Z'
M6$RA4[!).215M8``!T`=`'L`!\@#[L8QC&,8QC&,XR8D214<Y>FZ$R9/*B0?
M_"+G^JD3]@G$!-U\B`8?LS0JBAU5#JJF$ZBAS**',/9CG.83&,(_>8PB(_MS
MTQC&,9B]VA!L=2L4(4H&6?Q3I-J`]#T\1*#ED(=_(WQ:"(%$/<.\K7'OL?,`
ME-_&*(="4WVE$/L$H]@(?8(#C&,8QC&9SK>D/-B72$J;,QDBR#@5)!T'_P"Y
M1#0`7DW8#\O4(V*9)L`B'F>+-B"(`81"YF,C64/',8F-;IM(^-:-V+)JD'2;
M=JU2(@@B0.Q'I-(A2]B(B80$PB(B(C]V>@J%`>NC]]]>R:@A_P`8"==?K[Z_
M7GO\_EC`CT`C]WO[`(C_`$![C^P/?/`#V`"'?O[^X"`_O`0`0_8(`..P[\OO
MWUW^:;KKY?G=>7O]7??V]=9YQC`^^=:KQ(^/A-0;I-=Z^R^'I.WCO[`V312`
MC6*N*"A#VR)3`A0322?*.4+$Q2`"AT_DDDB^FR["NS&,8QC&,S6B,A<3)G0E
M$4V#913O[`67_(I!^WRF5,'^XS<>,8S$[+`.WJK*>@')8VW00BK#OQ.*2+E/
MSE45AY,Z8"<\>Z,7M)00,:.=F!VD`D,Y26D?1KY6=[4QU5[8FE&VM@19@_82
M?IH.D'[=/I8J@*#T"@=@8_E$4UT1(Z0,<AB&-5F?2[2N[EVO,5A=9O6VU-FW
M5L38KI_1BE\A0([HLTR.0!(2S1Z*<PW=N4`'XFO.EF,D!TEVX'L_UM+2,SQP
M=.Y-TJ\7&)(('5$!$@'13.8I/;ZI?,(B`?9WE0FJS&"N>+V0#F`@Z%XU&$@&
M,!!,7D=4`*82]^43%`Q@*80[*!C`40`QN[9.*`"AKJ4=(F%-8D6NH0Q0#LJJ
M:*AR*!W\C`8H"/V#UV/OWWG<MI&^["\+K=UPTR6P);2VULV3C=TS-96=K7RS
M:$I&R'<#;J#5%T$EW["*<U9FX<S,/"&:NYF/=6<!4>.I`C5357&JFZQU'JB*
MMZ)X5M'DCDDXA%FHT]--%NB!4TFR20^0@%(3\D``!4TRBJ(]]=SPX:\;97D;
M;8ODON6+53U9!/$I'2E$?IF*WN4@S636C]C3;4Q^EJI&+D%2HQCI$4[')$+9
M7)#P[.)"5N[``#V#_M_UB/VC\Q'&,8QC&,8QC&:JO4EZSQ&-3,/ILR@JN`?(
M7"Q?J%'[!%-$0']0K&#YAF"8QC&,8`1`0$/80$!`?N$![`?W#[Y7MMBMC6+U
M--$T_(RD%AFHWH.B?"29SK&2+[![MG8.FY@#OR@F7OYAWKC&,8QC&6(\/J$6
M.K\KL!ZD'QEB5/$PYC$$#)0L:X$KM8AAZ#J1E"&*/E#HR4:@/8^80"9^>I_S
M3?[D?^0<_FL<B4+_`+8Y5>-3#:_U7XP6XN556YK[$K?$387"F?VFZX^Z5LGT
MNZ6@XG;KVNVU!I5""_;?2+%NRK[APG7D531[Z#](L@TO<JOBB>*UK;E7<.*U
MLUSQIMNON`_`OC#R>YW7JY%OJN[98S7C?7KWR&A-=/JA;'=3L^R+?>BSL707
M)J2TJ<0HV6?SSEVU=('R._#7\)6Y=7ZXU6[\CN/NKK#QOV%H?D5N=X?CWIGE
MU5;9QV<:<H-VV?3:[M/:^Y*[_`MLUKLJOTM2#CK+J1](PC&7EVCR2?QBS-6`
M?2<U7S_\7?>_%Z<WCR,X[\0D^'O*GP_.5N]*)9]";2M--V_H7Z(TY?+?K&%V
M7&W;9Z5OV.[ND*QCHUQ*Z,JJ3JH/I=O9):8JYHIS'C!^[^-US)X2\7?#2IFN
M:AH77&IKSX8.FMXN^17*#7G+'=E#O&X)7SP2.C(NWZHLC^9I$JQ9QS=]*W/9
M<C:E14G(YS-FCV"L;(3.W]H>+!+Z+YO;BYHRU.JU[/7?P?;4W)MM5M:;GO=O
MU)/[*O7(RATF.K]8DRRJ5$DZ22WW!IZ^RVE`:7PM<8OV:BHNC+18;B?^,MXG
M'&65;4_FQJSA1(6#D/X:O(SG#Q1GN.2>YU(FH7C16D[)N@-8;[@;O:7;N;CW
MT7%M(^0FJ7-PD>D].1*+GI--VZ6B,QX`^,#XCFS.3_AJZVYE:OX?LM1>*%QT
MVAN333[CVEMEAL/7SW65%6O7FV+^/5ML-=<MK+%-$5DH2`17/$EL;1!2?7>5
MU^WE>U.'N`#]^,B;S6TB3>W'VY5MFV!>U0#<;I23``^J-DKK=PX(P()2&,)9
MR-/(P9R>Q1-()*"/F1((=4D![`!Z$.P`>C`)3%[#ORF*/N4Q?D8H^Y3`(#[A
MC&,8QC&;GH[`6<,#@Y?*K(JBX]_GZ!`])O\`N,`**A^I0!]LS'&,8S#IJBP,
M[)IS#CZ492!42-UW$-*NH@T@@E_<4Y$6G1G(H$\R2"P&2<I(&,B5;TP3*G[V
M".8Q5&LS"-:HLF:%8L/IH(%$I`,>*=F44,(B8ZJRIOKK+K'477/V=90YQ$V;
MSU%^C.Y_DA'^KI94GJO^][Q>_P"83C7_`,X^GY;/Q5_P92_\DNOZLKEP'A>`
M`\3(,!_V2-S?Z3+#_0(?,!^8#[AF5;!\.CBOL>])7V8I$E&/%I=.;L%>K%FF
M*]2K>_*N5PN>RU%@L6(<%D52@:9",1BC3@"J67,\*Y=`M-YHT:L6S=DR;H-&
M;1!)LU:MDDT&S9L@F5)!NW02*1)%!!(A$D44B%322(1-,I2%*4/HQC&,8QC&
M,8S\EUB-T%G"@])H)**G'[B)E$YO\@#UD>W3A1VY7=*CVHX646/^H5#";R_L
M*`@4/N``#/PQC&,8QF@.0-4-+5IM9&J0'=UI0_Q8E`?.>&>F(5<P]?,K)X"#
MD>P^JBHZ/\@'(78QC&,9R$3&.YJ4C89@03OI:09QC,@`(B+I^Y2:(#T`"(@5
M14IC=`/U2F'[,NSJ\`RJM=A:Y'%`K*$C&<:AT4""<K1$B1EC@'?Y1PH4ZZH]
MB)E%3F$1$1'.=SP(=@(#]H"'].0XXQ\'=-<3=C\L-H:Q>WEY8^8^\7O(#:Z-
MLFXZ7BF-WD&"C!PUIK5A`0Z\17A3665)'R;R=>%64'_5(42)H)\)#>'QQ\B^
M57)[ETZ;6JQW[EUIRE:)W'4;-*14GK&2U[1X4*\UCHRL!7VTBV6FX;MA8S/[
M!*-'Z!E"MF3`551/#;C]X"W"3C[:HZ69V;E)MJB56A[1UEK#0V]N2-[V9H/3
ME$W%#3%:OU9UEK9[]'LXB-F:U8)F$,65?3:J*;Y26*H:RI-IQ#'-%_@]O`_0
MLM,2T-8.3E^!/16X>..J8K;N^YK8<#QNU1O2(L<#L2`X]PTI#I,:&>5B+7.L
MDW3M*?,E])2#I1-=_*R[M_\`AL+\'QX77F!UA#0NS^8.H7FN^*54X53UDTGR
M#<ZXFMV<=Z8S7CX2B;T;1E36K5\:E9.W35\=.O0R4DW4;-GK99"(@TXS;<5X
M'_`2,F91R%)M\E4)7@/%>&^]U;*W([ZA#QUA[:TO+4Y>XQ.YDV5^-C)M/#?_
M`,<1DD)A(DPR;-)8A'I-6:?_``?3A!J5/9:KVZ\J=QS=]XR7[A_6;/OC?,AM
M"<T7H+95;EJE::1H89:O(1-`;KP$R]C(]<\5,C$,E7+*,2:LI2;;RDEZ!X3O
M&#7%[\/?8<!)[65GO#2U'=M+\>225MA7$?(U*_4=#7\XXV2V0J+12S31()N4
M[!Y$.*PT;R!SN58]PF";<EFX>P`'W8P/_P"G[0^7^7.I_P`T]3$TWR1V/6&3
M4&L!+R1;M5R$(8B!8*W"K)@U;`;YHQ<M]+1)>A$"E9%+\@#(KXQC&,9]\6P4
ME)!JQ3`>W"H%.8`_N:)?K+*#]@`1(#&['V\W0?:&2&33(DF1)(H$32(5-,@!
MT!2$*!2%``^PI0`/W9[XQC&,QVX?WHVO_@S/_P":7F;GU%^C.Y_DA'^KI94G
MJO\`O>\7O^83C7_SCZ?EL_%7_!E+_P`DNOZLKEP'A>?HF0?\Y&YO])EARQ#&
M,8QC&,8QC&,Q.Z//AH51(H]'>K)M@#[13[%57]PD3$@_[OK[<TWC&,8QC&?B
MY;(/&SAHZ2*LU=H+-G*)O<JK=PF9%9,>_;HZ1S%[^P1[^896_=:LZIMDD8%S
MYCD;*>JP<F`0!Y&+]G9.BB(``B9+\DMUWY7*2Y!_-S%<8QC&2/XL58MBVNQ?
M+%*9K4XYY8#@8`$IG@^6,C2A[#]8CAZHZ+]H"T`0]_<+4?EC&=2K\(PT#MC5
M+/6_+_3_`#]\0O3EAWARQXJ\:9K3VJN34Y1-!U:F7!G.5JQV&E4&OQ+-W$7>
M3)`M)=S+N;`_CG$VX?O7<,Z!PFFWV/S%YH[0\"VDZGXW:ZO2/)UA9:UO3>DQ
MR/\`%*YRQ1-@/BP,D5>.TA1(VMUD^UMD6:4.B2,IPL:2SIE<6DH>,DI@Y9"6
M>UW\*IX]O*SDG9>!FO>&7`>L[+O_`#3XENN3LLPN6^V]:B-,LJ;O.S:AV<27
MDW==@6=GJT&G391W`2J;Z!GYR3FJ]'IUT7*BS%;6<K^$4<L7:"/(6B\!*3.<
M#[SSLC>".I=P3V^W,!LZ1MY[DG`*WRU:[;525^!KTY%M9A:*CF?D&'GFA8:2
MFI(@`\<\'.?A23:$Y33U:<:7T<7BS7.9C_AH^<+\FH%ES`<*L9Q6L*<C6W'Q
M_&-"IZ03G$_27,X=E>HH>=->;;/DUDD=`:Q\>OG!Q2UGXC&PN7%2UGMJ?KWB
MG6CA%QQKK[<D?6*1K'9YW,@_L&N[!<_X,*H1+C9J*D0,A9&VY;`=*WV23<LH
M:;A*[&N'MGB)'POX35;)O2%WK=8XYZBVUS>C.9^F.%&MJAI'D(RV!Q>VS:-^
MQ=IF:#M"K[J:11'?XEII4NP1$E&*("L,W]#$_&%@V<SXU:5O@Z<C>8V[O$C\
M9:K\P8R9UK:=6.N"T1&\>F.W9W;&HM22$EJ2_IV"8T^ZDF\7&QE<VV2(A=A.
MOHV"BW;I6300G3/I..4<F[(&,92WXO&MBJQ6J-NM&X^JQD)37<XX`.^VLH@M
M8JYYQ`O8%0>QTZB03&Z`T@!2@`F'NCO&,8QC-K4.)%%LM+K$Z4=@*#3L/<K4
MA@%14/N]=4H%*(?,B78>Q_?86,8QC&8[</[T;7_P9G_\TO,W/J+]&=S_`"0C
M_5TLJ*U<[0)%^+C'F-TY><>N/;Q`GM]9"+Y):_(\-\^^TQDV@^P"'1Q$1#H.
M[<.*O^#*7_DEU_5E<N`\+S]$R#_G(W-_I,L.6(8QC&,8QC&,8QFK[^Y$SM@T
M`?JI(*.#!_MEC^F7O]8%1-UW_C#UFO\`&,8QC&,9I7==#/;*^65C4/5G:\19
M=%,@?E7\68!4?,2`'NHLD)`>LR?,RI%T2CYG(!D&?8?</<!^0_>&,8QC+".&
M%?*C7[C:%$P]22F&<(W4$/K`WB&@/%P*/S\IW4H`'#KYH%[]P'J:XB`==B`=
MCT'8@'8_<'?V_JSSC(+\_>!VO/$'U=K75>R;A=*5$:RY`ZIY#1,C1OH+Z2?V
M74SR5>1$)(_C!%RS7Z"DQEUR27PR"$@`)HBU=H]'`\4^<W@[5'F=RLIO+:*Y
M-[VXY;#C>.]KXI7Q34#+6[QS==&W.7L4I/0$-,WRJ69YKBRR*-ML,.YN]60/
M.IQ+Q)*,/%O$5WKSZ.%/@S:3X1;%XQ;*H^UMLW.9XM\3MD\0Z@TN04HC&?HF
MR=ZS6]GE@L80%;C%C6B&FIQ>!C5(Q1E&+0C=L9\Q6DQ7>K=9*_\`@\<^[7OM
MEH[6'%GDSI72C7Q-X?E`P0?<R]+7KP[:!18ZSMIRP[BH-!1KE=WVI=[#'(+L
MZY29N/D5*C'RCR)^#D9I4[QAV#V/@.:\KG(BU[,H/+_E?K?0>P>4<GS$O_$V
MC6&FUV@6+<TU)I3$\S2V#&5EIM*(U59G[=+\9M8,Y\\3(L#'CT'[(J+!PRQ[
M8WX/1H#8Y>7K-SR0Y)0<%RAY:1W.^KQ,"]ULV_L>.6K"?F9D^U]5R9J.>1>`
M[CYQ_35JY;%Y6-2J2_I-54+*TC+/'??=/`.H6U^.UHUEN7F5RPV7OJ7Y'4CE
M;4>5<G-TZ%N^H-PZV82,33%M.Z_K\`PUUKVFM8Z7ECR]6K\>T/,S,B,_]+L9
M")K8P<KO#T\+JN<!]F\HMUJ\C]^<F-N\OE]2RFX[YOEY2WDL^L&J(FTQ,?(P
MWXH5FO`Q9/FUJ7:IP[H[]K"147#1,4HFV9G,M:=C&0WY^4<MZXH;8:IH>L^K
M40UO4:/79DG%.D&TTZ,3KW`ZD0A)M^P_BK&`?81`>K`/78]#V'8]#]X?8/[\
M\8QC&<S`Q"DS(HM``P(%$%7BI?\`P3<@AYNA^0**CTDD'?YQO-\B#F_$TTTD
MR))$*FDD0J:9"AT4A"%`I"@'W%*``'[,]\8QC&,QVX?WHVO_`(,S_P#FEYFY
M]1?HSN?Y(1_JZ641M)=W$W+GFFV4$B<UJS5,"]*'N"K-]N"B.#IF#L/8%V+=
M0H^_E,0#="(`&7K<5/\`!C+#_P#RAU_5E<N!\+S]$R#_`)R-S?Z3+#EB&,8Q
MC&,8QC&,9I2W+>M/O`[]D2MT"_J\B)#F_P#;4-_^N8UC&,8QC&,>X"`A["`@
M(#]H"'N`A^L!]PR%&[=<&K<HI9HA#_4"8<B9RDB3HD1++B8ZB0E#V392!_.N
MT-T!$G`JL_;^UP/H;&,8#W$`^_+8>,426+TU5E.O*K+GEII7]?Q\HZ!`P_>(
MLT&W7W``!E8OC><G-]<9*=X>;W0>QY/6TAN7Q2>)VA=C.XR-@9(UFU1L(]V+
M;J>\)/1,J1LQFAC&`N'<:5C+)`V*#21;@=4#P0NGX3#8*59KJX'PT-Z6[3%.
MYZ;#\.Y/;]+W3JZ1/:N0M9<RQ:=4ZGK^8BH&QOI2[,6#227*_7CJW7$)!%F6
MW3TR3Z-6V!9OPBJ7HNCK5<;QX?.VZ]R%UYXA>O?#OV!Q@)N;74O.QVS-F46U
M72L3-3V5&0:]-N2#PU4<P:#!)*)BGCR0C))E;',$Z)(YK:1_"9;C24-KR^X/
M"XY`ZSJ?%GD+6./',^W+[PTY8H7C_9KY8TJ_1U(?Z-;(O-O.9;X:<>RI:HW8
M5:&;HUE1.ZR;6[0;T9J;4\;^O:PHGB[79QQTFY<OA1WS5U'EHU/9L<R/NX^S
MG;%BTDXUT:D.@H"<6N[,95J[;V\SM!,ITUT%5#((Z1Y2?A`UOT'NGF+JG7WA
MX;9W_!<'-9:+W5OG9=3W3KNJU^JZIW1JRI[&/8W419($T\[E:XZMS>%1K==:
MV1Y,1<+9[F\7KL%`O0)E>\/'N7A+_/43B-P*WQS*=:KXGZOYB\CY2MW?7FL&
M^C]6[@HD-LZF13MO8BV![=M@*4&9;6)_3JVG](*-S`G7OQC!E/JP40Y3QN.4
MN_\`F[IZ$XN:TFT>%&]?"VVCRA@9N7F].L+C7YF*:V)O-;UEV;UI+6=JYT+L
MJ"=:-GM0QT^\"XS[5U>X!";K)63MUQ/A0>//OB9U=X=6O>>/'?;B4-R[K^YH
M.D\^[)<=8&@=KWS3[ZY62W.Y#3U1C8^R5:G0,"UBZNVMCI)BI,OV0R,?7W\2
M60F&^_>+/X3)I_DIO#4NNWG&JS:UUGR4E-KP'&S:C_?>D;M8[C8=;,IA_&1.
MU]%TN4D-G\?_`,?BQ'P%2?WEFY824G(,#QJ\M`%D+"P^/4'X1G?=N<,)_FLQ
M\+[D)%:V=WC7&L-12;G:M"1HVSKS;;7<JW<GDGLV=KE<@=7ZGU>:J-FMFW%=
MF2-4-;9YI4E`CCLI"60_.,_"8*?+<9C;LB^&U[M.S(GQ`:+X?=DT=KC>NI]H
M`]V!LBGW.UTVSZHW!16\UK7;L5-JTUQ7F"$&]C8U],.B+QUE>P8LI:1Y&4_"
M/%=>UW<A=\\!]KZ2VCQ:Y1\>=#\M-8V#;M*G1TGK?DFTF?Q$W\TNL!6'-<V#
M623$(:)>0D*+!NX)/5"7B[:^C+$1=E;!P\Y_M.8O(CG5I^G:HD8/7?"G<<-H
M0=UN;>REHK;&STX5Q*[#@8&KMH!HO`)ZX7*P823MW/RY90TO'.&I&Q%3IISM
MNU>2MM.ME57*4R%EK4]7URG#LAD9F)>1JA3!V'U1*Y'OW^6=,`R"C4QFBP=+
M-#&:+!\_R[4PMUO_`/:D?_H]L]<8QGZ))*+JIHHD,JLJ<J:29`[.=0X@4I2A
M]HB(]?=]HB`=CF]J[")PC`J(^4SM;RJO52@`^97KV2(;YBD@`B0G^,83J=`)
M^@Y[&,8QC&8[</[T;7_P9G_\TO,W/J+]&=S_`"0C_5TLH.=?WZ\W/^!.FO\`
M2W4,OKXJ?X,)7^2'/]55RX'PO/T3(/\`G(W-_I,L.6(8QC&,8QC&,8QF@YM3
MU9B44[`0%\Y`!`0$/*FH9,ON'7?L0/\`I['W'B\8QC&,8QC/ADXUC,1[R*DV
MR;M@_0.V=ME0[*JDH'N`#T(D4(8"J)*EZ.DJ0BI!`Q`RO_8NOI&@S(M514=P
M[P3JP\H)!`KA$!$3-'(@'D)(M"B4'*8#TJ02.D?R2@E3U[C&>!'R@)O\4!-_
MQ0[_`.C+H-3L`C-94!D```HU"OB<`\G7J+1C=PI[D`I1$5%C")@#LPCYA$3"
M(C";Q&N`A^?<%Q/AB;3+JP>,?-?1/+\7)Z6-T"YDTNK8#J:_!$+15_H`UD3G
MC$):!5F"Q!VQ3F@),J@IEK@>^`(J\UJ[U\/*9(BCKQJ''B\?2_\``N8Q2(KJ
M'_\`H!^`_A0`14*@?R#L[XT"&5`5?Q!*F/H!D&YO`A6VWL#:=Y#D\E`ALCQ7
M>.OB;)Q@Z=/)_0Z.AJ#.4E73!W?\)C'Z04M0SBTD38`-F1(0$$VAJ9+"8[C/
M3DQX#RO(C4WB8ZO_`+)Y.IAXA_*_3G)DDU_`Z:;'4J.J5JFLK2S,/X3(O\=U
M9X:VL5.Q%=U0D6#],QH.1^$.5UI_F7^#T;9Y([!Y^.=5^(M8]":*\16;UC>]
M\:0'CG4]AK2.Q=4MV*M;>(;*<[`K%E:48;`U6G'U.AFT,\D2*-(B3L+YBQ`[
MB3]X\%=6X7/Q7K<3D8G'CXFW%72'&I%BIJ@SP=,+:<TBEIX;HHZ+L1I_""G8
M102L/XO$0IAXOH\9]-O^ROB:.V;X"NYFEI?W7B!XC%OXHV+</#32O#/ESZ.@
M:CM.'WE5]*:P@-1P%[K#.=ND)(:FNBU,A!BTY"*E9N2B$7:QH:=8JN),\CF\
M-X"S/5.P^'MAXY\IYS6M$XU<(-E<%+[2;?J2O['E-WZTVA)VZV6:<<6TMHJP
M:_LDI?[:M;7Z\!`O0(:.9Q$0M&1J\@DZ^O7W@3,ZAJCPB]437(II:XCPP;+N
MR7L1E]0JQ[;D-"[K2EF\S719EV6Z4UHBT:2JS,[SXV\'>H"<2HLU3D43T]P]
M_!UG/$_:-!?)<N:S==!Z8=;)?:EUFEPIX^4_<"[FWI39*@ANKE)&@_V;MN.U
MVYGG<E#I$0J;\[QNQ0CY*#AD?HG.5L?X/.,UX7?"SP\4>5,8K/\`##D(KR"A
M-DV[CQ$7W4^TY-:[[,MJE/VAQSG]D#'62I*-=CKQ"\6]V`Z:/46#D'[9RRF'
M#%O7IRE\"CDYQ]U/JVC:1W=;]RWOD+XU?#[E#:]KZ4XQ5K6KOBG&UG6^VZ?:
M]O,]>TVR2^OX^A4"PV:)LL)'LXJI5JJ1K6-J[XTBDN>4R3G)?PK;'QLX$^+=
MLSDO:>0GBB\M_$5K^OJC:'_'SCS'0EI:3U+%.O<<U*7I:NVV<:,*MJR^.*U=
MKO,-9!5.(J%70-'0"P0JX3-IO@9<*;9P4\.'2FK]IL95EON_J6'??(L9Y\E)
M6%3<^WGY9^?8V)^BLZ*^G:M`I5FER;T7S\[I[7'"YWK@RHJ#;R;Y?O+_`.\&
M=-S;\.%>VUM.!`H%+#[*OL<0H`(`";6V2Z28=&`I@Z3`H``E`0``#]8Z[QC'
M^41]@`/<1$?8```]Q$1]@`/F.;>J%:&.($D_3Z?JDZ;I&Z$6:)P]Q,'\5RJ`
M]&#YHI_4]CG4`,ZQC&,8QC,=N']Z-K_X,S_^:7F;GU%^C.Y_DA'^KI90<Z_O
MUYN?\"=-?Z6ZAE]?%3_!A*_R0Y_JJN7`^%Y^B9!_SD;F_P!)EARQ#&,8QC&,
M8QC&,CT_,!G[XP?(SUV8/V"X4$,^3&,8QC&,8QG!62MQ-KB',+--@<,W``8I
MBB!'#5P0#>B\9K="*#MN)A%-0`$IBF.DJ51%10AH"7RAR]#EA8OP%PQ<"=2*
MEDTQ(VD&Y1'V$.S`@]0+T#MF8PF3-^52%1N=-0<'QGHJ/22H_<DJ/]"9LN_I
MR)&]2JZ"?F$B%=@T2"8>S>1*+:$+YAZ#LW10['H.Q]^@S),8QC&,8QC`@`_,
M`'H>P[^P?O\`VX^>```#H`Z`/8`#Y`'W8^6=1'E,W*UY+[^0*4"`7;U[.!0,
M)N@<3KIT`^81$1\P+^<0$1$HF\OMY>@T+C'S$``!$1$```#L1$?8```]Q$1]
M@`/<1S:E3J?P_I2LJE_;'L=FS4#_`%O]I7#@H^PKB'NDD/\`</8YP]7HJ>Q,
M8QC&,8QF.W#VJ-K[_P#JS/\`^:7F;>TV[0<\:9`J1RF^&C4D5!`0$`/\*@;H
M1#V#YCT'S]O?*&'("-SYN&`!$H4K3)1,`#Y0,.VJD)2B;\T#&`IA*41[,!3"
M`#Y1ZO?XPO$F6I;`[4.4"-*](.E.Q]BI(,ECG,;KW*4`*/N/7M[Y<+X63A)W
MQ$KCE$X'37V'N)4AB^X"!]DSYO\`)WEB^,8QC&,8QC&,9'I^`%?OBA\BO78!
M^P'"@!GR8QC&,8QC&,9Q$[!1-DC'$/-,TGS!R`"=)3ZITU2@/IN6RI?RC9TB
M(^9!PD(*)F[#ZQ#&(:#FQ]53%%74>(`M)UE13IO+%(`J,_.80(UER$]FZQ?8
MA'8%*S=CT*8I*B*`:IST4#M)4/O24#^DALN]I2_Q-.JCGR^3XBM0*_D[\WD]
M6)9J>7S=!YO+YNN^@[Z[Z#Y9DV,8QC&,8QC&,?MSJ&<H'1GG)+?C@P"`GV_?
MR]"8#=%;V)ZU('8`7L`(@7KV#H.@]^NQT5GZ))*KJIH()G665,!$TDRB=0YA
M^12E#L1'_D#W'H`$<VW6J@G'"F_D@(L_#HZ2(=&09C\P'OW!9P'VG]TTA_N8
M"<`5S.<8QC&,8QC/R712<HK-UTR+(.$56ZZ*A?,FJ@NF9)9)0H_G$52.=,X>
MW93"'8=YA$/2'5:A92M5:\72OUR6`07A$'L9(,T@\@II@B:5BG;D2(E$`1*L
MNJ8A2E()S%#,'JW'76%6A+[#GC7]E4V>1(NP)BSOQ>R]D2:$,6/;G59)1S6)
M9Q(F%>):PS1B5@[`'I3J.RE7+==HWPM]52NH:0YD=P\C$(>WTV%E+!4VMQJ4
M4R>#+QB#E>/<RK&@MK*LP*940\BLL99=,P?$K+"/FRU+5&JJ)I+7]:UAK6"2
MKM,JC-1G$1B:[EXH47+I=^^>/'SU5=[(24G(NG4C)2#Q=5R]>N5W"QQ,?H-B
M8QC&,8QC&,8QFA)T@IS4H0?_`#YP8/E\E#BH'R]OD</V?(??.*QC&,8QC&,8
MQGYJI)+I*(+I)KH+)G26163(JBLDH`E.DJDH!DU$SE$0.0Y3%,'L(#D7M@:!
M`XN):B>4AA$RJU:74`J8B/N8(9VJ;Z@B/N2/>'\@=^1NZ*`$1R+;MFZ9N%V+
MULNS=H&,BY:NDE$'"!_S3$614*51,??V[*`&#W*(@(#ERNI)$LMK"@/BF\PJ
MU&!(<WU?=5O'H-5?S``H""J!P$`#H.NLV)C&,8QC&,8QC/!OE^\O_O!G34VI
M,EL6T=EV`AO,2;V)>95,P]]F2?6J6<(C]8I#>Z2A!^L0I@#V,4!`0S'HBOR4
MT?\`M5+R-RF\JCQ;LC<@A\P*;KM90/\`R:0&,'\<2![YN"%KS"$2Z0+ZSHY?
M*L\5*'K*=_,I`]P12[^29!]PZ%0RA@[SG<8QC&,8QC&,9ZG`1(H!0[,*9P*'
M0CV82"`!T'N/8]!T'N/R#.T[K6.-#Z[H<0=,4CQ=,J\>=(1,84SLX-@@<@B<
M`.(D,F)1$P`/M[@`^V9KC&,8QC&,8QC&,TM<4?1GG1NN@73;KA\_?M(J1OG_
M`+9(WR^_[,QC&,8QD8.2?+_2O$Z1X^1>XY"S,'?)W?54XVZH+7*RI8TWNT;F
MDHK!,I]1-^Q^@8)4J8@ZG#E>D:"(>9HH7S"63I%$U%2HI*HK*G.NFFDBLDLJ
MJ9KW\4"2:1SJ*BV`HBY`A3&;%`3+@F`".>H*I"5$X*HB1R8"-E`62%-R<3&(
M!&R@'$CDXG(<@$0,H?SD.3R^8A@#R11-0J!DU$U"NA6*U,FJFH5T9N`BX*U,
M0Y@=&;@`BX*W%46X`(K`0,]!<M@*H<734"(F`BQQ=-P(@<>NB+G%4"H''L.B
M+"0XB(`!>Q#OV]9$1Z!=`1]9)OT"Z(C\0L7S(M_+ZG?Q"Q?KHM^O66)]=),Y
M??/T,/E.BD;HJKDYDVR1Q`BSE0I@(=)LD<2J.%2',4ATT"J'(H8"&*!Q`!8Q
MF(6RB5FZMP2G8XBKA,@E;2;8P-I1KW\@1>$*8QT@'W%NX*NV-\A2#YAFVJ[=
M4:-#16KI:P`WE8$BC=BZET0CV\FQ?.W3]AZ+OSJ,BN$4'!&BJ*BK<QUTA%NF
M*9B`$B"F`P`8H@("`"`@/8"`@`@("'L("`AT("(#]@YYQC&,8QC&,8S7VS;S
M#T&F62?DY1C'K,(";?1Z3MRDBJ\=LHUTX00;)'\RJYSK)IEZ314*7S`8X>7.
MIA#T=$@).YM4'KM0I5EFR8F*U(NJ'J*@H</*HX'U#'$W0))"/8>0Y<T_R/YA
M<>^(B.O?X=+8^IK794S(UVFJ1]5FK`T7D(@L0:0(^/"-EB0[1J2<C5#.G8$1
M,FHJ8GF^'5`/IF>7FA(#DS6^(,E;GY=]6N!+986K-JU,O(I6(/!3%E36=6I!
M`T&Q64A(*0D$VSEP18Z(-0*43/$`-)L45BE]0R"Y$^BCZAT%2$Z/UY!\YB`7
MH_8>0>^C>8/+WV'?D4'`%$XMW!2``B)Q05`@`'S,)A(!0*'8=F$>@[#L?<,\
M>BN)/5!!<4O*)O5]%7TO('8&/ZGD\@D*("!C^;RE$!`1#H<%16.`&*BL8@]_
ME"I*"GT`^4PBH!1(!2B`@<PFZ+T/F$.AZTQJ#?6LM[O-HL-92\C..M-[,G-0
M[`2=0$I$#%7RN$!27C&8OT2?2[1L0P"268`HQ7]Q24$``1W.**P&`@HK@<2^
M8$Q15!02]B'F`@D\XE[`0\P!Y>P$.^P'`HK%,4AD%RG,(@0AD52G.(?,"$$@
M&,)?XWE`?+]O6:<WYO76W&;6<MM[<DK)UNAPDC`14C*,J_*SSM)[9I5"$ATT
MHJ,14?."+R+E%%95%,Q&Q#"JJ($#WVZ0Y5"$4((B11--0@B`@(D4(50@B`^X
M")3`(@/N`CT/N&>V,8QF3TF"5L]SJ-;0)ZBT_:*_#D)T`^89&6:-C`("!@Z]
M-0XCV40\H#V`AV&=J5),B29$DR@1-(A4R%```"D3`"%```````I0```.@`.@
MS],8QC&,8QC&,8QFLK^VZ7CG@?(Z:K4_S]A3,"R??V>X**]?;[?=FO,8QC&4
M'^.-$R<IL/P4S1L<_D"QWC(\:9&0,R9N796,>@4QUWSP6Z2H-6:)2&%5ROY$
M$P*)E#E*4PAUH]D\*M>SFMXSD8YINS/X:K_^$F;FXR6FU1%UV?!N/[%J_P!L
MET;K28N*@)>.85ZL6IQ)RJDW:(ALRFGZLD]:K6`S-8&!-@7/C5&13?;O""LU
M_8<+QAH_X43Q^U50-?QL[?ET-?Z4N-*W-"VN.I]B6D5K)"P;J$2B6ZTZC->N
MD8K*47E3RBH2#G3&X.%FNN/U8\2/9FDJ3LJG7OA9XSND=1</)6(O.V'IM-:D
MLMQLDC.P5"CW4ZZ9/&DRHTK?TC89)K+SC]*'@?7F5#$54D-L^(UN*,TSKG\(
MUX<WBI;?:;VY/\]]:[JTM!1FJ;Y-5RSZA;[`A+@]O:MWC8E>J0];1K:,>5-:
M2DVRDDO,P\=#MY(PR01.5<L.'^O]V7?\(QW?L:E7B9V%QGU1PCV#QHFF5BOD
M`RIVPI'3-):V.VP,-!/V$/8;$,5`1\&Y=2C28-&1"CUJV28K._BTXE\ZJCMW
M9')&^6?EM;K/"W*^</O#[L/"&^672O,#<6UG1G6DM9OK6;B.]T%<J?K>I;3_
M`(549Q/8R6\&D@QE;')3)HU5E<'"KF2_HGZ(2O:&CM+(;2>/Y'9J&HM9([%D
M96/5B):0O2-'@4[:^F8A=9RO%3;V>(_=3D6LY<JQTPL^9*.7!T!74VKC&1VW
M1'BG*Q,F!0%-ZP49J#UV`JLE1.4IN^P'M%R7V'VZ+\AS&*IM"\4P4TX:<<&8
MIB'^I,B(R,48@?-,C9P83M0-U[BQ6:F#[!^S)(UGE%&.!(A;8!S&J"'1I"%4
M&19B<1#ZQV*_HOD$P#L1!([X0^70_/-\P&QZ-9_*6$L\2[6/T!6AW)6C_L0[
M$HL7H-W?8?;TB/[<S7L/_P#OV>_Z_EGG&,8QCL/EW[_=GQ/I*.BT#.I-^SCF
MQ?SG#YRBT1+_`+I5P=,@?T]YIVQ<@M<P7J)-9%Q8G9`,'HP3<7#<%`]@*:27
M,WC_`"C]IDEUQ#_%$0Z&/5JY)W&8]1"NM6E79F[*"Q?+)RXE$.A'XIPD5FW$
M0[$/09G.0?<JXC[Y"_>ME??B)9Y*3D7;Z4F$V\.#Q\Y5<NUCR3E--8OKK&,?
MHK--R/D*)4R)E$`(4O097GE"_C7ZD4WI:N#NJ$"',^N]MY'0L,)"J&$MB-JF
MOO:V8`3^L<Q)UBP4*D'8*^02&*8GF#*\N-5DVINWE3Q6Y@-80S3<6[7'+*FT
M9-^JL[1._P".7!>DZXIA3*.4"D(TD=GN9UX"!P.@9XJL1R4RX.0'F.+$_6%=
MG^'^XTE<>0DOX@LOR-?L^==?N$ILYQZ.N4[#(%V2GL.'LR9*2T@6D2"!V1D%
M3NP!*07FTT)QA&%;8]J&AM:7HSAQRK@[/LAIN23\4]'3K^>7V#;UH5'4[JW2
M1I&F)5)5^:":Q$@[&0<2RI&)7TDK,S#20<N6CLC-'C[]/&2D=N.YBX<A&WB^
MM><:45K>IL)':")4M<A:8Y*&8UV#:MTZ&YUPK5OI`&YWITU56!H=LU;FJ3Q8
M7.ZYJR:TDN5'(A?D]<.6,'SNCN;M<@^-]5X_+3K^>:Z;;K`E1$=?P$VI$ZJD
M==NVOJ*V)S)JMW:D">+=035^VE[$=Y@]XD9R)I_*<E@D=C0G&^0\:2\M.6TI
MJL)9":0U$=HBJ0K]S`$-(MJFX=_'F=BV*+99^2"33!9^,.BMP\^JVG]+<P:Y
MQVN.W?[!USS)X90?'6TS,S<Q<1EGG)N::[/'6<W<S$MWT2TD56SM%61*5QYD
M:L^ERC-+*J+[<Y'0$7Q'6\5C2>LWNZ/X((^-X4O(VM,-NVWUZ\]V1(JGNL]+
MW27C[C/M:K8#-5(^[';H?2DVR?MJZ688M#-?AH2/YM1#C3XF&NJY;JS/ZRCK
M+PJME*BM<36X9O5)'\CL8(J;G-;.=ZNWFRI6,=+^2+D+++`@E8G;1%VP03AB
MP*"'=I9_ZS9_[R9?U1#/H,8"E,8P@4I2F,8QA`I2E*`F,8QA$`*4I0$QC&$"
ME*`F,(``CFL&6ZM4R-Q::_97J#7N$B5P:+AO.[2-,&:E\SE&%D%FB<3,.D"=
MG49QD@Z=>0BAR(G(F8P;0^?RQC)7\):B-NY(4$#D$S6LJ2=P=F\HB4GT$Q4^
M!$W7R\TJ[8`7OY&#OWZZSL0A\@^W&,T9O/DMHKC5$0<YO'95?UZPLTHK#5TD
ML+YW)3LBV:B]=MX:#AF4G-R8,&GE<R2[./6:QJ"B*K]=L5=#U<MU=MS66ZZH
MUO&I[S6K_57:AVY)JL2C>3:HO$B$.O'/BI&!S&2C4JJ8NXJ209R33U"?$M4O
M.7O8V,8QC&,8QC,7N#/XN#<&*'9VADW9>@['RIB)5>OU>B=01^_RAFE\8QCY
M9#NN\^N)EKYEVKP_(+;";KEQ2JV:VV/5"U1N[$&4"6M5ZX&=H79]76]!D5B5
MFTPLP9A'V5R_*T6=B+?U(R1(V<1?$`XG\Z%]NMN*6VC[24TA:X^B;0%G4+Y5
MD(:Q2Y[`2-CVJ]MKL"A:&C\:M.&;R-</+Q2R;,JI78I.VAUYG*?'HJ@DL#]%
MP=,J()*E=(N#I&'R$1*D<"K&2,/U")`42&'ZI2B/MD>V_*?3#KE+)<*4+M(F
MY+PVF&>^7^LS5FYI';ZBD;$C56MB)95(8E16]6?619*5MO-J3R7G*Z7B2-0]
M;-D[/V96-+ZTO^XMD33VM:ZU/2[/>KS8P8S4D6NU"H0[N>LCT(^':O91X+")
M8.G0Q46S<R#OT?1:LUUS$3-\ND]OU/D%J376[=,S\Q;=6;5ID'?Z%86L79H8
M)>HV1O\`'0TFK!R[&.F87XQ#M88^9C8]^W-V#EJDH`AGQ([OU4MN%QQ]0V=5
M5-YQ6OT=LN-2)SO=_CM8NY9*#0V":O@`.&U2<3:Z,62:*8K<\@JFW,/J'+WM
M432;4A3",HU27,)TS"+ULDX44`!,=,P^F190X%*(G()SG`I1$1`H=?C\(\`Q
M$_@G@'.<R2:?PCCSJ*$+YCI)D]+S'43*(&.F0!.0H@8Q0*(#GYJ)JHG,DLDJ
M@J3KSI+I*(JD[#L/,FH4IR]@("'F*'8#V'MGIC-:[7BAD*HHY(7S*Q#I)\'0
M=B"!^VSK]P$5(H/ZDQ_5D6<8$`'KL`'KY=@`]?<(=]]"'V"'N&93$7BY0`%+
M#VF>8)E$!!!*2<J-?J_(!:.3KM1+U[>7T>NO8`ZS9$?R(V>R\OKR,5*E+_%D
M8=N4PA]WJ1QV!OWB`C]O8_;F#;E-9R"7XVK0+@H=>;X5[),S"'E$#=>J5Z4!
M$_1@'W`"]DZ,/1\YPG*TX%*!Z,`G`H><26+HHFZ^L)0-#B8"]]]>81'KYCWG
MM_96C_\`44?_`+Q!_P#DV?$ZY52)N_@J6S2'HO0NYQPJ`"`B)^RH1J/8"7H"
M_6`2F[$?,'09C+_DY?G)1(SCJS'?/I0K1^]4#W'H>W#XB8B`=![I"`B`C_&Z
M+@<KNC9TN`E<6U^U3$.O3B4FD2'7770J,T".1[^WMQW^L,UR]?/I)87$D]>2
M+@WN*[]TX>K"/W^HZ45.'_\`:8`SY<9%CDE.%\M:K29_K>9U.O"`/R*`#'L`
M-T/S,(OE"@/OT4HY%;/4R9#&(8Q$S&3$3)F,F0QDS#["9,QBB9,PA[")!*(A
M["(AFK-N;ET_H&HDONYKS5=:4TDLS@D;%914;1X3,NF\69QC4K!@]=F=OD6+
MY;TVK4?,BU<+.#%23.?-BQ,A&3,>RL$*Z:2,;/QD=+,9A@*:R$Q$R;5O(1;\
MCQ,H'>,GC-=L[:*JG,0R2J*A0`?+UCMUN^O]:01;'L2U5"A5HDK&119NXRL1
M6X0DW-.!;P\>#^64:LB2DJY*9".;E.5V]7`4VY5#]AFJ+3RNXWT:?V3"W';-
M6K$]IZ7U[5=DDF&DZW6J,OMAFY>Z\A'T@2"6374M;-JZ48H1;I\U;D15)*&8
M#V09$G3]-4#JI^FNF02%.HF!5B)?7)Y4U3%]4J(@90O29P2,4RA0[*<X#Z>F
M1,%2>D1(%BG]8@)$3*N4X`"GKE`A07*<``%/5`X'```_FZ#-?RVSM;0.PZ=I
MF9M,)';)N\'-V6CT!TBY++3T!6077G)6(:)L#QQ&D4#=RLX%1RU6'T5E6Z2Q
MB&,&P!1(;U1%$@BJ4"+B*)!%0@?)-<1(/J$^XBPF*'R`H9ZF00/WYT&YQ$A$
MQ$[=`WY-+KTDQ\R8]I)=!Z28]II=!Z92]!U^OR`1^0%*)C#\@*4H=F,8?D4A
M0]S&$0*4/<1`,UK)N8RT[/J6L9]VO'5&58)S=A<MS>7Z707>KLF$:*I1#S1:
M2K11S(`F82.5%&R2X'01.FKA?+OAJP7@2/*L9U'JQ;E*8J\]$G.WE(&48CZ\
M;)1[IN8AT'C-4$S%%(Y2+)E$OYI@ZQ#C5OM_L5O):ZV.5O%;IHK<@6%J0A6S
M.YPA#E0:WRO(^5-,4'AS$3GXQOYS0\F85/*1B\0*A*W&6T^&50A`NQ]F.D1`
M#FCZ3#JF3]A*D!9J=,F<W_\`$4AT3>7[4S%-UUT-L^,T7R/Y$ZSXM:CLVX]K
M2RD=7*^FBW91S!(CRQVVR2)Q;P%,J$295(\S:;$^Z:1;`ATTDR@YDY%PRAXZ
M2?M>J&J]VSSAWE+[YW&D!)682^A:?3VKD7M?U?04G9W<71J^X,@V!T"2IQDK
M38#H).[7957$FL5&.;0D;%V"\4AA.+/+[4]:I1Y!TGR#9/M>[/KL>HH+%9['
M1KZQ4FZ.&"0"DM)5I>-DXTS]<@.6U8FI8BC@6I&R"78E2<(K"8J:A#'3$`4(
M4Q3'2,8.P*J4!$R9A#OHIP*8>AZ#V'K]L8QC&,8QC/11,BJ:B2@`9-4ADSE'
MY&(<HE,`_J$HB&1]?-#L'KIFH'1FRQTO]T0![3/^PZ8D.'ZC9\F,9X-\A_8/
M_)G0'\1;95@XA^+WXD/B.4V'>2UBXG[FXB:YE4X]R#9<:=RS\-_=.MR`Z4,(
MD48M-@5NDO?AUR'0^,,W<?452(8V@Z#4=V<`^*'B"ZBUW==D:BK</R@\'2B<
MU=K:A4EH^_ZUTWL3BW9;1R!M4+,Q!"3M>,^V5--X^5E&IT72WTD2#>N#(33Q
M)WM_=/(K9FJ]5>+C2/"WY8\H-T^'AKZ@</7R^\U[[?MG3>DK-L#852AMYQNF
M]I65"#LS5M+5%_,IW!O"%:IH10OGCMRR0CBS:VMY.9T!4N37BFO_``XN4>]]
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M_P!.-*9+1\M(OU!@*DNVF2*6$6=EP-.@[1IO@?\`$WE78O$4Y#1NTN:.Z=:5
MW8RG(#<.[TM$36MM<[%W1&P/'ISM#7#*<NW'RM6D&9;':-B2]FC(.W.H=\UD
MY.M%AV+@M]?X.%NB5VGQQY2U=W+;"F(;3W+2R4RLGG]_&Y0:IAHR0KK65-6.
M.V[9"+;66SZKB/0;N6[.QSUT79JRK&99V=W^,KT![$N,^=XT1?M'3%P4#(/&
MZS98!]_R:Z9DS#^TH&\P?<8`'(223!:+D'L<X`068NEFRG?\84CB4#A^I0H%
M.'S]C![C\\^+&,8QC&,8QC]X!]G8^P!W]HC]@!\Q'[`]\KIV59`M5UG99(_G
M9@Z^`CA`1$HQT:`M&QR_<"XD5=>W0"+@1_7F"XSKZ^*=*ON2'*_1/#R&U1M+
M>]-U;0;GOK=5!TVSBW=L"7N4$_I.KG1W$Q+PL:R1K2[^*FWI'3XAUF-L!L@D
MHNZ(&1>J_(+;UVX6<!]'M=H;2TIM?6G/>'X5;J=TFPO:I>8ZMMXV5BX1@_%)
MR=%TI'UF3)$,T)9&0CF]AJ!W!6ZR\<F)=?\`+B/MR>C><&E[EOK>EVI?$WGU
MHNNZYG-@[.>3UB&J;,B[6VEFEYGY)L<;"E5@KC*:J;I<K!"NSRDK--&R1I)V
MW'FN>-A,6/\`$H@HS9<]9J+3]D^%L%&NDA/#=7:\&XU397*5Y)+H"!;))V)L
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MG/CK`5X\:SL.\6\I%EE#G["@`(B`![B(@`!W\Q$>@#O]8_:.8C`ZQ-R-CK>4
M\T+2"KDBO%L*T0ZB)IY=HHLV>2<N"9B_$MC.454H]@OZC5`A2+*IF=+B9*O&
MSP=@XIW882<<O6>H'\XJ[A9Q<CIT&EK._7Z6?%1234=+:OLZWI(6R'2,*==>
MBA9HQ$AV[I!U<#HK;<;LV!7U]=TTF\^R239JH++(+@)CH$5;J-W*9U&[MJY;
MJHO(N0;J*-7[)=!=!0Z*Q!R`?,'C!8JQ88[9>MW2E=O50>GFJE8VB("":OE.
M"\?()^4Q'<+*H&492\>J4Z2S=50#$\WF`V?<?]YQ6[JFN[49EKM\K#A.&V)2
M5%!,YKDZ!!$KAH"AS+N:W,@11W7Y,_?K(@JS7-\8S6\^^B@8P@4I#',(@!2$
M`1.<PCT4A`#W$YS"!2%#W,80`/<<[*W&?6G\$^DZ+47"!$9<L429L7E`P'-8
M)TPR<D57S==G:'7)'@(!T!&9"AV``([YS#-B;#I.IJ/:=D['LT53J-2H5[8;
M19IIQ\/&P\1'I"JY=+F`#JJF_-1;-&R:SU^[5;L6+=P]<MT%.I'N_=NQ/$8W
MRTODQ'3-=TU2WCQAH_6DB"B2T1%NNVSN^V]BDX79J;)N+7OXL">8M.K2C6G,
M5#N!L<A-2Y.K6^/=%27,U,[L3XJ#&(B&3=1W(R4D[.FU91[%BV*HZ>.W3M5%
MJV:-TU7#UVJBS;D.HIY1T3O/<-LX?HJ4JHN&DQXDG("J@M(R9`0F([@_I.S>
M84I`?49.8]?<-R:D`C"-.H82O&R3LX#58-L-PQ_B[I/8_'6&/N2A[)L52O4>
MU=3DK-SLM)SA=B2"RIW\HGLAL_=G+<T)YTJLI)+2PJOP=N#N8E['R";=VAV>
M.-6[&/(C2-!V^QC%(0;;&._I*&45%P$3/PDJ_KUCCD70E(+QFTG(I^FP>BFF
M9VQ!NX.FFHH=,N],8QC&,8QC-8WN-$BS>53+]54`:N1#[%"`(H''_=$\R8C_
M`+1,/MS7N,8SA'=9K+\9`7]9K+\98[)66%_6X)\,LK&AU&JRPO(]<956-#VC
M5)$71XX/9B9N`B&?N:"@SEF"G@X,Y;$F*-A*:%BC%L2(MA9BC80,S$)]$69C
M,_2F0?)_"&%KY?AQ%/..A:73*U`*U.MTVGURJ+E>D7JE>J=<@:LN223%*2(X
MK,1%LH)P622$49$JT>H$@B(HO`72^IGY0-#HM5;),JM1:/5V:$<XAT&E9I=5
MKK5&(=JJKNHA)O"1#!%.)=+KKKNHLI`CW2ZZRSALJJJH<WX0NNM=UIB2,K>O
M->UR,39OHY..KU#I\%'DCI13UI./*QB(1FT"/DUORLFP!'X.15`%'R#@X`;/
M=UKZ@/WT-*/J!0GTG7(MW!UV1>T:I/)"NPC\BB3^%K[US#*NH*&?)K+)O8B)
M59QKM-99-PU4(LJ4_P"XTBE"]K<E^)=,"2I@K#39$M0K1)&G"X(LFX&GOR11
M7E4]=-PX(L%>7C`6*X<%4`X+K>?Q#4>DUR0G9>N4JEUV6M"@JV>6KU0K,#*V
M943F5%2R2</%,G]A4%4YU3'F7#XQE3F5,(J&,8?H>5*IR->6J,A4ZH_J+A`&
MKBI/JQ`/*FX:@M\0#5>KNHU6OJM@<"+D&ZD:9$'(BX`@+"*F?1`5VO52(:5^
MJU^`JT!'@J$?`U>#B:W!,`64%58&,+!,H^+9^LJ855OAFB0K*B*BOG.(FSF,
M8R.NX8$6LBTL""?2$D0&KP2A[%?-R?DCF^X7#8H!V/7F.@;[1S3.,8QC&,8Q
MC-8[=M?XJ4J1505!.3EP&%B^AZ4*L\3.#MT0`['^TV(+J]^W2ID`[[,&5^^P
M=`'R```/MZ`/8`_<&,9'"Y;<XCZ9V/)JW_9''756W+;#0AYMS;;+KJD[&LU>
M,H9M7!F'\FO'62:A?5CS(0P2#ERP3.Q%-D!!:])YI$:XT-92-KS`T#35A)8;
M"QV6SN<+4:!-$G;8V(Y3C-A-;/&QKLDM9&Y'+Q-C<4'[F71*X=IMY,GJKE-D
M#G6.L'9;>D\USKUX38;QO(WY)Y2:J[3O<@U2,@TD+FDYB526M^U0.=%H]GRR
M+ILF<Q&ZR91$,X]UIK3;UO(LGVIM6.VDN-5/+,WFO*8Y;2HT5J#&D&DVSB%4
M1D/Q,8E*RJ0O$UOQ99E!K"?`-P!/.8K.N]=4EE,1E,H5$I\=8W*SNPQM5I]9
MK<?/NW2"K9PYG&$+%L6LRNY;++MUE)-%T99LNN@<3(KK$/\`A3]::RU^WE6=
M`UYKZC-)LQ3SC2ETJJU5M,&(DH@49AO7XF/2E`(BLLB4L@1P0B2RR92@194#
MXU':+T]617D*!K+5VN+2C%6%A!7.E:RH$'8ZNYLL<K'O)2(>Q\`T537$QT'+
MAJ94K.5%JBUDDW#4QTQU=Q0XI5WBK`;(21O=GVI?=R;+F-K;1VC=F4+%V*X6
MF52*BF*L?`E+&,&$>0SU=LU;G4*9]+2KO\D5TFW0E@`_:`_K`0'^@0$/\@AF
M'L9>6U!9SWVM)G4K[Q?U;E!HD,8C?U3%!>?8MTR?ZW4^LI.MR>R9Q&52*`"]
M`)$[6UM3.1FO%9F+09OU'T<H#A$2IK`N19N(*H+%Z$IQ,0PE$!`2KI"(]"/8
M#3/77ELXSWZ(US/O%6D`20".U#<))S\.VAE%G*RZ6H+;(+F\I(.0=+&-KJPO
M3@G`2:HUUZH2'?)*,+IM;WJN;_I"D%-D!"Q,TUF;IJ\2,B]0>-A,@Y0<-U0!
M9)TW6(=)V@<H'`Y#&Z\Q1$:H>1NE+]H39+?<VJ6_I6:$`[>6A#BHG#7VK**>
MH]JTT1(Q4U`7(7UH>0,4R\7(D;N4#`9,@!:UX;:%7Y?7>E76NE47IE84"SW:
M,D"`$A`3%?<MP+2)]N()@E*A/':H+D`"I/8Q%:29BHT63SLVA[?]OO\`GGR/
MW[*+9.Y*2=MF$>P;+O'SYZNDU9LVC5(Z[ET[=+G(@V:MD$U%W#A8Y$4$4U%E
M3D3(8P=3WF[RXFO$&VNTUSK%T^2XI:XL*3J$53!5N&[[I$K'32V1)MSHI+_B
M/!N/63UA#.#'0EC][%D4?B7%50A=T4NL5'0E"5M5B%JR^#9&6("YDDO+Z:0J
M?GGZ`IO*43J'$0!(@&4,(")<UAM+=+OB]`UO?EXKK*U\O=QL'Y>%G'VPME#M
M=95Y0%6#KDUMJ&70,:.907G14J$6Y,V?N%'"4:S$D[*2KRH:KXG<:Y0\A/[<
MVQ,R5QOUWG'UTV#>[&8AYNX6J44,YD91^J)")()%$0;L6#8B,?#1B+:.8-T&
MJ"219LU6CVWE[LS^!C7+AY7]85,[-?;6PV*7D1@X@Y@]&`@EU$%V2]TGT`5)
M`,5BJ)QS,CJQR*1FC1!L_O\`->:_J6JZ36M>42&:U^I5**0B(2)9E$$V[9'S
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M2)`2K62C)]S&/(>92CM>[*_"%/"5U%N&S:-V%RC-6;U1-H7K36P326H-VHU:
MA['UX^D(NQ5NSW(VO0K;98)**DF48\8R$BPEE&2ZS%RJS`CD^3UOQX_"UL?'
M^;Y-CR73@-1U7=%9T!;Y:U:OV]7IVF[0N;&6E:K#VRFOJ,%K@(J;AX.6EFUK
M?Q)*L@RC9#X^79NH]\U;0XY7_A$O'5#@-R6Y6^'Y::EO+8_&C8FBZ;>M;[?H
MFV=>K0<;N/94336$_*U>;;4"VK1$I%KRSFMS4<Y/'_2;$&LFF5<AHY:<6X/&
M\\-;0/(H>*^W.1D?6MNQ<M4*S=@:T;8T]K[6UPO*:8UJJ;)VE`5:4H-$G9!1
M0`68V*?:_090,:R+0X(N10^C8/C9^&_J[DG)\6+MOEU#[(KVRZWIFVSG\&.T
MGFHZ5MNW)+*U_75SW6SJ"^KZU:7GHJ)K-).RHMHU=)VWE7C%6-E2L)P:FY1Z
M%WGL7>^IM4[$CKAL/C+;H:A[RK3.,L+)S0+98(QS,0\0_=R\/'1LHH]CF;M<
MCFO/9=BD9NLW7=).2&1#>$DQ2DF3ADL'U%TQ*!NO=-0/K)JE_P!LFH!3A]_7
M0^PCF@W#=5JNLV7+Y%D%#)*%^XQ!Z$0^\H^QBC]I1`?D.?CC&,8[`?D(#G#O
M[#!Q<I!PLC*L6,M9E9!"O1[I<J3J97BFR3R11CR&]EUFC59)=1(#`<Q#E!(J
MAQ\N>T_,M*[`SMB?B(,*_"3$\]$!*4?@X6-=2CH"F/\`4*8R#10I#&^J4P@)
MO8!SK>K^.5MZD[>K\MMG0E/BN.4[)H5P65'EI:P[02/+/4F\59XN7E'4>PGG
M[914C5[4#UR#9O1%PBSDVK\K)PY[*#EVU9-5WKYPBQ9M43N'3I\H1D@T;IE\
MZBSM1R9,C0B).Q7%<Q`0$#%5$HE-U]'_`&_I]P']@AT(#\A`0$/8<8QC&<'9
M(1&Q0C^(6\I1<HB+=4P?W!XE^4:K`/V>14``X_:F8X?;D,G+9PR<KM'29D7+
M591!=(P=&352,)#E'O[`,`]#\C!T(>PAGX8QC&,8QC'N/L'N(_(/O'(&;GN1
M;9;EF[-<%8:O@I&,#$-VDX<E4[DWQ/L,"SD@-T3A\V[5,Q1\I_?46,9UVN7=
M3M]R\6BP1%+XJ:=Y>2H\%*HHIKO=U@KU;J4"U/>7#4UW:O;"D9-:8BW#AO%(
MM(QQ'3"D?-2*C&29&1.N7$J9J+F9QC=^'EP`J_)`NA9??"/*JT;+E]>1+"]Q
M-+1*_;7&,B*HM/&0<N9.N1K)ZU8RL;,Q+)K+6"1<HNWP(?23[%]I\P^3Z=-Y
MF\E$>:)M47#BAR3;::UUQ)>PU+"M7^JU>>@ZXL[M]>EBIV^S3%^;.IF9=R3%
ML]3;KPT\8):);$B30OY<@^9G)J3?\]=GM.9Y^+=AXU.M:UW4'%H(VG**W)E;
MXR/&8=K,;(S4G9N?74>F>1<XQ833V(>`8TH$)!IM%0W#JO?/+':&]=[V"P<P
M+'KC3'%3C)Q@Y$V:KDUY`VMC<9.U\<JO>+2UF4XTM>FSUJ6GU+%8;+#LY)P,
MPZ<LXM@Q:-RIKQ\?M`<TN8+;9%=8S^[]QV^O;:X1\F]W,G.UW>D'JBEAI6M]
MD7"@;%U_1M<OK#*ZDC&DM5F2#*MW5\=>530D3_1[B$48(L<RHMWYV7.X\/*K
M)<_=MM&W,3AU>N0%G>1]%U\D\H,KKB`M-EBX2CG29-4F(S85R)8V.QH)1TL]
M1>3R:@.BNVITL'<<S^;6T]#<,[)";LMJS^=T?N:S[?K^C+?J*F<B+!,T?8=_
MJM9VA*P%ZCS+VND,H"M1YY=A3T&H2TA%VMQ(*Q,DJSET;Z^!FX9+??$+16UI
MNY/=@S]GJ3E.P7&2J#.AR4[/0-@F:]*N9*K1DA*14?(HN8L6;YQ#OUXF6=-E
MIF/!NA(`T;RZ$`$!`0`0$!`0$`$!`0$!`0$!`Q3`(@8H@(&`1`0$!$,QVFVV
M0T39$GC7U%M;3;PB+Y@`B*56>NE0*FFF4.Q3A'2@_P!IJF'J-=&!BH/PZK00
MV=R4X_TW?=`?2T>R:2C26CE1=H%(40635)V8P`3ZR2J9NC&$@@HBJ4JR0AT4
MP57:DV-?=([&9:^MSU^XMD=TC2[&[,(*;2K42D0"5Z3644,=SM6K,$B),#="
MI>ZXV(A^5GHU`)&YAH\J/)+79'"!FBLI\$`G*'D,)C&)[]!UWY#F$>@Z[2./
ME$`*/M77K7:NUO"^Y(O=VT2)D['J6XKL(GD7J1B1,!N568+K`UN-9353$C?8
M]'3=O'\*H51LA/,S/J_)*D;2`N6O<IU%MS7F]M9TS;VJK/&W'7U^@VEAK-AB
ME@5;/6+LH@9)5+OUF4FP<D6C9B(=D2D8>6:O(N0;H/6BZ).O3XFO."2Y&6^:
MX;<?IA8VK(&4<0?(/8$*Z'T]@SK!P+>0TW7)!FX$JU*A71%6NU'Q`\EEF4/Q
M#:JFAX^V$DL8T?J6NZMJ9;-/IH,F[!J"Y?5(0@=$('E\I!`H#[@!$DR@`&-T
M4.B%'K@KWMNG4*FLN7F]X`]HI99U6`X?<=/B$4)3DWMF.5(HVGWS545`)J.C
M."EEK%,/6IHQ]\+\<J5XS1A(FTQVX_:>V;OG9]KY*\C)L;?MC8KQK*VR=.@=
MO%1;%H0J4'2J?'***IPM-JK("QL#%('^L4BLE(*.I)X\>+3K68W#<UYA^-NA
MD4DI-TB"]NM8HK+05#J:*I$9*P32S<HEZ()C-8B.%1)Q8YTZ$8V.FC\6[:7N
MZ(T=1>/6MX76U!8F0C8X#.Y66>`BI.VNPNB)_2UJLKY%)()"=EU4RG<+>0J#
M5NFUC(])M&,6;9'<>,9T$^`W@M>(UPKU@SJ%O\);PM^5&PXC9<EL>`WANO<[
M)?9$$HH6NK5^`C9&.JZYV\759.`&5AA*[*HB^DGJI$T1-V>;G+/PQ?%%WOXK
M55\6*L:;XM,9CBULG0U3TGQUGK/5G+[>NG*LUO/\)NR=@[-%HI&UC:4?(3B(
MZH/*Q<Q(U)H]K2S%RW?ZR;FM<8>2_@\^+OO7D+N*P66AQ5]KG_=%J3RUUML)
M[S0:TK5:FBZ]95'<'JRJ<-ZS7(N@,=TP<*^(6Z;KV+).)9\6*4@:HYDQDY>S
MV*3&VO!>YLW35_,BL1M8UPO*[M_"`(_Q#Z.V>;$A4T5.-XR<PX=24HNJW,A'
M6Y)I*^FK4S"H]4`%TDE5R^4J\*O&&X3\C^.<!SJW1/06NOHGF/XTG`78O'-&
M4L24Q#SJ$!4]UQ`?PB1,4C](P$:XLTY&-Y9D<%7[F,/(KH$,)"'5WQR8\(+Q
M1N=D'XIG(;;6G-&:'W[R]0X8:KU5H*G[NB[54U:AQSVC1K1>=DWC82,<UB'L
ME)QM&8#3DY".1L1VTA+Q;^)A"LV))?X^3_@/<V+5RMYO5NIZT9[NXS\[^14!
MO8]TFN?.W]%:GUHW?21;%98/D-Q<IR;N4WW.5"?574U=8("266A3Q\7($502
M?'@:[Z\H_!A\3JR\YMG[`XUZWUMJ)#97**B;>9<G=<<LK)"Z'FJ)4SH-T'O)
M[@WM:,V<_P!I;O/'D<O).:I4O#T!>=DI@K.K+M9YZ^;]KGCE'\AF>[N7SG;N
ME=`:TUK(;*JR^@;UJ8WFV-N2GDKKM.<L^^/[:7_[[HJ5!K'PIA19B6*<.4`0
M4(@1TO,C-=W>%$Y2S#<G9DRE2>E*'N9,!Z2<?K]+OTU!^?IB0?S4QS6>,8R.
M_(5U,I1U31A[3-5'N5DG;^4@Y!>/<@U18)MDTU3("7XA#U'9S^@H)D_5`JGD
M\Y"*$P7B)=[S>&NWUK?9I:R,JSL1I4ZRK+BD==NS8UYO(R"@+IM6XN#/EI-D
MX,8ZBWID!,B944Q**T?.6I=AW#D=1(ZEU.WV*/UC1'2QQKL=(J%4M5]=D=`*
M<@W1^&:'BX>+AE3N5'!#(.%4BD`3%4%.9VKC[`O-`E*SO77P1X/XI:"?I2TA
M$O`MT')LUF,BVFXR)>J+L7BK511"0,/PJ;Y-?UD2-G0+`,##>#UQYD[TC.VN
MS72PT*`NE?O5&UN)VC,("7KDBTF8]&2N'F=3,PR;230J296S6)=O88ZD;+/'
MIE%G*TI>>MO>0/'2VQ<>H!9S9<Q"T)EY3`F;TIR0-*V%P0`$.B-X*)DO4#H2
ME(N4@`83D*;&N+6X+S,@QILY4+W*UHC=-M"W-Q69(C.(,BE_K23E7!$TG$,<
M0$C-R8QW4:(IH&*JS,`-9OOW[&*9KR,H]9QD>U+YW+^1=(,F3<OWKNW2B3=(
M!^0>=0OF'V+V/09Q=9M-<N<,VL54F6%@@W:SYNVE(U45FBR\8^<1K](IS$3.
M"C5\U7;JD.0I@.GY@`4SIG/S^,8S0FW*H('+:F2?93^FWF"$#\TX`";9\(!]
MAP\K=P80'ZX('$WUS9HK&,8QC&,9IK=%\+4JZ>,8+^6P6!)9LT],W2C"/$/2
M?28]#YB'\IC-&0^PBY4,J4>FI\@I\N@#Y```'Z@#V`/?L?8,8QF$)ZTUZEL1
MQMU.E5HFTG542HKG8)8Q(+:O3$'J<DC5E9COUSP:4@DF](PZ],')"*>XE+TF
MM::]L=UINQY^E5J9O^O&\VUH=RDHQ)S8J>VLK8S.P(5Z2./JQR4TU,9M)%2#
MIRB)DS?5,/>K;3Q%XN7?9;;<MPX^ZDLNU6KMC()WV:ID8^GU9**!L6*E'YU2
M?`R\K%@S:!'2DPQD)!F#5N#=RGZ*?EK_`.67A<7#E!MS9=V=[VUQ&5/:C.M1
M#XEKXRT6Y;@UY7H8Y!DJ]K#;B;R'E6K.61!=FW?V$KR7B8YS]&HNUFZ`J.K*
M*1H#3.O$Y<:KKBJ,']FHU/UO<IM2'9N)J]4VB5=K3*Q"W1VHD*5@:Q];:)Q@
M(.FWPQVYUD10!!3TBZ_K?"3AY37R4G4N,6D:S)(,[#')R$%0XN+?_1ULA%ZW
M9HY1XU!-PXCYVON7,-)L7*BS1Q'.7+;T2%<+"?8\?H72D2^H<G&:JHK"1U=3
M)/76MWS6!;I.:+0IEHY82U/K"H&$T97Y)B]>-'D>EVFLW=.$S"`*G[UI9N$/
M#ZXU&GT*S<:=.RU.U\65)1:^M44&S.HH3LHK-S;2`7CUV<C'L)B865E)2.3?
M"P?/U57;AJ=90QQD15ZO6J3786H4VOPM4JE;CF\17JU7(QG#04'%-"B1K'14
M6P209L6:!1'R(H)$*)C'4/YE5%#FYW/Q<MV[QNNT=H).6KI%5NY;KD!1%PW6
M(*:R*R8^QTU2&$IRC\P'L!`0`0]=6;"?:8L+>J3JZ[[7E@<_#P3]RH*QXIR<
M#F"#?*J&,8RR"0",>Z5\H23,ADU!^,;K>?Y^7_%NO;8JBU@@DSE,<$)5A)1"
MIF\E$2;50KN.F8A\@)7#)\R=$3<,W2)R*(+$\@CUV`P]XI[*VK7+-=HB48JN
M[KJR`)<=B1[!LN4MRUTE*L8.0W)78M%(P*DAWDE'EW'$M@+^+KB1;7%H@,&^
MEOHFS#9]=IVZM8K6]H#<3%8"HN8"%/V82!V4!+V!C`(@*9Q$?,00\P@(>]??
M#;D?LKCUQT\6S3NO+')Q475*/KC8VM!3<K%2UW/[DN"6I=@2E7$JO<0_>-9N
M*GF8,DTTTIV))*IF0>J+KN)&\.-0U9A6VC_X9)NTAF20E2$O90;-R>5/\H8#
M&,!2D\RQS"*BAO.HH)E#&$VZKQ:J9.U:^[OW2M,P/#O0KUK'V1K#H*IV3?>Q
MW+EJRK>C=?($=,5GC^RRCV/CYR0:KIMV#9V6)^-8G7EI.#AO0:WMKFKO!SR.
MWHQ:Q#@6#>N:VUK%"<M(T5JJ..0(+75.8`(,45$6Z:#BTS31LW5L4YZJWIH,
M$8]BTG[87TV$C6>/^BX4L_LRWG/&1C%!0&[=@BD@*LE-3CXB:A(J%B&8'?34
MHJ42LVI"MVZ;A^Y:-'-U_%;C+5>,6NPK46N$_<[`NC-[(OKEN5&3N5E],Y/6
M,41.=E`PZ2RD=6(0IS)1<:!E%3.)1]*/GDF\8QGP,96,E`=#&R#&0!B[58O!
M9/&SL&CU`"F6:.1;JJ?#ND@.05&ZWD63`Y1.0H&#N#.[O%$\/?C=N=IQZWMR
M\T;JW<KH*Z92@W"YM8R9C`M@(GK@V%04E8VL?2[9PU?M/QD?Q(C%NV<JIZ<8
M[;.U:_.2OC`<DB\OMX\-_#DX`2_.:\\2J?6+=RFM$IN^LZ+J5(DK<P+-5[6E
M,=6&#E_QXOLM"F.NBT;.6ZHR+*5BX^'ES0TJZ:Z#V!^$*[3>1_AVPO&OPY+_
M`+<W7S^CMZ,(_0VT]SQG&V[:QV-Q_DHIE=*3)2-^UPZK\RP69N92=A[<_>51
MA(0S)@)6*<O(.X>)VCI_QH*!MR!YI4SQ`^#%ZX][>\/FX:+D=I:.C6L/S:66
M>;E46-J&P4%?6E/6+)6@C\43+.&,,,?7&DQ%39;:FU4FBPEB/A:\^4/$MX>4
MWEJTU8^TVTNESVO66=$D[*2UR<>SUSL:P4=F^DI1."KJ24E--H9*5D(E)@JE
M"/'2\4E)2R;4LDYL2QC&>IR$4(=-0H'(H4Q#D,'93$,`E,4P?:!@$0$/M`<T
MA8H12%>B0H&,R7$QV:H]CT7OLR!S?^41[`/<>U""4X>XF`O`8QGHHDFJ42+)
M)JD,'?D62(H40]P`?*H4Q1[]^AZ]_P!F?,QC8R.%8K!C'QB;MP5R]%BR:L4U
MEO32;F>.BM4D2K*IMD4DS+J@90$$$T_/Z:9"ET!H;DG4]Z,7Q8\AH>30E;&B
MPC'#@5$IN'AIR0C&\S%G.!/5.JS:MWD@Q$@K,Q<"JD9=GVJE(L/+[=F(0O8=
MG.8")D#[3G./L1,H=F.<?8I`,8?8!R@_;WC=?P8[5-%)<>/I?1,3=BP\WME*
M].EIQ[4&\L>+D['`U9&`:QJ$FDD`2S"&DYITB^9"V0%ZBXD4U&MY-<G*CL.M
M56[5MW#VRKV6&B;;3K`BV2>,Y&%L,:A(1$W%'=H"LW))1;M!9,X$0=%16%!8
MI#@HF&4&$QN@,8QO+[`!C&-Y>O;H/,(^7KY=!UUD<-^ZT+<CU6>%F\F20;H[
M)W`E5>KM7:;U3U63U.-2.+8SUL[*=N9UZ`K`@Y2*=4$4?*'!\8M3WK4J%^CY
MQ1DWI=HL06RJ5]1<ZTY791ZF+6P(.#(^JP&+DDVT<Y13(X!ZA(-G)UT"@[.<
M)58QC/Q<-T';==HZ2(NV<I*(+HG#LBJ*I1*<A@^XQ1'W#W*/1BB!@`0B'<ZJ
MXJDNHT'SJ1[CS+1CHP?W9OW[HJ&^7Q+81!-8/;S!Y%@#RJEZQ'&,8QC&<+8I
M^-J\.^G)9;TF3%+SF`!#U7"IOJMV;8H_W1T[5$J*!`_C&$YNDTU#%KKM=FD;
M?//IZ3$`7=F*5)N01%%DS2`2M6*'?S2;)CY1/UVLJ95<WUE1`,=QC&,8QC&,
M8QC./E8MA-1[N+DVX.6+U(47"0F,F;KL#$415)^40<H*%(LV<I""K=<B:R8@
M8H=\WJ;9]NI+\FKIZK6_9+.1*H2L&JE=EK'+2S0XE3*U%A$,WRJ<DV.HBVD$
MC$20,8Z+YN<$5RE3G-IG@M-:XI7)3E)M6'+6;G-\<=T5+7VO5%&[F5IE8LM4
M7DIN5MCYFHHU+9YHL)&,4H%HLZ;04<BN9^Z6EWZC2)BAI[]&(W\@L_ZDWRI;
M5?\`>]XO?\PG&O\`YQ]/RV?BJ`?P92_M_P"*70?N%LKV'[\F]H+C-"\MO#66
MU#+R00LBKMO8]MI]@5;G?(P-VI^W)V5KD@\8E52%]&&72/'RK0BA%U(QZ[%H
MHD](W5)$9W%;DX_,H_2CG0^P%=K2;L(:$=UJ!D++4;8LNJ1HP?U>W1S(8=5@
MNHLB)E9A>'7ADU#KV!G%&16*C<9PNXDM>.U9?VFY+-+'O38#=LO?[00!60AV
M8&(\:T"L*J'.)*W!.C&4=/B`DO9YD%)AX4C9.(8QLW\8QC-$:.XY:OX[1EIB
M=7Q<G&LK=.A899*4G9.<$S\C%*/1(@M)+++(MTFR12``F574,)E'#A<X$$O3
M0\57PT?$5OG-_G!LGBUQ/VL]6Y)RG'E[6K-3-H<8]E\,M_MZ&E"Q2R_+GCWR
M90&1A9VDL67;5.'C['5U)5@ZE&L`+.?5F`G>QUEXJ7AB<[.<&]M!\%HKGOJK
MQ`*KI;93IEJ_<U#U*.E.0FL]>GJ]HK\FRV$FG,2.O)6PS5@<UHD8ATE4"U]N
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MFJS<A]4X=D4``$Z*I>_(JGW_`!B"/R^1BB8AOJF$,T=)1KF*=J,W1>CD^L10
MH"":Z0_FJI"/S*;Y"'N)#@8AO<HY\&?!*R;.&C'\O(J"BPC&;A\\5*DX7%-L
MV3%54X(M4EW*@@4HCY$$551_BD-UE<9^25@4VQ6V6H+2&PB[-MK:'_$>:2=D
M@V+KRD^FY5JZ73+,5N/CHY!:4<F9ID;"FT<J*,%3&,.6!7J-GIFEV^&JCYG'
M6.7K<W$0,G(>L5E'R,HP<1[62=%036<>FR^(%X":22BAE4DTP#W$0@_JS@JZ
MH;:`2>;BGF8U[X=2/0I,2UC#-W"(^8SDLO,G?.3.53B915R$:D90YS@)/3$$
MPL!!L0[3X-T/QZ1VOPCH7I$5/CDCH?#N?C$TDT4%`>)F4!TFFBDBH"JA"))I
MF`A:/]S^"=2-P25N@0W`^IVH9V=9S$/4XNKGEK/!-"NFSQ]`ISCV:91ZL:'D
M=Q;`ZC1=7Z(5:`^(N^9@X/8WRPL#747%>],:<T+"B%4A]54.,B@%`(OZ=(SJ
M$*RC@2\ADB0U?(Y,@9/R&328`KYB>0Q@UYQEY--K(:*UQ;Y966F@:L6<+84V
MKQV=RX(W21-$3:[=NJGZI52F*QF53@DJ3I"16`_I.E)KV&2D8>"EI.(A'=DE
M&+!PXCX!BY:LW,N\(3^UF)'CU9!JT(LJ)?B'2RG3=L"RJ::ZQ$T%:VJQ<>3M
M'V_%OY:08WA[M251&R:C4E!^C8IJB<6J$A2)),'K2KF@HI(Y':PA]$.VL><]
M@1<.!)(HV?#\QZ'L/L$/D/Z_WXQC&<#9*\QLT4M&/0\HF[4:.2E`56;HI1!-
MPE\NP]_(LF(^59(3$-T/E,6(4U#/X"1<1DDEZ;A`WL<H"*+A(W?IN&YQ`/41
M5*'F(;Y@/9#@4Y3%#BL8QC&?.[=MF#5P]>+I-6C1!5RZ<KG!-%NW1*)U5E3C
M^:0A0$1'H1$>BE`QA*48&;4V.O>Y?TF9ED:U&*G+%-3@9,[I00$BDJ\3[]G"
MY?,5LD?L6;4WI>RJJ_>JL8QC&,8QC&,8QG)0T/*V&6C8*#CW4K,S#YM&Q<:R
M2,L[?/G:@)-VS=,OYRBAQ]Q,)4TR`=54Y$DU#E[!7$[C1'Z!IYUY4K5]L:SH
MMUK7*HB"J;!)/\JVK,4X\I3?1L<<PG=+D\OTK(^=TH!D$F*:.S.1X`''G?``
M'0?P,[1]@_X#3V==G3WZ,1OY!9_U)OE2VJ_[WO%[_F$XU_\`./I^6S\5?\&4
MO_)+K^K*Y<!X7GZ)D'_.1N;_`$F6'+#_`"A\_P!_L(@`_M`!`!_?WGG&,8QG
M@![^_P#>`A_R@&4<<DO&OC=(\R]M\)M<<".;?+/:&E:AKB[7>0XUTFCW2'C(
M#9D!&ST"\7;R%PBYQF@F,HE&+KNXY%(\DDNFV,JD4JI^(L?CZ<;M8/=N1W(7
M2'(70,OH[ASK?F#L*K;*AZ!$W:,CMG7&-I<!IE"K2-XBW"FYU)&69KDK#EXQ
M;/&_K$;/C.411-^'('\(0X?:<8:\D=>:JY-<L26[B]'<S;B/%S7]0V.UT;QS
M=21XB1O&Y)I?8$1`UA>`E6<Q#V"(8R<L-?F(.086)]#`9HNXE3J+Q5N/V\N6
M6BN+&LX&\SSKD3P3@^?^N]HF9PC&D.M1V*TFJL5!R3-Q+!:V-S,Y(==W'J0Q
MF#$$U6B[X'B*J);/```#H```^X`Z#_)GG&,8QG#34*VFFOHK?463\QFS@H=G
M14$`[^[S)GZ`%$Q'HP``@(&*4P:5D(]W&.3M7B8IJE]RF#W353$1`JJ1OD8A
MNO\`=%'LIP*8!`/C`1*(&*(E,`]@8HB4P#]X"'0@/ZP'O,`3U;KM"\I;,;TZ
M#:WM&/DHP+*S9@T?*-)<J!)$7";84VCIVY2;IH&DEVRDD#<Z[8KL$'"R9ZO.
M:WB&;&TAMMWJS6-<K<=^(A8:6N5CO#891M:$IF$;S+2#A(Y!VP4CXTK5Z0%Y
M1)T>;?2"!TH]-DT;G,]W7J'Q$]?7?ANRY;76!=UMBI;;'K\U2KQG,N]E[C!2
M:\>P80YY!)K\`E86R(3"1YE?T(2..I\<^=N$/16^/BYXD%%Y#;*CM+3M)E==
M[2FX6RV6`C0EFMA@9>#K+89!\<KT[>*EHY^2-'UB).HM9F_6;O"LG@`B*83,
MF]W:OK5E>U.QVMM!3$>+<'`2C*2;QP"Z:I/$RDER,U8T3$16(*X*.$A0/V13
MH0$<R>8KM%V5"PYYR)KUWKQEFEB@S/$T)B'754:+)L9=ET<[-V4[)ZM\,N/K
M(F1<&,0!\P&"N;F=XB%7X23S#7='T*\VA8#5YE.3+"ISL-1H*J-I4SD(=M+(
M,:[,2+Q1\S:?'*"S8E(S:N6'K&,9VF`2FX?\K]=<R=)0&XM?'^!555-!7FFN
MG:+J9U[>F+=!:8JDN=(J8+D(FX0DH*5*BBA.P#UA)(IIJ'=-FT@4JI7D+(O;
MTHMN6QN(H(0\G]<521@NC/56Z"8F%%N+IR)5'JZ"9%W@(H$<**)HE+F0XQC&
M,Q&X5!C;8\$%A!N_;`<T<_`OF,@H;W,DL4/=5HL(`"R?YQ1`%4A!0O1HGR\1
M(0;]:-DVYF[I'W$H^Y%4Q$0(N@IT!54%.A$BA?8?<!`I@,4.-QC&?@Y<MV3=
M=V[71:M6R1UW#EPH5)!!%,/,HJLH<0*1,@>XF$?N``$P@`P@VMM9Q='!X>'.
MLUJS94!*`@9)>:72-V1X\+['(T(8/.P8G]R^SIR`N!33;Z5QC&,8QC&,8QC&
M<A$Q,G/2D?"0L>\EIB6>(1\9&1Z!W+U^]<G!-!JU03`3JJJ&'V`.BE*!E%#$
M3(<Y;W>(G$EAI&,+<+FW8R6U95N9-19,Q7;2G1S@@`I#0ZW7IJ2#@O834PB`
M"N'^I[(X,4U%'DX\TOR0_1YWQ_,SM'_Y&GLZ[.GOT8C?R"S_`*DWRI;5?][W
MB]_S"<:_^<?3\MGXJ_X,I?\`DEU_5E<N`\+S]$R#_G(W-_I,L.6(8QC&,9'K
MCYQV@^/,9;XR$NNP;JG;[+^,CESL">+//6*Y6"+`&[1P5JV,)52(@L\<K@=R
M\<"518X^0H9ULK[X6]FYD^.[XA-TV;8^<W'?33CC?Q6+K[<O&^_WC0=:V78F
M51K<+9*J.Q6==>UZ^!5SQZSEU6VCMTM`RB)G;U!)3R9%SQ!O#EWGLWE5XJE#
MI''W;N[:F/@O\?\`7&@[]?:;+W,FQ-U:<NFO'$,C7MDSL,G!6O?S6(KLS)J*
MPSTEQ5EW<@X20:J2@D4U;R3F]KV?PX=1<*7WA:^(3J'0UQX$0S74U@X8:*NF
MO]T/^:5(;V;7]]TKS#U76VK-C':&V#LL+!N:286N+DB;9C)N`V<V:2-E?.'4
M%DE,DN:'AU\W/#5Y";;\/?EYR&6UYX%^L.+.SH'B%H1>Y-*+M4VV[E,,:?*+
M5YM&:\AIFJ4Z'KJ%QA8B22%I,R7QD>P<LG8+J=O_`(<<DY7EGH6L;NF=`[VX
MRO['*6J-5U#R/IHT/;$"6LV*0@$G\Y6A6<?",;`FQ+-0*X*F*^AW;1V01(J4
M1E)C&,8QG%RT0SF&XMW9/K%[,@N3H%FYQ_C)F$!]AZ`#D'LB@!T8!Z`0TW,0
MCV&6]-R7SH',((.B`/HK!\^O?OTU0#\Y(P]AT(E$Y/KCP^59<W_"@TYS6OD7
MMF1V?MO4FS&#&%@WTO2Y1E,U2?KL2((&8R=$G"HQ[>57C1.Q&PQDDS<*@DQ^
ME&4LW9$;&V/?O#SUJMPUD.'^AYM?1T663C+/!7I2))L*:)=V#Q%V]MMH;2LC
M$_C'+V$J0M91X1TQ(P0%O]#,&Z$<RCR0Z\/SPG-D\<-V$Y`\BMXQ>Q[Y22V.
MOZVC]<-I.-K\G"ST6]AWEFO+B>CF<FH]=1\L^2;4YDB=HS?E"5D9Z3]-FR).
M7D-H+9=X@+ZC32UU[)VU59=-9:0^`?(E45(0K<BC]-)(@%9`"(BFZ[$2!T'D
M-Y0F?`0S.N0$%78\H$80$)$03(I0$H`TAXYM&H"!1]P\R38IA`?<!,/8B/8C
M6ES`\.DW(;9">RJ%<X2CRUEC`B-EM;(QF):/F08,F[&(FX=*.]15M*&8MT8R
M3:JG;LSD9Q\FT52=IND7&^.!O#BL\&./D;I"`GOQQD5+;<+Q<+PK%!#O+;9+
M7*"JFZ<LQ=/E2)PM?:0=;9"L[5.HA%'>"5!1\JB29F,8QC&,QNSU:+M3'X1^
M3TUD_,9F^2*7XEFJ/?N01Z]1$X]"LW.($5`.P$B@%4+%:RU:6JSSX612`R*@
MF^#?(@86CPA?F*9Q#LBI0Z%1NITJG\^C)B50V.8SB)V>B*U&KR\V^18,&X=&
M54$3'54$.R-VR)>U7+I7Y)-T2F.<?<?*0#'+![96U92^+BR;%6C*R@H!V\8*
MA16>JD,(IO94Z?U5%0[[0:$,9LT_.`5G':P:GQC&,8QC&,8QC&9I0=>7'9]F
M95&C03N>G'P@8$&Y0(W9M0.!%9&4>J>5K&1K<3!Z[UVHFD`]))>JX.FB>]_C
M%Q*JN@X\DU)&:V;9C]KZ4G911.#2)16*45X>L(+E!1HR`P>1S)*)IR<J`=N/
MAVOIL$I>XS2_)#]'G?'\S.T?_D:>SKLZ>_1B-_(+/^I-\J6U7_>]XO?\PG&O
M_G'T_+9^*O\`@RE_Y)=?U97+@/"\_1,@_P"<C<W^DRPY8AC&,8QG@1``$?GT
M'?M\^OU?M^S*(N1GX0/Q=XP;[DN.FQN,/B&O+Y_"19M64IY4^*,E-UC<-GJ:
MB190=+2R]RCG&RX\R+AN]:KUR.<.%F#EL].T2;N$3J2NXS>*AH+E)OZK\9:U
MKSD-K?;]HXJH\O@JN[=7(:Y?P&KW&T'>IT8NTQ;NSR$Y!WA6P-22:,"XASLE
MZT]82[>:5^)!L7"^<7C"<=^!^_-?<:;[J'E?N/;NR]7O]O5JL\9])'W*^/38
MRPS%;D'#R.C;3%3J:S)["O7#ST(AVP9L#(.73Y`5@3#?W`WQ#^-/B-:VMVR>
M.,Y:5D-=WR2UCL:F;!I\OKW8FO[Q%LVD@X@+54)KMVQ6.R>I*MW;=9XP751?
ML2N@D8J39L]3<J_%UX><-^7W&3A)N:<N#3='*IW76M$/!045(U&LDN%S/K^H
MO=C3CVR1;NM,+/:T7<7$NFD1-%$63IR]*S:IE6/91(3\)$KQS:5EXR,<R[D6
M44WD)!FS7DG@`!A:1Z3E=)1\Z`!`1;M"K+="`^3HQ1'\I2S5V#CRRTS.P\3%
MG5*B62DI1@PCS+'$Y2)%>O'"+453BF<")@L)S"0X%*/E-U];F8BF307[N28-
M60-E'HNW+QLW;`S12!=5T+A95-$&R2`@LHX$_HD1$%3'!,0-D?=J<GZ=JNY<
M=*>K3MHW\.2VPG6NZG:]64X+O2*<[:UM[9?QGV?964F@UJ-)<-V1HYI8B$E$
MUY99!J#<$O6<([U:6BN/Y5W`LYV'=3C`GJ/X9O)L%Y9B3\EV9[&(N#OFA2^N
MB!C.&Z92BJGV(>H3S1YXV\T>-/+;43S>^AMG,;;JAA=+7KU[;Y6'L5$9-K=2
MI@L#8HI5M?XFLOR?"2AR-FSTS4&$IZB2T6Z>(*IJ&DRQ?,I-HWD(YVV?,7:)
M'#1XS71=-7*"I0,FNW<H'40714*(&(JBH=,X>Y3"&?7GXN&R#M$[=RD1=%0/
M*=-0H&*(?8/W@8!]RF`0,40`Q1`0`<U?-TQPU$[F*`[IM[F,V$?,Y1#[D_M<
M$`/D']V`/;I4>S9@P@("("`@)1$#`("`E$/80$!]P$!]A`0`0'V'/&,8QC&,
M8QC&,9\4A',95HJQD6J3MHN'2B*Q?,7L/S3D$.CIJ$$>R*IF*H0?<I@'(\6[
M5<A%"L^@/5E(T`,H=H(>>29D#L3`!2@'QR)`]P.D`.`*'UT3]"H,3+[MVN4H
M%F*9RS5@(!B?1+14H)LU0]NI9X7SE9"7YF:%*H_,'MZ*0""@0NM=QG[G(C(S
MSTRYB>8K1FD`I,(](P_W)DU\QBI`(``*K&$[A<0\RZR@]`&+XQC&,8QC&,8Q
M@?8!$1```!$1$>@``^8B(^P`'VB/L'VY+WC_`,.-E;N5933Y!>DZ\5.512TR
MS4Y7LLV`1\Y:M$+>DK)"IT)2RCKX:'2]U$UGYR"V-=[J32VOM)UTM=H<*FQ3
M5]-24EG(E=3L\[3+Y0>3,F9,BKI0.S>B@0J+%F4PI,6C9+ZF;6QC-+\D/T>=
M\?S,[1_^1I[.M73[I#TGAK+7.1%5Y#Q5=AU5S1PIN%%DGCB+B@.V$#"FKZ2K
MP%#E`X=@BHD`E4]@I:B]QMJ1.\[J:A!N9]GR%UWIJDQT^Q=)IM8-:M;&@=AM
MI)1`Z9SOV\@W8%;'23.@=J@L=T)SJ)$:KW+\1-A5^687?73%11><K%'96&84
M+T+5N296>,D(TI@[,=^W*DBZ=E]B(D>MD?K+^L5*[;PN%DE>)T05)0B@H;-W
M0BL!#`;TEB[*GCF2/T(^50I3D$Q!Z,7S``@`^V6*8QC&,9'W0&G+IIZ-MS&Y
M[LNVZE[%91FHN1NP=.Z_'@Q0:!$M?[>?)B"RR1WCHS0L?'BN</@XMF'J>K39
MXNE/M5@\2?P"YJ!K-BFX>K<N]VO[/*Q,-*2<;7&3G6],*V>3KYDV7:0S1P=J
MN1!>05;(*F16!,QO35\L..3W**K\$?PBJU<D=Q:SY!6/4UE\*RCZ<C+#IO1]
M]VX'X]R.]U+6A&.RU2.<(MBHQ%7D5G:JKKSH*'9)*)`+Q-0NO=[H[-\2SQB^
M`>^>(NV>2G#JK7OPY>02$/O1SQ]8M[E5'M2WGM"KR53ME&W'7I*OQ'XR/V)'
M*3*4%I,R$`>+E(5VR)*-7@2]_!P==[#U#&^*3K3=WXSV[>U8\2O<2%YWU=X&
MUP%MY#1?T9&1=8VH_CI]5>,2C)IY$V9Y$DJSA2%22?.DTU'(E3D'O7GYH<=_
M$2\3/9GBX<X-,<5(:Q:\A-C576W';:5_L<YKC=FLZ)P/D65]2L?'76LM`F?W
M9?;K-F$B]\RJ!GDQ./XBOE5F2+();.Y>VZM<O^2N@.8GB)<5N8F[]`;?\(5I
M'\=*[I+6FT5ATWSPCI9RUV_'O8*K$AWU,O,3?8FQR$)9IQ-""=0[N@6&59R]
M;CV:T+$7BG5]4?V//@U[)\3#4>[MW>%K$<2>9\1#0=!JNTKM3*SR[DN8&\P^
MD]@Q&K5FM@:RUHHRM:BZ9)/GA4GCI*),Q61B("PJ1TM>*O!?9G(TG@!Z%YI:
M5WI*<;)7=GBO34!KC:Y;ZPM-5XI)4'5ELXZT;<,PP.QEJU!R]BKDH$#`S,G&
M(35559QL,3\79!DS'-N`FIMK4>+\*NBDU_M)A3M+>/'S>BZE7I:#N2K6DZD8
M:K(%809GG4P+$5)W(.YP(N2?NVT*\EY&5=+OS+NI1<T-_#MT1]%>)1Q<HT9I
M38?(1S<>0/(Z+Y%-MP<:>2G&OFIJW56Z(^R5:_2',S83*4MG&G;6L75>5L12
M0++8%Q5LA7%@@US5YW/Q[!'#Z=Q\IM4\+/7=`LNN-VZ5LVJO%>VE:N01[MPW
MVWNGCB6.K=3D([3O]EQ28B3A]D2^L&%//*155L>LZ=M0\`Y1MD#*UZ,F[)$R
M+WMB?@Q1;LR\/"TP=FTO,:=K<)R>W(WUH(N=LM->[$I+T*W)H[#TG1]XMV^R
MM:ZFF9=W)MH*H2Y?A_I5G-S948^6EIN,9]B[&,X"7K<;+@8ZJ?H.A#V=H`!5
M!$/EZI>O(L'V?E`$X![$.3-:2E4E8WS*%3^-;!V/KMBF,8H?>JA[J$_6)?4(
M'VG#,9_Z/8?VA\P_=C&,8QC&,8QC.8C8*3E1`6K8P(C\W*W:3<`^\%!`14$/
MM*B50P?:`![YL>(IS!AY%GGE?NBB!@\Y>FR1@'L!31'OSF`?D=43>X=E(F.:
M&WAQ`U+NTKJ4=QOXI758IA3N-:0;MGCA;RF],9V.$I&%@1`X@*AG94I+R%!-
MO)M@]\J)W#PSW7J(7DB:$_'>IM0,J-GIZ*[WX=L'9O5EX`0/-1?ID#S.%2(R
M$:C\QDC%]\B<`@8.RB!@[$.RB`@`@/0@(@(]"`^P@/N`_,,\XQC&,8QC&,#[
M`(B(``!V(B/0`'WB(^P!^L?;-Z:FXW[@W.N@:F5-V6$54`BUNG`4AZLV(`E\
MZA9-PD8\F9,#@(H0K:27'L`%,H=F+;5HW@3K+6HLYV]BCLNX("FN09-F"52B
MG)!*<IHVO*F6*_61.`@5].*O?,(%5;L6)PZ">!"$3*4A"E(0I0*4I0`I2E*'
M12E*```%*``!2@``4`````#K/;&,"/0"/W>_L`B/]`>X_L#WRG[Q3^=$GPMJ
M3Y+8M%83/'[=&K-B4@VQV,XG`R^M-A&@))G_`-\R$R;Z"EJS+1<PPDFBH/J^
M^C20MB4$\N4B""711W)XCKC0+387&R0G!#36Y-9*W[7]G0_U8B"6Z)DIERW:
M,5$53_0BDG,0<0BC,1;@\4Z.[]*7:I+@WG6]1L5XD4P9WQOD)II)D?TN:D5=
MYNHXK<HWQF:(1J49)M40,D@M()P"[V968K%;-"69-!9N*2`I"C,#C+XOMXUW
M7]V2,.[74V]O;8#;75`J3,'JJM8H4R-938+!,BB=O&@A(HNB/))HD_L4Q*2<
MN,6C#&>$EH[N;^&=XEL77Z/H[@%HBGH;.Y&O=@67\?I6;GFK:GZT@+?>K%;'
M]DFF$.\D;5-NHZG-9N<5CG(5Q-9PQ%#Z5='.81[5!3>8/M_>4Q?;[/S@+[]?
M/H/8?;/;&,8QC/`E`1`1[]A[#HQ@#]X`(`8/U&`0SU,0##V(G^[ZJARA_04P
M!^_KO/($`!`0$WL`@'9SB'N/?N`F$!'[A'L0#V`0#VSR!0`1$._<>Q[,80_<
M`B(%#]0``9X`H``A[]#WWV8PC[_[81$0_5T(=?9UE9',GPD.(?-[:$9NK:3;
M<5,VNUUD^TI.7O1>\MCZ6G+WIR2=RCY[J_8!J5,-&5MISIQ-S(.&$BS%RY:R
M;J.=/%X[T&B$U]`Z"U+Q?TUKKC_HRG,:!J;5-::52CU.,</W*$5$-5%G!_7?
MR+IY*2LC(/G3R5F)B5>/)28EWSZ5DG;A\[76/N`"@'77?U>^OK&]^_F)O?ZX
M_K-V(#[A[X`@!U[F]A$WN<X^X_?V;W#[BCV4/L`,`0H#W];V$1Z$YQ#_`(HF
M$/;[/;ZOV=9X],O^V^??YY^P_4`^;L"_>4/JCT'8>P9[``%#H._O]Q$P_P!)
MA$?\OM\@]L\XQC&<+(UZ)DQ,9RU*58WS<(?D5_VF.3H%!_\`ZI3A^K,)?4)R
M3S&CWB:Y0#LJ3H!25^?R!5,#)F'KY")$@^_KYYB;N%EF/F%RP<D(41`5"$]9
M+]OJHBH0`'YAV8!_5G%]AWUW[A\P^W&,8QC&?8VCG[T>FC-RX[_C)HG$G[U!
M`$P_>8,REE1I-?RF>+(,2#UV7OXA<`_W)!*D`_M6'H?F'MT.:1U2AV'E.9$7
MJQ>A]5WTH4!#[2H``(E_5V0Q@_QLR8``H`4H```'0``````?(``/8`#[@SSC
M`@`_]O?^G(X[2XH:.VV*[NQ4UK&SSCL36BK&+7I\5!$3"JY79)@SE#B(_P#C
MAC(!]W65Z;$\-*ZQ@N'FL;O$6EJ7SJ)0MJ0-7I@"^8?(@E*LBOH=ZJ!>@%1=
MK#)F'W'R9"BZZ`W3KQ1P%MUG;HYLV,8JDHUBEIJ%$"]?E"34'](QHIB`]@8[
MA,0#\\I![*&G@$!,)`$HG*(@8@"`G((#T('(`^8I@'V$#``@/V9YQC&,9X.8
MJ8=J&*F'WG,!`_I,(!]H9GU.U7LK8*Q4:30K99_,(`+B*A'JD>GV(!YEI59-
M"*0+V(=F6>D`/OR9VO/#CV_8S(NKY,U[7<>8Q15:%4"UV+R#[CTTC%T(5`PA
M[`*LXL8AOST!Z$,L!U=P;T/K8S5^[@5K]8&XI*A+W<Z4FW2<$#L5&5?220@6
MQ?/]9,5F+URGT']M'$/,,P$D4D$DT4$R(HHD*DDDD0J::29"@4B::9``B:9"
ME`I"$`I2E``*```!GZ8QC&1WY*[KX^:<H+@G)"Z0]+H5[;RU15<SGT^@TEOC
M8Y1-[#-I"OM%WK65=L5E31J;1PTEUE$SK0QCNFACH_SQ?%VY;;+TZE;M?:@Y
M*(<V.%9Y0/BZ7L^[7QW88ME)D>L8L2-;@_;R+B0K;*6>U:>DH:!<(O&SME94
MNXR6EH^(Z;+Z06=`FV*J\+&LU78Q<>Y>JNTXY!TN*QT41,5)$IS]$^)51;-P
M=*D]91(##T''Y^[9RX9N&[MHNLU=-5DG+5RW540<-W")RJ(KH+)&(HBLDH0J
MB:J9BG(<I3%,!@`0N6\*WEGOO3]G_$?CM*U_44S+O9.8VEO)]:I.-M:E<E5F
M+9>$KZB,K"+-7SYA&I1D>A&NG+PRZLI+OE!C?CFV?TS_``R=U<1X6HU_5U.Y
M8J<C>16R2)V?8-AG)+9<[8K%--XU9RX8P!+K&B]842F-`7C8\YCM&GJ"M+R_
MH3,^=$;C/GGCL/O#^G/.,8QC&,8QC&,8QC&,8QC&?"YC(YYW\4Q:KB(]^91!
M,3]_[OR^</W&SA5J=`K"(E:J("/_`)!PL4/M^13'.0/GW[%`/8/L[`>.4H48
M81%)V^2^?0"9!0`'[/FB4P@'ZS=C]^?*;7[<1^K)K@'7N!FZ1A[^_L#E#KK[
M.A_;]F"Z_;]_6DUQ#[BMTBCW^T3F_HZ_?G[IT&/*/:KYZH'W%!!/_**2GV_]
MOMSD$J5!)B`F2<K]?8JY4Z_>"7I=_P#;O.8;PD0UZ%"-9D,'R.*)%#A__D4`
MY_\`VLY,````````/8``.@`/N``^6><8QC&,9XZ#]GOW["(>_P"[K-:6S3.I
MKR*I[=KBE6!=;OU'DE7(M9^/8"`B$@#8CXH]#\RN0$/F`@/OD?K!P'XU3AS*
M-:C*UHY@,!AK=IG&20"8!#S$:/74DS()>P,4I&Y4Q$H>8@E[*.K)CPS]0N?.
M:$NVQH@Q@$2E<.:Y,(D$3E$`Z<035<Y2D`Q0`SCS"(@8QS>7RFQ1SX8%6.!/
M@]NVE`P";U!=UB`=@8!`/*!`;NF`D$![$PF,J!@$``I1`1'YT_"^@04(*NXY
M\Z0&`5")4Z'24,3[2D4/+K$(8?L,=%4H#\R&#VS)8[PR=8)&*,KL383\H*=F
M(T2J\8!DO+T!/-]#OC%,!_K>H4WN'U?3_C9L^#\/?CA$G3.]A[591)T(A.V^
M4*DH("`B*B$)]"I"`]?F@4`^L(?87K>]4XZZ,I)B*UK55(CW*8@*;U2":24@
M00^0ED98K]\!NO83`X`P^_OFY2)II$*FF0I$R%`I$R%`I"E+[`4I"@!2@'7L
M!0``^P,]\8QC&,9!'GSMNP:WU!+QC'AY=N6]=M,1(LK-`0[>NR-+BV12=]W*
M*%2;O+EL3R@_26K%$F0;&;D5"4BWA4E4_P"2?XIB,+);<FK-%\1KEQV<R%HD
MP=S<E(OG=>E4557)FU?`C@)L[V3CB)D%M-SUG)<W;!+TK''*N"$4:U2XQFV]
M&QK&5V=66LEJVR[F8`Z.LZUY5'K^/E9Q)),1Z%W&1<J]38M#"5R_(DDU(LW3
M,DM(L43J+E_J/>`YN22@]8U#7%1\-K8.KXF90:,[1NR"+`-VB*+,?38(W9U9
M)..@TXJ)0'SL*YK&VSK>/;F]5I26LHZ?`KV0B[%@CN"MBL[3YS.`;%.--LY4
M?.9;T0,*QXPJ94O./F%4Q@3!/\H)@(`CG6K\<^_>*5Q7V;Q_V[QD\2(=2Z;Y
M5<NN-?#NNZ!_L3]'W8-326SH.:96+:0;,NC>9L=W]>8K;F:_$UZPA6Z?TF$>
MSGFC=H4RFV=@>*EN[@`[D.'5JHNZO%LY+\6M'R_)3F_R"UC5M,\9XO7NE9VR
MV&P5F96UR:7?0\S=H37YHP"42FF*M+PC!K8#RZC][+(1OINS\(UTUJF<T]$U
MWB[R`VJUY>:6T_MG@=(TD:ZM_943.TK35:=+ZHCVRGKIZUV3K"<L+Q&]0EK>
MO!:)PQ56PJ(V&LJRFO+=XT>P.*6[/$36W#5]N<AHS6?,7@EQDU-QSHT'J*`E
M-66;DSH*7N$E5*3>&PL9+;97EU@WJ*K^[&CG2DFXCV=?7:0BBRJ4>]Q_A>^@
M^-VT[YHGD)P9Y0ZUW1JVRR51V'1BV_2EK+7)^.6$#LB62NVES`S)#M3MG1'T
M.Z>1JI7`?!O'B`$<J]P+&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&1JY2UKDS<=<KUKB[>M<:SNLL+EK(7F_P`1.3CF#C5$B$`]2912#IDW
MGUA.KZ4Q--)1K%@F0S>&>.EDW+#^61XW_&J1U5O2V5K9/*2T\F]^JS[OX2IT
M$S^Y5"*F74B![4I*2<C"Q<ZO,PHF&+LLLY0G9J5MC@L&>9=&@I@L;UV%D56Z
MRK==)5!=!11%9!9,R2R*J1Q(HDJF<"G343.4Q%"&*!B'*)3``@(9^6,EQQ'H
M$!8]HU4]TN6R=0MY9XBE0=EU!B+5F%H3?_!$BUIYTB5!C](G%6-:OFRKA).4
M*6-?M3IO1,C_`%B/"8T)S*T?JS6R%CY2Z=Y)\:)ZKL)*N';H6UY:8U%PW<>G
M(4V<-7ZW&0#<[HB9)VB/8,L1'R19)K&,ZH_0>D>W;]??W_2;_KR`G/\`X#U/
MGW7^-M?MM^L=`2XW\MM.\LX5Q7(J*E5+)/Z?&>^CZE*DE54BLX:9">6!Z_9"
M9^V%!+T$U"F4*,0><7@SDY3[_P!D<B=,<PMT\/+AR)T:SXT\KV&L*K0+C#[Y
MTPQ*[9HQ9PNK,S^AW0()X-:3N\`\<K(03-FU;Q**AI%:3CMN+\'!TSM"<U3,
MP?*;D#K$>)NG=*:EX&-Z62N-B\3W>I+/5KA+[/C1$6Z.S-F[2GH"1>WRQ6MJ
MR!T:P+)M&Z3:`JK:&W=L;P.Z'M'9>WMKVGD%>S6K=',OA#S1M8Q]+JS2.2O7
M"^BO*:QKT<T-(+F;P&R%I*0FIHXK&<5Y95%A$)NFJ!C+5Z<X/P2W07-OEGO;
ME?9.6^XZ-.[SO#J\2E2@:!1I.'@G;IDQ9G91[^0DT'KIN4&0*%5<HD5$RA@,
M`]>8>W!C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC.#LT(%E
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M`_PZ)U<VAK;BWL2TU]YL=>LOY6I4#:S"B;1K#$KUM<(=DU5BW$^](R*T454;
MLVSIRR?G8?%2,.NE\:Y8"Q(JY1[GOAB>&=-<5)[5UQW5K&:Y`^'CR&F4'4;-
M.$WDVGJ96Y.E:DI8;-.T:2:R58+`6AA7EY%](PL`R1;-Y\2O'RKD%DN\/QPX
MN:KXJUVP4W3B5KAZ5.SAK"C4)RYV"W0=<E%TS)R:E6)8W3]_"MYE7R/)5FD^
M5:.Y!/Z0!%)VN[6<R,QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC/04R"(F\H`81((B`!V(D,`E[^\0ZZ`1]RAWY1#*3>0/A?4>L\+
M^4=0UQ!MME<AM]2:$_8-AVH8F(EK!-SNV8:TKUV,=O%E&=)I"!W3P@Q,8](Z
M>$(+V4DY68,BX+`#;O@8Z@I6XO"TI%7A(N4A*I-S54V=*%6+&(.9.JU*5N=A
MEHJ,57`Y(N>H+"T:^AXELF<(F,BZFJY*I)(.I->:'&7PCM4Z.Y6<S869U_6+
M3QPY"T&MV"`BGZH'=(R\U:E1G8-Z@D^+*M)ZBEJM>0K=X:`TD58D8%TVE3V-
MI/+#:WQ<X\Q/%O3L-I&NV68M-1J4U<%Z>YL*3?Z:C*S9;1*6=C79)XU\B,LI
;!*2SF/3E?AF1Y%JD@LY9I./5\\B<8QC&,__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g477545.jpg
<DESCRIPTION>G477545.JPG
<TEXT>
begin 644 g477545.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]1$E32S$P-#I;,3):04$Q+C$R6D%!
M-#8U,#$N3U544%5473$Q-C5?,5]#14Q,1$587TM?3$E.12Y%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$M`B(!`1$`_\0`'P`!``$#!0$!````
M``````````@&!PD!`@0%"@,+_\0`81````4$``(#"0H+!`<%!08'`@,$!08`
M`0<("1$2$QD4(5%76):9T=@5%A<8,5EAD9+2(D%3<9.7F-35UM<**6FH(S(Y
M>(&QMR0S.*'P)35"4F(H-#9(5G)SE+*SP=/A_]H`"`$!```_`.9M9KYH:>_?
MV@#=3*TV;\3;[:T;<RI[TPRHR9RD>/\`*;)D2-8"Q)*<2L$(@3?-6MGF!TJR
MHK,81C4PY]<SRG)>G1*R;MX;)ICY^XJW$:@3?MUF%7GK7O"KEPU,8:'BGNF.
M1L3QYSF.XF0]@\08RGN537:9'2!!.,67.E,X>87B1#BIH<D"U^8[IGCEU:LP
MRR&$Y"A9]^(E,WX0F1K:/[2EQ49J_7<`F%C86UNX:$$DKP!S`42>I`)E2$*@
M.02$IZH`DB@)"0U18"<711+C7\2V,PK8J:2K)T5GK1,.&9F?>K7QZD&MF*\8
M1F,ND!SW"X#$G#$C"R92EF6)Q@641J4NR)"Z[00C'61GYX80.S2REMR-P.=)
M:[I;W<535,[%C3(=AH++&>#ZE/6UVP^1M;=:<'93>(;(9ME%4MBC-L!K5,LQ
M,^9X)I7C3'*4Z*CS[BD@V?3AZ;W1V4J"7]&ICJ/U>8FG3=D_%V-\DM#HW/;3
MD&!0V<-;RT(7EK:G=NEL;;)`B<VQMD1"5_;V]>F<2E:)"^)D[PD2G%)W,@I<
M6>`-P*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J);
MIH1HZ^9>-V`>M.M77C.QTD3S$W,SK@3%SEE0<M2%)R4DF%/ET7/E%W]*4D2@
M3N]W/N\@*9/U1X+DE7#W&2-+-1\PY?A>?\JZTX-R-FW'9;>5",JS;&$0DT\C
M!;.M.<F4+1)7=J5.2:[&Y*5#DQ"N<8)D<3SES2)&K,$=>IDVKVMJ.0ERU)@'
M#*64DY.E^:R9(GQG#B7TK,.0(L"#SO*8'4#/9:'(<SAA9<3E,QL=[OO\;+`R
M.J]4W!LFM8^(\,;ATP-#(FV':,:F1Q#+VB6QV5)FK`.,DI<CC4[,;#9?%WSH
MQRXG2+2$QE9A.<96".83_<ALM9N!9`EL56N>-$-+]H'2%/>Q.J^`LUO&.41;
M5!W3)F+(A+W"+LQ2@"LMA:%CNUJ#TT?"J+"I]P+F#9;J+7.$@N8(8A2J3)DZ
M).0D2$$I4J4DI.F3)RBR$Z=.06$HD@@DH("B222@`+**+`$LLL(0`"$(;6M]
M^=N_W_D^7Z/STI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4KYFW,"6.Y00#,L&]P!,&(L`AVM>X0C,"`P181"Y!$98LRY=KW'U8
M^CT;^<_AZ;T[997V\S9B#/F7X8TY:1PDM\?-'\R8CD&ODIQG-DF-8S)36_72
M="8WXS,F+([*G)SCDXFRMUR2"7Q%9$\XPAP:&AR40Q;+3!.^N8&;7W8+(&T,
M4@SIG*'[O98U4Q5A/"$B4.C=/)R%_8FK#6'(%-9E&X*ZR]R<"G;KY-D>10>(
M$M,?;)=D"0QU@BT67V36/POMEO%LYC?3?#;)DS$.(MB,X-F^<]S3G5BQ83DZ
M!Q-ETXV/18+11+%^-Y!+8N6]D2^33R&$7D\B<S%WO'B[^JLW-TIE")XCF3W1
M;8"1;1ZEX-SG,F1JCTUG$+`.<-+`(^\>33F..[M#YF.-A5JEZPJ-K)/'75='
MDZU>O7)F94A3K%RQ24:I-DQ)9&QP^.OTMD[HC8XW%V5UD4@>G`WJ$#0QLB!0
MYNSFM.Y7ZE(WMZ50K4F\K]622,?*_+E6/FW%^X9%S"2?CO:\V4*2!JDR:\\2
MA5*$I5R;'*2$PD]CSDQ`E"8*@\HL11`U*8!PP#4$V']NUUX:/EJ8"\]"_P!T
MIVNO#1\M3`7GH7^Z4[77AH^6I@+ST+_=*=KKPT?+4P%YZ%_NE.UUX:/EJ8"\
M]"_W2G:Z\-'RU,!>>A?[I3M=>&CY:F`O/0O]TIVNO#1\M3`7GH7^Z4[77AH^
M6I@+ST+_`'2G:Z\-'RU,!>>A?[I3M=>&CY:F`O/0O]TIVNO#1\M3`7GH7^Z4
M[77AH^6I@+ST+_=*=KKPT?+4P%YZ%_NE.UUX:/EJ8"\]"_W2G:Z\-'RU,!>>
MA?[I3M=>&CY:F`O/0O\`=*=KKPT?+4P%YZ%_NE.UUX:/EJ8"\]"_W2G:Z\-'
MRU,!>>A?[I3M=>&CY:F`O/0O]TIVNO#1\M3`7GH7^Z4[77AH^6I@+ST+_=*=
MKKPT?+4P%YZ%_NE.UUX:/EJ8"\]"_P!TIVNO#1\M3`7GH7^Z4[77AH^6I@+S
MT+_=*=KKPT?+4P%YZ%_NE.UUX:/EJ8"\]"_W2G:Z\-'RU,!>>A?[I3M=>&CY
M:F`O/0O]TIVNO#1\M3`7GH7^Z4[77AH^6I@+ST+_`'2G:Z\-'RU,!>>A?[I3
MM=>&CY:F`O/0O]TIVNO#1\M3`7GH7^Z4[77AH^6I@+ST+_=*=KKPT?+4P%YZ
M%_NE.UUX:/EJ8"\]"_W2G:Z\-'RU,!>>A?[I3M=>&CY:F`O/0O\`=*=KKPT?
M+4P%YZ%_NE.UUX:/EJ8"\]"_W2G:Z\-'RU,!>>A?[I3M=>&CY:F`O/0O]TIV
MNO#1\M3`7GH7^Z5>K!6]6H6S4M<()@+87&.6)@U1]3*G&.PN0@=71''4:]N:
MU3P>G"05<"$AP=FU&8=TKV">M(!R_#YVEC2E*4I2E*4I2E<=6E(7)5"-478U
M,K(.3*"KW$&QA!Y8BCB[B!<([6&6,0+W`((K6O>X1!%:U[8HM8>%TFP)L*Y9
M>EVP.5<T1"`68$FL&/YR9#PBQ.E18.08#6.LME4>AD?E>59<T8Q2GXWB,CFC
M\[*"X>O<W>7%RG)#JLFE29(T%U=<X_D>)91Q9#\^17).QDUVB7QG.\-@^3&"
M/Y2G"-.VN*Z+,[Y&3$#:F0-A:ML:CCTZQY(;7=X0J796E<#BKQH9>$3@_$D`
MQ7&]2Y].=19[AV<9^E\1S!AZ(X0.E:I!LR]V<\L0Z51F88LD&-I3'E")K@;/
M$SW6'&/\118EQ<6@>#R(RH2ND_\`7O!./M8\)8PP#BQ$N0P'$T.9X7&PNJRS
MB\JT;41<)SN^N024P7*0/B\Q8]O[B!*E`O>7!<K`E3`."07>2L>F2+?WHVHU
MN8N7Q(=]/_B%XZ=`_I^7\*_?^7Y/!;ED)Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8_O4Z-O"+[8
M_O4Z-O"+[8_O5K8-K?)S_P"(A7_YWO6M*4I2E*4I2E*4I2E*5CUR1_M1]1?]
MR'?3_K3H%60JE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2M+WM;OWO:UO#>
M]K?\ZTZ8?EM>][>$-KBM]8;7M5M9WFC$&+B#%62\IXXQXE*+$<8HG,YBT2)+
M*#T>9@QO[JWV""W2#:][_C$&WRBM:^)N*\9#"^0>)?$-.\>2R#S7#LMQBJ;F
MO+L;=DKPSO6PRA3[XVB(,4C;UJEE<F$4,;W%E$H3=9=7.UB5I3*;C(&2=FPM
M?G;G;Y+]^U*4I2E*4I2E*5L,,`26,TP82RRPB&8,8K`````W$,8QBO8(0`#:
MXA"O>UK!M>]8OM:.*-!-DL@3!D1X,SGC[%2:#MF2\69XE;"S.D"RG!5^.F+*
M:9Y5H84\2>1XH5R.!2%#.,>,>3VYA=IS#PJCDZ=JF#<[0=O[6,<5+7?(6"5N
M>,7QG,62&IRV;>-1L5P:/P=,U9%S;F=K<#$A+9!&.;OD20,,?<4*)\DUI3E=
MWQRSLL/C;[)Y,>RMB9.-7P"^*3CMRCK&AC&O>S<MV'=<E9DQ2OU`98QC`G/,
M;DVOS)'93EY:]N;[EIGP6**1>+S?'+XW2QGS*[,TV!D_';/"#W^128EH3SFP
M5FJ`;&X=QMG3%KFI=L?Y5AS)-XJL7(%#4Y>Y3XD`I+2N[2LL%8T/3<=<YM>F
ME6&RIK=4:Q`HMUJ<=[W8K'IDB_\`>CZB_+_X(=]/Q7\=.@7T?1_ZYVK(5SM]
M/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI
M^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/
MU7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^
MJ_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U
M7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J_JISM]/U7]5.=OI^J
M_JISM]/XK?)?\?>\%4O"YO$,BQAHFD$DC-+XD_IQJV61QY>G=F9T3%J3TAAZ
M%P1C-3J2P*DRA.,18Q6"<2:6+D(`K6J0PXHH`C#1V++!;F,PS_1EAMSY<Q&#
MZ(`V^D0K6J-^2-R]2L/E*S<H[+X(@0D7>4I91E>#M3@`7X7X%FPY[]TC#+]`
M?(HM(,R_0'R#^"+E$5QXRVAQZB[?C:>Y&S\\WN(!+1KS@/-N8#5)ENAR+3ND
M7@ID=,$+IAY7]V;%AZ0>F8#I@Z7`'Q%MA)H8$G!O"TW;EG3%T"W+,Q&*-9V,
M7,RX0FB'D2;K)``FX>B/F*.V,M:_(0`]$8@[??\`<9?(0C_>_KMH_KB@.!?J
M#\LYOR=G*0)`C#?ETV?%L,B+"H4EW$&UP^[_`'-80!BL(T/1"+:'5GB>3X%Q
M9-XF#!C=*JZ5ED>UFU+@3`(DL5P7N6@FF7'_`"*^%#MR$$*F[:`RP>5[`L.X
MA5M'PE(!+RPVSSMQOYL($P=S%S5.-I)=#XHKO?O#*]Z>'T>/&HI*:'D$:<-Q
M`N$-@6Y`M8%K@Q?A(\.V!V5N41U'PDNEETBGW.DV4XHNS6O(=!)S`(W!>=DU
MYD3@Y`)57+4JR+."4Y;8)P.ZB#3Q*`X7T/\`9G)<US9'DEHWU.9)VVRPB>-;
M^RZWHVB[1,$CX&2H7=H0H,N)T;86WOH"E;>W(BR4:,@DE"06!*6$%O5>R$.R
M5F:4[\X)'5\(;4!+RYH$`VI"XNI:0D#DO1-9BQP,;4BQ:$]2F0&+UPT9)H$P
ME:FY77#[2E*4I2E*4I2E?!4!08G/`E-*(4C),"G//($J)(47`*Q!QJ8)Z82@
MLHWH&#)"H($:`(@!.*$*Q@?-?P[]0=J\9[\Y-GZK`AVH$)2&)%.R#=C?*KT?
MJ-LS+GW`C.PW6:Z8`N]/3'%FT>:A.>9TL[<&N&S;'K">HPZ\`D#G(I(!FEW*
M<);S8=PILTUZ[1UO5Y$SMQ"<CY4LZ1J?8X8)S&=;LAW9U;W*L=O64H])<<,^
M7CRH\5'F(B:QF3-D:"^JI(8RO2MG1MJFU./]>MEM>CM:]AL*:1N!LLQ.3N'C
MC+6O\FVS@&0LRY?/VC<,'9$4[./NR$_.2L,NGKIDS![2VY"2RV1)I"7"WD9\
M93KDL1CT$59,-`\!S+6/3W`V$LC.C*[Y#AD*Z<^61L1IL<#-Y0]O,TEJ&/*E
M"5`H7,33()(X-+0XJ&YM/<F]"G<#FY`8I$C)E3(V)%*(^^QIR.=4[?(69T8U
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M'WO_`.5=0\\.[5J.(3'.09:W)8FXFPA&KWKB7[X-*,H(0"&(1BIQV53$`"$`
M!C%<1EK6"$0KWL$-[VAADH?!TQ(,Q/.^(-EEM7E"$`QF;.+5NW+)`$P'+I%6
MCT.V8D#T,ZUQ!#8D"`1@A"""P;B%8-6-^%+AQR8\23!S9QH]F%`@VNF.P?F[
MBM.C,KN*X@V$1)IMG.#1OJ+C#</=8W4*3E:X['7+`,0=B?$^;IU_I,2<.7B7
M(&\^U@IWC97C2[+81))$,%[@.6QJ.[,9+EP20BMS-)"C*4V!SMT`&W`7?']Q
M'8/N;J+AEIF4WE@,0N>3']3"H3`\;\0WBH;$9(4VLW&K9"\G.60\Y,V,$K;&
MFH9(W,;M%WY`XJ'-O:+-*L*TRU1XX+F*'?:?)4EU]F6[.].NQ,/BA4NQ5C;"
M.9IG`\?R%C2NJ@<_1-S6N5+8Y''QK7NS8_&IVF.E^[B5V=7%0,U6@47,]0QO
M!BU$E))P<UR?:C8Y6>6,)J_.&V><Y(*YIG*XE!;8PRV+L*<X(N8BQ$-00EW$
M*]@WN(5[T6T<`'A91U[!)(]@F=1U_+`(!3LP[-;.LRLH`Q`&*Q5V_+J<LJ]Q
M`!>XRRPF<PV_#Y7%84C&[AC:WLZ4"!FG>ZK,A*#8!2%FXC&^K0A+!;Y`%HFW
M8M*E+!;E;\$!-K=[Y*^@N&;KI<5Q"R%NV(=_E$+B0;]W%?\`.*^Q][W_`.-Z
MU[,_77QA[M^D@W[]H^M>S.UW\86[GI(-^_:/IV9VN_C"W<])!OW[1]=6^\.3
M6^/,CP_+)]O(:D96MQ=E1:;B.[\C4&)VU$>N/`0`S9(HL1PRB!A*",PL%S+A
ML(8`WN*T)\(;::.X!DBZ<0=+O<]N;G&SV10CRYLGG'.\>+;5:IN=C#D41S1L
MA.XLW/83FU.61($#2G>TR0Q:WIW$M`XKR%&=>*2-%,(O&Y8VE*2&Z4,#/(D!
M*T!9:PI$]MR9S2E*RR33R0*2R%18#P%'G%A-L,(#3`VL,7?TI2E*4I2E*4I2
ME*4K'KDC_:CZB_[D.^G_`%IT"K(52E*4I2H+YXX@&'M>LB*\:3*.9$<GQ&SL
MST8KC;2P+&L25[+4&I2P'.$F;%-SRPIA]>$20(`W$#JS#+7O>URM:MKL>[2(
MY>N@+/+VDJ%K6="Z!EB!J0F'FO25:K2B0V:WIXL:666A-"?<X2<01B+L`)EK
MB$&3U*4I2E*4I2E*5I<0;<K7O:U[_):][6Y_FKI7^2QZ*-BE[D[XSQQF1AZ:
MMV?W-"RMB8'>MTU"]S/2)"0=_OB,."'Z>=[5@UWMXX&`-:\H:V0[$N1,=YF8
MWO*8C]E73';ZUY"*@&&TC:K95Y:99&5JU&"<CD#RW29O:"%1[@<SPIY;CTI0
MGU"8*0(.*VV31.(S`.C_`!`<\EG`"8U/S/KJLQ?"'4@TH)Z5:GEF:7Z"$A0*
MTYA2E.HLWFB,3G%&@*'U@+""V0XK>0.YP8\X=>*,/)5/.Y;WLGMLP+%!!8O^
M[,5P_"<0ERX!@;7L88F]W+"O>PB>M!>UC;ZWQ)QBLAF<Y=MUI_KRC-%S&DP5
MK;+LLO"4H0.5P$2+-,X;FTQ0$0;=%09%NKN(8C+D6#8!%M;<-++$U$H-SQQ-
M-\\A=UVY*F?',U@6N46-",-NN)"UXFA*)U+3#%T@A+"_]8`F]BKG#OTS#.W9
M.#)P\$AY#C,\(.&:GPD831OV?\IY8S6O5&AMWQJ4T_FCNRCZ=^8AE@:0$B%T
M?]'8(`!#-''.K.M.'P$@Q3K]A7&]B`@"6.#XMA$8/M8NUK`N)2T,:54,=N72
MZ8SA#N*]QW%<=Q"O?`\Y(B3FJ5)Y29*G*$8<>><$E,044'F,1IAHP$$E@#;\
M*XQ``&UN_>UK=Z+,LW2U^C;L*,L$G696F=A=`$,PNQ..3Y`(S\*PBCO>N2J:
M&\=A!N`7NF[(K`%?F/HAL*]L5'$<G67LJ,F)'"1X%EV*XTD>Y@.,>[[PWO<Q
M?1J&QELJ,>XK%B7$$1(3$%D"3EN+LJ5JCCC"KD$=0(0X\:'PK)C[L,V-L0ED
MAQ.]&PV9&%S(R#)Y'9*F*3MUU*`#9*DP&81CB$0"PJ#NDH3V*$),'IBN(.<;
MX#-IO+:D'ZA\2_\`^FM@\`;)K+VLY[M3[H%VO<FS%B+$#(9TQ<K"NI,,9W*R
M@NP;6ZLNQ95RQW$+IBL+HUM^+EGSRV<P^86&_P"4*6U@RTJN(YUW1V&.57OT
M>DU(L5L:2Q0;6L6&R!/!5!5C;7Z5S#[#L(WF'I!M</.^OQ6<D>6;LQ__`#>,
M?Z?5O#J,]B#82C;?;@T\5ND>85DB.I2C#A=\P9:8B$6)3EB'>]P$$VL42&]B
MR[6`&UJU%J$XF6N`[:_;LTD=NB:5\*C01UI8N\,OKDT-)4$],-[AZT@THXOG
MTBC`#L$5J>ENFI%HK)?<W/6V;NX7CSX%"U*LZOBQ,Y*Q-2L*9N4I3$18%2=<
M=<"0].88$M04<,DP5@C%>L!_Q*MLA(^C?`.00F"1]&Y=DC-:P3+I^5RPAL\\
M@V"*_0"&U^5K6M:U[\J]2N(6MP8\48Q97=&<WNK1CV%-;F@4V"%0B<&^,M:1
M:D/L`0P6.3*2323;`&,-C`"L$8K<KWN)2E*4I2E*4I2E6NB&;L/9`FV0<;0?
M*$`E^0<3JVU!DZ$QJ7L+W*L?K7A.)6UI9DPMR]0YQQ0X)P#,2E.R9*,WJS`6
MM8TLPL-5*)M#DC/(I`JE<;3L40,=298\GOK42U1@UB)LH>BY"XFJP(V,QG($
M$]T`Z'I!-Q(K&K+$%WL*ND<<MXL9X0AR8[9(@39CET*:SVV?.$RC:*%.!#V<
M4G93D4L5.A4?5DNZ@\DAK,3N)@'`XTLI&(X8PAO7Y9@#0`,+$$99@0C`,`K"
M",`K6$$01!O>P@B#>P@BM>]A6O:]KWM>UZVGGD)2#E*DXI.F3E&'J%!Y@"2"
M""0",-..-,$$LHHHL(AF&#$$``!$(0K!M>]L:.1)Q"SN)GJB^$RZ,&LS?I7O
M*A7NQ<@:#&Q$M=<QZ**&M&K<`+!)$RIR(9W8]`G/.`:L);'`Q.$P"%4(G)>4
M<4>46>286:2<6`THTL83"C"S`V&6868"X@#`,`@B`,(KA$&]A!O>U[7K?:]K
M]^U[7_-W_P#ESKK7-[9V4BZIX=6UI3!MS$H<UR5O)M;Y>=S5AI)=K?G%;_G5
MEI-M/KE$+#]WLV8V3&`O>PTR65M;LL#>UPVZ/<3,>X*[CYBM:P+$W%>]^5K7
MO:_*R#[Q&-8FH)EVI^F$PZH)PABC&/I2-+8*<704"]TWY"P-(0)Q"+LH-&N"
M41UI?7#+L+O6(E_%IPW'^NZAC8&<!(U!0E.6-@]<L2$`-3);+#@')'C)+N]E
M#+3=(^Y%VFZFX+E!`2(PVQ88WO\`QJL:C.,+;]@-!HAT3`@[GOFC)&>'@L`B
MQ'V-LW87QVH1*`!*N6$PPMTL06H$6D..(4J`%%T@=Q0RIAWF':'*LD..N&PF
MO6/AD[&S`0.977*R29!DF-W+LH;4]@J%H1(`GE)SP'%%&=:78C#9Q.-DI@V(
M$$R3%[+LTMRJF0-$3D6SN)1X;R.>U1,1*F2/S7%2VUO;?>RE`O:6E@4(@'#$
M)[4V7W*4E=4')EPI-YH)C?$<NR3D"&9+3PC(2-G=54UBV/99)XVR3"$EK6&1
MPT:AK:3$ZUP&Z.00-Z=I6+UI8CD"54@([M(/OE*8.,GPSGY26A-VUQ[$%X^=
MKH,GH)EB=64*W6<PFEY'C$9`#H]7?F*YO0_#)O85[*$]S9<PG:[5_)0218\V
M+P7.NON$)08CEN`2`P8QB,``%B6R0*#NF(9)H+`N785QE&AY<RQVM?@E40I*
M`<G-`>28$(BS2!!/*&$0;#"(!I-QEB"(-["M<(KVO:]KVORO;G]>F&WRBM;Z
M!7Z-_JORO6ZU[7^2]K_F[]*4I2M+WM:W.][6MX;WY6^N]?(U0206,XXT!1)8
M!&&'&BL6266&W,0S#AW"6`(;<[W$(=K6M:_.]0SS!Q%]%L#&')<J[6X.C#L0
M8(DR-%3YED4PZX(K`N25#8F>_2@X_I7L&Q!32(V]^=NAWK\HUBXLT2GECB-7
MM1=W=HC!BZ#9(HA@)YQCC5=<5[=6<+(N<5>/6HE$8&_6`5%(5=A@Y"++':_.
ME\K\8/+)EK0;575+59F4%<K.>Q&<I)FR8IRQWO;NJT*P<Q-4>`K`7>Q@$*J:
MC+ZP/5G*`VO?H[0:0[W9/L0+87BA92:&TP?6*X=J)B#&^O;>6$?_`'R0J</9
M&1\@GDW#^`6HLXHE`+<QAZ)E["#WC%P;=$@N%G[*<`F^S$JN?92;*-HLOY,S
MFM/4=*XQ'&,\PDAT0`,P=^F,)$:+*Z5K6"6$`;!K'AL/_9PL>YWS)/,HMVQP
ML3L$I<RO>UBS'6O./V*#P&*-K>E9V")LC>U29H2'$-[8C*LO<S&Y.K>W(]<Z
M+2PG*Q%EYU]5L*R/7?7W%V#I7E!TS.X8OC1$/1Y$?V,A@>WR/M!YY$8(=F].
M[/2<:YCC_N:P#<`++C<B6LE:H++5''=*0EK6M\EK6_-WJ5U;P^,T>;U+N_.S
M:R-2,'6JW-W7)6UN3%_C,4+EII"4D%K=^XC#0VY5$UXW@PT:XJ&#%:>:[!2@
MBQH3&?",57S)$G-#:_0LX2V_<$-;R1"_!&<:^F6*MS$(%^7*_4^[&\64^06F
M,8OUDCBD0+V<98X&9?R:2G%:W1-)CS+[EP9M6""+IW)<'5TLG%:P#`#N&_2^
MZ?26(RD\MRS]D?*6PSG8=S1M\WDZEC@!1O2Z=@H<;PT3)&RTW2Y7NG<+.EA6
M#:Q@A6YVO*F(0.$X_;"V6#1*-P]H+L78+;&61N8T?^C!8`!#(;4R8!H[!MWS
M#;&&"OSN(5[WYU5?*WYOS<[?+^;E3E^?Z[^NM:4I2E*5MZ`/_E#]FWJK=2E*
M4I2E*4I2E<1>98I$K-$2I46*3'F7(1=+NP_JRACZE)T#"1]U&\N@FN`TL5CQ
M%W"8`7(5O'[PJ3\5L.\%L/X^5X>V&AC]C!;%H1E>`)9+A'=;7J#G:R0I\E16
MV,0@4C?&I0[.<A0,F)LQ2^2NL`F1>WZ)-*R84W3E?(+L%Z00+&^'M>93"9?=
MT*U#@G'[DGQCE.5)D]3Z."PPJ7G+FEXV#GN8WR3/,PQV'8AXQ&[SR3Y.D;V2
M,($[A*'4;6D4FE4'BIXTV;,XP:3YSOAMMX6ZW:7BNWUY=,H7QL'251-%\;U'
M#&'2-&R"YF(3(V_.#=OS;$*Q#R:W,U=D<F,C/]UK%JLYG"5*E9/#AU!*EZ.2
M-ZL.'&;WO-\N`85(D..A.3N/%")S).O<\DU+BT4-(*(47[I(2@3E*;!/`9:T
MP,Z7!;">8+F"+`7\%N0NF(X00E!![T'BXA&B'^`$NP>=QW%^#8-KW%WK7K\W
M9+M.F,V<,E0U15\6*TA>-!I@!)[E]Z@!C`FD_<]K=3=7[X!FR(!P@7,"V*#D
MP16!<0;^W:^-^)_(L?146/=@=<(BA4QECNUH00B2G61M%VA-=IL8[W8G58J6
M=P]Q7673W3%6.L<%.:,JP##879(T8XXT\">0EWTUJ9DIU@VZ@U@V.5%VM?EU
M@1IFN4Q]`9;D$-@7[B#;OC$,`KB[U@CN#)Q'G\VY^0MF<'38PPPT1]DDKSE#
M+'`-(N78KNEKA+DZEW*4#,5`.`Z=:/IV3F7$`%QC[I!P0,X`O8<DA6J$_-_T
M%Q"FVT?$=5IS1%%W";UC='99&&^Y:LSHJ%">Q%B0G@+[E"F)+L3>N6K@WY(:
M#P*`ZB\)Q\-`86;84X<=X<B7,-+-N>(Y1:=2R0A4GJC;W$XGJ`FF.G>"XB5!
MM8-K^0_0/9>`A*M$-.^"&PC)#T"U"+!>7[*@ALK[N#_VP^-G*Q7+5V">5<1X
MA%&!#<JX+`#:TC6"!<4"*@ZN+P?A71HNUS[V`P178MF!S5""-3?HMS>FMS4#
M``9_>_TP@!$9TKAM>U4=7Q>OEY\.3O=[O&;6VM]5A6M_Y5`;9_AA;3[ES]NR
M?L?C+0S($S9XRBAS0M3YCW^B+8U1Q"M7.12!NCT3E#2R)!GN#DK6.*TI'9:Y
MJ1EF+CSNYDP2;C:VZ,;NZDP":8KP7C_AYL..<A.XWZ6PR6SO=W)\?<74YI(8
MU:HEOR"\/Y+<%R:TJ-,[)D(24KH)"A4+"35*4HVW;MN`^(7@?'&25]H/IUF>
M/A`)5"=?$B',4XBD4&>66K=71C/R44MF9R(#DD+4W@S"Y*23B#K79D`G)$0!
M5'%HTWF&W,>,EK5JIP0YBG+5F-SL,O"V?HC+V!W3]0!2SR1"WLK!)H^[IKI`
M$&)'"Q`S2BAW3#/1FB&;U!/!KSRSWN=!<:Z;8B76%813AA?:'B=8Q-3#L(%[
M"3HV')MV<N]K`O:P?<L0.F:>?T>Z#+&@Y(N&YQIH[T18EXBK#CVQ/5W2(I9E
M78O/#.1U5R;EEB0Y2C*U6>1;JQV$28Z<A@,`2,5R">J-DMC?7SCV1420N6[]
M:;3E*1<H)@)'K/(UAIP"[EAO8Q1'C(.N,$(HKHC&)P"88,T\=S0F"+,+O8X/
MO&PAR`^P(!PYLU'%D"`E/8YQG[#KD<<`)5@'J6Q_9)HU7ZSHC$802])0=8;?
MH*"2DX`J(C3[;G^T%0P^YJ;AG:SR5H+/L$]9$<[NTL6!26N:,U0C:44F0.2X
MXLDL-RT@DJ,2DX8"+&%"%S#;!3Q5>)A$4YBO-6J[#@Q&D+-.=7F3ZD;S3:+M
M"=*5URY:LDV+C9>@NW(22EZI0O`5U($#<<N%8))Z2Q\9\+\>O=W-,PR%"\;X
MEPUE25HGA4X8]B..L,[/3EYF$/1%DM:IZ:TL:6(U$5C*90D1R!4Z9,,;G9,.
M;)F<\HDMDM8>1S#.RW'IRB&YL@T(U(Q(V+;'!;'W)V;IRR#3`%_]T6.D.8S9
M=+`CL"X35#2-$C-"+I)O=$L8>NKLLS:]\>C)Z6P(IO)IKA4M<25[HLN-\%SW
MHH1"'>ZA*WR^67EDE4""5>Y1+H3=F'<?1.NW`Z-P&1C'PB-UY@$L_8B8X#VT
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MQ46@PO%M+,^+`J2R%JG'<-W`1Q%`"YH0&&'Y#E:1FAY@K%WN,H"->K+,OT;#
M/)!>XPS`E3;Q1<A8ZO[W'O5O!,X,0%%`2FDSF;B,<#`7`K/6.11#LF:$A0N0
MTZ)K`[+1VO<L;XG&&QUX@(]*.(>O6)7S*!.AN=Y6G-+/$_9AEVY,K;^M!?I6
M"@@YS@&%-24!G,1*4EF/ZJPNA<T8;=^4K2R<6)@0)VIA9^&8QM:0NQ29L9F[
M9YJ;DY8;6#8!*)`2G2EAL&U@VL$JUK6M:UN]:U=G_>^?X</^:JG][Y_AP_YJ
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M+KF1-&EL=8ED=1A0@2,2IG;E+,F`V#*-;0)VHY,-O(`WF$$F(0E)@!1C)*$F
ML4(L%PU!:W+O?^O_`%]-=<[M#4_M3FQ/C:A>&5Z;UK2[M+HE(7-KHUN28U$X
M-S@B4@,3K$*Y(><E5I3RQDJ$YIA)H!%C$&^%G+.BNF+EQ`M<L2G:L8#28XG6
MDN\ZF5Q!DQ;$(XU/#DTY.TICK&^F68&IM4)9-&V6:2M!%I2A.32*+%R%V,CS
MFVGK##;V&UOS/DO@_;!0_A[;ASB1SS2/,TA-9N'1N9/5QBD6/7-68<:V:/;$
M2U=<1:>3LR8L1>$YZ_.0$\N9@)V!.,DLJS%!_1?:]A6M>U^=K_\`#Y.]>U[7
M[]KVOSM>U[6O:]KVO:U[5K2E*4I2E1*R[K(-\E)F8\'R>^'L\$D6+42-$FNH
MB.1$I-PF%1_*T8+#W/(FXZX+$EO1189`U6$%0G4*KIR$X=^(-G`R.3AP_FJ,
M#PYGE*GN8&*.2GKXO/DI-QEFR+%,G'?N64-)UR[G#:[F!?FNPAIU*=5W*H5!
MEE:]K]^U^=O#:E*TN$-_E#:_Y[6O_P`ZC_M+@]RV0P#DW!37DJ38BME&.&Q!
MUG4,1H%DE;(VYJ"`29`TE.8PH239$Q!7QU4K,"8:E;W18:DL!78DTO#GJ7P"
MH9I[L)C;8;&^V&85#_CYU.-4,"Z&X^3,DLC+HB.:I)#GRZ`DI39F?6I0808)
M.*QZ)60WN23DK;T][>@P(;!M:UK<K6M:WXOQ>'E6M*4I2H^Y:V;Q/AY:ECSV
M[K9'/W3HA8<701M42_([Z</HW*+1Q=JZQ2C)-Z=N3@]&-;8`/,8EG*UZ\QF9
M8SDJ4Y?RG)E&+,BL:B0Y"F#V<RJHF^KU308Z/RY:)L4K6QN4MJM0BN=W.>H;
MU!Z,PTL8DQQI/0,%F4X?FK&(7;"$0R)DC$R!YR,)[EQ?7Y":G1P,:DS=)7)$
MV6;(Q)[C:F6UTI1:BZA&S)SEIQ@EIIYQAEC*RM)TJ9(04E2IR4R8@L!1"<@H
MLD@DLNW1`6424$)10`VM:P0%@"&UK6M:UK6M7WI2E*4I2E*4I2E*4I2E*4I2
ME*4I2E:=(-[7O85N5OEOSMRM^/OW_->U_P`U[7^2].D&UNE<5K!\/.W+Z_DK
M6E8]<D?[4?47_<AWT_ZTZ!5(3:G5C!^Z&"<@:Y;$0AOGV+,CM`FQ[:%?^@6H
M51([*6>21QU+#=7'Y9&7(!#Q&9"WB+7-#JF)4$B$7<X@[$CHOL[FO23/#'PI
M>(C-W&9/ZY*I[/S=:5W[B;-Q<:-?4A*Q-.7$WK$3;M'BU`>C9G9K7NAKID9M
M)1N9%G!U5L[S.<^EKVO:U[7M>U[<[7MW[7M?Y+VO^.UZ4I2E*4I5J<OX5QWG
M*,6BV0F,+DG3*+.#([(SS6R219Y*Z(DS[%G])<#BQNZ4P!9A:I(;8!O0"2L)
M5)KB(%%5'E7+.IJM/'-BU3GDW"`U!*.-[)($`SWZ)$FFV(2->=&1"`PPL!=Q
M%D%Y!:2#42N_0,=R`*33A)IX-+NUOS:A>61Q0N[0YI25S:YMJHA<WKT2D%C4
MZM&L2F&IU*8\L5AE'DF#+,#?F$5Z["E*4I2E*L%E_9C$6%#4C5+)"8X3-UN`
MJ/XWB2(^59$D2DZX;)T[5$VFQSA_V@0K!*6.%D#=SO>XUH;6O5DC&W;+8D%P
MNZL6I>*EG+I-C*J12/8.0MXK@%<"Q[+ZV+XRLJ*MR$6V!>I"C%<9)J@L7.K^
MX>UWQ)@M(K+Q]%$Z)W=;6%()>ZJ%#[-Y.HN*PS5,AECJ8H>'$9QH>O&G$H+0
M`-O<1"0JW*UKU]&W_P!7_`0K6^JU^5OS6K6UN7>[_P#QO>__`)WO>]:TI2E*
M4I2E*4I2E*4I2E*4I2E*4I2K!;4..9&K6_.3AKPMB;?G9-BV:#Q`LG"IL11<
MG(XF-67#[NJI\&!A)+&]C2%I1R`5F#N\:2S[831=:&_F,Q=NIG^.8*SA`6+8
M3>=PS7(=QHA!"]?,Y8JQRHWG8\<2+;S-6/,E..H^3W-C7ZUY5DCM!(9[WW)@
M3'R##VODQQAE18TRZ$L#S"F5CE9KMG3;?9]RPEJ6^;,9LP2N>9YQ%':8Y`=8
MU@QEWGCD(U/G.O\`%,)X?RLC4XUF&"&[)#BV[&,&3)^^0F#.R*7XT:L>'MTA
M.]^,N7*\N'#KSI-]DM*]>\R9*6,SID&5P:Z::OL>3)T+')I1$W]\A#W+&E`D
M"!&WM\L<(T?)4S<B+`B0%NMD:,`$I!(`R[D;ZBB\??9*Y$NJAOCS,Z/B].Q,
MCQ)7L]&T(3W!42SQR/(G)^?W0TA.8!O961N7N[JL$2@;42I:H((,P4SSB$X*
M7<1O5J9DP;<$#0SZ<[JL:M(JT#W>1R4U;),M:2N+><VP]5@`F5/#2G3Q=Q+?
M'UI9UK)&EJAD;I$X-:^1,2=?.;M,M>/%]N[Z.#?SV<*AIO;D_1'B`8!?\%YA
MQKO<VF75I97C+)T5X<V_;9DK".5V"PU$*RYBZ2%ZXEK8]-(DY7+4IE"5022Z
MH!+6%U">U.2HD4;^'QQI'"#A!I7Q'&#8=/MG!SW=JPOD=JTRVRL\;YX5B8'4
M"386(X=287-R1%Y*E:F)2/+3`Z1I.B1.Z=:]MJCJA/38PY6^TSUXO\F/MW?1
MP;^>SA3M,M>/%]N[Z.#?SV<*=IEKQXOMW?1P;^>SA3M,M>/%]N[Z.#?SV<*=
MIEKQXOMW?1P;^>SA3M,M>/%]N[Z.#?SV<*=IEKQXOMW?1P;^>SA3M,M>/%]N
M[Z.#?SV<*=IEKQXOMW?1P;^>SA3M,M>/%]N[Z.#?SV<*XJWB2ZV.212@<,:;
MJ+D*U.<D6(UG#9WW4I%:506(I0F4IC];C"5"<\H0BSB#@#*-`*X#`"#>]JA.
M3MC!\`RDM]U0@>YKSC^0/26\KUHF&@N^$?BQ"ES5@)62+%,SD.O135CI66(V
MRAQ9'E2&)*">L.N)(6G)*3S5+XH>M%W-='KQW:)PE+&E0&RR.PO3+:S*I\/6
MK^O!9FD;OB?$,WC:)W3*$JE*J1!>3#"CB>0K6L85T^;VF6O'B^W=]'!OY[.%
M.TRUX\7V[OHX-_/9PIVF6O'B^W=]'!OY[.%.TRUX\7V[OHX-_/9PIVF6O'B^
MW=]'!OY[.%+\3/7BW?OC_=VUO#?AP;^>SC7#3\4?5E3(+1`2+9%FF)[6-T:8
MI.-/MI,7/,@!UP4R9&PVRGB>%(')Q<%0[)T",M<$9XNF;>X$Y9IP(HS/B"SC
M)<F?HFYQ7;C5Z`L[B>U+%T-T(W)S%ER6%D#"!0-CF,3P&_8OB*`T-[@+=69P
ME*\LX([H5IP`V-O<;$.T>C>$;+%<)PQNX.3NPAFR&?R3AU\0.2Y!DRHV]Q*%
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M(\L-5IBG1B?$@T:T@M:WJ$CDW*P`'90@=&Q8C=&M>2F<6U8E7)4Z@O&G`>#E
MKM&H1.&.99#V!R=DB3Y8595BNPDCS!+4N=,2.#=E.?98@R+%<V0KNC$#(_)<
ME3!RERY`VV)S`^221.N3VR0)'0EE;KBJ>%=KE?'\8BS-+=B8GD"+Y%R'E8O9
M&)9^GC%LR^3K+[4ACV6'>3Y@3*1.KXFR!&6>.1QW8E*`,>:6J(06T1:HVM@<
M/6LDZ,38J@.#<90/#V+(XDB6.L9Q1DA4,CB(U4H*:8]'D)3>VIAK5YZIR<E?
M4DV.7NKHL6NKLO-4N3HM5KU2E2;<.L>F2+?WH^HOR_\`@AWT_'?QTZ!?3]/_
M`*Y6K(5RM]/UW]=.5OI^N_KK'MQ%N'[#-]<3,K21+'G"^Q&(7\K(^K>ST'*"
M5DK`65VVY)R!^8EY1B9:OB;\)*F:L@PNZY.@EC#:P>FE>FYD=&^R?#1XA$XS
MVZY`T[W-BK5A?B/ZRHTY>;,9HC#"HKEB#C-3HHSLW@I68$*:1XER&!0B5+$S
M:>J4P*0+[1]Y+2$*F<1^77E;Z?KOZZ<K?3]=_73E;Z?KOZZ<K?3]=_73E;Z?
MKOZZ<K?3]=_73E;Z?KOZZ<K?3]=_73E;Z?KOZZ<K?3]=_73E;Z?KOZZB[FC6
M=NGKZ1E'&\C6XASRS)P%LV28X2$13VG(M:Y<=R+'^D!OF\756`60>F<BQN",
MH)8D"L("`I3*?Q=LNZ$RY'A78Z.I<4YH/#<#`K*5FGXSRV25:P1.N-)*JL6`
M:LR_(:J'.HRG]O&8$DL"P5A@)F%:UK_)>_UW]?UTY6^GZ[^NG*UOEO?[5_75
ME\O;`XGP<@(4Y!E:9`YN/,#!$VX)SS-90JOT@DHHU$VVRAZ=E!YH;$EC)2A1
M%F"#W2K(!S':/)+KMIL4(06AO/U)Q.J#?D\OB=OD6P$D1#$(-KM[$8,^-XT"
MI)YW[H=?=9_1#N`TA/SYW#??$NMV*<-G*7>-LBIWFKGTAOV29HY*Y?D60'F6
MO8XYSEKT)0X@`?SYC0MMVYL#W@EH@AM:U7WY6^GZ[^NG*WT_7?UTY6^GZ[^N
MG*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG*WT_7?UT
MY6^GZ[^NG*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG
M*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG*WT_7?UTY6^GZ[^NG+EX?KO?\`
MYWK6E*4I2E*4I2E*4I2E*QZY(_VH^HO^Y#OI_P!:=`JR%4I6+7B4</APVN:\
M?YZUZFA>!]_-75BR8ZO9]0IP%EFJPE'GNV$<N!("%3*L#Y0L,]FET>5#4$M`
MW$]]2(UR8U^8I#W'#7XB37O!"IS"\CPHW`VZ.MSZGQUM]K"\J1&/6*\@V"H"
MC?(\H,&:&2XHR"G1FR+'$P;E;HW+FH_W,,=5RQ`):NR94I2E*4I2E6XREB7'
MV9XFLA62(T@DC"K$$XLI2$1:QM7E6O9,[,KD1<M>SNZ,5^FD<F\\A22*W1Z8
MRA&%#@S+<H9QT78U%Y\D=MBL")3DR")SZSHW-N5H28L/*3M<9R()PL!!*FX8
MQ60M,O3=6O,/L2F=@`,/2DAMNR<73&KH\M+:LQ%D-N2.#DB1*5Y3@P/!J(A2
MH+)-5%-#5<YS=#20#N,MN;B35JP=@ITQ8CC`6O(0R1[9[$FB*A3.+57$ZH7(
M,RF[<E>\ZR)N'TPW/8(,,PUC@'=)=^12F3'KGA+TBE1*8([7)M>_$FLF)L/+
M54B8V=9(\@.EA7?<HSMR43#([X:/I=:-9*7;K%2,DWI7YM[,6UM@0VL$*/D&
MU2"M:UODMR_-2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JRNR&<8YK/@+,N
MPDO:GQ\B^%<9S/)[^SQI.G4OKFTPMB6OJQ"V!6J$;<2I4E([E66NRYO9VX`A
MN#NX(6Q*K5DXOH%Q6LCWP?/<FY;U<0,\C'F4[#^OB;&&=X;-,0YWDBS)^5(!
M=C2YNE#3!66&JL8-N))5D/,LI>6`Z%M^)4B/)4'<)5=W*AJ"X:3B0Y9D<3P]
M'()I\NE>T.97#-:J*XB(V"QR'#[YC7`A,24S'-T.V;:F1_C\NQ3)+Y%QRPXU
M=2L?-;_(9G+@QZ31V$)8W+'MFGIK/GV);1X$Q3L#"$+PT1S*L-:Y6D89&2E3
MR.-+%5C$SU%9$2A4K4!4@BKZD<XX]@0+5J"SHUJKHEBI+<H\=]+WY6O?P=_O
M6O>_U6[]_P`UN_6/+)`[=J/J+?D/_P`$&^M_^['S[V:=`_Q='GS_``;][Y;_
M`(/*WX0>>0GK0^`S]";]RG6A\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N5APXCVA
M62YI/(5Q!M"%K5`>(OKNQJD#`F<KW:L>;;XCN84KD.L&?+%G-I;HR/28D\S'
M$E<7!,.$2P2(T#@U$#1/T8E7H!OIBW?W"%LF0ML?8'D&&/JO&^P.")HE4(,E
M:_YKCI11<QQC.&I2F2*['MBVYAK$_61IT4F9!IG$@I*M"YM39.3K0^`S]";]
MRG6A\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<IUH?`9^A-^Y3K0^`
MS]";]RG6A\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<J(.]&,YOF+7
M&60/'3&.0RMR>88K1-=U:%KZXAJE+8XKS.['=0A0E]0B3G'=$Q2`9O0ZLJPS
M!!!?#Q@_0_:R(9IQ'+)%BP;?'XSDJ%/[XOM+88INB:6F0H%S@JLF22`Y6?<A
M*2:;U*8DT\SH]`HL8[V#?TB]8"WR!,M^/_N3?E\/^I3K0^`S]";]RG6A\!GZ
M$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<IUH?`9^A-^Y3K0^`S]";]RG6
MA\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<IUH?`9^A-^Y3K0^`S]"
M;]RG6A\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<IUH?`9^A-^Y3K0
M^`S]";]RG6A\!GZ$W[E.M#X#/T)OW*=:'P&?H3?N4ZT/@,_0F_<IUH?`9^A-
M^Y3K0^`S]";]RG6A\!GZ$W[E;@CL*_*UAV[W/\(L8;?6(-K<_HY\_JO6ZE*4
MI2E*4I2E*5:;.T7R3-<.Y)BF'INSXXRB_0][;H%-9%%&Z<1V/R@](.S2LD,2
M=2CD4@8#%%@HWMM,+N:>U*E?<MPJPD7MYJ,5<&'-+FRY5R"^Z_:=X>=V[:MK
MS;`=+TTGETJU2S,]XUV.S]+4DMRR>BQ6QLD13N&(\OE8XPNY0_!;DX,T<AT'
MD^3XT^W&#&L0FACO0;;W`,NCVS6"XYJ8PY<%DK:=T7ZAI9OD*#:L8_Q;LU$M
M?6PZ,XZR?&\+N;^&3L>2-9(3FJ:.2;`428LCRK(V6D)#7%URMIE"C)SI-KNX
M:HZK82P`]RHN<R/'4+(;Y;,$Z(;:BDDT=W%QD\T>&MM-$,]O9UTK?7DUE0J3
M#E:1INB(5G&J0&F"D7)XXS3&-R"(R)'[HQ^4LCM''UONH5I++F9\0*&QT1W5
M(%"5<F[J0JCR.Z$:I,K)ZSK$YY)P0&!P'3OA;:+-W$5U=@"/!P"8D_:>[H25
MV:?A*S(996]Q#+&E#5'5O=QN13',BS<@E\@([F3+24BSN\1JXA2>F0&I)Q]D
M+P]?)^+_`%J9S_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO]:F<_ZHT[(7AZ^3\7
M^M3.?]4:=D+P]+\[7U]*O:]KVO:^4\Y7M>U^]>U[7RARO:]N]>U^]>U8E>(K
MP1X'B58Q[L</?`K?*L@8P":MV*T[5SW)R&*;H8F2@7J'LE,\HYF5*D>QT*1*
MUSGBB4#D!Y3H>"S`O:GI0%J:7.8^F^H_"%WLU^A&R.O^(!/D$F9*I.H;G3)>
M<6R70>5M!W<<IQ[/V"^533XY.(@YV&W/C4<,PDS_`+,[-*IQ871J<UDH^R%X
M>OD_%_K4SG_5&G9"\/7R?B_UJ9S_`*HT[(7AZ^3\7^M3.?\`5&G9"\/7R?B_
MUJ9S_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO\`6IG/^J-.R%X>OD_%_K4SG_5&
MG9"\/7R?B_UJ9S_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO]:F<_P"J-.R%X>OD
M_%_K4SG_`%1IV0O#U\GXO]:F<_ZHT[(7AZ^3\7^M3.?]4:=D+P]?)^+_`%J9
MS_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO]:F<_ZHT[(7AZ^3\7^M3.?]4:=D+P
M]?)^+_6IG/\`JC3LA>'KY/Q?ZU,Y_P!4:=D+P]?)^+_6IG/^J-.R%X>OD_%_
MK4SG_5&G9"\/7R?B_P!:F<_ZHT[(7AZ^3\7^M3.?]4:=D+P]?)^+_6IG/^J-
M.R%X>OD_%_K4SG_5&G9"\/7R?B_UJ9S_`*HT[(7AZ^3\7^M3.?\`5&G9"\/7
MR?B_UJ9S_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO\`6IG/^J-.R%X>OD_%_K4S
MG_5&G9"\/7R?B_UJ9S_JC3LA>'KY/Q?ZU,Y_U1IV0O#U\GXO]:F<_P"J-.R%
MX>OD_%_K4SG_`%1IV0O#U\GXO]:F<_ZHT[(7AZ^3\7^M3.?]4:=D+P]?)^+_
M`%J9S_JC3LA>'KY/Q?ZU,Y_U1J]^!-$M6-8Y>XSS".+@0J5.T=4Q5>ZAFN2)
M'<]A6.#<Z*$'<4OF<A;2K&+FE`?W20B*6@ZCJBU("33RS9=TI2E*4I2E*4I2
ME/\`U]?RTI2L>N2/]J/J+_N0[Z?]:=`JR%4I2E:7M:]N5_5]5[=^U[?BO;OV
MOW[5YX]T,"YEX9VPLTXJ&BT+=ISB#("I&\<3K3*)D%F&9/B3*"P5.UF!H\6%
M(B;M@<?-AKF[3MK+5)6[)S`%P<'`JSR-[<5F;K7[/N)MHL-8[S]@R9M.0,59
M2C2&50Z5,YEQ)U[<M#<)J96F,Z*MI>FE:6I:)"P.12=WC[XB7LSLE3.")02"
M\=*4I2E*TN(-KVM<5K7O\EKWMSO^:WRW_P"%1YVFVHP;IE@J?[&[$3AOQ_BS
M'+5=R?'E>$PU8M5'&!2M$=CC25_V^12J1N1J=HCD?:RSESNZ*B$Q(0`N:<5Y
MR.$?_:C,*\0S:.>ZR9G@;=KA(9O.UA.GZ]>]C7(<BQH8"DS3C3(#D><8W,^<
M7`Q.>[LP6DPN(RP3D*$LERY,RM1T[]7MA6%SY7M?E\MOQVO\O*]OEM?Z+VM>
MW@K6E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2NK?'QEC#*[R22.[7'X['V
MMP>WY^>W!(TLS(S-*0Y>Z.[NZ+SDZ%M:VU"G/6N#@M/(2(DA!RE2<424,88_
M:V;A:S[?,LN?];LQP[++;!)0LB$N%&EA_=;&\I5:Y&G&M:W),@=`LKZ)M7*H
ME)@(AQN9-:8UVBKJ[MP!J0\.8;KZC8_PVT;#379'"T8P=()`X15@RL\Y#CB*
M"/TC:7=]8W5E8Y$8N[@>'%L<XO)2'%,V&*AH2H\^+%75(6E>J(D:QOC+)F5H
MDD;=VN01Z0-;>]L+\R."1V9GMF=DA*]K=VAT0'*$+DV.2%00M0+T1YZ18D/)
M4ICC23`#%VE8]<D?[4?47_<AWT_ZTZ!5D*I2E*5I>UKVY7__`.VO^*]OIM7F
MOSM#YIP,,\3/<S`D4?)7PL\^3(4IWGUSAS8K>W74W)DA472JMO<$1A$4'N7%
MSB<-&#.>/FTRR9F2A"^,:&[8G94\/]$D#GD,RA"XMD7'<H8IK!9NPM<HB,MC
M+FE>8])(Z]HRE[2],KJB,-2+VUP1G%*$JH@P0#"Q\K]$81@#5M*TN((;<Q7L
M&WAO>UK?7>N,J6I$*<Y6L4$I$J<H9ZA4I,`G2D$EAN(9IRDZX""BP!M<0AF&
M!"$-KWO>UN_6.//'&%X7^M-U:?,&\^N#$\(+B"NBD?R,TY'G248>?^C-@>,1
M3*8`-&(-P%%C90B-,M<LNPAVO:T3K\<V,Y3'9%I;P^^)!N*)<5<UBG,7UK=,
M(X1<07N#J#%>6-@W&`)VXA4$=C"1WC:HZY5^L,3`!80PZ?#+_:!L[7+OC[3G
M0[19D5VY*%>T6PLVV?R$B0F=+HJT<3UT8XQ#0/'5B`,+:Y2Q0A2GV$!0K6%@
MZ`];<,[B0YI`+XV/&HV(0LJT73/@FC&&L2:AH6HH=[=<WHLE"0Y&R<XDF`M<
MONY8N2JRPWN).!,=S,%4<9_L]W"_(=;RK+^()YMCD`P@U.JR%MYG?,FP,C6!
M4@&!4>:BETR#$2%BD1ESC%B",)%03[%G$FE&$DB!CTUQ_LB_#WPYEO/\\GLB
MRGE*+RU^0JM9XVDFTLQO)=:&PE0@?_=1NR%"G]ND$QR$QR).)OB$M<[ITC;$
MTJ<#NQODF7+WP$T;Z,<6[4&PS]&N(TAVDQRW!"-NUUXHD86Y&=P$E7N-2F9M
MM\5E,65BS#$EK-[$CED<=FIN,+3G+U2@`E1@_J7QJ)IK88!JXIN@>RND"8BP
M@JL]P5L'MWJ0802:%/9Q6Y>PDV.$AA=W&XBUB5GED%+6)$@S>[55A)3AWRRZ
M];8ZT;91$J=:TYVQ7G&+#*)-4.>,YLQ2P34,^UKA1O[:V+#7>-N1?.P5#7(6
M]K<DIG,M2E*,M<-I!VO:]N=KVO;OVYVO:]N=N]>W>\%_EK6E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*5%/>:+QJ;:>[*Q&98XR/ER)2/#,\9I/CK#QZ8C*TI
MCZ]C4D.Z#'%E9@"%,V*0"/7QEO$6K$YNR)*W%-SF:K`W*_-5J2X[GY]A6T6.
M]97""[50R69CF+%DG;F70EXT?SXNQ<Y;B;$OV2->"<RL^,WB.S6:9$B+FCR0
MG<8+BJ!D:U(,V9";"F1KR*[PT;7<K45T?]1XUP_LQ;>:ZN&OV`<)J>*_A1E;
M84QY)R\R8A?,N[&Q"68:<7*$0O$:1_B[#(X5#<PX:QJOM&%S:[L@HG9M=4Y^
M76>,7S:<*Z`SK&7#YU6A>1XJ\024-6+DAXX)(.Z2WV#,+T^/C_#84\I%I9*U
MK<XE#'6/1Y<R+2$ZUB4-QC,K3IU"$PDN=$E2/KA'7]!&'E''9*M975)'I`X,
M_OB0,;XI0*"6EX6L'NDS^[B1L<!IUREG]UFOW3)(&A]T4/7]U%8&9YA?B$%<
M1?5QK6[R835S-3IWNDK9I85HZ8C:FEA0Y9TG(DS*JB?QI%'NJMD+BX1M>WO-
MI`WACY#`N0";'CWP"5M,Y/@'XE_S@N!/1]W]KNGP#\2_YP7`GH^[^UW3X!^)
M?\X+@3T?=_:[I\`_$O\`G!<">C[O[7=/@'XE_P`X+@3T?=_:[I\`_$O^<%P)
MZ/N_M=T^`?B7_."X$]'W?VNZX3EKKQ'GEO7-+OOOKNZ-3HC5-SDV./#Q)7-[
MBWKDYB1<@7HE.W!J96B6I3CDJM*H+,(4IS32#@#+,$&_CEWGW*W#_LR<Z2:D
MZQ;/:Z9\QKF5#(]@(]@B2X1D#>;JL_RJ8FV<XO'8V7EA^.B&%)^`QX?8+'QY
M%?WA*]L3J>%@96U0J?)A.?7KCW9ZV=QI#I#@O,F>M@,PKV=E'DS`.MO!GDF6
M7K$,I=+*R+LTHR6JW%B&+;,:Q6W+EL>DXY$19PCEB'!S:V9T*<F9OE-&,Q?V
MI;+<D+#C#`NK^'<='B!=++]UHQ"X-)EI!M^83AXYP%GC,TC8C"@6YJ43I8\^
MQ@@E$C'8(C+S'<-*..1F]HZ&8>+OB;6H2EM"D7Q'3#2Z/."42RY80&*R\H9N
MF*R<E<N9G*[(A8#!&]4<0-(`L2<R&#E_9FY]D&0!D^S7$GR3NNXDKRUZ-MV[
MQ]F7)L/1"),L<4F*A$<W0@49.1`-M<=D2QO4I.8KAL18%^C4]\*\)S+&MQA1
M^OF3N'GA-84$L(G/&?"6@L6?5(B0]$HYPDJ/:*\E<U(`_@V5.3PK4\K6M<V]
MK6M4JQ8'XEX[6"/B#8$&&U[7M87#[$*UKV^2]K7V\O:U[?BI\`W$NM\G$%P)
MZ/N_M=T^`?B7_."X$]'W?VNZ?`/Q+_G!<">C[O[7=/@'XE_S@N!/1]W]KNGP
M#\2_YP7`GH^[^UW6T>`^)8,!I0^('@(19X!%G%BX?/2`<6(-P"`:`6W=PF`$
M$0@B".P@W"*]KVO:][5BPSO_`&>-\SI*T^3T6S."];\ZH5ZEV0[$Z:Z2.^K6
M;0.JTSK%RYSE&+]O&UGDYZ^][]W*)5&GM8IY`$)7818!6JR9:O\`]H;U/QJ:
MV:I[\:Z;^`:DJ<Q'']U,'7QYE\H"8NQ9S5',GPJ:C8)BJ7FWN>!5E5V;E1'*
MQ1DB&$-[FQ8;^*_N5B1Z:H3Q&\W2;AGS-<:B;+2/.W#".R3K<^ORL0R[HH5L
M[A;;.40%R1DFEB"<NDR&))DH3";GJ1!'<8<PF+&K=3.,103_``OQ4]1<MP1U
M#8;9,\::5Q^<Q9>"X`F6NF?HQN8Z-@[V"*UQ%W4V-!?F$8`BM>UKD6P1Q+KV
MYVX@V`[VO\E[</N][7_X_&\I\`_$O^<%P)Z/N_M=T^`?B7_."X$]'W?VNZ?`
M/Q+_`)P7`GH^[^UW3X!^)?\`."X$]'W?VNZ?`/Q+_G!<">C[O[7=/@'XE_S@
MN!/1]W]KNGP#\2_YP7`GH^[^UW3X!^)?\X+@3T?=_:[I\`_$O^<%P)Z/N_M=
MT^`?B7_."X$]'W?VNZ?`/Q+_`)P7`GH^[^UW3X!^)?\`."X$]'W?VNZ?`/Q+
M_G!<">C[O[7=/@'XE_S@N!/1]W]KNGP#\2_YP7`GH^[^UW3X!^)?\X+@3T?=
M_:[I\`_$O^<%P)Z/N_M=T^`?B7_."X$]'W?VNZ?`/Q+_`)P7`GH^[^UW3X!^
M)?\`."X$]'W?VNZO5@G&FWT-EK@YY]VDQEFR'GQ]2B;HK#-7+X3=$$B,<&X]
M*^GRGX=LG=WH4[>0Y(3&+W!2=T'N!"[W5)]S^Y5<LZ4I2E*4I2E*4I6E[6O:
M]KVYVOWKVO76-+&RL!"A*QM+:SIE;F[/2M.UH4R`A2\/SBI>'QV4%)2B@'.;
MT[K%CJ[+S`B5.3DK4KUIIZI0<</LKAM>W*_2_/80K7\/^M:]A<OHY\JW6MR[
MUJ5CUR1_M1]1?]R'?3_K3H%60JE*4I2E8<.,+P8==^+MB)KCL[5@Q=GB!!%\
M$.P[''4K](XBD4JP*'>)25E&X,OOXQ\\VN<H-C"QZ;CFA\N2_1YT:U8W4EWE
MSH-H)KIPX==8IK=K?%+,D79`V<9/)G*R=3-<FS54F3D/D_R"]$$)[O4E>1)R
MR[6"40U,340@CL<;VM@;$#>3-6P0AMR#:P;>"UK6M]5JUI2E*4I2E*5U+VPL
MDD:7%@D+0V/C&[I#T#LRO"!(Z-#FA5`N6I1N+8O)4(%R506(19Z=6G.*-`(0
M!@$&][5APREP'M''F7K,LZPDY7X=^<U5["'E?0K(KI@$UP`6=W44VR3&;86X
MX=D;(<LYG.;:I@20US+&:0>NL`SF&VMVWCV:96L-K>-:.+GB-I%>WN6_DIM+
M-RE""QG13)TC^F$_:Y2]2V-]^:M8[)F!W?UB>P@`3G+!6*KK'O'DTX(EK;BC
M<9@S7PWLVKU(D)$!W=QL[8OC#RH(N6%2OB&<4`7S"LCCHQG%W;WH^9L=UQ5^
MM"A*Y#"&7F<^*#H;KC,M=(+EO9C%\=?-J7SW'PV:GDB!\9'M*.QZ=++'>1,9
M[@R1>!KWL":+M\W?UR&-K9,N3M1"\0B',YNGK8TN_>Z8+7M\H;BM85OHN&]^
M=K^&U[5OL(-_D%:_/Y.5[7YUK2E*4I2U[7MSM>U[7^2]N_:__&E*4I2E*4I2
ME*4I2E*4I2E/D^6MO3#RO?I6Y6^6]^]\OR?+R[U_Q7^2_P"+G3I!Y<^D'E?O
M6OSMRYVY\[<^?+O<K_5?P5N^7Y*5CUR1_M1]1?\`<AWT_P"M.@59"J4I2E*4
MI2E*4I2E*4I2E*?+\M4-D3&&.,N1)V@.5(%#,E09^3B2/<,GT78YE%'=*,`B
MQIW*.R-"Y-"PD8!B"(!Z,=KV%?PWK\]#C"?V4K.)>V<1G/#7B;2_8'V,R-9K
M?L=*5B".LVJ$@?C53F[.2H1100%Z[DD%N3BSGL[<N>X<<`,&NT/![A%5+OZ8
M\0<'/<G#>*L9P2'\;G?1K<X1!HW#%@%T9P'/(,6D9&A*B$DB,<R'`7R0,K6E
M4I2B6`;]+),]MK"20T*'-3^$<&N#>'KQ>&@0_>=QY\B"2HS>FS-N2.'UJ/."
MKDW'80D\F=&JT1>WVU[#/O8Y&M93@W[F`$024XBS?J5J9QTV$)J=%Q<];)X`
MRW=`'";\-J-L"Y.=8%P>YQ)$)S82@$WBN66<)6H`<OL:>?:UNI*)+N.@G]HI
M9>K/8]A.$C-3CK")5(IEKUM3$D:(L(0C`L1*XIE1R5K%8S`B(,3J@)TI9`Q'
M`Z9W1`#XE/\`_:0&$0!NF.N#3D)$A,$6I!',D;EX^>9"5<8BRU2$A]ATH:8V
M.UQEJ#DBQP>K!)(.)*4FGG%B+Y0MA./='K&IW7AU:+Y`4!#W86X07>Z719`8
M3U=[V:`(IQA(Q==TL82.UUIAA#7?NM,&U[!)4FUP[;Y<:1K$$3YP(274E0&]
MDX(!Q.-8WI4F-!<`A^ZH)7#H6G(3C`/HIS4*AP-&>68`T@@KH'#YQ?$\X@#*
M64?/N!CNHV$IKV3OEL>YLU.RF>E7"Z1-@,21KR0S*9(W]V=`%W0H"`D*(0W`
M982@6+'!;B.?VAG8'5+5+(\Y9N%9OCA#*H[M48A&2=EL8P0K6R'O4N&8A:'^
M73C'^298-R=4)EC#6>#W;VY,_O8$+,YR)K+5W+405X(G]JAATJQ4]XDXJLY<
M8M,L>C3#C6V5H#)WF(SUL>EQ]D48R\GQI$W9'!IXW#ZX+'*[L[3$)@PI!IG&
M[-*&FZB6^K;#7$MX?&PAB1)A;=;5W(SLML7<B.1O.&/#I9_I@],L)T25OR.3
MIC!!L+D2H:"C;7",-P6$`5K38)4D*"RSB#`G$F@L84<5>QI)@!6YA&`XOI$C
M#>W?L(([VOX:^MA!%_JB"+\U[7_Y7K=2E*4I2E*4I2E*4I2E*C?N"OR`VZM;
M`*L3Y,A.&\H_!+.$V.,H9'=FI@A,(GBYC5(8B_R%]?$K@S,J)(_*4`0.SHTO
MB!M5FIEJI@?22!,ZWS@ZKY2>4.,]C\2Y9V7WFTY5,^>%DORO`\MR1VV$R3(L
M;H-M<]8F?HSICL;CZ4Y/G[UDG+V0DF/,!3=K@G=4M*F<4<GG"^/X_(\JDRPV
M2>(F7:O*$NUPU)S-FO;_``1A_,JW?O/N-Q27*!L1WB48,P\[ZS1?7C'>5LP,
M`'"5H'Q$]9PR1E)RCSG('#(7O,8<50G,+L[JVJ>1E?E2X:&9)UGW1;6W*F2Y
M`7,)W(<?V12::EID:+W\N43D#["Q3HU&W)D38E4S8F-DRI6G:D:1J*5NYX6U
M,0AL06&9\E>#H]'7Y^3,;U)U#(RNKN1&XV4@/D4@.;4"A:4R,)#HXM#8<].Q
MA`6]J*<75L0&+U"<"QP1)Q&*2L#4\W:GBOB+ZN2H?#ZWR1+&O3S=)G)ABR(:
MY@E[R0_Y9TF7*7YH2D;-J&0QDC)C`F;I&8N?D+B2X22.@:FUV3*7)4TSE^/U
MD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B
M+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/
MM8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/U
MD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B
M+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/
MM8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/U
MD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B
M+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/M8T^/UD7YM3B+>8VL/
MM8UI??G(E^7/AI\16_*_.W.#:P7Y7\-O_M8]Z_TUK\?K(OS:G$6\QM8?:QI\
M?K(OS:G$6\QM8?:QI\?K(OS:G$6\QM8?:QI\?K(OS:G$6\QM8?:QI\?K(OS:
MG$6\QM8?:QI\?K(OS:G$6\QM8?:QI??K(E_EX:?$6O\`G@VL'M8ULOOMD&_R
M\-#B)WY_+S@FK]^?^;"J%R;M5?,V/IABG*G"BWUGV.,@1]RBTSA<HQGJPZQ^
M21]W3B3.#6Z-ZC:\12A.>4+G:]N@<G.`4J2FD*R"#RXP:/-.$N'?A-3@+5[A
M$\0R)P9U>W:1RA4]Q#6*3RR</;N:;TU\XD[IM:-PDYC<W#(8&4IQN-,T1]"C
M;$1!8`J#%'3YGQCI3L*-8JS'_9]<YSEX7%FE*9,Y:N:3(9@(!W2N98J9,6S+
M1*TXKB'<RQB=Y*-";T30CL8``PPD,X<^KD-",S5W17CX:.K;FC5%':E[*Q"$
MMY"P8^LZXF,S;=/(D5+(L.UK";@LH6TTOI%')1EC'87V3L?&0Q><`.`-C^+*
M\QY#SNEAVYFC'#TV*LY6#:UBB'7)D1VQQCD(D71L&QBU,4JN/_2BNBL8;8TJ
MKXIQ"_[2-`Y#9MFG"0Q_LU#B!V`1)X3(T&K$J5D`N5;K71DF.<,VLQ"TX'6"
M$%M(,1!-Y\NK+ZL`YJIN,5LECIM1+=I."SQ+,9W4I1*%2[`\4QCM_'6NX`_A
MW<56*YJUR)$1<81A"8IBX#"@7`H4E$I;FGE1T<_[5MPXH[+"81-,7;H8VDQX
MQ%A;LLX5@^)`E&A$6`1:M=DK,D5;D`@W-#<0ERM,6`/2,&,)8!"M.[$W&"@6
M?&P+U@S4O:S,S4(%C0K<5O\`I#/P=6(%S`C&1%MTW165:Y81&<CDY8N@&XNC
MT;7O5X`[^9$%\G#3XC%O_P!T$UC#_P#U;86JIL$;^1/->P+KK&\X-SM@?+[5
MB4[-@XKG`>!6MW58^+EB"%D/2:.8[SSDN8EI5[\M.3(7%?&43(?9M<+"=BS@
MI"5D]J4I2E*4I2E*4I5&Y$QY",LP678RR3%V::P&>QUVB<PB<@1@7LLACKZC
M-;W5I<DAG*QJ58D.,+'T1`-+%<)Q!A1Y99H,=L(X/NDT3BDFC+M%<G3U=)<P
M*<RCR!,]@L^N&7&A^22K)$HAC0QY?39-1Y.:H]!%&5YU[D-R*6$EO+O)'^:2
M[WP3J0/<C772>N&IJ(_8VC6+%L/R46PPR8R>=0^1(MDMET.5XJ^S:-BATS)C
MF<$^7@YE9(Y+HH8;'9+#6Z=IX>\M)IB5:Q&\[##,''N/H5B>"0[&6.(RT0R`
M8_C+)#H9$V%*%$S1R,1QN3M3(RMB4-Q6)1-S>E(3$`$(8[A+Z9IAAHAF"K'Y
M?EK'GD@`.U'U%MT0\OB0[ZVY=&W+E\-.@?>^3_ZA?:OX;UD)ZLO\F#[(?53J
MR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(
M?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\
MF#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4
MZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^
MR'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+
M_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]
M5.K+_)@^R'U4ZLO\F#[(?53JR_R8/LA]5.K+_)@^R'U4ZLO\F#[(?53JR_R8
M/LA]5.K+_)@^R'U4L6"W?L`-K_)S#:P;_7;E?_SJDYCCZ"Y#:3&&?0V+3=D.
ML()S/,(\SREK."/_`%@FM[\B<4@PBM;D*PB;VO;O7Y\K5C-RYP,.$;FP2@V8
MZ":\-"Y2==48\XJB1V"Y#9;<T)_=Y4@PFX8_=BE]CPV.[L`ILHZWF9UG2$*]
M[%'\"R&P`P2[4[B#\3K4XY&F,*9(G#=LY!E7$R0WJQ63W<<:YW:LA)79&2;<
M)@TGNXA--"'J2UR<)@[W\0CCPUN.OC+CJ-##')M/I7N0^S-1F&.[MGC<@XLE
M&)2%A+&[Y7ESV8A5,C9C=N8S$T*FN%ER%19%W0CQ(SQ5V1N\4*=_U.(Z0^IF
M!D3RAP;':2D-#83('1E:E+$SN3X4B(+=G!I9%CH^*V=L6N`5*E`U*GIW4MR0
MTE&>Z+S21JSNYI2E*4I2E*4I2E*4I6/7)'^U'U%_W(=]/^M.@59"J4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6WHAZ72Y6Z7+ES_P#7_#ZK>"MU*4I2
ME*4I2E*4I6PT8BRQC"6(T00WN$H%P6&9>UKWL`%S!EEV&.]NB#K#``N.X;#&
M`-[BM@ZX;G$KSONMGS*T<?8WKU;&C$V,ZY?!(#D!>#8C5J1+8FPO@<<["PN8
M#;'.4R(+PXOD#G"Z,12(AQGE"++8S=IE<6=&^8D9R+7Y]_\`YVO;_P`K]^N.
MK5I4"52N6J2$:-&G.5*U:HXM.F2IDY8CE"A0H.$`D@@@H`S3CC1@+*+`(8Q!
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M/$,WJPAZ8QBYBO5?PX89\;.,_/\`B'\9I\.&&?&SC/S_`(A_&:?#AAGQLXS\
M_P"(?QFGPX89\;.,_/\`B'\9I\.&&?&SC/S_`(A_&:?#AAGQLXS\_P"(?QFG
MPX89\;.,_/\`B'\9I\.&&?&SC/S_`(A_&:C+AS=6&Y!SGMUC.03/$K1&L!9$
MQ1$8.^)9FTD*Y4U3W7_'F5W5P=%"]_,;E1[?(Y8[LB0QF*3)@H&XDI0`Y>4J
M/')KX<,,^-G&?G_$/XS3X<,,^-G&?G_$/XS3X<,,^-G&?G_$/XS3X<,,^-G&
M?G_$/XS3X<,,^-G&?G_$/XS3X<,,^-G&?G_$/XS3X<,,^-G&?G_$/XS3X<,,
M^-G&?G_$/XS48-FMV(CAH>O(85+\2RBV6MI</8.E%ULR:EGN#$LB7DMGB0H?
M<9_*ZAT;?<1/W$<Y=<V!ZXWNI,=^!T).@SEAH0`"OEC&=KB"$5[>_P#B/>O>
MUKWM_P"^OQ5N^'##/C9QGY_Q#^,T^'##/C9QGY_Q#^,T^'##/C9QGY_Q#^,T
M^'##/C9QGY_Q#^,T^'##/C9QGY_Q#^,T^'##/C9QGY_Q#^,T^'##/C9QGY_Q
M#^,TMF_#@A``#*^-!#&866$-I]$A7O<P806M8(7FXA7_``N]8-KWO?O6M?Y*
MC+J#NM"\_P""FG)T\FF)(G(W#(.=XJ8RMDU9T:,#3B_/F3\51MP`2^2!2X=<
M]QN$M+VL-N<)*>N<%)S>$EO&F(*DU\.&&?&SC/S_`(A_&:?#AAGQLXS\_P"(
M?QFGPX89\;.,_/\`B'\9I\.&&?&SC/S_`(A_&:?#AAGQLXS\_P"(?QFGPX89
M\;.,_/\`B'\9I\.&&?&SC/S_`(A_&:?#AAGQLXS\_P"(?QFK%G[4-KGN#AS7
M6$NT`ET7R!KUL5F"2OC(_)WQ_8GK$,_UOB,9;2;L[LH;4S4^H\QR50X>Z",Q
M6<J9&VS<I3E%.)1\QJ4I2E*4I2E*4I2N.K3]UI5*7KCT_=!!Q%STIMR5)-CB
MQ%W-3G!M>Y1Y=A=,DVUKW+-"$=K7Z/*^"+"O"@R6Y[63W+6Y4[Q/GB&,4.+Q
MI#I,CQ,!CS)L9#Y'KBR:_2@G9^9+YI)@N+,",-HW"30>*M3#&L@9>NERTF(B
M*!D882ES2XMQ7CO"<!C>+<3P]C@./8@D/01F(1M)9`R,B-2O5N9Z=O26&.Q!
M1K@N6*QAL*_,Y0:/G^%RJK7IE9I(SNT=D32V/T??FQ>ROC&]($KJSO+.ZI#D
M#FU.K8N*/1.+:XH5!Z->@6$')5B4XU.H*,),&`6+N2<)S41RVJPWEAHU!TT0
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MV!@5JK*EJ<]190I`!0=8RQIP`&#$&U5=G/P^?(5TX_9@PA_(M.SGX?/D*Z<?
MLP80_D6G9S\/GR%=./V8,(?R+3LY^'SY"NG'[,&$/Y%IV<_#Y\A73C]F#"'\
MBT[.?A\^0KIQ^S!A#^1:=G/P^?(5TX_9@PA_(M.SGX?/D*Z<?LP80_D6HUXA
MX3.I<.S=MA.IIJ-IJ_P/+N0<7R+$$;#@'%[J.#1R*8'Q]C^4M1C.Z8\):(T)
MYG\>DDF"AC9ZM$X`=K/"\PEW7+DY<E.SGX?/D*Z<?LP80_D6G9S\/GR%=./V
M8,(?R+3LY^'SY"NG'[,&$/Y%IV<_#Y\A73C]F#"'\BT[.?A\^0KIQ^S!A#^1
M:=G/P^?(5TX_9@PA_(M.SGX?/D*Z<?LP80_D6G9S\/GR%=./V8,(?R+49-EN
M$OJ?DT>`!8LU)TUAH<>;-8ERED2P\!XQCWOIQ=#[R*\NAP+1_'BBSV8^6<V[
MH,#UW.PN7<M_=%41U!/3DR#AR\/L(`!%HMIQ<5@AM>_Q8<(7YWM:UKWYW@O.
M_._X[]^MW9S\/GR%=./V8,(?R+3LY^'SY"NG'[,&$/Y%IV<_#Y\A73C]F#"'
M\BT[.?A\^0KIQ^S!A#^1:=G/P^?(5TX_9@PA_(M.SGX?/D*Z<?LP80_D6G9S
M\/GR%=./V8,(?R+6E^'/P^^]<.BVG%KV$`7/XL.$+?ZHPBOW[07G;G:U[=Z]
MOSV^6HV:D\)G4K$&$6N"YCU&TUG<[23_`#C(%4C+P!BZ3@.CL[SKDJ?0)JL[
MR;'B1V'>-0&3QB,C0C("B9QLXF=H,/:$"%0;)3LY^'SY"NG'[,&$/Y%IV<_#
MY\A73C]F#"'\BT[.?A\^0KIQ^S!A#^1:=G/P^?(5TX_9@PA_(M.SGX?/D*Z<
M?LP80_D6G9S\/GR%=./V8,(?R+3LY^'SY"NG'[,&$/Y%IV<_#Y\A73C]F#"'
M\BU0$1T&Q-A_<S%.P^OV&M?\)0R-ZY[#XBR(V8MQS%L:R.6R+)F0];I;`EBI
M)"8DU-K\S1UOQ3.2E)[TZ`5M*Q]0`:$*HIS=3TF0JE*4I2E*4I2E*4I2GR5T
MK9(V!Z4.J1G>VEU5,2T3:]IFUR1+U#.XAMTA('0A(><:W+@A_"ND6@(4VM:]
M[E<K7O;XIY7&5;$=*$LA8U,;3$K%"A_(=VXYD((;AFEN!YSN4I&W%DH3"#RU
MIHU(2T@R30*!%B+'8.]9)XXW-21\7OS,A95]V\*)V6.B!*UJQ.QA136%,XGJ
M"T1]W(P\DMOL4>.ZX9Q04G77,!:_>VOS[_\`Z_\`7T4I2E*Z9SD3`RJFI$\/
M;0U+'U;[G,B5R<D2%2\.%P].R!J(5GDG.*VX+V'W(B`>HZ-["ZOE>U[_`$,?
M64IW3Q\UV;2WU6B/<DK,->D`ZJ6Y*:60I7D-HCK+3D*<\THD]840-,2:8`LT
MT`Q6#?AG2Z+)[2"ZB1L)%HF46=*+G/#:5:.$G)KK"37ZYBH/N,6:CM=64-S[
ME":EM=07<1-KCMPXY/81,#5)$3F$6DQR,`#594>D3*]F)2QBZ`!J"VM<K&0`
M8_P0C-"`(A?@VO>_>JK:4I2OF::4048<<8`HDH`S#33!!`666`-QC,,&*]@@
M``-KB&,5[!"&UQ"O8-KWM3Q$RB2J.F2]-)X\HBA2=0K-DQ#VUG1\M*D&,M4I
M&]E*QM8$Z8PLP"@\2NQ1`P#`:,`@BM;EK)&P-R9L6+WII1)'E6A0-"E6Y(DR
M=T7.=KB;4;:>>>64O5N`;7$A3)!G'K`VN),6:'OUO4R!C1N[<P*GAK3/CN2K
M4-3,H<$9+LY)T`0C7'M[::<!:N)1@$$2LU*0<6F"*PCQ%VOSKMZ4I2E=**1Q
M\+Z",">V@,C,07=2V`3DAL]#:PFW($Y`:;G^Z`F\)UKE"6A372V-M<NYUAVO
M:WV1OC,X+G5K0NK<L<F,Q,4\MZ5<E4KFDU:1W2C*<T9!QBEO,5IKV4)2UA1(
MU)%^N("87^%7#3RR,*V97(DLA8U+`@[O[N>T[NW'M"/W*,-)<^ZG0I2-`GLV
MFD'%.%SE`+(C"C`*NJ$`5K=J@7HG1$D<FU6F7MZ].4K1+D2@E6C6)5``FD*4
MJI.,PA2G/+$$PD\@PPHTL01EC$&]KWY=*4I75O+VSQUM5/+^ZMK(T(0!,6NC
MNN2MC:C+&8`D)BI>N.(2)@"-,+*",\XL(C#`%VO<8PAO\5DC8&Y,V+%[TTHD
MCRK0H&A2K<D29.Z+G.UQ-J-M///+*7JW`-KB0ID@SCU@;7$F+-#WZ[`U<B(4
MI49RM,4K7=?W&F-/)+4*^Y2PG*>YB!C":?U!0@F'6)`/JB[V&9T0WM>N(0^,
MRIU7,29V;5#TV)TBMQ:"5Z0US0)5_6=PJ5K>6<)8D3K>I-[D/4DE%*NJ,Z@9
MG0%R[6E*4I\GRUTS=(V!X6.[<U/;2YN#`I+1OB%O<D2U8S+#07,*2.R5*>:H
M;51I=KC+3+2R#S`6N(!=[6O>VYKD#&]H#'5G>&IU;"C5A!C@VN*->A`>WG&I
MUY(EB0\Y,$Y$>2:0L*N;8:4XHPH\)8P"#;[#=VHIN`\&.2`#4:0G4EN0UJ4+
M>8G5]5W*>!:(VR49*CKR>H-";<L[K2^K$+K`<^QI2E*4I2E*4I2E*50N3U+&
MBQO/UDGE3I!HXDA,L4O\U8W`;4\Q!E(C[B:ZRAI="TJX;<YQYO`I>&]>!$L&
MC6(B5($J@15B1^/.R?7"1Z^9]SQIXKP#@?$T<TG@.(7[%N#<TXQG.[F=-87K
M9/7F3Y\VVW01XD?34L0D,:P*W9`+;+R-SR!E5N+S1EN090F4(ETC/Q\AOA+"
M]/T&R<XAV-+8A;>%FMWZT*19M9<:WQNCTF49#>=0]J%CFPR-%&AEX>#$WO,;
M9HN9DID5D@;'7(2V!WD:16N>+]TQS!&H3D6=1G&9TIT)B6AC,LXK;QJ&?O)$
MB,AZB.;,R[/Q5C7->!(Q'LL8C@[@C98HJF2&`3!KF"X[$>#E<F<\315R0.;R
MI:/5MHM,$\_TQU5FB*"/N,4$DU\Q&ZML`DLDDTS>XFV*(.RV;&5=,9J89-)<
M)(W@363RB9"M+9`C$F=I*`M[5KBPRLI2E*\U?%E2:?Y(SYDO`\J<]:B=F\GZ
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M5W73+&*<F:=8$<&+1;*<<U[A.?%[`2QXF=)CEK-L9AN0)V6CB#'CUZS"@Q,U
M-=IJXM**=RVR\0'IRYQ_)C+M.HQD?I7']4.)@LX="7*"['QV*"(PQ;[9Y:KR
M#68^2JS&:T]C6*2,!H,`OL',!)&3$*J*EX_5I8XM!<^@9RMD3AD8&3<TRC!%
M\T8S7\$-NR!#<TMEE_$Q7Y"3P372?2ZVATM5.3<MQ_&9])YBX1>0Q7WKSH,Z
MR6S;0HE3K%#'<XYN]OH.^'\?^L.W?\-ABM>]OHOR_!MW^0>5N=_EK?2E*T%R
MZ(N?/ET;\^7R\N7?Y?CY^"O,@X-VG>7N(F1'<12G7>%Y@Q)OV9E++NT.=<Z8
MR#NEE/,$42*&=5I?JS`R5J7,%L($IE#/@^1BFJ^,01N@:&3PW'6.<KKW%7/&
MG'0ZN>/FK5+!<HUE<P@W!DG#2WC<^)O(\6KHO?90U<V.>%Q9\>]F5C`JO.2L
MF1G,9N4$&-G*;"]WV!T+FK5"CD=TZQ,7*;+\>T^)GFSS=J>KU0#I7$LB\*N:
M2'$GOG:(?H#GG."TW9YIE>$YS,<51F>8PACG.,=J=6I>\/4\B3O!'2=13!J+
M)Z<UOE;<M'E@X+YCD=@'8`]'%L:0?%"C=38,[`D*P7)ETSU_B6,1WAGNNP8-
MEJF-0Q!(L>(,Q6RN`ETB\1C<'.DUY."",Z*(%LY5LP-*4I6(KBOS?5>$MNM*
MS9*,Q#+KRIRI+082U]S/E7&.*-9,A9$*QC(>[9EL2^YD3J\?$PK$,4/>)*S.
MBUIF4E8I8Z-*S'V.9S/CHZVD8;#\<ZA8ZAC+C/<;*.K^7-=X]PN=HYOK(^LD
MAA3YJLP9GDVTF7Y7F^(Z<NTV>W8B\UUUC#]@?#.%G6.JTF0XOC^--*-E1Q4:
MIU8460;'^.Y01M7P3,SY9D&6UN;YKJ5D^+95CF0)[,'*-LDK0:CXM=YFM2XR
M=W0Z)1*?.LL`M]_,E:6='(GT\CN)[7JTZ4DDF,6FAN&Q9\X>K\Q&Q,_B(2+;
M[B-,N]RMK51`>?U&/&>/;16FC3L8%G4>_2V-8QDAJUB08G12T-XVPH0XA2Q(
ME*B7,0%'J?MSY6Y_+R[_`.>E*4KHY,:B)CK\<Y.Q[`WE,SH8N?4JDI$I9D9:
M!0-4[)U9Q1Y24YL("8N*4F$'`(,3A-$2;8%RQ>,P'Q>91@#8+.6B+QA##\9@
M'#NROC9H8\59PQE-N(SMEC";3/"\HRQM=M4U8S=#G5B=HEC>-SB9PL4U=9AF
M\$US!*IA-S\/254=CQPR-8[Q!J3D^5<5'$.G[VV0W4!9J]J<^JE.EF2"\88R
M)S\&);)+YLDADKP&]M*!!(9'A=JU[OEM`UK"5<FC"J'AE%EB-X(NL^6S&,FB
M>\!75"3.C_/6@_&6L>A4U:6>(3Z50^+2)T)+UU(3-^0HQ'7-O9<AQE&*]EJ2
M*R]*[1\AT*3N8&_NY,F4$^C8K_5O_P#Q#O\`^Z.OI2E*4I2E*4I2E*5\5"<A
M60<E5$E*$RDHPA0G/+`<0>0<`19I)Q1H1EFE&EB$`PLP(@#`(01AN&][7HYC
MQICN,*%*N.0.&,"I:B.;E:EDBK`TJ%2!0,LP]$H/;FY,:>C/&46,Y*:,9!HB
MP",+$(`;VZ]!A[$[5`EF+&S&6/6_&3B0X)5^.T,)C"."K4SJ<-2Z)E</3-14
M<4D.2@P:A>2>V&%K#QB.4A-,%<5'[#V)Y5&(_"9/C+'LBAL3/:U,7B;["8P\
M1F-J60BZ5F4,+`XM2EI9CFA,(2=K-;$:4QO(O<I((DN]PWN/:UK6M:WR6MRM
M^:U*4I2J(D&-,=RQ=[IRB"0R1N-B`)K+WZ*L#RM[F+Z703]UN3<J4=2#I"Z!
M76=6'I"Z(;<[\_L9CN!'3!NR$="8B;/&=C-C#3-3(TR#EK9&U!@CCX^WR42"
M[VA8SSAB-.:$J\IO-,$(9B80A"O?<QX^@D9?I5*8["XFPR:<J$BN:R%EC;*U
M/DO5H"!)4*J4.Z!"G<9"H1IA"3I#WA2M-3$"$42,!8KAO4R-&D;DB9`@2IT2
M)&04F2(TA!29*F3D@L620G3D`+)()*`$("RBBP%EAM8(`A#:UK<FE*4KJGIC
M99&W*&B0-+8^-2KJ^ZFQX;T;HWJ.J,":78]$O(4)3NK,"$P'6%"Z`PA&'D*U
MKVH\[$&*5,8?X2IQIC]1#96`!<GB9\*C!L:D99?5]66_,`VH32\`!U170`Y(
MU00=47T;6N`'+DO>+<:21LBK+(<?0A]9X*O:76%-3S$H\ZML0=&$CN5C<HN@
M7MJA)'E[,F_[.U+&<E$I;2/]"B-(*MT*^COC+'+_`#"/9"?(%"WF>Q).>DBT
MV=8JP.4NC255UUU2:/R9:WGOC*G4W4*+J"6Q>E*.N>=<P(KFF7%7%*4I2J&^
M#''/N]:4>\*%7DME]G6T@]Z<?]W+.=AW,LX6=_<WW1LNL9>X[++*>Z;#O<76
M]*_.N2R8^@D:?I5*8[#(FPR6<J$BN:R%EC;*U/DO5H"!)4*J4.Z!"G<9"H1)
MAB3I#WA2M-3$"$42,!8KAOTS?AO$C5"'7&;7B_';=CE]NYW>X"@A$710IX]V
MS;G//NI$TK45'W'W7.O<YT[L;C_=`V_6*^N'RO:M61D9XVT-D?CS4VL;$RH4
MK6SLS.A2M;2U-J(D"=$WMK:A)3HD"%(06`A*C2$$IDY(`%$E`+"$-NTI2E*I
MN20Z)3$E,FED8CTF3HS1GI")"QM3V2E.,#8`S4Y3HD5ED&C`$(1&%!`,0;6"
M(5[6M:W0.>(\5O37&V-XQM`75FASX1)HDTN4,C2YLB\C2G'J$S_'6]4UFHV-
M[3'JE)Q#LUD)'`DU0>86I",TP0JY-0HCU*58<D3'*D/7]QJ34Y)BA+W478I3
MW,>,`C2.Z"K6+/ZD8.N!:P#.F&UK53;?`(,TRY^G[7#8HVSJ4HV]NDTS01QE
M12N1-[2`);4A?9&F0E/3PB;"P!`WI7)<I3H@!"%,658(;6JZE*4KYFE%'E&$
MG%@-)-`,HTHT`3"S"S`W`8686.P@#`,`KA&`5KA$&]PBM>U[VJC&+&F.XNO&
MZ1J"0R/N9B<](8X,<58&A<-*I$6-0F&L;FY,I$0>,HH9Q(C;E&B++$8`5P!O
M;[P['L#QXQ#B\"A<3A,:,5KUXX_$8VR1IC&N=31'NBT30R(4#<)6Y'#$<O4W
M37/6&B$-28:*_.N_&T-9C<!G,;4`VHHA.F+;!HDHF\M.DZKN4@"(15TH"4W4
MD]04$FQ9/5%]4$'5@Z/8TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I6VXP!OR$((;_+RN*UK\O#W[UI<TNW_`,8;_185KWO?\5K6MSO>][]ZUK6O
M>]^]:U[U$[".]>HVQ^8\Z8`PAGJ`Y'S!K8[)&7,T'CKD:>YQ%<JL`LP11QZ8
MAODJ!I<AWCTD=8FL?&N+RPLZ)2)8V2,D;9:6/6%_E`?:#ZZZ]X>F>/M#I('Y
MU;61A8VY<[O3V[KDK:T-#2V)35KDYNCDM-(1-[<WHB#E:Y:K/)2I$I)JA0:6
M26,8;3X1V0P'LG'766X`S%CC,D;8GHZ./3QC>6LTN1-#X2G)6>Y;F-G5*AH%
MA[<J2.J(I6`KW09UJ%X074M:U*K.KA!D:`.DI<(.V3:*.,S:O=;W3B:&0-:N
M2-_N"GAZM[[M9"%1CDFNT)<A0-2YV.3@NA(F<5-4]6!_:Q*>X8Y+'I.F5+8X
M]M3^C0O+]'%JIF7IG-,CD$6=UD?DK&K/1F'%)G=@?6Y>S/+<<("MM=42MO5E
M%*DYI0?A+)?%X)&7V9S20-$5B47:UCW(Y)(%Z=J96-G;R1*%SFZN*P925"B1
MD@$:I4*#`%D`#<1@@VM5F\8;;:O9K<`M.(-A<,Y.=!K5#<6W03(\5E*TYP2(
M7-R6("$S.YJSCUJ)`RNZQ:D)`,]&G:W`U464%&HN7(3IAYWMW^]\O>%R_-SY
M<KWM^.UK\[?+?E:G2M?_`.;Y.?\`JB]7R^&WRV_':U.F'O?+SO\`BZ(N=OI%
M;E^#;Z1<K5P5[LV-04HW-P1MX5JU*VHQ+5)*2RMQ7&7*1($UU`R^O6JS;7+2
MI"NFH4&?@$E#'>UJX<<DL?F$?9)7%7ILD<9DK0WO\>D#(L(<V9[9'9*4M;'5
MJ<D@S4B]`X(SB52-4F-,*4IS2SBA"+&$5^[Z5N5K\^5K\K=_O=^]^5K<K\KV
MO>_>Y7[_`#[WRUT4;E$;F3(VR6)/S/)XZ\)[JVE_C[BD>&5R36,-)NH0NC>:
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M<:7^P^W#/XA]K6Y\<_</GRM_^7O4#_\`SC6]_KOSJ_CYI5L.=HGG?7"=[7RW
M;S+$^-<GN,3W/T5@4$;5B1&?$G=LPW(V_#L;8D)>-I.JBJYBE#J>WO;W9JF\
M@$(A>WID;)4>]F<+;L[%1=1.VG73&>(%CID;$H<A8D9)W#W_`"_FR`0/&V<D
M5T.5\H-DD@,`E,(A66,C0)]Q3CI3*$BIA0Q65SMP=E+V]LN-&^S'9][NM3&B
M<'>2K,@2FY,.!EMT09A'&\B9RA@5'##!F/'XLD(+0YR:Y%E"*ZQ9GC"Z9&K(
MG[Y3DK:&1.+`@R(Y+4-+8XT(WLB>1,'*VLE\A./&3*C[.VMLOG1!D%^P;'GC
M>S.V=,B,S]*'^1`79`>,SZ]2S&V,)0-,RY#]^#<A7XXELGB3&SI)JORB\/;!
M^?L(Q?*+;L*M7OD@DTV02."N2K+DBRJ1#\2'LQ96/<!EKY+9.X*ENO;2`>/W
M?(AR*R[-ZX%\L/RTZ22)W0-4:,NZ&9CR%A[&$*3ED(G^"9*XDN0B%;%DIZAB
MQN>-A#ME5^!7-)(8LN9W41J=WR9#7-V2@663L:XBZI:2J.9RQ!CQ,=&N(9-<
MR9E=%.094R-<Q3+R!9#C69;1=RED!?DNO""/XO3.+/(#)@R+\7F1O*LA979)
M'805&)$:]/48ETR5Y=E"8NU&V.LN\^/I?L3.(-"I>FQ:[LTUQ/$[8XVJRH0X
MOL"D\LUB:L$B&H=)]))O&'5I00.81B3.L2A<.OB-5,W%XBH,AMKW-9L;6[EH
M[Q#W"50)5'W&0P;&A65I\]XF@9^=2)K*=0F5VSQB>4-\@<IG(9(J]]"]5!(]
MDP*!!'"<QEQV*S)PP*E:DT)DSR\I+A"U*W0R`?C1)F3'$@?V?7V;ZKK(\%-L
M>A<%>0I'C+;'+$KFV7F9$&6Q\EK2M6'9-"W1"3-71/,G9,0YQ0ABNYQQG+?*
M:3:5;QM[3.2)9'LC3W);IAF!Q!KSE!MVWN`.K5C=LUOPYCV08"B^-7TMVA$H
MF1>:&/*F13Y+,4L"C<R'("9(MS!'Y:\"''LG^CK?G/'>.HYA#,6,G)B41../
M<I1S@,R<96R&HY)F7(P(O`#Q2*>91>FV5,$#;X\^NT>;,DSZ'0M"]MD.B\E4
M,K2UAOCG2\.G;INC,3>87/W7'F9L=X^UY@>*9`VYOG14`@!C,EV$3YC=%F,V
M9Y)@<F3.*_)<0='@MXB3RMEP&-LL`)BJ+LUDTX.'_B_,6"XD3")5@J28YC\A
M6#='DR3;8.NQ#BTR=@Q]CUL?Y.;[Z#'=<WBS!D(V</MT,>E+V6H&TF9`F9<?
MEL^<8VWY*Z4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2M.5K7O?
MEW[_`"UK2E*4ISMX:4^7O?\`*_+Z?Q=^G.WA^C_CX*4I2G.WAI2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E1[REFR7X\D9+$QZ\YCRBB.:DSC>2
M0,F%&LA1YZA628U&7?9:SN`5Z4*8L\^UT5D]RE:>Y)QM^ML7#?:;:+*YN`<E
M%MFONQF'UXFA#W-DAP40UG1Q4?N\T=):>Y1R<+'M(%07TVX(VY*><(:P)8P!
M(&<87AGBFRVQ%I9%[FYGS*\E6E$<N:S%Y"DIQCP59\07,:"R5+N!*<8Z`L)O
M`2I,`F-&IL6H&`D0Q6]#'QILCVN*UM--F+VL,=K7[DQC\G2OR^3(8K=ZW>[P
MA6[W>%>W*]Z#VGSME\G1;8[*$"9IQK/EA@AK^W0)[GD>@\G>XJ_*1,[:SY`3
MQ>[A*(N_M[4L>!JB&1\N$IV.:ST:I.6F/*4BQ]/G%2S+`)%F>(RQ!C1)FK%)
MVOV$Y=A^9G3)AC;5G$41W`RAE.7X\41""RB:RN#93Q-B'&66,?+).L88U'<6
MR0I]D4A97Z.R:///9/?&?E#6QE3D&',;"A<MPQC"48V&++;XN"\Y,R'`=?9<
M[L[Y-XSC^2P&-QK%*[.BRV5FB2.,=RI%\=0!3EU#"I!&Y6S(4U'-W%KS1C>5
M2"*Y,3X`FK^T[:3;'<V9(YD63*"89BY%L!@?6]@4PB0-.,$<:N@)?Y[+WTY3
MEE^:)2.:LKCB=*V/1K>LE;/,C2?B*3/:?+@X3(L?8SBT:D^`7C8N%BAV3'69
MY$B\;19O?,/IH+F&&J(FSDQJ>E%LACL[D,S@XHT\@"_0Q$6J.BYSVZX\\?;O
M[IM14.5G9H:<@3?+[1A^7QP4@.P3/]5YI!9AN?KGB"59*PC*L-1N#Y_PFW-L
M4S6.((L1[/XZ<GUP&Y(#6O)+GD/%DW*E4@4'%[R1)BV!CCV.-?$<GSBX8XOA
M-Z79U>'F%XC;,C9&RA!"FS<4QJA21PQGD!H)Q<Y=R1",J75+)LD'/6(R']G5
MQ!=,76[6F?$2G>=MDY3A68LT3)9I$H?IK`\A,TV8Y5B9_;6/`6KTH<,3:Y3Z
M.,K>#-B^.2#)DHR;,)#*$<57(('(X\;&$LQ3I9.7CN',XX@VW[%(LRX';Y^W
M7R>HW^<9MBZ9>]&)B/8N'3CS;8K!.58Q[CF,%V1R?63(43)P&"4.H#WX2?.L
M/?;O":2H$[A:0$(XM62,DY4=<5X_QKA"9KY)DS%;!B=_:\J3YLCSE`LAYCV$
MQ:Z2M\/D6+6QZ>`1EOP<5)2'*(1Q1%I0O?5\48G@XAG2R]WMCC7B[Y=^`J*`
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MK*.0XXZ9&R/BK8!L9A;"X>"''BF"`@&O.:X+EENE;)/XJH;G"<2C&IK/D+>L
M[*$VTN$H''90BD<&ROC#8=.ZLJ2[2-1&<B8/?,4K;.!O13>[:%02WS:21&9,
M#HH`>RO1$73JFY`YA<K'P$E7$$V1QQ)9^V-$&QUE2/P7)6T<KFCK-IHYP%[8
M\/XIVAQA@^-0C'[5$,>OZ"0R8ICG3T]E/$O7MQ)JB/-S2Y*5(WT]X:+"CXN&
M>UL\CLD+A^-6B"98QA"#L50%JDKGD:10UZRCMF[X-:Y?GV+-$5C4X:9)"F.$
MR`A;`(0^J6R435P<\>HGAO=8HJEADMM8N)O*]A,U:^8?78CBD),S7A0S.:]\
M49'`Z$QUH9??]&W&"($R5KZA]R%.Y'$D62L.-%G%$*6:Y),F9&=$S0[8Q6L#
MWF#_`#TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E:7"&_RAM?\`/:U_
M^=4+DK&\3RS!Y#CN;(#G"+2A*2C>$25<L:U"A.G6I7`H!:]N-3K$UPJD:<=Q
M$'`$*P+@%>X!BM>);9PW-36AS;7=#"'\M<TN2!V1&#R!-#0%K6Q80O1F#*,>
M!%F@`I3E#$48$19@0W`8$0!"#>=O0!W_`,$/?O>]^]:_?O>][W_XWOSKA.34
MV/*!2UN[<@=&Q87U2MO<4:9<A5%=((^K4)%11R<\OI@`/H&EC#T@A%RYAM>U
M'R?%&,)K=<*8XY@DK$YK8\Y.-Y+#XX_77N$2&K-BJY;=V;%EU2R-&KUQD?5'
M]8>RF+%0VPQ*)2=<=--.NN`&%6[N#'@_$#,OD$4.@C\M:L90=M5O<)4)@HCX
M>[J43"0<YQ4Y($*4V.K1GLYB:UB#$0BK!!;XJ-;M>E;6T,:K!6&U++'POP&)
MH/Q;`SFME!*0IPR8#2WF1\21M#(0I$H7T*(DBSN%,GLX]TV)+Z/Q8==,017,
M+GG2+0QGC&07V)O$0D+A'&]M8TDD2/DI:I>XNTC1MB%+9\DISPSH[^^!S-4N
M-DO7)Q&B">8*_:F8"P8<BF#:=AK%)S;D)2G6SUO-QS#3$,V6)'DV1)54O2"9
M+D292F?SCGQ.>]EKC27@TQT*&%<8-0+F+,)X<<&V<,Z_%&-5K3DUT+?,CM:N
M!Q-2W3]Z*.*4%N\V0GM!B66.A9Y!!P'"0%.*P!I)1H#@F%@%:ITD(AJ$YN4H
MHG&DBAG7V=&D]*P-*<YL<[1L$.LXMYA*,`T2^T2+!&++$HBE-HZ`+'8VS6&R
M2WQ.@$&4*+JU$-BAZJX7$%U)T<9C3[@=Y"EESJ"YPT(C+A<I4A125P#<7);(
M$:5Z56-<TY*H%.M6$<-L4D/F3+B?&C1+E3HZ/BF4M<!B3?(U#R]JRU[R['OB
M-G(=#7-W6DDK'-P,5B5N"HHM0K...`$=M9#A/#DM:3&&4XHQK)&,U`W-9K,_
MP.)O+28V-#J>^-3<-M<VA4B&A;7M4I>$",1%TR)T/.<4Q12PTPX7/%BC&-RY
MJ6''L*)^$EC01K()J:+LB11-X^U,2F,-3+*U21$0I?VQJCBQ6PM:-T-4D-C0
MI/;D`$Z0P15Z8C&OF'HN1C`1,!C#T^X=A[%!<>3:4L3-)<@QR.1QKLSMB-#.
MG=O42<DP*"PRU2HER*4+C3U:I8,Y4L5''=TMPMA]R/CBIPQ5C=<IAS@XNT24
M+()%%1\7='=\!)G5RCIQ[088QN#G(RBW]P6M8DBE:]%@=E)IK@`*FWR0X9QV
MV9(3Y4;X^0AEJ*-3"+H3$1@T32C1Y#EC/-L@N)+$CZAJO(IS(XW&5\KDAZ8Y
MZ>KQUI+5K!!).[HJ@Z#0M3=;=1$8P?=R`XE.-SH^T&]WEN[B0[NI:WK$0NZ@
M.3JE3.3@!1U@5K@G(6J;&J2BS0T8KU_P4X`FI:[#&)UA>231'Y#+5XWA:D$[
M.$\6D(SIF$]C,#*C1OUK/0C'ZS@,3O:SG>_=UK**JYOQ_!&FS=9KAD4;;,ZA
MJ5M(4$<9D86Q4QQ\<395+>%,A*LB4-$6,'&VL]+8HUN8!C948R&P0DMZOI2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*Z%SE,:95`4CQ(&1J5#*">!.Y
M.[<@/$2,0P!-"2K4DF"*$,L80F6#<%Q`&&PKW"*UNN^$"#?BF,5O?\5K2-DO
M>]_Q6M;N_OWO?O6M^.]0IP#Q&\#[`['[3ZZQM\:$+KK0\Q9K]\:V0MH6K(1+
MFB,22YQC76]S@$D@LV3*88[&`4JBU"RZ-:G,[G6`"&:WP@07_P#644\Y&3]_
MJV>>MB83@/`>5=AG-!(,@Q7$T0>Y:Z1_%I#3*IC([,I!9MXY$&PYX;&YUE3H
M<>F0L[0H=T'=J]4F374%"/+O>SUN(=J@G;CY(]Y0:(M!!X]PCD9BR!)CB6J-
M2ULSV#+A\-98T2(XZ1K96WHL)SM?*H\<PIE\>1M:LU8#_P!D2*S/7"[=O49L
M<GEI<-C</(E<?QN7EYVNJG3&G1I<;FQY@EP);=S-5`:SFN\3E<5E%^YEIRH$
M;E$;?1I@M3\TJU=LX%Q*M-)^H2IT.;88R^[>6I+AN$FR!]:494_E$4>H/$W5
M7%KIEJT?N*"=9"C6.[+'X#&>7D!6&'J4J=\.2(U-[\8;5ZX9IFLMQSB?-6.<
MA3J"A7FRN+123M[N\LR1KDJR&.+@H2)C!7.:D4O;7.+'NR,2EL!(VIU9+*[N
M38N3)X5L?%EQ`-AC4NR#B+,.)H?/,;1W,&/Y-+77!3TADV-GW,V',)JI*L1X
M^S+,7N%`CK_GC'+X\()TTQU6?'W!U+80/,F872.$2O1[N:E.#UC&.HM@\6*G
MS,J=,IQJUDRE&-9*@+I$]P]O+1DV[Z52Y3"-2.'M:)T]SUCG+8^^1A`G4OS0
MX-Z:WSMQ,=!6-"P.3GMK@\A!*VH][BRLJ;(EA$F:2G%8R$+XZ8A`I"]IW:0-
MZR,QX;7=5>32D@<8CH7207"VBKJ,;S:@3-[QQ'(ML;B5[>LMPUKG^.T*"7MY
MADGBCVR2>2,[FC,$("=,)S881-'9$W.1R%V4(8?*5!:`0(\[W1]`S<0W2B0Q
M-IG+%LKBMWB;U+%\-1/C=(+JT0'1K0MKNY+G#J4HCV>*(6-\C\C53QY);X(1
M&))&),;)0L$E87%QJC*VZ&M6&8RT2R;Y5CA#0^S1O@C7[D*!/J]8^J<XQ;7-
MU"G;6L*A:>DB67)@S1.8JB23`QY>::0K`)0`"<VEVG?S50Q?&(]+LRXZQW-9
M3`W[)R.&RR>PLQP2P)@O+5!TF7OD<?GV&)VY>Q0:6REHZ4E[I<XW&90Z(TYQ
M,4E'N/5F+]PL#YKFD7AV(IDBR,"50[)\O3R>+'I%L<:KXED^)XO*XP_B.4IG
MMGEEE&9H8Z(6A6R@L<Q*#'0]0G3J6F[G%,OBTX!3,F4\BR"#9>C^!L5G9+0.
MV?O<J#2J!B?,69#;<9/<:D;%`Y]*<FXCDC_)5ZCWAL6;X)C9RF*1F=PMR<MS
M*1M:V4#CO+I^TG9>3.&R.'4ZK`J,:W+B.\Y93%L')+>4D9-"ZHR5!JHY45+'
M%MAIJ%L)<%Y,U<FV&G)2Y2X(V<_YXFW6UYS7*E$5@,[:G8U4YQQIA;J!P:AM
M>35D@QB9EE27`+)UY[F[#BD52N`9H0O;6M7&'5L<&YU3D'D6L+H9KQ`-4<5/
MLS8,S9>B&%U</R@\XH+-R@_,\:3RI\C>,L597DKM%177*C5D9C47S#$12)Y<
M"FPEB/&M.=`I&L"5Q5\-ZXA^HK+EE_PX/,L.<91"X=DR9Y#4,[\T.C9CU-BV
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MRBMU\7471HI`XG(V!I=U!7=QG=0&18[E/%D-^JLN,0@2"4)@'"/+\9.FK;"B
M-J]>&S(V/(AF"!/N68/!99CZ<-O=+!(F*<O:*$+AF6*%<2)T;+/@'YG7$EC"
ME=FU+<2<U,(TD7OZ#P<^&%>W_@FP/WKWM_\`A91W^5[VY_\`O+\?+G]%7?,T
M-UZC>M>2-7,)0B/X"QUDQ0K<WE-CAE(2@+D"XYA$LD/<BHXP"IT/31QK0B.4
M'7Z*5*0`OH6)!:HOY#X43'()IF^5XSV'R=B5IS?E6%Y0>\>-B-.ZP5H/9XOF
M]HG<8;4R-WC4BO%,A3;/,QS>IC8Y(&-M^935#XZ,<HB;P[PE7;-/P;!G1U/%
M7[:22#;&K&V.8<T+(?B]F@[F[R?#<9PVRXBE64&Q#+G#'>3$D`=\&0F1MI3A
MCYIR(O`6IACQE==CY*Q15F[>9\)"731:YO:W<27I'B2Y8E^;)2U(L6,J/'!^
M07O,F-\SQ]W8\?-TP;TA0V-?B^.0ES4S9UR"\/$'`>)G=HE.ECI.7+F:LZPJ
MM5MYHKC-/DQQR!"(YHQ+HOBMO=8JQ,+I"<?L^S[`^-,=>GMJ&:JG#PDO*_<L
MR2K"V@"AM96PR[(6\JGYW>9,P/AQ:\8RP9#,.P.(0F(/<=.U[42C+46QE!8W
MD#)9VOV6H)F!N-G#JRM2)8]&RJ2P>PW@Q>N6"3J7MR=4]QN-[&CL1D#A7.4K
MG<3E\?VEG<<:8CD5'E5J@[G#T$EBJ&:-VUF3]IRU[:U%29@;06?'C*"R'RU>
M\MS_`"A6SQ:)J8E)818A^;Y!?ABX?T&CS-C1B;IJ^E(,8XTT/QDTEA9V<JRQ
MLT/S`[9?B*Y0618LDE3.G)U&TR$D@L*=K2D`6-0>Z17M:*$VX-K;-79H3N&T
M63!XX;SUAA^/%L=0*T:1%(T6=8W/&F(*DS^VM,4(F$1V`F%SGV\9>9P@FZ%C
MD5I<LB2,S')_,R1PBW3,#)$4N3]J7V5R&/0Z5XC<G>V&H-'F=RP;+XOB>)NT
M'2QF*NC(!0_J4F(VIS52;(3KDJ/*G21R=+?'Y<4][,7C5=E\,:1(7U2O:MEU
MA4?BKR^N^#H>Y8A85S7C;WR;N8EWB=$LG<4,L9Y!D@`9KB5I@B`P3K$;I84K
MN8<!7(4YSPOX;?PKU\5;)E%L:[8Y.QI#<BP]G;9J1'H%C1QFI^0(KBN2X?A\
M\B<[E#0^J8(0UQ9X8'!>R1QI3NZF40]"[,4QBZ5[DK6[7/U#X>QFKN2Y%D]T
MS6ZY.=GXC(X@H%$/M'DK>X962ZYIY<?[J.,MF<G>4@1ZV1,QF#(WYX?4X7I]
M"]2-_-$B4);1RSA/HI:[S*4+\Z7'.G7'^8H%$\FF8:A:;*+BERD\-CPR?&+G
MS`Z1]_V49L7A8VE%#X\^*(:0>8WH9`]K'"8-[=(D?+>^%;[N.25S/V3EY=\:
MSN09-U?;PXY@P6_"$WF.S,'VQE:F1"3]RN^9&!7D^!,[*TL<H=VDYMQZ>M;5
M[L^3L:?(R:XV+N'`SXTV#9=K!9ED\DV%.NW,V2,@G0V'1DO)^-C(8XLLIQ.\
MQ:'I6*--<-=)N9&\HQ\YM;K2:.RN%,1KH_RPU?*ULCK&=:!Q&<3+.$T4SY_0
M+LV1/96*KDY3,T*28Z7LGAO6O#;VN;AGBZ:LZ--FMC(\-I*GHE+U<F=4B[DF
M1H[WB[(>#XT/[.FB-]A9$G@$$)RPHP7&[X[8?=3'S[EO;'$FX3JOEDT0/S7)
MLA-S3DG$R%A;&I`L@:FT*>%!1KO>8MZ"9@NKB'AAQG$D]UUR:AR_(G*::Z?"
MJ;'#`0^--\?>5>QLZDTYV@6NK8,QQ>#EF7%;C"D#6Y+9(Y/<")QJU."-V>WJ
69Y3<IUE+MSY6YWYWY=^_R<[^'E7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BUSINESS COMBINATIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>BUSINESS COMBINATIONS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATIONS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(3) BUSINESS COMBINATIONS </b></font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Acquisition of CuraGen Corporation (CuraGen) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On October&#160;1, 2009, the Company acquired CuraGen, a former publicly-traded company. Following the CuraGen acquisition, the financial statements reflect the financial position, results of operation and cash flows of the combined companies. In connection with the CuraGen acquisition, effective October&#160;1, 2009, the Company (i)&#160;issued 15,722,713 shares of common stock of the Company, or 0.2739 shares, in exchange for each share of outstanding CuraGen common stock, plus cash in lieu of fractional shares (the "CuraGen Exchange Ratio"), (ii)&#160;assumed the obligations under CuraGen's 2007 Stock Plan (the "CuraGen 2007 Plan") and each outstanding option to purchase common stock (a "CuraGen Stock Option") granted under the CuraGen 2007 Plan and (iii)&#160;assumed the $12.5&#160;million in 4% convertible subordinated debt due February&#160;15, 2011 (the "CuraGen Debt"). </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The transaction was accounted for under the acquisition method of accounting. The acquisition-date fair value of the consideration transferred consisted of the fair value of the Company's common stock issued of $85.4&#160;million and fair value of CuraGen Stock Options that were attributed to precombination service of $2.9&#160;million. Of the CuraGen Stock Options assumed, all but 1%, were immediately vested upon closing in accordance with the terms of the stock option agreements and employment agreements. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company recorded the fair value of acquired assets and liabilities to net tangible assets, intangible assets, goodwill and a severance obligation. The difference between the aggregate consideration transferred and the fair value of assets acquired and liabilities assumed was recorded to goodwill. This goodwill relates to synergies from the CuraGen acquisition and a deferred tax liability related to acquired IPR&amp;D intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Cash and cash equivalents</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">51,654</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Marketable securities</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">18,638</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Identifiable intangible assets:</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">IPR&amp;D</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">11,800</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Amgen Amendment</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">14,500</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">TopoTarget Agreement</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other current and long-term assets</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">756</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Goodwill</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">8,965</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">CuraGen Debt</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(11,503</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net deferred tax liability</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(5,190</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other assumed liabilities</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(3,778</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">88,242</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The values assigned to the intangible assets acquired, including the IPR&amp;D, were determined based on fair market value using a risk adjusted discounted cash flow approach. The values assigned to IPR&amp;D related to the development of CDX-011. At the date of acquisition, CDX-011 had not yet reached technological feasibility nor did it have any alternative future use. In December 2011, the Company completed enrollment in a randomized Phase&#160;2b controlled study for CDX-011 in patients with heavily pre-treated, advanced breast cancer. The Company expects to incur approximately $1.4&#160;million in 2012 on the Phase&#160;2b study. Estimated revenues from CDX-011 are expected to be generated by 2016. The remaining acquired intangible assets arising from the acquisition are being amortized on a straight line basis over their estimated lives. The net deferred tax liability primarily relates to the temporary differences associated with the IPR&amp;D intangible assets, which are not deductible for tax purposes. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the CuraGen acquisition, effective October&#160;1, 2009, the Company, CuraGen, and The Bank of New York Mellon (the "Trustee") amended the CuraGen Debt to provide that the CuraGen Debt shall be convertible into 353,563 shares of the Company's common stock at the rate of 28.27823 shares of the Company's common stock per $1,000 principal amount of notes, or $35.36 per share. The initial carrying value of the CuraGen Debt was accreted ratably, over the term of the CuraGen Debt, to $12.5&#160;million due at maturity. Interest expense on the CuraGen Debt was $0.2&#160;million, $1.2&#160;million and $0.3&#160;million for the years ended December&#160;31, 2011, 2010 and 2009 and included $0.1&#160;million, $0.7&#160;million and $0.2&#160;million in discount accretion, respectively. In February 2011, the Company paid the Trustee $12.8&#160;million to satisfy all outstanding principal and accrued interest related to the CuraGen Debt. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CuraGen employees who did not receive offers of employment were terminated upon the consummation of the CuraGen acquisition. These employees were eligible for severance payments upon termination of employment under certain circumstances, including following the CuraGen acquisition. U.S.&#160;GAAP requires severance obligations that are incurred by the acquiree for the benefit of the acquirer to be recognized as an expense in the post-combination period. Because the offer of employment was at the option of the Company, the Company has deemed the CuraGen Severance to be at its benefit. Accordingly, the Company recorded $3.3&#160;million and $0.9&#160;million in CuraGen severance expenses to general and administrative and research and development, respectively, in the consolidated statements of operations for the year ended December&#160;31, 2009. In addition, the Company incurred $2.9&#160;million in acquisition-related expenses including investment banking, legal, accounting, and valuation services in the consolidated statements of operations for the year ended December&#160;31, 2009. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Appendix F<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]D-3(T9F8X-U]B-F1D7S1B83)?.38W9E\S,3EC
M-V8P8V8P8S,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3D%455)%7T]&7T)54TE.15-37T%.1%]/5D525DE%
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5-34%2
M65]/1E]324=.249)0T%.5%]!0T-/54Y4/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0E5324Y%4U-?0T]-0DE.051)3TY3/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-
M14%355)%345.5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y-05)+151!0DQ%7U-%0U52251)15,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y04D]015)465]!3D1?15%525!-14Y47TY%
M5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5$%.
M1TE"3$5?05-315137T%.1%]'3T]$5TE,3#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D%#0U)5141?15A014Y315,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/5$A%4E],3TY'5$5235],
M24%"24Q)5$E%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E1%4DU?3$]!3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-43T-+2$],1$524U]%455)5%D\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2T)!4T5$7T-/35!%3E-!5$E/3CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)1DE#
M04Y47U)%5D5.545?05)204Y'14U%3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3$Q!0D]2051)3TY?04=2145-14Y44SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/34U)
M5$U%3E137T%.1%]#3TY424Y'14Y#2453/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4D5425)%345.5%]3059)3D=37U!,04X\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y314Q%0U1%1%]1
M54%25$523%E?1DE.04Y#24%,7T0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1592
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET
M>2!);F9O<FUA=&EO;B`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!E>&-E<'0@
M4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@
M86YD($5N=&ET>2!);F9O<FUA=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#96QL9&5X(%1H97)A<&5U
M=&EC<RP@26YC+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`P-S0T,C$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4
M>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/D1E8R`S,2P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A
M;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L
M=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E
M9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-38N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@
M4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-RPQ-C`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,PT*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D-3(T9F8X-U]B-F1D7S1B83)?
M.38W9E\S,3EC-V8P8V8P8S,O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%44E!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4
M140@0D%,04Y#12!32$5%5%,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@07-S
M971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$Q+#@Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$L,C@W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87)K971A8FQE(%-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#0Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Y+#@Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@86YD($]T:&5R(%)E8V5I=F%B;&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@86YD
M($]T:&5R($-U<G)E;G0@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@0W5R<F5N="!!<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#8X-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#DT-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD($5Q=6EP;65N="P@3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#`Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#@S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!!<W-E=',L($YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L.3(S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#,V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/=&AE<B!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L.38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^."PY-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDW+#DY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P.2PY-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N
M="!,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C;W5N=',@4&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($5X<&5N<V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`P.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT
M(%!O<G1I;VX@;V8@3&]N9RU497)M($QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@4&]R=&EO;B!O
M9B!497)M($QO86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PQ,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE(%-U8F]R9&EN871E9"!$96)T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPT,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R
M96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-"PR.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1E<FT@3&]A;BP@;&5S<R!#=7)R96YT(%!O<G1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,#`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX.#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R($QO;F<M5&5R;2!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PY-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#4Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PR-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PV.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YT($QI86)I;&ET:65S("A.;W1E
M<R`Q-"!A;F0@,38I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S
M)R!%<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@)"XP,2!087(@
M5F%L=64[(#,L,#`P+#`P,"!3:&%R97,@075T:&]R:7IE9#L@3F\@4VAA<F5S
M($ES<W5E9"!A;F0@3W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$@
M86YD(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"`D+C`P,2!087(@
M5F%L=64[(#(Y-RPP,#`L,#`P(%-H87)E<R!!=71H;W)I>F5D.R`T-"PR,3`L
M-C,V(&%N9"`S,BPP-34L,S@R(%-H87)E<R!)<W-U960@86YD($]U='-T86YD
M:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R,#$P+"!R97-P96-T:79E
M;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET
M:6]N86P@4&%I9"U);B!#87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-S$L,#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,R+#8W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@3W1H97(@0V]M
M<')E:&5N<VEV92!);F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPW-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D($1E9FEC:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(P-2PP,#8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38P+#(P-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C@L-S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S4L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3&EA8FEL:71I97,@86YD
M(%-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#DW+#DY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3`Y+#DT,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?
M,S$Y8S=F,&-F,&,S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0U
M,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,R]7;W)K<VAE971S
M+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4V3D%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H4&%R96YT:&5T
M:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].4T],241!5$5$($)!3$%.
M0T4@4TA%1513/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@4&%R(%9A;'5E
M("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@4')E9F5R<F5D
M(%-T;V-K+"!3:&%R97,@075T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!0
M<F5F97)R960@4W1O8VLL(%-H87)E<R!)<W-U960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!0<F5F97)R960@4W1O
M8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@4&%R(%9A;'5E("AI;B!D;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<R!!=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3<L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Y-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<R!)<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#(Q,"PV,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPP-34L
M,S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L,C$P+#8S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#`U-2PS.#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0U,C1F
M9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]D-3(T9F8X-U]B-F1D7S1B83)?.38W9E\S,3EC
M-V8P8V8P8S,O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3%1!
M1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-
M14Y44R!/1B!/4$52051)3TY3($%.1"!#3TU04D5(14Y3259%($Q/4U,@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4D5614Y513H\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!$
M979E;&]P;65N="!A;F0@3&EC96YS:6YG($%G<F5E;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,"PQ.#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-C8R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYT<F%C=',@86YD($=R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#@P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!2;WEA;'1I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3$Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS.#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#<Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(%)E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,C8U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#8L-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L,3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]015)!5$E.1R!%6%!%3E-%.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,R+#0S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(W+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(V+#$V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.2PQ,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#,Y-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!3
M86QE(&]F($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V5N97)A;"!A;F0@061M:6YI<W1R871I=F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,C0S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-#(X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,3$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@06-Q=6ER960@26YT86YG:6)L92!!<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!/<&5R871I;F<@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3(L-C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3,L,C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L,#,P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S+#,Y.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#0U-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-BPX-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E<W1M96YT(&%N9"!/=&AE<B!);F-O;64L($YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-SDV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,S,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<R!"969O<F4@26YC;VUE(%1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-"PW.3DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPU,S,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S<L,#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC;VUE(%1A>"!"96YE9FET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#0L-SDY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-3,S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#4R-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N
M9"!$:6QU=&5D($YE="!,;W-S(%!E<B!#;VUM;VX@4VAA<F4@*%-E92!.;W1E
M(#(I("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,2XQ,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+C@T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(%5S
M960@:6X@0V%L8W5L871I;F<@0F%S:6,@3F5T($QO<W,@<&5R(%-H87)E("A3
M964@3F]T92`R*2`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,SDL-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$L.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.#(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@57-E9"!I;B!#
M86QC=6QA=&EN9R!$:6QU=&5D($YE="!,;W-S('!E<B!3:&%R92`H4V5E($YO
M=&4@,BD@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Y+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,Q+#@V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Y+#@R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#3TU04D5(14Y3259%
M($Q/4U,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M-"PW.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,BPU,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S8L-3(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!#;VUP<F5H96YS
M:79E("A,;W-S*2!);F-O;64Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@0W5R<F5N8WD@5')A;G-L871I;VX@
M061J=7-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^56YR96%L:7IE9"`H3&]S<RD@1V%I;B!O;B!-87)K971A8FQE(%-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;7!R96AE;G-I=F4@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@T-"PX.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#,R."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,V+#4X-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0U,C1F9C@W7V(V
M9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]D-3(T9F8X-U]B-F1D7S1B83)?.38W9E\S,3EC-V8P8V8P
M8S,O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2DQ#23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/
M1B!35$]#2TA/3$1%4E,G($5154E462`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T
M86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T
M;V-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N
M86P@4&%I9"U);B!#87!I=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%C8W5M=6QA=&5D($]T:&5R($-O;7!R96AE;G-I=F4@26YC;VUE
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D
M($1E9FEC:70\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@1&5C+B`S,2P@,C`P.#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q."PQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,S8L-C8Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#8P-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(Q
M+#$T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`P.#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-S@Y+#<U-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);F-R96%S92`H1&5C<F5A<V4I(&EN(%-T;V-K:&]L9&5R<R<@17%U
M:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!)<W-U960@=6YD97(@4W1O8VL@3W!T:6]N(&%N9"!%;7!L;WEE
M92!3=&]C:R!0=7)C:&%S92!0;&%N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@27-S=65D('5N9&5R(%-T;V-K($]P
M=&EO;B!A;F0@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;G,@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,BPU.3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!)<W-U960@:6X@0V]N;F5C=&EO;B!W:71H('1H92!#=7)A1V5N
M(&%C<75I<VET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M."PR-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@X+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5S($ES<W5E9"!I;B!#;VYN96-T:6]N('=I
M=&@@=&AE($-U<F%'96X@86-Q=6ES:71I;VX@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#<R,BPW,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+4)A
M<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPP-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#`U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F]R96EG;B!#=7)R96YC>2!4<F%N<VQA=&EO;B!!
M9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5;G)E86QI>F5D("A,;W-S*2!'86EN(&]N($UA<FME=&%B;&4@4V5C
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8L
M-3(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,V+#4R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`P.3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,L-S8W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C@L.#8S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU-#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-3<L-C<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PV.#4L,#8Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN8W)E87-E("A$96-R96%S92D@:6X@4W1O8VMH;VQD97)S)R!%
M<75I='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F5S($ES<W5E9"!U;F1E<B!3=&]C:R!/<'1I;VX@86YD($5M<&QO
M>65E(%-T;V-K(%!U<F-H87-E(%!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@27-S=65D('5N9&5R(%-T
M;V-K($]P=&EO;B!A;F0@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;G,@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W
M,"PS,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPX,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R96EG;B!#=7)R96YC
M>2!4<F%N<VQA=&EO;B!!9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@*$QO<W,I($=A:6X@;VX@36%R
M:V5T86)L92!396-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#4S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R+#4S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q
M,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,C4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S(L
M-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPW-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-C`L,C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N
M(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPP
M-34L,S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(L,#4U+#,X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-R96%S92`H1&5C<F5A<V4I
M(&EN(%-T;V-K:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!)<W-U960@=6YD97(@4W1O
M8VL@3W!T:6]N(&%N9"!%;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M27-S=65D('5N9&5R(%-T;V-K($]P=&EO;B!A;F0@16UP;&]Y964@4W1O8VL@
M4'5R8VAA<V4@4&QA;G,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@P+#(U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S($ES<W5E9"!I;B!#;VYN96-T
M:6]N('=I=&@@0V%N=&]R($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPQ-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPQ-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!)<W-U960@:6X@0V]N
M;F5C=&EO;B!W:71H($-A;G1O<B!!9W)E96UE;G0@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!)
M<W-U960@:6X@56YD97)W<FET=&5N($]F9F5R:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,RPV.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#8X-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S($ES<W5E
M9"!I;B!5;F1E<G=R:71T96X@3V9F97)I;F<@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#4P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+4)A
M<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#,T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F]R96EG;B!#=7)R96YC>2!4<F%N<VQA=&EO;B!!
M9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^56YR96%L:7IE9"`H3&]S<RD@1V%I;B!O;B!-87)K971A8FQE(%-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T+#<Y
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T-"PW.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C@L-S(R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<Q+#`S,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BPV-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#(P-2PP,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@
M,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#(Q
M,"PV,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-"PR,3`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14950D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].
M4T],241!5$5$(%-4051%345.5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V%S:"!&;&]W<R!&<F]M($]P97)A=&EN9R!!8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#0L-SDY*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPU
M,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@S-BPU,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(%)E8V]N8VEL
M92!.970@3&]S<R!T;R!#87-H(%5S960@:6X@3W!E<F%T:6YG($%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<')E8VEA=&EO;B!A;F0@06UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#(T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S$X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU.#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO
M;B!O9B!);G1A;F=I8FQE($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PY,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDT.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&%N9"!0<F5M
M:75M(&]F($UA<FME=&%B;&4@4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E86QI>F5D($QO<W,@*$=A:6XI(&]N
M(%-A;&5S(&%N9"!-871U<FET:65S(&]F($UA<FME=&%B;&4@4V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA'86EN
M*2!,;W-S(&]N(%-A;&4@;W(@1&ES<&]S86P@;V8@07-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-38I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#@P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM0V%S:"!);G1E<F5S="!%
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO;BU#87-H(%1A>"!"96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@3W!E<F%T:6YG
M($%S<V5T<R!A;F0@3&EA8FEL:71I97,L($YE="!O9B!!8W%U:7-I=&EO;G,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S(&%N9"!/=&AE<B!296-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@86YD($]T:&5R
M($-U<G)E;G0@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<B!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PU.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(%!A>6%B;&4@86YD
M($%C8W)U960@17AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PQ.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPT-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!2979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.2PS.#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,S@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L.#8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T($-A<V@@57-E9"!I;B!/<&5R871I;F<@
M06-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L
M-C4X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,P+#,W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R.2PX-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!)
M;G9E<W1I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!!8W%U:7)E9"!I;B!T:&4@0W5R84=E
M;B!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3$L-C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y386QE<R!A;F0@36%T=7)I=&EE<R!O9B!-87)K971A8FQE(%-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#`P
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0R+#,X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@36%R:V5T86)L92!396-U<FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,BPW,3<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38L
M-3(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#DL-34Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-Q=6ES:71I;VX@;V8@4')O<&5R='D@86YD($5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3`Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,3`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@4V%L92!O<B!$:7-P;W-A;"!O9B!!<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@0V%S:"`H57-E9"!I;BD@4')O=FED960@8GD@26YV97-T:6YG($%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,34U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V
M+#$V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-2PP.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($9I;F%N8VEN
M9R!!8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@4')O8V5E9',@9G)O;2!3=&]C:R!)<W-U86YC97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#`R,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y296QA=&5D(%!A<G1Y($QO86X@1'5E('1O($UE9&%R97@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.34W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@5&5R
M;2!,;V%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&%Y;65N="!O9B!#;VYV97)T:6)L92!3=6)O<F1I;F%T960@1&5B
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-3`S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y
M;65N="!O9B!/=&AE<B!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3DW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!0<F]V:61E9"!B
M>2`H57-E9"!I;BD@1FEN86YC:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(X+#0S-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#@Q-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-#8U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T
M(&]F($5X8VAA;F=E(%)A=&4@0VAA;F=E<R!O;B!#87-H(&%N9"!#87-H($5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@*$1E8W)E87-E*2!);F-R96%S92!I;B!#87-H(&%N9"!#87-H
M($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y
M+#,X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S-2PW,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L-S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S
M(&%T($)E9VEN;FEN9R!O9B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q+#(X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4W+#`P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#(U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%
M<75I=F%L96YT<R!A="!%;F0@;V8@4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,2PX.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,2PR.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPP,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P
M<&QE;65N=&%L($1I<V-L;W-U<F4@;V8@3F]N+4-A<V@@1FQO=R!);F9O<FUA
M=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R97,@27-S=65D('1O($5X96-U=&EV92!/9F9I8V5R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE
M;G1A;"!$:7-C;&]S=7)E(&]F($-A<V@@1FQO=R!);F9O<FUA=&EO;CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(%!A
M:60@9F]R($EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-38P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F
M,&-F,&,S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W
M7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,R]7;W)K<VAE971S+U-H965T
M,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.
M05154D4@3T8@0E5324Y%4U,@04Y$($]615)62457/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DY!5%5212!/1B!"
M55-)3D534R!!3D0@3U9%4E9)15<\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3D%455)%($]&($)54TE.15-3($%.1"!/5D52
M5DE%5SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\8CXH,2D@
M3D%455)%($]&($)54TE.15-3($%.1"!/5D525DE%5R`\+V(^/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[0V5L;&1E>"!4:&5R87!E=71I8W,L)B,Q-C`[26YC+B`H=&AE
M(")#;VUP86YY(B!O<B`B0V5L;&1E>"(I(&ES(&$@8FEO<&AA<FUA8V5U=&EC
M86P@8V]M<&%N>2!F;V-U<V5D(&]N('1H92!D979E;&]P;65N="!A;F0@8V]M
M;65R8VEA;&EZ871I;VX@;V8@<V5V97)A;"!I;6UU;F]T:&5R87!Y('1E8VAN
M;VQO9VEE<R!F;W(@=&AE('1R96%T;65N="!O9B!C86YC97(@86YD(&]T:&5R
M(&1I9F9I8W5L="UT;RUT<F5A="!D:7-E87-E<RX@5&AE($-O;7!A;GDG<R!L
M96%D(&1R=6<@8V%N9&ED871E<R!I;F-L=61E(')I;F1O<&5P:6UU="`H0T18
M+3$Q,"DL(&%N(&EM;75N;W1H97)A<&5U=&EC('9A8V-I;F4@:6X@82!P:79O
M=&%L(%!H87-E)B,Q-C`[,R!S='5D>2!F;W(@=&AE('1R96%T;65N="!O9B!G
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M;"!P<F]G<F%M<RP@:6YC;'5D:6YG($-$6"TQ-#`Q+"!A;B!!4$,@5&%R9V5T
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M93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[070@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@=&AE($-O;7!A
M;GD@:&%D(&-A<V@L(&-A<V@@97%U:79A;&5N=',@86YD(&UA<FME=&%B;&4@
M<V5C=7)I=&EE<R!O9B`D-3,N,R8C,38P.VUI;&QI;VX[('=O<FMI;F<@8V%P
M:71A;"!O9B`D-#`N-"8C,38P.VUI;&QI;VX[(&%N9"!A(%1E<FT@3&]A;B!B
M86QA;F-E(&]F("0Q-2XQ)B,Q-C`[;6EL;&EO;BX@5&AE($-O;7!A;GD@:6YC
M=7)R960@82!L;W-S(&]F("0T-"XX)B,Q-C`[;6EL;&EO;B!F;W(@=&AE('EE
M87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2X@3F5T(&-A<V@@=7-E
M9"!I;B!O<&5R871I;VYS(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$Q('=A<R`D,S4N-R8C,38P.VUI;&QI;VXN($EN($IA;G5A
M<GD@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"`R+#0U,"PP,#`@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!U;F1E<B!T:&4@0V%N=&]R($%G<F5E;65N="!A;F0@
M<F%I<V5D("0X+C4F(S$V,#MM:6QL:6]N(&EN(&YE="!P<F]C965D<RX@26X@
M1F5B<G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#$P+#4P,"PP,#`@
M<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@:6X@86X@=6YD97)W<FET=&5N
M('!U8FQI8R!O9F9E<FEN9RX@5&AE(&YE="!P<F]C965D<R!T;R!T:&4@0V]M
M<&%N>2!W97)E("0S-RXW)B,Q-C`[;6EL;&EO;BP@869T97(@9&5D=6-T:6YG
M('5N9&5R=W)I=&EN9R!F965S(&%N9"!E<W1I;6%T960@;V9F97)I;F<@97AP
M96YS97,N(%1H92!#;VUP86YY(&AA<R!G<F%N=&5D('1H92!U;F1E<G=R:71E
M<G,@82`S,"UD87D@;W!T:6]N('1O('!U<F-H87-E('5P('1O(&%N(&%G9W)E
M9V%T92!O9B`Q+#4W-2PP,#`@861D:71I;VYA;"!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K('1O(&-O=F5R(&]V97)A;&QO=&UE;G1S+"!I9B!A;GDN(%1H92!#
M;VUP86YY(&)E;&EE=F5S('1H870@=&AE(&-A<V@L(&-A<V@@97%U:79A;&5N
M=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!A="!$96-E;6)E<B8C,38P
M.S,Q+"`R,#$Q+"!T:&4@)#@N-28C,38P.VUI;&QI;VX@<F%I<V5D('5N9&5R
M('1H92!#86YT;W(@06=R965M96YT(&EN($IA;G5A<GD@86YD('1H92`D,S<N
M-R8C,38P.VUI;&QI;VX@<F%I<V5D(&EN('1H92!U;F1E<G=R:71T96X@<'5B
M;&EC(&]F9F5R:6YG(&EN($9E8G)U87)Y(&%N9"!I;G1E<F5S="!I;F-O;64@
M;VX@:6YV97-T960@9G5N9',L('=I;&P@8F4@<W5F9FEC:65N="!T;R!M965T
M(&5S=&EM871E9"!W;W)K:6YG(&-A<&ET86P@<F5Q=6ER96UE;G1S(&%N9"!F
M=6YD('!L86YN960@;W!E<F%T:6]N<R!F;W(@870@;&5A<W0@=&AE(&YE>'0@
M='=E;'9E(&UO;G1H<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@
M<F%I<V5D(&YE="!P<F]C965D<R!O9B`D,S4N.28C,38P.VUI;&QI;VX@9'5R
M:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD
M("0T-BXR)B,Q-C`[;6EL;&EO;B!D=7)I;F<@=&AE('1W;R!M;VYT:',@96YD
M960@1F5B<G5A<GDF(S$V,#LR.2P@,C`Q,B!F<F]M('1H92!S86QE(&]F(&ET
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M(&%L;"!O<B!A('!A<G0@;V8@=&AE($-O;7!A;GDN(#PO9F]N=#X\+W`^/"]T
M9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C
M9C!C,PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D-3(T9F8X-U]B
M-F1D7S1B83)?.38W9E\S,3EC-V8P8V8P8S,O5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5-
M34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-5
M34U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y354U-05)9
M($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L
M<V5R:68[)SX-"CQT<CX-"CQT9#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&(^*#(I(%-534U!4ED@3T8@4TE'
M3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`\+V(^/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^/&D^0F%S:7,@;V8@4')E<V5N=&%T:6]N(#PO:3X\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
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M87)E+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y5<V4@;V8@17-T:6UA=&5S(#PO:3X\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#M4:&4@<')E<&%R871I;VX@;V8@=&AE(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I
M=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I
M;B!T:&4@56YI=&5D(%-T871E<R!O9B!!;65R:6-A("A5+E,N)B,Q-C`[1T%!
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M(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA=&5S+B`\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,CX\:3Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(#PO
M:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!C;VYS:61E<G,@86QL
M(&AI9VAL>2!L:7%U:60@:6YV97-T;65N=',@<'5R8VAA<V5D('=I=&@@82!M
M871U<FET>2!D871E(&]F(#DP)B,Q-C`[9&%Y<R!O<B!L97-S(&%T('1H92!D
M871E(&]F('!U<F-H87-E('1O(&)E(&-A<V@@97%U:79A;&5N=',N($-A<V@@
M97%U:79A;&5N=',@8V]N<VES="!P<FEN8VEP86QL>2!O9B!M;VYE>2!M87)K
M970@9G5N9',@86YD(&1E8G0@<V5C=7)I=&EE<RX@/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M/&D^36%R:V5T86)L92!396-U<FET:65S(#PO:3X\+V9O;G0^/"]P/@T*/'`@
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M;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDL('=H:6-H(&ES(&$@<V5P87)A
M=&4@8V]M<&]N96YT(&]F('-T;V-K:&]L9&5R<R<@97%U:71Y+"!U;G1I;"!S
M=6-H(&=A:6YS(&%N9"!L;W-S97,@87)E(')E86QI>F5D+B!)9B!A(&1E8VQI
M;F4@:6X@=&AE(&9A:7(@=F%L=64@:7,@8V]N<VED97)E9"!O=&AE<BUT:&%N
M+71E;7!O<F%R>2P@8F%S960@;VX@879A:6QA8FQE(&5V:61E;F-E+"!T:&4@
M=6YR96%L:7IE9"!L;W-S(&ES('1R86YS9F5R<F5D(&9R;VT@;W1H97(@8V]M
M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I('1O('1H92!C;VYS;VQI9&%T960@
M<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+B!296%L:7IE9"!G86EN<R!A;F0@
M;&]S<V5S(&%R92!D971E<FUI;F5D(&]N('1H92!S<&5C:69I8R!I9&5N=&EF
M:6-A=&EO;B!M971H;V0@86YD(&%R92!I;F-L=61E9"!I;B!I;G9E<W1M96YT
M(&%N9"!O=&AE<B!I;F-O;64L(&YE="X@/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^0V]N
M8V5N=')A=&EO;B!O9B!#<F5D:70@4FES:R`\+VD^/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[1FEN86YC:6%L(&EN<W1R=6UE;G1S('1H870@<&]T96YT:6%L;'D@<W5B
M:F5C="!T:&4@0V]M<&%N>2!T;R!C;VYC96YT<F%T:6]N<R!O9B!C<F5D:70@
M<FES:R!P<FEM87)I;'D@8V]N<VES="!O9B!C87-H+"!C87-H(&5Q=6EV86QE
M;G1S+"!M87)K971A8FQE('-E8W5R:71I97,@86YD(&%C8V]U;G1S(')E8V5I
M=F%B;&4N(%1H92!#;VUP86YY(&EN=F5S=',@:71S(&-A<V@L(&-A<V@@97%U
M:79A;&5N=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!I;B!D96)T(&EN
M<W1R=6UE;G1S(&%N9"!I;G1E<F5S="!B96%R:6YG(&%C8V]U;G1S(&%T(&UA
M:F]R(&9I;F%N8VEA;"!I;G-T:71U=&EO;G,@:6X@97AC97-S(&]F(&EN<W5R
M960@;&EM:71S+B!4:&4@0V]M<&%N>2!M:71I9V%T97,@8W)E9&ET(')I<VL@
M8GD@;&EM:71I;F<@=&AE(&EN=F5S=&UE;G0@='EP92!A;F0@;6%T=7)I='D@
M=&\@<V5C=7)I=&EE<R!T:&%T('!R97-E<G9E(&-A<&ET86PL(&UA:6YT86EN
M(&QI<75I9&ET>2!A;F0@:&%V92!A(&AI9V@@8W)E9&ET('%U86QI='DN(%1H
M92!#;VUP86YY(&AA<R!N;W0@:&ES=&]R:6-A;&QY(&5X<&5R:65N8V5D(&-R
M961I="!L;W-S97,@9G)O;2!I=',@86-C;W5N=',@<F5C96EV86)L92!A;F0@
M=&AE<F5F;W)E(&AA<R!N;W0@97-T86)L:7-H960@86X@86QL;W=A;F-E(&9O
M<B!D;W5B=&9U;"!A8V-O=6YT<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4F5V96YU
M92!F<F]M($=L87AO(&%N9"!09FEZ97(@<F5P<F5S96YT960@.3@E(&%N9"!N
M;VYE(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q
M+"`Q-"4@86YD(#@U)2!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,"!A;F0@-3(E(&%N9"`S-"4@9F]R('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,#D@;V8@=&]T86P@0V]M<&%N>2!R979E
M;G5E+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/D9A:7(@5F%L
M=64@365A<W5R96UE;G1S(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
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M<R`H=&AE($-O;7!A;GDG<R!A<W-U;7!T:6]N<R!A8F]U="!H;W<@;6%R:V5T
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M;F5D(&)Y(%4N4RXF(S$V,#M'04%0.B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
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M(&EN9F]R;6%T:6]N(&]N(&%N(&]N9V]I;F<@8F%S:7,N(#PO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.TQE=F5L)B,Q-C`[,CH@3V)S97)V86)L92!I;G!U=',@;W1H97(@
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M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[3&5V96PF(S$V,#LS.B!5;F]B<V5R
M=F%B;&4@:6YP=71S(&)A<V5D(&]N('1H92!#;VUP86YY)W,@87-S97-S;65N
M="!O9B!T:&4@87-S=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A;G1S
M('=O=6QD('5S92!I;B!P<FEC:6YG('1H92!A<W-E="!O<B!L:6%B:6QI='DN
M(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/CQI/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@/"]I
M/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
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M960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+B`\+V9O;G0^/"]P/@T*/'`@
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M/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
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M960@87,@:6YC=7)R960N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/DEN=&%N9VEB;&4@
M07-S971S(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M)4%(F86UP.T0@87-S971S
M(&%C<75I<F5D(&EN(&$@8G5S:6YE<W,@8V]M8FEN871I;VX@:6YI=&EA;&QY
M(&%R92!R96-O<F1E9"!A="!F86ER('9A;'5E(&%N9"!A8V-O=6YT960@9F]R
M(&%S(&EN9&5F:6YI=&4M;&EV960@:6YT86YG:6)L92!A<W-E=',N(%1H97-E
M(&%S<V5T<R!A<F4@;6%I;G1A:6YE9"!O;B!T:&4@0V]M<&%N>2=S(&-O;G-O
M;&ED871E9"!B86QA;F-E('-H965T<R!U;G1I;"!E:71H97(@=&AE('!R;VIE
M8W0@=6YD97)L>6EN9R!T:&5M(&ES(&-O;7!L971E9"!O<B!T:&4@87-S971S
M(&)E8V]M92!I;7!A:7)E9"X@268@82!P<F]J96-T(&ES(&-O;7!L971E9"P@
M=&AE(&-A<G)Y:6YG('9A;'5E(&]F('1H92!R96QA=&5D(&EN=&%N9VEB;&4@
M87-S970@:7,@86UO<G1I>F5D(&]V97(@=&AE(')E;6%I;FEN9R!E<W1I;6%T
M960@;&EF92!O9B!T:&4@87-S970@8F5G:6YN:6YG(&EN('1H92!P97)I;V0@
M:6X@=VAI8V@@=&AE('!R;VIE8W0@:7,@8V]M<&QE=&5D+B!)9B!A('!R;VIE
M8W0@8F5C;VUE<R!I;7!A:7)E9"!O<B!I<R!A8F%N9&]N960L('1H92!C87)R
M>6EN9R!V86QU92!O9B!T:&4@<F5L871E9"!I;G1A;F=I8FQE(&%S<V5T(&ES
M('=R:71T96X@9&]W;B!T;R!I=',@9F%I<B!V86QU92!A;F0@86X@:6UP86ER
M;65N="!C:&%R9V4@:7,@=&%K96X@:6X@=&AE('!E<FEO9"!I;B!W:&EC:"!T
M:&4@:6UP86ER;65N="!O8V-U<G,N($E04B9A;7`[1"!A<W-E=',@=VEL;"!B
M92!T97-T960@9F]R(&EM<&%I<FUE;G0@;VX@86X@86YN=6%L(&)A<VES(&1U
M<FEN9R!T:&4@=&AI<F0@<75A<G1E<BP@;W(@96%R;&EE<B!I9B!I;7!A:7)M
M96YT(&EN9&EC871O<G,@87)E('!R97-E;G0N(#PO9F]N=#X\+W`^#0H\<"!S
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M+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/CQI/D=O;V1W:6QL(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
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M87)E('!R97-E;G0N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/DEM<&%I<FUE;G0@;V8@
M3&]N9RU,:79E9"!!<W-E=',@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H92!#
M;VUP86YY(&5V86QU871E<R!T:&4@<F5C;W9E<F%B:6QI='D@;V8@:71S(&QO
M;F<M;&EV960@87-S971S+"!I;F-L=61I;F<@<')O<&5R='D@86YD(&5Q=6EP
M;65N="P@86YD(&EN=&%N9VEB;&4@87-S971S('=H96X@8VER8W5M<W1A;F-E
M<R!I;F1I8V%T92!T:&%T(&%N(&5V96YT(&]F(&EM<&%I<FUE;G0@;6%Y(&AA
M=F4@;V-C=7)R960N($1E=&5R;6EN871I;VX@;V8@<F5C;W9E<F%B:6QI='D@
M:7,@8F%S960@;VX@86X@97-T:6UA=&4@;V8@=6YD:7-C;W5N=&5D(&9U='5R
M92!C87-H(&9L;W=S(')E<W5L=&EN9R!F<F]M('1H92!U<V4@;V8@=&AE(&%S
M<V5T(&%N9"!I=',@979E;G1U86P@9&ES<&]S:71I;VXN($EN('1H92!E=F5N
M="!T:&%T('-U8V@@8V%S:"!F;&]W<R!A<F4@;F]T(&5X<&5C=&5D('1O(&)E
M('-U9F9I8VEE;G0@=&\@<F5C;W9E<B!T:&4@8V%R<GEI;F<@86UO=6YT(&]F
M('1H92!A<W-E=',L('1H92!A<W-E=',@87)E('=R:71T96XM9&]W;B!T;R!T
M:&5I<B!E<W1I;6%T960@9F%I<B!V86QU97,N(#PO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI
M/E)E=F5N=64@4F5C;V=N:71I;VX@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL
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M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%S(&5N=&5R960@
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M;V=N:71I;VX@8W)I=&5R:6$@87)E(&UE="!F;W(@=&AA="!E;&5M96YT+B`\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
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M86EN:6YG('!E<F9O<FUA;F-E(&]B;&EG871I;VXN(#PO9F]N=#X\+W`^#0H\
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M9"X@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3`L('1H92!#;VUP86YY(')E8V]R9&5D("0Q+C<F(S$V,#MM:6QL:6]N('1O
M(&]T:&5R(&EN8V]M92!R96QA=&5D('1O($E24R!1=6%L:69Y:6YG(%1H97)A
M<&5U=&EC($1I<V-O=F5R>2!'<F%N=',@8F5C875S92!T:&4@9W)A;G0@87)R
M86YG96UE;G0@=V%S(&YO="!P87)T(&]F('1H92!#;VUP86YY)W,@;VXM9V]I
M;F<@;W!E<F%T:6]N<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4')O9'5C="!R;WEA
M;'1Y(')E=F5N=64@8V]N<VES=',@;V8@<&%Y;65N=',@<F5C96EV960@9G)O
M;2!L:6-E;G-E97,@9F]R(&$@<&]R=&EO;B!O9B!S86QE<R!P<F]C965D<R!F
M<F]M('!R;V1U8W1S('1H870@=71I;&EZ92!T:&4@0V]M<&%N>2=S(&QI8V5N
M<V5D('1E8VAN;VQO9VEE<R!A;F0@87)E(')E8V]G;FEZ960@=VAE;B!T:&4@
M86UO=6YT(&]F(&%N9"!B87-I<R!F;W(@<W5C:"!R;WEA;'1Y('!A>6UE;G1S
M(&%R92!R97!O<G1E9"!T;R!T:&4@0V]M<&%N>2!I;B!A8V-U<F%T92!A;F0@
M87!P<F]P<FEA=&4@9F]R;2!A;F0@:6X@86-C;W)D86YC92!W:71H('1H92!R
M96QA=&5D(&QI8V5N<V4@86=R965M96YT+B`\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y2
M97-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS97,@/"]I/CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0VQI;FEC86P@
M=')I86P@97AP96YS97,@:6YC;'5D92!E>'!E;G-E<R!A<W-O8VEA=&5D('=I
M=&@@8VQI;FEC86P@<F5S96%R8V@@;W)G86YI>F%T:6]N<R`H0U)/*2X@5&AE
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M8F5C;VUE(&MN;W=N+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y0871E;G0@0V]S=',@
M/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
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M8VLM0F%S960@0V]M<&5N<V%T:6]N(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y
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M('9E<W1I;F<@;W(@<&5R9F]R;6%N8V4N(#PO9F]N=#X\+W`^#0H\<"!S='EL
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M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4N(#PO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI
M/D9O<F5I9VX@0W5R<F5N8WD@5')A;G-L871I;VX@/"]I/CPO9F]N=#X\+W`^
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M="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$P+"!A8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M
M92!I;F-L=61E<R!A(&YE="!U;G)E86QI>F5D(&=A:6X@<F5L871E9"!T;R!F
M;W)E:6=N(&-U<G)E;F-Y('1R86YS;&%T:6]N(&]F("0R+C8F(S$V,#MM:6QL
M:6]N+B!);B`R,#$Q+"!T:&4@0V]M<&%N>2=S(&9O<F5I9VX@<W5B<VED:6%R
M>2!V;VQU;G1A<FEL>2!L:7%U:61A=&5D(&EN(&]R9&5R('1O(&-O;G-O;&ED
M871E('1H92!#;VUP86YY)W,@9F]R96EG;B!O<&5R871I;VYS(&EN=&\@0V5L
M;&1E>"!4:&5R87!E=71I8W,L)B,Q-C`[26YC+B`\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\
M:3Y);F-O;64@5&%X97,@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&
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M=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
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M;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
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M;W!T960@82!N97<@52Y3+B8C,38P.T=!05`@86-C;W5N=&EN9R!S=&%N9&%R
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M960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2X@5&AE
M<F4@=V5R92!N;R!S:6=N:69I8V%N="!R96-L87-S97,@=&\@:6YC;VUE(&1U
M<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@
M,C`Q,"!A;F0@,C`P.2X@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^3F5T($QO<W,@4&5R
M(%-H87)E(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M"87-I8R!N970@;&]S<R!P
M97(@8V]M;6]N('-H87)E(&ES(&)A<V5D('5P;VX@=&AE('=E:6=H=&5D+6%V
M97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@9'5R
M:6YG('1H92!P97)I;V0L(&5X8VQU9&EN9R!R97-T<FEC=&5D('-T;V-K('1H
M870@:&%S(&)E96X@:7-S=65D(&)U="!I<R!N;W0@>65T('9E<W1E9"X@1&EL
M=71E9"!N970@;&]S<R!P97(@8V]M;6]N('-H87)E(&ES(&)A<V5D('5P;VX@
M=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<@9'5R:6YG('1H92!P97)I;V0@<&QU<R!A9&1I=&EO;F%L
M('=E:6=H=&5D+6%V97)A9V4@<&]T96YT:6%L;'D@9&EL=71I=F4@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('!E<FEO9"!W:&5N('1H
M92!E9F9E8W0@:7,@9&EL=71I=F4N(%1H92!P;W1E;G1I86QL>2!D:6QU=&EV
M92!C;VUM;VX@<VAA<F5S('1H870@:&%V92!N;W0@8F5E;B!I;F-L=61E9"!I
M;B!T:&4@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92!C86QC=6QA=&EO;G,@
M8F5C875S92!T:&4@969F96-T('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T
M:79E(&%R92!A<R!F;VQL;W=S.B`\+V9O;G0^/"]P/@T*/&1I=B!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P<'0[(%!!1$1)3D<M3$5&5#H@,'!T.R!0041$
M24Y'+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,34E.R!724142#H@-S`E
M.R!0041$24Y'+51/4#H@,'!T.R!03U-)5$E/3CH@<F5L871I=F4G/@T*/'`@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\
M(2TM($-/34U!3D0]041$7U1!0DQ%5TE$5$@L(C$P,"4B("TM/CPO9F]N=#X\
M+W`^#0H\(2TM(%5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X-"CQD
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M=&0^/"$M+2!404),12!#3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R
M('9A;&EG;CTS1&)O='1O;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G(&%L:6=N/3-$;&5F=#X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/&)R("\^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0X/CQF
M;VYT('-I>F4],T0Q/CQB/EEE87(@16YD960@1&5C96UB97(F(S$V,#LS,2P@
M/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^/"]T<CX-
M"CQT<B!V86QI9VX],T1B;W1T;VT^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!A;&EG;CTS1&QE9G0^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT
M:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@
M1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\9F]N="!S:7IE/3-$,3X\8CXR,#$Q(#PO8CX\+V9O;G0^/"]T:#X-"CQT
M:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/C(P
M,3`@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(^/&9O;G0@<VEZ93TS1#$^/&(^,C`P.2`\+V(^/"]F;VYT/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^4W1O8VL@;W!T:6]N<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C0L-#4Y+#`S-#PO9F]N=#X\
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$
M,CXS-3,L-38S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXS
M-3,L-38S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS
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M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S:7IE/3-$,CXV+#`P,#PO9F]N=#X\+W1D/@T*/'1D
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M;VYT('-I>F4],T0R/C$V+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
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M('-I>F4],T0R/C0L-#8U+#`S-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M:7IE/3-$,CXS+#DT-2PW,C(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E8VEF:65D
M(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^4F5C96YT($%C8V]U;G1I
M;F<@4')O;F]U;F-E;65N=',@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
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M<R!O9B!O<&5R871I;VYS('5P;VX@861O<'1I;VXN(#PO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.TEN(%-E<'1E;6)E<B`R,#$Q+"!T:&4@1D%30B!A;65N9&5D('1H92!G
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M(S$V,#LS,"P@,C`Q,BX@5&AE($-O;7!A;GD@9&]E<R!N;W0@97AP96-T('1H
M92!A9&]P=&EO;B!O9B!T:&ES(&YE=R!S=&%N9&%R9"!T;R!H879E(&$@;6%T
M97)I86P@969F96-T(&]N(&ET<R!O<&5R871I;F<@<F5S=6QT<R!O<B!F:6YA
M;F-I86P@<&]S:71I;VXN(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN($UA>2`R,#$Q
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M<V5R=F%B;&4@*$QE=F5L)B,Q-C`[,RD@:6YP=71S+B!4:&ES(&YE=R!S=&%N
M9&%R9"!I<R!E9F9E8W1I=F4@;VX@82!P<F]S<&5C=&EV92!B87-I<R!F;W(@
M86YN=6%L(&%N9"!I;G1E<FEM(')E<&]R=&EN9R!P97)I;V1S(&)E9VEN;FEN
M9R!O;B!O<B!A9G1E<B!$96-E;6)E<B8C,38P.S$U+"`R,#$Q+B!4:&4@861O
M<'1I;VX@;V8@=&AI<R!S=&%N9&%R9"!I<R!N;W0@97AP96-T960@=&\@:&%V
M92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N>2=S(&]P97)A=&EN
M9R!R97-U;'1S(&]R(&9I;F%N8VEA;"!P;W-I=&EO;BX@/"]F;VYT/CPO<#X\
M+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F
M,&-F,&,S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W
M7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,R]7;W)K<VAE971S+U-H965T
M,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"
M55-)3D534R!#3TU"24Y!5$E/3E,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0E5324Y%4U,@0T]-0DE.051)3TY3
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)5
M4TE.15-3($-/34))3D%424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*
M/'1D/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CX\8CXH,RD@0E5324Y%4U,@0T]-0DE.051)3TY3(#PO8CX\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CX\:3Y!8W%U:7-I=&EO;B!O9B!#=7)A1V5N($-O<G!O<F%T
M:6]N("A#=7)A1V5N*2`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[3VX@3V-T;V)E
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M:7-I=&EO;BP@969F96-T:79E($]C=&]B97(F(S$V,#LQ+"`R,#`Y+"!T:&4@
M0V]M<&%N>2`H:2DF(S$V,#MI<W-U960@,34L-S(R+#<Q,R!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&]F('1H92!#;VUP86YY+"!O<B`P+C(W,SD@<VAA<F5S
M+"!I;B!E>&-H86YG92!F;W(@96%C:"!S:&%R92!O9B!O=71S=&%N9&EN9R!#
M=7)A1V5N(&-O;6UO;B!S=&]C:RP@<&QU<R!C87-H(&EN(&QI974@;V8@9G)A
M8W1I;VYA;"!S:&%R97,@*'1H92`B0W5R84=E;B!%>&-H86YG92!2871I;R(I
M+"`H:6DI)B,Q-C`[87-S=6UE9"!T:&4@;V)L:6=A=&EO;G,@=6YD97(@0W5R
M84=E;B=S(#(P,#<@4W1O8VL@4&QA;B`H=&AE(")#=7)A1V5N(#(P,#<@4&QA
M;B(I(&%N9"!E86-H(&]U='-T86YD:6YG(&]P=&EO;B!T;R!P=7)C:&%S92!C
M;VUM;VX@<W1O8VL@*&$@(D-U<F%'96X@4W1O8VL@3W!T:6]N(BD@9W)A;G1E
M9"!U;F1E<B!T:&4@0W5R84=E;B`R,#`W(%!L86X@86YD("AI:6DI)B,Q-C`[
M87-S=6UE9"!T:&4@)#$R+C4F(S$V,#MM:6QL:6]N(&EN(#0E(&-O;G9E<G1I
M8FQE('-U8F]R9&EN871E9"!D96)T(&1U92!&96)R=6%R>28C,38P.S$U+"`R
M,#$Q("AT:&4@(D-U<F%'96X@1&5B="(I+B`\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4
M:&4@=')A;G-A8W1I;VX@=V%S(&%C8V]U;G1E9"!F;W(@=6YD97(@=&AE(&%C
M<75I<VET:6]N(&UE=&AO9"!O9B!A8V-O=6YT:6YG+B!4:&4@86-Q=6ES:71I
M;VXM9&%T92!F86ER('9A;'5E(&]F('1H92!C;VYS:61E<F%T:6]N('1R86YS
M9F5R<F5D(&-O;G-I<W1E9"!O9B!T:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M
M<&%N>2=S(&-O;6UO;B!S=&]C:R!I<W-U960@;V8@)#@U+C0F(S$V,#MM:6QL
M:6]N(&%N9"!F86ER('9A;'5E(&]F($-U<F%'96X@4W1O8VL@3W!T:6]N<R!T
M:&%T('=E<F4@871T<FEB=71E9"!T;R!P<F5C;VUB:6YA=&EO;B!S97)V:6-E
M(&]F("0R+CDF(S$V,#MM:6QL:6]N+B!/9B!T:&4@0W5R84=E;B!3=&]C:R!/
M<'1I;VYS(&%S<W5M960L(&%L;"!B=70@,24L('=E<F4@:6UM961I871E;'D@
M=F5S=&5D('5P;VX@8VQO<VEN9R!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('1E
M<FUS(&]F('1H92!S=&]C:R!O<'1I;VX@86=R965M96YT<R!A;F0@96UP;&]Y
M;65N="!A9W)E96UE;G1S+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].
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M('1H;W5S86YD<RDZ(#PO9F]N=#X\+W`^#0H\9&EV('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,1494.B`P<'0[(%!!1$1)3D<M0D]4
M5$]-.B`P<'0[($U!4D=)3BU,1494.B`Q-24[(%=)1%1(.B`W,"4[(%!!1$1)
M3D<M5$]0.B`P<'0[(%!/4TE424]..B!R96QA=&EV92<^#0H\<"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CPA+2T@0T]-
M34%.1#U!1$1?5$%"3$5724142"PB,3`P)2(@+2T^/"]F;VYT/CPO<#X-"CPA
M+2T@57-E<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%("TM/@T*/&1I=B!A;&EG
M;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*/'1R/CPA+2T@5$%"
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M5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^36%R:V5T86)L92!S96-U<FET:65S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<VEZ93TS1#(^,3@L-C,X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CY)9&5N=&EF:6%B;&4@:6YT86YG:6)L92!A<W-E=',Z/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1'=H
M:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^#0H\<"!S
M='EL93TS1"=-05)'24XM3$5&5#H@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T
M.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/DE04B9A;7`[
M1#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C$Q+#@P,#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^06UG96X@06UE;F1M96YT/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,30L-3`P/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!4
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M-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.
M1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^3W1H97(@8W5R<F5N="!A;F0@;&]N9RUT97)M(&%S<V5T<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C<U-CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,3!P=#L@5$58
M5"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/D=O;V1W:6QL/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ
M93TS1#(^."PY-C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T-%149&
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^#0H\<"!S='EL
M93TS1"=-05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/D-U<F%'96X@1&5B
M=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B@Q,2PU,#,\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
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M<R<@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH-2PQ.3`\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
M('-I>F4],T0R/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CY/=&AE<B!A<W-U;65D(&QI86)I;&ET:65S/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
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M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
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M86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T
M(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/@T*/"$M+2!E;F0@;V8@=7-E
M<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%("TM/CPO9&EV/@T*/'`@<W1Y;&4]
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M)#$N-"8C,38P.VUI;&QI;VX@:6X@,C`Q,B!O;B!T:&4@4&AA<V4F(S$V,#LR
M8B!S='5D>2X@17-T:6UA=&5D(')E=F5N=65S(&9R;VT@0T18+3`Q,2!A<F4@
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M;W0@9&5D=6-T:6)L92!F;W(@=&%X('!U<G!O<V5S+B`\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#M);B!C;VYN96-T:6]N('=I=&@@=&AE($-U<F%'96X@86-Q=6ES:71I
M;VXL(&5F9F5C=&EV92!/8W1O8F5R)B,Q-C`[,2P@,C`P.2P@=&AE($-O;7!A
M;GDL($-U<F%'96XL(&%N9"!4:&4@0F%N:R!O9B!.97<@66]R:R!-96QL;VX@
M*'1H92`B5')U<W1E92(I(&%M96YD960@=&AE($-U<F%'96X@1&5B="!T;R!P
M<F]V:61E('1H870@=&AE($-U<F%'96X@1&5B="!S:&%L;"!B92!C;VYV97)T
M:6)L92!I;G1O(#,U,RPU-C,@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@8V]M
M;6]N('-T;V-K(&%T('1H92!R871E(&]F(#(X+C(W.#(S('-H87)E<R!O9B!T
M:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C:R!P97(@)#$L,#`P('!R:6YC:7!A
M;"!A;6]U;G0@;V8@;F]T97,L(&]R("0S-2XS-B!P97(@<VAA<F4N(%1H92!I
M;FET:6%L(&-A<G)Y:6YG('9A;'5E(&]F('1H92!#=7)A1V5N($1E8G0@=V%S
M(&%C8W)E=&5D(')A=&%B;'DL(&]V97(@=&AE('1E<FT@;V8@=&AE($-U<F%'
M96X@1&5B="P@=&\@)#$R+C4F(S$V,#MM:6QL:6]N(&1U92!A="!M871U<FET
M>2X@26YT97)E<W0@97AP96YS92!O;B!T:&4@0W5R84=E;B!$96)T('=A<R`D
M,"XR)B,Q-C`[;6EL;&EO;BP@)#$N,B8C,38P.VUI;&QI;VX@86YD("0P+C,F
M(S$V,#MM:6QL:6]N(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2!A;F0@:6YC;'5D960@)#`N,28C
M,38P.VUI;&QI;VXL("0P+C<F(S$V,#MM:6QL:6]N(&%N9"`D,"XR)B,Q-C`[
M;6EL;&EO;B!I;B!D:7-C;W5N="!A8V-R971I;VXL(')E<W!E8W1I=F5L>2X@
M26X@1F5B<G5A<GD@,C`Q,2P@=&AE($-O;7!A;GD@<&%I9"!T:&4@5')U<W1E
M92`D,3(N."8C,38P.VUI;&QI;VX@=&\@<V%T:7-F>2!A;&P@;W5T<W1A;F1I
M;F<@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T(')E;&%T960@=&\@
M=&AE($-U<F%'96X@1&5B="X@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0W5R84=E;B!E
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M:6]N(&%N9"`D,"XY)B,Q-C`[;6EL;&EO;B!I;B!#=7)A1V5N('-E=F5R86YC
M92!E>'!E;G-E<R!T;R!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!A;F0@
M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT+"!R97-P96-T:79E;'DL(&EN('1H
M92!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&9O<B!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#`Y+B!);B!A9&1I
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M,#LS,2P@,C`P.2X@/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#4R-&9F
M.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F,&-F,&,S#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W
M9C!C9C!C,R]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y4
M4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y44SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&04E2(%9!3%5%($U%05-54D5-
M14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\8CXH-"D@
M1D%)4B!604Q512!-14%355)%345.5%,@/"]B/CPO9F]N=#X\+W`^#0H\<"!S
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M3U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/"$M+2!#3TU-04Y$
M/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O;G0^/"]P/@T*/"$M+2!5
M<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\='(^/"$M+2!404),12!#
M3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
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M5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;3X-"CQT:"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-"CQT:"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D%S(&]F/&)R
M("\^#0I$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(#PO8CX\+V9O;G0^/"]T:#X-
M"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB
M/DQE=F5L)B,Q-C`[,2`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY,979E;"8C,38P.S(@
M/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/
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M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,3$^
M/&9O;G0@<VEZ93TS1#$^/&(^*$EN('1H;W5S86YD<RD\+V(^/"]F;VYT/CQB
M<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A
M;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^36]N97D@;6%R:V5T
M(&9U;F1S(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3$L,#,X/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M=&%B;&4@<V5C=7)I=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A
M;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@
M9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^#0H\(2TM(&5N9"!O9B!U<V5R+7-P96-I9FEE9"!404='140@5$%"
M3$4@+2T^/"]D:78^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/B8C,38P.SQB<B`O/CPO9F]N=#X\+W`^#0H\9&EV
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,1494.B`P
M<'0[(%!!1$1)3D<M0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`Q,"4[(%=)
M1%1(.B`X,"4[(%!!1$1)3D<M5$]0.B`P<'0[(%!/4TE424]..B!R96QA=&EV
M92<^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/CPA+2T@0T]-34%.1#U!1$1?5$%"3$5724142"PB,3`P)2(@+2T^
M/"]F;VYT/CPO<#X-"CPA+2T@57-E<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%
M("TM/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P
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M+2!404),12!#3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG
M;CTS1&)O='1O;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R
M("\^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,
M63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I
M>F4],T0Q/CQB/D%S(&]F/&)R("\^#0I$96-E;6)E<B8C,38P.S,Q+"`R,#$P
M(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&
M3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQF;VYT('-I>F4],T0Q/CQB/DQE=F5L)B,Q-C`[,2`\+V(^/"]F;VYT/CPO
M=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I
M;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$
M,3X\8CY,979E;"8C,38P.S(@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C
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M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^
M#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,3$^/&9O;G0@<VEZ93TS1#$^/&(^*$EN('1H;W5S
M86YD<RD\+V(^/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&
M1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
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M1#(^,3`L.3<U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M;VYT('-I>F4],T0R/DUA<FME=&%B;&4@<V5C=7)I=&EE<SPO9F]N=#X\+W`^
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M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L
M:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@
M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS
M1#(^-3`L-S@V/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U
M8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\(2TM(&5N9"!O9B!U<V5R+7-P
M96-I9FEE9"!404='140@5$%"3$4@+2T^/"]D:78^#0H\<"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H97)E(&AA
M=F4@8F5E;B!N;R!T<F%N<V9E<G,@;V8@87-S971S(&]R(&QI86)I;&ET:65S
M(&)E='=E96X@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE;G0@8VQA<W-I9FEC
M871I;VYS+B!4:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!C
M;VYS:7-T(&UA:6YL>2!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!M
M87)K971A8FQE('-E8W5R:71I97,L('-H;W)T+71E<FT@86-C;W5N=',@<F5C
M96EV86)L92P@86-C;W5N=',@<&%Y86)L92!A;F0@9&5B="!O8FQI9V%T:6]N
M<RX@5&AE($-O;7!A;GD@=F%L=65S(&ET<R!M87)K971A8FQE('-E8W5R:71I
M97,@=71I;&EZ:6YG(&EN9&5P96YD96YT('!R:6-I;F<@<V5R=FEC97,@=VAI
M8V@@;F]R;6%L;'D@9')I=F4@<V5C=7)I='D@<')I8V5S(&9R;VT@<F5C96YT
M;'D@<F5P;W)T960@=')A9&5S(&9O<B!I9&5N=&EC86P@;W(@<VEM:6QA<B!S
M96-U<FET:65S+"!M86MI;F<@861J=7-T;65N=',@8F%S960@;VX@<VEG;FEF
M:6-A;G0@;V)S97)V86)L92!T<F%N<V%C=&EO;G,N($%T(&5A8V@@8F%L86YC
M92!S:&5E="!D871E+"!O8G-E<G9A8FQE(&UA<FME="!I;G!U=',@;6%Y(&EN
M8VQU9&4@=')A9&4@:6YF;W)M871I;VXL(&)R;VME<B!O<B!D96%L97(@<75O
M=&5S+"!B:61S+"!O9F9E<G,@;W(@82!C;VUB:6YA=&EO;B!O9B!T:&5S92!D
M871A('-O=7)C97,N(%-H;W)T+71E<FT@86-C;W5N=',@<F5C96EV86)L92!A
M;F0@86-C;W5N=',@<&%Y86)L92!A<F4@<F5F;&5C=&5D(&EN('1H92!A8V-O
M;7!A;GEI;F<@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%T
M(&-O<W0L('=H:6-H(&%P<')O>&EM871E<R!F86ER('9A;'5E(&1U92!T;R!T
M:&4@<VAO<G0M=&5R;2!N871U<F4@;V8@=&AE<V4@:6YS=')U;65N=',N($)A
M<V5D(&]N(&-U<G)E;G0@;6%R:V5T(&EN=&5R97-T(')A=&5S(&%V86EL86)L
M92!T;R!T:&4@0V]M<&%N>2!F;W(@;&]N9RUT97)M(&QI86)I;&ET:65S('=I
M=&@@<VEM:6QA<B!T97)M<R!A;F0@;6%T=7)I=&EE<RP@=&AE($-O;7!A;GD@
M8F5L:65V97,@=&AE(&9A:7(@=F%L=64@87!P<F]X:6UA=&5S('1H92!C87)R
M>6EN9R!V86QU92!O9B!T:&4@<')I;F-I<&%L('!O<G1I;VX@;V8@=&AE(%1E
M<FT@3&]A;B!A;F0@;F]T92!P87EA8FQE(&%T($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3$N(#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^34%22T5404),12!314-54DE42453/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DU!
M4DM%5$%"3$4@4T5#55))5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-05)+151!0DQ%(%-%0U52251)15,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM
M97,L<V5R:68[)SX-"CQT<CX-"CQT9#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&(^*#4I($U!4DM%5$%"3$4@
M4T5#55))5$E%4R`\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[02!S=6UM87)Y(&]F
M(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!I<R!S:&]W;B!B96QO=SH@/"]F;VYT
M/CPO<#X-"CQD:78@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$
M24Y'+4Q%1E0Z(#!P=#L@4$%$1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%
M1E0Z(#$P)3L@5TE$5$@Z(#@P)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)
M3TXZ(')E;&%T:79E)SX-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(
M+"(Q,#`E(B`M+3X\+V9O;G0^/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!4
M04='140@5$%"3$4@+2T^#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M(&)O<F1E<CTS1#`^#0H\='(^/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%
M5"`M+3X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N
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M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(^/&9O;G0@<VEZ93TS1#$^/&(^06UO<G1I>F5D/&)R("\^#0I#;W-T(#PO
M8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF
M;VYT('-I>F4],T0Q/CQB/D=R;W-S/&)R("\^#0I5;G)E86QI>F5D/&)R("\^
M#0I'86EN<R`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY'<F]S<SQB<B`O/@T*56YR96%L
M:7IE9#QB<B`O/@T*3&]S<V5S(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,3$^/&9O;G0@<VEZ93TS1#$^/&(^*$EN
M('1H;W5S86YD<RD\+V(^/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$
M(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T
M.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^/&(^1&5C96UB97(F(S$V,#LS,2P@,C`Q,3PO8CX\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,CY-87)K971A8FQE('-E8W5R:71I97,\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`T,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^36%T=7)I;F<@:6X@;VYE('EE87(@;W(@;&5S<SPO9F]N=#X\+W`^
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M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,C`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B8C
M.#(Q,CL\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4]
M,T0R/C(P+#`Q,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T-%149&/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#0P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
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M<VEZ93TS1#(^,3`L.#`X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG
M;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S,'!T
M.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^5&]T86P@52Y3+B!G;W9E<FYM96YT(&%N9"!M=6YI8VEP
M86P@;V)L:6=A=&EO;G,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,S`L.3,W/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^
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M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#0P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CY-871U<FEN9R!I;B!O;F4@>65A<B!O<B!L97-S/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^-2PX
M,3<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/C0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/C4L.#$V/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C
M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#,P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,CY4;W1A;"!C;W)P;W)A=&4@9&5B="!S96-U<FET:65S/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3`L-30W
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXW
M-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^
M,3`L-#<V/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N
M-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'
M24XM3$5&5#H@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0R/E1O=&%L(&UA<FME=&%B;&4@<V5C
M=7)I=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U
M8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N
M,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F
M('5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/&)R("\^/"]F;VYT/CPO<#X-"CQD:78@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,'!T.R!0041$24Y'+4Q%1E0Z(#!P=#L@4$%$1$E.1RU"3U143TTZ
M(#!P=#L@34%21TE.+4Q%1E0Z(#$P)3L@5TE$5$@Z(#@P)3L@4$%$1$E.1RU4
M3U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/"$M+2!#3TU-04Y$
M/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O;G0^/"]P/@T*/"$M+2!5
M<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\='(^/"$M+2!404),12!#
M3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
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M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^06UO<G1I>F5D
M/&)R("\^#0I#;W-T(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D=R;W-S/&)R("\^#0I5
M;G)E86QI>F5D/&)R("\^#0I'86EN<R`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY'<F]S
M<SQB<B`O/@T*56YR96%L:7IE9#QB<B`O/@T*3&]S<V5S(#PO8CX\+V9O;G0^
M/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@
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M1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,3$^/&9O;G0@
M<VEZ93TS1#$^/&(^*$EN('1H;W5S86YD<RD\+V(^/"]F;VYT/CQB<B`O/CPO
M=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&(^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,#PO8CX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY-87)K971A
M8FQE('-E8W5R:71I97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,S!P=#L@5$585"U)3D1%3E0Z
M("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/E4N
M4RX@9V]V97)N;65N="!A;F0@;75N:6-I<&%L(&]B;&EG871I;VYS/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`T,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^36%T=7)I;F<@:6X@;VYE('EE87(@;W(@
M;&5S<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
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M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#0P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
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M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`S,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&]T86P@52Y3+B!G
M;W9E<FYM96YT(&%N9"!M=6YI8VEP86P@;V)L:6=A=&EO;G,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M93TS1#(^,C8L-#`R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#0P<'0[(%1%6%0M24Y$14Y4.B`M,3!P
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M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@
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M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M/3-$)V9O;G0M<VEZ93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R
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M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R
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M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
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M:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C
M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
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M97(F(S$V,#LS,2P@,C`Q,2X@/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L
M93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F,&-F,&,S#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F
M7S,Q.6,W9C!C9C!C,R]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY04D]015)462!!3D0@15%5
M25!-14Y4+"!.150\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4%)/4$525%D@04Y$($5154E0345.5"P@3D54/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!23U!%
M4E19($%.1"!%455)4$U%3E0L($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R
M/@T*/'1D/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CX\8CXH-BD@4%)/4$525%D@04Y$($5154E0345.5"P@3D54
M(#PO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M(#<P)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O
M;G0^/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\
M='(^/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL
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M($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;3X-"CQT:"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-"CQT:"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&
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M;W5S86YD<RD\+V(^/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#
M145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^3&%B;W)A=&]R>2!%<75I<&UE;G0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXR+#8S,#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,BPY-#(\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$=VAI=&4^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%
M3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R
M/DUA;G5F86-T=7)I;F<@17%U:7!M96YT/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<VEZ93TS1#(^,2PY.3D\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-I>F4],T0R/C$L-#$X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'
M24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0R/D]F9FEC92!&=7)N:71U<F4@86YD
M($5Q=6EP;65N=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^3&5A<V5H;VQD($EM<')O=F5M96YT<SPO9F]N=#X\+W`^/"]T
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL
M93TS1"=-05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/D-O;G-T<G5C=&EO
M;B!I;B!0<F]G<F5S<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&
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M-S`S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T
M.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T
M.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^5&]T86P@4')O<&5R='D@86YD($5Q=6EP;65N=#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
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M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3DL-C`V/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@
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M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH,3`L,S<P
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M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R
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M='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS
M1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P
M="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S
M97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[1&5P
M<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@97AP96YS92!R96QA=&5D('1O
M('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@=V%S("0R+C(F(S$V,#MM:6QL:6]N
M+"`D,BXW)B,Q-C`[;6EL;&EO;B!A;F0@)#(N-B8C,38P.VUI;&QI;VX@9F]R
M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"`R,#$P
M(&%N9"`R,#`Y+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D-3(T9F8X-U]B-F1D7S1B
M83)?.38W9E\S,3EC-V8P8V8P8S,O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y404Y'24),
M12!!4U-%5%,@04Y$($=/3T1724Q,/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DE.5$%.1TE"3$4@05-31513($%.
M1"!'3T]$5TE,3#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)3E1!3D=)0DQ%($%34T544R!!3D0@1T]/1%=)3$P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM
M97,L<V5R:68[)SX-"CQT<CX-"CQT9#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&(^*#<I($E.5$%.1TE"3$4@
M05-31513($%.1"!'3T]$5TE,3"`\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26YT
M86YG:6)L92!A<W-E=',L(&YE="!O9B!A8V-U;75L871E9"!A;6]R=&EZ871I
M;VXL(&%N9"!G;V]D=VEL;"!A<F4@87,@9F]L;&]W<SH@/"]F;VYT/CPO<#X-
M"CQD:78@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'+4Q%
M1E0Z(#!P=#L@4$%$1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#$P
M)3L@5TE$5$@Z(#8S+C0T)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ
M(')E;&%T:79E.R!(14E'2%0Z(#,W,7!X)SX-"CQP('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/"$M+2!#3TU-04Y$/4%$
M1%]404),15=)1%1(+"(Q-3`E(B`M+3X\+V9O;G0^/"]P/@T*/"$M+2!5<V5R
M+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q-3`E(&)O<F1E<CTS1#`^#0H\='(^/"$M+2!404),12!#3TQ5
M34X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
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M/3-$-3`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('=I9'1H/3-$,3(^/"]T9#X\(2TM(%1!0DQ%($-/3%5-3B!724142%,@14Y$
M("TM/CPO='(^#0H\='(@=F%L:6=N/3-$8F]T=&]M/@T*/'1H('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1L969T/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\8G(@+SX\+W1H/@T*/'1H('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#$P/CQF;VYT('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#@^/&9O;G0@<VEZ93TS1#$^/&(^1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
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M/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-I>F4],T0Q/CQB/D5S=&EM871E9#QB<B`O/@T*3&EF92`\+V(^/"]F;VYT
M/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ
M('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE
M/3-$,3X\8CY#;W-T(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D%C8W5M=6QA=&5D/&)R
M("\^#0I!;6]R=&EZ871I;VX@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^3F5T(#PO8CX\
M+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!
M34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT
M('-I>F4],T0Q/CQB/D-O<W0@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^06-C=6UU;&%T
M960\8G(@+SX-"D%M;W)T:7IA=&EO;B`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY.970@
M/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^/"]T<CX-
M"CQT<B!V86QI9VX],T1B;W1T;VT^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!A;&EG;CTS1&QE9G0^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M1#$^)B,Q-C`[/"]F;VYT/CPO=&@^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XM
M3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0R/DEN=&%N9VEB;&4@07-S971S.CPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/DE04B9A;7`[1#PO9F]N=#X\+W`^/"]T9#X-
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S:7IE/3-$,CXQ,2PX,#`\+V9O;G0^/"]T9#X-"CQT
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M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3$L.#`P
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXF
M(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE
M/3-$,CXQ,2PX,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O
M;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^06UG96X@06UE;F1M96YT/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0R/C$V)B,Q-C`[>65A<G,\+V9O;G0^/"]T9#X-
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE
M/3-$,CXQ-"PU,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/B@Q+#$R,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/BD\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C$S+#,W.3PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T1W:&ET93X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.
M1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^5&]P;U1A<F=E="!!9W)E96UE;G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M<FEG:'0^/&9O;G0@<VEZ93TS1#(^,BPT,#`\+V9O;G0^/"]T9#X-"CQT9"!S
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M,T0R/C(L-#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.
M5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M0V]R92!496-H;F]L;V=Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R
M/C0N-28C,38P.R8C.#(Q,3LF(S$V,#LQ,28C,38P.WEE87)S/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXQ+#DT.#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<VEZ93TS1#(^*#$L,S`W/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<VEZ93TS1#(^-C0Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^.3`X/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY3
M=')A=&5G:6,@4&%R=&YE<B!!9W)E96UE;G0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^-#`V/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N
M/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H
M:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CY';V]D=VEL;#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S:7IE/3-$,CXX+#DV-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ
M93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<VEZ93TS1#(^."PY-C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-I>F4],T0R/C@L.38U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M,T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@
M9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD
M(&]F('5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[5&AE(&5S=&EM871E9"!F86ER('9A;'5E(&%T=')I8G5T960@=&\@=&AE
M($%P<FEL(#(P,#@@86=R965M96YT("A4;W!O5&%R9V5T($%G<F5E;65N="D@
M8F5T=V5E;B!T:&4@0V]M<&%N>2`H87,@82!S=6-C97-S;W(@=&\@0W5R84=E
M;BD@86YD(%1O<&]487)G970@02]3("A4;W!O5&%R9V5T*2!R96QA=&5S('1O
M('1H92!#;VUP86YY)W,@<FEG:'1S('5N9&5R('1H92!4;W!O5&%R9V5T($%G
M<F5E;65N="!T;R!R96-E:79E('5P('1O("0V)B,Q-C`[;6EL;&EO;B!I;B!E
M:71H97(@<&]T96YT:6%L(&-O;6UE<F-I86P@;6EL97-T;VYE('!A>6UE;G1S
M(')E;&%T960@=&\@9G5T=7)E(&YE="!S86QE<R!O9B!"96QI;F]S=&%T(&]R
M(#$P)2!O9B!A;GD@<W5B;&EC96YS92!I;F-O;64@<F5C96EV960@8GD@5&]P
M;U1A<F=E="`H5&]P;U1A<F=E="!087EM96YT<RDN($EN($9E8G)U87)Y(#(P
M,3`L(%1O<&]487)G970@96YT97)E9"!I;G1O(&$@8V\M9&5V96QO<&UE;G0@
M86YD(&-O;6UE<F-I86QI>F%T:6]N(&%G<F5E;65N="!F;W(@0F5L:6YO<W1A
M="!W:71H(%-P96-T<G5M(%!H87)M86-E=71I8V%L<RPF(S$V,#M);F,N('=H
M:6-H(')E<W5L=&5D(&EN('1H92!#;VUP86YY)W,@<F5C96EP="!O9B`D,RXP
M)B,Q-C`[;6EL;&EO;B!O9B!T:&4@5&]P;U1A<F=E="!087EM96YT<RX@5&AE
M($-O;7!A;GD@<F5C;W)D960@=&AI<R!C87-H(')E8V5I<'0@87,@3W1H97(@
M26YC;VUE(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$P+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$=7)I;F<@=&AE('EE87(@96YD960@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@=&AE($-O;7!A;GD@<F5C;W)D960@
M86X@:6UP86ER;65N="!L;W-S(&]F("0P+C,F(S$V,#MM:6QL:6]N(&EN(%-T
M<F%T96=I8R!087)T;F5R<VAI<"!!9W)E96UE;G0@=&\@86UO<G1I>F%T:6]N
M(&]F(&EN=&%N9VEB;&4@87-S970@97AP96YS92!D=64@=&\@=&AE($-O;7!A
M;GDG<R!T97)M:6YA=&EO;B!O9B!R:6=H=',@=&\@:6YT96QL96-T=6%L('!R
M;W!E<G1Y('5N9&5R;'EI;F<@=&AA="!3=')A=&5G:6,@4&%R=&YE<G-H:7`@
M06=R965M96YT+B!$=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,"P@=&AE($-O;7!A;GD@=W)O=&4M;V9F("0P+C(F(S$V,#MM
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M;B!U<&9R;VYT(&9E92!O9B`D,"XX)B,Q-C`[;6EL;&EO;B!A;F0@86=R965D
M('1O('!A>2!P;W1E;G1I86P@;6EL97-T;VYE('!A>6UE;G1S+B!$=7)I;F<@
M=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`P.2P@=&AE($-O
M;7!A;GD@<F5C;W)D960@82!G86EN(&]F("0P+C8F(S$V,#MM:6QL:6]N(')E
M;&%T960@=&\@=&AE($Q!2$D@06=R965M96YT(&)A<V5D(&]N('1H92!U<&9R
M;VYT(&9E92!L97-S('1H92!N970@8F]O:R!V86QU92!O9B!T:&4@<F5L871E
M9"!A<W-E="X@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[06UO<G1I>F%T:6]N(&5X<&5N
M<V4@9F]R(&EN=&%N9VEB;&4@87-S971S('=A<R`D,2XY)B,Q-C`[;6EL;&EO
M;BP@)#,N,28C,38P.VUI;&QI;VX@86YD("0P+CDF(S$V,#MM:6QL:6]N(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@,C`Q
M,"!A;F0@,C`P.2P@<F5S<&5C=&EV96QY+B!4:&4@97-T:6UA=&5D(&9U='5R
M92!A;6]R=&EZ871I;VX@97AP96YS92!O9B!I;G1A;F=I8FQE(&%S<V5T<R!A
M<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!F;W(@=&AE(&YE>'0@9FEV
M92!Y96%R<R!I<R!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^
M/"]P/@T*/&1I=B!S='EL93TS1"=0041$24Y'+5))1TA4.B`P<'0[(%!!1$1)
M3D<M3$5&5#H@,'!T.R!0041$24Y'+4)/5%1/33H@,'!T.R!-05)'24XM3$5&
M5#H@,34E.R!724142#H@-S`E.R!0041$24Y'+51/4#H@,'!T.R!03U-)5$E/
M3CH@<F5L871I=F4G/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CX\(2TM($-/34U!3D0]041$7U1!0DQ%5TE$5$@L
M(C$P,"4B("TM/CPO9F]N=#X\+W`^#0H\(2TM(%5S97(M<W!E8VEF:65D(%1!
M1T=%1"!404),12`M+3X-"CQD:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@
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M3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^,C`Q,CPO9F]N=#X\+W`^/"]T9#X-
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M3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4]
M,T0R/C$L,#$T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXR,#$T/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CXR,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS
M1#(^,2PP,30\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T-%149&/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^#0H\<"!S='EL93TS
M1"=-05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/C(P,38\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXY.30\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@
M96YD(&]F('5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX\
M+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F
M,&-F,&,S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W
M7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,R]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!
M0T-2545$($584$5.4T53/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%#0U)5140@15A014Y315,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^04-#4E5%1"!%6%!%
M3E-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\8CXH."D@
M04-#4E5%1"!%6%!%3E-%4R`\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[06-C<G5E
M9"!E>'!E;G-E<R!I;F-L=61E('1H92!F;VQL;W=I;F<Z(#PO9F]N=#X\+W`^
M#0H\9&EV('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,
M1494.B`P<'0[(%!!1$1)3D<M0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`Q
M-24[(%=)1%1(.B`W,"4[(%!!1$1)3D<M5$]0.B`P<'0[(%!/4TE424]..B!R
M96QA=&EV92<^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0R/CPA+2T@0T]-34%.1#U!1$1?5$%"3$5724142"PB,3`P
M)2(@+2T^/"]F;VYT/CPO<#X-"CPA+2T@57-E<BUS<&5C:69I960@5$%'1T5$
M(%1!0DQ%("TM/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D
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M9G0^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CQB<B`O/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY$
M96-E;6)E<B8C,38P.S,Q+#QB<B`O/@T*,C`Q,2`\+V(^/"]F;VYT/CPO=&@^
M#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S
M)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\
M8CY$96-E;6)E<B8C,38P.S,Q+#QB<B`O/@T*,C`Q,"`\+V(^/"]F;VYT/CPO
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M<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A
M;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^06-C<G5E9"!2;WEA
M;'1Y(&%N9"!,:6-E;G-E($9E97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y
M;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-
M05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/D%C8W)U960@4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($-O;G1R86-T($-O<W1S/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,RPP,S4\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-I>F4],T0R/C$L,C$X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&
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M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^3W1H97(@06-C<G5E9"!%>'!E;G-E<SPO9F]N=#X\+W`^/"]T9#X-
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!
M4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S:7IE/3-$,CXW+#`P.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M/3-$)V9O;G0M<VEZ93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R
M/CPO=&%B;&4^/"]D:78^#0H\(2TM(&5N9"!O9B!U<V5R+7-P96-I9FEE9"!4
M04='140@5$%"3$4@+2T^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^3U1(15(@3$].1RU415)-($Q)04))3$E4
M2453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]42$52($Q/3D<M5$5232!,24%"24Q)5$E%4SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/5$A%4B!,3TY'+51%
M4DT@3$E!0DE,251)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-"CQT9#X-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^/&(^*#DI($]42$52($Q/3D<M5$5232!,24%"24Q)5$E%4R`\+V(^/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[3W1H97(@;&]N9RUT97)M(&QI86)I;&ET:65S(&EN
M8VQU9&4@=&AE(&9O;&QO=VEN9SH@/"]F;VYT/CPO<#X-"CQD:78@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'+4Q%1E0Z(#!P=#L@4$%$
M1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#$U)3L@5TE$5$@Z(#<P
M)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O;G0^
M/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^#0H\
M9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\='(^
M/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL93TS
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M1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;3X-"CQT:"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-"CQT:"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
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M86YD<RD\+V(^/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&
M1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^1&5F97)R960@4F5N=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY3979E<F%N8V4\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@
M+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3F5T
M($1E9F5R<F5D(%1A>"!,:6%B:6QI='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XM3$5&
M5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/DQO86X@4&%Y86)L93PO9F]N=#X\+W`^/"]T
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C4R/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S:7IE/3-$,CXS,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('9A;&EG
M;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T-%149&/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CY,;VYG+51E<FT@4&]R=&EO;CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B
M;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E
M8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^4V%L92!O9B!4
M87@@0F5N969I=',@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN($IA;G5A<GD@
M,C`Q,2P@=&AE($-O;7!A;GD@<F5C96EV960@87!P<F]V86P@9G)O;2!T:&4@
M3F5W($IE<G-E>2!%8V]N;VUI8R!$979E;&]P;65N="!!=71H;W)I='D@86YD
M(&%G<F5E9"!T;R!S96QL($YE=R!*97)S97D@=&%X(&)E;F5F:71S('=O<G1H
M("0P+C8F(S$V,#MM:6QL:6]N("AC;VYS:7-T:6YG(&]F(%(F86UP.T0@=&%X
M(&-R961I=',I('1O(&%N(&EN9&5P96YD96YT('1H:7)D('!A<G1Y(&9O<B`D
M,"XU)B,Q-C`[;6EL;&EO;BX@56YD97(@=&AE(&%G<F5E;65N="P@=&AE($-O
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M<G,@<W1A<G1I;F<@:6X@,C`Q,BX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^3&]A;B!0
M87EA8FQE(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);B!$96-E;6)E<B`R,#`S
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M9R!A;B!A;6]R=&EZ871I;VX@<&5R:6]D(&]F(#$U)B,Q-C`[>65A<G,@86YD
M(&EN=&5R97-T(&%C8W)U97,@870@82!R871E(&]F(#4N-24@<&5R(&%N;G5M
M+B!4:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@<F5P87D@=&AE(&9O;&QO
M=VEN9R!P<FEN8VEP86P@86UO=6YT<R!F;W(@=&AE(&QO86X@87,@9F]L;&]W
M<R`H:6X@=&AO=7-A;F1S*3H@/"]F;VYT/CPO<#X-"CQD:78@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'+4Q%1E0Z(#!P=#L@4$%$1$E.
M1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#$U)3L@5TE$5$@Z(#<P)3L@
M4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-"CQP('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/"$M
M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O;G0^/"]P
M/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\='(^/"$M
M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=VED=&@],T0Q,CX\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1R:6=H
M="!W:61T:#TS1#<^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('=I9'1H/3-$,S`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
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M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^,C`Q-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^,C`Q-3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXR
M,#$V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CY4:&5R96%F=&5R/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
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M<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY4
M;W1A;#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
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M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$
M=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E8VEF
M:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X-
M"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#4R
M-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F,&-F,&,S#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q
M.6,W9C!C9C!C,R]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY415)-($Q/04X\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5$5232!,
M3T%./"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1%4DT@3$]!3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A
M8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\
M8CXH,3`I(%1%4DT@3$]!3B`\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@1&5C
M96UB97(@,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@3&]A;B!A
M;F0@4V5C=7)I='D@06=R965M96YT("AT:&4@(DQO86X@06=R965M96YT(BD@
M=VET:"!-:61#87`@1FEN86YC:6%L+"8C,38P.TQ,0R`H36ED0V%P*2!P=7)S
M=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!B;W)R;W=E9"`D,3`F(S$V,#MM
M:6QL:6]N("AT:&4@(E1E<FT@3&]A;B(I(&9R;VT@36ED0V%P+B!);B!-87)C
M:"`R,#$Q+"!A<R!T:&4@0V]M<&%N>2!H860@86YT:6-I<&%T960L('1H92!#
M;VUP86YY(&%M96YD960@=&AE($QO86X@06=R965M96YT(&%N9"!B;W)R;W=E
M9"!A;B!A9&1I=&EO;F%L("0U)B,Q-C`[;6EL;&EO;B!F<F]M($=E;F5R86P@
M16QE8W1R:6,@0V%P:71A;"!#;W)P;W)A=&EO;B`H1T5#0RD@*&-O;&QE8W1I
M=F5L>2!W:71H($UI9$-A<"P@=&AE("),96YD97)S(BD@=&\@:6YC<F5A<V4@
M=&AE(&%M;W5N="!O=V5D('5N9&5R('1H92!497)M($QO86X@=&\@)#$U)B,Q
M-C`[;6EL;&EO;BX@3F\@861D:71I;VYA;"!A9'9A;F-E<R!A<F4@879A:6QA
M8FQE('5N9&5R('1H92!,;V%N($%G<F5E;65N="X@5&AE(%1E<FT@3&]A;B!A
M8V-R=65S(&EN=&5R97-T(&%T(&$@9FEX960@86YN=6%L(&EN=&5R97-T(')A
M=&4@97%U86P@=&\@=&AE(&=R96%T97(@;V8@*&DI)B,Q-C`[=&AE('-U;2!O
M9B`H02DF(S$V,#MT:&4@3$E"3U(@4F%T92`H87,@9&5F:6YE9"!I;B!T:&4@
M3&]A;B!!9W)E96UE;G0I('!L=7,@*$(I)B,Q-C`[-BXR-24[(&]R("AI:2DF
M(S$V,#MA(&UI;FEM=6T@<F%T92!O9B`Y+C4P)2X@26X@4V5P=&5M8F5R(#(P
M,3$L('1H92!#;VUP86YY(&5X97)C:7-E9"!A;B!O<'1I;VX@=&\@97AT96YD
M('1H92!I;G1E<F5S="UO;FQY('!E<FEO9"!B>2`V)B,Q-C`[;6]N=&AS(&9R
M;VT@3V-T;V)E<B8C,38P.S$L(#(P,3$@=&\@07!R:6PF(S$V,#LQ+"`R,#$R
M+B!);B!-87)C:"`R,#$R+"!T:&4@0V]M<&%N>2!A;65N9&5D('1H92!,;V%N
M($%G<F5E;65N="!T;R!E>'1E;F0@=&AE(&UA='5R:71Y(&1A=&4@9G)O;2!$
M96-E;6)E<B`R,#$S('1O($1E8V5M8F5R(#(P,30@:6X@<F5T=7)N(&9O<B!A
M;B!U<&9R;VYT(&9E92!O9B`D,C4L,#`P(&%N9"!A;B!A9&1I=&EO;F%L(&9E
M92!O9B`D,S<L-3`P(&1U92!U<&]N(')E<&%Y;65N="!O9B!T:&4@5&5R;2!,
M;V%N(&EN(&9U;&PN(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN=&5R97-T(&]N('1H
M92!497)M($QO86X@:7,@<&%Y86)L92!M;VYT:&QY(&%N9"!P<FEN8VEP86P@
M:7,@9'5E+"!A<R!A;65N9&5D+"!I;B`S-"!E<75A;"!C;VYS96-U=&EV92!M
M;VYT:&QY(&EN<W1A;&QM96YT<R!C;VUM96YC:6YG(&]N($%P<FEL)B,Q-C`[
M,2P@,C`Q,BX@06QL('5N<&%I9"!P<FEN8VEP86P@86YD(&%C8W)U960@:6YT
M97)E<W0@=VET:"!R97-P96-T('1O('1H92!497)M($QO86X@:7,@9'5E(&%N
M9"!P87EA8FQE(&]N('1H92!E87)L:65R(&]F("A!*28C,38P.T1E8V5M8F5R
M)B,Q-C`[,S`L(#(P,30@;W(@*$(I)B,Q-C`[=&AE(&1A=&4@=&AA="!T:&4@
M5&5R;2!,;V%N(&]T:&5R=VES92!B96-O;65S(&1U92!A;F0@<&%Y86)L92!U
M;F1E<B!T:&4@=&5R;7,@;V8@=&AE($QO86X@06=R965M96YT+B!4:&4@0V]M
M<&%N>2!M87D@<')E<&%Y(&%L;"P@8G5T(&YO="!L97-S('1H86X@86QL+"!O
M9B!T:&4@5&5R;2!,;V%N('-U8FIE8W0@=&\@82!P<F5P87EM96YT('!R96UI
M=6T@;V8@,24@:6X@>65A<B!T:')E92!A;F0@,B4@:6X@>65A<B!T=V\@;V8@
M=&AE(&]R:6=I;F%L('!R:6YC:7!A;"!A;6]U;G0@;V8@=&AE(%1E<FT@3&]A
M;BX@5&AE<F4@:7,@;F\@<')E<&%Y;65N="!P<F5M:75M(&EF('1H92!L;V%N
M(&ES('!A:60@;V9F(&5A<FQY(&EN('EE87(@9F]U<BX@5&AE($-O;7!A;GD@
M:7,@86QS;R!O8FQI9V%T960@=&\@;6%K92!A('!A>6UE;G0@9F5E(&]F("0P
M+C4F(S$V,#MM:6QL:6]N("AT:&4@(E!A>6UE;G0@1F5E(BD@=7!O;B!T:&4@
M96%R;&EE<B!O9B`H02DF(S$V,#M$96-E;6)E<B8C,38P.S,P+"`R,#$S(&]R
M("A"*28C,38P.W5P;VX@<F5P87EM96YT(&]F('1H92!497)M($QO86X@:6X@
M9G5L;"!P<FEO<B!T;R!$96-E;6)E<B8C,38P.S,P+"`R,#$S+B!4:&4@0V]M
M<&%N>2!I<R!A8V-R971I;F<@=&AE(%!A>6UE;G0@1F5E(')A=&%B;'D@;W9E
M<B!T:&4@;W)I9VEN86P@=&5R;2!O9B!T:&4@5&5R;2!,;V%N('1O(&EN=&5R
M97-T(&5X<&5N<V4N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!
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M($%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L('1H92!#;VUP86YY(&)E;&EE
M=F5S(&ET(&ES(&EN(&-O;7!L:6%N8V4@=VET:"!T:&4@3&]A;B!!9W)E96UE
M;G0N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.T%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3$@86YD(#(P,3`L('1H92!#;VUP86YY(&AA9"`D,"XR)B,Q-C`[;6EL;&EO
M;B!I;B!C87!I=&%L:7IE9"!D969E<G)E9"!F:6YA;F-I;F<@8V]S=',@:6YC
M=7)R960@:6X@8V]N;F5C=&EO;B!W:71H('1H92!497)M($QO86X@86YD(&ES
M(&%M;W)T:7II;F<@=&AE<V4@8V]S=',@;W9E<B!T:&4@;W)I9VEN86P@=&5R
M;2!O9B!T:&4@5&5R;2!,;V%N('1O(&EN=&5R97-T(&5X<&5N<V4N($EN=&5R
M97-T(&5X<&5N<V4@;VX@=&AE(%1E<FT@3&]A;B!I;F-L=61I;F<@=&AE(&%C
M8W)E=&EO;B!O9B!T:&4@4&%Y;65N="!&964@86YD(&%M;W)T:7IA=&EO;B!O
M9B!T:&4@9&5F97)R960@9FEN86YC:6YG(&-O<W1S('=A<R`D,2XV)B,Q-C`[
M;6EL;&EO;B!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,2X@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:7,@;V)L:6=A
M=&5D('1O(')E<&%Y('1H92!F;VQL;W=I;F<@<')I;F-I<&%L(&%M;W5N=',@
M9F]R('1H92!497)M($QO86X@*&EN8VQU9&EN9R!087EM96YT($9E92D@87,@
M9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H@/"]F;VYT/CPO<#X-"CQD:78@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'+4Q%1E0Z(#!P=#L@
M4$%$1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#$U)3L@5TE$5$@Z
M(#<P)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T:79E)SX-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q,#`E(B`M+3X\+V9O
M;G0^/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H\
M='(^/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT9"!S='EL
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M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^,C`Q-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^,C`Q-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@
M+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&AE
M<F5A9G1E<CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B8C
M.#(Q,CL\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O
M<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^
M#0H\='(@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T-%149&/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^#0H\<"!S='EL93TS1"=-
M05)'24XM3$5&5#H@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M/3-$)V9O;G0M<VEZ93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-43T-+2$],1$524R<@15%52519/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-43T-+2$],
M1$524R<@15%52519/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-43T-+2$],1$524R<@15%52519/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF
M.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/CQB/B@Q,2D@4U1/0TM(3TQ$15)3)R!%455)
M5%D@/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/D-O;6UO;B!3=&]C:R`\+VD^/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[26X@07!R:6P@,C`Q,"P@=&AE($-O;7!A;GD@9FEL
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M92!O;B!!<')I;"8C,38P.S(R+"`R,#$P+B`\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M)
M;B!*86YU87)Y(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O
M;G1R;VQL960@97%U:71Y(&]F9F5R:6YG('-A;&5S(&%G<F5E;65N="`H=&AE
M(")#86YT;W(@06=R965M96YT(BD@=VET:"!#86YT;W(@1FET>F=E<F%L9"8C
M,38P.R9A;7`[)B,Q-C`[0V\N("A#86YT;W(I('!U<G-U86YT('1O('=H:6-H
M('1H92!#;VUP86YY(&UA>2!I<W-U92!A;F0@<V5L;"!U<"!T;R`U+#`P,"PP
M,#`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@9G)O;2!T:6UE('1O('1I
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M<R!U<&]N('1H92!S86QE(&]F(&%L;"`U+#`P,"PP,#`@<VAA<F5S(&]R('5P
M;VX@=&5N(&1A>2!N;W1I8V4@8GD@96ET:&5R($-A;G1O<B!O<B!T:&4@0V]M
M<&%N>2X@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3$L('1H92!#;VUP86YY('-O;&0@-3<U+#`P,"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K('5N9&5R('1H92!#86YT;W(@06=R965M96YT(&%N9"!R86ES
M960@)#(N,B8C,38P.VUI;&QI;VX@:6X@;F5T('!R;V-E961S+"!A9G1E<B!D
M961U8W1I;F<@8V]M;6ES<VEO;B!A;F0@;V9F97)I;F<@97AP96YS97,N($EN
M($IA;G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"`R+#0U,"PP,#`@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!T:&4@0V%N=&]R($%G<F5E;65N
M="!A;F0@<F%I<V5D("0X+C4F(S$V,#MM:6QL:6]N(&EN(&YE="!P<F]C965D
M<RX@56YD97(@=&AE('1E<FUS(&]F('1H92!#86YT;W(@06=R965M96YT+"!T
M:&4@0V]M<&%N>2!W:6QL(&AA=F4@=&AE(&%B:6QI='D@=&\@<V5L;"!U<"!T
M;R`Q+#DW-2PP,#`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@=7!O;B!T
M:&4@97AP:7)A=&EO;B!O<B!E87)L:65R('=A:79E<B!O9B!T:&4@.3`M9&%Y
M(&QO8VLM=7`@=VET:"!T:&4@=6YD97)W<FET97)S(&]F('1H92!#;VUP86YY
M)W,@<F5C96YT(&]F9F5R:6YG(&EN($9E8G)U87)Y(#(P,3(N(#PO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.TEN($UA>2`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@,3$L
M-3`P+#`P,"!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:R!I;B!A;B!U;F1E
M<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG+"!I;F-L=61I;F<@=&AE('5N9&5R
M=W)I=&5R)W,@97AE<F-I<V4@;V8@=&AE:7(@9G5L;"!O=F5R+6%L;&]T;65N
M="!O<'1I;VX@=&\@<'5R8VAA<V4@86X@861D:71I;VYA;"`Q+#4P,"PP,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX@5&AE(&YE="!P<F]C965D<R!T;R!T
M:&4@0V]M<&%N>2!W97)E("0S,RXW)B,Q-C`[;6EL;&EO;BP@869T97(@9&5D
M=6-T:6YG('5N9&5R=W)I=&EN9R!F965S(&%N9"!O9F9E<FEN9R!E>'!E;G-E
M<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@1F5B<G5A<GD@,C`Q,BP@=&AE($-O
M;7!A;GD@:7-S=65D(#$P+#4P,"PP,#`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@
M<W1O8VL@:6X@86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9RX@5&AE
M(&YE="!P<F]C965D<R!T;R!T:&4@0V]M<&%N>2!W97)E("0S-RXW)B,Q-C`[
M;6EL;&EO;BP@869T97(@9&5D=6-T:6YG('5N9&5R=W)I=&EN9R!F965S(&%N
M9"!E<W1I;6%T960@;V9F97)I;F<@97AP96YS97,N(%1H92!#;VUP86YY(&AA
M<R!G<F%N=&5D('1H92!U;F1E<G=R:71E<G,@82`S,"UD87D@;W!T:6]N('1O
M('!U<F-H87-E('5P('1O(&%N(&%G9W)E9V%T92!O9B`Q+#4W-2PP,#`@861D
M:71I;VYA;"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O(&-O=F5R(&]V97)A
M;&QO=&UE;G1S+"!I9B!A;GDN(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/D-O;G9E<G1I
M8FQE(%!R969E<G)E9"!3=&]C:R`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[070@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@=&AE($-O;7!A;GD@:&%D(&%U=&AO
M<FEZ960@,RPP,#`L,#`P('-H87)E<R!O9B!P<F5F97)R960@<W1O8VL@86QL
M(&]F('=H:6-H(&AA=F4@8F5E;B!D97-I9VYA=&5D($-L87-S)B,Q-C`[0R!0
M<F5F97)R960@4W1O8VL@:6YC;'5D:6YG(#,U,"PP,#`@<VAA<F5S('=H:6-H
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
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M($-O;7!A;GDL($XN02XL(&%S(%)I9VAT<R!!9V5N="`H=&AE(")2:6=H=',@
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M:6-H(&5X<&ER97,@:6X@3F]V96UB97(@,C`Q-"P@96YT:71L97,@=&AE:7(@
M:&]L9&5R('1O('!U<F-H87-E(&9R;VT@=&AE($-O;7!A;GD@;VYE('1E;BUT
M:&]U<V%N9'1H(&]F(&$@<VAA<F4@*&$@(E5N:70B*2!O9B!397)I97,F(S$V
M,#M#+3$@4')E9F5R<F5D(%-T;V-K(&%T(&$@8V%S:"!E>&5R8VES92!P<FEC
M92!O9B`D,S4N,#`@<&5R(%5N:70L('-U8FIE8W0@=&\@861J=7-T;65N="X@
M5&AE(%)I9VAT<R!W:6QL('1R861E('-E<&%R871E;'D@9G)O;2!T:&4@8V]M
M;6]N('-T;V-K(&%N9"!W:6QL(&)E8V]M92!E>&5R8VES86)L92!O;FQY('=H
M96X@82!P97)S;VX@;W(@9W)O=7`@:&%S(&%C<75I<F5D(#$U)2!O<B!M;W)E
M(&]F('1H92!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VL@;W(@=7!O;B!T:&4@
M8V]M;65N8V5M96YT(&)Y(&$@<&5R<V]N(&]R(&=R;W5P(&]F(&$@=&5N9&5R
M(&]F9F5R('1H870@=V]U;&0@<F5S=6QT(&EN('-U8V@@<&5R<V]N(&]R(&=R
M;W5P(&%C<75I<FEN9R`Q-24@;W(@;6]R92!O9B!T:&4@;W5T<W1A;F1I;F<@
M8V]M;6]N('-T;V-K(&]T:&5R('1H86X@87,@82!R97-U;'0@;V8@<F5P=7)C
M:&%S97,@;V8@<W1O8VL@8GD@=&AE($-O;7!A;GD@;W(@8V5R=&%I;B!I;F%D
M=F5R=&5N="!A8W1I;VYS(&)Y(&$@<VAA<F5H;VQD97(N($EN('1H92!E=F5N
M="!A('!E<G-O;B!O<B!G<F]U<"!A8W%U:7)E<R`Q-24@;W(@;6]R92!O9B!T
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M;VUB:6YA=&EO;B!T<F%N<V%C=&EO;B!O<B!I9B`U,"4@;W(@;6]R92!O9B!T
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M97AE<F-I<V4@<')I8V4@;V8@=&AE(%)I9VAT+B`\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-43T-+
M+4)!4T5$($-/35!%3E-!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$]#2RU"05-%1"!#3TU014Y3051)
M3TX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4U1/0TLM0D%3140@0T]-4$5.4T%424]./"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\
M='(^#0H\=&0^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0R/CQB/B@Q,BD@4U1/0TLM0D%3140@0T]-4$5.4T%424].
M(#PO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!H87,@=&AE(&9O
M;&QO=VEN9R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@<&QA;G,Z('1H92`R
M,#`T($5M<&QO>65E(%-T;V-K(%!U<F-H87-E(%!L86X@*'1H92`B,C`P-"!%
M4U!0(%!L86XB*2P@=&AE(#(P,#@@4W1O8VL@3W!T:6]N(&%N9"!);F-E;G1I
M=F4@4&QA;B`H=&AE("(R,#`X(%!L86XB*2P@0V5L;&1E>"!297-E87)C:"=S
M(#(P,#4@17%U:71Y($EN8V5N=&EV92!0;&%N("AT:&4@(D-E;&QD97@@4F5S
M96%R8V@@,C`P-2!0;&%N(BD@86YD('1H92!#=7)A1V5N(#(P,#<@4&QA;BX@
M5&AE<F4@87)E(&YO('-H87)E<R!A=F%I;&%B;&4@9F]R(&9U='5R92!G<F%N
M="!U;F1E<B!T:&4@0V5L;&1E>"!297-E87)C:"`R,#`U(%!L86X@86YD($-U
M<F%'96X@,C`P-R!0;&%N+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y%;7!L;WEE92!3
M=&]C:R!0=7)C:&%S92!0;&%N(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M!="!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!A('1O=&%L(&]F(#8R+#4P,"!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&%R92!R97-E<G9E9"!F;W(@:7-S=6%N8V4@
M=6YD97(@=&AE(#(P,#0@15-04"!0;&%N+B!5;F1E<B!T:&4@,C`P-"!%4U!0
M(%!L86XL(&5A8V@@<&%R=&EC:7!A=&EN9R!E;7!L;WEE92!M87D@<'5R8VAA
M<V4@=7`@=&\@,C4P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<&5R('EE87(L
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M8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3`L('1H92!#;VUP86YY(&ES
M<W5E9"`V+#8R-R!A;F0@-2PX.3<@<VAA<F5S('5N9&5R('1H92`R,#`T($53
M4%`@4&QA;BP@<F5S<&5C=&EV96QY+B!!="!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$Q+"`T-"PS.#(@<VAA<F5S('=E<F4@879A:6QA8FQE(&9O<B!I<W-U86YC
M92!U;F1E<B!T:&4@,C`P-"!%4U!0(%!L86XN(#PO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI
M/D5M<&QO>65E(%-T;V-K($]P=&EO;B!A;F0@26YC96YT:79E(%!L86X@/"]I
M/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H92`R,#`X(%!L86X@<&5R;6ET<R!T:&4@
M9W)A;G1I;F<@;V8@:6YC96YT:79E('-T;V-K(&]P=&EO;G,@*&EN=&5N9&5D
M('1O('%U86QI9GD@87,@<W5C:"!U;F1E<B!396-T:6]N)B,Q-C`[-#(R02!O
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M;G-U;'1A;G1S(&%N9"!N;VXM96UP;&]Y964@9&ER96-T;W)S+B`\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#M!="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!T:&4@,C`P
M."!0;&%N(&%L;&]W960@9F]R(&$@;6%X:6UU;2!O9B`S+#DP,"PP,#`@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!B92!I<W-U960@9F]R(&=R86YT<R!O
M9B!3=&]C:R!/<'1I;VYS(&%N9"!O=&AE<B!!=V%R9',@;6%D92!P<FEO<B!T
M;R!-87)C:"8C,38P.S<L(#(P,3@@86YD(&=R86YT<R!O9B!);F-E;G1I=F4@
M4W1O8VL@3W!T:6]N<R!M861E('!R:6]R('1O($]C=&]B97(F(S$V,#LR,"P@
M,C`Q-RX@5&AE($-O;7!A;GDG<R!B;V%R9"!O9B!D:7)E8W1O<G,@9&5T97)M
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M;VYS(&=R86YT960@=&\@:&]L9&5R<R!O9B!M;W)E('1H86X@,3`E(&]F('1H
M92!V;W1I;F<@<W1O8VL@;V8@=&AE($-O;7!A;GDI(&%N9"!T:&4@97AE<F-I
M<V4@<')I8V4@;V8@<W1O8VL@;W!T:6]N<R!C86YN;W0@8F4@;&5S<R!T:&%N
M('1H92!F86ER(&UA<FME="!V86QU92!O9B!T:&4@8V]M;6]N('-T;V-K(&%T
M('1H92!D871E(&]F(&=R86YT("@Q,3`E(&]F(&9A:7(@;6%R:V5T('9A;'5E
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M('1H92`R,#`X(%!L86XN(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T$@<W5M;6%R>2!O
M9B!S=&]C:R!O<'1I;VX@86-T:79I='D@9F]R('1H92!Y96%R(&5N9&5D($1E
M8V5M8F5R)B,Q-C`[,S$L(#(P,3$@:7,@87,@9F]L;&]W<SH@/"]F;VYT/CPO
M<#X-"CQD:78@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'
M+4Q%1E0Z(#!P=#L@4$%$1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z
M(#$U)3L@5TE$5$@Z(#<P)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ
M(')E;&%T:79E)SX-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^
M/&9O;G0@<VEZ93TS1#(^/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q
M,#`E(B`M+3X\+V9O;G0^/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='
M140@5$%"3$4@+2T^#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O
M<F1E<CTS1#`^#0H\='(^/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M
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M93TS1#(^)B,Q-C`[/"]F;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY3:&%R97,@/"]B/CPO
M9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@
M<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@+SX-"D%V97)A9V4\8G(@+SX-"D5X
M97)C:7-E/&)R("\^#0I0<FEC93QB<B`O/@T*4&5R(%-H87)E(#PO8CX\+V9O
M;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,
M63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I
M>F4],T0Q/CQB/E=E:6=H=&5D/&)R("\^#0I!=F5R86=E/&)R("\^#0I296UA
M:6YI;F<\8G(@+SX-"D-O;G1R86-T=6%L/&)R("\^#0I497)M("A);B!996%R
M<RD@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^/"]T
M<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3W!T:6]N<R!/=71S=&%N
M9&EN9R!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$P/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY'<F%N
M=&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^.30R+#@X
M-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,BXY
M,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
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M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
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M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY/<'1I;VYS($]U='-T
M86YD:6YG(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^/"]P/CPO
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M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-I>F4],T0R/C8N.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N
M-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
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M9"!%>'!E8W1E9"!T;R!697-T(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\
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M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C8N.3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T
M.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^3W!T:6]N<R!%>&5R8VES86)L92!A="!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M93TS1"=&3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,CY3:&%R97,@079A:6QA8FQE(&9O<B!'
M<F%N="!U;F1E<B!T:&4@,C`P."!0;&%N/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<VEZ93TS1#(^.34S+#$Q,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE('1O=&%L(&EN=')I
M;G-I8R!V86QU92!O9B!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9"!D=7)I;F<@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(#(P,3`@
M86YD(#(P,#D@=V%S("0P+C`S)B,Q-C`[;6EL;&EO;BP@)#$N,"8C,38P.VUI
M;&QI;VX@86YD("0P+C,F(S$V,#MM:6QL:6]N+"!R97-P96-T:79E;'DN(%1H
M92!W96EG:'1E9"!A=F5R86=E(&=R86YT+61A=&4@9F%I<B!V86QU92!O9B!S
M=&]C:R!O<'1I;VYS(&=R86YT960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"`R,#$P(&%N9"`R,#`Y('=A<R`D,2XX
M,RP@)#(N.#(@86YD("0U+C(Y+"!R97-P96-T:79E;'DN(%1H92!T;W1A;"!F
M86ER('9A;'5E(&]F('-T;V-K(&]P=&EO;G,@=F5S=&5D(&1U<FEN9R!T:&4@
M>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@,C`Q,"!A;F0@
M,C`P.2!W87,@)#(N-B8C,38P.VUI;&QI;VXL("0R+C4F(S$V,#MM:6QL:6]N
M(&%N9"`D,BXV)B,Q-C`[;6EL;&EO;BP@<F5S<&5C=&EV96QY+B`\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#M4:&4@86=G<F5G871E(&EN=')I;G-I8R!V86QU92!O9B!S
M=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3$@=V%S("0P+C`S)B,Q-C`[;6EL;&EO;BX@5&AE(&%G9W)E9V%T92!I
M;G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T:6]N<R!V97-T960@86YD(&5X
M<&5C=&5D('1O('9E<W0@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!W87,@
M)#`N,#,F(S$V,#MM:6QL:6]N+B!!<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$Q+"!T;W1A;"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O(&YO;BUV
M97-T960@96UP;&]Y964@86YD(&YO;BUE;7!L;WEE92!D:7)E8W1O<B!S=&]C
M:R!O<'1I;VYS(&YO="!Y970@<F5C;V=N:7IE9"!W87,@87!P<F]X:6UA=&5L
M>2`D,RXS)B,Q-C`[;6EL;&EO;BP@;F5T(&]F(&5S=&EM871E9"!F;W)F96ET
M=7)E<RP@=VAI8V@@:7,@97AP96-T960@=&\@8F4@<F5C;V=N:7IE9"!A<R!E
M>'!E;G-E(&]V97(@82!W96EG:'1E9"!A=F5R86=E('!E<FEO9"!O9B`R+C4F
M(S$V,#MY96%R<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^4F5S=')I8W1E9"!3=&]C
M:R`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[02!S=6UM87)Y(&]F(')E<W1R:6-T
M960@<W1O8VL@86-T:79I='D@=6YD97(@=&AE(#(P,#@@4&QA;B!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!I<R!A<R!F;VQL
M;W=S.B`\+V9O;G0^/"]P/@T*/&1I=B!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P<'0[(%!!1$1)3D<M3$5&5#H@,'!T.R!0041$24Y'+4)/5%1/33H@,'!T
M.R!-05)'24XM3$5&5#H@,34E.R!724142#H@-S`E.R!0041$24Y'+51/4#H@
M,'!T.R!03U-)5$E/3CH@<F5L871I=F4G/@T*/'`@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\(2TM($-/34U!3D0]041$
M7U1!0DQ%5TE$5$@L(C$P,"4B("TM/CPO9F]N=#X\+W`^#0H\(2TM(%5S97(M
M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X-"CQD:78@86QI9VX],T1C96YT
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M<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O
M;G0@<VEZ93TS1#$^/&(^4VAA<F5S(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/E=E:6=H
M=&5D/&)R("\^#0I!=F5R86=E/&)R("\^#0I'<F%N="!$871E/&)R("\^#0I&
M86ER(%9A;'5E/&)R("\^#0HH<&5R('-H87)E*2`\+V(^/"]F;VYT/CPO=&@^
M#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O
M<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3W5T<W1A;F1I;F<@86YD('5N=F5S
M=&5D(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S:7IE/3-$,CXY+#,S.#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,RXY-CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T
M>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^1W)A;G1E9#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C$R+#`P,#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,RXR
M-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T-%
M149&/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CY697-T960\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^0V%N8V5L960\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&
M1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^3W5T<W1A;F1I;F<@86YD('5N=F5S=&5D(&%T($1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE
M/3-$,CXV+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
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M:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E8VEF:65D
M(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^/&D^5F%L=6%T:6]N(&%N9"!%
M>'!E;G-E<R!);F9O<FUA=&EO;B`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E
M;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"`R,#$P(&%N9"`R,#`Y('=A
M<R!R96-O<F1E9"!A<R!F;VQL;W=S.B`\+V9O;G0^/"]P/@T*/&1I=B!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P<'0[(%!!1$1)3D<M3$5&5#H@,'!T.R!0
M041$24Y'+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,34E.R!724142#H@
M-S`E.R!0041$24Y'+51/4#H@,'!T.R!03U-)5$E/3CH@<F5L871I=F4G/@T*
M/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CX\(2TM($-/34U!3D0]041$7U1!0DQ%5TE$5$@L(C$P,"4B("TM/CPO9F]N
M=#X\+W`^#0H\(2TM(%5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X-
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M/CPO=&0^/"$M+2!404),12!#3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*
M/'1R('9A;&EG;CTS1&)O='1O;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\9F]N="!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/&)R("\^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&
M3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQF;VYT('-I>F4],T0Q/CQB/C(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^,C`Q
M,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT
M:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@
M1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\9F]N="!S:7IE/3-$,3X\8CXR,#`Y(#PO8CX\+V9O;G0^/"]T:#X-"CQT
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M1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)
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M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO
M<&UE;G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY'96YE<F%L(&%N9"!A9&UI;FES
M=')A=&EV93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N
M/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#
M145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE
M<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\
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M8F5R)B,Q-C`[,S$L(#(P,3$L(#(P,3`@86YD(#(P,#D@=V5R92!V86QU960@
M=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P@
M=VET:"!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.B`\+V9O;G0^/"]P/@T*
M/&1I=B!S='EL93TS1"=0041$24Y'+5))1TA4.B`P<'0[(%!!1$1)3D<M3$5&
M5#H@,'!T.R!0041$24Y'+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,34E
M.R!724142#H@-S@N,3$E.R!0041$24Y'+51/4#H@,'!T.R!03U-)5$E/3CH@
M<F5L871I=F4[($A%24=(5#H@,C(X<'@G/@T*/'`@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\(2TM($-/34U!3D0]041$
M7U1!0DQ%5TE$5$@L(C$P,"4B("TM/CPO9F]N=#X\+W`^#0H\(2TM(%5S97(M
M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X-"CQD:78@86QI9VX],T1C96YT
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M3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O
M;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-
M"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB
M/EEE87(@16YD960\8G(@+SX-"D1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@/"]B
M/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O
M;G0@<VEZ93TS1#$^/&(^665A<B!%;F1E9#QB<B`O/@T*1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY996%R($5N9&5D/&)R("\^
M#0I$96-E;6)E<B8C,38P.S,Q+"`R,#`Y(#PO8CX\+V9O;G0^/"]T:#X-"CQT
M:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1H/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T-%149&/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I
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M-C@F(S$V,#LF(S@R,3$[)B,Q-C`[-S`\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,CXE/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M/CQF;VYT('-I>F4],T0R/C8U)B,Q-C`[)B,X,C$Q.R8C,38P.S8X/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)3PO9F]N=#X\+W1D/CPO='(^
M#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^17AP96-T
M960@;W!T:6]N('1E<FT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M:7IE/3-$,CXV+C`@665A<G,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&
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M93TS1#(^-2XU)B,Q-C`[)B,X,C$Q.R8C,38P.S8N,R!996%R<SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T-%149&/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY2
M:7-K+69R964@:6YT97)E<W0@<F%T93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-I>F4],T0R/C$N-"8C,38P.R8C.#(Q,3LF(S$V,#LR+CD\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXE/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXQ+C@F(S$V,#LF(S@R,3$[)B,Q
M-C`[,RXR/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,2XX)B,Q-C`[
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M12`M+3X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#4R-&9F.#=?8C9D9%\T8F$R
M7SDV-V9?,S$Y8S=F,&-F,&,S#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V0U,C1F9C@W7V(V9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,R]7;W)K
M<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY324=.249)0T%.5"!2159%3E5%($%24D%.1T5-14Y44SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY324=.249)0T%.5"!2159%3E5%($%24D%.1T5-14Y44SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y324=.249)0T%.5"!2
M159%3E5%($%24D%.1T5-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*
M/'1D/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CX\8CXH,3,I(%-)1TY)1DE#04Y4(%)%5D5.544@05)204Y'14U%
M3E13(#PO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M!('-U;6UA<GD@;V8@=&AE($-O
M;7!A;GDG<R!S:6=N:69I8V%N="!R979E;G5E(&-O;G1R86-T<R!A;F0@87)R
M86YG96UE;G1S(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQI/D=L87AO4VUI
M=&A+;&EN928C,38P.W!L8R`H1VQA>&\I(&%N9"!0875L(%)O>6%L='D@1G5N
M9"!)22PF(S$V,#M,+E`N("A04D8I(#PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M)
M;B`Q.3DW+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@86=R965M96YT
M('=I=&@@1VQA>&\@=&\@8V]L;&%B;W)A=&4@;VX@=&AE(&1E=F5L;W!M96YT
M(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!T:&4@0V]M<&%N>2=S(&]R86P@
M<F]T879I<G5S('-T<F%I;B!A;F0@1VQA>&\@87-S=6UE9"!R97-P;VYS:6)I
M;&ET>2!F;W(@86QL('-U8G-E<75E;G0@8VQI;FEC86P@=')I86QS(&%N9"!A
M;&P@;W1H97(@9&5V96QO<&UE;G0@86-T:79I=&EE<RX@5&AE($-O;7!A;GDG
M<R!L:6-E;G-E9"UI;B!T:&4@<F]T879I<G5S('-T<F%I;B!T:&%T('=A<R!U
M<V5D('1O(&1E=F5L;W`@1VQA>&\G<R!2;W1A<FEX(')O=&%V:7)U<R!V86-C
M:6YE(&EN(#$Y.34@86YD(&]W97,@82!L:6-E;G-E(&9E92!O9B`S,"4@=&\@
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M>&\@;6%Y('1E<FUI;F%T92!T:&4@86=R965M96YT('5P;VX@.3`F(S$V,#MD
M87ES('!R:6]R('=R:71T96X@;F]T:6-E+B!4:&4@;&%S="!R96QE=F%N="!P
M871E;G0@:7,@<V-H961U;&5D('1O(&5X<&ER92!I;B!$96-E;6)E<B`R,#$R
M+B!.;R!A9&1I=&EO;F%L(&UI;&5S=&]N92!P87EM96YT<R!A<F4@9'5E(&9R
M;VT@1VQA>&\@=6YD97(@=&AE(&%G<F5E;65N="X@/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[26X@36%Y(#(P,#4L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A
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M96UB97(@,C`Q,BP@=6YL97-S(&]T:&5R=VES92!E>'1E;F1E9"X@5&AE($-O
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M;&QI;VXL("0V+C0F(S$V,#MM:6QL:6]N(&%N9"`D-RXW)B,Q-C`[;6EL;&EO
M;B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L
M(#(P,3`@86YD(#(P,#DL(')E<W!E8W1I=F5L>2X@/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M/&D^4&9I>F5R($EN8RX@*%!F:7IE<BD@/"]I/CPO9F]N=#X\+W`^#0H\<"!S
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M<B!M861E(&%N('5P9G)O;G0@<&%Y;65N="!T;R!T:&4@0V]M<&%N>2!O9B`D
M-#`F(S$V,#MM:6QL:6]N(&%N9"!M861E(&$@)#$P)B,Q-C`[;6EL;&EO;B!E
M<75I='D@:6YV97-T;65N="!I;B!T:&4@0V]M<&%N>2X@5&AE(%!F:7IE<B!!
M9W)E96UE;G0@86QS;R!P<F]V:61E9"!F;W(@<F5I;6)U<G-E;65N="!B>2!0
M9FEZ97(@;V8@86QL(&-O<W1S(&EN8W5R<F5D(&)Y('1H92!#;VUP86YY(&EN
M(&-O;FYE8W1I;VX@=VET:"!T:&4@8V]L;&%B;W)A=&EO;B!S:6YC92!T:&4@
M969F96-T:79E(&1A=&4N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4
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M8F]R871I;VX@=V]U;&0@8F4@.2XU)B,Q-C`[>65A<G,@8F%S960@;VX@86X@
M87-S97-S;65N="!O9B!T:&4@<&5R:6]D(&]V97(@=VAI8V@@=&AE($-O;7!A
M;GD@=V]U;&0@:&%V92!M970@:71S('!E<F9O<FUA;F-E(&]B;&EG871I;VYS
M('5N9&5R('1H92!C;VQL86)O<F%T:6]N+B!4:&4@)#0P)B,Q-C`[;6EL;&EO
M;B!U<"UF<F]N="!P87EM96YT(&%N9"!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@<F5I;6)U<G-E;65N=',@=V5R92!I;FET:6%L;'D@<F5C;W)D960@87,@
M9&5F97)R960@<F5V96YU92!A;F0@<F5C;V=N:7IE9"!A<R!R979E;G5E(&]V
M97(@=&AI<R`Y+C4F(S$V,#MY96%R('!E<FEO9"X@/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[26X@3F]V96UB97(@,C`Q,"P@=&AE(%!F:7IE<B!!9W)E96UE;G0@=V%S
M('1E<FUI;F%T960@*'1H92`B4&9I>F5R(%1E<FUI;F%T:6]N(BD@86YD(&%L
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M(S$V,#LS,2P@,C`Q,"X@5&AE($-O;7!A;GD@<F5C;W)D960@)#,Y+CDF(S$V
M,#MM:6QL:6]N(&%N9"`D-2XR)B,Q-C`[;6EL;&EO;B!I;B!P<F]D=6-T(&1E
M=F5L;W!M96YT(&%N9"!L:6-E;G-I;F<@86=R965M96YT(')E=F5N=64@=6YD
M97(@=&AE(%!F:7IE<B!!9W)E96UE;G0@9'5R:6YG('1H92!Y96%R<R!E;F1E
M9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P(&%N9"`R,#`Y+"!R97-P96-T:79E
M;'DN(%1H92!#;VUP86YY(&EN8W5R<F5D(&%N9"!I;G9O:6-E9"!09FEZ97(@
M<F5I;6)U<G-A8FQE(&-O<W1S(')E;&%T960@=&\@=&AE(%!F:7IE<B!C;VQL
M86)O<F%T:6]N(&]F("0P+C@F(S$V,#MM:6QL:6]N(&%N9"`D,RXR)B,Q-C`[
M;6EL;&EO;B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3`@86YD(#(P,#DL(')E<W!E8W1I=F5L>2X@169F96-T:79E('=I=&@@
M=&AE(%!F:7IE<B!497)M:6YA=&EO;BP@4&9I>F5R(&ES(&YO(&QO;F=E<B!F
M=6YD:6YG('1H92!D979E;&]P;65N="!O9B!R:6YD;W!E<&EM=70N(#PO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
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M92!O=F5R('1H92`Y+C4M>65A<B!P97)F;W)M86YC92!P97)I;V0N($%S(&$@
M<F5S=6QT(&]F('1H92!09FEZ97(@5&5R;6EN871I;VXL('1H92!#;VUP86YY
M(')E8V]G;FEZ960@=&AE(')E;6%I;FEN9R!D969E<G)E9"!C;W-T<R!R96QA
M=&5D('1O('1H92!09FEZ97(@06=R965M96YT('1O(')O>6%L='D@97AP96YS
M92!D=7)I;F<@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P+B!4
M:&4@0V]M<&%N>2!R96-O<F1E9"`D-2XW)B,Q-C`[;6EL;&EO;B!A;F0@)#`N
M-R8C,38P.VUI;&QI;VX@:6X@<F]Y86QT>2!E>'!E;G-E(')E;&%T960@=&\@
M=&AE<V4@9&5F97)R960@<W5B;&EC96YS92!F965S(&1U<FEN9R!T:&4@>65A
M<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!A;F0@,C`P.2P@<F5S
M<&5C=&EV96QY+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y2;V-K969E;&QE<B!5;FEV
M97)S:71Y("A2;V-K969E;&QE<BD@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H
M92!#;VUP86YY(&AA<R!P<F]V:61E9"!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@<W5P<&]R="!T;R!2;V-K969E;&QE<B!O;B!T:&4@9&5V96QO<&UE;G0@
M;V8@=&AE:7(@=F%C8VEN92P@1$-687@M,#`Q+"!W:&EC:"!T:&4@0V]M<&%N
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M<B!O9B`D,"XR)B,Q-C`[;6EL;&EO;B!A;F0@)#$N."8C,38P.VUI;&QI;VX@
M9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P(&%N
M9"`R,#`Y+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO
M=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T],3$%"3U)!5$E/
M3B!!1U)%14U%3E13/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-/3$Q!0D]2051)3TX@04=2145-14Y44SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TQ,04)/
M4D%424].($%'4D5%345.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-"CQT
M9#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#(^/&(^*#$T*2!#3TQ,04)/4D%424].($%'4D5%345.5%,@/"]B/CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
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M<R`D,2XT)B,Q-C`[;6EL;&EO;BP@)#$N,"8C,38P.VUI;&QI;VX@86YD("0P
M+C<F(S$V,#MM:6QL:6]N(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2P@<F5S<&5C=&EV96QY+B`\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\
M9F]N="!S:7IE/3-$,CX\:3Y-961A<F5X+"8C,38P.TEN8RXL(&$@<W5B<VED
M:6%R>2!O9B!"<FES=&]L+4UY97)S(%-Q=6EB8B`H365D87)E>"D@/"]I/CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
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M;BX@5&AE<V4@86=R965M96YT<R!I;F-L=61E.CPO9F]N=#X\+W`^#0H\=6P^
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M06=R965M96YT+"!A<R!A;65N9&5D+"`H07-S:6=N;65N="!A;F0@3&EC96YS
M92!!9W)E96UE;G0I('1H870@<')O=FED97,@9F]R('1H92!A<W-I9VYM96YT
M(&]F(&-E<G1A:6X@<&%T96YT(&%N9"!O=&AE<B!I;G1E;&QE8W1U86P@<')O
M<&5R='D@<FEG:'1S(&%N9"!A(&QI8V5N<V4@=&\@8V5R=&%I;B!-961A<F5X
M('1E8VAN;VQO9WD@<F5L871E9"!T;R!T:&4@0V]M<&%N>2=S($%00R!487)G
M971I;F<@5&5C:&YO;&]G>28C.#0X,CL@86YD(&%N(&%N=&DM;6%N;F]S92!R
M96-E<'1O<B!P<F]D=6-T.R!A;F0@/"]F;VYT/CQF;VYT('-I>F4],T0R/CQB
M<B`O/@T*/&)R("\^/"]F;VYT/CPO9&0^#0H\9'0@<W1Y;&4],T0G34%21TE.
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M+B`\+V9O;G0^/"]D9#X\+V1L/CPO;&D^/"]U;#X-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[56YD97(@=&AE
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M;&%T97(@;V8@*&DI)B,Q-C`[=&AE(&5X<&ER871I;VX@;V8@=&AE(&QA<W0@
M=&\@97AP:7)E(&%P<&QI8V%B;&4@<&%T96YT(&%N9"`H:6DI)B,Q-C`[=&AE
M('1E;G1H(&%N;FEV97)S87)Y(&]F('1H92!F:7)S="!C;VUM97)C:6%L('-A
M;&4@;V8@<W5C:"!L:6-E;G-E9"!P<F]D=6-T+B!5;F1E<B!T:&4@=&5R;7,@
M;V8@=&AE(%)E<V5A<F-H(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E96UE
M;G0L('1H92!#;VUP86YY(&UA>2!B92!R97%U:7)E9"!T;R!P87D@;6EL97-T
M;VYE<R!O9B!U<"!T;R`D-RXP)B,Q-C`[;6EL;&EO;B!U<&]N(&]B=&%I;FEN
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M8F]D:65S('5N=&EL('1H92!L871E<B!O9B`H:2DF(S$V,#MT:&4@97AP:7)A
M=&EO;B!O9B!T:&4@;&%S="!T;R!E>'!I<F4@87!P;&EC86)L92!P871E;G0@
M86YD("AI:2DF(S$V,#MT:&4@=&5N=&@@86YN:79E<G-A<GD@;V8@=&AE(&9I
M<G-T(&-O;6UE<F-I86P@<V%L92!O9B!S=6-H(&QI8V5N<V5D('!R;V1U8W0N
M($EN(%-E<'1E;6)E<B`R,#$P+"!T:&4@0V]M<&%N>2!E>&5R8VES960@86X@
M;W!T:6]N('5N9&5R('1H92!297-E87)C:"!A;F0@0V]M;65R8VEA;&EZ871I
M;VX@06=R965M96YT+"!W:&5R96)Y(&ET(&QI8V5N<V5D(&9R;VT@365D87)E
M>"!A8V-E<W,@=&\@=&AE(%5L=&E-86(@=&5C:&YO;&]G>2!T;R!D979E;&]P
M(&%N9"!C;VUM97)C:6%L:7IE(&AU;6%N(&%N=&EB;V1I97,@=&\@0T0R-RP@
M:6YC;'5D:6YG($-$6"TQ,3(W+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y2;V-K969E
M;&QE<B!5;FEV97)S:71Y("A2;V-K969E;&QE<BD@/"]I/CPO9F]N=#X\+W`^
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M14,M,C`U(')E8V5P=&]R('!A=&5N="!R:6=H=',@9F]R(&5D=6-A=&EO;F%L
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M('1H92!H=6UA;B!$14,M,C`U(')E8V5P=&]R+B`\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\
M:3Y$=6ME(%5N:79E<G-I='D@0G)A:6X@5'5M;W(@0V%N8V5R($-E;G1E<B`H
M1'5K92D@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN(%-E<'1E;6)E<B`R,#`V
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M<F5Q=6ER960@=&\@<&%Y(&UI;&5S=&]N92!O9B!U<"!T;R`D,2XP)B,Q-C`[
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M(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/CQI/DQU9'=I9R!);G-T:71U=&4@9F]R($-A;F-E
M<B!297-E87)C:"`H3'5D=VEG*2`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@
M3V-T;V)E<B`R,#`V+"!T:&4@0V]M<&%N>2!A;F0@3'5D=VEG(&5N=&5R960@
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M;6EL97-T;VYE<R!O9B!U<"!T;R`D,2XP)B,Q-C`[;6EL;&EO;B!U<&]N(&]B
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M;VT@3'5D=VEG+B`\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y!;'1E<FES(%1H97)A<&5U
M=&EC<RPF(S$V,#M);F,N("A!;'1E<FES*2`\+VD^/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[26X@3V-T;V)E<B`R,#`U+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE
M(&%C<75I<VET:6]N(&]F('1H92!A<W-E=',@;V8@06QT97)I<RP@:6YC;'5D
M:6YG('1H92!%1T92=DE)22!M;VQE8W5L92X@5&AE($-O;7!A;GD@;6%Y(&)E
M(')E<75I<F5D('1O('!A>2!!;'1E<FES('5P('1O("0U+C`F(S$V,#MM:6QL
M:6]N('5P;VX@;V)T86EN:6YG('1H92!F:7)S="!A<'!R;W9A;"!F;W(@8V]M
M;65R8VEA;"!S86QE(&]F(&$@<')O9'5C="!C;VYT86EN:6YG($5'1E)V24E)
M+"!I;F-L=61I;F<@<FEN9&]P97!I;75T+B`\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\:3Y4
M:&]M87,@2F5F9F5R<V]N(%5N:79E<G-I='D@*%1*52D@/"]I/CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
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M;6EL97-T;VYE<R!O9B!U<"!T;R`D,RXP)B,Q-C`[;6EL;&EO;B!U<&]N(&]B
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M/&D^,TT@0V]M<&%N>2`\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[26X@2G5N92`R
M,#`X+"!T:&4@0V]M<&%N>2!A;F0@,TT@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!L:6-E;G-E(&%G<F5E;65N="!F;W(@=&AE(&5X8VQU<VEV92!W;W)L9'=I
M9&4@<FEG:'1S('1O(&%C8V5S<R`S32!#;VUP86YY)W,@<')O<')I971A<GD@
M26UM=6YE(%)E<W!O;G-E($UO9&EF:65R+"!297-I<75I;6]D)B,X-#@R.RP@
M*&%N9"!A9&1I=&EO;F%L(%1O;&PM3&EK92!296-E<'1O<B`W+S@@86=O;FES
M=',@*%1,4BDI(&9O<B!C;&EN:6-A;"!S='5D>2!W:71H('1H92!#;VUP86YY
M)W,@<')O<')I971A<GD@05!#(%1A<F=E=&EN9R!496-H;F]L;V=Y+"!F;W(@
M=7-E(&%S('9A8V-I;F4@861J=79A;G1S+"!W:71H('1H92!R:6=H="!T;R!S
M=6)L:6-E;G-E('1H92!T96-H;F]L;V=Y+B!4:&4@0V]M<&%N>2!M87D@8F4@
M<F5Q=6ER960@=&\@<&%Y(&UI;&5S=&]N97,@;V8@=7`@=&\@)#,N."8C,38P
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M;W5T:&%M<'1O;BP@54L@*%-O=71H86UP=&]N*2`\+VD^/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[26X@3F]V96UB97(@,C`P."P@=&AE($-O;7!A;GD@96YT97)E9"!I
M;G1O(&$@;&EC96YS92!A9W)E96UE;G0@=VET:"!3;W5T:&%M<'1O;B!T;R!D
M979E;&]P(&AU;6%N(&%N=&EB;V1I97,@=&]W87)D<R!#1#(W+"!A('!O=&5N
M=&EA;&QY(&EM<&]R=&%N="!T87)G970@9F]R(&EM;75N;W1H97)A<'D@;V8@
M=F%R:6]U<R!C86YC97)S+B!4:&4@0V]M<&%N>2!M87D@8F4@<F5Q=6ER960@
M=&\@<&%Y(&UI;&5S=&]N97,@;V8@=7`@=&\@87!P<F]X:6UA=&5L>2`D,2XT
M)B,Q-C`[;6EL;&EO;B!U<&]N(&]B=&%I;FEN9R!F:7)S="!A<'!R;W9A;"!F
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M;6=E;BD@/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,
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M9VAT<R!T;R!#1%@M,S`Q(&%N9"!#1#0P(&QI9V%N9"`H0T0T,$PI+B!#1%@M
M,S`Q(&%N9"!#1#0P3"!A<F4@:6UM=6YE(&UO9'5L871I;F<@;6]L96-U;&5S
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M=&EC<RPF(S$V,#M);F,N("A396%T=&QE($=E;F5T:6-S*2`\+VD^/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[26X@8V]N;F5C=&EO;B!W:71H('1H92!#=7)A1V5N(&%C
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M<R!O9B!U<"!T;R`D-RXU)B,Q-C`[;6EL;&EO;B!U<&]N(&]B=&%I;FEN9R!F
M:7)S="!A<'!R;W9A;"!F;W(@8V]M;65R8VEA;"!S86QE(&EN(&$@9FER<W0@
M:6YD:6-A=&EO;B!A;F0@<F]Y86QT>2!P87EM96YT<R!I;B!T:&4@;6ED+7-I
M;F=L92!D:6=I=',@;VX@86YY(&YE="!P<F]D=6-T('-A;&5S('1O(%-E871T
M;&4@1V5N971I8W,@=VET:"!R97-P96-T('1O(&1E=F5L;W!M96YT(&%N9"!C
M;VUM97)C:6%L:7IA=&EO;B!O9B!T:&4@041#('1E8VAN;VQO9WDL(&EN8VQU
M9&EN9R!#1%@M,#$Q+B`\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.0T]-12!405A%4SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)3D-/
M344@5$%815,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^24Y#3TU%(%1!6$53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\='(^#0H\
M=&0^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/CQB/B@Q-2D@24Y#3TU%(%1!6$53(#PO8CX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#M4:&4@8V]M<&]N96YT<R!O9B!I;F-O;64@=&%X(&5X<&5N<V4@871T
M<FEB=71A8FQE('1O(&-O;G1I;G5I;F<@;W!E<F%T:6]N<R!C;VYS:7-T(&]F
M('1H92!F;VQL;W=I;F<Z(#PO9F]N=#X\+W`^#0H\9&EV('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,1494.B`P<'0[(%!!1$1)3D<M
M0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`Q-24[(%=)1%1(.B`W,"4[(%!!
M1$1)3D<M5$]0.B`P<'0[(%!/4TE424]..B!R96QA=&EV92<^#0H\<"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CPA+2T@
M0T]-34%.1#U!1$1?5$%"3$5724142"PB,3`P)2(@+2T^/"]F;VYT/CPO<#X-
M"CPA+2T@57-E<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%("TM/@T*/&1I=B!A
M;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*/'1R/CPA+2T@
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M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#@^/&9O;G0@
M<VEZ93TS1#$^/&(^665A<B!%;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`\+V(^
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF
M;VYT('-I>F4],T0Q/CQB/C(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^,C`Q,"`\
M+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].
M5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\
M9F]N="!S:7IE/3-$,3X\8CXR,#`Y(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S
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M)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M('-I>F4],T0R/DEN8V]M92!T87@@8F5N969I="`H<')O=FES:6]N*3H\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.
M1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^1F5D97)A;#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX-
M"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.5#H@
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.5#H@
M+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^1F]R
M96EG;CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
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M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-I>F4],T0R/C$R-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.
M5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^
M17AP:7)A=&EO;B!O9B!.970@3W!E<F%T:6YG($QO<W-E<R!A;F0@4F5S96%R
M8V@F(S$V,#LF86UP.R!$979E;&]P;65N="!487@@0W)E9&ET<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C
M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
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M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
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M,#`X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
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M,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
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M<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T(&1O=6)L
M93L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`R+C(U
M<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\(2TM(&5N9"!O9B!U
M<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^/"]D:78^#0H\<"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.TEN
M8VQU9&5D(&EN('1H92!S=&%T92!T87@@<')O=FES:6]N(&%B;W9E(&9O<B!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#`Y(&ES('1H92!E
M9F9E8W0@;V8@82!R871E(&1E8W)E87-E(&]N('1H92!D969E<G)E9"!T87@@
M87-S970@86YD(&QI86)I;&ET:65S(&]F9G-E="!B>2!A("0P+C4F(S$V,#MM
M:6QL:6]N('1A>"!B96YE9FET(&1U92!T;R!N;VXM8V%S:"!T87@@8V]N<V5Q
M=65N8V5S(&]F('1H92!#=7)A1V5N(&%C<75I<VET:6]N+B`\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#M!(')E8V]N8VEL:6%T:6]N(&)E='=E96X@=&AE(&%M;W5N="!O
M9B!R97!O<G1E9"!I;F-O;64@=&%X(&%N9"!T:&4@86UO=6YT(&-O;7!U=&5D
M('5S:6YG('1H92!5+E,N(%-T871U=&]R>2!R871E(&]F(#,T)2!F;VQL;W=S
M.B`\+V9O;G0^/"]P/@T*/&1I=B!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M<'0[(%!!1$1)3D<M3$5&5#H@,'!T.R!0041$24Y'+4)/5%1/33H@,'!T.R!-
M05)'24XM3$5&5#H@,34E.R!724142#H@-S`E.R!0041$24Y'+51/4#H@,'!T
M.R!03U-)5$E/3CH@<F5L871I=F4G/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CX\(2TM($-/34U!3D0]041$7U1!
M0DQ%5TE$5$@L(C$P,"4B("TM/CPO9F]N=#X\+W`^#0H\(2TM(%5S97(M<W!E
M8VEF:65D(%1!1T=%1"!404),12`M+3X-"CQD:78@86QI9VX],T1C96YT97(^
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M1"=&3TY4+49!34E,63H@=&EM97,G('=I9'1H/3-$-3`^/"]T9#X-"CQT9"!S
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M34X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;3X-
M"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-"CQT
M:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/C(P
M,3$@/"]B/CPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[
M($9/3E0M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(^/&9O;G0@<VEZ93TS1#$^/&(^,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\
M=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CXR
M,#`Y(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/CPO
M='(^#0H\='(@=F%L:6=N/3-$8F]T=&]M/@T*/'1H('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1L969T/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\8G(@+SX\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^
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M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[
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M86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,BXR-7!T
M(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CY,;W-S(&%T(%-T871U=&]R>2!2871E<SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
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M=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,CY/=&AE<CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R
M/C8V,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<^#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,3!P=#L@5$58
M5"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/D5X<&ER871I;VX@;V8@3F5T($]P97)A=&EN9R!,;W-S97,@86YD
M(%)E<V5A<F-H)B,Q-C`[)F%M<#L@1&5V96QO<&UE;G0@5&%X($-R961I=',\
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M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C$S+#DR-#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3DL,#`X/"]F;VYT/CPO=&0^#0H\=&0@
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M='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS
M1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
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M87@@*&)E;F5F:70I('!R;W9I<VEO;CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
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M93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,BXR-7!T(&1O=6)L93L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^/"]T
M86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E8VEF:65D(%1!1T=%
M1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[1&5F97)R960@=&%X(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,@87)E(')E8V]G;FEZ960@8F%S960@;VX@=&5M<&]R
M87)Y(&1I9F9E<F5N8V5S(&)E='=E96X@=&AE(&9I;F%N8VEA;"!R97!O<G1I
M;F<@86YD('1A>"!B87-I<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S('5S
M:6YG(&9U='5R92!E>'!E8W1E9"!E;F%C=&5D(')A=&5S+B!!('9A;'5A=&EO
M;B!A;&QO=V%N8V4@:7,@<F5C;W)D960@86=A:6YS="!D969E<G)E9"!T87@@
M87-S971S(&EF(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@<V]M
M92!O<B!A;&P@;V8@=&AE(&1E9F5R<F5D('1A>"!A<W-E=',@=VEL;"!N;W0@
M8F4@<F5A;&EZ960N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U1H92!P<FEN8VEP86P@
M8V]M<&]N96YT<R!O9B!T:&4@9&5F97)R960@=&%X(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"P@
M<F5S<&5C=&EV96QY+"!A<F4@87,@9F]L;&]W<SH@/"]F;VYT/CPO<#X-"CQD
M:78@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,'!T.R!0041$24Y'+4Q%1E0Z
M(#!P=#L@4$%$1$E.1RU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#$U)3L@
M5TE$5$@Z(#<P)3L@4$%$1$E.1RU43U`Z(#!P=#L@4$]3251)3TXZ(')E;&%T
M:79E)SX-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^/"$M+2!#3TU-04Y$/4%$1%]404),15=)1%1(+"(Q,#`E(B`M
M+3X\+V9O;G0^/"]P/@T*/"$M+2!5<V5R+7-P96-I9FEE9"!404='140@5$%"
M3$4@+2T^#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS
M1#`^#0H\='(^/"$M+2!404),12!#3TQ534X@5TE$5$A3(%-%5"`M+3X-"CQT
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M5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;3X-"CQT
M:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/&)R("\^/"]T:#X-"CQT:"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D1E8V5M
M8F5R)B,Q-C`[,S$L/&)R("\^#0HR,#$Q(#PO8CX\+V9O;G0^/"]T:#X-"CQT
M:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQF;VYT('-I>F4],T0Q/CQB/D1E
M8V5M8F5R)B,Q-C`[,S$L/&)R("\^#0HR,#$P(#PO8CX\+V9O;G0^/"]T:#X-
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M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&
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M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&
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M4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3F5T($]P97)A=&EN9R!,;W-S
M($-A<G)Y9F]R=V%R9',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y
M;&4],T0G34%21TE.+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY487@@0W)E9&ET
M($-A<G)Y9F]R=V%R9',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R
M,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^
M/&9O;G0@<VEZ93TS1#(^1&5F97)R960@17AP96YS97,\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y
M;&4],T0G34%21TE.+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY3=&]C:RUB87-E
M9"!#;VUP96YS871I;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M;VYT('-I>F4],T0R/D9I>&5D($%S<V5T<SPO9F]N=#X\+W`^/"]T9#X-"CQT
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY!8V-R=65D($5X<&5N<V5S(&%N
M9"!/=&AE<CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
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M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L
M:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9#L@1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T1W:&ET
M93X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4
M+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXQ,34L-#DY/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P
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M"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,'!T.R!415A4+4E.1$5.5#H@
M+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3W1H
M97(@06-Q=6ER960@26YT86YG:6)L97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M:7IE/3-$,CXH-2PV,34\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,CXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XM3$5&5#H@
M,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R!&3TY4+49!34E,63H@=&EM97,G
M/CQF;VYT('-I>F4],T0R/DE04B9A;7`[1"!);G1A;F=I8FQE<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
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M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P
M=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T-#145&1CX-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q
M,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
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M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH,3`L,S$S/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^*3PO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R
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M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^,3`U+#DV,#PO9F]N=#X\
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M;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#0T5%1D8^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^#0H\
M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,C!P=#L@5$585"U)3D1%3E0Z("TQ
M,'!T.R!&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/D1E9F5R
M<F5D(%1A>"!!<W-E=',@5F%L=6%T:6]N($%L;&]W86YC93PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/B@Q,3`L-C(Q/"]F;VYT/CPO
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M/3-$)V9O;G0M<VEZ93H@,2XU<'0[)R!V86QI9VX],T1T;W`^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&3TY4+49!34E,63H@=&EM
M97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P86X],T0R
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H="!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
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M;&4],T0G9F]N="US:7IE.B`Q+C5P=#LG('9A;&EG;CTS1'1O<#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`R+C(U<'0@9&]U8FQE.R!&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT(&-O;'-P
M86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#(N,C5P="!D;W5B;&4[($9/
M3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX-"CPA+2T@96YD(&]F('5S97(M<W!E8VEF:65D
M(%1!1T=%1"!404),12`M+3X\+V1I=CX-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(&YE="!D969E<G)E
M9"!T87@@;&EA8FEL:71Y(&]F("0T+C<F(S$V,#MM:6QL:6]N(&%T($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3`@<F5L871E<R!T;R!T:&4@=&5M
M<&]R87)Y(&1I9F9E<F5N8V5S(&%S<V]C:6%T960@=VET:"!T:&4@25!2)F%M
M<#M$(&EN=&%N9VEB;&4@87-S971S(&%C<75I<F5D(&EN('1H92!#=7)A1V5N
M(&%C<75I<VET:6]N+"!W:&EC:"!A<F4@;F]T(&1E9'5C=&EB;&4@9F]R('1A
M>"!P=7)P;W-E<RX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[07,@;V8@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,2P@=&AE($-O;7!A;GD@:&%D('1H92!F;VQL;W=I;F<@
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M;R!T:&4@;65R9V5R(&]F('1H92!#;VUP86YY(&%N9"!!5D%.5"P@)#,S+C`F
M(S$V,#MM:6QL:6]N('=A<R!G96YE<F%T960@8GD@=&AE($-O;7!A;GD@=VAI
M8V@@97AP:7)E(&%T('9A<FEO=7,@9&%T97,@<W1A<G1I;F<@:6X@,C`R,R!A
M;F0@9V]I;F<@=&AR;W5G:"`R,#(X.R`\+V9O;G0^/&9O;G0@<VEZ93TS1#(^
M/&)R("\^#0H\8G(@+SX\+V9O;G0^/"]D9#X-"CQD="!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`M,3%P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CXF(S@R,C8[/"]F;VYT/B`\+V1T/@T*/&1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^4')I;W(@=&\@=&AE
M(&UE<F=E<B!O9B!T:&4@0V]M<&%N>2!A;F0@059!3E0L("0Q,S(N-"8C,38P
M.VUI;&QI;VXL(&YE="!O9B!E>'!I<F%T:6]N<R!A;F0@=71I;&EZ871I;VXL
M('=A<R!G96YE<F%T960@8GD@059!3E0@=VAI8V@@97AP:7)E(&%T('9A<FEO
M=7,@9&%T97,@<W1A<G1I;F<@:6X@,C`Q,B!A;F0@9V]I;F<@=&AR;W5G:"`R
M,#(X+B!.3TQS(&]F("0P+C@F(S$V,#MM:6QL:6]N('=E<F4@=71I;&EZ960@
M:6X@,C`P.2X@)#$S+C`F(S$V,#MM:6QL:6]N(&%N9"`D,3(N,28C,38P.VUI
M;&QI;VX@:6X@3D],<R!E>'!I<F5D(&EN(#(P,3$@86YD(#(P,3`L(')E<W!E
M8W1I=F5L>3L@/"]F;VYT/CQF;VYT('-I>F4],T0R/CQB<B`O/@T*/&)R("\^
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M(&%T('9A<FEO=7,@9&%T97,@<W1A<G1I;F<@:6X@,C`R."!A;F0@9V]I;F<@
M=&AR;W5G:"`R,#,Q.R!A;F0@/"]F;VYT/CQF;VYT('-I>F4],T0R/CQB<B`O
M/@T*/&)R("\^/"]F;VYT/CPO9&0^#0H\9'0@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@+3$Q<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,X,C(V.SPO9F]N=#X@/"]D=#X-"CQD9"!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/E!R:6]R('1O(&ET<R!A8W%U
M:7-I=&EO;B!B>2!T:&4@0V]M<&%N>2P@)#4Q."XS)B,Q-C`[;6EL;&EO;B!W
M87,@9V5N97)A=&5D(&)Y($-U<F%'96XN(#PO9F]N=#X\+V1D/CPO9&P^/"]L
M:3X\+W5L/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N
M="!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#M);B!G96YE<F%L+"!A;B!O=VYE<G-H:7`@8VAA;F=E
M+"!A<R!D969I;F5D(&)Y(%-E8W1I;VXF(S$V,#LS.#(@;V8@=&AE($EN=&5R
M;F%L(%)E=F5N=64@0V]D92P@<F5S=6QT<R!F<F]M('1R86YS86-T:6]N<R!I
M;F-R96%S:6YG('1H92!O=VYE<G-H:7`@;V8@8V5R=&%I;B!S:&%R96AO;&1E
M<G,@;W(@<'5B;&EC(&=R;W5P<R!I;B!T:&4@<W1O8VL@;V8@82!C;W)P;W)A
M=&EO;B!B>2!M;W)E('1H86X@-3`F(S$V,#MP97)C96YT86=E('!O:6YT<R!O
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M,"XT)B,Q-C`[;6EL;&EO;BX@1F]L;&]W:6YG('1H92!M97)G97(@;V8@=&AE
M($-O;7!A;GD@86YD($%604Y4+"!T:&4@0V]M<&%N>2!E>'!E<FEE;F-E9"!C
M:&%N9V5S(&EN(&]W;F5R<VAI<"!A<R!D969I;F5D(&)Y(%-E8W1I;VXF(S$V
M,#LS.#(@:6X@2G5N92`R,#`Y(&%N9"!$96-E;6)E<B`R,#`Y+B!&=7)T:&5R
M+"!P<FEO<B!T;R!T:&4@059!3E0@;65R9V5R+"!T:&4@0V]M<&%N>2!A<R!A
M('-T86YD(&%L;VYE(&-O;7!A;GD@97AP97)I96YC960@82!C:&%N9V4@:6X@
M;W=N97)S:&EP(&EN($]C=&]B97(@,C`P-RX@07,@82!R97-U;'0@;V8@=&AE
M(&]W;F5R<VAI<"!C:&%N9V4@:6X@3V-T;V)E<B`R,#`W+"!U=&EL:7IA=&EO
M;B!O9B!T:&4@0V]M<&%N>2=S($Y/3',@<')I;W(@=&\@3V-T;V)E<B`R,#`W
M(&ES('-U8FIE8W0@=&\@86X@86YN=6%L(&QI;6ET871I;VX@;V8@)#0N-28C
M,38P.VUI;&QI;VX@;VX@)#(X+C,F(S$V,#MM:6QL:6]N(&]F($Y/3',@9V5N
M97)A=&5D(&)E9F]R92!T:&%T(&1A=&4N($%S(&$@<F5S=6QT(&]F('1H92!O
M=VYE<G-H:7`@8VAA;F=E<R!I;B!*=6YE(#(P,#D@86YD($1E8V5M8F5R(#(P
M,#DL('1H97)E(&ES(&%N(&%N;G5A;"!L:6UI=&%T:6]N(&%M;W5N="!O9B`D
M-BXP)B,Q-C`[;6EL;&EO;B!O;B`D-C<N-R8C,38P.VUI;&QI;VX@3D],<RX@
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M<"!C:&%N9V4N(#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,
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M979E;&]P;65N="!C<F5D:71S("@B4B9A;7`[1"!C<F5D:70B*2!O9B`D,C`N
M."8C,38P.VUI;&QI;VX@86YD("0Q-"XT)B,Q-C`[;6EL;&EO;BP@<F5S<&5C
M=&EV96QY+"!W:6QL(&)E('5T:6QI>F5D(&EN('1H92!F=71U<F4@<&5R:6]D
M<RX@1G5R=&AE<BP@=&AE($-O;7!A;GDG<R!A8FEL:71Y('1O('5S92!T:&4@
M<W1A=&4@3D],(&-A<G)Y9F]R=V%R9',@;V8@87!P<F]X:6UA=&5L>2`D.#@N
M-R8C,38P.VUI;&QI;VX@86YD('1H92!R96UA:6YI;F<@9F5D97)A;"!A;F0@
M<W1A=&4@4B9A;7`[1"!C<F5D:70@8V%R<GEF;W)W87)D<R!O9B!A<'!R;WAI
M;6%T96QY("0Q-"XP)B,Q-C`[;6EL;&EO;B!A;F0@)#DN,B8C,38P.VUI;&QI
M;VXL(')E<W!E8W1I=F5L>2P@;6%Y(&)E('-U8G-T86YT:6%L;'D@;&EM:71E
M9"X@5&AE<V4@<W1A=&4@3D],<R!A;F0@9F5D97)A;"!A;F0@<W1A=&4@8W)E
M9&ET<R!E>'!I<F4@870@=F%R:6]U<R!D871E<R!S=&%R=&EN9R!I;B`R,#$R
M(&=O:6YG('1H<F]U9V@@,C`S,2X@5&AE($-O;7!A;GD@:&%S(&YO="!Y970@
M8V]M<&QE=&5D(&$@<W1U9'D@;V8@=&AE<V4@8W)E9&ET<R!T;R!S=6)S=&%N
M=&EA=&4@=&AE(&%M;W5N=',N(%5N=&EL(&$@<W1U9'D@:7,@8V]M<&QE=&5D
M+"!N;R!A;6]U;G1S(&%R92!B96EN9R!P<F5S96YT960@87,@86X@=6YC97)T
M86EN('1A>"!P;W-I=&EO;BX@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4W5B<V5Q=65N
M="!O=VYE<G-H:7`@8VAA;F=E<RP@87,@9&5F:6YE9"!I;B!396-T:6]N)B,Q
M-C`[,S@R+"!C;W5L9"!F=7)T:&5R(&QI;6ET('1H92!A;6]U;G0@;V8@;F5T
M(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@86YD(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N="!C<F5D:71S('1H870@8V%N(&)E('5T:6QI>F5D(&%N
M;G5A;&QY('1O(&]F9G-E="!F=71U<F4@=&%X86)L92!I;F-O;64N(#PO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT
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M>2X@070@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"P@=V4@:&%D
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[36%S<V%C:'5S971T<RP@3F5W($IE<G-E>2!A
M;F0@0V]N;F5C=&EC=70@87)E('1H92!T:')E92!S=&%T97,@:6X@=VAI8V@@
M=&AE($-O;7!A;GD@<')I;6%R:6QY(&]P97)A=&5S(&]R(&AA<R!O<&5R871E
M9"!A;F0@:&%S(&EN8V]M92!T87@@;F5X=7,N(%1H92!#;VUP86YY(&-O;7!L
M971E9"!A;B!E>&%M:6YA=&EO;B!B>2!T:&4@26YT97)N86P@4F5V96YU92!3
M97)V:6-E('=I=&@@<F5S<&5C="!T;R`R,#`X('=H:6-H(')E<W5L=&5D(&EN
M(&YO(&-H86YG92!T;R!O=7(@,C`P."!T87@@<F5T=7)N+B!4:&4@0V]M<&%N
M>2!I<R!N;W0@8W5R<F5N=&QY('5N9&5R(&5X86UI;F%T:6]N(&)Y(&%N>2!O
M=&AE<B!J=7)I<V1I8W1I;VYS(&9O<B!A;GD@=&%X('EE87(N(#PO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
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M<&5N9&ET=7)E<R!A;F0@4B9A;7`[1"!T87@@8W)E9&ET(&-A<G)Y9F]R=V%R
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M,C`Q,2!A9V%I;G-T('1H92!#;VUP86YY)W,@;F5T(&1E9F5R<F5D('1A>"!A
M<W-E=',N(#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)
M15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,N/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13
M($%.1"!#3TY424Y'14Y#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\='(^#0H\
M=&0^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I
M>F4],T0R/CQB/B@Q-BD@0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,@
M/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,G/CQF;VYT('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.U1H92!#;VUP86YY(&AA<R!F86-I;&ET
M>2!A;F0@97%U:7!M96YT(&QE87-E<R!T:&%T(&5X<&ER92!A="!V87)I;W5S
M(&1A=&5S('1H<F]U9V@@,C`Q-RX@0V5R=&%I;B!O9B!T:&5S92!F86-I;&ET
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M:&ES('-E8W5R:71Y(&1E<&]S:70@;V8@)#`N,B8C,38P.VUI;&QI;VX@=&\@
M;W1H97(@87-S971S(&EN('1H92!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E
M=',@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,"X@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(&9O;&QO=VEN9R!O
M8FQI9V%T:6]N<R!F;W(@8F%S92!R96YT(&%N9"!#04T@8V]S=',@=6YD97(@
M9F%C:6QI='D@86YD(&]T:&5R(&YO;BUC86YC96QA8FQE(&]P97)A=&EN9R!L
M96%S97,@87,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!D;R!N;W0@:6YC
M;'5D92!T:&4@97AE<F-I<V4@;V8@<F5N97=A;"!T97)M<R!O<B!E87)L>2!T
M97)M:6YA=&EO;B!P<F]V:7-I;VYS("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^
M/"]P/@T*/&1I=B!S='EL93TS1"=0041$24Y'+5))1TA4.B`P<'0[(%!!1$1)
M3D<M3$5&5#H@,'!T.R!0041$24Y'+4)/5%1/33H@,'!T.R!-05)'24XM3$5&
M5#H@,34E.R!724142#H@-S`E.R!0041$24Y'+51/4#H@,'!T.R!03U-)5$E/
M3CH@<F5L871I=F4G/@T*/'`@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,CX\(2TM($-/34U!3D0]041$7U1!0DQ%5TE$5$@L
M(C$P,"4B("TM/CPO9F]N=#X\+W`^#0H\(2TM(%5S97(M<W!E8VEF:65D(%1!
M1T=%1"!404),12`M+3X-"CQD:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@
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M3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^,C`Q,CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C(L-#`U/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX-"CQP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4]
M,T0R/C(L-#$T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/@T*/'`@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CXR,#$T/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O
M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M63H@=&EM97,G/@T*/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S
M:7IE/3-$,CXR,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1B;W1T
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M:7IE/3-$,CXQ+#`Q-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$N-7!T.R<@=F%L
M:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
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M>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&]T86P@;6EN
M:6UU;2!L96%S92!P87EM96YT<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@86QI9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-I>F4],T0R/C$S+#$X,3PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$N-7!T.R<@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#(N,C5P="!D;W5B;&4[($9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"CPA+2T@
M96YD(&]F('5S97(M<W!E8VEF:65D(%1!1T=%1"!404),12`M+3X\+V1I=CX-
M"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#(^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[5&AE($-O;7!A;GDG<R!T;W1A;"!R96YT(&%N9"!#04T@97AP96YS
M92!F;W(@86QL(&9A8VEL:71Y(&QE87-E<R!W87,@)#(N-28C,38P.VUI;&QI
M;VX@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q
M+"`R,#$P(&%N9"`R,#`Y+B`\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE
M/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%5$E214U%3E0@4T%624Y'
M4R!03$%./&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)%5$E214U%3E0@4T%624Y'4R!03$%./"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%5$E214U%3E0@4T%6
M24Y'4R!03$%./"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B
M;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R/CQB
M/B@Q-RD@4D5425)%345.5"!3059)3D=3(%!,04X@/"]B/CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.U1H92!#;VUP86YY(&UA:6YT86EN<R!A(#0P,2AK*2!0;&%N('=H
M:6-H(&ES(&%V86EL86)L92!T;R!S=6)S=&%N=&EA;&QY(&%L;"!E;7!L;WEE
M97,N(%5N9&5R('1H92!T97)M<R!O9B!T:&4@-#`Q*&LI(%!L86XL('!A<G1I
M8VEP86YT<R!M87D@96QE8W0@=&\@8V]N=')I8G5T92!U<"!T;R`Q-24@;V8@
M=&AE:7(@8V]M<&5N<V%T:6]N+"!O<B!T:&4@<W1A='5T;W)Y('!R97-C<FEB
M960@;&EM:71S+B!4:&4@0V]M<&%N>2!M87D@;6%K92`U,"4@;6%T8VAI;F<@
M8V]N=')I8G5T:6]N<R!O;B!U<"!T;R`T)2!O9B!A('!A<G1I8VEP86YT)W,@
M86YN=6%L('-A;&%R>2X@0F5N969I="!E>'!E;G-E(&9O<B!T:&4@-#`Q*&LI
M(%!L86X@=V%S("0P+C(F(S$V,#MM:6QL:6]N+"`D,"XR)B,Q-C`[;6EL;&EO
M;B!A;F0@)#`N,28C,38P.VUI;&QI;VX@9F]R('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"`R,#$P(&%N9"`R,#`Y+"!R97-P96-T
M:79E;'DN(#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0U,C1F9C@W7V(V
M9&1?-&)A,E\Y-C=F7S,Q.6,W9C!C9C!C,PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]D-3(T9F8X-U]B-F1D7S1B83)?.38W9E\S,3EC-V8P8V8P
M8S,O5V]R:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4T5,14-4140@455!4E1%4DQ9($9)3D%.0TE!
M3"!$051!("A5;F%U9&ET960I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-%3$5#5$5$(%%505)415),62!&24Y!
M3D-)04P@1$%402`H56YA=61I=&5D*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y314Q%0U1%1"!154%25$523%D@1DE.04Y#
M24%,($1!5$$@*%5N875D:71E9"D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-
M"CQT9#X-"CQP('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@
M<VEZ93TS1#(^/&(^*#$X*2!314Q%0U1%1"!154%25$523%D@1DE.04Y#24%,
M($1!5$$@*%5N875D:71E9"D@/"]B/CPO9F]N=#X\+W`^#0H\9&EV('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,1494.B`P<'0[(%!!
M1$1)3D<M0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`Q,"4[(%=)1%1(.B`X
M,"4[(%!!1$1)3D<M5$]0.B`P<'0[(%!/4TE424]..B!R96QA=&EV92<^#0H\
M<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4],T0R
M/CPA+2T@0T]-34%.1#U!1$1?5$%"3$5724142"PB,3`P)2(@+2T^/"]F;VYT
M/CPO<#X-"CPA+2T@57-E<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%("TM/@T*
M/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*/'1R
M/CPA+2T@5$%"3$4@0T],54U.(%=)1%1(4R!3150@+2T^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1&QE9G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('=I9'1H/3-$,3(^/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0W/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!W:61T:#TS1#0T/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S)R!W:61T:#TS1#$R/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M-SX\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=VED
M=&@],T0T-#X\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<@=VED=&@],T0Q,CX\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R<@86QI9VX],T1R:6=H="!W:61T:#TS1#<^/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('=I9'1H/3-$-#0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('=I9'1H/3-$,3(^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0W/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!W:61T:#TS1#4P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!W:61T:#TS1#$R/CPO=&0^/"$M+2!404),
M12!#3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS1&)O
M='1O;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@5TE$5$@Z(#$W<'0[($)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)SX\9F]N="!S:7IE/3-$,3X\8CXR,#$Q(#PA+2T@
M0T]-34%.1#U!1$1?4T-23U!0141254Q%+#$W<'0@+2T^/"]B/CPO9F]N=#X\
M+V1I=CX\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-
M24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@
M<VEZ93TS1#$^/&(^43$@,C`Q,2`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY1,B`R,#$Q
M(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*/'1H
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!&
M3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQF;VYT('-I>F4],T0Q/CQB/E$S(#(P,3$@/"]B/CPO9F]N=#X\+W1H/@T*
M/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE<R<@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^/&(^
M430@,C`Q,2`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&
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M/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*/'1R
M('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP('-T
M>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&]T86P@<F5V
M96YU93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G
M34%21TE.+4Q%1E0Z(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,CY.970@;&]S<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A
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M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH,3`L,C,V/"]F;VYT/CPO=&0^#0H\
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M,CXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!V86QI9VX],T1T;W`@8F=C;VQO
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M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^*#`N,C<\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH,"XR.3PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0R/BD\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D
M:78^#0H\(2TM(&5N9"!O9B!U<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@
M+2T^/"]D:78^#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF
M;VYT('-I>F4],T0R/B8C,38P.SQB<B`O/CPO9F]N=#X\+W`^#0H\9&EV('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!P=#L@4$%$1$E.1RU,1494.B`P<'0[
M(%!!1$1)3D<M0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`Q,"4[(%=)1%1(
M.B`X,"4[(%!!1$1)3D<M5$]0.B`P<'0[(%!/4TE424]..B!R96QA=&EV92<^
M#0H\<"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G/CQF;VYT('-I>F4]
M,T0R/CPA+2T@0T]-34%.1#U!1$1?5$%"3$5724142"PB,3`P)2(@+2T^/"]F
M;VYT/CPO<#X-"CPA+2T@57-E<BUS<&5C:69I960@5$%'1T5$(%1!0DQ%("TM
M/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*
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M04),12!#3TQ534X@5TE$5$A3($5.1"`M+3X\+W1R/@T*/'1R('9A;&EG;CTS
M1&)O='1O;3X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@5TE$5$@Z(#$W<'0[($)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)SX\9F]N="!S:7IE/3-$,3X\8CXR,#$P(#PA
M+2T@0T]-34%.1#U!1$1?4T-23U!0141254Q%+#$W<'0@+2T^/"]B/CPO9F]N
M=#X\+V1I=CX\+W1H/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R<^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M
M1D%-24Q9.B!T:6UE<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O
M;G0@<VEZ93TS1#$^/&(^43$@,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S)SX\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9#L@1D].5"U&04U)3%DZ('1I;65S)R!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\9F]N="!S:7IE/3-$,3X\8CY1,B`R
M,#$P(#PO8CX\+V9O;G0^/"]T:#X-"CQT:"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1H/@T*
M/'1H('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!&3TY4+49!34E,63H@=&EM97,G(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQF;VYT('-I>F4],T0Q/CQB/E$S(#(P,3`@/"]B/CPO9F]N=#X\+W1H
M/@T*/'1H('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60[($9/3E0M1D%-24Q9.B!T:6UE
M<R<@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&9O;G0@<VEZ93TS1#$^
M/&(^430@,C`Q,"`\+V(^/"]F;VYT/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].
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M;VYT/CQB<B`O/CPO=&@^#0H\=&@@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)SX\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T:#X\+W1R/@T*
M/'1R('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-#145&1CX-"CQT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X-"CQP
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^5&]T86P@
M<F5V96YU93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!
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M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
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M/3-$)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^3F5T("AL;W-S*2!I
M;F-O;64\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S:7IE/3-$,CXH.2PP.#<\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
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M)TU!4D=)3BU,1494.B`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R<^/&9O;G0@<VEZ93TS1#(^0F%S:6,@;F5T("AL;W-S
M*2!I;F-O;64@<&5R(&-O;6UO;B!S:&%R93PO9F]N=#X\+W`^/"]T9#X-"CQT
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M<VEZ93TS1#(^*#`N,S`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,CXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(^)B,Q-C`[/"]F
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M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-I>F4],T0R/C`N-S$\+V9O;G0^
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M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G
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M/3-$<FEG:'0^/&9O;G0@<VEZ93TS1#(^*#`N,S`\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U&
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M,T0R/C`N-S`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H\(2TM(&5N9"!O
M9B!U<V5R+7-P96-I9FEE9"!404='140@5$%"3$4@+2T^/"]D:78^/"]T9#X\
M+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R-"YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A
K<G1?9#4R-&9F.#=?8C9D9%\T8F$R7SDV-V9?,S$Y8S=F,&-F,&,S+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001047469-12-002276-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001047469-12-002276-xbrl.zip
M4$L#!!0````(`-9E:$!HLZD:7:(``%8P!P`1`!P`8VQD>"TR,#$Q,3(S,2YX
M;6Q55`D``X/P6$^#\%A/=7@+``$$)0X```0Y`0``[%U;<^,VLG[?JOT//#JI
M35)ER01O(CV7+8\O4]K,C%VV<WLZ19&0S`Q%ZI"4;>77;P,4;R!$"I1D>Q+E
M82*)1/>'1J.[T6C`;__]-/.E!QS%7AB\ZZ&!W)-PX(2N%TS?]19QWXX=S^O]
M^_T___'V?_I]Z2S"=H)=:;R4/N,H\GQ?.@NC>1C9"1"0^OWLQ8\XP%'VZN7B
M#R^)%](H2(!38D^Q]-NO=N!*'V1DR.M:C6Y&M])U%"9`^)<4H:0,Y($R4-,6
M3^/(]T[(OQ+T(HCI1^]=[SY)YB?'QX^/CP/RRR",IL>*+*O'7@#,`P?W5N\[
MOOM4>=W!ON_BI^0>4,SQ(O&<>."$,VB-$%)4E#7TO>!K`Q_R>&S'.1^0X]2V
MYWF+B1V/Z=NK!Y1^7T;]@@,AZ!9]*=,WCM.'^:MQM<^/:O8F.O[M\Z=;YQ[/
M[#[;=R\.-04-FZ25OI$U<#$#)\;.8!H^',,#7@=J,EKA0I9E'=.G/1A$27I+
M/I[$%.4-GDCTT4FRG.-WO=B;S7T"F?YV'^')NQX9M'XV((.GV.U)QRFA5!^<
M$+3L*9$\]UWO'-Z34S;Y<QPD7K)<_9;_ZKGD]XF'(XE"P17H65?/1C_UWLOP
MWU`#T9AOC]G&&:MC#J\5ISF.O-!E^</@1,DYJ/Y[`IF(4D89E>(9TP@';M$$
M*2#]@K%;:I#]6F*=_;225H,`9>N;$Z!L"0L0FNQ%@*-O1@-3`Y%PE"E[L@M9
MH&]-%F@_LCC_9F11L4Q(W#*A_4TL='WY38BPHDZRT5?EO4RMVZMO31I*7U;Z
MBK67R?5_9^%L%@:W2>A\_8QG8QR]@'2*682G,YQW+7_@`HRGN>\Y7I)BE%P/
MWDNC\55T>'*;P(0AK2_^?P&(H5_S,("O\>F3%_?>9Z_5^OOVF,NB@';,P_97
MLA"R>=""Y]*"8EK+YM[B!QC04]?UR&+3]J]MSQT%9_;<2VS_;S&XC7W_RPVT
MXRQF"Y^D`Z[(BIP()<+W1'0/>!3`NAS_/09]4SG\U13@!B>V%V#WPHX"+YC&
M?XO1YG?Z+S:TWUB<NB]9T.S*P:&]M$-[I:FC5#L.\>O?6PM&WTP&MF0OK;W:
MRT-<^#KCPE<Z@U*M.023SQY,OE)]&!W\Z@LM*?;D%D:',/HUA-'/-M`'__\Z
M_?]S*<#!E;]D7FA_L3V2#T;\I8WX*ZU#HOO;AXG_DA-_7Y4PZ=`>G/JK=^I[
M5H"#Y7\MX?M^!_JP\/[+#&@:LQT&]!";';3@):;UGNJT5TNQ0T3V.B.R5VH&
M4JTY+-%>=)OE%>G#Z)#0>65A_1Z/]1S<Q:MU%\^E``?+_Y+)N3V&@H?<S(L;
M\5=ZPN;\D+I]S9;_56O-P5V\[$+A9?5A$7BI,OQ\>\Z,^0S;\2+"[U?73YS`
M&QFA[%&9.*'$I7Q[;T<X7D-\U6GZ2B?J@.H:1Y0'P\+U'D#'6#&2AE\6,W*[
M21BQ*K9QI\N"YE,LL3O'03CS@F:&;8)@.=:)9D]+_:Y+CUS:`=K_@(,%OHS"
MV744N@L'J#U@/YP3K3X-W$^>0^95,#V=1IC.IIC*^N[T(^I)+G:\F>W'[WI]
MM2>M=.J&W`B2WO(A$6[T.]4I34;F$&;_V^.NO%/DV=3]%7O3>S#MIP\@\2D&
MR<,4O9J<>_X"?DV5[6J1D+"+7)Z3`5=:@,M6"7BFLL@R%95B[\A])]!5$9EG
MT%5D&N;NH*]SI)=A!&2#LT44X<!9WD5V$-L.B=-@+.DWG]Y(=.K^L8@3,IQ?
M<'(UN;.?KL.(/DB2R!LO$GOLX[OP&D`$2=9Q763,J+*!8:ST^5EA5R4&#5)>
MG\(X/GVP/3]]MY2OO@]]%T?Q!SOVG*S/AGB?54-7]$JW!7EOI*4U!:G`'NYU
M>O%Y5V&?SLC(_$F'[6HR"N#-J0>]/HUC7-@O4]A^J4BK8FQFU`64)3SFEF9U
MQ^0X$:8Z7&ET[L5.N""14N!>1WCF+6;Q*'C`J?H7#D`6EB#2JE@[\:_VX;,=
M?<5T\MUB9Q'!PA#''R&B(_J>(^WBJ\I`FYAT@"/D@=*9K70%E/UZ%=S:/KZ:
M@*N%>#!97OMV&AI3=YM#$_(PZ:RH^I;-^&V%41,6GZX;6X.DE@>L#7:)%P$7
MDMZOEX%J\U!UP2FF7'51?`Y"*,1]ABKKIC`*9K[B<9+-V=5\S0&U>8.Z6(:*
MV6#0.+RZ0FMS`'59(1-M`PT<<01Q/#['Z?]'`1C`S-#1^.0&.]A[(-,Z-Q:*
MN)7M*T2O2CB%&.\"<YN]Y89KIKH_T#`><]MSS_$$0YSG7CP1Q<89H:H/5MK,
M<UWBNF:T8-\$P$X[T6;(.4,PU-I&0+P7T")]EX::O]C^`N<0P8X_Q=Y)X/GO
M>DFTP%6,(XZ@LVLEBQQ/$;^F:9Z<>*,]YM%^/X38N1H\U\E7V;.YHU*Z$41$
MTD8YG$;#S(731P;XAV$%4#O#6H#7EO\D;C!;T>1H&ZTV%ZTRU!$;VXFPKN(N
MK4[6+^,K]GOTY;(99;X:5F1=5TVE0-K$K`76*(X7V,T16?M"E/)I`7.Z2.[#
MR/NS`*3*G0`I%M&ZRF@V,%N+"I;"5Q'-PKITWF?)N1P=$D)72>_)`YDD2@6X
M-IFE]?D6I9,`2X)K8=2.JJIBJKH/0#SUXKW'T3"MF\JS^M7,3=PXJ'HK+L3!
M1;8E9$,U]F`<5&-?B'BCMV:+M-0VQ]7!UJN*,62R#JW\Q(U7NWWG">RYC%>[
MK4>[-EXN]DXNZ-;2#9YZ<1+!8O6+/<LQ:7(]5$6]]V?I#>K27>D*]2,)7/#@
M[?$ZDBS#,U@.1[8_"H#03SB/LC3$Y5C>XEM+HV!Q'D*H``_OEO.B+PJ7,I+[
M/Z4TRXWJI*[IEM=%NAV6T^2$\D"SO(VVED;!XA2>N>3YI6_G]D;3N*0GH!TX
MI5II5E!+\\[)):P;;?]W;$<L9IU+N%\&O(X&.XB_@B+\%(2/P2U$\R&$D=1R
M1#DK@\OJ2U@>Q#4T6%:_A#ZLU.QH>>GY$#SG+(8;L&#:UE0Q[>T-GI/%=S`E
MTV51<#"Y''XG6VEM-%A.E/\9"'(:1H7*6UP&$.YB?_6'$FB[,KL*(9;+]6+L
M>\ZE']K%;D=US:]S;,OU92TYH1MH9?BXQ&MRW,"-ZNTA&KGBN&Z%]2&L7JC;
MVHQA?087VGP)O^3CJ_/M`OFW.GN9]NL8I).\RH)O)BY_YS$HM:_ZDFR)EIEP
MND\!*^75)EO.K!)`U3O'+M,++])'`U,KO$@+OUIN`=9?L.Q:K>`_X`"6CX7^
M==ANTQ6+31[P6'0*P_5NL=/^PG!]N`]`W<-PO5NLM%487GVW+5[2Q=;&;+R$
MUF'LLMQKPVJT+YN;8KLML7;=+1;?X^HKNEK-^#W_;K$AE&P5+FG89+MX0TMM
MJ,V6>KW^]D$IS*TL-1D.4B=S!BR]8`&MK^8X_0-/\0<\"2.<FUL<7SQ!F!U&
MT%N(H48)GL5?PH"`C4+?AZ;T3S[A.+?V1MM^VB::LT><K$#27U=N)>^$^/X;
M4M4ATX<*:69:AD&8]H4@(YU@$;3MO7&V#12]ZC37,F%*<*KOE/>6#?$-M[ZA
M,7EO#GUVH1S3;9@5NH*[>%&%KBJ:R2S7J\29O6+Z]\A\>'[JSKR`KED3[Z$V
M&FV5%!Q]D#5FZ[&%U[I-[',OGH>QE^X*5K=EAN*[>7K513>R8;8GPJ7M)TM&
M,D-Q1X$4><AL1%1(L[LB,43=SCTQ:45!'XM"?)--&1J,+!HYL:!HL6$Q$.*%
M#IHQM%2&?TJ4*_;5PYRAN)4U5-/@27U%F5_&24QO9#MT!GTDZ9RBRQU*%%8;
MR>U,=A+##%M-**H9+TT;6M;N@IAG\+?#5A.]22^?S>&NL_7#5EM?ZX:N&(8F
M8.LY>X;L5N50O&*.5$F:.ILA7L>H;5.>;F[F#I,I,>Q0NZ'KEL(.]`8LMX+9
MH5QCJ.P#95;A<6TOR9PECM=Q(E@4?_+LL>?3,K<<M;@'Z2-D;5IDT@1AI]WH
M4*BA:,;NN\%Z2+/58=7FMZ48>H.#W/;$@2F>EM(-0]GAB8.2"ZF4LICBY1VJ
MPEJ@"N4J7Y[>B._;J9IA5@/<M<I`)V_I*7$4:<X\Y]]H_KG\P;15:T36<]FT
MS,=L-/^<3`U$529KN]K*?#C2MQHM.Y>O8BE#93/I,S7AC8:.R\N":($IM>:5
M?]/?SJKC:C7:(RXW'?2*Q^V,-Y9G=DSB=?(_(NL'VZ=G\I(S.XJ6,/4J\\IJ
MM$'\S6FDF-6URD8<MP'96FI6DQA")A/.=0$))L-+2^))2QH!3G'@E-74V+K$
M;A,NPU8NK`18+J6I`%S6SW=+W.H@&>:"NF[B<;D]^Y+`ZA+%#F5=>YDEP9H<
M'!AWX6YH.AM';I.#0[)X*,NFG[;/P2&YPP$/U3"9[$;G+!R2Q6-*&`:5K9K9
M01H.R>*'-=`0PO0]Y^&0+!Y+&G)UNFV=B4.R^'$-4[5VG(E#LM")O73.&,BP
MY!VEXI#<X22&CDPV%[AY+@[)XO9V2"H:=I>,0ZVGYWC'3V3^8J8M';=!'@5U
M."/75U2%3=UOF$=YD4/$J,/IME=SB+B^Q,].8;#*W7H^CC.2JJ6:;0D=AE]G
M>!V*2\`YF;M%5\U.<59XJ/4L'2^_9#()$`'&.T#<Q9#7T\K=`(-"D\7+=122
M.R?<#\N?8^Q"ZSP!"-/A@;;C!:9%'\2SRGU5-Y@SC-N!V4_'Q#<D^ZJL,BF#
M5]BQU@.*O/ELF49MTV9G':-K:0=6<F`.B'NDG]/PK$`MOE#0D<$LN!H8L?5'
MH8.Q2]=EY,0Q>(7/=D+.;2^O)KRSW`5.\2RWIJC,44IA]CM#+[X048RAME/P
M]I(F+^["U4@U`Q;WG6!\F'SB1BRW0BGN0BV=*37I`++CKBYJ/OS8>/?8GG=[
MBWB,R(%_AH76:(W9\_`W.)WJ(*SHP7-P6@=\@YUP&E`JE10A4EJM?]N5CK4S
M.%I5Z?;=E4TS\DAMG//IGY&OWTS/+G6J:ZVV%%T3G+84,L`1DCQ2#<-`.X/7
MECPF\#:^S;%F2^7=R;%MBPN`;CB)P?DBYM::;8"U;821]$+M'@=5$^>?UF>?
M@VT,INDDH3/C8C;WPR7&:8WO(G+N88:1FT0*B.T)#C$=M-"P#E\4WDY[V.'B
MHN?M0RDV*QRIUAZ[=K-5&X!H"0`J5]*0-&S]&ASQC(V2G1`29[NMI-M3XF)3
MP#0597,%VJW@NZ37S9W(G0V&Z=5%I)`!/`&3X=;$0UFFR+.=67=PXA$LNSTB
MBF[-"C.]6&SSY:[6H49107KM5KXML.RG7QT*QY&!C(WR$R_:,?'=!4V7F4J5
M7?:KK+C$7-F!`\K+.9J/M"Y%[&C]\IG+K2LX73SO8S"'=@2QT74I=C^%P?0.
M1S-RWU:!IM$9<@L#3--D@M`Z_;55"DS5#-);BW0X6PN*O+8<BU\[$X*^10FY
MSO%V,4ZW[>G5/^.DAJ>UC(=3Y:\Q=Z:V\]OXLB>DM]_VU%8DLAH?;G?%KWM"
M\!]O^-?VCJU6JV$0+P(T454!UK"H7>K$%'+6D(C7!FJ66@UCUW*I@2G7F=:0
MB-?K6&KM(BD.AZ:".:2W5@5N4B7$"R(^AJ'[Z/E^SLIH+02L#[K%;!)E1#GJ
MEF*H5U^BYN.>_/)/IFB8RZ!6Z%.Y/A;<X,63XR_(2<JZ*#J80,-4V9OSVCG6
M/!8_<H:F!;8.YE`VF1K=)DX;5%:BYH.67!"&8FE#CE:N,[_D=C[NK7PU+!T,
M)GNW]`;\^,:"<X$C";!8B%V*JFL7#+<SK&+DI<%KR#K47ELFXVX:&'6KC43-
MIR\W+!06JXT4*I1%S8<R1]R%,V@_$Y3LN9P7-9_1Y"84-4W1MRXZIK*FY3N<
M!`8_=5]@[E#WR*RG.["OXC_'\P@@T"?PV<>K^I?R+;D%8/'LA#)DHJ5-&&X#
M43Q'H>C,SJLX1.',6NNA24XJQ5286*=;[NS9ML]:CTR*9@]KMUX_[_;9\PE.
M//GQPJ+INLF\P3FZ3?>G=OQ7-!H\=O,9N]%F^P],E+K%5EKS`;N1^#13%-,T
M.):F([S6+4AKB[U2]@[O;8"V;DENK(NPEF<+8K8!UA8A<NJ>50#PC'NES2?Z
M5G\'76B_GLV([FJCD2_B#4X&;CKVB@Q6:&=*:;5F#$3^;F1M(:_OS`IM<-Y1
MT`H-D;P[([G!`<EVFZWMI/P@O=UJK<X6,:+5?!UR^T9W_G>:AHIN*:USJ0V8
M0.^X,:_5?"&@0'_TH0+JH6[8H_6A\-8CU'R#7VKW-NF1.@1=1SL>(1+5Q%>3
M53JE?`F_S+]S^%]^\H;F-J0X6?KX76\"[_1C[T]\@N1Y\D:BWR?VS/.7)]_?
M>3,<2U_PHW03SNS@^Z.$_'`4`]+)F]Z_ILF;?_Z#4HQ*G]WB\SSC<GGUY:Y_
M>?IY].GW$XD2H:W).X2A1`"0N]NR'\?DPP_H1^G+Z=W/-Q?2U:7TX>?;T9>+
MVUOI],NY=/7+Q<TOHXM?)?+R\3AK=DR(Y5_FVP*Q9_,W_XL,>4>?N/<]%X_)
MQ<_2#V#=I1XQ[W:P[$EA!%_29KT?)2^6;&GLA7/0D9GM4`JV#\-,WX:A<Q80
MZ$NP5"94W.*XEV0'+GEMAB-8\_K9@CJ<2#$F]_+YDC>;+8(PH<B64H*=^R#T
MPRDI;IT`"$(OB;!-5QNDG4.V!"-*E[:27&\R\9R%G_23L$]?A9]B<E(A'I`>
M2ZL^?1]+/K9=R8T64T+%]5SP:C#?`I),QA+,!#><X[DW6R32#V?GO_41DG\\
MDD@D4L)(^RX]V(X#_AH:@V#FWD,(KD:Z)G.E$*L*0[]PE_QN3'TO'/MVG(!Z
M'TF$&\P2RLR&Z30.W64_!1H&?RRF]/IGPBH"W.&,7O3)<%/&3>QL]X'(S97&
MY`Q'4I9BVE-E",RE<A?O%[,2FI0]PQ.56*XH@A!!-:@YK$A?@I:`(O/1DN-[
M`=4A`H%D1++O\RB<1O8L/EH-##$M%*(FI_(YO3Z3[NQHBJG5N<L49IG",C53
M>9,1206KKAK24<22`UHMS4*2TOR34+"G(*.CDBA4G8AB%OH8M`KD>$^N80[N
MO;&7D&DPMR,J4B+C%<EX&2=X!B+P?1`Q>4!FAD_O"UD]9%71"7U8,89I.8#T
MZ"7WTD???@IO9_#Q)Y_HU@_TAQ\EL,J@W>3:R2"C79].-Z"!D?=$.QJ2>94.
M7P0_/WC1(LXT=B"]?G-UFDCGV*'NK#2;8!`5.D>2BE:!>;'C^R/ZKX2+Q"H=
MT%F>40=[DQ?-@[B^T]6!6A`'IP/S,7@C/8;15Z(43AH]TE<U>:!Q7B7T;8F4
M!4B?0A#UV/;)%*!-D#Y`M2;5^>"E^VN$AD].BE-.VL"L-<LG]!+;D80#%]JL
M%\]`(IM<5!C4)(/.A$4%C!`IZ1&F['>J/AARNC(*I/_8P<*.EN1=I3HJ,<2M
MDG*DZ?(1!+52^H>+J?&FX0KH&"D;60#_%,X96!E`EM^Q0V4;V1[IP'?F0*_+
M!+H50#_GJW(1BN<2CZ,U@+STKF8D'\'ZB<%$9G4%%[%T08KN$30FP8$TIY>F
MP]L33`*F="3+`*0DK#!\Q!$&V0TYLH,I.DF(W\*T-`V4+6=%ODPP3G67E!'-
MZ.WQ&5L)KP[>URWK-,W24PPY.7+-OBVI<M^UEZ`%U%0`SODJJI,6<_*5&/DI
M2)XZ&9`'.M*'.I51R5RO&4)H[H3@QZ60.G,_3)."8+O!Y03+*LXQ]CUP^G%J
M4:DE$YVY=KMEX.O+2ID:5,XK%)KPIZ2XXY?16EGC)CTA[^1:2:AZ^2T?=.4L
M44TF!6-`;P*40')T`WT,O5Z0L,8CT$#*,PS*5F@$:Z8B3$M&9[GX"#%I#@8I
M(/I3-0`@1)\&`0E5XB?X\(C]!PPN+TCNXV_!0Y35:C4<E=E(C"D8+JL^>"Y=
M\0@802+-[S1CH#322A[#E?A6%+-A+P5H%J6H2),HG-%&,>@[SP(-I/."<GV`
MJJ9M!G,[L;]B&/*(QL.@3'-JCZA@*C'72ELR?2)\_3"8]A/BQ'P/=,@E>8T@
M-:D@Y!@7*@;4:+B4US52UJOH^4@:0]1,?H`XF:BO[T$@0PQ2>`1:CLEZ8A9&
M.`N<)A#^A(]`[X1^];-KUNCS/*3+@\$T0,)/'BVM),0"6!J68B@0#HG+`C!Y
M1](<_"FI%P%,0!/'5+IC4JE&YL`1]0:9JW;Q&(*_E5LL/ZC8.7B>+C9*MNC!
M@U@P`J,%9A-FFK.:??`J8P5`E+_>>S22+(;-28M",1VI&..OQ>C<1^%B>@^6
M.Z!7EA,P,VP'Z;A'9$0"(N$`3#?@C2A@:E)+0SV!W@8.D55F3^QLCX(8'8@%
M\3RUKF3L5P8;*/C^46[^BF`UP/]M[UV;&D>2A>'O$S'_02^G)P8B!.LKV#T[
M&^$&NL=[NH$%>O?L\V5#MLI8V[+DU07P_OHW,ZM**LFRL3$&R=1&S+:QI:K*
MK*R\55[N_,BAK%M#EC5!WB:6?"AI@XV`OT2<,(!%A<`1038EVP:<SP?9@WP<
MP$#UA(@,R^S#5V[H%\"4$:H2%%JW#R<M(HL#/DKBSY)$P'B1A7#L3&$74A<A
MB1N@]!1-N&08VL:*Z_AJ5IX##D+%(?<;D4WZ-D>?1+`I#L:]CV<V=.X\!S@Y
MR!LNZ:8\T-\`\\^Y$VR96\GWS*."(`0XBHG`&4:Y9?!0C!FNC[-UABBV$E+G
M>JERGI`AX&-W0)$9HX-O$S<N<#,#JEY"^K&D=J(-N1S05EAN,0RH&*S1(1`%
M2#^@$)<SMRD/NP^%O%7\`:"HC7*:&3PD-Y1S+.(/*`R![H!80A2>*[$LV`;.
M@\86WT$;]G^&X-C8A)<?N#D/!1POE4&E]J?Z$H[!!_,.[WR!6+2-A\Z4)')B
MO\*F`2F;8@O@S3A*V1A('-"!D-G`&49M;@COF@)N#K,594C&%NV#:5,\L2^Q
M-[+N81N+SR]N.=JX\`>M,F.Q"KPO%/+TB7O2^,<@_8CS<44@=2;.^0%S;D)!
MEJ<I`\:&R&#QQ`&[!='VR54BR!NUXEX^E?(=-@]2C^'IY;=/_8O>;?_RXF:[
M'D/XTL$/:F4#V/)3X*5?@`V?^L%4.AOVQ9<'?$5.-7R8EYYQ.8S\C))&.EJM
MFU6(+%%^0<*.SAP02Q,F!;,[.P2.B$K:4!Z&SU(=X2,)I%DI+OD4@N&C/80]
M6[C`#]C(98)/IP](,6D*#DLZ::*(<X:/TF`$\X;R<'(U)5F8P[AA"R<".&'J
M*%JX1I"_C+*=5D35OG.0/B%MY+9YTFB8)_7F(J,ORTF(W]2.&B?-KG@!/7?`
MW,#&].X861S,&H[YCX0%I9V3!$.=`!0X-PXY>F`D8)@QOC8*>/VDU!H5+FLQ
MQ+F<\1I1O'=@`G@J?*A83(2)K,I>+J/$*"#4`$TG!D]LH6OH["ST*WZ_=\"M
M=`1-A:C`SLY@;]]*!^.S7-(;,)XTXA4K-3\KS0EP+0+L0[VQP%W2^@7I2"9O
M@'F99F]P;<8&,3=OM0`Y<#LHBP9,B=@[J(JI&*75M\BI97%IA4:W'RCH5@X3
MJ!O1V+?)=Y[(-N[/4)XZQ"L$8V0Y@7%/45;)00;MRY:'G:;G:3#\EY![=3C+
MF'M9=1*K;BE^/M&T[;0+/)+<[L^,5D1G0I\C!Y4E:HR1G49>^%1,@PY!$5HT
M8:/`E#XR+D<9(LW.(JC2)#4$C</Z+R:?U9G`]V!-,'=F"-]'/(4)42L03A-$
M>6"3%9!P/*Z,"AP)3L3/FI76!:<C25>8W(^8_%(54DV\&@PQ($YU=E<3`6?Q
M'!>N\*?%OV`KT1DBLR;$8\B5Y[ZZDQD;W)G-[^3(`$X8)*=YO&1C6,D.C&H6
M/3#&G5^IXW`QQ4MS,@>$6'L"2PX(R=3PN*:X\),5X[+`=D@`(%-/6-,SCP7\
M`E%Z6@JDI0#9%OEI@*['9`$S,1S-F"RQ?W5->X7_G<UC\\BX(#N"$VBR,"=,
M%'T<#6U,[OC%-Y']"%<@S@\2`_0&Z=\=I4H)UWWCR<3"MGMA#I_)J5@5J<*N
M5K%!C&R??)I^',*+X<''Y4?&=N[EH;GJG9WU+[X<7O>__''[T2"57'[W]?QS
M_JM/E[>WE]_$E]]ZUU_Z%^*Q>ON7WXQ_],]N__AHG-1^25^YO;R2@US>]%&?
M_BBL^WNV]P*Z\_]W>(C*^K?>Q=GO,.6_;GN?OI[30LR]>JWVRYYQ>/BDGHR#
M?`>V>1C"?H,!!Y@&H^;+^9E!PXDA4NQ9<,:\W_>&Y,=0#1/:;KRG#*<6^A=^
MW\.8"OA[BBX>\?>#8T?CW\7J4)BS`+]7[1N)C3_.Y<8\9B#FRSJ]_/K]VP5'
M^XUQ<WZ;66AD+\&I!,%EHR@9^4^J,;7\=0E#XSDOB[D#;/.7#'6RP3+:M1>%
M81F6SR_.5(K*F**%VX8GG<`=^%'D3V#'[X:^Z\.6_\_IZ?GYY\][*ZZWX+!D
MCR"=LMOS_[L][%^<G5_`5X?\NW7.%&:YI$:.<KGSM-MA11B>DLAS\SR3L!;.
M]6'[4[3KYG&[M<$\&R!J8[I\&#L1*Q=5?BNZ5*P`19:"WNL=\[C9J2@QEI))
M]FUTFH\<(L@Y??+CNR?,THY>+M[8>!EB5*V;=T]ZJ_+$NMFIU2I*A"_,$U^&
M#'N3.[#3>Q/FV>BWT82X(B&V,+*MHH180FYXZT]]'F2<AHAI6ER-%AMFJ[*D
M6$H]\9*'MHB2(^342T(@N*ZH27,UTCQI'U>4,$MH3<OB2YKX5B.^CMD];E>4
M_$K)%]7+:$V$JQ'A/I@L[5IS&V`<O"?FAUDVQ7>'FA)7I,2V6>]N14_<'B&6
MD@UR]5#>[2KWO9H25Z3$IGERLA7/]G,HD<:_Z?^_<Z"/HS820R%M1OYT53+,
MTW,!?E='Z7/'^G1Y?79^G=S]_P^U':@9]6F$Z8*.74CS<R<Q>^<+IS*<6MX"
MFGEYF'91D-UBZGH%.$5Y;F4[';/1:I1.D7]??*-QU``8#=N/!RZK&._@'V4V
M!?UE._?IA!@TPCP*]8R?#">:?[TTL8PB.`TT$\`0#W^C++O\36<2L*;6?,`G
M,W=2(GK49NCWHBAYJBZ(63$4"L<SAD6$8<QS%8W`"7\8%I4KQ#AGD4S#E.![
MPYI.`]\:CGG07<&:LW%_2F1@02:1*.1Q9/1XB)TMDJHS8?KB(2I>@.F2,X;Y
M5;`$'#8I@(+)1"-FA8X(2?0HC\G&'"?*;Z)<!Q>0X?%DMU$<Q3RMCI(&9$IK
M0=$$7IP"@6!>X+NNS']^HKP()N;@X\Q6RGY(6.#U*:R#@G`I9'?,K'O'Q11.
MQJNR4"QP81F2;)HXCY:D2$ZJD<`WZ)$RGV&\#_6BV&?'X[FUH@+-@MHH1\9Y
MDD(=R)[C%"0JP<`4A5RXYAVUFL>_!U1:X)@O-V`3R_%X1JP(MRP@[(`G1B:!
MJ)D`U`"#:6D$7ON5$[-%"7O(I`PJ`S+`#"M*L,<1@-#3-'`7]CU,BQ$LB&6=
M!@[&C;HS-4B61U1/,"DHF"GAO43Z/M:GQ>!;&7O]1.@K',VQ,QP31$C0N0C7
M;&CK`EVC1+QKBRDWII*5!!P>=^Z3Y5%.#2:L_=,/?AC?F.OZ,N_D-D#6Q3#;
M9,(SR]6E4,,3"MVG+C1*RJSZ0#BV>.*LF@!":;/-=M-L'ZN9/DL2$,30@6!I
MC<Y1XZ336/'E*9#OASJ5E0!Z]#!MTD6ZCSG?!*K!Q"$@%LS;;Q[3\S0P)V\'
MJ\-2"CLOEIW+F%"A%0D>`3$X6"S(64Q2$N>'T@B*WC,1CPO29S`UQL+44MYD
M%OFKJ.,@*G)(OC.WD`^U@L(!)C*Q@GH"5&J@5E"7)E.W)7RR9@']?XV&0P(4
ME2<H3Y\FF"]-8^+7!:4NQ(H*U@H,-TE-Y=B6R6Y3?A[<V5Q1EIP8PDX!](6@
M<<)^0?T;#.D'T1*.9CRE54FV4D@)H_EY@Y*TRD9.5JN[4P4^)-?+1$T^D*QC
MGW0`9+(!=2Y@O,P`'3\E\854):XH64F"C<Q,PCP"F2"Z@+')Z@_*U#@B`UTW
M8>MIMHA(:0_%-&):,8.R*IYI!1(?BYT:0R<8QA/<RR'+E/L:/96->61\/[HY
M2A'UI=>[DC50PL(L%I'UA`(J*;P$XCP1R0%CR2$;@,`?.4G&M/@]$.I`P&M5
M_Y?R;PR1QHTL0-2#`2D7':IY5%.JKGAD?&)#*Q;I[;1G^2VS0LEB15Y3/M$R
M6_@J!#'+)CF!<)/`SE=K\91Y`1*HI918!:AU<^,E.38?B@IC24904%`%P):3
MIXB7A8HH8X?T)W%";:`,APH2.*3"HAX6`E,;\FAQ19O.\A(S+7[FD;N(J%K)
MPE6S:]>J<U7K$I^2M3-R=:,DK11FP/%,M3094+*;!/J4I'F5']KG`<A[JAGA
MLCL+RVTDZ85<)T#)ELG`"[<*^].NGX66:Z8.P$J)_MGB`)_!;*,:R^F384%-
M@,*&BM6J"=`Z,#[W^M?&WWM?OY\;W\Y[-]^OS[^=7]QNN2K`%HSZ7%8:LML(
M:4XJR8GZE^;""V,HC`?_ID1Y7\T%G(`A&(O256^1<59+,\XZ.N-,9YR]:L99
MO=ZJ/A"MMH:A##`TCU\4AF5'=N/T1>7Y\;JG?9UKDT%@_"E=YGC%:0MFJC]]
M05,X^O.N/;-\>NZNHG!I4MGHH4*HPO[S3TO*&RY3/]X'OKZBS:%X[31*\BAI
M:)3D4=)\<Y2\+>-]<I5OSGC7(8!Z?04*V.^KQ3&6;/^K@[XN*6`(P+-CVA83
MU%8SMWV/S>05KRB4N*WJ`H57^FOJ'<^?[37B7)XW9;UNUC9*`->(W4G$EG(;
M^=R=1KU175`U8E<!=3/IMU9$YAO)OJU5+:D$P;T!0V[5S59]DQP9S3?*SS<T
MQ98'L:7<QM)1[!))][Z"ORN5-*)ATC"5(.E@%SQ#61"UPOMB4[:Q65^]'%)N
MIQ!;<==.>1&K%5ZM\+X?A;=RV8X:+@U7&>!2.`C_6-JL6S=W<:R#8'40[/L(
M@NUTJ@_#+L2/[@(,.@9VGE>^>2A6N6-@:V\>RO?V^-(QL#H&=FV4Z!C8LC->
M'0-;U9N.(A&O8V#?WNU<KYG=DTV*.&O$[B1B2[F-I?/GEWZVJB)V,^FG8V#+
M3G!OP)";7;-3KVY(0"FWL71\0U-L>1!;RFTL'<4ND73O*R2@4G&(&B8-4PE"
M`';!,Z1C8+<T9;MFGG0V:0^G$;N3KIWR(E8KO%KA?3\*;^5B#S5<&JXRP*5P
M$/ZQM#&P+U6D-F"\1<J`,<_P?",*+"^45=)%-5H_,)16>?!H](!/8PW;XNJT
MQM#%KC`C9\@++6>ZEF3JW3I>&`4QK\V,-9N=$'L'.)X[P_GIOK;HXM84=[LY
M+[=IA&,_B$2[9UXL.A35W_%1,_UR:LWH95Y*>Q"I!="S35;N>9L;K`U>.*D1
M1X"9__+2U3:;8AUI0,$T<#`P-JU,S?M^>'XPL5P`SPZPK+<8ACJ/#&6'%5RP
M%U$3DBF`@W7+`\MFO%ZU@Z-3QQNL*^],'-<*,BB86#^H40IU\N&83;K_8*<>
MVA9L)3'`I1$PM.G64`#?BPSLL`-ON52A/!PS[)AB18`_Y25QN^YXTYA0,Y.-
M$_AJX:\1PLHKA0\"_P>6<0\`V;"%@?&?F+>Q&#@V-K,0A?D#PS+4@O"\K'M(
MS8$LL*/C8(A]46Z6[K)L<)#;Z``+TH]<WJ]&E`G'IVB7$6.9FN$IB2K5PRV@
M;#^,DAXN:;>=4#T)V`-#]%%0Z-&SJ.E0`I)"^D?&)[E#LG5Y@EW9GX$FL>XM
MV&_:,C]3?1TI(^UTKIY6ZLDBZ01_Y:$0HD$'48PZT("Y#KO'<O39TYV!E2JL
M%[872;M,(.4JE?EO<5U??8O7Q_=@\].=B98TZ'BQJNM+*ZAGBZVG-V@WR;DJ
M*+;>JGZQ]?8!9C?\[SF753?GI]^O^[?]\VJ56N\9U*8C()%1S**=$$_B@X?D
M[3_HVNDZ;>1=I8VTNM6'H5W7,)0!AA>FI64G5J>-%'BZ2A+@WI-]&%7X?_[I
M%-3C-X]U?WOL?`G\,,QBYKL7@.4SC[$O8.V&&F7KH.PK/,DTSJ+?T*;)HH8L
MG#?'S-NR:YULLGC[=;+)RP?<)KNPV(NQ[$!6+BY!SZ9GT[/IV=[5;)O)L:VF
MC31TVHB>3<^F9].SZ=DJ$,C=?!%YA6WMC3O_G@4>A9S0I7;L.?SV68GFT#),
MSZ9GT[/IV:HU6XDMKM8+65P8@D5A@X;O,6/&+(J0<UFX"T*KO,D@]:[9[5:W
M('IY$=NH::3N?IK-3F&W43-K96F.4&JK[85EGC6*,!Y<BKUH'/CQW1C_9?RK
M71"!I3QD]9K9J56WSTHY<=IH5!;$4B*TNLGEI40GYI4W6N6`<HF4>U]9NI4J
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MRDYU?<;E12KP@%8%:A^\+^6X<CTS-5P:KC+`I7`0_K&TO5O=7!^&>1V7SZ,;
MT>4QHAO1K7MZ=KIYV)O`L`M-W'8!!MV(;IY7OGEG(]V(KES8T8WH=",ZW8CN
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M?;95*=YL=TM"\*6?;5645A;`4J)S%^XO2HE8//HE"<Q>(NOTS45IO<<:)@U3
M-6\N*A/QHQO5O4T@BMGL:OMZ"XCM:J1J1U`%<`H<H%4K";%JY;B*"HJ&2<-4
M3>58-ZK3@G'AE,VN>=S6-1*VH'&T=:,ZK1M7`:?``CKUDEQR:-VXJOW!-%P:
MKC+`I7`0_K&T?>I>Y-/MF!5KS<:8N;8QF!D1/''J3V`/9L8#"Y@QAHTQ'.^>
MA1%EG=X%ELTH]Q0>A=_I(<]?,&PTMJ+,F$/?"QT;WH'W?6/`#!^'.83GO,.(
M3=#='3CNS'#@<0>?LD+$^,(F"O4CXVF-?^$N__S3G_\4AX=WEC7]F):ZODG6
M?\L>HT^N/_SQEY]_,HP_RT>O`G_*@FAVY5I>U//L\__$SA2Q<^:$0]</XX`E
M;QJ._?L>4$BCUD;R]B+XX9J-?M\[P]7O_85HF:.-TP="<HA$\)';1?3WR)H`
M5C[^>HOT8ERP!^/:GUC>KR81D`GTZ(Q^4R69*A3M3:G0E0U%C@^,J^O+J_/K
MVW\:O8LSX_QOW_M7W\"*,XV+\]NE'6:F)3L*<@^)E)G<0*#TH1L#@2/-CGS7
M]1\<[^[C(AKC\&RE-60[;0UYHEM#ZM:0*\S]<NW\CEL:A@(9HEL2RIFJTPUM
ML>;PY@W12HR<VILCYVU/TFYUBVNO0`JZ6=RS[C->IEG<5VN`<3Y^,#,26^)I
MLT9[,9_O&3:/F[47G%;C5>*UVRJ)UWTSMK'5&,&781K?+"\>64.11+-+?*.4
MIZEN=KLEB0DJ_6PKH[15EN30=Z!D7(Y&SI`9G^/`<X!I<">N9AM;I_%F67)*
M2S_;RBAME(43[[R2\959(1O[KFWT)]/`OV?(*W8AR*J<E-TT&YWJVB6EQ6FK
M)!SX'6@9I[X71D$\Q$K$6,/F*O#O@MVH75-*\FZT-+]X482>E*5KQQ)F\;ZB
MVRH5?;^+,)58RWW)?(),2(@VC+>>#6JVCDO":DL_V^HX/:Z5)#_C'>BZ7T&O
M-7K#83R)72MBMG'&I@$;.M2&@[A(;^('D?-?^D(SDNT0_7Z]9C9/7D4+/MAY
M7';,DY-7,987HE*KO554$7<1IA*KO>O+KRR`E9,\Y0UYZ)JU;G75V/+B%:1Z
MIUG^6)+W)9,JE^"UJW`I%,D_[G;BVIQA92F&E<$>I\P+&<^#X9EET^+TG@<K
M-#[`9J<C3QS7A3%,_/ID[FMZ'7XYGO]EY`>4)40%BA'!9/\M"C874=4X7*-6
MZYJP5MP'S-IQ9R^6P[9.8EHVI>V+[]L/`!F\U/<BR[MS8/A>&+(H7)K4=ES]
MI+:3`Z-_<=N[^-+'8]"[N3F_O:'LMB^7EV?_Z'_]6JF\MG3W#(NVSS0\%N'A
MMQ1'A7I\3*+*.T$`AH610:%(?@O?(O6MEJ:^'3>/6JT5L]]2R=L\J8O\K@T)
M9&DR7+O4R7#M=YX,1W,G>63=MUK&R^6SM=K5A^&X7GT8=F$?=@&&7:"E=NU%
M85C&P'6.:H%Q_PIIF/7:DK6Y[SU)M;,)<G22ZGLX2D\3R'D(+Z)9H\+\\T]?
MG1%[<PK9[O%9)<?[U`\CC8;?E&OZ+)FH5_0:3[]=,$TM^M#H0U.Y0Z-UD;5'
MWVF@YBV1DQ4H69<!><-X0L5WSZ]>/LXCHW*1&WHV/9N>3<^F9].SZ=GT;"5,
M-JE`AEK_ZIJP@/^=[;)6V/=L-G(\V)!R4-9NQ=36S4ZMNOGBY44L![?:;<K+
MBUU-MAJQU4*LY@?OA6PWTSPKT6VQ-[ECGM&;,,_>]8((=270GP+[RT%DI9]M
MU8/;,MME.;BEGVW5E.V&67N=*JH[G_U>;YBM3DE2#DL_FS[R;UCQPJPW7J4'
MY^X?^:;9/-'%9%]'D;SUI_ZM%=RQR.C=!8SMB#;Y=,#J[AB%I3S$(+:UB'EQ
MK?*5<+KS(D8?>WWLWWRV-8S)]HD^]B^`RF:K)%6!-E,K*^&A//4#9MRRX=B#
M1=_-=D"G7#A;ZZB=+_L`HJ6NK*)>US[,;5J,9K=5DJ9%I9]M=7]&LZ:ESDN@
M\KCU*GZA]T.;^KAOX[C77J=KQ<X?]VZM)+2YF9)9`=_E3118$;MSAL:5%40>
M"[0+LPQT5_K95I7;%6Y'7$J$[K\21G=>Q.@CKX]\-1"ZWVB\;>N"74%DJP(]
M9&CBW:N[7=:Q=J&?@X9)PZ1ATC`M@VDS/T8EJHSP9H=SM49VP(NQR[.5-QNG
M63<;)R5Q0^X48O>/S6:[736+IKSX;+3,;J,D01D[A5C-`;;%`5IFJ_4J"2GO
MA`,<FYVF]FWL@#]"VRT:)@V3ADG#]%J^C9+ULRT2NK*)W2Z[,G1]K"U.V3&[
MQZ]B<+\?A]0NA`]H@M5XK1)>2[F+FA&\$X+5CHVRC+4KS<XU7!HN#9>&:P.'
M!_^(';23OVSG/IT0VZ8RS\8^Z?&3O;KG7R]%Z_?;,3.8[(5HC"PG0$S%S+"B
M*'`&,7X;^48$C_6F@>,:C5JM8U@RC<78+ZK/<V`,6/3`F$?OG?H3V,"9L6^%
MAF6$\7#(PM`/<-C3.+"^,.^`NLFK(_WI1AWY@/=K9Z%<BACRU]`@*@F-V+-9
M0#\5K0=?"]B0.??,B*?XUP>E9N/$<5UL2>9X!G-@B,"8^A&\Y5@N4-]DPH(A
M?H3'`%&^QXRI-<-10[$J0M`HCN*`&1Y,&UKP(!+%)^8ZGA]&5F0`N/7:+_@E
M8B*$P^`,F1<RF!2F8')UMC&8J1"HV+T2LQX<&7W/^,P&06P%,^II:JKO4#8.
MC.1XL"P+(#BTV3US_2EA`A&=`B6[L:7[.8*5*NM^`(08-T#741!/C*NQ%4RL
M(8LC9VBYH9GBL.\-CXR'L3,<`RAA[$:T@/Q>(9#`#``+'YI'M?D=@!]R6RB!
M/C)N%4J"@;!)/2!^[(3&T`K'R=A`8Y>TAWV.6(0'Q\2D=CRL\-+BWK!'Q@(O
M8(D.[%D<.-[=RC#!_T=%F+.`WN$K)Z!==_V0*/9#[:A9>##F,MG"L3/-'C!+
M;>\'8SEIL)B%P6(&>YP2R=O`7>;.,=#LQ/&2E\6QAL=@&.:Z0(`QG,%IX$]9
M$,WX>7=G'!-`IT^L[\A8$VVU+-H>`N`(A_Z(,-0HQ%"NG,0Z&*$#_5?+$^>Y
MULU.GCO0TS@8CBW`8WIHZ91^]<<3R_.,G@?,W#7^8)8+W_;Q98Y7^')_[VOO
MC_[>`:XN!+0:#B!YZL-YA9GOK>'0\8!UT>((^?CTD?$]8:[S<YOT#+!$AV@J
MGHX"/`$CQ@0]=>:QA3R(!B#."=Q48;CS7';=O<NC+R5YX\YR/+&L`OZO<'-\
MG^!**7P`8(.HYSQ-!1/6&]*7R/L'OO]#"%#!S.2HA-0J,)A,FTYY9I&-YLDW
M-!Z`VWZH'W7G<&DB@Z\7[SP@?_Z%#)\.5V!JU,H;A^,;#D('A12(4'?&986B
MU'#1;!7!57`JD?[Q^V6SR]5Z[!&(`-4*OFZ'7A[YKNL_A,:^H_9%_+A\[T$U
ME+M_U3L[ZU]\.;R6;H[H-T-^QZ^^,E])E9N^S-Z0M7_YS?A'_^SVCX_&2>V7
M])7;RRLYR.5-_[9_>?&1$RJ`4G3OMA8]"LWX]/+;M][%V>\PY;]($::%F'OU
M6NV7/54I7H01'.3[DWIUBCVAX"OIR,(N0`W>&`*[`T,".-S=[WNU/?I[:MFV
M_/O!L:/Q[V)U`^08`7Y?Y)%2_4\JQ'Q9IY=?OW^[X&B_,6[.;S,+76ZD"!`R
MO477L'$D#(WGO)PUN\10)QLLH]E]41B68?G\XDREJ/4[VCX['+_@L&SADAJX
M3D%$WS,NJ+?L^GX%5_=J4]3-6F>3"KW;<66O1H%K!4V\&OT5Q$"7COY*0=U`
M>O5-4HK?DO3*ROP*\*F);]>(KYQ\K^""5)/>KI%>6?E>0=J!)KZBN;K=MR<]
M_G$+UT6K3/?S3W_^4QP>WEG6]*,,:>UY=IJQRQ-VSYQPZ/IA'+!;]AA]<OWA
MC[_\_)-A_%F^2\[SKXXU<%PG<EC1"X9C_[X'2V[4.G@]!];V8W3-1K_OG:%S
M9.\OA&ZRN07&$6V'B-:/_!#0WR-KXKBSC[_>X@X8%^S!N/8GEO>K25MB`H*<
MT6\9\UO=S((3N*Z/8H`?]KL'QN7M'^?7QM=+](N<7W\SOO9[G_I?^[?]\QON
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MNO-J1<(L9#9`X$^,&\NEP$]D()^8QT:.+F2Z+6)OUTNB09=^MJKJ<>]`[?CJ
M6QYF(M%=JV84VV$4C5?IY?B.$-K12L;KL`>Z=]=\85M\H;(0EA*?S9+@<PE7
MH(EWK^#++E2#W$682JW`ODP?4NK>H274EAS`9KTL+N#2S[8R2ENU3;*WM/:Z
MAG&+Z>NG<1!@DOL5IDC[GF85VZ'K_4;]5<AZYYM-[G?JK](Z9"$BM?I:155O
M%V$JM?KZ4OY7[^[P%E,:=D<^E3?HJ6UVCTO2[F;'\-KNEM\E^[ZD5^6J4^XJ
M7`I%\H\EJ[H)7SKXH2AV@.<4.,ET\X)IDYE?.$DP4VFNH#H@KT)I3:>!#WO'
M`R;P$4S0_"L+0C8SSH>^YT^<H7&FU)7LQ='8#YQHEJON1E7FE)<C0-Q`(NX!
MQ/EX036V?9@E=,((*[\!PJ_I"?SOC,88!LR&(:B2'=8R]&PVQ:IA6(MP[`2V
M,;6P3B`6ZH+QVW/CJU7ME&)V*C8F<1@9$POK@SF>85$%.%P*EB"D*F*85JG"
MAI,IQ<!$C;`,Q#3F@/%Z>0-K^`,KREE8U_`0QJ0YG#!;:\Z+,94%)^;##F%Y
M+HN8G:V)Z5!]3?_.<_XKB^4AX$926_.>95871H`@?!)@P/)"6RE-)X^->H->
MM>,BDXFPTEQS:65&ER&%4#%&?.J;%8;6<`Q,*H*=5P_+9\?#6&>C=\>\X<QX
M&,,H@]F"HVBXB#PL,2O>PL<&L>/:AWY,Q52)L.!0CZQAQ$LEPB<*B\3-_6S!
M";R&L0(SNZ0CXPH>'CI3..=X:!V"!N@SJ6\K*)`68`6\<N<$4#YV9\![<2+\
M0:VK!T?#\8DWUY4SQRDN,X<U'`8QUIJ$CP;6[L1WVD?M7W`(>!2H?HZ^_0$(
M$UFB,6!8.#*3SPS'*(%GXL<(@2S4QT'0I?ET(K1.A,;2?+47A6$9EG5IOC66
MNT4[^17LXE5#0C>88SM&;Y7K4^FZ?"L'Q%64[LK*]G11OE6OLS>)@=<<3U?D
M>R[=%<B&2M!=63F>+L>W*N5M<H&D.5XV>`^]0]8H>J$8\W=`?8U&^4I_OZ][
MM9V.H*B&N'JYF-]2G.G7<$QLE(*FV8:^MBY%]=\5*OAF2_YB>!5&5YVQ0510
MY+=;_2*_]=J!P4O[7O8N*E73-WO_F&]+E[M_I%M6O&6[8<.8[N+3]F7[^-X>
M/9%\N7?`+RN_.?:I-16WDH[E*GT=OWX]-?;Y[P?8_2V,+8^Z_?%>C^IB!GX0
M^`^PF@_U@M:.?'X*XL-%P-046L"'I@9XWZP`1N1!"5:8&7IL87.YR,&[O8C9
M6218$]XMC'JV9>`C7"3+0MS8MB,ZX7V8#PG@*_K"/!;``^?8<S!PA@:LSP%1
MB@W^ICZ_^#?VOYR?GAY@C`*U)J2V8RHN^0KWON+*@I#WVW.\84`7Q!1R0/>3
M!BU,Z5TJT4,M2NM%40L7O@J%9=_CE7!(M[/6O>6X="33$;,(X3>JZ2SR$C:]
ME<7;V)'S2.CRL.-B\A/=T;+_X'>B01Z,"M]19,*^<Y"N%7\+XPE]W\M]_[4/
MK-^XQK&P':S-1HZ7M@K-KA8(SHU#8_^3,L8Q2(A??L/0BGU'G=,R)H[G3&!6
M>9?</6K7?B'"NF'3*#E!N8@7]HB-4$-.'OZ4-A?``V:'O!J?E`@X]#W88W&_
M/9@9:L@*7HF'G'PNAY&?J3PJJ[+"J-1`-_]+(TO\C96).[O,B17Q(V\C_+04
ME7$T\7'UBQ;B/&#P$N^]5]"[L=$V42A3/$_F[,@'FB=F&Q[`J(!X2@T41>1`
MTL@UH328;!2[;A7Z'_8EQ8OH!P6($$,CZ(3)*`A$3AIU``\`,HA]B8TS$?)F
M2QP<#&D"UHS\(AG!\4+@+BX/N*#.O-Z08IZ\A?32<UTXXA1"-,U$</#SK$19
M$$L2O1'EL<W`@WM',`BX!,S,"EQ''&WU"!<4UJV9G)SP2'[*G7:B1>K/FIW8
M1Q7E`8Z=,6!8EV=^'2D'PU+VH22H(G:6A&MA'U$>%0+X-(U!'!F>'\G^G$C"
M^/4<:8;QX-\"/988@&@8/DX<SL;JO^`V4N_1:`R3\\:3RI</OAS7!TW4\:A5
M;38696YB6CVP;=@%SR^:V!FEH2M$>@YJCR/:G%DR]\B/@[E(&<L-_6RXS,3Z
MP1`^,4?:G[5`#G)9+5HO&Y\9`P%&!_Q9I-&<(XT5F06BD+<)7SSV/.1P!%@D
M(^`4&%`P`&G->"!<9JNH6\+<*D3O83I'2:/>\K,OQ(?8>0I1%'!)%"U2#4B#
M0.84\";DJ`8$&`N&>X!R!3;=XU2`Q!]*#3-!D4,G"7@9]?%UZ1#F)O\U!$2*
MD$YB5^C4/+2&_XF=0';(#4UX!GM54&AB%"[H_\R?58,XL^!DI2C0A7+*4\O+
M&@&0$PJMH@5Y[([_,00B`648.7(<@@6(X;(\NI-49.].X!4&CF93QJDPAU",
MH'5L1KP'UI,<('\XI&S+(9W`(8"#X:7IHM@]C[T;H79DQ6ZTVAK,'*95&EBX
MZ<@S!P![C.-34W?<N.&0N1CBBN*+8A.3M:\Y?#A&(H`)'!!KM@,CPO`Y5@_B
M+%JY??F``1G>H\8:X:8"WB@:UJ&XR"3P,B\ERG]HEZ)`M#G.&W]H%"WL1C[D
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M]ET,%CS_3^Q$LPL_8@6!NTE4;KVV`U&Y]0/CYO;R]'__N/P*U'?SJW'^M^_]
MVW]N-T#7%26)3OW)Q/<,0GW52A)18%C!E?#(<:EB4#AF[L@(V)T31B)B-8RL
MB%_*)]>[(DK88;PTS_GC<&QY=S3:Q`E#$0K)1\':43YP02Q_AC,-_<G`\3)W
MK!B$0"$)83JNS<)AX`S2",^E*XNG/`C+]EW7"I2XJ0_U]GQ(,0^Z*!APP(;6
MA!EL-.*AN06A=(T&;P=?A7O;I17;<A'@R!("C$FV,>(0XW-\P`*5A,*M"]-2
M9R+(Z]2"%X/YD'#Q_6<G^N\=AD/;N97A?^E7I_Z1L<]?>2I*'"-.@+A$#`A5
MA^/;3L&F%'`:CJV`4Y(C0B*)2O"<\G)T@'\*9J1_QX$?W\D%FX8UY.%%".I<
MB&!:E@ZONP6,%DTA"!ZE`5_.+Y*N[P(_##&:9PCOBBA?9@%8XC"("W1G,@#`
MF1P53XN,[1&1#<L#+F@G>3TV$:B9WQL!2^Y;BK7`HPCC)W$ZH2A3B.$W\X@-
MQ(/,,VS`@^='SI!AT!=S,#!33B%N^P7RCHPS7EMLY:"(+*6"!6(;[9-V;HLS
MVYL&$LU!B7@.+(K4_M!8$/3BL2C9)Y-'EP$'LF-.$LHN6R3WQ<&0NT-QV,I)
M:Q2LOX%*Z0M`T"D*N\Q!H`:W98)@\R-GU_D`HQECZU[D&?#VN$DE1D[<=;,[
MMQ%S9RV-^'R<.H*UPK0R_O/!PI)R<DW=VB&2$NHHAS!'(F,('P\@#5B0#T7\
ME0H6\@#0D21]XS,;!,D.5(0]?[.*6#-Q.=N`K]M/,S8L,.FEV,*C.06EVQDF
MR#%S<5`*9BFNDN<Q"!P[`8^@Q<BL0V`"?L0C;9,$!V#2(.U#EHOL+UJKND[.
M@E0JE5'E"?EA2/.'9O/H9([`YX]D`@/5+&1"$2DXF94@@PSI%M-"[65H8>5M
M.-E@&U@(**0`L8(-4:4JT!$(26!*(D\E<^8MH\E90P'M"7T/P+T#7G8G$G>`
M!@5S4@AS`;N%UX<4?8C_E]`Y,']G9)#,VJH!X<&DD8/6UE4@`PRK9T^L$7Y+
M>7B\T"\&EC8+5+9I@@F^0R(*G"N"))8&#/4.%H)!3]1UZEIAJ.B2<\A,^5XS
M*WR7#'H#!,O440_KZ1]_C3U,++C"`KB44HACG\:3F,?^S2V`J\H%0^:?W#O8
M*L7=(-C<36!<HX,E-*Y<.#Y5HK;;C`+PR;<"FQB(90.#(.-U`924514"RQM1
MT6AA3Q8\K.A%:A[6@$4/2"29[#I@<_@Y1E:%(QFW`19H%K^;QL51[XB&2<9.
M3:?\=+CY5XKM,Z>WS:\/O^4HL-D03%Z"WW8P;0!69J-)ZPQB:63[WCQI7DE>
M2H,;^Y98%^;7DK(&!\2/(TS+H!/$H9Q3Q+(R_AS?HF%,<<9(!62\WC6PVB2)
MT$2SQ8E<RG)`K4-LA<KEDQ+B$NL(!PBU0QD5#+N)IHI8&X+PW7,0`OAVA4/'
MDU:'5CA.M2"P]H<B1[%]!`P#:PKCH&8FV\O^-VQV:EF)_2$%.@HL&_-AIE;`
MLQ82*#+R!PF(GN=Y;'(!(I7.I=+.5-\;Z(NKSV!-@M@CBI=Y+W6T-0-CXJ<[
MHVY99L+$=A,KP3024NTH92<_#:$UHB1D+L1Y,MZ#'X,M`_N)R264MP-;G'^7
M+P\7L-;ZR(#DV78H_,4D/KIH)$5P)Q$]GBMZK=C,8-':*%[)<AKR/!.",4Q/
M/%EL9*'<TV,+8(`)UP&!SHR@8T*@.%KL<<BFD4B6G14B[4"@=L#DN1#.`:KE
MS7<NH=$P'HU`_.#*D33#5<D=\WXIF]1"MWC,`7K@[I!0&&SY8Y"PGQS*<DE2
M"4E2O?L)"^X8N0'XK@ZPY#<F4ZK./S@H7L@W")\$O:M=F\-URFAXWI:P(SU*
M,_!!5Z4,+4"YN0GV%6^C-0`N=9`0>A'ZLV0[$KDEDN:'B34-W$DB.LU^7QW=
M3U_ZK72)L/(-0?9B(7W@<H2;`-H[;=LUICDP^Q1S8$B$?L*.`R*%(RRX;JCO
MP'5#0UPW''[JW9R?86K&U?G%30\3/RI5$R1O>V73=HB@#WD'B:&RY<84E*CP
M(SW=J-5:QOEDZOHSQO*:!*F47,7AS]U<7=&7>P>F?+LC7KKD1AV*P;Z'OAQ2
MGS,#=))W3YD+]/MH7+.08;D#8`?P>]O@]%P\0/X=_@8?D?M>$1EQ8'UAV,:B
M=D*_R=1JU"<\7YH+:7T,2J.,(S@6W'!5W78+)^3:XOQ46U3XEVY1E;3^)VQ,
M4%(P0`)9YW&#:DHLL/=Q0^%[%F!G#-Q%=*Q0\F>Z@UFB5;VHV5^$K)EFK$`F
M,4[5!+*.BD9[X;I0OT2?N)G<1TRM&5[$2"\+J"\F5U230;FT2&1*)[UQ<$DD
MBC]&%JC5$ROX`:9/*N_G%-%(.N_QIP&[<SQ/=,XA94=Z<&1_#M'X9CIUG2$=
MB42(8<V&.5]_^*2S?T&2JG!\'9O'C1-ZI&UVNB<2C8LVS90U*ZBPSI,9PJV6
MV>PT$J\`R]3"69%*7N\4+^:953K1MU(0T,JG>`<5A>*^#$L`<-IS$@"%GC7E
MFOP^Y@'SPC:^@2?`&<W(OD>UCF_2#;\<2V=L-1H]2<^4-(Q^P6O48V.D-YL[
M#[N=8]7N!['C^=XAG\))O%)B':8\/=,I*(D.EY,4N@(_`4Q`.Q.B&VZ:QJBF
M$VUB8:@H]7&ATYH.G_4`QGS(S9W<0Z!2NPZ+B76@K3KPO1AM(53G!8'`V%@A
M!@PF*CU`%0E@\0E/LD$W'T9^4`F'^`INQ91^T'7[(%@Z&![6(Y5R`E0US>[2
M"PE$']87X&QF1*:`)<HGJ,<M5#:IQS=I@A9^4F*$"C"E"SVA=7;HK73$]+QF
MQ\X.-5<"JL&+E9QDW.:@_0S(]8.%'N3&@KC@U[G"M)!Y]-R/0[.9TI-.\L/D
M5)*T"!-80D0(STWZ)AI9TD\O52>JEH4N@;F'[X&`@=`DB'>\+)H[HQ]XRK\E
MQ0F6V:%R5'@7015IN-3@`!<``4?`PY?$&WC%P<7,OM*A#(&0#".Y7_"%<4C[
M038F.1OJM41ZWOM1H@?G#-!499RWV;(,2JP/2"LM'[26-*:J`^)&@^N8^W6Q
MR/DQ2$8M8)4O!/F1\7>6---#IWS"51:RF<Q")&OC)79D?1!1$,80D4,\K`$C
M4(SYXF[)::\$]\(*=E1R)4<:Y(RZ=T1KP95C(0AO25$$705!5T%X5U40VB];
M!>%M*CEL\G))8#AIO2@,RZA]XVH4RO/C=0_*.D'_@\#X4[K,\8K3%LQ4?SJ]
MH'#TYZ7M9%G<7*1]X=*D+_2&:XG+G)[O`Q'_8'BTF*W2P<\_]3"8Y(YEOSP7
M&F/VVRM4'W-?H?%*]J+&[QKXO6;8:AE$</;K4]0G+:K^E_V!BE#M]SWCGV@L
M'+PYLI_)Y4J>N";-OTOEMM1:8MD79&R5+LEMNZ.OF-_6,FOUKMGM%%0TJA8@
MKY`+>'S4?:-.9F\^^LH8T@VW7HSG?>$>%\W)5J.];JMA=CIO5.RI4GRL<=1]
MHXSF-Q]]K:(1;P?);BIQTG31+&U%,MP_KN.%]3;`.-@13O96M1G>?/3WPLE*
MJ)B=XEV\J]G8RFRL!:I9H[:54HB[P<=.CMIO5"#WS4>O/A][7[5X*E7%ZXW'
M*J#M$JZR<F/MIG6TKHN[0&!H]:-HKI;9:G?-6E.[AE9QX-8ZI453*3;A^*BK
M-9`WU4`J5PU0:R&[.-;&6D@)/1M2!\$871&=??Z("3`\\/?OHC>SUDE>0">I
M-\Q&6^LDJTC<(KHJ"9I*L0EEU$EVP!([5ZIH:*[W$M<U9J?>,3O=-VJ*4RFN
M=W)4U&JD)&@JQ2:T*\OU2JCYB5#L7B9?^4NN*$&2.J49WHHQ2>VF6=?:2[FO
M=MY\](K@26%[_.,6FAKD&-TS`7BQR@*\'(CC18'CA<XP3;7-YL;*+%[;L->M
M5\&CU475BEJ7-P*O'=6:Z:-)O=0/]:/Y\O/T*KQ1]$*V>@4"]"`2(0R+YS[P
MM-Y#RA"F?.`%$,KLWY>!KW[4:9I8/[O3X,MO'S6Z1<OE^%^VL'ONJ7B9=34*
M&K#3.@NJ9-.ZBU_(PK%`5I:,TM/2MT]2N[_J!=428N;;N\:D]ZE'BBD>J?LG
M/5)+%]&C)/:E]2&(`C,%K(8^S!GPRF6X!DQ:%\M;,YD]I(H%,X;##?T[CZK9
MXGJQ$(C_2&6/W9GQH5EXNK'N,I8S2.HC@\HV8@Z6DPIEP4PGS*!KP-29K%!6
M4I9U%.;8@ZS3,S(RAT!45=@":;NB6,UU6K>D@J6,U:S]^3(M,G._0+'6V?RK
MT8C.YM?9_'NME\TB?Q,8VCH3?NZ,ZDSX(L;U/A"Q1J8V]TZ=@>J3_?XSF@M_
M1S4R^_T^5D>DPE35R]+&T(UGWYHL/L=;O451S010AV-/ZO!;S]LNO,/?GOOF
M36=;U1-I-IN;1'95`LB-KF6>-V7SJ+O)-<T+HG4SEK+6E<3;,)27S(?6'&)N
M[GH#ZUON.I1OPB(:FX3YE(9%5$+KX)%KFD=LAY3WZ^W7TB,V2NRK$&\X+HE6
MMO/JPXMF[6K>L&#N3J/>J"ZH&K$;LHKWE8FB<V%+G87R#M3=9SG97B9>67/J
MN;F/M07]?BWH]R7Z=!)FE<0?_UBR>$U7A/K@59V5]*(Z%[W=C;Y';8_H!YJR
M(L$_-XL:'\I8*S7$YWF!BAC#%=@\@DL'_^C@GQ49QTX%_S2[&H8=A&$9M>L`
MI@*UM"1Q.Q2.2BL:%+/>=X.&FD;#;Z2IO#4:WI9)/+G*-V<2ZVQZ9X5-QR8H
MT=B/0]!5PX,EN__JD*]+"15T!"9]PM%0L-D]<_WI!'9Q@0[\`B;GFC)Q%_U2
M=:SB\H+3:KQ*O!XW-JD1H?&Z"*_-SB8=;'2XP1K1BKQ1,?%CRYXXGA-&`;E`
M=H`EE_)`=9O5O7LI)4+K9OUDD^83&J5%DNVD)))M"0=^7U=9E8[BT#"5$Z9W
M8'+>4FF$\(GKKAW0=LJKT#?,9DL;H-O`:Z>F\;J%0!ZSUBY_O/O[4G\J'\FC
MX2HW7,I)XQ]+%H>TA6I::<4R*C"U=EFHERNWQ@+&%V(#1N58GUP+=+:;X=AW
M<8$TZ>$T<#!\Q9CX-G.-!R<:T[,\OHCBB\,PGO`%OG6T4>>H7E\QX"AEWHU&
M1X34Z/@C'7^T:=Q+IZ-AV$$8EE&[CC\J4*9+$G'R3ZR7=X[2447`SS\M*9Y'
MZR^.4-!(6U">1R-M;:15,!*J@L[(I$T15Z11F07%UT<=T'6BV0)5[,V\#Z6?
M;=6,MT[>!.HTZG5E22>O<B?[R\[CN?T$GH]?Y:)6X_EURG4LQ/-FG+P"83,)
M'^=>"0/D\T0S[RT1^U'-0&TFK"R@)45K0Z/UY=':/GJ2-Q\URX3X=Z!U7SOA
MC\-1P*B!`\-*]T8@ZO%JAKV%Z+&CUA-'H+%13S2M!Z:8?LJP:1Z]2H"`QC1@
M^E6*?VB=V["=>\?&^]>9PUQ=*&]+%'_A>P42LB(P:HQJC+Z5%LT_;B%Z9)7I
M?O[ISW^*P\,[RYI^/'/"H>N'<<`N1Z=*S.LU;PIVZH=12!T]/F%8[)4UPTS,
M\)8]1I]<?_CC+S__9!A_EH-1O9A^&,;,/J-PCROJN855<=BYB!.A9Z[B8#B&
M`:E/E&/_O@=0->JM/<,&,">6&_Z^=]C$RPQ0Q1^C:S;Z?>\,[VSVC-AS^-_?
M;\[V_E*OU5NU6BT%YUDKR`+1L_\=AQ$'T^_9MH/HL-PKR['[WJDU=2++)8Q0
MH'`69_^)G1!DY`T+[ITAXW-?\RYE^``M(X6W_22\_UHP_S>ZGLECH]&I-3+8
MV#8H;X6XX[4)Y8U1<\&BOC?T)^RK'X9)8^);'\:=^!X1Y-AW;1:$<,R<80)I
MH_XTB5RSR'(\9I];@0<$'Q;3QF&CW6QF,+#FF@I.NOCY'/`1S=(U-Y:MN4]K
M5N8H7FZS,7^L,].MOISFT\M9[Y0U&\<GW;66=\VF@G%>CFYBC%ER/.2N9VP0
MI0M]BOW5NG-+Z;9/,@M9-E%V25>!/V3,#C\'_@3Y)5:4OAQ]];V[6Q9,L@M[
MDD_5\PMK\[OK=&%/3_?\Y:W/#>JU3=>G(OHR&K.@>&DGZR^MNWA'YR9ZUIHZ
M:Y-9_>3XN6L")G-JA6-`+YIC]J?9=^"F?>\SD*6'$7X]WD#28>$IK,+Q8OCN
M<LH"BP>/)HON/F./._63/,/;8"U;@:M96WLS#ANMX_;6X#H?C<!^OAR=/X)V
MY-VQ:^`>EQX.W_-L_`?9&VC$N/G+(7M:<LUQLPQ4FZYD6W`ME6[%.U;?)F0+
M=G\Y$$ME8N'F'#;;)_65Z&Y+2UY?.M8;)ZT76O$2_:*Y5#H*_6(XC"<Q&53$
M+U&=#-@8-$KGGG$E;(&N<=*NOY0BU%PJ)_OKZ))@Y#9J)VLMC$-Y:SVF!F=B
M1*9+/"G2+?Y"-CK%A@LS'6WK0[2]/W(/(?T]LB:.._OXZRV:[<8%>S"N_8GE
M_6J2'6^"%>V,?E.]EZH;5/$&/#N6GJ+B]NOM`Z-_<7KY[1QL]/\[OUD:,5>V
M@J^8\(&9K[Z'S`>]#P[MFQ%9CTG15RN*`F<0\QV)?-HQ?GP,/SVX\&WHA-36
M.Y-[\=;Y%KJZJ\ZN>-6H_G9-PU`&&%KM%X5A&;7K[(H"%_@KQ+RO4MHQC7E?
MD'NX3%Z7,<+]O=7ZU`6!WPX-.FE&%P2N!)-X::FQ.P6!Y>7Y<Z,S"\RB+<3Q
M]%.S<\`\-G(B8W^*;IL0C,N#CPL,IO5TN^<H3'IT/;H>_85'WYB%K168^!0#
M:[P(`_O,;*R96P%&]1HEME:,GSTV&[5-`F3?#:+,]D;%VM\-GAKF27N3K-VW
M9&HOK)>]#%N[B5XJ)Z:TTNCER*]IUIL%#6I+`D0I4'1RLDF2SSM`T'X=6-@F
M"?$+1SYX5^J8'S!8K.9<JU%=I[Q:6"GP4Z]MY4CN$((:QUKM>CGV=?XX=7A@
M!<937+#($)%*WIV!X=LLI#J9LG-6+K0#_S/.TD9:QJWU:)P&S':B@OQRS1$+
MY7"KOA55;J$4K@QBZDVSNU%/^QW&#:"FNQ5#_3G*&XW_;FJ!5ZK%AH:I&C"5
MRS1:_ZHM"Y.6](6J:]>LU38IC?8.<+1?KYOM[:CXE1?Z)V:]\4;68=F,GY>)
M!3AC(Q:`M4+1`-@`@!M"%@:48YZ>-F%6/;1;XVR5/[3;XV<[1#_'9KO[NN2C
MK9DJ:LD:IFK`I*V9,K#55XB#2&K1-2HOA#2V2H:M=N.-;O"U;E#5+GH:KFK!
MI9PT_G&WNQ[VO:$;8WZ@XU'J>H@Q;^1\2#(0#&O@WV-2>Y`T-'RBGV&M:S@A
M/<RH_`=BR*(*TUB4(6!6R`R?SV>K_@XK#%E$E[NN8PVP`8Q#C1A'^/5@!F-\
MJ*G5Q">.ZU*S`25SPHXI3Q^[-0ZM<$R_87H^^T_,O"'OZX@3G\:!]84!<$->
MX0S&.5J>K5^*_>H9`0-PAH`<[AD:L.B!,8Y,:^+''F$[8%,_B&A;D]P2Q*OR
M%)8^B*-,?\GO1S='!D8]QI$?S/B&P6#-UB^BI,&;-Y#4!0UT08.5U3A=#$##
MH`L:K,#SJI2/K+/3[W1VNLY.U]GI.CN]0,?=PHWT5<`.R<#R_1_2G-AW_3`L
MN,C2;NF%4^RW6N9)=RONPTTNI$N$H(;9;C8U?A;BIWEBUMJO&WN\A*-IMW.I
MW9@:KFK!M;'N\,;7TT5L!9-U#"M2/(I8_5EGX:P<PM8V&_722<1RX*;3U+%]
MQ40#:M3)ZV9O[:;=(_,+Z=Y$32C4R81K4J1YTM31\PM0TWKE(-,JH:;]NE2S
MBRH8E;#!%&BM=JV1Q[JE2C;5/Y1;JF!3><1LK6[->TV#HLXQFF.M1GW'Q[KP
MUO(LQ;JN8/,$_ZJWWXB&=E'KTA5LWIJ@MU3`9G<0M+U"-KN#HZT5M'FO6MTI
MM8#$4/._)YGM/9W9ON;)U24[=,F.3:R%;26VZRRVE:^G*Y4YK6&J!DR[:$DI
MK7'V18;709J95@&5H3SQ8SK36V-K:_K6EA+C=6#BS@6Z:;BJ!9=RTOC'W<Z'
M/YO+1P_G$M*M@%$6]IT'"[&-@17"_V,:.IM,_<`*9H;MC&`8GF^N)FB/',_R
MAH[EB@1M=`A36C;F5UBA0]GI"V;E:=JC.(IA>FQ//\3D;>99]"_F:H='1J^H
M9B`FX^-Z`\S9M^XLQPNC@L3[T'!&AA/ATQ,?YG"='\R=P;HMS_#\"#^@-@SJ
MF!_@X#*3OFBD!P=^QY<&B"H@-4!4%=+K;P&>:>#`'DUADS!%WO>8%X7+8)TC
MCVAA881ZG9[&]#T3\(('!+/5W9E)1&6%.L]>Y]FOJ9KM1I[]<4O#4*#CZASU
MZF4E%S)_%1<__Z33V-?`U-MGNK_M&=NM%._V"G2Q.RG>Z&5X]J7L8GK:ILOU
M2X!I6XD=A,$G/5)T%^A?+V!WKBE3]&QZMI+.MAE_6.L"9EWN\#+-V>:#V8Q3
M*PAF(S]XL`)[%YC$:[C5GS=ENV-V:IM$)&G$+D!LS6PT-@F**`T+V;**\3),
M)`UHW3GF4<H3U0#R[K0K"V4I<5H_,;L;Q5&5AF540.M(K)'SQRGSPA=*9M14
M/1_R7#=K%=8P2HG31M,\J96$^[X#Y>(F\H<_#OFE[*D_07Y!]Z&:96R)99CU
MSB:))!JE!2BM'6\2O%X:AE$!U>*S\PB,0GLXMRH!S=I&\8$:I?/FA]G=J.)`
M:5A$)72*WG`8Q(KY05$\+U>C0-/W/'UW2T+=I9]M9<MNDXSHUV$7[RMTNU+)
M1;L(4XEUVS?H#ZIYYKP0JK?-UD8UVS52Y^;NGIB-8^T.>\-PGJ]IL+I67_5L
M>K9W[@(C0];H82-,9!%]+[*\.V?@:O:P+1FXWS([)Z]R>;Q1[Y-*H+)M'M=?
M19UXL<+!%72`]:^ND]IT9YI#O`J'V*RLI^80)4+ESJL0B7WQU1FBA]PX]<-(
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M*PS]H6-A8?`')QK3D]D0'B<)X4G*6,OX/X?7*C^-`^L+\_CWH8.VI&F`2C$<
M4ZUJST<0[7@8T2`C/R!`IW$P]4,L1;Y`<)=HIWI4UGLQTDV.!W\"IV5FC"V;
MUW"G"MU4BYW9++!<VFT_J8GF8KSU_L7EUP-CJ!8W^K@4(;&;?G8=B1W7":-#
M^OP1$.ZIRIS-RY-;P^CW/?%!_37**6V2BQS6Z^OJ:#+&H'&<58KX#MN1,NLR
M?K%P_*O`0>+A]#QAP1T+9+EUB7ND_M[?>Q>WIO&AV3RJS9^>!RLT[IB'FX`E
M^6>9USG5,NS*RO"<W5LP91P:-IVD,+)X)7X@_$:MT:39[GS\)AH'?GPWQJ\[
MO\U3]#RJ7+5VK?K7_.;;]KO8KGJS<=2:VR^3'YH1WQ1R5'&7=QP!F_RO);A-
M?E-IT+6VL]Y8L)U'!AQ18@`?:D>=`H("7BI6PWEBHU;K'B$\1>2'<WRH-X[J
M\S_!JS037Z\8:F$C`$UEHBQ#PF57([.3YE%W1:X`W'+@>/#W\#GLH5-(3\WZ
M;_2]WKP,BW"D7L'UAQQ?AFUKUSM'S17V32@C15J%G2J9MIM\=)WDHRI:2Z%W
M]#T!G&L"T1C^`WP.Q\[4&%)_7!/[@(#V2#0*L-\@;_`]13_I-.11Z&-U;0]T
MD&MVS[P846LSXBBQ"[@?!?[$B`++"ZTAY[&.-PR8%<J#E<X-`PY9$%E`Y>$8
M%+RQ[X)V$V*OERE8&L[0N`-BGX92/0RQS!*UJX%S%*`.*G>8FL=0UYBVPBE!
M/\):X-8=,Z9P>+"ERCT<:0L/$6.',V;!1`P(QSXR;F(XCWFTA*!.P=K`Y`"+
M`#Y&[@S4ZHD3T7*LB1][)%&`V685+]ZX9F+-L!F-RM%%+QT^*VBLMPIO&<:@
MN],<O-6.&(6WQT'==W&+'%5Y)F4PNYK\0H!MT(Z'`#2(15]H^#;7RT'MQ!9"
M,%32P0=5;7R8!F>Y=>/CN!+D;2ZC85`Z6>Y,=!?B+Q6(5=,8^P]`14%6[1TP
MUX%O0P%ZP"9^Q#B@'[J-^:,K")-+ZA7`G]L'WA!IC.)7/!O&`V#"7H1]DVC'
MA;[@>^I*?X4WA8T%G`?,1_H1U@LD+?5RQ@5^JU:@DAP9:\H<]6LDDL!!X\M.
MR-51C_8*1QJ>_VOL,5(T:!YIF0C5XW,<(%I,;%"4:F`<T7RQV37!E!9*+QC)
M<L%X2.2=NEA++#>[6OCC<ACY8NZ3(Z.'8W&N(C&2/Y_YETQ5E\NA$?:*=*($
M$O5%)#/8\G\#CO`GHE\OSNR]L*+;!>3G&1\:A3*%LX8,Y;.18%41R?J5P`R?
MV"=3T*X3%J\\950?CHLT203@^*3(08"KAR7"!L9>'-+)S@\N#@R>.'2:$(<%
M%"(_"0QDL:$ICY>R$/PK.PCLG0?</Y$(0R<8QA.DI2&#(?B93#;(_G<<1A/@
MEMA`C$QDRPG0/03R:&[?4>^7'H<`&VK!TB9T+F`H&!CXC?^`4@>F98\P7=)[
M*],DC1B@'(?S7)3BBW:-@TTOQ9YL2,;9$TR%+=%DDS31U,V.`\D(1J"8J_+)
ML$:(SJ)IJN#UN(&==JT<_T#L2)DU+T"M`5#2`K&PLEB4WA+:""`UY,TA8!7W
M$;ZR8337GQ(9#:DV=&CL[ZDN*_[MW@&=G4:AT<;-L%:AP9EMMT8-ZG)RB#8[
MIQ,D3/=)2<-AFD<>JDC3:>`_.A-X`-#RH=,I]/^)<YE*K'F,S:/CR<D`&XOL
MU>[1O/S.XVE>!$NU"QOZ@>81*I!SV3V_;+F?*YOL\^95L98S8QE-!P:*[9G@
M`6$Z+^Q2"D#$%/8'._P=OG23=X&,DP%)&Q//$;,:,%S6%.G6XQH:\OC8DVR2
M'*`^MW4JP0H`*>P_,1ZY.3&7L4(`MB*5Q01<Q2[L.#\DA>IX@7,TQUR`3)[D
M!,1!4/_/:LXH_UPZA?YHA-JR.+ZP$=3'SZ'VX578"I6ZX02[#K%60&0<C?V`
M1/,],^YBQZ:.GGB$AT/",9H#A#8G'`)Z$7R\/I%$"4P*A5O:1UT2:"C\'@$C
MOW^88>^`T40RPW.,MM<J'">O(2]L'^IS1A+BJF#WXJF/$MZ"*82[#P9W8^RQ
MB/3@N[$<'4=-C*+I%*0W26T,C+WC*@MP/-042#=)NK'2[<AP[(&QZ**"[*1M
M/--#^IDTC0+D3!B+$E.@6*C!*M%*-A/M1%"]HD8X^;ZOQ!`GU%*4%`X['G+5
MAY0P"[3X$)NF4J=[3O5CTN/O0&GA6@=,/W)&L*UPJ$:H@M'"G+'OT[T9YU&)
MBD-8QK%!I2698,`QB5Q:0GHW!-AE]\`=$0KJ22NH;@;ZYHK=3!\8W9``QT0%
M*T$`*6T<'&I/.XI![MX7]*A-[%S8RWM'[53KQ\%J?5?1D'9&I'8K*FDH*9PV
M"M7R],<'8E\#)MG'8)9[6VQ,P8)1(,6AU/:3@0!^ARYCY*M#("8,-^(6A^42
ML.&8(5L,4G+`K1-LDMPT>3#('2T!J0)#^P:[9`T!14!N@*8+]F#\%20,XR;T
MJ>]Y*%"&<422E4X0.H(X1LC(XNQ)92U@+DY`<8!3R%'%B`\@Y8B_R9M"7RAG
MVF./<=Z[HWI'%!XD'91S;K4;%MP[L'%T8H2&A#L,%E\GX:-H-O(S#U0@C&(4
M37'`G\/%!`P$E)==C5"=4Y<3-[YRZ\(G?>+#_P;;)+0=X='C_']&HZ.54@7B
MR.MRC!\P9BO<&<0=;J;'[KCL8\@5\/`,`$AD4@EKX\Q.N6!'3C]W!<^YAGJ%
MC50`F(3?DY;/[FP5G07T'FL*,IFS6%4I1]>*!QI+'(@BL>J/N(HBK7U>MU6M
MXM2^6FQ;.5':<3MAOH0;R7L1K'G%?`%;-;GOB%,T_+&8:Z.C'LT5(=.?B&$0
M#'W>(5"PCH5DO$IDR<\__?E/<7AX9UG3CWWB!+?6XUFB(-VRQ^B3ZP]__.7G
MGPSCS_))6!/HKR2<>YX-+`JW'T@.A$O!NX9C_[YWV_O2:'8PI@8XQF-TS4:_
M[YTAL'M_H0`:TD+%@4-0#O%4?>1QDO3W",ZX._OXZRT>0.*2U_[$\GXUZ42:
M(:@MH]_4<"PULLO>]%B[LN%F_?B`>G#W;[^=7]S>&+V+,_C[XK9_\>7\XK1_
M?K.T!VO9V<O(&G+>@)2/,I0;%RZS0NG!6&2:IC9H_>3(.!6&7F)A)B.+L9`.
M\`%@Y.P!CIH_)29M&L"S\-32J4YTUGLGY+_BNM*_Q8I"T%NEM8I:+0X:&5-K
MQM5';C>10I!7W>$99&X3/*K`'/D)91Z=V"$5YM@_[7T[4)U<M'Y:7Y8;4?M6
M$FKHZ8/'HH@[Q04C2Q!`DM$R.'``^?>CFR-%[\6##VR1(.<<F"QMEUR3@I&B
MD`/U%.0@#F@SD@,\LDBNT$XG!"Q?C=%I,0T'<7"GJAA9$)*+$^!G40!B$WWT
M5CA.;`K2U-#IG)^:!P<47'*@5.<F$>>90LU?K.N%*X1W+?RY5A61GH9&^0-7
MV&9<04GIE[2_WC=!AUS3R9Q/CEC/]PZ'B#^76*@BC?E!LYZ(W3)LGZ0AMRGY
M"6&/+!B"O,<WY0%%BB<M<MD!-?8=M2'QQ^7;83OW<D.N>F=GP$(/KV68+;!]
M^1T/H\]\):_TZ<MLM'W[E]]X[_>/QDGME_25V\LK.<CE3?^V?WGQD=,UJ$Q%
M,?SKB@>,R$3!``+A=YCR7Q2`20LQ]^JUVB][:C#F(HS@(-^?C.=,L2<"2T7O
M:$7@$2T`36``ZQ"HX?>]VA[]/;5L6_[]X-C1^'>QN@$>_0"_5V5H41*%"C%?
MUNGEU^_?+CC:;XR;\]O,0I<'QPH0,CV]UXBME3`TGO-R-MQ7#'6RP3):[1>%
M81F6ST'Q4"AJ_:;KS\[=+#@L6TAX0??VTXKMBLM]BK'/S?-,&EHXUT8I%JM-
MT3!;&S5/VP!/&U/@6@E8KT9_!<F5I:._4E`WD%Y]D\YF;TEZ965^!?C4Q+>`
M^%J:[[TDZ15@4Y->,>FU:YMDX&N^-T]\!>T<-?$MTO<V*<>C^5ZVP!1>3U+`
MFB;`%2M"F85:RAL3X/O*W=[I(AW5D%F\,MW$\9Q)/!'7`_+NH0*LI#P.C#HV
MR-ZD)H1F*+IHPGLHFI"&!$3$>S+718QWWN71+JX[=_&*@0@?&D49(?+^D-(?
M$%%LR56;N'`3<6V8=?,TKUNX56H4PGJQ!=FXA"N`'""!]ZB7PI4?1@&+G(`"
MQSZ)`(^E$0K='8A0.#DPKL]O^]?G&*%@W/3^WK_X<F-<?>U=5#8V04;.8+!-
MJU;?_W%@7+F6<D%NW5L.OP#-A+!CF!(>`C:9NOZ,,8IBMT5.BKC1Y(&NRJ@F
MB.\@<C#,"<,',+"?N2*,#8DC<`9QQ(QXBE_4V[^((9R`XJ2`!$64KCA.&$`4
M1WXPHWCX(;R-"348`)Z+9\*))M8/9K1KO\"':#C&:]QD1IG)Q^=M_<)32I6E
M8K8%3W0*+=<*9D>&(/D,3\@!R_E!T=V]N>!*GS(B:D4)_!LQD&P^Q8NQD^>R
MA"QC^5L,:&:!._LLXS3Z'D`[H9V>9R.MV@ZPD<Z!<7/^]?ST%@3CW[[WKF_/
MK[_^T_C<O^A=G/9[7XVSWFW/V/_N6;&-.2X'JS*7K=SZU]);_XZ^]=>W_J][
MZ]_2,&@87@:&=NU%85AV8C>.(%&>'R];G><_!-;T]SW^[_SAGY,+N<(MQ+\%
M=Z^?X!]/><.*F'8]*^`H]JV(A=^<7E]>79V?77__>F[B="J2%H@W82=R/(Y7
MQ,OB-2YS5Q2._CSO8%:.S%GN2]'WM[J18'`15MX))AH:$P(338T)@8E6.3"Q
M9<9>I,6ML\I,0:^WH(QU]KU>7V'C]_M*_+-)=3F`RJ8LX+6B9)+\P1+">'6D
MK$LD)>];5V2JW0H_*>4H+K#%UE2Y=*'TPBD;9KLHA$/C=<,IZ^5I%+13>&V8
MS>-7::+R[O#::I8$KYO)MXKT!L'<ZQT0;*4\/MAJM-;6;5M?"I>-YJMH".\`
MEW7SY.15M()W@,N&>=)\6UR^`T/LDQ4Z0U&%RXTQ^]L3PHN,9)&+3[:REF9;
MHO3:4;-RG:S*BLG&B<:DQF3),/FVFJHBQ?C'T@9DNLM:2NB(E248T1$KZQZK
M<D49[$*DA(:A)#!4J.:)\GPE(U9J.F)EPXB5VIO?R9<`$PV-"35B16-"1JR\
M/2:VS-AUQ(J.6*F$HU1'K+S6E$WSI*C2E\;KQA$`W?:K^)G?'5Y;M8[&Z\OS
M@1/SI%$2@MU,P%4D9&4?K_T.1`.*'1!QI3Q(^\=FNZ-#!%X$E5VSW=BDTJ!&
MI8+*6D=?^+V(.M`PCX]W0FQ5PB[C`2Q>7GSIZ)77XARUH]=1TG:><6`<T";U
M(S4F59I\%8MLYS%9.SK9"5%6`0OL3(F_U*),B[**8U*+,BW*2H5)$&6O0I)K
MB3+^<0L!F:M,IY9E6ZV@6K8(V]>TA?$I[P!KV+"\B>6&O^\=-K,EU_I4<LV(
M/8?__?WF;.\O]5:CVZG5:NDZYL?,SGDIVZGQYIA?,5%A\:1G19,>MIK-;C<S
M:\&H<PTVIP$;8^VZ>\8?NF#1Y>C6>EQ_^E8G!_22T;/+.!]AW^S+T?DC;])[
M;47LTCNUPC&6YH1_SO\3.T"H6*R35^J,`:C+M#OSNFO-HFG3Z;/``(CXSI7H
MFOUI]CUD=M][F74W.UD4KS%9CN"P2F'!!GWW9*?R/WP7(V._6(Z'A'/IW?!N
MC$#"O<`)X:<SZE9YQ0+'MU<DFUH>I$:MF279+:VK#-#7NO.'IO,&T)^2TGT3
M`>>[0<4[[(=A#+PW77S_XO,<FZMU_J6\^(VJ;2KP\)&`][5/.MV3]G&VTF[!
M="^RINY*:VK6CSOMVG']5=94KZVVID:MW6YV&FNNB7[F/Z@;_7?+C8&Y/M`O
M3_*5I0OD$JR>H<N59EUIH1RRHI7.X?+II28T5V]3X-J3"\[-OAI3^.P'#%0D
M+K>'L]O`\D*+>KV#>*"_7.*P/?O?<4@5I>6QN_(#^B'BE7510;GUKZPG5`H.
M=V\XC"<Q]<-=M+#BK<L)MU>%JK0(!4;Q?(36&QJC!:+\^1@M/3ZWK`5M>KK?
MC;ZT`9[>1+-Z*ZUZDZ/X9OKWA>]AUW<^/CQR+JK'KZM#MQL%$F_!X-EE]#&0
MF871E>78ZQHNQ[569E9UK.?.,@\<:-,KSK),12.,O(!2N+).2!.NH0_F%[B!
M+M@^::^N"1:L$TX2!:)?63.4&_!G`*\J_AM9XE_Y*JWK+YP[::G^JI?G[QP8
MO=/3Z^_G9\;Y_UV=7]R<WU2JNX?8/]F:(L3+)S>V&360&/FNZS\`37Q<U`9B
MBXG9[30Q^T0G9NO$[%=-ICW>@83@%X9A&:6\6D+P$WEC3U[%O'G>V.MG%!9V
M_E%Q\?-/I:B1715,Z=S,LI^Q=>BBO0)=9%(S=0+FZ\9'207UVI]9;C2CFG5?
MG2%9PI\9VX5BJ^7-Q:J;]9-7J6+USO#::92D-OMF#*0"X962?5Q9LP"L66(?
MYZ(+I>S+N`L\I)0GJV'66Z^2J/5^4%HWNZ^3^Z:SC%3E@X7,"H9C8A]G[)ZY
M_A0OU`P,)`JL(7X(-1_9%M$WS5JS)$1?^ME6YB.->DFJ%[P?'23P1RS$-LB6
MNRNV2RF)N]%]E9SF]X/05JLD5N`[T#GX7:_D&>)>7K.*;:D6%>[F54J$MBN@
M5M#$-_W_=PYG]JB-!W0A\]ADW=DE;H:#5<9ZWHW)TFV>NT#1,*T/TTXIN%D`
M*R>$RNL3/C%KNI[<-G17L_LZ?<ZT2%J9?3>.&@"C8?OQP&558.&["I="D?QC
M"7*27S;"-)^RYKK6P`\H6K`7!)C.BH[<]/W="4VMMPXP3.MK#XBUAW&21N_+
M]?GY-Y#RU8I1O1TS`T/N+6]FC*W0H!@.H#O'BWS#%;$`UEW`:"M#XP%H@PUF
M%,*JOA>P(8-MM^4[H>$'AC_EJ<;*4!$;CCU0ONYFII%2^=2*:'1XAW\TK.D4
M7N'9PT>&LLI?0S&6X]WQ)GO*E<$P)4'?4Y=]QSP66*X[,Z8\71FH*3`"$?<P
MM6;\,?:?V')QN<K26("!+=8=@C3"U^UX"'MBN4!NL``/WY#032S`&\-L?YB`
MX0-(Z#P;6D(&(X1L&-,*AWBS05!,??S1@;%&<01'Q0`R9V'D>RQ=':PK&CL!
MHBO`@VG$4]^CG;"&8P?00#B`10Y9$,%*5-18K@E[=(=I&GY`D1Y_\GD)'(`/
MITWF`W1?^%[`1K%GTW&4P`%`,I39>(`M_U`_:J6$!.^[`)*)7]?FOB88/]2.
M3N9_P8U`&&;,"I#^;(;70`718EB\G_]_C8;#G`4$"O<*68X[.UH>2OWL,^_@
MAV_,M@+V:*9KZGO#(R`!(XP'H6,[%N`5D/\I<`"/[N&W&0-X;OX3.X.!L2_>
M/N`K=*K!'"3(`",6KF`!#P9GG`)G)FU#EA/<LRP+R82Z*R?2-!@0+>(+;##X
M@`0%9QX.)[P)_,6"L_1O/W`BPJD38?"\S:9('I@=Z`"_`4)&?N3#7[;A^1&?
MW?)P8DI4@0\T?Y1F[Q$KR7(T$93_<>EVQ&[ZV77DWKBPTX?T^2,LP%,M2=O%
MPS6%67_?$Q_47Z.<Q2B5G<-Z?5V?)M^N3J-QG*4H3FEVI,RZ3*U9.'[/,WIA
M"!H/<1<U1*PGD0B$`+LWH;-K&OM//7X`NV)%DA.'"0>PTO<4)B8%`JI'Y+[%
M[75=V'_DO#`(<&B@$E+R."^U4FGC)\,(6E8$4$+,@DQ3`=.[.C5NK>".8?T2
MXS9Y0Z"ZU6G\QB="OA8YAZ"`>,#420A.(Q1B7$KPI^8(JUBO2.)@U;_FB=*V
M*TI&V8O^TT3R./_ETGH1-:WZ6IZJ5+[TX$3CA!($I<"N^P/Z@CT"!\!T0U4>
M)GH,/(=$%C@L0@X_\3T?U%F\9L2]'_@V2N+`<D*@).L.Q@/&(Z?")T#U`$D=
M@3+]7Z0F7):DQ>]NY'SK#52:G`))(J^E0\&UEHAK.G*N(B%GIQ:`[28?W53,
MJ/RK%*+E.^PN/_7`JR>D6N$?3W,:=5LGULP8X+$#(1OP@PS*DE#K'$JXHN=!
M^ARBO@C*C.W<H3`AC61&A0%5C0Z78<E9D[C8PT]`@+@)5^)1V)H>GOMOXMS+
M[V%^N;5@9#DNGQQX3(`#[SL'*?SX"RA3CE!5!?BN%=(H]`N32C`J80H7W'?R
M`^%/>#X\H.$@%'H(25XG0&I,J5H"&<9PH%P)IT#!D;%@5U8_N2OL3JIHDKD[
MQ>\_G!3IC*3>\C.*V.?`<"4!]>2L_DJ0X9$3SX&Z(.P'OJERFU$A%P-:*0;$
M\>(AT'-F@4)&N-J)8Z]&3J%*$<2#A+8J18YJN^`JO9E\/U07FMTMA>U4D\KZ
MGG$#<I(T?%+GLW3#'G$8#JDP(0%029BKTZ(T59TH7<,H\"?)CEC#(0M#N1?$
MC*T,,X9?Q`[1;$-E-F:,XXF0_V(SX.G3L\:)*31*W+C3L_\#4=PXV:IA<NT/
M?[`1JD0!'&#:'%2;]Y7OJV5V`'U<@!T@R*/6SI('[H0*<L;<L.9]%HEZF8KY
M!S]P[0?T`J2Z`-_.L_/3PT:MG6AR)C^V^#H]2KZ!>)#HEV/5H\']%/*W.[`Z
M@`V%RKRB\1CI*2H(R"EC7+-'_H8)4"Q7=<&H@%,SPK^#.\L31$[KC<7TQ>N6
M)UG`ARA@</CH=8M':@?R($WC8`I2+.MF68M[-X^ZK\2]HT0KCU)4VRG8+\^^
MU7W*LW"5?><91(;C%F_25KG"6?R#J>S@4X`*Z6T\`2R=HH,*_J&C8^SCHY7C
M$*H$J1W/LPB"_TG>0$?Q#OT&F?>Y8."G9,2P!!"38F+H`CT/@61M*[*DALY]
M%C0EON20^):N2'13`.HI=3QA1G(J&%6.0:_Y#QX<`1<I/.$\G\]Z(@L?Z=Z'
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M`D_MP*5$OL@4E^M4U_]J#/QV[$^LT/@K&X&L#P$LU8JZ_>OWRE$4(-9CPY1;
M^G&P(O6HU,<W5Q!?RK.C!U\Q:8JNB'%*0!MJ2/#V9S8(8O06`'TW\S[WA#XY
MZQ?^4NF(2MQ183)1^'P?4[,:?!HQ5VZ%I_DMP7_%#L9?8]"!L9STO"JC`/5"
M'@5A1:0#@Z:BWB3T)Q-<#JB(0(,P_C??QI"#P,2O'"#HB6\K-TZFL4]W3K;M
M""O^%DR,PZ_.#QQ#V+\G?^K`.GW/P;B"_=NOUP<'G(BEU1)&L3TKTJ'4E2W2
MI\Q$)P-V>0_P`7N`!?T[OK?H2G=M7\GSCG'G)8XQ#$@WT/+\Q2$78\X\9"]X
MN!4J>WE%+!U\J\=?D8ZPHAL_!B-Z`M3GF<;W_S7VE2\J)SA5MV..1SS)%&@_
M%>!5[W&!K_C!"NQ0.(RM-/S'G1G.9.J#6>1);Q>1KX/,@IR"UI3P?F\%CA^'
MPG1ZOOE"A^31F8!4AKD+8WI**"15/#_K($G/_%:ME@GH,G-6"GY9N8/QC9P8
M/.)J_5-!,(L;)^D?NPK8T,%\72%I8)!^AL:OY$TX1@.A\DI7L$5>!-S+9JW.
M;X3.6C58QAU=8>$?7P^.YA[X:E@!XT>*@65DQ\*W)HVDD/L%P10)F"5$EQ<C
M8Q`!)AAO)D.3^"A41I*_AF9-X+ORET#(]XT\#,TJ'$J^S2\OUVC<_+4:[.=6
MI=P-LZ((X/["`-8B=T/^@<J=Z;R52.<Z#BP`2+46<ZIR&,8381/.G_8!BQX8
MO)X,`_N=QU-R+YN9*YBS,U6%5%[/']I!?(<+_W=\AQ[S_=[9Z8%*.%(_?4+!
M522QU.73`-P(#GV41*&1>'W^T3TY:K_-T5WOEFM^DYY[BF%',D'>V5-;JR\^
MM?1IC5R&-?(-UB@'+@M8T4-7,8@]D``@B[P7ZA?3J37:K15+A"]>2PX@Y\X#
MTQ%H-1()'CB0#^<3*'QWDBX:!\;-]V_?>M?_-"X_&S?]+Q?]S_W3WL4ME@F_
M_'YQV[_X8EQ=?NV?]K==*5Q*"6R53L?]"J_3O8@?A2H)@EOR+`\Y:\-C"E1"
MV;_DIAO)UH6P5/B"<YB`C5QB"_"JGS:4$PQ`=:HXE#$"YW1VZ#^@*S$-E3\R
M>J[+0[7%Y,;`<I';<AU+"=H.>63W`"4+<YT)W@21SJFL5<9VI]Y+6AB/`<2;
MSY#=R;`@C#=W>(#H`,U^]-+`XA469P*/]^(13$]G<C''\\!@I`"LY%J"V#>W
M]\8,./,81$C`MFN0A^3..`\C,N/"RM'?-&!3*QNC]C05\NU'"P$U<9)75L+\
M8$@0/,X4Q5N:^X,>N:D@'0KY`N8,?]U$A#7T@\,.`QLU]K\?W1RE:_S2ZUT=
M2'D?(FU8=R)^P(>_,-`@P3V2"O>0@:(D\Y_0++"HTR-7<AA:^!C@-J%L/+H6
MX<YX?-U-<^^2#`L[$6JDE5!6T1T)XP7O\9EL"=EJ.)6S%2TP@./AQ6))24L#
MFQ^0]"5"/LDP..$\1A]P%KL4$A&[-D""URQ<LX_&&#Z;(&^KIP1[57(+$#\H
M;34K=US2ZT$/F"D9I<!*QZ`YNV@Z`61(X?>,-Z8*,<"+-`=;G!(@6>1K<&J0
M%'!ON\K-B&W-*!'/I1"8E(PH^TV,A'0/&C!VN<&<.8G)(XY;Y1N^QC"2YY&.
M(0P$:A)#13KX@?ZMV+-#D<LW`/0E/7VVF\]%DY/NDW81JBPM\/T.2>)BF&$8
M\MU)9"JPO$D*<8IC14&?@+)*>V0,?-B,]!G30'YHW(&P"T1P_AVV1<L\@ON'
M-'AX%U@V,IM@ZE-8$PZ6<WX,7<SU&1&C`M(5&5[%Z[,`$M$*65Y8>O/L3,!I
MA&.&CPS8T!(1DC-R]ECWEN/BT(<@,0[)IB)/COP:*1KI,)DK56R.C&_%"PL8
MYYTV'I.1Y028&AZGQB=\$2>MJPQ*#>%\V@^5;C`VI;O073\<"A$(GK;4$I&@
M0[4M%K[J3\#\Q9$.%)7&@O61)&79\4(T($`/0V;Q*YU/S-[CT>,4I#VW.`1.
M+OW(Z..U/9@_+EZ+".&I`.R$"2^2"SX$F><=@EQ!(@A@L@$Q(+1!$Y0S3-2!
M3>,>!@55N`;2T%`'!&$12$_0D[A(HO14VE`$'.!"W=CKA9N#\-L,0X?H"ER0
MG$@+'AJX\(A,+E):)@PDF<TI*F#ISCJ>PH@S*6RX9A-M\>W*/-_#Y.54M3H%
M5#J1<>V$/RK%ZI(6Z@;F5P6Q2(BFA"_EZ@3,BW]+)4N)L!RJ:"`B&'(\!(@'
M$$W`><#`3805^7W"L3DGX,Q%/(J<PKRT@DB%QT>R3$]ET<7#TSB+N#07CBKX
M9&')7->!R%%*E@&HH11:1=-S1(@B88$GO@G;!WZ)`\K>!VTZ[ZF&%=R1'JEB
M;3#C#TOM3Z'S:#9E`A2A9^!-<`J+R-,#@SG`G#MKZE!Z.B7/8S0@5V$<T9"`
M9_62:)$+P"Q]^#F[3*Q"0%G`F'Z-6CP2!.JI@8-,QI8OBP-._`2WHF#?I!X,
MAJX/QUF.#/#!KPZ(&)[ZB5G-/-4?L(QU2:)1[";C;>5@O_"QNN8Z/4?&%]=Z
M]`GTJQ',B<G>4^[5`'B[G5_H)PSDS*3LKY"Q7V_Q=SOM7]9ZE:?YMQO\[69K
MK;=K73)[?""MA$2$"?.*10,^HY"DMH3&-V;A&9M4VN3`HY`DMQ9;GMS8Q0H6
M'."\=B35AP+[,WN@0\9^A-S"?@1.\U]^#Q=S9X<_0.Y!A]7QIC%&NPAK@N+R
MD]@UHNS0![N%94L("/LSF>Z`'WI,#_'F9HN]@OFRUPNJO6\-_!@8D?\@+1PJ
MV(&J-<7'D1D,4F?(%N#P`.](/('`)+HR1:'0EXM?3DH<+'`,!"Q5O\7%K<@,
MB,8!8V#WP:E(?`9I[09E_K$#*A18@G@=!&)I1)@&@3#O-7FBN6$IZ/LK`IS^
M6?]H7,YM-BG)`.Q_8I_*7^#FD0BEJV`F]ID[_[ANB,%6TEX)LOO3R[U&;UGB
M0*E/S[A.+YZ"V;BBGW&-*L43\B_[8$6(I*4P'HWP-H`('S0.LMZ0-.Y]%[0)
M<=]&A7$0-MQOAWQK0G/T*!?3N_/QEP$ZO:L@WG([VRC:6:Z0H[5BY`E!;+.Y
MUNZ'P#Q<D$Z%>T\HSXZR`L6DMKO"75$AX=-7<">:'XWO!2PUL1'G6"NHJ?)&
M5A![UKFZF,^*#!))U<5'9:LZP)4L44+]<4"UY;>H55(!,B"P!`3@3JD#!&M9
M"2?>%&-[N//B7J1M2Q\O;0BJR2Y0;B)E9%2X('\9BXG^E<#"B(!#\CQP,_O(
M^"H3ZV;*8LBZ1BX'0BL./(>J:&77RXWZW.I&>()Y\2EQS0.TB'G%*I@%,*&L
M%)E#WS*719D7K0GZQ/\K7PM1`R4G19IW]!5CC-`Y@Y%_6`!)6'>X_.S;A)$Q
M>N8#B;D"O(Z8D69='5(`@W!Q*8E0$N,N3J[>TG,]V6,/EJMP&XR#\CT8A4>`
MD)MGQ`4,PGQD+*`0GK>/=C58K3S6!)U%J?YAA;E?\:CZ=X',O\SC/E!QXN%R
M1A%3)2"\,'6M(7>^((,!@CCBI=YMH@G.<M5*;3S/<PKZC5"/QAB19HN`-5[O
M#(U!*Q2^I9![DL+TVCV[=5Q,L\>(>3)29L0DY@DE+EVU\A73E-P(YMZV[Q@>
M$K#("41%MX`"-<QD=N6^R'9"3-ZV>?D(.WN:%"]B@D2*&X$9E8M47LIH)NYI
M<&'H#B,&*1QQXL8WO3E+F?.*GK;R\SA*%<R$_M`^<_<1)]"TVE26RKE5D3BF
M/2L2]W0IN<B]";&2H+C"2ZC^B+<XPE,8!T&*99B.W%E`T!Y&"IDP$Q*=F3TS
MW`\$([LNW]\IWM&$><+"LX8"4EU8)A4H9WY%_C1,WQ<<.90`D862.79XMX]A
MR]P5)W/7Q.FR;!Z<Q2NY1=QV!Y9U9'RFTZ@RT&(LY^+0W-!7@`LS$&&%5MN*
MTB6+PR)U9>4(SLV,'K'<986`1,PAYTQ\JG*VI)[CBZ&&4X6ZA;*#/(6F\KJ.
M!@5!T5@C!`(#)7CK/7XGPVOE$<7`Z;;XM0VQQ>W>KWV2H16G:?)N=1T?@$,?
M`_;G+7%YW8"W'YP*U&L+R@.BN`$PY))H$W%+`;MQYY"_,;75Y<V"T(OG'I'!
MDG-VO0C,%#QH(`.3^#U4NN2Y.UTEU#-+]USM9D4P\\6H:L/\2J71Y'B'XEBE
M)4?R=5OW^U?7A'?\[^S`%!J@15D.C`=:<^5/O:\4WDFQK(EO,Q=(^MRB><7)
M6^"$2KP_P&BD*Y`GI\Y;$APKXHHG#H5B(/2N''((Y1E@)#KPRD?<B(89S4&U
M90)V9P5)\JX25%*P+&'?4/A)4EX"5X8+L8B[\+DSVEW!0#GG578-L'6#Q)\P
MDJP+?\U"*415*"\C^>)$R(P2ZZK6H%4#7OFR\(E4(OE"Z>-!OT`SI&7\M@B(
M%%U9$")4=.Y4!0FU.M)F%!$O6'(Q5"O,"<.+RKUTJS-R_0=QR9!&%F?";G]+
MED.(``,5-PWC?/#ZP."$0IZA8II,G4"*BH%70:@6<'$FOD\QF81%*RXDK@UR
M/=?F!Y9K(5N5#OV47_3X`:F29"@\X0EKIF#MA->KM2O@#`@=@!M5*%/F>)-R
MF8@.;*0`[KH>X>OLT*4ZVW,,-^_W#5ARHU;D5%D6/<$#`Y@C7&.I(JHH3O#U
MA%_\RQH%JB.2(C#P6A[L(LL)DA@".9#ZHK!KK""@@3."59HR>6@+3&O^^$3P
MF=0N5FTO_NZ`W3FD3R=Z-L6K*0Y6!61UI3D@.(AA`B-B`-<U@!WTO><#]A`X
M$?H';"P&!,P)%<,\?7AB5E[VG`Q6BI@`:>`M`TMYBZQW()M"8GYP7!=#O(`)
M22I47R5_L"A^SE4-)1"0%RG_3VRAH\)$K(#4=QV,>QBIHXA,!E^8W4*<5\%6
M["_6RQ8??A%\QT\Q)\NGN,`\A=^AA<K=/_">YT^<(5?MN?BFJONX@JSC3&B#
M8A"8H]!MM%6&_\7W;2*J*O'Y6XJ\'<D28#*]B0Z7#(44%WE"EA?IR4\K[4LD
M!D7(^4-9-.-.H/'(2!"*)0:%SE?]@YKH!PH,(^.K[]T=?B6Y5T%M036JY$Z%
M0@H,\5`J"C;R>A>AY5)^WM!:Y!P1P4`YMD2NB*$3#.,).B#$)3AN)A/.7<]`
MEW3$4UD3G&.*&P7><!<OBKXS$0V7UAO)+MY1[F]P5&D@T?6Y5&N10N>TY-3O
MF)AEXMX]E=DRFX06B\3,'9_";.WS,\DA(;C(^E3FD%=FB>K/(YB5>U$LK,<A
MRHIM'@*?K9ECJIH.#BU$]J$4V7DNJUB(VZT%*P)ZK@&2.\^I9#:2ZG(!&/Y+
M!AT'B\A91`QGHQ.&L`&@[E@B\B3Z2)9];/&ZJR+0E-N`\$B2*PCT@*52?C-L
MA@<NX!$NDNC)\RY\94H.4H`N.OCY-^[1I=J@E&#JI&4B!_&,D38X<A[Y0#*:
MU*+V5?RJB=H8*`=H_IJE"MI0/D`H5PXP<6?+SC:6J!O`'Q@X_A3TUXDUI`0J
MQ4S.Y)SFZDL-U>1/LHP]3(20'MZ%GB9..#);B[L69,GMM%Q@<C&I3(O+ENY7
M+],@A[PY(DLL[4W$^__@0_07MAL2BS+GLFDS7FBSJ/=/FNJ+>H-(Y<VF\0)-
MDLP@)IKIA)38AA/DLU,,O7:9N!%-CH*X<?0L=_9?SA^3^&<\=XDM*$X*0D[5
M1XB-BJAS(G3EX1G,2+&I\P8MJ*@\.QDS9$7,NTC>(GZNY'*)30TS;HLP?Q_`
ME:245XB#*.ND"(BS0089SRC?_IP"EPRG]&*0R!/`)P/*U`'D""(';4B>H1$=
MAUS7+/+9\^@3ZJ;#\[[%$$D5^&RYV%_1K@ZCC'"ULO/1,.*DI80MY4)&EZ16
M.;8#S!$%JH2*V)#@O+;"<6FE$AN!(E_RK%?L%PAA,61%>!A=;:E<)8W7S[$!
M4;BPX)PFF!:^O[0F@(DZ=233491TB>1NZ)Z9B4$HL$^%`D"50>^YC"V>3#$$
M68V&45MW22V-"@B+@V@I"U4OHRAYXMYW,1#CW[$M\F/54(""T)N4$L6[PD(0
M/<BD::$40T`TJ@PDJU`)S`D_"WP$L4?::;XI#\AS"DCS\#Z_/R)M;A$:U=DI
M'T.ZW6PF[F6XLS1!=($'29G/\`=84H;KFN6GY2LI-)*F?$ERDVR!DXA'7LE&
M!H8J&+%23KK$G;1H(($\U%\R,>94&\<:"H%&)?+#',<141:)WI49+MFW0"1.
ML1'\(,KL3_G5:9H>1E,A$_.#'_0F:%HN2XI/*OEL<VQ6ODT]IKAV<63,(Q;I
MWKXG&E%B99(2EY(/*Z3$8Y"*J=#*:;H9#,N[B#Q^SU)[?J6@^JS<3'#YH5[4
MG`^#@Z,T8TF%K7]]8_P-$S%&9";=*EH55N#P29O^PG=82<<3?1%4'?Q!Y%>H
MP0GI3OC>(0\[K58XB>P)).NSR(T5.4:\F>0</=$A$75UDNL?2JOF-C?7].@^
ME=GR?DGJ"D2!O-,4RR$Q*:B4E&9)TI:RQSZ-74BX-!T<<AU1?"L:UG-%9_@H
M(FD\R[JY;!ARKDXS*M==5.!+F`@HW`*;#DE:2%*&J>5+#6W9BE:LAS-%5S^7
M:>]5LJFO%]E"=#V8N\0'ABCZ@T@.F'(@\?SB^\*%,R7E`F2&'0I9G@F>5":-
M`KPB%7-DPW+4QU#MQ2>!C?F/SI"7?4HU-:QO2NG(4RKE[+%D2#4"SE2;FO)S
M(`TUC%N+HY!*N0IPJL!N3K-H3!`N+=;DB_QM<(+89)NSK6;V3Z\O#[AIA`H?
MCZ(FO@,_")8@1;5TC)!EY%IW%.X:X*8!^&-@V_\@0S"(629<:_Y]9[XZ&<RF
M*AF)T86UK55S*,3+E;1"AXES.Y@0*._#N:M4WN$IM3SH5UICDHG(HQ5X.2Y,
MCE<N<G!>P@`ZY:WXC@E^)1PX3%:54=>'^GERFQ`FUPE"S1@NV$)R]":>Q$5/
M)8*<_%0H3LE7)8]+PNNQJ&UZI;=0LYO)"]P?GO^P':TWB8_GK8IXL%N5&*M8
MN(BR6,@53[.-3-/'`^9,!G$0SOD&>+6Z>1]8QK\D?5Z83S13QRJ8)]67GQXW
MK>:75'R9"_HM3M[;(HU0!;3#3W3H<1FPUFJ6VLK'$U)EAD/.S88J8#+RG%1`
MU\T\:/'BP1.LLX$17Z),7*C$>^)=72:=IO`N0FK;!8.K%R68V2W#!KGZ;DME
M#N\G!4<A#P?P;&!\5/&!+E1XI3#!X0"6$>-!^$?9;5P!VB6`9@W(Y=DCJ:DO
MTR$0.I+\0=;'L,,$10^)WHHAWU*^TY@QDF(Y0T#S4:_949(B)`$[3*(N$V1+
M)!/2TPL_9(LD?,!JY'24M+I_"I#MYFW[P%#OJ)!I0+F2%&[G5H_G7+!H:1&:
MW-WK2,`]E'!'"MSYTB9/5F,!T10MJ0P@S*O%CHH5R^"(->&=@C</;L8?LPP\
MH.H/C:/C.2<(74?P2@8Y*2A&2XL:4CHMJ(Y43827L9"E"I/X7"7P;L%X2DU%
MNB$[9:YKL\>EW8^V&JI)6+ZU'BMF^*KL,9:![&DX09HH+20#[]E!;@^N'!/<
M$<*=[ZNDWG]0Z4@9[F\]JL'\F>_5P)\D:]OC$;U*8`0^BC3"L[0I7A]4_4$<
MR3)5=H$)4:"0);7[1&B2$RAE+V@6D<?]-Q[_X\[RGL%[ASWP<C5%\/$;3>[G
M@X-N\,`6XA-)810GS!1-29Q+<HX!<QUVG]1;YQ'[6'+%=7Y@.P)*RT9;1OQ>
MO!**@N(6CU*SZG2,#D927@N6)GUGW/+!]'?^*<_CLB<4)Z4\^5#D*BK6$SHI
M:,JJ:@ZQ)Z\'"$P17)-H_X4%(RD%$X/%GM@ZBNDI'#^)-`U!^/-89;KU8H]6
M$FPDK"-XC0R4&$YKD-:ZF`,DJ8E$AC[SQ*6Y(@>6@)J>^E=1-$XS`NTKYEM6
MB<5FER_314E*.R(K%44R_6`I%U##]'`6U:9++U.HWX,M/>-RK'QA+2'_EVLO
MBGI)15J7:$7^XF*)A8H(7Q.H"5*;F=<78'Z?:L^BDO)04"I%C7C`FTP;K!ZA
M5">59S&N#I[@%;5D^A,=#:IS)!)T\@J23!P6!0%#N2OR5QF[FGUBB<(E,@,H
M:E5$<?"*M#%&6J02:.%ZA.OIP4_K%8*`XV)O&).`RE8%`J)"K"5X2;*7N5`7
M7>(5I*P,2RXI-K-X3HR<V&C[D@+%^?78CLV+C_%B98G7C?&BOW/9%T+%HX0H
M7APW4Z@MC6R\':]8S#`I7I`[CDFQ;J*0@@?4FEKA"M6\DL)<6&.+%HCQCXSB
M*S.);<".78LG$/H2VW;VLO(9\VV1%Z.M1!SX"HB%*O!7BA=C+?IARFZGG.(G
M&$%"L"0!NB1?<0L>&'I'F'UHH9O^3C:Y$><V>3.D&Q$D==P[90NYYF,*)BVH
M&935(2=4]`X0(\>@0/)&.]3H@,ZZP^]\9[#<>\HQ0=^X&^.;KP^",77C4&VM
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M"@DUFYI:>!7W^UYMC_Z>(O6*OQ\<.QK_+E8W(,\#?J\,$TAL_'$N-^8Q`S%?
MUNGEU^_?+CC:;XR;\]O,0B-["4XE""X;1<G(?U*[@2Q_7<+0>,[+8FYJ)I0,
M=;+!,MIM#<,.PK",VL\OSM23G>EI4WA\J!`(@COPH\B?J,=MO.Y!6:8LY/G,
M(##^E"YSO.*T!3/5GYIIP>B?+J_/SJ\3WOT_-?J?49_"P*BW_F8L`5NP.`R]
M!98&7W26+,T5K8#^B8%NYTM41UKMH)@MOP:*WI9DGESECI%,8P62H0N'MR:+
M4J"AIM'P&]6'?FLTK,LD(G\*ZMP=QKR!/O<_IZ?GYY\_JSQCJ1!<R&H2S3BK
M;Y-*?7O^?[>'_8NS\POXZI!_MXX"?:->$2_0D-<4Y@5PK"LQJS);5G]:.'?+
M;+6[9JW9JBR@)45KK=XUNYU&90$M)5J;9OODV*RWN^4`=#,F_#!V(E9N%GSJ
M>_<LB*@J`+80T5QX.W3-Y^XTZHWJ@EI*Q#;;P#*.FY4%4R-UNSRX$HKP=>YB
M1'/A[=#UL0F68V6!+"5*NV:SV:DLD*5$:;U$9+J$^=+$-_W_=PY<\*B-+&\A
M.]YDW=DE;H:#5<9ZGKMIZ4[/>9\T3!JFG3,OLP!JA>6%G'?';>V\>WFT-CL-
ML],IB853^ME6=MYU6VWSI%$2GZC6781,;!PU`$9J0HO5!<LO%S5<U8)+.6G\
M(P:B)7_9SGTZ(0;4,&K&AEE73X2\S;^^:>D6O`\V>FDL_57@>SXF?%2O\^YG
M*H?K\/Z<^*])4>=*HL`T"QR/D>4QMCQG)FV<KJ#D1H2MA\8G'Z/7]S_W;CX=
M4.UP441%A+6'+*(7!KZ=:>TK<QER)0VM-*$\V7,>78HAI!B_?F1\]URJC($3
M/3@A[W@1AZ$LEU^<&A:)TO7#2%0>!G`Q\XC#&B;P9-IC8FQQ.GV2)9:/T9?C
M+BYRD.0J\2*>/%X_$WQ/\<@R1:`*"6!]S[AAL(>Y9!4D!,.:\*A\2O?'%%8J
M@2?*0O%2XI',F1\E%<ESI<=%UH08*AF&GJ0L/,I%L#R'YP?P0H.BLSLOOXCU
M?S"[/U.)-)-K=LASS0XQU^PPR35+%C1!5HFI94F#!K44(1\FJ5<@<@"I(!5E
MU#SXAV'$INEP2GEL!%]FY=BRR:$HW5F0QB-36+)8&#"%.D=S%>A&<"X`T[*F
M&XY7$.M6HP2)1C8ARO99J%2[YANW-'\%@%^<NH)YERLGK%2"]+]9LSS1"U9B
MY3EL+A5KZ%H!,C:13#R=NK(J$&8<B.PV*BJ=ZYD]2=N_IW1`I7T>8<]$9S'D
MA:X?)ETJB]]7V)S:QX%6J^3?9)J6[^<[\!Z(IKM%V55.J%`FM9,`.9.D#J>U
MX`0S$*7G@6PFH@B<J)_I8+^NM-L*9Z"\8><\*=?;/.-G0;J5NC@O5\A]58Z^
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M=0[3!6,NQ_'SCTZ[>WR\%,^+#M`II0]2"._?20=95_ZT,M/FA\L1=9)\>07,
MM^^=\JZWRDMKD]=)O=;,LO:G)YD[:;(`$2$M4^Z`U\7!A&'@@9>C6^MQ[14>
MMQOY\[?.?-G%7C->/^/<"E#="I7!SAAVN5F;<@X;->!.6>)Y>A:^JJ%K/WX4
MM;_1CR'J(2O5=$&8?955!WMI@?W%:SPK%-]UKE0\=[[BU9[ZHDXYO"1J6*^Y
M+L%CGAXXMXF\LK(LFK[FI-UZCJ5FA\O3"R_X"BM1L"34GK7!;;2:N:F7#5\(
M]#.G7@1TX51?@'CQ"%UZ9VD#J<N1Z"JVYLSMK#Z[=.S<,JB;B`NXZ=G8K0$K
M%:)Q]5P4`/:S2UD^?H[+\3:#%E]N7L%;^T!V<T;'\N&S2P%1E!AIG-\]EQZ[
M6;:U<.`Y'9I*!SUSUOI);MK<>-G))`N]8@%5FZ`"#GA<1!V$=/+&DW/+,8!I
MUX_JS70%3TR27=$_1-F#'J]Z<$&U%"Y']&)XF=8WX*4F5D<.'P!WI5VK9Q"T
MUHP%&E*!A!2U&V7I1J51,H"MU''L)06!I#R]XH7V>TK!M5O_RGI"Z2JDA,,"
MU?:UUKH:FKXG]8_^\%VRWA+VE3H'>H&#XI+WF+@BC\X*RLYBC*R`DDW7E87^
M3*GZ#I^Q=SGA5F5*ZT+2:+2RROPJD\R;</RI#',\$VT243NX"MC$B2=AW\/Z
M*,_2C0[)XY(U[]:?]6G_E-RAM=>7M7V7#;U(BM]8+KL<99PDB8=D;7'>62#.
METV2,Q4%BV5VIKSQN@36;&7M@N)AETEQ-"CEOHH]75N$UDZ6R/&""?*B=(C5
M\-D9X__VO27^OO4IN]W*"=HU9GMJH<(#>"9J319Z`M=><:-5?V+%JTS[U-+I
MT4NIZ3QSJ<VG<%LTRZJ[+SQ;R![GO$UK'Y3:25[?>LZTZR%U@_4>UIN=M5"[
M<)%7H@40VI3(G@"N;Q:V2XEFEZ,B1KHV,P1JG?-$KS=E;L6B5]"MW^/ML%]D
ME8V3G(Q;:9HG5K;0Y[Z^@=A=OKB%,RW?;1)&Z-X`K>EY9_RXLW1OYR=8O*!^
M&,9XFWDY6LU9M\A=TEA,;H53Y+T9LAD5/I2DO#[AK"VVXAKM'.DO&7SQ*KB;
M=36G<>$Z.GG/VY*Q<V8TBTZM<'R%I8IM9G^:?0?5H>^)8"#@V$DC'?1'.5X,
MWUVFT2SK<N%.*R<Q-IN_V"1'C^W:.]D^KA7:XSA83G-#DNI3$(!J59"G^EQT
M1*!GKN)@.`96C4?VJ?7\:X'#^1O=?<][#[)4]ZPEO0)4;[QNHOV7Q7PCKTX^
M.?\++[=@0>UM+>B"/=`O3Y[S]7#8;!YW5D=BLH@MK+M@9=W5L;E@9:D'!J5W
M,6+(3!ODS;1KC!/#MF0WO,\9G^LZ[2#PU.7::C;BMA>X\&Z0^^HX-A4H^A>?
M"ZZ8_J6\.$='TDW8:C7JM>/F<>'=H3J=<GFCQ-J(VXZ>TMO\+`FL2L)N"E#\
M%XJ7YC6_>9P:Q@`=8C#:1YX917^/K(GCSC[^>HMQ:P;0BW'M3RSO5Y,"V<P0
MT#?Z3<TJ4!,4[!>(=*::5?OUYH%QT_]RT?_</^U=W!K7YW\_O_A^;O2NKWL7
M7\Z_G5_<WBRM<56VP+R>$<:3"<9BSC6!S=:53CJI*KV$,YWL5RM3NUFD^1?7
M>O1O)DXT_E]L+Y6",76'QC[]>D`KN[)BUQ!W4L9G;,/<[ROM6[X>71T9^U?7
MGP\J%9O>]XQZMWN2#=JF4FQ4C)BWET][R5'/1$(*[X$C^ZPG@<7YAG34##S`
MN#SII9WO#(RM)0,_LNZ=@.K.!QA\B2_SB2S@$=@S&MN>8-]1T>TEZ3$6#WB3
ME2C75%$05-+T/K.T1'/-A-PJ+78/127FN851T";V.HY#'K8HQN6KA1&N?>P<
M]*B\>6\-AQ3U3,AN\SZG#]3I2&E@BIAIUG[!(4\=U*^Q;89Q.G9<.V`>#/R'
M'Q+[-[XQF\`\I8TR]D]/_SC`#<"JT;RG+V^4H78CIM7E&BZ$LB,Z!R3IEYDN
MB_?L//V#?Q"-9V1G8+$]:2_?6Z4=6\$#.&$T#OSXCG<%9H]3)\@0A6N%20G_
M@+GL'AD%;X2([2CNB2I%MD(RK`E['(UI5#[AQ)H9/-!<-F=*ET`1_MU:>@!L
M:X;M%!V@IH?`B6`JC$MUAJ*<-ZTHMQ2$(QR.F1V++N0$"&VOVCBB<61<^&HU
M\J2=?;;ALBV[JO/5\S#TS*HK%8Y=:Z_,3+#GP&!&7XY&<*I%[U=@HL94V!08
MRGT"AR)I!B..91$N/3MW`M1E4`BA.!)X5A[\P+4?L#\P;\8-\XJ#2[UC*18Y
M.4%6VIGCP[%"/+*_.BRJ8$'I3B)$RFZN1Q;X<B%1W.9'3JD^G"-&$\;(I>R`
MUD1I'7D6&(C8H`3I-)ID:UD4\W!ZT3>"$OKI1-"R%O0LS;=2)RX-ISO@#)Y2
M)$3;<MXO"EM[S&3;+&1&3I@96`Z8-/I9U+0=9\H]K+83BI9C044"\O\/W:/Z
M'"F80"!'K7D*P:D_G!R=S/^R4>,.4VD&YLZVV]]W!-\&!K6IV^=_5$[5Z0&C
M=Q%QG5Q3']3O.'Q9=F5\E1WK<RWDD\@S8Q\'VA-O)U_O'8@SRP^(^!G)1K;I
MQ"9`&'%-+5Q2;B0E+[9==3S;G[*I,XDCS+A+N$EN+E-^0YUD8=QX"HR#Q-6,
MLX4,;1,7:Q5P,821#V%\J!?\+IHZ.<F=<JZSFN!(N=6!=`Y]WF[-%OVJDR['
M]#M(`/$.+`S5-=[R6'9>SF<G%C05YUV/I"Z*7X<.YN6D;3'2Q,7RTZFJHHTM
M.\V:L]/^>4J'6ZG#\01&0234O2N#D#'U!1DPF10EML(*T^9/:,#3'B1)+GG)
M8#/7P0@?NNM=.!<<L@GOG9FT-<D0^P(2-]/>];SI8GK:DM;RR.VS^7KS>T_M
MXJQ`=&14.OS]VW=4(T&=`,T45/Y85D-&]*>Y60GVDZ0E=1M$@YA%JWJ0^.\>
MM=.]YDP_:="+FA!E4,K656ICPON$FV3TFK3?RX2M1ARYI7&0"SE"/#W,<A*2
MH(MV*7.L0ZX4..AZHF8XJL1.VC]F)'/:^YFVF?\B6@\#D<TA3F"F"F<:9,\%
M0"*UL9I9R,A)/B0ZG)T5+;?B>]B7O8/$M*4Z`F'^*''<@P83!]Z<;G,DYY7=
MS@1O!D:`E]=2)4FG.S)Z(?V(R7:2*N=7E>\[FNPFM^;0NJ2>2OF]SVE@<TBA
M=G!KM[O/]RA[2K.J%36AA!<^-+M'W07Z7/NH46@+/&>Y\4+QOG:WM<7J8<;Z
ME_*5YWW>^["X1`N21YGW*2)Y7+Q-62:'FD7MJ+,`7<TB=*VE_BZ&[%PI$"`T
M@B(*%=]1\JGA^MX=_#&*O:0AL+IC6*$@HX%5@LT4Z4;S"J-Z4C%8*6OA%A&\
M0PVR%7<5,9VS^`<#S125@A!U0]R>V[$_`3[V5]2\`F0GZ>\+SABLAH*T!6,H
MF(=[\$2C8"'.,_T4!Y9+\BX<,]FU&9FIQ8/=Q/9.B$_F#,"DMSW(ET,I5G)2
M?4L<<-G!RO"__)H%1]B(K[6+C%$ZI[6B7[`#^U+3>=D.OAP'VZ*!>^T/?P``
MK@O85TAZ7_F^6@9O5I,-4QMLL9X=3S'O'W=4Q4:!;Y^?`2IK0+YMTS@[_;OU
M>%BKP0[.:ZD!4H:H$&*<GOW?8:.%#UH..O8MJ8*(4CB1X%_D_7*\D<K._NC_
MG9\R[EG_X?D/U#"6]T'L]<]N0+V1;K2<W8L.*;)OJ18"%>3A)B^O-Q#*3NJ%
MYX7,]D1:T](R*"+)5R#?Z$35BV3B"TF^#8L</._6=:5\$Y&;,I<$LLV,DT5S
M_@5A?1P$KO,1_Q_^_/\!4$L#!!0````(`-9E:$!V).Y)\PX``*S5```5`!P`
M8VQD>"TR,#$Q,3(S,5]C86PN>&UL550)``.#\%A/@_!83W5X"P`!!"4.```$
M.0$``.U=6W/;-A9^WYG]#UKW69&=;-M-)MF.8CNM9YQ88SN[?=N!24A&2@$J
M2,I6?_T"O$B\`"!`4>(QVY<X(L\Y.)?OX$[@_4_/RV"TQCPDC'XX.7MU>C+"
MU&,^H8L/)W$X1J%'R,E/__[[W][_8SP>G7.,(NR/'C:CSYAS$@2C<\97C*-(
M"!B-QSGASYABGI-^BK^1*(Q'5S02)45H@4>__A=1?_3Q].R'TXPK(/2W=_*?
M!Q3BT7-(WH7>(UZB:^8EPC^</$;1ZMUD\O3T].KY@0>O&%],7I^>OIELN;04
M\M<X)QO+1^.SU^,W9Z^>0_]D)'Q`PZ1LBT)R<J%AB?KI34Y[-OGU\_5=HOR8
M4&$O]79<0J8?;1F+17P_25]N26L*946<O7W[=I*\/1&.&XU2UW$6X%L\'\F_
M7V^O2HP>#@(?/T>/(B8K'$?$"U]Y;#F1M)./*)`:WCUB+,M.A$6;%?YP$I+E
M*L#YLT>.YQ].O,!_%@X\.SM[G;KONS+_I`N5[B(!G26FT<W\2J!QB=OHI1#2
MB7+G*'S\%+"GL(U2!>:N/747,>^W1R9H>7CY>TRBS9Y>4PD\3'C/4>"][B3&
MF:2BFIYX%`=)'7(M?I=*$1IBZF,_+T>JM[<=2=EYZ0'S2B4&LCICO&Q8L3:8
MH_`A27-1^RX06DVDP1,<1&'^)''!^/0LJ[^^RQ[_[YPM5QP_8AJ2-4X5^H*%
M;O?H.2\N0`\X^'!B01F12+K"2#GIRU*A0JK+-0O#Z1H185>`[YG0=LEH$;<?
M44B\BO4MN3./.'.7O51`XY27'8;XMBSQWQH4R\U11C$)X^4RD38F`HLY_YRS
MI5V8V;[^*!CT;F0H<12QD7-)C(L?6;_D"9/%8Y3]Z`UZ-[(J4)CYB7&A'SV/
M.1<=J,T]1S1$7A)FZB>_LJ#[W^(PDI5&[I@9X\F+*.+D(8Y2C\R0$!-5@-M+
MV5F8CUPV^*3I,Q8N*7=D/>-0Z,=6D@`%V_Q]#3]_OU(QM`G(']C_1=1`8OCS
M,R)45E,W]`Y[,2<1P>&4DU"\NA`_Z6*&.6&^IH4]=#$-6;E_,2\V`3OV<!>Y
MMK]*61Z]T>31^XFJIWN4/G!I]-=74D_#$$=A)07+#[-PY@][JW]2!=)JM]J^
M*]^5%-^^ZR\]*VYE9K5+Z9,2RDRIL,#KYLEQNF@(Y1\Y]%VC0"@:3J-SQ/E&
M).A_4!#C2OB<>/+QE1U/W^&N!I>ULU:!ADRR!(6E1'A@^8SX;SCI".VJ<W6&
M6U!FKC)2`H2#O65F$!CEP.M.3CV/Q1*EU$]:_UOL88%<H7XH6F]-->_"DU?_
M=CP`@='&6C-$+"4V])EZ`,N,XQ4B_N7S2O0.<:Z^J4?@P)&YSHH#($S<+36#
MQ$I>!I%_0H((6V$>;6:B5QT)K65#N,I&WS5L-)-N06$B[1L-91A8&Z7I6IHE
MP&M!KFB$Z(*(VBNU0:AY^>P%<3).9,Q_(D%0B;P+2^8L.Q9(2&AAI`81=I+@
M-1>%&NL+HYZR@3#2%">)ZC20@FUCAB:Z&E9X5;LFF358AIF4;HE72Z[OX43C
MFJ`'$J0S;]37KYUG4;(ESQS23`[!<+V->G/ZQ*-U$)C)F!)8FT1*&)=$P9M]
M**BG'D3H">KA!3!$4$6.65BABVLEA(`G'?.![0QMY&C6/'N@)JI,%U2)0$35
M,$E@-$H78,740%4.R%CS&/N-R=M(MXNXC@YPT*U,LXN[3A2\$5_28VT,?`-5
ML6__DH)N9Y9%R+6"X`WDDIEL[%_@!\V,L)X@\X>*`&J$&XVQ"*Y*!KP1W3FC
M:\PC.;-P%S\(_0B56][U<;9GV&Z_;&:`B@-G8RUP82,3WE@S0_,UHXM[S)=2
M6W4%H*(HUP!E"A"A5^2^P0Y3+UW)#;_]-D_.&0DUK3B,:3I-C*VM,H7:)`1@
M`]XT/=0X(=0\!01U(J71-.?Y%)5$>%D^$[*P0&1JA&J_CX%BMQA;I^@O[.9`
M-YM3BK0ZMDHA\$;?A0\.E#NY-*]W'\547D.-:8,A%@&M2X"7JE/?)^F.\QDB
M_A4]1RL2H:"@>G52Q9HAGUVQ8("*`6=C+5!A(Q->,S[UO'@I+<.^;JNVW)6M
MV=+?DGLW/^?&#19.>[G!!ENN!<";&+C%$2(4^Y>(4T(78<&D"SPG'JF.%.P9
M,C_:,$!%D+.Q%J"QD=DP,=#C1Q3U3]7_^K+6^<O:H^[9RM7\)/!^SFA$:"Q@
M=[/"Z4D8X4<\9SRKK40EA</+YXBC=,**;ZY$M),AK^`4`!#Z+9*S,7!8K1B.
M4-)VA]@!2^JO*FH+279,WY<J.$>-TQUN!]04WN@M,TLJF=M=G7G34^13;BJ*
M_F!Z#*PQ&[^4H'A`K9))0)4V\.!VB]>8QK7M4M7'VYY9_K@_-)G"S+2:ET*O
M$)'VLW+6+N-4/]A%/LD=+[$WX\R/O>A"/`E8LIU[2OUKXLE1`5U,%QPG_2=-
MC-I(*(?334)_D:^%EG7AA!(R\B(*<'`3?5SDR%J+(R_Y7.AGCHP8T=/6T:"B
M!1OW1L-L(JP2`F\R\)9M4!!M,KVKL5:^S(-;>0DLFB;5]>&K<,&;E#MG88*H
M[$NM:G;J7F^GXJNOP;:Z#9;8M+YU$:K\&_?=70JQ<)?\E+O0&&0JU^I>"]IM
MW6ND[?/`$DU@F9N!E:-&RD+3NM@H#&#/.:U]-+%7OBS7Q="C:S*A.9P5;GAM
M:7J*:R#TGOI+0DD8R5IIC=4!M:3./W!JHH89<C<C&S'0*`[>XL;N\*(+$JY8
MF"P$WLR59_!8T>:`,-,"A8.#@<U@,`M3]=UZ;NNG2WD8W!\H5;3ZH6UU`=6*
M.%\O;2"&"0<G$QOQT"0-WD[7+XRR<M=5W50TTN5+0GJZP<_5VOKHF#.V!IW@
M]5YRQ=40U+S=G9=0?CMXN)G]<4R0U30!V/!M3<N4_"CZ<?/:MHX&JM+*JX+J
M!:^:-MG<S8JGHI2F"9$>=WGLSO[O<7>'5&+&V9H(,SYNOH98[MY39'!]9X<K
MYVY7ASUGGR?*J[3<SL--/3$J2[]&:NTL1V%F_UD+Z[42<<8,Z]A[U7K&5J'L
MM/J]%($W'_>"=W<!`*XK`KN]6F$_I09R^\(%7G'LD<0F\?\`)WB@?G&D7$&M
M"TOF=SN6(>"SA7,Z!J6=!O`&EW_&F:_N<-=^GFQ_Q%G.J@%:(I>GFZ1Y45+]
M@H3;@W!G'"])O`ROZ!JGUW74,+B7D,(I,VV$#`*S73BP:RRWU$FUJM3SC(KJ
MX.]\0:0"91M2PS'J.](AP-+!&1V#SURR:G&B9X@5KEU!`;Z9EXX*WIX3K%W"
MM&&JK66:F88`P%8.ZAB*MCIDH/P!$"CO'A''8L"%??FA(Z:A:A!C)LK/F-`0
M#0%D5@[H&%2Z,C,0_0BH@UAN_?%#E/<`LM;?.!XQT"N')$KZ(8#,U2T''9@H
MB\^@]R\XT+NBH@<J<N0"IW^OJ.%ZCOKRF#OO;M',A7<(\-S'71U#U5&5?"+Q
M%%"[6S<ANS+D(CO!1GEU2"."781HH6PG9)B8;N'`@X/;3J<<Y6>@49ZHO/.&
M':I-3%H4JYF&B5H+!QT<I6H=<E1"^D1$WWQD!W?+!8#:D<[6O0<;(8W="+.0
M8:*XA0./UK$PZY2C'-"L?=V4O/U0?YMH3:^%;HU^F"@UN^7@@*P5GV,/T#<:
M38V#2ZW:R&G9`?@3U)^VKCIR5T!94P+Z:B#15NX'%FZH;NRLP-.&M'BHLI9T
M"`!T<$;'B#.7G$'L+1R$:2Q.UT0[VM[I*,R\O=-:&#@<M]S>V<Y[!]C>::T(
MO#U)R07JWN\Q$;T3^65&\O_T*\(*A"THBQ?4ZRC!@<\51<S%%39@LU1@>]V]
MKF!X6R^%I1[&?O+)CUQD%0.QSRB2R_Z;F[EJ*T`%<JWY=W<8N_(/`9[[NJUC
MT+90!UX].4.;9!_4/<ORSP:^+CPY9.UX!@'3%N[I&IIV*@#\F+"FN?8.\R90
M-C+JD&E@'"0\;1UU:(P:]`"X1[-:^R<;K>2I?V2MWOANSZ!IY54,@P"DJV,.
MW(ZKR@=XO(3:[D^$(NIU-(QW%&8>QEL+`X?IEL/X=MX[P##>6A%XGWL4<_,J
M#&-AA\A/_6TVUO2*.E9##PZ.KKAB[FZQ`:&E&M4:5E-\'(IBV4JRH`#BF/\6
MK[(.R\V\>M]F!80VI-N#'$VD0X">@S,Z1IVY9#7@(.T,46>-X>94>P9C[0?E
M7M5#5W^V-[,>JOXKEZ_&(Z"FN)A.A;N'&^H_#:6B^JM1#@%Y]JXX8.57*UB-
M-4BCZZ+ZZ?VX^FK/BE8!.`7MT"#7Y(X#@DY1M!IVD+Z*O)S/L1?=S"^?O4=$
M%_A6]!=N:+(Z17WY1\Y)K5$@3;085G<E+HO6_N+`X;L)S!U[<)_!]?ZJ-)Q?
M#./2/<5]A7"N&I]A3IA?W>-5R3I7-NVUY#JV?N]>EQU(,8B)N4!7JF%R&?'E
M<A6P#<8)S2SF`J0AEE/I*N^TE5%TE;L,2)=P-D""=>.HAMLZU4IL[X5W+QS\
M+(K)KL*FCVI#ZLIF@=,RVW"@:7#'0=!8+@_\*-9DRA?\E+QQ05^-QP)Z!9[A
MX$[GB(.`KE"8Q5BVYP,)_&]Q=MC0/=-<%I\<K_!0/5[A%J>IA>\P7Q,/IPZX
MQ1Y;T$1*XHL*6(]57'X<PL&+>UDI<F3WM\ZNP^MI,=H'\*F%M(SC1WDSXSH[
MI/T3XT(_>AYSCJFWN>=(6.XEB*-^\BO#W]:%8B1Y,[]'SS-Y:(5X$46</,11
M>J3H3#BQMENIE[*+'X,<K^R7E;]]!J9U,A]9:75F_P`_L[]2X;*`_(']7X1C
M19>B<%;6=EODE!-Y2VNQSY%[Q3*)NRJF(5_W+V88J=FQNSO/POWU4R<<H$.W
M_CI,_6"H[_#8=!<P.Q>KQBB@T[E,X\DD=1U&_25ZBQ%_1O^RD.?J@(.,]+."
M+';K@$17,H0*[9<MVDDP(]`L`:;'M'/<EG-SME)L/&>2TG-&MX2+/KD=_59/
M>3>-#-G?K,E+7>Q(+7-?[=#SV:`8U'K'@7#KM/;1,5*'L0Z2VN*X$*)ALD$E
MG*60`T'2?EFD8SR^I"42HR$.?7,%@PT(8?3.#P1`NYYZQ^!KU6O7[G_*7LA_
MY&J$>/)_4$L#!!0````(`-9E:$`'WM%X^A0``-))`0`5`!P`8VQD>"TR,#$Q
M,3(S,5]D968N>&UL550)``.#\%A/@_!83W5X"P`!!"4.```$.0$``.U=67/C
MN!%^3U7^@^(\>V3/9I/LU$Y2&MLS<95GK+(]2=ZV:!*2F:4(!21M:W]]`!X2
M#QP-'F)+\<N,;38:?7QH`(WKY[^_KH+),V&13\./)^?OSDXF)'2IYX?+CR=)
M=.I$KN^?_/UOO__=SW\X/9U<,.+$Q)L\;B9?"6-^$$PN*%M3YL2<P>3TM"#\
M0D+""M+/R7_\.$HFUV',:XJ=)9G\^U].Z$T^G9W_^2PO%?CAKQ_$/X].1":O
MD?\A<I_(RKFA;LK\X\E3'*\_3*<O+R_O7A]9\(ZRY?3]V=D/TVTI)87X[;0@
M.Q5_.CU_?_K#^;O7R#N9<!N$45HWH)*"G$M8H7[YH:`]G_[[Z\U]*ORI'W)]
M0W=7BO/TXFW!<A4_3K./6]*&0'D5YS_]]-,T_7K"#3>99*9C-"!W9#$1_W^_
MNZX4=$D0>.0U?N(^69,D]MWHG4M74T$[_>0$0L+[)T)$W2FS>+,F'T\B?[4.
M2/&W)T86'T_<P'OE!CP_/W^?F>^/U?+3/D2ZCSET5B2,;Q?7'(TKTD8N"9->
MA+MPHJ?/`7V)V@A5*MRWI>YCZO[Z1#DMBZ[^F_CQIJ/59`S+0CO,+>3.?RR+
MOH6V'\93SU]-<YKI$Y>&N<DC.>5_):&(/&9!%<VR:#.B2?^8RB_EWH/4'ETY
M?GBZ(JM'PGJ4M\:W#TD+O4\SWGT*VV#=K[QDX20!(`BU$;C@W8/$3A#T*&/*
MK2P5%]4/?='GW?!?*Q7Q,$!"CWA%54*<EI$^K;"H,J!NI9Y`=+J4235*M5DX
MT6.J$A\C+!UG/15!9$J"."K^DH:5T[/SO)?]8_[G7[8!ABM'KOF/VS@:.(\D
M^'BB)HC]6*@K(YB.KLZ#\[B#0%V5RL>Z&OG'J@H[$,Q851F.PH)3#D@KQ"X8
M76F-3`UR[R3[,&FRF<1T4B].&>]"^.CR3`PO,_A_<`,:$>_C2<P2LOLCY2/$
MU_@J2$OS=D66X@<,[KUW2>@PG\Y>?25@931U9U=IAO2YII^M8:#J90K32`J#
ME%,%`E4.%22,Y]1<IN]AM":NO_")=UGI*@O'FN@*YZKIAG2PJJ.O>5?J0PK7
M3NKH,M/4WVIF1^+S7]ZC\WIUN-35[0T%>W+\^W$=/XLB$D>SQRAFCAO7O%W]
MV+!`O>R@?I5-,""=M4$'<W==U_+@_&;EM;VK<)$PQDVNU41!4U&H03,2&A6V
MIS!=RG"L<MI!L<$!1Q<B<C>ST!/_B73(LQ-P(:-9?.$PMO'#Y3^=(*G/`*S*
MY"8"EAG5_2HGTW8J-U%1JT"``\@8!UB^.NQ7$HOA\#UQ$\9U(X5.-8@`*',K
M:2FQP@&N'@@$6G9(>B[7I8E`9NC=BD3,'7$)1RL7.?I&8CD(K,H4W0*L#%9@
MM%$9!!$@XQPL/XP+ECDC:\?WKE[7?%1/"I$KNM6@8E$BMQJH!%:8V*L+`@F(
M;0Z1/V$8"2OBAL8.!^+@SJZ4.^W'L=LU71,6;^:!PZ4-/3%B68NIUS?2;-!F
MTFU+UI&BFQ!8:*:?%^@9X>CVK\/8"9<^[V8R^;EH5Z]ND(B]%%\H]5[\71(^
M][Q-D=Q.L"+HD-!"4STB8`QQ]/&EKN4;#5UI(-?2Y!91T*!S-D07O7<5''#T
MQXK&K(`QXD;9JN$U&M?('6TFH718)!T/(?2#5%I(HFSK@S^/ZX,;WWGT@W0N
MSCOGYKXA1>X36JR1TX;7AS)CWUIO<RX?;AD<7>/`R.D)-^,81+]P8"9L*HUE
M"<':?=1"WW(C@594:SI(%R"*Q-;<V8ALECZ3*">JI0[K1./C`9`PU&JF\+XF
M35AGA\;7+"%>4X6FN_5T.X^KZ+`[':2?E=]5''$D$M+)C]'Q!JKRE/'@G`[3
M#>YR)3\<@Z!T)8MXE^11L3JD)BCV(DD(4'O8J!'<N3)6.!(%%S1\)BP62:K[
MY)'+Y(?B2)3:S_`"Q58!0`'4.+#6&(X+"&L<*0QCK#>&PH.+\#T&=TU<'SDM
M<DD6A`ODW9%G$B:*\;J>*+>&B@BUCT&:P?VL8I?[^J]G9RAZ\1L:+A\(6XDX
M(^_&9135?KQ*,;Z3P9-TLX9M9^=2SCC'Z_HU'BVA8M2.8+6G#1K`^K8%A:X"
M'$/[DG#J/EW=F1^4N]4:]9"2PS.F7ZW\>$6R_65\C!G[X9*$;M/!`,KM*%Y#
M>4``@&O<%A#:&G`,YL%K&!;K/@A7N%J-#MJM=%D-$\PK7B-/"GK`1VMT['=?
M:S9<3Z63'8W04.SVK38I1EO1A2#<K%-U"5<'92DO'(L3(@S34.E9U>=2=U?]
MC-JG!FW@#FTRPC%_F7E>*K\3S!W?NPXOG+4?.T%)W/J:$[A`L?@$*(`:`]8:
MPU$!88UC+C-SW625!"*)FDZ\N(AK1I[$:>1GDEVQ=$,CL1/S=O'@O#87*MN4
MWBU?VI7&#:=.MK#`EFT]..98=R3F]B7>E<-"/KZ/2FI<<MU=OSY4@A?(30@I
M@!I!UAK#00-AC76J91Q"&X?.R/UNU`CN9QDK'%,DTX1/G4G3D@,W`1[4E-I2
M]QX2<8IJ<N3\!=6*FS(3;Z23K[L=:!X>JFU;=&CX8UF<TVP&4(+$JHQY0\:!
M@J>-%=JG=T%U;4%53H/\/*W9\H;_NH];%9OWS(Y^6=W-V]6*;U<KOEVM^':U
MXN%=LU=W[NB7[+U=K6A.UZ3#/M5=;:K/VU1,_3/*,WL&+<R1N\D@B7A!NLZ2
MO]T7`YIWN8N_%-[YS'6<,^HE;GS)_Q+0]/H$/B*[\5T!]7`Y6S*2BET/PATX
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M*\JQX6Q%6>S_YF1PKM^"6(,(C+C88F<@1@P0*SVA^#`QE<-CY"U1=84,4P;#
M5`&UTPVZ0-W<9"-W[,A[HF[7XCU=/USNMFW6?*NA*(Z5RBA03@+-NICG?U(>
M*&/Z-QK2JK#R'M](E]M&0X?2VU"]S#[7<$(9KM,7L4FDF.8KONYN@JY^1>E;
MO0YFCS;*HXS.NQ!3)/+],.$8S&,0#:-/9$%9ON?^P7DET=4K[X*R+4YLDZHK
MMCB))0`:!"E\,\4;F!B\IBV^!JP)*5;W95L([@>41=Z&1MZ[N]4D;^J?^/QL
MT3CJ8:"J8%="A1AW)IV@F)'PD?O[KR./>DB\`_GLV?$#L</I@99.ON4;13\Y
MD>_6QT+M2A<C)-O2*''3S0:`T90M?SG.?AH79\4YICEA]T\.(ZFL(O_O!TF\
MV_2;XPI(G=O02(T2-W8ZFG%BY*=:5AD7&/\B_O*)RS=[YEWJDGQ+A!UO%ZD*
MT6T21[$3BN=$9.&G5=G<H)9E44*HB_YF0%ER5\!KY&4[A1)YHVCH`@.8J;0>
M8NK2AP0RH`U:PTS-7P&TD1<4):>ZBQ/=RITCX!*[.SO,)5""R%Y7R-82`$\%
M6#"\166X!V`N%CZXV^*8^8])G`WZYH[F,8J>N9:O0>R#ZVBK&'#HT:&,6%T'
M,0JTO5:Q#T%0;J=1:?>9,MX?A-F]LN[F@3EAQ+402H9>^EN0)EYFWG^2*,X?
M'S39`MA.!JW;T)H&JGND-M=W(]*TRWTXK=QZ>U)-U\('4NF@XL#WD!$G\'\C
MWC]HD#XGN=U*M'MR?,9\<0KCDO\:+OF\UZ>>XMZCH:LQM.[NU1Q_0^[9%7MN
ML]VEQ[$O4C,X@4]?X-.60QD5PI5M,=+3,C?OGAWMSH4+)WKZ'-"7Z.VNA;>[
M%M[N6GB[:^'MKH6WNQ;^'^Y:X+VSZ/OFC#[[O/?\M/G.P\]UN-WK...3M>=T
MQ"?;,J+(WO7+=+?$W@M3E$GE02P&6I#OI5J4YZ+>]H.84=DS[GK=0]*/;#WN
M.QG[!=]MCBQZH'>$#PI=/R`5W;A*,(LI`O>056RO;A^BBJ-I/GOPP#!M;!C!
M478LEV3-^&`NM0'_.2!Y/KM\P*O6L&R*;*^*A109"?B#PI2VLE<9UD.(EUU,
M"Q$+9^_Q_W;.<VB(MCXC.A0XVYTO'?NM&-=E62NJ2'_I1RY-LE?9YHRL_&05
M78?/)+=;':Z=F.Q>!&G%Y%CAW8=-]P+[EH*BO+'AJ\-^)>F*W6ZIK5A^JX$>
M0IJ[04]ZI`"VL,\^8*H7!^4QXM*ZKQ.0VP77F.L8;^:!$\;BLO7UJKDCR:Y0
MXZH9?:$CA6HKF^T#M%#!4)Z%+HZ.$$^L2I,PDDW,]$3%0H:"Z$CA"++)/N"G
M$@3ED>W:\(,\QL40)!]^:.=8&GKI-$M*?Z1XM+74_B=;4IFP'HIFA+>H2Y+]
M7U(T?RA2D1JV+[@[.@TN>*0`;FV[?2#91CB4YW&;"O`I83'U2S<Y<FL1_UF,
MO>N3J%9EE<#6EAT)VRVP)T4LW"YET,)KET-16RO*/&M3!]XAK!W?*QXUR^]2
M*#22YE^[,5'B$\;DP(':PE)](A96/<I<K$1U(?.N_X!!55=(/2:0%CIP*`(L
MT2?TY-6AS'.J(_W<V8CP+A;57)<EQ"N]]P?NO"%,C+VXGLF!0[.%I8;HU_75
MH\R*-I6I/5=J1*F"7@G(!OV!8T^O?Y\P:]2$,E%IBN0V$=!8$M@#'U.L@]ID
MN+X8$-7&O@Y8R"NN]W.BI_JU;S7004C+ATB5I$>:[;&PSS[R.WIQT%S=UV$;
M8J^G#WH]=7!$&U-[M>I@V[P[B8ARIJ10*MO*TO,!G99,]4W%FNDA'=#I9K'6
M!W2LJT4);:'9S/UOXO,1NKB4./TY>UBGAE<`97%`7T>)*QBWQ0ZUL0<@TEK*
MD1[SU]6/,BW/E78)\=++K\5>EEGH?75BL0]K<[N0[<VJ(;!U^=P/+<H?#5J[
MVFX8#+>0"F76?NYL\DE#WB(A:+8I4R`85N9X4-O"1@,A%28)RCZ^(7ME"Z%X
M)DFQC]2^H`JGFH+'"U:HM?:$6(TX*)/\]<XAW?KJ)<(`\A-3\`**`8&LP/'`
MT]8Z^^GR96*@7"'H9H)>)_^]3OJ/".*]6G48^'<5$>7"A4*ISW[HA&[/^;&6
M3/5-Q9KI(>7'NEFL=7[,NEKT@Y#K*$JX2KS+*EU:HAF#:.DE0Q`%/:[PW!9-
MU-XV@`AL*4U]`**0`F7V[(ZL\Q'][>(^><S>A(N))\X]U$`((<UMK"<]&NA9
M6&08U.D%P)G4DC:4&QHN'PA;26`'+Z`-?M4"1P-!:^OL,_Q5Q4"9Q2JW(*[D
M,V&QN%G#$/X4E)+HUZ`\&N3![3%\[&O4CW+45Y8XW;NCB7H@6@G>)+1'B3B3
M38;'G$2"0\HP`;7O=?K<Z[3YB(#=JU6'07Y7$5%FF*X6"^+&MXNK5_?)"9?D
MCH^=;\-T"T3HB?_$8L:S$X@&#V@<?;$K7HSMS`YE/JEG*P'>G.U<X2'%]?9!
MO'W$/B#TM=>]=<KR@`*BO%',N%J,;;@"_W2"QBDHJS+EO7SF,B@1U$9?P#NA
M,*XH;QXIGMC9'D4H5IU"3S(^$+>I!#1*&%$].=L3NQ+6NK%#"\,>K01#:+<*
MY>`=^8!*FIS_PIQ0I$U+;YZE#2Z]INK1=-%8>P[;MW):<!CK3;*^<$?[L%SE
M(;..DF6O^+20".7"SGVR7F>O2CE!89GK<$'9*I5:$7LM2Q7XA99"&4G;Z0QX
M%`S*%^G=2S%AO`'-'=^K@43V:7OXN/QI+'=;.I1J5:HX&L8Y.SA<YBB)":.]
MB+A%Z^VB_$"*&';&F[=7$M]>27Q[)1'NWJS5B/$`#=,9F^:U1!UMW?ER6NRO
M)P(T!+ZB*.>$8VA5DTWZDJ*6IDCPRFD0O*"H]2.%:2=UM(QQFJ.5,SQP?__R
M'I7'R<))@KA/ES<4[-'IX[\Q7FS=^UH98^Y>%I=_W[TG7O\^TG!8WUBI696R
M4Z7,\O?!ZTQPM-Z9Y_G9U$H,Q:_#_)(?J5-!M-OG[K2T6)UMHR+(\0:&.%KS
MS'6351*(O9'IO@W):_9R0-B6VSTY!"V'%B@M58>!!LX<RS[!F(M.O"N'A7ZX
MC*1HT1-M=VO)B;#B`*04R.DJ3CAVYS5O>FMF1^YH$'RF[,5AS9Q8J]+*._L,
MI5$F4KO9P)P_L.:/H^])A12;HB5+"E>K=4`WA*0T\X2Y3UPO<91:ML;4ED=Y
ME<F>!YHK(F%@HOT82W]CI%:4[3J2O0@X5Y+DNJ2K89%2F686K!,7/8;-7$8+
MF%V@J,:RI=FJL;6%2!I,FT4Y)%2G9BA=>@6$L;(8(/96BQU7N-689,`(6ZT5
MY;DC;6.RQY^Z'"1PHD"@-8Q,T1&(/6B]QA`(01WBH/>-O*1?;")>HPP@W)7*
M'%>L4QECP$!7JA+EB3=M>[$$G*(0)+Z-#SD[W)@B&P1IH!J-,<T(L-&3^Z6K
MU169:/FVO3N216MR3]BS[Y),:W$[^S(SH6RO^[ZJVRXQ#%W=X47@/;N@8_`>
M7EJ49Y-4.7UN&>(OPXN$,1*ZFP?&YX>.FP(N]-+?@FPCW=9LWTA\NWAP7N?B
M45;^(8Z9_YBD-V0^T#DW7.-ZR5'J+K^*L;^Z#Z_UCNF<CDUYSZ*C/!^FLL'W
MD%LQ\'\CWC^X!?D8HO2\_/8>VQGC\2Q<E@<9A26`3;BO:@RMM7LUQ],P>S;Y
M0&VPNY0H#]95G@B:/3M^D,6(TEZ;W%J?G,AW:ZVH9>G=45^[TH>'^6X&Z@AE
MZ\KQGIZK'B"03.:E!.6)>XW@\*!D5+./)%"-/\IC0R7X9AF$++.@WCPIHVIN
MH:Q2'1X^8`IW!(FR$E7J!EOLR#KENN;&B*(OIHPSJF*'AZZ6)ND])JEJ5>`/
MYV)(UG3@4&S'`9*V1@90:Y29TMC6((5*8$QK6P(5)4[3_%\Z(;)8L*O0`Q;K
M<OH##8D61AAPD2ZO#N5MO-I68@$N20%(A!L77G",F"*9"5'&FHP12PLBR+'R
M_._B'['6P/_R/U!+`P04````"`#696A`Y>=^I3!#``!Z"`0`%0`<`&-L9'@M
M,C`Q,3$R,S%?;&%B+GAM;%54"0`#@_!83X/P6$]U>`L``00E#@``!#D!``#M
M?6MS&S?6YO>MVO^`S6Q5G"HIMN-D=I-WIM^B*<IA128U(IV95&IKJD5"4D^H
MAJ:[:4OSZ[?1%_8-U\:5LC_,1.X^!P#[/.>"`^#@+__]>+\#'V&21BC^ZU>O
MOWWU%8#Q!FVC^/:O7^W3TS#=1-%7_QW\S__QE_]U>@JF"0PSN`773^`]3))H
MMP-3E#R@),SR!L#I:4WX#L8PJ4G/]_^*LG0/YG&6]Y2%MQ#\X^]AO`5O7[W^
M\ZN*:Q?%?_R$_^\Z3"%X3*.?TLT=O`\OT*9H_*]?W679PT\O7W[Z].G;Q^MD
M]RU*;E]^]^K5FY<'+BH%_M=I37:*'YV^_N[TS>MO']/M5R#_!G%:]"W024V>
MC[!#_>E-3?OZY3_>7ZR*P9]&<?Y[XTW#E;>YS0Z,[2Y^>%F^/)`.!E1U\?K'
M'W]\6;S]*O]P`)2?+D$[>`5O`/[OAZLY]9?\^!)3O(SA+1;/17@-=WF/11/9
MTP/\ZU=I=/^P@_6SNP3>D-O:)4FG*?Q9?\2?]?6?\6?]4[>'EZVA[O"CB_RO
M3K_P,8/Q%F[KGG';#'D473<?X=`VVG1:W6'XH*3[<S:[[6,^W->O7W]78N!/
M^,D_K^!'&._A>8+N+Q.TW6^RL_S)#CW<PSB;Q-N+:`/C-%>-R6T"(7Z8UNT6
M/^FO7RFTD$49_KVC6GC9_01X+)V/D,`4[9,-[(VV^(_*KQ81$59YV(59^4M5
M>K_?Y;\!FR@8GWY8?06BK4I[044)6J0`VZ<#,6BH__*R^83#SSY)NO`+DTW]
ML_,_.=^KHGBY0;G%>,A.=^VO=I/_(C6`(0T2;\ON)S"B(9`AH#`*VTC_YW=2
MYLAGF.<_):C8``83^()Z<>E_=KA_(X/[+=KL,5L1J'F+_S=?!>N[*`5P5SP`
M"7S(/ULAG*2M%P^57FQ[>K$[Z$5X:/3;SU0QWGBJ&'JBORF*LR3<9&G>Z[LD
M9,9Y=-IA1$>BU:79]''HC=*(_0@I*H$S.#PK-*Q\ZHU*,41+4AXN$H9*,F0A
MJH-=W!B(>72"9A#'/&\,"<0@?J+(7`2A%4T"40$,DQANP7:?8.>?W4'P`),(
M;4&81$4\T`X;4I"BW1:@!*0P^9B[K!2_^1AM\Q;V\18F10.YO;U/`;H!(=A4
M8_H63'8I`E&\V>VWD-]YT6F,XM-\Q.%3>+V#(-W?XS;O40R?0/@I3'"G.13"
M&.0_*,J>\#\V89(\`;3/@QJ0/L!-=!-MP,,^>4`I!&%KM%$,;O$W\C+<4=<K
M?@BC3Z\4PI)5=!MC$>7M5GU.DKR3VU(@9U&ZV:%TG\#)=5J,HJ>I8]FKCR+/
MKF11QHY6S5&-Z)5N;:0;"U;S=XOY^7PZ6:S!U>S7V>+##$RNKB:+=[/WL\5Z
MY5;G1@,(J0JUJY>RK32JJHQA"]J[AH_9V[SA/T:J[X!?4G];_%84>#!>.QK<
M[E9=A9O6@A9+[4%`FPDT7.!WS`<*QO]W'+H]1)>T<M,`*JG=AV;DU=L9Q.7F
M4_Q(V#'8\?RK$S'?AT_@&H)]6@:;F_`APS#'H>H&X;7$#()M`_\\?,W"*"ZB
MV59H^G4>.+>4J`Y_-YW)7=@:FN-8U(7NT.:"SUI[I.:1G#R6:]5Y\URB/:VH
MILS$G*):(>8[JRQX/AV<%:9M'M^@Y+XPZ)19F@Q+]9'$6)1T5694:O&;8$]T
M511J(*BI"E]2TH$6H5O5D\(`&B.CKGJ)<#8:-0IN(DK4W@EU$Z;7Q3?;IZ>W
M8?CP$BO72[C+TOI)H6ZGKUY7>[?^5#W^YRJ/EPKE7MZ<1W$8;Z)P=XG2B*%S
M,BSU;$J(1<T_2HQ*<<XDUA/#_8DT$$R7B]7R8GXV6<_.P-O)Q60QG8'5S[.9
M<U<G(W\T1CX]=R;`V?)@8Z#F0-_6./%,TZS.R[X.52_U:$NG)TUZ4;<IH`$E
M:7#X=S['QT]<3^_)<AABF22G/FH+&@(^R6)T@,35!L9A$J')8]1?KF?2]''9
MI=$#3U*_FE#::UH`K!V.!K,GH'X!?L>O?`$O469###-$VX=RFY2`:"8`+`*[
M&L:'N%JE@]LS=!]&<1_</+H:X'0Z-9#S^E<$.J-Y!MBI7$']Z@2T7H+?R]>N
M0<^5)1+^[#WPT\A;"B`,$`?6_2**X3S_DVK:!P1]N]XBT&/4!SUJLNCM=@7,
M>4/>CC_P4U`\=@UINH"&1IPFQ+X%/]`1S+<Y.<LE\GFI2%5QXSS\X>DQRIB:
MS5:3LCWC-$E3F*64]`+Y9?5+^R^5@$KN2<T8#=JD([-'&I3_SF/(ZHEC^T.1
M`V)_O2XBNS0-&@V*4:NM&2U-;&,FJY7S7(V<$&F&9:08;1N4Z3Y)<*:595<H
M-!WS,J#1`$]*OSJ,S;!I'DK[')7I.0'5"\]L$$UF2.@3DZ#<(^TCV@(`#)@I
M91Q@HU4CH"3XZ7C%S[9EB@"P9]FF87HWB;?X/[-_[Z./X0XOQ$ZR*=Z,',6W
MOX:[?1]V4CS5UQ'D45($J7&I64;1KN@:(M9"@-\7JZ+%'RW*$Q!FH"8&!;5;
M99)#!1HEM*ZJ";$VJN<-!+7:9DM(+&PW#8O/%W@T*W^TT)/:M%4>:,FG]DGF
M'H!O&`#$MO`MO(WB8O<BN@&7Q<B?,2XI6[..%I??R^-R%F_=H_)[#BKS07X6
M>/S>(1[M1<OOP^0/F.&%]17<[),HBV`=R_>P+T!9?2DFI9+F"8Q!+0IF=T!7
M+19?T+P$S=M#ZL"M"HE(%4E\_JZR,!@:%7$"%ZT1JP'4X.B4B)OG`1=:%*H=
M,!8SJIL-VL?%T=QE=@>3*[B!N;W/1YDN8$:VJ5(\=<95C$<M`2<S+L6,K&!7
MC,R<4`M!358$-@4A:%&>@)S6$YLLAPHT2FB]%)\(:ROEYPL$]>:$[2"Q6.AB
M8O'YHH^:8K:!/WNNX!+7R8BVL\<'&*>P'F4G4=[#O`1']>6$.)0T4&),:BY`
MK".ZVHGP!Q41J*A:FM=;RG.K?3)`0",DU=4[`<9&Z[Q`G%:+;P%XV-K7T&L@
MUUTS?)Z(H]EZXYASM(F"M7F"M6E"YUJY@4T2XHOB@TT1'BV%<Y;`!1:^*0O>
M.J4G:=M0%NX8T>PX(18E%W#+7MDH&5D*;6,0E:;-F!'A<A5/E[F4BJ.O_]Y'
M13G2/*(=!(M\TD.4R")5=-;\4:C&A<P>6'Z9P1C4;T]`\;X\H5U3%'D`UPY9
M0+Q(1@Q]!TSG:'M>)\C1'-\9`%`9T97OGS%VZ.&;=O38,[+S.,L%'EWO8&GV
M\]','G$1S"B^?8?0]E.TV_4@*\-2?2DQ%B45DAF5FA$6[(FN2T(-!`W583Z.
M`?7B0`IJVF_<:I@4'M`8>77U382ST3M/H*?5BEM!(+;J9`P^5[C1#+P%P-DS
M^*UTP2+_R,29.I.F^C84&B5%8O:K9K1I3=-UA,P1=#.DS1NW2L&6&!+ZP%W0
M$TD;E%L3OU;#J0D%V#2V<7"\LJ>9/"W2MV?4*)$J)8[0Y/;U1I5"?KN)#NN_
MW$*/[F_9(=S0:VJ6B5:K(24:;!N.13@T[9<0C^VE!>*:`G$Q04L>6N?R@4#*
MN5XP<%Q>M_=5$?F;D)+)_2RR%B$86`40D$63]_?!R;-%PL[P<X5B3XDOHO`Z
MVA7[$R?Q=I6AS1]W:+?-[2_.AV5/E'/7LFS55Q!G4T*I[.C4C(E$;W2("S<2
MM"@/N=WLR9O3W=+(0&.EUM4L4>Y&]SP#H]8(R2HFL6&^F$_>SB_FZ_EL!2:+
M,[!:+Z>__+R\.)M=K;X&L[]]F*]_>^[`I!E]B]"T6(ML__!07GD0[O#1H?,=
M^L0O[2W)55<M$^52*W$E-S8=5:^$>V24PA)L(V@3MB]@03?E&3K,Z$_];UF@
MH)%2[!7;$F-N5>#R"9FZKJJT",NB;%L;F$0H>A/<F$8EM0B<+5PZF7A0:L$,
MIQKL8D`L0ET1'&4$VB80,N5^&&SM28)_!:`$)$J*O=C2'\9:U')`#H!B*KC7
M@Y=VC:@6E>-"47I@(A"4ZP"*_4.<E^4UM^Q3FV2BWC'-/I&60W'DGO4<Q!RT
MS3_OUF-ICK=5+WS9$<Z6V^`H&U.^=<Z12#L\JF8!!D8.0RJCH7/<L7IUS##@
M'6%4!()54Y?LX79HAH?6CDW7&#P:G2K8V?TKFSUJ\TRL4[B"ZA4@18G.@<^1
M)!+^Z`/PD\D[^+<+#]WF4"=**J-8X*0ZV^9ZQ4T#-ABF41\Z+.\=Y)I'#E5[
M_Z!V['/ZUK"'4!+P-)YJ_YA_)I$G/23XJ0G[R5APMPH'_7L*]:"B/3&^1$F1
MBT0WX`+%MZ=KF-RWX7+<*&'N.]2!$XLK4[CB$MR>P6M*22,Z0;W>1"!02^!3
M>]2QBD1JG)&9'Y*3,%["&X6NUX'HLD+\K]O+H@_H6@ES\R+7MCRC*N]BT:5\
M"O!C3QS=.%%3ETS4A&VQ&#R*/\)<[7"MN/TU2K91'&8L\R7.4)>!%V!0JS8K
M/"(UY`OUPR@NRV</6C2@3>23HD@``,F+J%=+ELO7*B3K'F=ZJ[R;AEL17K(`
M]QQQ1JWN;A9I+E>VN2O:W)5L[0N3IE:N)5<@R2O5OJT[BJPWBJXRLE87M4M9
MZT9]96$/"_=X,WT>)W/QM64IJ=LS56?P!N9CV%[!CS#>4]:2V435+Z<1*0&:
MW;.:Z:*V34<TA26HGX/JA2=VC",W)/:5N\@FTS;HM@@#K:&>-C10,H9]B!PS
M,FA63Q,VK"<*<3879[MP]$C.%)(HNJG"+H6.Q!&I3WW)PE[KW.Q1ASXXY`9/
MP`ZF*>@!WHLT$E%F_3P20[#=-%*;<)!',BM\S6E#%<FW$X?%&DB&@5!F1GPI
MO#%6_)P\XG@`N%L-9I>381)2UH3U5A9ACD#ORK!,<1$R&VE]V!?,"\B3NOXG
M5':&2$]?`[0`$Z,KQLIH:>K1',%2\3BTB"X8*^+%2=J.GJ^C)^KTY6ZTI^9$
MTS2=9)PW^1AF(H:;?R$F7O3)RE2"351D34KMZ$0GD#P3$Y[-I=K[^RC#I^KP
ML>PIBK,HOH7Q9F@R!"@/B[,,2L75,NX85)=C61VP%L;H?$'K97F_9_NUZ_4P
MOE"1Q-?OKW]1&=H+7P[0HGE153MHRF54"FPZBPS@Q0)E^7]>?U\0O?ZSXTJ]
MNA!%7U/5C"F+R3G14D3"A6*,57C14V"(E[@;5\.%54FH_>[KJHZ0XS.?,F59
M9"L$B11><8`1;?D]W0`ILGT$B(!)EB71];Z\]C7_=)=A,;WSY7BY'@Q1\X%Z
M463UQK]R_:487>?>\0JI#(KF1K\AA>I]:K0^U=2!W##SHK0!?7!X6(K]!!3/
M3\`\3??0\<WR+&DA@<\[N/*L3]BYXLR\V.7LX$>87"/.Q7FJ\N]OSQN@X7]_
M^^HUMGXE+/X+O#EY]>H5_A]8W>4V,063?7:'DN@_</M?8('JIR5ZRKOV]EF:
MY7_@VR/"#)S!#;R_A@EX\_H$8#TNB/(_7ATGUA@7[*FAS>Z<'\54FTE[W9K=
M=U\K3])(O:G/XWNMLN=A'>*@?.*AA:3*!O&^YW`6U:;J3IT,BE>S2522<SW)
M;B2=6[^N^?ONQ__#,H#??W_RW>M7)W]^\^?"JKWY[N35#S^<O/F_WZG8Q1.0
M<S[`319]A+NG8\,;:]X^$G$6JS-LMQ'>[A'N+L-H.X^GX4.$RXTU(^R!7)RA
MKM<@P*!V,E]X1(H5'$3Z81S2Y[,'#0W`1""*045V`MIZZ_@,OS@$D+R0>F?Z
MN7RMP_WND::W&(1IP!7E(;J0.YT?(/<<048M'6$69E:K[>SO]SM\D*98H,]'
M]9#`.QBGN6^=QQMT#R]0BJ_/6MZLP\>^<1_'W53FD>-6+<@R9JS*57PD.V56
M;9%J*V@QU/>[MUE`R0->8*YORGL-\1GP\-%YR9=1H$**DAX4AY%II%,RQE]4
MZRX^Y`K<5:$B`7A_7EAFE#IR@V9[GNP*9F$4P^TL3.)\!IFV1GX&;Z)-U%]#
M%&>HOJ4(@Y(RBX](S2L)]4/750'VH*8!-1%XT=;7BL[Q2KP$`I"\C+H:R.=K
ME,X#H&EU%,;QUG<'U>/GB"Z:A3>,+Y=[0+A[/[A[/K2OXYM:O9=<M9=:J_=M
M@5YD85YT.9ZU#*]=^%KW_RICH-D-3,+",0I=?!>&7;&_D1'[`TPBM%UE89*9
M%/Z;KX*W84Z^<3S1&2GI-WY*^GMY2<_BK4DY?W_<<O[>3SG_H#'(59?Q#\<M
MXQ^,R-B?6U%[H!(E%[P%U?"%DWH"5H%>QM\L2;OEU)N336PQ"]\<2583'I?X
M/9&&D63J])M^0!'/R17`\B]2U@^SL1>3*@#-60TK:M$#+AVYDI6VL^S<_K76
MLQ(\PD[G(E2U\J7<`5^2M`I&O&('5')J%2/S\#!9YTH5)=BL>EW::A0V!`M<
MJ:'#BP+35&,IQ<,O,ZU-2Z3&I;HK6JRK406`VX:64W+:%ZLK!PF1@L`\:RS$
M*E04V"[^;!6AU@G#XRU%K0R^$06I]<'/U?F_RS!9)JL,C[#81WX)DV(7?@_U
M<DS$4X)T)HTGR'@CTWF6D-&7Z/$R:A/#$X?X?`5*0$E<GK0`.7EY9L*G4V%<
M<%`.B@F"JE)*,5[:83*G6-3J%JQ!DGL(\G``"+R(8K!%NUV8I.`AAVB*^1WO
MZS&+4;'SC<90ZLIYE.>UFK-=3*=!(R8ZBR&Q1L6DC42G<R#T(:J!`]:A,QB<
MJO-)N:B"IB@5!QA$5>KST%3(*HX,&G:-<.(:\F<-+C%+K0U>;BUS>9!6P"IW
M"1D6N2;4KD7=$>BWQ(?VY=2F8J-:8!^.MPL(E*D<1.$SU*(ZGLU4"<,X,6YI
ME>`B:F&?#WADK*H"?-Q:TU8M`@&32J!FV-4.M7:E(8Q%OX7M=B*G-VU>JJUM
M$?FG,R1Q,Q6'C@^&[K3+83`5R!J>C%MB3;`2M<G/%F0R)EH+S)R49A),9TMP
M#`LX&4H>2HQ)6YFG4?E"$?Y>B2"/D]<R4"#5[Y%+6PLP$FO\N,.<]J+/AJ$W
MK$_E=V+:%/X$2DJ90:`3N\_)1`M0#NV\YMRAP!BTV76I="&+KZ=*GJ4&1<1*
MTAFQC#.#@:@A]O!BRB;K@LW0!C]3X`@863W0<6A4B4ED#A7-F&I)"W+ZUFQ$
M!3*!-!ZB#GA7$I6=\Q,3-`WV_5R?54"8M9+C<4&UCL\!&,(6T2TT])_;U@F0
MY@1W,64IIBFI/_.4<<"@G.OV#!BZCWGKA,7WSQ$6E&/@VF#A,'*B+QB)D-)B
M*'VI?9%1:(ZF1+/Y3$9*7.5-ZEY(NG3%X*X,L3@8"F('.&:C+AWXH<9?SQ!`
MPN&8.H1LEG4L#M6EE(O@:*\/)1O[KQ7KYI%[4RW'.&B550RO1QS43[RYBXLJ
M$\3[COV2=EVJ=@$[HV+57/Q00;K8?%W-?ITM/LP<7](G+U1ZI<+18K5H=M!3
MN,N>JA'UC0[Q96UR>B_5D$GL2='<]-MDP+%+&E3_!EZ<^J9(`;&_70^+'9H6
M$LT)4:]Q&2M+;%@N$[3=Y_I7OG%^T[*</*G699Q$[0<TE$"&$L!H\G!Z`Q8A
M5]8$*'XX,+KC8KNKH9O2)!.M!96D1-,42/+#H',EQ`LI!&1D,T64%I=KSQX?
M8)Q29S`\LD-JB$:F.+MG]ZZ:$J*VSIK.4YB"XDU9&:YZY\V<ARM%)/K%^W-W
M,G5[WFX5&)I3/AKQ@:W9\G)V-5G/%^_`[!^7L\7*]:Q)'1;TI(XV8-B,?5*8
M?[6[?%1GN8'>H8=[&&?5``<!D0#M(4IBTBJZ:8%QJ,93["Y8GIS%&=2O"YO9
M(JCMIVM_+R)A)"6(?ES`8&D'"X[@HSG19`1%10J*@J/G@Q]Z9&D`0=;36!0+
M2WS936-I4@)B3UK26$+X[I(>TEA^6$&R%/II#[:=Z]`,DAXFA&@BC24OR\(X
ME4^.28J<Y)6L'.W9DW<PADFXR\W<9'L?Q1&.*/$MW&0#(TA=?0,NM1)Z!<>B
M9I/XG="!S>,-*H+"!W=)_#!DHM)&DB+IJ@B'J=$9IW#2:AT-H@K;3SJNGA>>
M:$;7&*(LFN4PBO$UG,OX+$H?4%K<-[V\F:0IS/H+#4*TM4EFTZIID,@X%,TQ
MIPN&VC`Y`_RZNC<9H!BT:/`-RB658^41DC*2$D9/;5@L+:5Q!2%!$_QC":(8
MWN+3C@PC;`9+A0'&:,(;U,(=?([XH1I>$PBR9W0G]RC)HO^$Y7#F<9:+'Y>;
M(%I=,>+J^_"(U6X,%QJ)FN'E]L&X")S-&K3?8V5I*+S0&T$Y(SEI]"[S9O*T
M[NYV!R.]]\R;0E-Q;7`/3Y/-O_<1+A7SK(%%O2?^"*`E=9SK(TRND1MPO?G,
MC!7MT)<A3+G;R,'9P,'9N*%Y7=[,1@VI!7C2Q@R_EMWYR^UBB^STQ77-4M6Z
M)TQ)N,T>L>4#Q/F.^-:/=*.\C$6W4DA(V9X1.GS]>;Q!]Q!/B'I(8E!4OY=(
MH81;1I]J!HG<,!VV)/J@06SYM$K9N,4M2TQ(X+MVL4L@;.!K1=Y:394&L1?;
MP`Z"QT^.4]XT:Z4L<7LV:X%BU!T0>9V02U=]`0:=$JJY_:O9,E;S=&C3N8+V
MJX-IJ]XZMFY\42+AK][%/96\0;]U?&A-<VB&";:#\_@C3+-BQQ\.SI?9'4PJ
MP)R`!72\?TL'5FA64BM:[%G,?-8+<RA2ML12WE:_?/!6"?.4OM0LX;!1.K#[
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MXS`U>N4445IC&(/`PC'*`$:@CEH*L-6&O[A8X\4*0K!`&03??>/E;22Z04@+
M98S!T)XY_SN,;N_R(4P^PB2\A8O]_35,EC>#0HFDB?(HWNH+2O(JJ>FH<:JY
M`=DNZ;HKUU)0DX.*'I0,>(_6L#ZH%[';.!0A)>%VU5BJB4:IO86P5K_C",G8
M)U6`_9#F<,Z]S#3<;?:[<FVP%,7!13W4\=#0-WE17]PFQFG.R@G*G3NRRL/R
M2IF/Y&8[,SJW"5O`&ZL1A\;H5-H04-N2=6I>3(3&(HJG](*09"L]K1&NVOL!
M:1L.S@:R.4YN,!,[4C=G#/.2KLX\ZFWNI\#9PN(F2[P+AE*"D4-UV%]!H5)<
MFF?VK;K?@M8X:X6>S!-,EXO5\F)^-EG/SL!JG?_G_6RQ7H'E.:C*[N4$8+(X
M`]/E^\NKV<^SQ6K^ZPQ<+%<KUVOZ;/DB06'T5_B)Q.V5?C'`6%WQGX;IW66"
M/D9;N'W[A.WI/#[L&IULLNACA$M!3U&</]CGSZJ7**85,-7;:+,_0$NCJHM;
M&G^9GA5:/0-BKH;IZ"+`C8#S'?J4@O-<"5NG1YH6'!?GU`Q<9`8V@Z4S#6UW
M5M2>BY[)A;O,M>7C4+)ZTT2A:G5;X/H)O*C"Y&^(6G<"FD9!TZHWI93]5DO&
M?HUC4$R+Y3&V_]J7>\_3-;J"6.#1#G96\-=(\"=2(@^37=2E.(QTH78\WN"O
M5BS[869DC!/X)CH,6JUB?3RT"X;;?O!F'SGKZXV9-:H\R`98>V4&#/34*D[P
M>=@!O75;GH,Y*&K$L`Q"?0"SL`-U?M+#V<[QZCNU6,WQ:[R]<.P,/B1P$Q7A
M8?[W#N(_<"G+5M65GIF18:DD(\:B9/9D1J46S@CV1+='0@T$;:H3<*`KZ[&V
M*-V:#RDPH#'"ZBJW"&>CK)[@3JO[M`(_[-[:=)\-ZFA.Q0+N+,[!-YND'%*G
MMM99E&[0/BY*VUPF\#[:WZ?-4?%!Z4JE1NIY],A&U")DI9$KSH7']LT(;\<U
M&1SXP(LVYS=X8\B!N5#\FOT$M!IP'+:JH0_IP4(O\!S55BNT/!YET'Q4W!NM
M&)3^;,$?Z\7[,/D#9L6!KA7<[)/(_?VX;C6!.@GS0Q?L^=0&&0TPZA+5/<43
M(:V^)IM42?%%1J'FZS@]T'67R1@0=?`$M(KONU5((?$B&3%T58O%T2B0(^1H
M=@Q&(%1>71?NHO_`;9FG>X%??5,7VR^#GO=A5O%Y:OCUX8QFQ`T@S<7E)UBF
MRYO+!)=URIXN<\1DLW_OH^(NOA[`Y9@&UZ&PF31=:B$R,C7#+=R7R.T6S";Z
M5Z;4=UW4Y*"@!P<&7VZ_$$('X1H,"515.BC&2[H6PSD8C5VU8AB5V#]4'J&P
M=`=<)M65/N'.O_M83""2?T.+44S:\Q7UL6*XG:)[7'^+M.[!)JJ^$(U(2=W8
M/:O9>FK;="VBL)2',4ZO\0O0?N-613AB0V(?N:L`9-H&\!91H'5M01L8BK,Y
MN.[*Z=L!'/PHZ*<&"YIEU`0,5[=5G<'KK$ZQ5.F5?M9?E)YX9Q617N.E,(SQ
M**;M!;H1O1&&Q#VX$@83';+PX$5%YSBS(2Y\RMTP?+S4Z4,>&^U^&`<(,WBI
ME7:@%7O#47Q:[$KRJ\*J"7")W6>E&5Y6CS$F,'<F9[#\;VN3T31\B+)P1S_9
M*,G8''849E0]_R@Y0N4CD>+],4])BC83U+3@14W]37>/8,7AS=;@$:A!X^4Y
M.%4IR-\Y:.D;6+7Z"NN8Q=YC>I>W`M/>;M;RSC:<-K^(PNMH5ZW)X(VP]>6)
MY06MKK>[VL$PO?JW512[]$23S6&AMKA?X@IN8/01KQ+TET-'\5+]$9-7LY8+
MC%.W5V)W*:/DK)9HOJGF:5T;TF+S3;-%8,10;G$44K6;T01+P3W!L/;[()R`
MN=C2\P6W/8EZ@%R7WBF?NSV$T?8,WL`D@?5%CO6HB5>UJS5"]5=BC6A6>IF1
MZ_9@@GW+:+]0DS2?5C'729"6B?!A@4\1=0PS,0*]5&LATA;+;'BK!,9=H"-M
MP$ZQ!GX#^.D^9XBS+\"7<)1.H.\TQ8C'U1QF%'.5+"9Z:I'(I#M3PQB9]I0B
MN2^IU`RI"6HJL=#J?IK&-[UF8H.5?.%CBIYV(?`R4RZNH&C<`1G"9''=LL=1
ME$[0263[3,#.ARS?9?B$)WGXB.-FD^QS"#9I8.%TGT@CW+P?NQ%#R1.1D9O*
M!'+Z'I-%83;)S0U6W.61X9*_O2K@FR600I]`VD4"Q=SL"ZLMD32,=\I@>/W+
MD4YT4HPD^%=1_6>-??G<HU7TN_2B]>3O"GZ$\7YXO;<@/=4W#N@U:SYE/+H]
MWK`;&47N<]/\6$T'*D+?=)8F?(9ZLO%"U<,>&TOE+"/,L!O1"K2RE,ISQY2X
M==>(*G_28#+3'2ZG8$+,9"S'':/9U-CX<(W>CFB2S..I"A\YPIF+$9,2:@/B
M&0PGD#6]Y\XT<IM4VF<'S;&9->W@/):[.'JZHJ<Q+7=O.+T+0,H`H"S<T0V`
M\D!,E?]O%?UGE9L]YB+^0UNB%>"5<5%K4U>I?J?ZXL>=&0:51>\=&5]TB@2=
MH]`JYXZ]K%XF?7\)V\&/;)3MZ*4;-6'`1OXR<Y=LR0](VJ;)=C&X9.O0@#]E
MYS4#EV>\U!2";<(DV^::LF/4,\,!@W]*)A!`D+3N2"_9\D0M)6,+WQ337JR1
MCWP#X3;%UA^77)K$VZJ<X=/RAE2OKV<:1O-7<AG!KV3$1H]7S5J-Z99NF.1;
M"VH6@+6W+%+6*EWYY&GARO'H0LH"[QH.Z68:&^$]Q+6FO1TCO2@G=3R565T`
MG.8;G4+<HL<+GZH[F8IB`PD4\7(R/+5G$^-14W69<2EZ,,&N&+HLU$)0DV%T
M581>:JX4)-`HB?7T4X2UI9.^X$_SP01+0"S.O>4__"Y,_?4>!C%(]1(V4.C0
M&W0JSN9^C%;_6YZ1YA<8C'J5DSM"S1Z"U9^$=M*;(?J*FORDK`A^4@2"GI0%
M'P$:NM:*`HZFN%1^AO:ZQZII;V(:M.4)@$.5JTX)^\\.J<).QBQ6W:7;B@KG
MVSW.$D+B`6EQ!DI"C<2@-;U`'Y'>E!FQ'_',`8&=E!0KU;&B\^)$J@0"J#D!
M+FHH*8`A'WW.[P!H1A-7VO%65M(8(LZ_NR+,0$XT[Z09=,>R;T/K?@VM^S2<
MKAN;WY`I/A!32\6M!>)F4;B]5$Q:(#[FY5_=R[XF%GMU+?(ZU1X_=EL85!V]
MNRN^Z-3H[9FNM<JYFS^/XC#>:-Z>.;)1MMN7;M2$`1OYR\QMSY0?D+1-D^UB
ML#WST(#WVS/'`I=GO-04@FW")-OFFK)CU#/#`8-_2B800)"T[DBW9WJBEI*Q
MA6^*Z29?/$_3?3YLN+R9HOM[%!>WYC'2Q4QZ0K:80J\MA\<<C[Y<,:T;L=0=
MF;N7MZN)<+ZN)`,%G3]9.[;LB4D[$;@0,G9$-G+"S@G`C.6(#>"L]D6]+''Q
M16L&CU+#ND`FDAC6#C/7-OP"Q;=KF-SC>^*$C#B)@6G%NPP&M(PT(A-VO->/
MK()UV!F6'-.=Y@;@OKA2TT<U(T*`HV<,V##5K,W'TS.K2+-@T#4"#IOT-LCP
M\QQIH>.KKLW@2\Z0:T.8/5-^!1^J72;+F]7^&B7;?":1P2W!B(N05E^)3:JD
M3B*C4#/9G![HNL-D#)JW6&O:[SVPSD*R13(RZ.H+BZ/1%$>PT;P!SPA^L-6]
M@KL"+I<AWEJ'32XX*XL(OH?;,(&/SP5#-*MK`$5N+&U1?(L1+PO1$FPM@5:;
MUE#'H<_:DKH04Y<A9\_>5D7D/`J(Q61,U!<>)`CJ,F`AZXM5`!FTNQJ15&QR
M*U^W@.1+-4*=*!(QN]IP="RKVUI7M;6N9CM=73._B4U\(*86U$8MHQWS(IGN
MQ3$32V*ZEL*<:H\?:](&54?O&O07G1J]B<VU5MES\[.;&[C)EC>SQ\U=#FEX
ME4>+RQC_EDF\Q?_!IZ4^ACL<H`@X>EW-55)2;T[)7.GZ-6KF2L,HZ`9+N?&@
M;`$'^74;`#<"4%S:,7R8L?BCU9*7%DL;=I%N_'1MEFJKC=4Z<O72N@+DM9;A
MP("F9]/B[Y2I;U\42RP<\%BUG,_\QT_SQ\_I[4U!S+EON0ZEIQ:CIN`>>M\Q
MV.%-#I1GUZ."?K>@E72*HY),)K%;SX%;5RX=KF&*O'5QMM`K.8\UAU][[@@/
M$1]]6>1?/_^S.1<6;PG3Z[,HW>Q0ND\@Y8"5KN:J[Z_>G))AT/5KU%R<AE'0
M;8=RX\WIJ1-0-=(Z"XIM"2FI!IJ6O#G,H0V[2#=^NM9(M=7&1!VY>FF=H7JM
M946]W?W#PP[BM<QPUU:??,J:-WMZ4,-<^VY0<E]XEB\*14/,T:B4O5"@V,'_
M+@ECO"]IG^0#O81)A+:_AKL]7-V%";S.P\3M%-WCR],+?/746J&%2AZC6E`R
M0@IC5G/KXSJFVY@Q[07E`8^*"Y1LH.0[`07G"2AX3PMFT.8^P7$Q-C_G*+F!
M49:CV/$\005_2`,@ND9E1$.-'3D*1=#J@#W0A\+-XC=I<60EQWLNC]DCW.R+
M.G7+FYMHD_^(SQ/D--_I'.8V/628%1'8\J;V\[1*(R*D!Y_'(E74:?XH5+T8
MLP>6>C(8@^ERL5I>S,\FZ]D96*WS_[R?+=8KL#P'T\GJ9W!^L?S[RK4>"D@8
MR4BBKU=TCK8"28#'GJ8LD]LPCOY3*.P4Q2G:1=OB'WD<?)E#%L]B\#^7-U54
M'.X.OX2F4EK;K+ZUIC:5E%3K[U+39EU#H:N]GAZ"Q63]X6J&S<';#ZOY8K9:
M@<GB#"Q_G5W].I_]W:UET`M49`0G75NCI>G&*)G1*GO6ZVV81NGR9K+9H#W.
MUM_V]);ZOOJJA/=*%H+:GYJVDYJE:^Z0.B@>%>5T#P_![VOXF(&WN73^<)S/
MI4L)<3]L5ST&9`W4C8M:ZQQ+4>+%ZJ'/EG>,R&GS&B6AV[-5S2`N<S.[B2`M
M?.(35K^?1:B$;?X(U.P9LWTZS!ELP>K#^_>3J]\PW%?S=XOY^7PZ6:S!9#I=
M?EBLYXMWX#*?IDSG,\>3$0'A(G$Q=!6!3M]HA`1F+*YMH_N'!-[!.(T^PGF\
M0?=P`?.)TCI\I"U?BW/4*]0B'&JK9.)C4EQG%NJ(L<@EP!]TB,`%2AUGTV0D
MCD:(I+?.Q&=L+27Y`"V]:ZSF$89#E.GR_>75[.?98C7_=08NEJN5X^JMID!&
M7<XT#3.W-AQE$$\RBCF&@`$GD3.L=Y=<NWZ11J/?;O=ZD5.I#G//8I<DX`6V
MW-\`3.K1C$]8^DPE8^"%H5]M+K9R6028<>NM#6>%W3Z"V$`-3C(&6Q.@+!YV
M#),XGP"DES`I5NXH,3:/K#Z<2"53.Q7%Z5WQ,"&]=<;Q)1I3L5,;JP'>D5%N
MPW!\U(@G.B3ZF7L'@RC4K0,_HFAP!W=:2,*EHP!>EX_@]J\7\F+N@,X5U*\:
MT'L48?"%254!3DQ!):<K@7&$Z#T"JA<H]4D6G^WC&'10#T_JQ(<]*WD>1DFQ
MF:?9ZDI+4(N05M^$3:JD#"*C4+.8G![HNL!D#,XG\ROPZ^3BPPR\GTU6'Z[*
M+3-N-4)(IDCFVW>U@L71*(847-SJ!BV*$*)E:(<N7R$T#OWZ(>8LV)P!?EUN
M:FZ=GT@]BB[$A,Q4%TZ4P61A*XP5!&F-.`P!"4<>1V-LQ\*'%H88`9`]DUN>
MQRGV&>$*D-5]]=G3"F[V27$DAQ*<R#-6WTV&44FOY$>H9J:E^J.KFD0SP?O)
MU2^S]>3MQ0RL9M,/5_.U\X7W$;A`XR76U45Q_D8Q%>!H3TO?A\D?,`NO=[`9
M%BTP$J*MOAN'5DG]A,:AIG&\+NA*QN8,FM>@>>]17"0F8R0EBJXJ,5D:[7$&
M(*UQD2$<X;C(0PNM$SRTJ,@(?.S9VW<(;3]%NUWN#>9QEHL^RH<X25.8\2M^
MC.*MOIXDKY)ZC1JGFKV6[9*N=W(M!?/%>K)X-\=:.%FM9NMRB^Z[Y?+L[_.+
M"[?J.`XO2$F,7665:J)17C6P>J;,M&AJ'+.,.NMRE^-&:D&AQ3RI9%-!35]4
MU&DX0,G2*:?C3=@V$DQRNLX)[.3:D-1V-UC6&@LZ@W1Q9=^Q^REMX*4%EH[@
M:\];X20$-\9D$U5?C$:DI)GLGM6\";5MNHI16(+U[.H]N%A.%FYUAB,G)/95
MNQI`IFV0+BAV>XANWS!$"[.8--7OI]`HP9G9KQJ::4W3P4SF"+KWH7D4SK"%
MAH2^<1?;1-(&VM80H#6BT`0$'!]X8M94!$]S[%I$;[&>1W%W6G/!'-=EBS/4
ME3@$&-3*;`B/2+&&AD@_C`(9?/9@N?YY=I4KQN+=::DB\\G;^84'N58)J2-Y
MN?1J5G#Y6@4IY,'E@V[1P@<)#JYVZ7(L$F,RI5]BWD:$/QC<J.EGAD4&"`(*
MQPE7!!A%5,XBXK0&-A:`AX.>(S3N:F"CA4C&X6:YM.X=VFUSA)7[+?"A+6KI
M0!'B=L%<!K%Z25#N2#24P67UP:GP26<-5NOE])>?EQ=GLZO5UV#VMP_S]6^N
M:P8*B1;)"8!0CY/*TRN]*8X<U\K"CXJD^9@JI-]?28_/A&+).BWQ5H(VZ=>@
M)"Y/B'L9.\G#A:.6PG&4,#M/61UB5'_I9WM0+<H\'XEOT(M'9@UG6XBTN+AT
M&,WRIEU"^@KNP@Q7E4ZSM"DR?1D^L<K/ZFFL7JQ2;$QM44O++U%<_%(=`V.1
M3*WITC2<OIVL9F<`EQ*:+5:3]7SI>FU-#_R07A#TUNJ4VFRMZ>G5#@\-SMOV
MP&D!K:;69$T.K34[-H?]6RP9'>H@-%@=2MM!*TA&-YV+5D#5!B@:Z5[(4C?D
M46"M"[;RIDI(#V1M%;G1$<;*1[W2&L9[K%Z'D/]X_;HE;:%-$;S5%YN'1W&Y
MK77XR%W]%J`\'`]E4"J>!^6.0?4`**L#UHE/.E\P7^2J.0/KR3]<+W>(R!!)
M?.S^V4TJ0_NPIC@XG*H!+8(5(:4K@BX?*3(*[:H@YM:8C$%5;#-_[6<*54B\
M+!WAQ&@L#J:6V$".UM#)"(#*+?8>V].18*&%*`;@8O'.F7T:Q3!-\Y#H.HK+
M>^$IT84(:7T3#9-4[:82@5&H655.#XR+2UB,P>'>DEPSWLX7Q1S`L6X(213)
M?/G>728,CM:U)C)@<:H9_,A#CHFN+?I]BMS(M&N0K(,1;"*HZ4"+T,^H11(:
M++43CF3$>)FJZ`J)>B^@L@5('/L<AZ'7B#WJ559VT"?K$E*X^?86?7RYA5'I
M#?(_^DX@?_3/69S_G*<K>!MA7Q1GB_"^#V@625U?F4BB5CB7T:MB565RRXPZ
MN22&H'P*FL<`/W=<))<E*B3R:7N%<0F4K9JX(E(W"]PIC/.N=_-X"Q]_@4]$
MY%)H.M`=T&C`+J5?'>`=-LU#;Y^CAF_U'!0O0/[&!P#3)(:$/C`)PCW2/H9Y
MXC<%XC.TV>,4_#IOMK]`37A5KS9W7JDM<1%Z45P'[K;(6'5J$P;UOP#^I^-5
M(]*71ZPOUEO-:5&TEF980C.-KTN81&@[B[=G848#&I&FA[@>C1;H$?O5@\%^
MTWPP=CD:5);/<V.R!?B-'P`E2VR`5)9@>Y#MD`ZQRQ:_*1!/\JZWN/OS7=B_
M+9KXKKYKM?M.[7I54C]J(.TWR;A$M4,9'/X)\+\=WXU*_/Z(^=EZ-Z"V25J7
MGC*%9QQJ9S#=)-$#GIW1$$<@Z0.O0Z('?X1>-<&PV[(`&ML,+5"V'GN"39*D
MAA"ER[./U!8E`;`LH9O"[72?)%A7HG03[GZ#84)V]3RR^N9&*IG:A7J<WM5P
MS&B=<7,>C2FHWH#R%<#O//'^7"$BT0_>NR>/0MVZ'T\4%V;G_'^'N]TO,?H4
MKV"8HAANYVFZATD/<T*TG1P`E59#+H`S#ATY`7H7O-P`C;/.$>#WIW]@`E!3
M@)+$AV0!3\1(2A*DY`&%I9]$$,6/6>WX%>WV<18F3^?1#B8I42LH-!UM&-!H
MT`)*OSK0/VR:A_H^1XWVPW-0OO`!XS2!(:'O2\)TC[2/99[T#6=U2T=S!1]0
MDD7Q[2H+LST9RFS2;HZ70JHCU<L<A9:,+ZT';N*7S'C(_U9QSN$]*`E\0#U'
MMOULL`@2NDEA(L<@-RP&&[,:4:CA-(^U;E%"7N4@4G3PWZ/0`'MBGSK0WF^8
M!_(N?8WMXBFH'_N`:+*0D,!7)>&W0]B'+5O:9M%ZN;_>19OS'0H'%U33WG>0
MVGFO`:>$_G2@M-LL#Z-MZAJAY3-0//0!GR3!(.ZW)&&S1=9')DNZAN,*='^/
MXN)T?7$*)EWNLS0+XVUNULG1A0!#-\9@,NB(-`1&I"7>8/?#C3I8[(?8HR`J
M"R14)R]3T"+T02.$$-"/1,11TXU'&'R#J$0&:*:7%YN,T'G^I!^H<ZAZ2XP#
M*BV+C)2^]2PS#AOG+S3V>9JEQG;&L7CGQV(C37J#Y4:VF"O`4XB'2XX\.-B!
M=KGPR0<W@8X([PZ=1H`3^M<)\6[SHB!O<PU@7BVL>P=TDB0I4*<+G0CV%CD-
M[BQX.#B+.'O$!XGA6QC#FXAZ')=,E?5.(/:I]!PA(_>MZ=SAH'&!$V,]GO9I
MP^H5>%&]_,:3HV,4^0U/C3$%74&>0DPX*68#$(+;['\L(1'#6WQ8_L(&,HIC
MA`TVJJ?'C0CN$4)53-@V@1<H3<_S3S-%>>@=[_,(>_D`D_(,UUMX@Q)X&#E,
M9X]9$J(DC\/#Y&F>P?MTD7_JG#/_[/GX;N=Q!G,,D\VHT9XZIMA03QJTU^@W
MT.$23`V09SS,]%N;GQ>X^6\`-@&@Z0$T78#KH@_0F"N8GH!./Z#HZ`1TNP)U
M7SZ8-;,:ABQ"F61<C738-]"?F>F0/*.'LG#'"QV>E07!(<P"9@`W#MX.;<07
MK=>+PF>N]_:".UP@*X%W>:09?:R&GN-X>9./OV=C!"CKK9,L2K7=D_PQ*&Z@
M9';`V$/)X`LZ+T$GU,C#A-QJH!ML)4[`),N2Z'I?7.".@7<9XD5WQSLM!<2.
M).33VV])9VAMN72!)ZT>SP"LL,?I`@L#ZGE@A6;GM:/%\AU<A*&=YQXCNHW+
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M==,^W)CML8+*!C+>J:C%M9$PO9ML_KV/$KC%:S[%WVE$J(<B0%FOC;`HU7+9
M_#$HKHTP.V`DL1E\`7X)ZK?EQHO6>\?I;`&I(HG/WTMFTQE:R6P7<-$ZBS>`
MFF+IHX.;*/]D=Q!/E\-W,`;A<T,0=4%$-X;L&==6%F.-)MMM,9YP=QE&VWD\
M#1^B+-PU5S!.._<XE>.'*YA\C#:PW"A^!3?H-BY:^37<[?N@M]5=7?W*>'=J
ME;0L?0W%JESF1\FH\&6Z\Z#5`U;6I@^`.\$VK>JF>R%CNZL3<.@,5+W5ATE:
M_3FN0&9+\Y!M=/<JHQGNM55E[?,V+EK#DV=M8XI+*0O3\79@.KX8!5.H_&S,
M@KU@L3CB7502VY[MDRB^+4=8#&MV_[!#3Q`6-)>Y5;K+?]YEKG$]XZ341B73
MD6THF5.E<:L%8&.[IEN\<2T&Q:.RW-X6E(Q5G',""MX34'.7E11`S0]P`VYM
MG1KPD!8<=&W2J*8:0W,T6J`U4O!$&0X^/:WU81]O85+!?ED6Y,6[FU@*X7CC
M@$N-H/EI+W3"#X_:2A#U*SW(L@GXS2Z;,2-!&ITY[]CK;9P-Z#0BX@/;#/YJ
M.!$G0DK-0)B`%K>YQ137`32MN2SM"!TZ)IS!0G$,RQVWGZ+LSL\LO7FPCG$Z
MFN'JW+64V*#Z0D%/(]H*V_'P6S&A[*)C-^*6!#J7M@'<-IE.J^1FS]S\=&/"
M(.09"DDTLZT&KS&N$?%3*VQX1!?*H6<B!U[D7C8MFG%<0\FUKDCZ6/O:XHD'
MEI_=T?E$O*SY()H^/H.>5#5^)K0BY"V]G^,QT"*FXJ-G>4-V025V`5%[;DT_
M4E6F>D?BL#3A=Y13THU@FXXGS"!>@5S>%,.]0[L\I$EG^>"R)\IA'"F>@\,1
MXE'49(EQJ3H:L:Y8JBO20C!=+E;+B_G99#T[`ZMU_I_WL\5Z!9;G^;^6TU]^
M7EZ<S:Y67X/9WS[,U[^YUD\98*!1<NMKI0!K6R/'H-"!-I8CPBO^*,;;`R:/
MT3#T$Z#M:Q^95H_6L<:A2=LH70AH&9$S.+P^`24!:"C`[YC&\=D4,2$/-4D`
M$WT-(K$0-$<(0?8TIC><,W0?1OU])$R:^AX,,HW:U1>L?A5ONZ`TS;C@@L@1
M]&$/?B_?.,8]6V1(Z`OW[JH@D;:NIQ"2O]4J;_5%&>_A_?7@GE#J^Z:B6_^]
M:MTM<G\Z#IP0VF96V.I1!]/6C2S.ZVE1Q(*X7W)0.:M+UJF795:VNHZW*@JV
M*IAV$"WXO7SNV#:-D3&C/MIX*=L\^D/<FTJT3$*TAT,W3%K%3>T"X]"R'YW=
M#VLS.8LSZ!TO.9T?CI>XW@DN(F`D)8?^#FP&2WO[M"/TZ+*/AJ"#[68?/,W9
M)$^LJ$X4T7?R&\"11:N[V>SO]SM\JP?M:#[9`LORU=98G$]-MV3'I\-*2_3)
M4#OA5H(6*:#7S7"L@])`0:-EV--,4?:6EOJ&3FU>P"XT"^\@!,ZZC)(G#L,"
M6*F.Q"9<[3F8*YB%40RWLS")H_@V)7H3-E'UG6A$2IK([EF#4Z!V0%<S"DM'
MH\[@3;1Q?1T61VQ(["-WU8!,VV#>(@IT&5]M$,!FM7X#ZE>>F$XU+-",HB8T
M6+T6+8%A"L]@^=]Y/%P$O$*[W3E*/H7)MH?&D=S-]65RW*KW"HT9JP:3*M\S
M\_8?J;:"F@&\J%F^P?M<VEQ?5PL!SJ_W&84EI"C@P24\,HUT+M;Q%\RZ/(-#
M)%?7:XIB&?R.>4'%[-C7V(8VXX8I-^"VO&FX,ZYR@UG_%PPVCLBQM;<,"[&I
M;\>4&)VNO9AB77*V8HHT$I!4^*0N`D50>]<[4"31@L9*DK#?4H"[M]W2'X#J
M\D-6T5GL$_Z"3XH@G2'4DX,HXNYE7`LBAU/,Z?2X,9L^"S!6V27;$SK)XK4-
M&`DYL1,"TIY+KB'!,P.^8%^K:W,+_(/#^P+]D1#P#/PBKG*SVSX6#O#U=Y7[
MPT_^.<UG=>$UPG<#?X23),E!5FQY/HO2S0ZE^P12#L3(,QYV:8HS*F[QDQVA
MZLX_B?Y86P*%FPFFRXN+R=OEU60]7R[`Y-W5K#PJXWJSH#0TT'BA]3<7BO*W
M=QV.1J2](/4R00\PR:/G'#;9)-[B6/KAGGY[E#!]]?T$Z)6T47@\:DHHT@U=
M]_C<P>75\G)VM?X-3!9GQ0&T2ZQQ)V`Q6[O5.G&!(VF9='6,R]:HECRJ/-"H
M1N_7\#%[FP_A#U'E8K#R](S(:D;E&*/4,+63[':$-I(:.D+%9(&%KZ-\J/'4
ME=""@.:ZQ:FN:9@3D.*)5TU_4E3&R<K:.34/:)C`[Y@-%'R.E[?L`9@VPW(`
M88M^*'S"5XJE^0@GFTVR#W<I+:;C4]9>AD6IIJS\,2AJ)K,#AB(R^(+)='KU
M89;[A7]<SA:KF>,)DH@<D<0'[RD+G:&E&Q(`L7L"-"HO!\@'-D5Q%N5SL7@3
MP50@(3&"MW5R5()7^>2A]#C5SR3*=,D^KRC>4C!=OG\_7Y?5.W!8-ETNUO/%
MN]EB.I^MOG6=I1B#%Z0DQN%!2.$FNH<DQX/5,V6FS;#&,<NHLZ[H==Q(-1TA
ME^I84:U;<RVF7A^!6C/"527@R2@V(6#U&+<ZC\<[`6U]L+[B*.9='1X_YUYV
MX<PZLN\`T%9]U>&>J7RD5S"+$M%U,&G.QDN)<ZJJNNP8E;5<HD.FB@NW$US-
MUO.K8OT+K":_YNYH!2XO)@OG^BL-#Z0@MX'>BC;04=K1N+28-<&G"HL!%D<-
M+U$^HL-(W\(8WD290)RIVDR=;QG=C%HR1G'T.K+]XX?`R.6,;=1/(Z`,,J1+
MX+U,T<C66FFDX\*]MM4#GT!?K"J4O$546QYN[[*#FM_/*->]@E!7'OQ1$7N^
M]6_[,,G-_N[I/(K#/%H/=_/X!B7W14C`C8A'<E??79I;R9",'*N:]9#OE&XT
M9-L*5K.+V1075O[;A\G5>G9U\1LXGR\FB^E\<@'.)NL)>/$A#O?;*(-;Q_L\
MQP()*4JW:P$D&VD47Q7)GN@[+7*68Q+1;EW1@=S(-,3`PAV.U.-6?/M<U)?A
MPD<!2T19"<[9(SSJBDVM@1''G0=*<"`%+5J/0DRS:*2%CY;P:,]5T.HZ?8@3
M&.ZB_\#MSVBWC>+;=V$4XU):RW@%-_LDRB*83I(HS5^USSDL8+:\68>//<4Q
MW4TE)7/=*!D,T[]>S<`8'!W=)!GK-.#6@CL!32>@Z@7@;NI:<;A6\Z$O4'76
M/U25=PC0#<B[=&L'C6L6LH7BKJ4UU5MCFS\S8Z'UZJ]G93-PX-,R"945*"Q"
M;@K>A\D?,,.;ZUI6X8O.ZP+CL]5ZY_4.BMNY%_!3\4;PTDTR#[NF09_'V(WU
M@W$9.;D]Z&K<)?5-"\RSV04MCB8^E01^WJY)@870C?0T-%4:+\0J=A.]50S:
MN$E3-Q2)-VA^P/<_?\KM6P9CL+RY@9C[^:)0\M"_7APZ]PFE]"6=`H5)I-*-
M896DC,QT/1LEE>PW(:B11W*#K;QZLM'%ULX>KV`5#KN@M%)H1B<B1<O)>!ZS
M:,+CJ"(Q^A!I.1.\R#]SF-Z54Z)\5C-[Q%L'^_`7(6UG9*FDZHD2SBATI3KH
MW7#2%33&(']Q.LW?X`QBO9O'@ZP"3ZI(YNL3YO84CM[\W#Y@=%EI(VC!%KE,
M:U<$=4(;8Z>B>2[886:&]*+'9M7^W,C`-,-W<_6@27IUJ+???J58?WS8BY9*
M^9UF6<7#6X1!8??PG^`&):!^Y[KF-T$.B/7]^K6Z&XIV(6XC(M17'WZ$_,K*
M[N6_"RD>B^#H9=:E1>=\(E\D&@IK)Y'8[=`+)'4K>F/)M,YX#*?1ZK[&I=!*
M[N%4?8KB&&Z*K3&?HNP.3,,XQP&8W":PV`_LY<R(@`6A'!H)/@+9LS)R$<J<
M60&<X0FY+K3QIN'5RD%!^_Q@-B9-JPPTYU:]M"\29IW`()*6-:AGA!&93L>.
M5K8VN[QM/Y*,K)P&T@$EDO<2TT";&+22?=4!0-&LJ[_V7A%NHQ*MZH"S>A4V
MVL=96I7J*LITP>U%%%Y'NW)W276DK/6H.58RW2=);G1HIS?,--Y<JJVU<=6[
MC0W\4C7KH'U,S#N2=785U.W59>9.0-4D:#5PTCJ(VGK<.GQZ`JJF/3HB8$@G
MD%DD#FYMUMA'YVKGYZK26G?F'*UF%U>D>U4E\[C4D7&-^C$JI,W22[S;%^@U
M`J4YA>\@T5=E37J,IF\A$:VN)MY.T"$&+6H_RTV,`8[$#27<ZH#"#<C<4>(`
ML5H]IP/@%C4!C_0*'3T(I1?\LXQ1BZG4Z#:.;J(-K@E?^E`\[T>["%<EI+D:
M.:8ZI2K(I);2DAJ9CM2J:(>,[)98$\'JP_OWDZO?P/(<K.;O%O/S^72R6(,\
M3%U^*`K.@LOEQ=Q]S5E)=*!QLNNEN81X6ZDN?\"H+<=J"XE%KK6A!`TIJ&E!
M$]P\9RQ2DZYVT&C/2US!A_"I*%R[O)FB^"-,LBB?9IW!ZWZY*P'*ZELQ*97T
M3F`,3&3]6*I:#&_#+)]$4C6.W0]=S5A\P67Y"I^.;[T#JWT>2FRC&(\(8$JW
M>B4B9B0ACZ[^,!@:I7&"'UW&V@!TL%EN7O?Q\WP@0S.ZND#3_DH7^5_YP_I1
M_G_780KS)_\?4$L#!!0````(`-9E:$"72O<.>R```*0,`@`5`!P`8VQD>"TR
M,#$Q,3(S,5]P<F4N>&UL550)``.#\%A/@_!83W5X"P`!!"4.```$.0$``.U=
M67/C.))^WXC]#]Z:YRI7=>_T3G5T[X3*1XUC7&6-[9Z9?>J`*4C&-$6H0=*V
MYM<OP$/B@2-!0B()UTL=8B*1F?B02%R)G_[\L@Y/GC"+"8U^?O/AW?LW)S@*
MZ()$JY_?I/%;%`>$O/GS__[G?_ST7V_?GIPQC!*\.'G8GGS!C)$P/#FC;$,9
M2CB#D[=O2\+/.,*L)+U,_T62.#VYBA)>4X)6^.2?_T#1XN33^P\_O"]*A23Z
M[4?QQP.*\<E+3'Z,@T>\1M<TR)C__.8Q238_GIX^/S^_>WE@X3O*5J??O7__
M_>FNE))"_.]M2?96_/3VPW=OO__P[B5>O#GA-HCBK&Y`)24YE[!&_?Q]2?OA
M])]?KN\RX=^2B.L;!?M2G.<BV16L5O''T_SCCK0E4%'%AX\?/YYF7]]PPYV<
MY*9C-,2W>'DB_O[E]DJIR<=307$:X95HGFOT@$->8\8BV6[PSV]BLMZ$N/SM
MD>&EG%?(6(V5,.M'8=8//PBS_J%>PRE0U`"'X0*_)(\</AN<)B2(WP5TG=?T
M"87"F'>/&"=FH8-P\<*%^O#APW=Y2_^A7MZY2'/$<,3).`4"&%4O7X.9$V'O
M$MXB:\[V9GG%>_D:=Q%2PL2)<&<H?KP,Z7/<1:A*82?"G),X"&F<,OP5)?S/
MF^6G-"81CN-9M+CA#O.)X.<N@@(9.U;B+EVO$=O>+._(*B)+#JDHF04!3:.$
M>_HY#4E`<"?#V]?A6+4SNMXP_(BCF#SA:QKWU$+"SC6@<"+XSC&[>^1]O">(
MFLP<"WN)"/L["E/\!2/Q?]'O>UI8P=*QX%\0^PTGZ"'$=SA(&4EZXUO.T;'8
M/$1"T8KP2F9QC!/A%#Y3NGCFD58_Z;6,'2MQC]GZFJ*HG\1[+H[%NQ$$US1:
M9340]$!"!_!0<W7MRQ,:_/9(.2F++WY/2;+MZ;<E_`XA\B<>/"^$>^6^-8OH
M'8@MX>F\0XH0YQZ]],5'C9%C(<L0@EOB@429(7I**^?H&A;[0.$6/^$HQ3/&
MN)=R,<J8>+M1A0:IX,>=Z06/<I+M5;2D;-T=W5I^KJ<`;AR)@:%KR.`0!WQ6
M^;<4L02S<'O)T1D%!(7G*$$](6/@[5B56SZURZ.?._3$(^1X'O8=,A4LW4?<
M:Y)D_8@#]8QF\3V.^L\@M(R=*Q&&Z*%8N)JM&';A=)1,'0O/IU4LQ8N+%S'N
M];5ZBYEC8>>,;C!+ML*I<:>P$2;YVFW]!L"T*CR?R,7\]ZPUKOD/M1JYX#A:
MX$59IY"ZXTI45F59:4B#6CVA6+^D3+J>EJVE+5'\D"VHI?';%4*;4Z'R*0Z3
MN/PE,\+;]Q^*!<L_%#__6G&].U<UIS')T/<0)PP%.S.'8AGNYS<V1?@`)$P"
M*W(ZN!'NQ=1,I6[M8U.QXF-=A2IX9JRN#F)!R8O_LX6<^L)Q07&ZR1;TW@:/
M)-R!;LGHVK)1J$&KJMP_GD!8GR3TI,DRC3DKNA%D8O61,CZF__SFPWNQ03!\
M4]\%.$*,T-D+B54M+J-I-GR=9OCVK[<GA6FC:/",5ZUIZSS&V<*%B+]$\08'
M/'['BW.Z1B1JMK*)KFQI-=WPK2UM4PI73M'P5;99^ZO9C1,#I2)\R,97_)_*
M+MXB:/;O"L'PS:WNW"H]P#V[PD#>I-]E3<KY+3%CQ9Z<1JM,);%7BVN[=P.`
MH5BLE`<S\H^%\9H?AP=`NYFI00<%`':,!`B:#'1]>K(`.$N9,*\6!PJ:&AQ:
M-(.A0M'N%*9-'1AU7GM0M'AXA@VQZ2L6"OA?8A+XA,)LZ2`Y0XQM2;3*=ID:
M6+$J4U@;6&9@+*D00[LI+8-8HPJ!-"!KSY`GVPLLC-/`&X"R,+B6<KS8@BL(
M1)26H6_A37X^(CO[(1::;G&`>1_BNL=?<2)'E%69<O2#E1DORKHH#<0;D+4<
M>=]/%7ESAC>(E*N^I>XU(S5P9U&B:`!0B?%BSEYA(.)`C.5X^^^IXDV'+)U)
M)X,6![@`(>"/71!`$Q0.C8!RRT;L22:*S:"=JS&3[GR,CG2$TSL+W4RS/#TK
MST*EY@$VKN/%2Q"FXJI"\XA<`2.;(H7)845&"*L.NIK@!6/I65Q4&8J_TBB0
MCE=:FL*X"IH1(@>BC0DJ"AZ>Q3`*-Z/H7J-V%QU=@JG;=PI.QM"TN:K2N%0:
MD(ZR4:7RPI:*50WZPU2CS<H);!X9M4\F*K82;(L51H87&^DV5$>](1M4<-:>
M1:P5Q?7[5V;"-LS&LY-E#1UJH7$=8-"J&K#S?1^L7,&<HZU8MM0O&\N)&NO$
M3:(Q@`NP.JS530DES9IPDZ%_P!%'?]NV:&-'3[>'CXIN_`@":6@)(A5/ST:Z
M_.Z;"44&JNK$>8((@FEG@Q\E1\^67+)M7KPXQP^*'4\U07G@3T(P<K@8=;)!
MBHR99VLO9S1ZPBP1JY%WZ0/71MQ*U($&7J`\Y0,H,')06>ML`S((<\]6A8Q#
MFM'?3W`@<SJ&P8>OR:XTG1<2%]>,Y4#1$Q6&51&-'#`@W6Q`HV(H!\Z?WK^?
MJG\IQNTR:X1PI?+01T91CWWJ%&-`#'@QR*QC]U4@*6_/9U_Z?4LMH6(.-HH=
MS"[0`FO<'6&Z*CR;J$ERY;3C('4`-#'LJ'5RLBCM=(8VAC@(D!9B-S4S)Y`H
MYV3&C!`301-<Y^[HTM;AV=0,O*,+WLL<Y:YMIWBJV^ZM55AEO8O;:7HW!J#-
M2Y$SG657RC04^X/P;8H!3P)`4&36JKGYKP.,E)N[W;0GS![H\%@1#IA&2J"H
M/E<&N_KGD4/$H(\-/MJLW$W21@*.V6)!<FWFB"RNHC.T(3QLJVC>W'4%%RBW
M7P$%1@XI:YUM0`9A[MF4;18$Z3H-Q4)]-E&MI3?.4U**_,%?<7*SO$<O[7W_
M+J7WIP'L2H\=F[VL8054VYH\V^R[Q0DB$5Y<(!:)-(85>YSC)0E(,\B'%RA:
M`U)@Y'"TUMD&@1#FWL\HC3-)XPQR]"`RZF0#&ADSSS;[3)-D];JHEAQXC'QB
M"Q&6VCM95E54)(?A_TP5AHT=4N6.CY%.OO,\V?T>J+[=H::IP;OM:<V)'R7B
MK,J83UY-%HE=[-!GY1]4FPJA;@ZP_W3::IAK_L/Q$S+7G\X:/(_E:\[.7%_W
MY0USPS*)%]DJ7_,-).F"NJF0=(U=76CX"WC`+,^=K*"XD&?(_@RMRK/K+W6U
M,QWC69H\4D;^O?=#4E"JB*5@;!-/%(0&K5V`KUV%9Z>U9.I>Q7$*`ER=4`.V
MDG#20)-JZPYD)7O/EOQEJMZDB7B'5F1N`:!,0JV!6HUZTGA3Z^T.=+4Z/%NV
MKVRD`2,]BQ+M37(/8CQ[_;LA$52/9^OY%9T-H1V`LHV^"0=U<'U[HPT:SDWV
M>%A+5VDL9Z!2H6MR41Q,3T>HTL=OG=;V1XDH=?`&(55A:YIAFX7&CE`&"-C^
M-/WETXIY\O,EPR^;.G[/[=L[9>XZZ[=WRKZ]4_;MG3)E0KUF%V\1?'NGS+=5
MW>(X@.JE,M7GW6G$YN?A8=!N;&K40P&$ZVHZR#:+T>PJM1\<%K^4;7O)[3-G
M=)$&R3G_):2;XJGV:Q*(D[G1JOV,=+WYNW"H(\2.PV`@4L*$NK!%'67-NBH8
MLZMC0C`45SN%KN)@R&>&M(!3T[:A):,=.XB,^EG!1<;-MZ&*;E&8;`NEF\"1
M?BR1TO@X3FCH-`!@H5'<L\W!4F5%?**(2\;:U'*IP1W>QQP,<>:ZBJ>E5.&H
MB6RW9J@B&VEX"M0+$J:J6?DV''!;<+N+1SPK05*A=LM-`&AWOD-+.QB"C!BA
M=GK6P:3BGGL=+=?1Q)].PPP%D*0?ZV'&1*"BT\0"&PTVGCF9SSC"#(5<^=EB
M32(B%$_($Y:C`TA=OK-CHAXU?NQTA0/*R->SLT>?$8G$G>B;Z)S$FV)C[V8I
M?=<'1%NB2T\[;FQ9Z&F!+#U7!Q.FCSFN(KP2IY2&1M9L35E"_HUR-9N/XC6@
M!2,N$R08B$<-+BM-X>@RL?7ND%K=%(:)FF&"-G+(&+2!@Z3-R+-KYC<;+(;K
M:+5/]M%`AH:B3.(JHQCIQ-VL#63.+N7B<`%O#,CX2B-:5U,>0QOI"KMJZ$:*
M%:AF$,1H>'D6'_.1%'.#*!9V%%_WCR+7OXX4&7HM('AH<7`0;HPKFMV[QG*[
MBT0I1W_A.VD4?\)+RHHL4_?H!<<7+WS@S>^4LVUF*G&G7&R4T3#,.DYNM!:F
M#E[3#I\'K&FT6#^6=6']YH#2>!;;[6Q0.)E/.,++5D8S`U4-^1*J4:/6I!4<
M<1).#FX#C,MC?\7)OGO-GA`)Q;FZ>UHYJ5[D!?F$8A(TX\!NI<OHT+;T2''7
MSPJ@2-*V!H=7"<;@U<I$@>5UPDQ+L=-%PC1IW8<"4A?V-U*/%'5V6D)09N0H
M1]7'J<Y:_H')ZI$K-GOB<<0*?TW7#YC=+%LW<V2>KU/9HBTLRXX4?WTL`$&C
M)7_5!K=GX"SZHNGN7L?2>H"J2T\+HD`K]`"IN@8%3"=[$$.2/+I,'*T\'@8N
ML;]=:BXQ4@C::PL[/P;@JH":VV,>1]T$@IO2<50.J-IAF#Y99P!))S\7.[`<
M*TG"R$.:Y`;*<RHJ'(9CKM57"%UPG4I_.(P9._439Z)X=I!-99=+RGB<$>5/
MU0;;>X:BF.LOS!,MLO^%.>`6_TKC[(DV@!6!O>R@=1OZXH'J'JS'NNZ"FEY]
MC&:K]WU'RNG\PX&4>B6C\"\1PR@4>9+^PH,0/AO9G[7+'C+.DT$S(JXNGO/_
M1JLY9H0N%,_W'+H:@V_H7\UK<`..&^/H/;Z__%./"30A%7QB#9]03R>>A:O;
M*4;5LO?LV%>NWFZI03$/,U#5-HTE5(/ARB0W-61^JL-'P:V6B:3@8DXL,VA6
MKC,4/UZ&]#G^EHWK6S:N;]FXOF7C4K7IMVQ<W[)Q?<O&53TR)8;..:-/A`^^
MG[:_Q'AQ%>WN!\R"A#QE$Q/9445%<.66Z?Z`E1.FPP-5NK=V$)L!CV,YJ=BS
MA:=O9PDAF':,6L<[G6ZD&WHS=`R3ZOTB='Q/;W%`HX"$N&85;@R8K16#QB&K
M*&\1'Z0*CSK?$=K@4#WT,*)[%NV=8RYT0#+K\7^'N-ANJEXE;W1+FR*[)W(A
M10;K-@<%.>UDL7JG.(2`^8.\$,$\B^->84Z*0P.\1SZ+0T&[6RZ,+G[\";,'
M.@)8!P'+^V]-\W,2!S2-LI0/<X;7)%W'5]$3+FS>A'LO)F4WZ,C$W^[APJI'
MZC8=1?4N<]$7Q'[#V8;^?B>^W)UO=!H(:=&(>E)O.X"%A8X#<[U`#M)7C`O,
ME6,E*,0W2VXM;I]D.P]1E%S\GI(LFV8#UG:%6BG?](6\A7HGJQT']%#1O,O;
M45[WQ`MQ[`5'L6Q:JR<J][D41-["&625X\!7)8IGCV(V`B_\D)3!5Q%X:6>H
M&GKI)%5*[RV:;6TUQ%15*I5GSW1R@S',>_(YSO^NF.@,;4B"0O4A/<N"^W-[
MX(+>PK^S]8[3#VS$\RQ70UMU/A$O)]S9Z7%N9TR>Q(RE.?WL5%;9+;1EASSD
M:HM<*=[AEFD=BP76+P>RMEX'Z^OCBK?;^O.!;(/(XKQ0IL@[55I#NO+>CXD2
MWS`FDP=Z!UNY13Q,``>K\&.'?J;O?N2#05U72!W12`M-'LH`6[B%KKQ"[U:X
MU:/4'&W%T"0V@H.`I5Q4@AY(F`5LX.`#PL08A>B93![:'6QUF+A$+X!WZ9R;
M9BA'*?F[CF!Z)9Q;])-'KMX";D':JLNS=RQ,(Y"-]S66!$8/?OE9J%4.&4<`
M/.IDUZPS344*:A0_-I,+-R`+(:WF1E"2>KM*9V&AXZS+Z07JDWQW#-CM=^#8
MZ3TGI_>;O#J&[M2N![P2TDM(S](N*,R1'QMS?)&P(U-]1[-F.JV+A/ULUN,B
MH77%GMVY$#:9!;^GA$LMGOS(_IT_!=E`.X"RS'FCHQS;0-`5>=3&(B`O;RE)
MECE')X%G5R6XN0*,%]G#-.+,V"Q:?$&)."^YO5G*SE`V\-NY?-&&'<I[A/6^
MUCM4#^@@EV<>?(ZVQ32K\`20OF!3IL0_K(Q/F.]@I8/A'":+=QM#+;UK!X7%
MT[&*$^/V!54XUQ3T&>Q0>QT-\1J!O+LDT1S6L@/RBU083WXW%%Y`$<[("O@$
M;UO['"M@D0GBV9Y2/^,Y771QNMCB50=Q:M=#=9Z^0GKV`JG"')<D0E'@>%6S
M(U-]1[-F.JU5S7XVZ[&J:5VQP^7^,8PXU4'V*HY3;@P^T%;286FB)RV])'A2
MT(]M:.B*16IO'9#WMY2G&3HIY/!LS?,6;XI9T,WR+GW(7]GFTQ-Q+ZL!80AI
MT3YZ4H^`:V&30V%6+X)W1\[E7?2:1JM[S-82V,(+:%UOO8!'$+:VSW&=;UT0
MSZ*(:M_-SAUI<`RBE?A?":U'Z+6QRC$\L$0&[Q),]+.<T\F@TTF@5QW#J5T/
MU7/Z"NG9:DO5D7"%GS!+1!(_PV"@H)0,!2U*C_`.M\@QAH&6!-/?,+I8+G&0
MW"PO7H)'%*WP+1?J)LK.!T4+\9?8+7M"H3``P.^[8E<T:G]V(UWX<VPGR))?
M_RH]NT*G\!'=HYONH<RDL-M=^QXKTS:([+3A.89(0=X99]P@C&VYZG]'8>MB
MIU69ZD%;<YF1XJ^+QA#D`?FZBTXWV3NH7!B6>(N\7[][?=AKZ7QP]'5)HI:C
M[R(:/`2]2S>;,#,("H7ZXL'+JVA)V3IO;_EVLV6I,O<EM-1(\==-:PC^P)R]
MRUK&Q<!Q,D=DT8"8[-/NZGGUTW!@L80#U2K5@`F,=WYMO,ISZINGI;*[V\+E
M(:%H(5D_$&DN0QJG#"L<E2MVE?&S'[N1NC;'=H*.N?VJE#O#R=XCSTY#?&8H
M$CO-*>/JS[,H(0L^LMS%#Z8,U-TY[)YA[<!A,$P[0RUU8;LZZ/O*EC\6VT$F
MST[3[)S'S;(TJ>H0)(2T^=RPE'1X)ZW3@"H?*-8Z7PG+VH/$!2OS^](_G;;,
MPAW[;_DWZ:>:R?!+@J,%WFG>,EJ`PW#!J1XQ0QN<)B2(WP5TG6-RWU&^BAN#
M^&;Y*8WYL!)GF5&?,'LB^/G-8&ELV`I%12+N,QK%-"2+'#?9JS<[H]PL"Q^`
MPIW]5:AVRK-,C..&YV!.0;R(&M\LB^1SW"\V;*;\7N@O^3Y8GW?;OM2L?-T_
M.*E>.!))M8<<BD;BA>[2]1JQ[<WRCJPBLB2!N.:V,\&<6S,0=SP'?-.M(8KJ
MJ5PCX?YM-B7A<$&"SOCWO!4_A>WSXW:%RL`!6&BXY&+FAJ0==6\D"U-6E(45
MP`I\]`DB'F?XD8?DY"E+FC98]Z])DF=>^XIY)'B/7E0+)O`2Y9H(I,1PZTD2
MZ6B"53X!2J[1O4X^W-S8HB&IM>*-N:ZYKFS%QUB':D7GO4_N@9M&.`4^E<^F
M\(,YAPO$(NZ4=X(H/(*)K#PMI"0;[GA50R15IS?2*50<0S<WM@Z%ZU?OU"K.
MV7$F-<=7T84O$6'9(MP7C,3_\S=LA\+Y3IJ]@*HP'T):H$%/.EBGEHFEZM@@
M6HVZ8^C@H!:C=KK6.[JN!M'9#9Q?P21?FK9IN#WSW:O9XAQTD5,GV>Y%4SY]
M9UMPM]\.+SBJY[95?@%$JWEP>PQ^H4-K*M[1AGD)>'VJY[%?E\^XXA5$*W%;
M(4\0Q`WVF=+%,PG#P5Q'*0"7I2F>\21%I[+EF]YV98=[Y1PBI\JI="ML8Z$Q
MN)UN,*`]S5-W158R9.^66];]"MR3N$M[35$TF"\J7RG6.AT]40$.%=%@;J1Z
M5UGE+;0TA6(*FL'ZOJ$U*$RK>E^6\Q2=5L'K%?3-VH7WZJL_@[[.4Q'$V&_A
M!:HO]1@*#/LXD50X5>^V*&$TP!AZOD5[TB[:-XXD&&O;/2IDJN45>(OLD.`C
MY:0LSJ=D@_F)MBAB?T=Y6@]"7#V7JB$>]M!N2S"SA[`NIS7$N+P%L&5I=RLT
MCSCJZML=I(75\UH\QJ?6R>'!9@+[P&=9%>@6AR))PQF-DWA_V+G,,*Z:,3AA
M5LXL>C(;S"N!!?]4%5SEJQQQLS6JBMMP\Q\WV**N+=J84?624GC+WM*]`A^Z
M>\9RT)V@0@;C?`Q`N7_65TTYY`/'3:E4S@I"JM9U#&X&TEC42M'F3HZ2?_$,
ML8;O*^C:Y842[OH>1-[7+-O)8#<=),(H.CF$M+S_H"4=[EI'6RQSA[<KI#;`
MN)P`J#%I1^WK_D!757:Q`UC%*W`-E5/MM_@)1RF>,2;R>74]`!:$BY>L-WSX
MKN@+XI=?]?48A_NNQ=MW'(#%.WB,GIH#+G78E;?4?0P^HG,ST_YV:JS`6$K2
MN"$"E<!?#T.#5*@M3M5$W,+;2JX/=UY%5XMJ.<6B2#F_!Q7I&6/$.'BWHD^G
M"TSR\(+_HQE5\)]^S26XQ2LB*HZ2KVC=S*2E(RD/?DM)AEN'L&D4"M*PL80`
MJ"`[!BYE;+Y!?J1F/^,J,!1>\7[Y\E>\E;:[@J;6\"V:B;6\7L<^3=_BK'L;
MXTAM7VIPS]DJO%GU4\-KY9\FT\`:C;JU:YVA[FV((S?GO,R8=XX25;M*:1H-
MW*"97$OK=.S7Y`W.NH3#1VK[&1=K(42[#%$SQ8/T6WE'O?YM,FVLTZE;VS8X
MZE+V'KM-SW$<,)+)HFI:"4FSA6LDTVMHM88]V[O&6)<U]TC-?I8R8;Q+/JU#
MX?]AQ.2>W$16WKM6DDT&`D!-N\%`S5R7PO:HP?D_^'SXKQ%]CNXPBFF$%^)]
M*LP:>`#1UH)U)>UDD&&C<Y_@75F#+J_B43'R=QJF7#FVO20A9JWG+G0T-4RT
M:":&!;V.?3#0XJQ+,'S<R7ONPF[QAC*1.T8DG4KE$-"3UJ?R"M*)`0*D<:^)
MO:("U=K.\?&1`?:,CVDKRN1+.U**&AH:%!,#@4Z_/FW?X*MH\@'6\^;I0TB"
MRY"B5HX2U?=:<]>^3ZRQU;KU:>H:5T5#'W7QKO`^^]>ALW-F\4V:Q`F*%NU,
MC_`"]7%`6V!BV+#0OM>8H*U&@9Y!U@KW\YY+_DLS:#!0-=8+6U23`0=,SWYK
MABW>"A@<==FP+ER^K&D&@H1."H4:W43!H-;5!1QJW!6`^.-8$DI7\F./ZB:5
M+,%W,\^Y+/MW\^/PB=NOFP].--5H$315J1`,GYJ];G0*T$.1D#UC5$O!7F&@
MVTB=8!;_JRA@&,7X'.=_7T7MSG9+P_"2LF?$VF\!=2J]/^9M5WIXC+611/M:
M00'"Z^J3+-8U>/?61&L`:+HL%8'R>N:P%PDZ`49Z,5,+)\N:Y%<R7<)I1*\[
M=@!5ZPU#?V%E>*[QL,#JCJPQO-PH],RV;-IO`UVL-R'=XORF[SQEP2.WW3Q$
MT@>CNO*H8M.>QV3AV]-<;O!M+X3N*-=4A^JV%?*%*:49VE.07EST/<#,9=@,
M#9V!K.X)EH:3I'&P%4K3(\S"^!B^*@PX"[@OB4E^F1$^",B*`?Q^O9AOKEYC
ME(-Z]WJ]NK-\_H`W[\3VZ%67@SCMD>#7&H0FSPQ&+K1FH_N%8':R#G>V^%=:
MY$2^I[/%@N2*B9>8KZ(SM"$)"N7/=-[BW"SX3KQ8&.#<9+<XH*LHXU*\.%^#
M^K&J*\_8'KRZ*0X,1VZ$W@/*X>75'2F=8*?^BI,\!89XI&?VA$@HUNGO:67[
MN["W>/$P:/31CJ6+UK8N/<4>U,]$O3N$=?7:,V\3!'C;0GG/;MK2N$RI+Z9<
MNE05FR*6.QKE`(N<JGH/>2[G0-$^'([=.$!F`*,#J3723'.!#D"%RF"<%5B"
M=5BLMLZ]Y5HU\&B@*B\NJ:BFZ/Q@*O?V=<IJ>AR*&-'^8"]XM;;/7@/`W.\9
M*JVVX3!AG)X[H>:):`^W#;_BY^R+S0IQJPQ@>;A29HJP[&*.@RX,5RJMW>V=
MZN1$%398XE-1"!+^C0&A=C`SA7LP8(+J-(9W;3Q.=HDW>V5"\G`U[YF8K*+\
MGERPO6<HBE&0H2):9/\+<XSLEM_*%['GXD8=_Y`DC#RD2;[X,,]0T(#U('4G
ME?=(CE?W%(>!(9NG]W!R9.%K=\@]<@._1-S@(?DW7OR%&YN[P<^(1&)A\2:J
M/(S)2,P_5?UD:31@CW=5C:%S]Z_&IW[LV.@'Z[+]Y:S=\I]@[]1%+9G5+.8S
M-7K`7*:@GR+P;<UPT#E,46$MS9@_4"PNS,*Q*"D`F;<,C48XI$SS%3,`C749
MYREUS$UVCK*[S)-W.C%$T$AL^,]>B/+2G8ZV>?].3CO\-2GU53R`=N!;>7)>
MH]RJ:(AZ3M<\%&@@0$M3)DF0TPS?XMIVI3#E%`TO8YTE/Y"S'&7[5]:QO^#U
M0VNP47YO[QZ4WP=K<WU34K,R]7:6LFNL_9=LO#NF*#WU)44(B'9W0%!+.U[D
MV"@)1)&!I6?7N6=!D*[3[#4XU:Q4CB[;<B72X.5&C+J.RD,1"&?OV5VP6YQP
M&^#%!6(1C_!C*?3T1(6I543C!15(+2""5+QTF<`G"!=MQA?E8]4699K3)WV9
MX8-JD$Y4.>_21M4ZWK595L'3'%:/Y2DP'.*`^]J_I8AQ6(?;2Q*A*"`H/$<)
M&BQQ4%N<2LHFX\-A'4L7$+`N/9@+T$JJ>EK,KA#$)F-X1*QKD]..!JG["<O:
MA<>`UNKO8V$[L_`!F[#,>]ZA)S%B9]>T!UQ\V-T=FD6+O7!&M].AY'[!`EYR
M,'<S%T%X)F`6F<\IEV@GZ2<<X26!O&W8ETUAL^YL!G-270!"G1FL[K(L9!'N
MJKL,K\"!B;4WDE].Y`8ZHY'(-8ZY4Q_P576-3!!'9E^VLO9J47;0-6:CG"H7
MUJVPC85&XJXZP(#V-$_+3<%E*-?!;>I^%>XIY+BE+,?,BF'7[SQ7*GBJ/G\+
M<#2V!7=]"%YP0!=C$E+M7ZQ+@@TS#L]BW>ZTCU6:/@5:>^Y0+&KUT7W,@H"E
M>''Q(N+%`2.:.=J*Q37AUC.14!@KW`J`LIQ$Z"B'W)>B*??0A71%`UP3]$#"
M_!AD$897?JJX^_S1&Y5O.0SS_0Z74^:#>2@(A.B!C5GW6AJ)BGTSIY+XZ,GF
MC&XP2[;B'8#?4[(ISOT/Y]$*><1Z5U(52N77H/2E=S/3#[>8I)(-L(#4H:C)
M(N.*C^`-37N9H^%A3+5F"T%6M0TSNRJ^B#]$.BC^R_\#4$L#!!0````(`-9E
M:$"0@#LM(`@``(`]```1`!P`8VQD>"TR,#$Q,3(S,2YX<V155`D``X/P6$^#
M\%A/=7@+``$$)0X```0Y`0``[9M?<Z.V%L#?.W._@^J7MC/7<9RTVR:SV0XF
MV&&*P0LXN_O4D4&VU96%*T3^?/M[!"9V#%&P[^[<O1U>$B/.$>?HAXZ.A/3V
M]X<50W=$I#3A5YW^R6D'$1XE,>6+JTZ6=G$:4=KY_=V_OGO[?;>+3$&P)#&:
M/:(Q$8(RALQ$K!.!)52`NMU2<$0X$:7H,/N+RC1#-I?P)(D7!'W\@'F,!J?]
M-Z<;K8<TODRC)5EA)+%8$.GB%4G7.")7G:64Z\M>[_[^_B0BC,7D02ZA^C7)
M)(W2DRA9]<Y.^_W^V7D?[&=D1;@<)F)U3>8X8_*J\W>&&9U3$G<0.,S32WC:
MLVKOST\2L8!:3ON]CV,GR`TIA2,6/QQH1*'(*/_\3/%A)ECYH/.>NCW#*2G%
M><)YMJI7B*7HR<<UZ8%0%Z2(H%&I!YP6&*^?%.<XG>5*FQNY7=W3?G=K&2<+
M1>=%XRYZ(F'PL$+LJ=5`@FH<HASH\NC)H9ALI7/)E$0GB^2N!S=JC'JHM-<&
M2__BXJ*7W^W`JX)0_K)@SA.9OW=Y65FZ7E,^3S9%4*BT+LN6]LD<Y?5<JK:\
MZJ1TM6;*W+QL*<C\JJ-H=TN2?ZX%.0'K2A%))0.]B2`IO&/%6^]L,>8RJN4T
MC90W['JG`F=K7%D%%E&EEDI;0"7)F@A)2;KS*O6^F.L19C6NFYA%&3O>\VBK
M_ZTZ'I-YC>,03"BG1_L=/ZE_JVXS/*MQV\$SPH[RF"G-K^NLJB<$]Y#Z,?7M
M1E$Z-VZ`F8I4P9(0V4$4(N&SDJ?GE$_:XGL'8P0,6BB`WIN/-/#;]-S`<^QK
M([2NT<!P#->T4'!C66'PMK>OOU]UEI+8X^_RW_MQ8:.]$=%I[O6KYHK/7\QZ
MO4UIV=Q?A<($"_!\24`"LRJ2Y[=?X?-+<S[HQV<U_]3RTO!Z:E-O;D.:N"(%
MIVJQGL^9MO\$(?P;6RZP\8;(FUB^$=H@@`SW&B3'$]^ZL=S`OK60XP5M!],!
M,W&Z'++D/BU`;2_U@'X^`)!I!#=HZ'@?6A(Z$M<TC5B29H*X6,)?;S[(4LI)
MFAH\]F`*=D?)?4&IF:B.8+\8HK85P85KA%/?4L0&T\!VK:#H4-ZMY=_:UH<6
M7B-X0;9:8?'HS0.ZX#"EC#"71A0E&9<P9YXDC$:0LNQS;*BE1WI601I,QV/#
M_Z28!O;(M8>V:;@A,DS3F[JA[8[0!#JM:5MMUVQ&UTQ6X/N2\)3>$2=)*R"K
M`CIFO]5TPV<U(%5%RZ99V"12M=:$B&`)&5LE5.[=UG,YK89'(G,:"&I`>14M
MET9<AIB*6\PR,B987:N,H=)OZH7T\>[G"J.A8?OHUG"F%AI;1@##69Z%M*`:
M@1IC\9E(/&,D(%$FJ*P9J&IE])A^J6"",>D/*S0&#LRQ+!.L#=L1J"DD&YSF
M"PH`C#0E4F5\HR2)[REC^ZQTHGIDOU:0V6YHN"-;(3."0$V+56XX\KSK#[;C
MM.P:L0N)6#D)YON@GLJU5/K5,2FT_#',<0VW!=`(@*<$G(0O\A:G>$99;91[
M44[?;2XJ@+SPQO*!D#OJ%JQL8V`[;;P[8#XED^CS,@%1D5I_9U0^5N9.50E]
M/ZKFW$'HF7_<>,ZUY0<_(.O]U`X_M7R:\QE@>*R:N,"L)?>DEE%52L^I9CZK
M.'4'1F`5"WV6&^1+?RVKAKF#6GL-\4,UXNW>TE.IIG.V"RPL%!H?VZC6D$2Y
M7@>]849Y[D8%2:V,?@`ZK[!Y6LH#1`/;+1;*6TC-0MMV+<XG=X1GQ!`",NKZ
M&>PKTOI.506WNU[G6[>6"W-:P_<A"6_GM*\S3*),-3O,>"PN(2.P^3P1J]VA
M22>A__91I.$;_=V?:L=241G:J:T%U>Q[X4N)GEY$C^K\@,]4;0YX?*`DC$22
MQ.\S+"01['$(XQ6/*&;76.)*H-1+ZP/E;]5`:3F6J7"^GQH^3+*<3V@(`YUK
MVH:#`+2!?IQRG,44'ME^O&\&U">2%FNP`;ZC?)%.6'75HEY(CZ^ZL.1;H5TL
MTZ+`N+7=48`F3KN@T?Q[U(K*/,.`D<Q,\L^%A-=]8M2)ZJ&]J7ZC\L9C.RQ"
M9['I(O^::+GMI\0#T#&&9YN=T<9"D/JT\B4Q/;+JIQ'3<QQCX!5;99`Q\JTV
MCSR`EA%%(B.Q]:`6+ZJ=:_^V?II6'<0,T_2G,(99']6:1MN'&E*9%'M`'U46
M#_G@6G4-M]RO^;J8GE(U[$U\M=DL_)3'/)4A3E07^C=RK;`%=LBN0+5'_.R%
MK8'%/7U>?];_@OL#D6DX)CK[!Q-\V]L_^;`I>7Y"(C\?05?K1$C$:P_7O'0\
MI3B7XR117IE&15UU2[VN*NKVS[KG_1-X=+E[^W4SJJ<^#K!`R1_]Y)>.LQS6
M`*7>?V]&_:F?)M;L:KJ%HC+G0IG3?W-\J^P?#&IB"Q/BF=91AF@/-;U@16Y!
MK6*/,)F6)=UM5<WMT9YGTMFSKZ-^Z"S8G&?+3;CJ;-8>AR)9P;`79Y&\AA*6
MK#>K70Z-U-8ROMA/.=59CS^/TB[.C^1GORY7"2<2BT<;0K.*0.!J-DLEE9ER
M="22;%V*PH1\U4$8[@H<R:O.'#,52SA5":\Z_B$AI>J@0GA6[/0',P6!J7Q9
M#,,Z3>(P-R#.Q&:!KTGCJ`F0>FZ^*T+@%YNA3N[_QV']HO3N#H0'.6!)]'FG
M$8[0+1JF.*9X*<ORQDU3WQ)?R65CP^$(C[>JNV\"E$''..(]*)S](L[KEK5K
M'&XF_JTYN3,EOMLEI&5[B-+_T.$B,2N&![C\#U!+`0(>`Q0````(`-9E:$!H
MLZD:7:(``%8P!P`1`!@```````$```"D@0````!C;&1X+3(P,3$Q,C,Q+GAM
M;%54!0`#@_!83W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-9E:$!V).Y)
M\PX``*S5```5`!@```````$```"D@:BB``!C;&1X+3(P,3$Q,C,Q7V-A;"YX
M;6Q55`4``X/P6$]U>`L``00E#@``!#D!``!02P$"'@,4````"`#696A`!][1
M>/H4``#220$`%0`8```````!````I('JL0``8VQD>"TR,#$Q,3(S,5]D968N
M>&UL550%``.#\%A/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`UF5H0.7G
M?J4P0P``>@@$`!4`&````````0```*2!,\<``&-L9'@M,C`Q,3$R,S%?;&%B
M+GAM;%54!0`#@_!83W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-9E:$"7
M2O<.>R```*0,`@`5`!@```````$```"D@;(*`0!C;&1X+3(P,3$Q,C,Q7W!R
M92YX;6Q55`4``X/P6$]U>`L``00E#@``!#D!``!02P$"'@,4````"`#696A`
MD(`[+2`(``"`/0``$0`8```````!````I(%\*P$`8VQD>"TR,#$Q,3(S,2YX
M<V155`4``X/P6$]U>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``YS,!
#````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Basis of Presentation </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Use of Estimates </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Cash and Cash Equivalents </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company considers all highly liquid investments purchased with a maturity date of 90&#160;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Marketable Securities </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the consolidated balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the consolidated statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Concentration of Credit Risk </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue from Glaxo and Pfizer represented 98% and none for the year ended December&#160;31, 2011, 14% and 85% for the year ended December&#160;31, 2010 and 52% and 34% for the year ended December&#160;31, 2009 of total Company revenue, respectively. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Fair Value Measurements </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&#160;GAAP: </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2: Observable inputs other than Level&#160;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Property and Equipment </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's consolidated statements of operations. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Business Combinations </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Intangible Assets </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IPR&amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are maintained on the Company's consolidated balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs. IPR&amp;D assets will be tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Goodwill </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Impairment of Long-Lived Assets </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Revenue Recognition </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. During the year ended December&#160;31, 2010, the Company recorded $1.7&#160;million to other income related to IRS Qualifying Therapeutic Discovery Grants because the grant arrangement was not part of the Company's on-going operations. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Research and Development Expenses </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other studies, personnel costs, depreciation, license fees and funding of outside research. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clinical trial expenses include expenses associated with clinical research organizations (CRO). The invoicing from CROs for services rendered can lag several months. We accrue the cost of services rendered in connection with CRO activities based on our estimate of site management, monitoring costs, and project management costs. We maintain regular communication with our CROs to gauge the reasonableness of our estimates. Differences between actual clinical trial expenses and estimated clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Patent Costs </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Stock-Based Compensation </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the vesting term resulting in periodic adjustments to stock-based compensation expense. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Foreign Currency Translation </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&#160;31, 2011 and December&#160;31, 2010, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&#160;million. In 2011, the Company's foreign subsidiary voluntarily liquidated in order to consolidate the Company's foreign operations into Celldex Therapeutics,&#160;Inc. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Income Taxes </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Comprehensive Loss </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. In December 2011, the Company adopted a new U.S.&#160;GAAP accounting standard which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements. This new standard eliminates the option to present components of other comprehensive income as part of the statement of equity. The adoption of this new standard did not have a material effect on the Company's operating results or financial position. The consolidated statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&#160;31, 2011, 2010 and 2009. There were no significant reclasses to income during the years ended December&#160;31, 2011, 2010 and 2009. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Net Loss Per Share </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="55"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="55"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="55"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>Year Ended December&#160;31, </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2009 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Stock options</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,459,034</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,019,982</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,576,159</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Convertible debt</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">353,563</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">353,563</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Restricted stock</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6,000</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">9,338</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">16,000</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,465,034</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,382,883</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,945,722</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2"><i>Recent Accounting Pronouncements </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In September 2011, the FASB amended the guidance on the annual testing of goodwill for impairment. The amended guidance will allow companies to assess qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. This guidance will be effective for the Company's fiscal year ending December&#160;30, 2012. The Company does not expect the adoption of this new standard to have a material effect on its operating results or financial position. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In May 2011, the FASB issued a new accounting standard which clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level&#160;3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after December&#160;15, 2011. The adoption of this standard is not expected to have a material impact on the Company's operating results or financial position. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
        <td class="nump">$ 11,899<span></span></td>
        <td class="nump">$ 21,287<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
        <td class="nump">41,413<span></span></td>
        <td class="nump">39,811<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and Other Receivables</a></td>
        <td class="nump">170<span></span></td>
        <td class="nump">324<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and Other Current Assets</a></td>
        <td class="nump">1,202<span></span></td>
        <td class="nump">1,525<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">54,684<span></span></td>
        <td class="nump">62,947<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
        <td class="nump">9,093<span></span></td>
        <td class="nump">10,832<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
        <td class="nump">24,923<span></span></td>
        <td class="nump">26,836<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
        <td class="nump">329<span></span></td>
        <td class="nump">363<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">8,965<span></span></td>
        <td class="nump">8,965<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">97,994<span></span></td>
        <td class="nump">109,943<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
        <td class="nump">935<span></span></td>
        <td class="nump">931<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
        <td class="nump">7,008<span></span></td>
        <td class="nump">4,936<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Portion of Long-Term Liabilities</a></td>
        <td class="nump">219<span></span></td>
        <td class="nump">818<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Current Portion of Term Loan</a></td>
        <td class="nump">6,136<span></span></td>
        <td class="nump">1,111<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtCurrent', window );">Convertible Subordinated Debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,412<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">14,298<span></span></td>
        <td class="nump">20,208<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Term Loan, less Current Portion</a></td>
        <td class="nump">9,008<span></span></td>
        <td class="nump">8,889<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Long-Term Liabilities</a></td>
        <td class="nump">5,966<span></span></td>
        <td class="nump">5,591<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">29,272<span></span></td>
        <td class="nump">34,688<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingent Liabilities (Notes 14 and 16)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December 31, 2011 and 2010</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 44,210,636 and 32,055,382 Shares Issued and Outstanding at December 31, 2011 and 2010, respectively</a></td>
        <td class="nump">44<span></span></td>
        <td class="nump">32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional Paid-In Capital</a></td>
        <td class="nump">271,032<span></span></td>
        <td class="nump">232,679<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income</a></td>
        <td class="nump">2,652<span></span></td>
        <td class="nump">2,751<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
        <td class="num">(205,006)<span></span></td>
        <td class="num">(160,207)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">68,722<span></span></td>
        <td class="nump">75,255<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 97,994<span></span></td>
        <td class="nump">$ 109,943<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsAndOtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleSubordinatedDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 42, 45<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecuredDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer), excluding the current portion, if any. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecuredLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFUBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">$ (44,799)<span></span></td>
        <td class="num">$ (2,533)<span></span></td>
        <td class="num">$ (36,525)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Cash Used in Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
        <td class="nump">2,248<span></span></td>
        <td class="nump">2,718<span></span></td>
        <td class="nump">2,583<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
        <td class="nump">1,913<span></span></td>
        <td class="nump">3,143<span></span></td>
        <td class="nump">949<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization and Premium of Marketable Securities</a></td>
        <td class="nump">17<span></span></td>
        <td class="num">(14)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Realized Loss (Gain) on Sales and Maturities of Marketable Securities</a></td>
        <td class="nump">5<span></span></td>
        <td class="num">(4)<span></span></td>
        <td class="nump">24<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) Loss on Sale or Disposal of Assets</a></td>
        <td class="num">(58)<span></span></td>
        <td class="num">(38)<span></span></td>
        <td class="num">(556)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-Based Compensation Expense</a></td>
        <td class="nump">2,342<span></span></td>
        <td class="nump">2,802<span></span></td>
        <td class="nump">3,058<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-Cash Interest Expense</a></td>
        <td class="nump">307<span></span></td>
        <td class="nump">728<span></span></td>
        <td class="nump">181<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeTaxExpense', window );">Non-Cash Tax Benefit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(529)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Operating Assets and Liabilities, Net of Acquisitions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and Other Receivables</a></td>
        <td class="nump">154<span></span></td>
        <td class="nump">220<span></span></td>
        <td class="nump">1,283<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and Other Current Assets</a></td>
        <td class="nump">241<span></span></td>
        <td class="num">(546)<span></span></td>
        <td class="nump">743<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other Assets</a></td>
        <td class="nump">34<span></span></td>
        <td class="nump">5,592<span></span></td>
        <td class="nump">722<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable and Accrued Expenses</a></td>
        <td class="nump">2,076<span></span></td>
        <td class="num">(1,193)<span></span></td>
        <td class="num">(2,463)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred Revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(39,382)<span></span></td>
        <td class="num">(2,038)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other Liabilities</a></td>
        <td class="num">(138)<span></span></td>
        <td class="num">(1,865)<span></span></td>
        <td class="nump">2,699<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Used in Operating Activities</a></td>
        <td class="num">(35,658)<span></span></td>
        <td class="num">(30,372)<span></span></td>
        <td class="num">(29,869)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired in the CuraGen acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">51,654<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and Maturities of Marketable Securities</a></td>
        <td class="nump">51,003<span></span></td>
        <td class="nump">42,383<span></span></td>
        <td class="nump">2,674<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of Marketable Securities</a></td>
        <td class="num">(52,717)<span></span></td>
        <td class="num">(56,522)<span></span></td>
        <td class="num">(9,559)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of Property and Equipment</a></td>
        <td class="num">(509)<span></span></td>
        <td class="num">(2,100)<span></span></td>
        <td class="num">(528)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale or Disposal of Assets</a></td>
        <td class="nump">68<span></span></td>
        <td class="nump">77<span></span></td>
        <td class="nump">850<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash (Used in) Provided by Investing Activities</a></td>
        <td class="num">(2,155)<span></span></td>
        <td class="num">(16,162)<span></span></td>
        <td class="nump">45,091<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from Stock Issuances</a></td>
        <td class="nump">36,023<span></span></td>
        <td class="nump">1,014<span></span></td>
        <td class="nump">668<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSubordinatedDebt', window );">Related Party Loan Due to Medarex</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,957)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of Term Loan</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">10,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of Convertible Subordinated Debt</a></td>
        <td class="num">(12,503)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Payment of Other Liabilities</a></td>
        <td class="num">(86)<span></span></td>
        <td class="num">(197)<span></span></td>
        <td class="num">(176)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Provided by (Used in) Financing Activities</a></td>
        <td class="nump">28,434<span></span></td>
        <td class="nump">10,817<span></span></td>
        <td class="num">(2,465)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of Exchange Rate Changes on Cash and Cash Equivalents</a></td>
        <td class="num">(9)<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="num">(12)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
        <td class="num">(9,388)<span></span></td>
        <td class="num">(35,715)<span></span></td>
        <td class="nump">12,745<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
        <td class="nump">21,287<span></span></td>
        <td class="nump">57,002<span></span></td>
        <td class="nump">44,257<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
        <td class="nump">11,899<span></span></td>
        <td class="nump">21,287<span></span></td>
        <td class="nump">57,002<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Flow Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares Issued to Executive Officers</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash Paid for Interest</a></td>
        <td class="nump">$ 1,560<span></span></td>
        <td class="nump">$ 604<span></span></td>
        <td class="nump">$ 157<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27405-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(c)-(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's financing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in financing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's investing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in investing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's continuing operations. This element specifically EXCLUDES the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in operating activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeTaxExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeTaxExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfProductiveAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfOtherLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSubordinatedDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of long-term borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in case of liquidation of the entity's assets or underlying collateral.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfSubordinatedDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. This element is not the recognition of equity-based compensation expense in pursuant to FAS 123R. That element is AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue (Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743629&amp;loc=d3e3913-113898<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418191&amp;loc=d3e15009-113911<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(16) COMMITMENTS AND CONTINGENCIES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has facility and equipment leases that expire at various dates through 2017. Certain of these facility leases contain renewal options, early termination provisions, and provisions that escalate the base rent payments and require the Company to pay common area maintenance costs (CAM) during the lease term. The Company entered into a letter of credit facility with a national U.S. financial institution which is collateralized by a security deposit for the leased facility in Phillipsburg, New Jersey. The Company recorded restricted cash related to this security deposit of $0.2&#160;million to other assets in the consolidated balance sheets at December&#160;31, 2011 and December&#160;31, 2010. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&#160;31, 2011 do not include the exercise of renewal terms or early termination provisions (in thousands): </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2012</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,405</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2013</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,414</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2014</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,445</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,503</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Thereafter</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,014</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total minimum lease payments</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">13,181</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company's total rent and CAM expense for all facility leases was $2.5&#160;million for the years ended December&#160;31, 2011, 2010 and 2009. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited) </b></font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 17pt; BORDER-BOTTOM: #000000 1pt solid"><font size="1"><b>2011 <!-- COMMAND=ADD_SCROPPEDRULE,17pt --></b></font></div></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q1 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q2 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q3 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q4 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands, except per share amounts)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total revenue</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,516</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,952</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,363</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,433</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(10,059</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(10,236</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(11,772</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(12,732</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.31</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.27</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.27</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.29</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;<br /></font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 17pt; BORDER-BOTTOM: #000000 1pt solid"><font size="1"><b>2010 <!-- COMMAND=ADD_SCROPPEDRULE,17pt --></b></font></div></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q1 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q2 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q3 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Q4 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands, except per share amounts)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total revenue</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,713</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,951</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,408</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">37,721</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net (loss) income</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(6,582</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(9,525</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(9,087</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">22,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Basic net (loss) income per common share</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.21</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.30</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.28</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">0.71</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Diluted net (loss) income per common share</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.21</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.30</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(0.28</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">0.70</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 23, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 30<br><br> -Subparagraph a-j<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952194&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NATURE OF BUSINESS AND OVERVIEW<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS AND OVERVIEW</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">NATURE OF BUSINESS AND OVERVIEW</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(1) NATURE OF BUSINESS AND OVERVIEW </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celldex Therapeutics,&#160;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase&#160;3 study for the treatment of glioblastoma, CDX-011, an antibody-drug conjugate in a randomized Phase&#160;2b study for the treatment of advanced breast cancer and CDX-1127, a therapeutic human antibody in a Phase&#160;1 study for cancer indications. The Company has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&#8482; program, CDX-301, an immune cell mobilizing agent, and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's collaboration with GlaxoSmithKline (Glaxo) resulted in the commercialization of Rotarix, an oral human rotavirus vaccine. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2011, the Company had cash, cash equivalents and marketable securities of $53.3&#160;million; working capital of $40.4&#160;million; and a Term Loan balance of $15.1&#160;million. The Company incurred a loss of $44.8&#160;million for the year ended December&#160;31, 2011. Net cash used in operations for the year ended December&#160;31, 2011 was $35.7&#160;million. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&#160;million in net proceeds. In February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&#160;million, after deducting underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. The Company believes that the cash, cash equivalents and marketable securities at December&#160;31, 2011, the $8.5&#160;million raised under the Cantor Agreement in January and the $37.7&#160;million raised in the underwritten public offering in February and interest income on invested funds, will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company raised net proceeds of $35.9&#160;million during the year ended December&#160;31, 2011 and $46.2&#160;million during the two months ended February&#160;29, 2012 from the sale of its common stock. During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms that reduce the Company's economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccounting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred Stock, Par Value (in dollars per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible Preferred Stock, Shares Authorized</a></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="nump">3,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred Stock, Shares Issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred Stock, Shares Outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="nump">297,000,000<span></span></td>
        <td class="nump">297,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
        <td class="nump">44,210,636<span></span></td>
        <td class="nump">32,055,382<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
        <td class="nump">44,210,636<span></span></td>
        <td class="nump">32,055,382<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(11) STOCKHOLDERS' EQUITY </b></font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Common Stock </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In April 2010, the Company filed a shelf registration statement with the Securities and Exchange Commission to register for sale any combination of the types of securities described in the shelf registration statement up to a dollar amount of $150&#160;million. The shelf registration became effective on April&#160;22, 2010. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In January 2011, the Company entered into a controlled equity offering sales agreement (the "Cantor Agreement") with Cantor Fitzgerald&#160;&amp;&#160;Co. (Cantor) pursuant to which the Company may issue and sell up to 5,000,000 shares of its common stock from time to time through Cantor, acting as agent. The Company agreed to pay Cantor a commission of up to 5% of the gross proceeds from each sale and to reimburse Cantor for certain expenses incurred in connection with entering into the Cantor Agreement. The Cantor Agreement terminates upon the sale of all 5,000,000 shares or upon ten day notice by either Cantor or the Company. During the year ended December&#160;31, 2011, the Company sold 575,000 shares of common stock under the Cantor Agreement and raised $2.2&#160;million in net proceeds, after deducting commission and offering expenses. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5&#160;million in net proceeds. Under the terms of the Cantor Agreement, the Company will have the ability to sell up to 1,975,000 shares of its common stock upon the expiration or earlier waiver of the 90-day lock-up with the underwriters of the Company's recent offering in February 2012. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In May 2011, the Company issued 11,500,000 shares of its common stock in an underwritten public offering, including the underwriter's exercise of their full over-allotment option to purchase an additional 1,500,000 shares of common stock. The net proceeds to the Company were $33.7&#160;million, after deducting underwriting fees and offering expenses. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7&#160;million, after deducting underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Convertible Preferred Stock </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2011, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated Class&#160;C Preferred Stock including 350,000 shares which have been designated Series&#160;C-1&#160;Junior Participating Cumulative Preferred Stock (the "Series&#160;C-1 Preferred Stock"). </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Shareholder Rights Plan </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company's Board has adopted a Shareholder Rights Plan, as set forth in the Shareholder Rights Agreement, as amended, between the Company and Computershare Trust Company, N.A., as Rights Agent (the "Rights Agreement"). Pursuant to the terms of the Rights Agreement, the Board declared a dividend distribution of one Preferred Stock Purchase Right (a "Right") for each outstanding share of the Company's common stock. Each Right, which expires in November 2014, entitles their holder to purchase from the Company one ten-thousandth of a share (a "Unit") of Series&#160;C-1 Preferred Stock at a cash exercise price of $35.00 per Unit, subject to adjustment. The Rights will trade separately from the common stock and will become exercisable only when a person or group has acquired 15% or more of the outstanding common stock or upon the commencement by a person or group of a tender offer that would result in such person or group acquiring 15% or more of the outstanding common stock other than as a result of repurchases of stock by the Company or certain inadvertent actions by a shareholder. In the event a person or group acquires 15% or more of the outstanding common stock each holder of a Right (except for any such person or group) would be entitled to receive upon exercise sufficient Units of Series&#160;C-1 Preferred Stock to equal a value of two times the exercise price of the Right. In the event the Company is acquired in a merger or other business combination transaction or if 50% or more of the Company's assets or earning power is sold, each holder of a Right (except for any such person or group described above) would receive upon exercise common stock of the acquiring company with a value equal to two times the exercise price of the Right. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Celldex Therapeutics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000744218<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 156.1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,160,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(12) STOCK-BASED COMPENSATION </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan"), Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan") and the CuraGen 2007 Plan. There are no shares available for future grant under the Celldex Research 2005 Plan and CuraGen 2007 Plan. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Employee Stock Purchase Plan </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2011, a total of 62,500 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the 2004 ESPP Plan, each participating employee may purchase up to 250 shares of common stock per year, through payroll deductions, at a purchase price equal to 85% of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date. During the years ended December&#160;31, 2011 and 2010, the Company issued 6,627 and 5,897 shares under the 2004 ESPP Plan, respectively. At December&#160;31, 2011, 44,382 shares were available for issuance under the 2004 ESPP Plan. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Employee Stock Option and Incentive Plan </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&#160;422A of the Internal Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash bonuses to employees, consultants and non-employee directors. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2011, the 2008 Plan allowed for a maximum of 3,900,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to March&#160;7, 2018 and grants of Incentive Stock Options made prior to October&#160;20, 2017. The Company's board of directors determines the term of each option, option price, and number of shares for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five years for options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the date of grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee director stock option awards is accelerated upon a change in control as defined in the 2008 Plan. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A summary of stock option activity for the year ended December&#160;31, 2011 is as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="55"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="47"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="74"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Shares </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Weighted<br />
Average<br />
Exercise<br />
Price<br />
Per Share </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Term (In Years) </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Options Outstanding at December&#160;31, 2010</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">4,019,982</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.93</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.6</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">942,884</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2.90</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(61,627</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2.50</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Canceled</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(442,205</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">7.51</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom" align="right">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Options Outstanding at December&#160;31, 2011</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">4,459,034</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.08</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.9</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom" align="right">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Options Vested and Expected to Vest at December&#160;31, 2011</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">4,412,254</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.11</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6.9</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Options Exercisable at December&#160;31, 2011</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">2,818,895</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">7.16</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">5.9</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Shares Available for Grant under the 2008 Plan</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">953,111</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2011, 2010 and 2009 was $0.03&#160;million, $1.0&#160;million and $0.3&#160;million, respectively. The weighted average grant-date fair value of stock options granted during the years ended December&#160;31, 2011, 2010 and 2009 was $1.83, $2.82 and $5.29, respectively. The total fair value of stock options vested during the years ended December&#160;31, 2011, 2010 and 2009 was $2.6&#160;million, $2.5&#160;million and $2.6&#160;million, respectively. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The aggregate intrinsic value of stock options outstanding at December&#160;31, 2011 was $0.03&#160;million. The aggregate intrinsic value of stock options vested and expected to vest at December&#160;31, 2011 was $0.03&#160;million. As of December&#160;31, 2011, total compensation cost related to non-vested employee and non-employee director stock options not yet recognized was approximately $3.3&#160;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.5&#160;years. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Restricted Stock </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A summary of restricted stock activity under the 2008 Plan for the year ended December&#160;31, 2011 is as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="44"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="54"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Shares </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Weighted<br />
Average<br />
Grant Date<br />
Fair Value<br />
(per share) </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Outstanding and unvested at December&#160;31, 2010</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">9,338</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3.96</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">12,000</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3.24</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Vested</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(15,338</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3.68</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Canceled</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom" align="right">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Outstanding and unvested at December&#160;31, 2011</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6,000</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3.24</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom" align="right">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2"><i>Valuation and Expenses Information </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation expense for the years ended December&#160;31, 2011, 2010 and 2009 was recorded as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="39"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="39"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="39"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2009 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Research and development</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,412</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,625</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,383</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">General and administrative</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">930</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,177</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,675</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total stock-based compensation expense</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,342</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,802</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,058</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The fair values of employee and non-employee director stock options granted during the years ended December&#160;31, 2011, 2010 and 2009 were valued using the Black-Scholes option-pricing model with the following assumptions: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 78.11%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 228px">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="88"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="88"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="88"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Year Ended<br />
December&#160;31, 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Year Ended<br />
December&#160;31, 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Year Ended<br />
December&#160;31, 2009 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Expected stock price volatility</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">68&#160;&#8211;&#160;70</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">65&#160;&#8211;&#160;67</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">65&#160;&#8211;&#160;68</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Expected option term</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6.0 Years</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6.2 Years</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5.5&#160;&#8211;&#160;6.3 Years</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1.4&#160;&#8211;&#160;2.9</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1.8&#160;&#8211;&#160;3.2</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1.8&#160;&#8211;&#160;3.4</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">%</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Expected dividend yield</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">None</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">None</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">None</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements', window );">Product Development and Licensing Agreements</a></td>
        <td class="nump">$ 110<span></span></td>
        <td class="nump">$ 40,187<span></span></td>
        <td class="nump">$ 5,662<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromContractsAndGrants', window );">Contracts and Grants</a></td>
        <td class="nump">36<span></span></td>
        <td class="nump">220<span></span></td>
        <td class="nump">1,802<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Product Royalties</a></td>
        <td class="nump">9,119<span></span></td>
        <td class="nump">6,386<span></span></td>
        <td class="nump">7,716<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
        <td class="nump">9,265<span></span></td>
        <td class="nump">46,793<span></span></td>
        <td class="nump">15,180<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSE:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
        <td class="nump">32,439<span></span></td>
        <td class="nump">27,650<span></span></td>
        <td class="nump">26,169<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
        <td class="nump">9,119<span></span></td>
        <td class="nump">12,077<span></span></td>
        <td class="nump">8,397<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on Sale of Assets</a></td>
        <td class="num">(50)<span></span></td>
        <td class="num">(50)<span></span></td>
        <td class="num">(604)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
        <td class="nump">9,243<span></span></td>
        <td class="nump">10,428<span></span></td>
        <td class="nump">17,119<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Acquired Intangible Assets</a></td>
        <td class="nump">1,913<span></span></td>
        <td class="nump">3,143<span></span></td>
        <td class="nump">949<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Operating Expense</a></td>
        <td class="nump">52,664<span></span></td>
        <td class="nump">53,248<span></span></td>
        <td class="nump">52,030<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
        <td class="num">(43,399)<span></span></td>
        <td class="num">(6,455)<span></span></td>
        <td class="num">(36,850)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Investment and Other Income, Net</a></td>
        <td class="nump">396<span></span></td>
        <td class="nump">5,259<span></span></td>
        <td class="nump">248<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
        <td class="num">(1,796)<span></span></td>
        <td class="num">(1,337)<span></span></td>
        <td class="num">(452)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
        <td class="num">(44,799)<span></span></td>
        <td class="num">(2,533)<span></span></td>
        <td class="num">(37,054)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">529<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">(44,799)<span></span></td>
        <td class="num">(2,533)<span></span></td>
        <td class="num">(36,525)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted Net Loss Per Common Share (See Note 2) (in dollars per share)</a></td>
        <td class="num">$ (1.13)<span></span></td>
        <td class="num">$ (0.08)<span></span></td>
        <td class="num">$ (1.84)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares Used in Calculating Basic Net Loss per Share (See Note 2) (in shares)</a></td>
        <td class="nump">39,501<span></span></td>
        <td class="nump">31,868<span></span></td>
        <td class="nump">19,823<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares Used in Calculating Diluted Net Loss per Share (See Note 2) (in shares)</a></td>
        <td class="nump">39,501<span></span></td>
        <td class="nump">31,868<span></span></td>
        <td class="nump">19,823<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">(44,799)<span></span></td>
        <td class="num">(2,533)<span></span></td>
        <td class="num">(36,525)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other Comprehensive (Loss) Income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
        <td class="num">(9)<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="num">(12)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (Loss) Gain on Marketable Securities</a></td>
        <td class="num">(90)<span></span></td>
        <td class="nump">203<span></span></td>
        <td class="num">(48)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
        <td class="num">$ (44,898)<span></span></td>
        <td class="num">$ (2,328)<span></span></td>
        <td class="num">$ (36,585)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromContractsAndGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_RevenueFromContractsAndGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents revenue from product development and licensing agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_RevenueFromProductDevelopmentAndLicensingAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTaxAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569643-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(6) PROPERTY AND EQUIPMENT, NET </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Property and equipment include the following: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31, 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31, 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="5"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Laboratory Equipment</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,630</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,942</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Manufacturing Equipment</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,999</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,418</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Office Furniture and Equipment</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,314</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,299</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Leasehold Improvements</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">13,280</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">13,244</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Construction in Progress</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">240</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">703</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total Property and Equipment</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">19,463</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">19,606</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Less Accumulated Depreciation and Amortization</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(10,370</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(8,774</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">9,093</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,832</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation and amortization expense related to property and equipment was $2.2&#160;million, $2.7&#160;million and $2.6&#160;million for the years ended December&#160;31, 2011, 2010 and 2009, respectively. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>MARKETABLE SECURITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">MARKETABLE SECURITIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(5) MARKETABLE SECURITIES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A summary of marketable securities is shown below: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="49"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="51"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="51"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="49"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Amortized<br />
Cost </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Gross<br />
Unrealized<br />
Gains </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Gross<br />
Unrealized<br />
Losses </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Fair<br />
Value </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2"><b>December&#160;31, 2011</b></font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">U.S. government and municipal obligations</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing in one year or less</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">19,993</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">20</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">20,013</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing after one year through three years</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,808</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">122</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,924</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total U.S. government and municipal obligations</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">30,801</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">142</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">30,937</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Corporate debt securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing in one year or less</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5,817</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5,816</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing after one year through three years</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,730</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">72</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,660</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total corporate debt securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,547</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">76</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,476</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">41,348</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">147</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">82</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">41,413</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;<br /></font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="49"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="51"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="51"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="49"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Amortized<br />
Cost </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Gross<br />
Unrealized<br />
Gains </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Gross<br />
Unrealized<br />
Losses </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Fair<br />
Value </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2"><b>December&#160;31, 2010</b></font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">U.S. government and municipal obligations</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing in one year or less</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">14,836</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">35</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">14,871</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing after one year through three years</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,428</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">103</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,531</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total U.S. government and municipal obligations</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">26,264</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">138</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">26,402</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Corporate debt securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing in one year or less</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,798</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">18</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,814</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 40pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Maturing after one year through three years</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,594</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,595</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 30pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total corporate debt securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">13,392</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">19</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">13,409</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">39,656</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">157</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">39,811</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be other-than-temporarily impaired as of December&#160;31, 2011. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RETIREMENT SAVINGS PLAN<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT SAVINGS PLAN</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT SAVINGS PLAN</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(17) RETIREMENT SAVINGS PLAN </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was $0.2&#160;million, $0.2&#160;million and $0.1&#160;million for the years ended December&#160;31, 2011, 2010 and 2009, respectively. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT REVENUE ARRANGEMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_SignificantRevenueArrangementsDisclosureAbstract', window );"><strong>SIGNIFICANT REVENUE ARRANGEMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_SignificantRevenueArrangementsDisclosureTextBlock', window );">SIGNIFICANT REVENUE ARRANGEMENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(13) SIGNIFICANT REVENUE ARRANGEMENTS </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A summary of the Company's significant revenue contracts and arrangements follows: </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>GlaxoSmithKline&#160;plc (Glaxo) and Paul Royalty Fund II,&#160;L.P. (PRF) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In 1997, the Company entered into an agreement with Glaxo to collaborate on the development and commercialization of the Company's oral rotavirus strain and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. The Company's licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine in 1995 and owes a license fee of 30% to Cincinnati Children's Hospital Medical Center (CCH) on net royalties received from Glaxo. The Company is obligated to maintain a license with CCH with respect to the Glaxo agreement. The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon 90&#160;days prior written notice. The last relevant patent is scheduled to expire in December 2012. No additional milestone payments are due from Glaxo under the agreement. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In May 2005, the Company entered into an agreement whereby an affiliate of PRF purchased a 70% interest in the milestone payments and net royalties the Company will receive on worldwide sales of Rotarix. We have received a total of $60&#160;million in milestone payments under the PRF agreement. No additional milestone payments are due from PRF under the agreement. The PRF agreement terminates in December 2012, unless otherwise extended. The Company's retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. Product royalty revenue and royalty expense related to the Company's retained interest in Rotarix was $9.1&#160;million, $6.4&#160;million and $7.7&#160;million for the years ended December&#160;31, 2011, 2010 and 2009, respectively. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Pfizer Inc. (Pfizer) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In April 2008, the Company and Pfizer entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide license to rindopepimut. Under the Pfizer Agreement, Pfizer made an upfront payment to the Company of $40&#160;million and made a $10&#160;million equity investment in the Company. The Pfizer Agreement also provided for reimbursement by Pfizer of all costs incurred by the Company in connection with the collaboration since the effective date. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company had determined that its performance obligations under this collaboration should be accounted for as a single unit of accounting. The Company's deliverables under this collaboration primarily included an exclusive license to rindopepimut, research and development services as required under the collaboration and participation in the joint clinical development committee. The Company had estimated that its expected performance period under the collaboration would be 9.5&#160;years based on an assessment of the period over which the Company would have met its performance obligations under the collaboration. The $40&#160;million up-front payment and research and development reimbursements were initially recorded as deferred revenue and recognized as revenue over this 9.5&#160;year period. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In November 2010, the Pfizer Agreement was terminated (the "Pfizer Termination") and all rights to rindopepimut were returned to the Company. Pfizer did not provide a reason for termination. As a result of the Pfizer Termination, the Company recognized the remaining deferred revenue related to the Pfizer Agreement to product development and licensing agreement revenue during the year ended December&#160;31, 2010. The Company recorded $39.9&#160;million and $5.2&#160;million in product development and licensing agreement revenue under the Pfizer Agreement during the years ended December&#160;31, 2010 and 2009, respectively. The Company incurred and invoiced Pfizer reimbursable costs related to the Pfizer collaboration of $0.8&#160;million and $3.2&#160;million for the years ended December&#160;31, 2010 and 2009, respectively. Effective with the Pfizer Termination, Pfizer is no longer funding the development of rindopepimut. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the Pfizer Agreement, the Company paid a total of $6.9&#160;million in sublicense fees to Duke University and Thomas Jefferson University. The Company recorded these deferred sublicense fees to other assets in the consolidated balance sheets and was amortizing them to royalty expense over the 9.5-year performance period. As a result of the Pfizer Termination, the Company recognized the remaining deferred costs related to the Pfizer Agreement to royalty expense during year ended December&#160;31, 2010. The Company recorded $5.7&#160;million and $0.7&#160;million in royalty expense related to these deferred sublicense fees during the years ended December&#160;31, 2010 and 2009, respectively. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Rockefeller University (Rockefeller) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has provided research and development support to Rockefeller on the development of their vaccine, DCVax-001, which the Company refers to as CDX-2401, aimed at providing protection from infection with HIV, the virus known to cause AIDS. Payments to the Company are made on a time and materials basis. The Company recorded grant revenue from Rockefeller of $0.2&#160;million and $1.8&#160;million for the years ended December&#160;31, 2010 and 2009, respectively. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_SignificantRevenueArrangementsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_SignificantRevenueArrangementsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_SignificantRevenueArrangementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element may be used to capture the complete disclosure pertaining to an entity's significant revenue contracts and arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_SignificantRevenueArrangementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER LONG-TERM LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER LONG-TERM LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER LONG-TERM LIABILITIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(9) OTHER LONG-TERM LIABILITIES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other long-term liabilities include the following: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31, 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31, 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="5"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred Rent</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">435</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">450</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Severance</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">685</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net Deferred Tax Liability</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred Income from Sale of Tax Benefits</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">510</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Loan Payable</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">527</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">581</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">52</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">32</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6,185</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">6,409</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Less Current Portion</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(219</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(818</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Long-Term Portion</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5,966</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">5,591</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2"><i>Sale of Tax Benefits </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to sell New Jersey tax benefits worth $0.6&#160;million (consisting of R&amp;D tax credits) to an independent third party for $0.5&#160;million. Under the agreement, the Company must maintain a base of operations in New Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. The Company is recognizing the $0.5 million over five years starting in 2012. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Loan Payable </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In December 2003, the Company entered into a lease with the Massachusetts Development Finance Agency whereby the Company received a loan to finance the build-out of its manufacturing facility in Fall River, Massachusetts. Principal and interest payments on the loan are due monthly using an amortization period of 15&#160;years and interest accrues at a rate of 5.5% per annum. The Company is obligated to repay the following principal amounts for the loan as follows (in thousands): </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="30"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2012</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">51</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2013</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">58</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2014</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">60</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">63</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">66</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Thereafter</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">229</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">527</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS AND GOODWILL</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(7) INTANGIBLE ASSETS AND GOODWILL </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible assets, net of accumulated amortization, and goodwill are as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 63.44%; PADDING-TOP: 0pt; POSITION: relative; HEIGHT: 371px">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"150%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="150%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="left" width="79"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="61"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="61"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="10"><font size="1"><b>December&#160;31, 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>December&#160;31, 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center"><font size="1"><b>Estimated<br />
Life </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Cost </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Accumulated<br />
Amortization </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Net </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Cost </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Accumulated<br />
Amortization </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Net </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="17"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Intangible Assets:</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">IPR&amp;D</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">Indefinite</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,800</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,800</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,800</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,800</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Amgen Amendment</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">16&#160;years</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">14,500</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(2,018</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">12,482</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">14,500</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(1,121</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">13,379</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">TopoTarget Agreement</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="center"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(2,400</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(2,057</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">343</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Core Technology</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">4.5&#160;&#8211;&#160;11&#160;years</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,948</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(1,307</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">641</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,948</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(1,040</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">908</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Strategic Partner Agreement</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="center"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">630</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(630</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">630</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(224</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">406</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total Intangible Assets</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">31,278</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(6,355</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">24,923</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">31,278</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,442</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">26,836</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Goodwill</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">Indefinite</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">8,965</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">8,965</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">8,965</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">8,965</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The estimated fair value attributed to the April 2008 agreement (TopoTarget Agreement) between the Company (as a successor to CuraGen) and TopoTarget A/S (TopoTarget) relates to the Company's rights under the TopoTarget Agreement to receive up to $6&#160;million in either potential commercial milestone payments related to future net sales of Belinostat or 10% of any sublicense income received by TopoTarget (TopoTarget Payments). In February 2010, TopoTarget entered into a co-development and commercialization agreement for Belinostat with Spectrum Pharmaceuticals,&#160;Inc. which resulted in the Company's receipt of $3.0&#160;million of the TopoTarget Payments. The Company recorded this cash receipt as Other Income for the year ended December&#160;31, 2010. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2011, the Company recorded an impairment loss of $0.3&#160;million in Strategic Partnership Agreement to amortization of intangible asset expense due to the Company's termination of rights to intellectual property underlying that Strategic Partnership Agreement. During the year ended December&#160;31, 2010, the Company wrote-off $0.2&#160;million in Core Technology to amortization of intangible asset expense. In January 2009, the Company entered into a purchase agreement with Lohmann Animal Health International ("LAHI") to sell its poultry vaccines assets to LAHI. Under the purchase agreement, LAHI paid an upfront fee of $0.8&#160;million and agreed to pay potential milestone payments. During the year ended December&#160;31, 2009, the Company recorded a gain of $0.6&#160;million related to the LAHI Agreement based on the upfront fee less the net book value of the related asset. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization expense for intangible assets was $1.9&#160;million, $3.1&#160;million and $0.9&#160;million for the years ended December&#160;31, 2011, 2010 and 2009, respectively. The estimated future amortization expense of intangible assets as of December&#160;31, 2011, for the next five years is as follows (in thousands): </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="39"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2012</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,089</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2013</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,014</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2014</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,014</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,014</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">994</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 42, 43, 44, 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(8) ACCRUED EXPENSES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accrued expenses include the following: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31,<br />
2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31,<br />
2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="5"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Accrued Royalty and License Fees</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,179</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">826</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Accrued Payroll and Employee Benefits</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,145</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,925</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Accrued Research and Development Contract Costs</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,035</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,218</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Accrued Professional Fees</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">297</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">449</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other Accrued Expenses</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">352</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">518</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">7,008</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">4,936</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TERM LOAN<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>TERM LOAN</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">TERM LOAN</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(10) TERM LOAN </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In December 2010, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with MidCap Financial,&#160;LLC (MidCap) pursuant to which the Company borrowed $10&#160;million (the "Term Loan") from MidCap. In March 2011, as the Company had anticipated, the Company amended the Loan Agreement and borrowed an additional $5&#160;million from General Electric Capital Corporation (GECC) (collectively with MidCap, the "Lenders") to increase the amount owed under the Term Loan to $15&#160;million. No additional advances are available under the Loan Agreement. The Term Loan accrues interest at a fixed annual interest rate equal to the greater of (i)&#160;the sum of (A)&#160;the LIBOR Rate (as defined in the Loan Agreement) plus (B)&#160;6.25%; or (ii)&#160;a minimum rate of 9.50%. In September 2011, the Company exercised an option to extend the interest-only period by 6&#160;months from October&#160;1, 2011 to April&#160;1, 2012. In March 2012, the Company amended the Loan Agreement to extend the maturity date from December 2013 to December 2014 in return for an upfront fee of $25,000 and an additional fee of $37,500 due upon repayment of the Term Loan in full. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest on the Term Loan is payable monthly and principal is due, as amended, in 34 equal consecutive monthly installments commencing on April&#160;1, 2012. All unpaid principal and accrued interest with respect to the Term Loan is due and payable on the earlier of (A)&#160;December&#160;30, 2014 or (B)&#160;the date that the Term Loan otherwise becomes due and payable under the terms of the Loan Agreement. The Company may prepay all, but not less than all, of the Term Loan subject to a prepayment premium of 1% in year three and 2% in year two of the original principal amount of the Term Loan. There is no prepayment premium if the loan is paid off early in year four. The Company is also obligated to make a payment fee of $0.5&#160;million (the "Payment Fee") upon the earlier of (A)&#160;December&#160;30, 2013 or (B)&#160;upon repayment of the Term Loan in full prior to December&#160;30, 2013. The Company is accreting the Payment Fee ratably over the original term of the Term Loan to interest expense. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The obligations of the Company under the Loan Agreement are secured by a first priority lien upon and security interest in substantially all of the Company's existing and after-acquired assets, excluding its intellectual property assets. Under the Loan Agreement, the Company is subject to specified affirmative and negative covenants customary for financings of this type. The Loan Agreement provides that, upon the occurrence of certain specified events of default customary for financings of this type, the Company's obligations under the Loan Agreement may be automatically accelerated, whereupon the Company's obligations under the Loan Agreement shall be immediately due and payable. At December&#160;31, 2011, the Company believes it is in compliance with the Loan Agreement. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2011 and 2010, the Company had $0.2&#160;million in capitalized deferred financing costs incurred in connection with the Term Loan and is amortizing these costs over the original term of the Term Loan to interest expense. Interest expense on the Term Loan including the accretion of the Payment Fee and amortization of the deferred financing costs was $1.6&#160;million for the year ended December&#160;31, 2011. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is obligated to repay the following principal amounts for the Term Loan (including Payment Fee) as follows (in thousands): </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2012</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">3,971</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2013</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">5,744</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2014</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">5,735</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Thereafter</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">15,450</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(15) INCOME TAXES </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The components of income tax expense attributable to continuing operations consist of the following: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>Year Ended December&#160;31, </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2009 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Income tax benefit (provision):</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Federal</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">16,204</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,512</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">12,750</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">State</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">3,131</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">779</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(1,757</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Foreign</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">84</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">107</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">126</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Expiration of Net Operating Losses and Research&#160;&amp; Development Tax Credits</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(411</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(13,924</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(3,992</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">19,008</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(11,526</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">7,127</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred tax valuation allowance</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(19,008</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">11,526</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(6,598</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">529</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Included in the state tax provision above for the year ended December&#160;31, 2009 is the effect of a rate decrease on the deferred tax asset and liabilities offset by a $0.5&#160;million tax benefit due to non-cash tax consequences of the CuraGen acquisition. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="50"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>2009 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="8"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Pre-tax book income (loss)</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(44,799</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(2,533</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(37,054</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Loss at Statutory Rates</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(15,213</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(838</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(12,571</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Research and Development Credits</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(1,736</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(1,498</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(1,456</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">State Taxes</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(3,131</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(779</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,757</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">661</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">717</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">1,151</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Expiration of Net Operating Losses and Research&#160;&amp; Development Tax Credits</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">411</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">13,924</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">3,992</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Change in Valuation Allowance</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">19,008</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(11,526</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">6,598</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="bottom" bgcolor="white">
<td style="FONT-FAMILY: times">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Income tax (benefit) provision</font></p></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" align="right"><font size="2">(529</font></td>
<td style="FONT-FAMILY: times"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The principal components of the deferred tax assets and liabilities at December&#160;31, 2011 and 2010, respectively, are as follows: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 15%; WIDTH: 70%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="64"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31,<br />
2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>December&#160;31,<br />
2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="5"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Gross Deferred Tax Assets</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net Operating Loss Carryforwards</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">58,802</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">50,228</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Tax Credit Carryforwards</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">20,285</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">17,998</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred Expenses</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">31,002</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">23,705</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Stock-based Compensation</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,184</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">3,066</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Fixed Assets</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">2,029</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">1,957</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Accrued Expenses and Other</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">197</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">311</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">115,499</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">97,265</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Gross Deferred Tax Liabilities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Other Acquired Intangibles</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,878</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(5,615</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">IPR&amp;D Intangibles</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred License Costs and Other</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(37</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(9,539</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(10,313</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Total Deferred Tax Assets and Liabilities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">105,960</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">86,952</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 20pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Deferred Tax Assets Valuation Allowance</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(110,621</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(91,613</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Net Deferred Tax Asset (Liability)</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">(4,661</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">)</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The net deferred tax liability of $4.7&#160;million at December&#160;31, 2011 and 2010 relates to the temporary differences associated with the IPR&amp;D intangible assets acquired in the CuraGen acquisition, which are not deductible for tax purposes. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of December&#160;31, 2011, the Company had the following federal net operating loss (NOL) carryforwards:</font></p>
<ul>
<li style="list-style: none">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">Prior to the merger of the Company and AVANT, $33.0&#160;million was generated by the Company which expire at various dates starting in 2023 and going through 2028; </font><font size="2"><br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">Prior to the merger of the Company and AVANT, $132.4&#160;million, net of expirations and utilization, was generated by AVANT which expire at various dates starting in 2012 and going through 2028. NOLs of $0.8&#160;million were utilized in 2009. $13.0&#160;million and $12.1&#160;million in NOLs expired in 2011 and 2010, respectively; </font><font size="2"><br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">Following the merger of the Company and AVANT, $73.9&#160;million was generated by the combined company which expire at various dates starting in 2028 and going through 2031; and </font><font size="2"><br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">Prior to its acquisition by the Company, $518.3&#160;million was generated by CuraGen. </font></dd></dl></li></ul>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In general, an ownership change, as defined by Section&#160;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&#160;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOL carryforwards that may be utilized in future periods. The Company currently expects that it is not more likely than not that the CuraGen loss carryforwards may be utilized and, as such, no related asset has been recorded for such losses. The Company has not completed an analysis of losses generated by AVANT, however, the Company believes it is remote that $92&#160;million of the AVANT loss carryforwards may be utilized in future periods and there may be substantial limitations on the Company's ability to use the remaining losses of $40.4&#160;million. Following the merger of the Company and AVANT, the Company experienced changes in ownership as defined by Section&#160;382 in June 2009 and December 2009. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change in ownership in October 2007. As a result of the ownership change in October 2007, utilization of the Company's NOLs prior to October 2007 is subject to an annual limitation of $4.5&#160;million on $28.3&#160;million of NOLs generated before that date. As a result of the ownership changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&#160;million on $67.7&#160;million NOLs. Any unused annual limitation may be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the Company's net assets are determined to be below or in excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Similar to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development credits ("R&amp;D credit") of $20.8&#160;million and $14.4&#160;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOL carryforwards of approximately $88.7&#160;million and the remaining federal and state R&amp;D credit carryforwards of approximately $14.0&#160;million and $9.2&#160;million, respectively, may be substantially limited. These state NOLs and federal and state credits expire at various dates starting in 2012 going through 2031. The Company has not yet completed a study of these credits to substantiate the amounts. Until a study is completed, no amounts are being presented as an uncertain tax position. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subsequent ownership changes, as defined in Section&#160;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future taxable income. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of being realized upon the ultimate settlement with the relevant taxing authority. At December&#160;31, 2011 and 2010, we had no unrecognized tax benefits. A full valuation allowance has been provided against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Massachusetts, New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company completed an examination by the Internal Revenue Service with respect to 2008 which resulted in no change to our 2008 tax return. The Company is not currently under examination by any other jurisdictions for any tax year. </font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss carryforwards, capitalized R&amp;D expenditures and R&amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance was maintained at December&#160;31, 2011 against the Company's net deferred tax assets. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJLCI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2008</a></td>
        <td class="nump">$ 18,134<span></span></td>
        <td class="nump">$ 16<span></span></td>
        <td class="nump">$ 136,661<span></span></td>
        <td class="nump">$ 2,606<span></span></td>
        <td class="num">$ (121,149)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,789,756<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
        <td class="nump">917<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">917<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">172,592<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares Issued in Connection with the CuraGen acquisition</a></td>
        <td class="nump">88,243<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="nump">88,227<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares Issued in Connection with the CuraGen acquisition (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,722,713<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
        <td class="nump">3,058<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,058<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
        <td class="num">(12)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (Loss) Gain on Marketable Securities</a></td>
        <td class="num">(48)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(48)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">(36,525)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(36,525)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">73,767<span></span></td>
        <td class="nump">32<span></span></td>
        <td class="nump">228,863<span></span></td>
        <td class="nump">2,546<span></span></td>
        <td class="num">(157,674)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,685,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
        <td class="nump">1,014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">370,321<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
        <td class="nump">2,802<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,802<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (Loss) Gain on Marketable Securities</a></td>
        <td class="nump">203<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">203<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">(2,533)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,533)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">75,255<span></span></td>
        <td class="nump">32<span></span></td>
        <td class="nump">232,679<span></span></td>
        <td class="nump">2,751<span></span></td>
        <td class="num">(160,207)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="nump">32,055,382<span></span></td>
        <td class="nump">32,055,382<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
        <td class="nump">173<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">173<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80,254<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares Issued in Connection with Cantor Agreement</a></td>
        <td class="nump">2,155<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">2,154<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares Issued in Connection with Cantor Agreement (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares Issued in Underwritten Offering</a></td>
        <td class="nump">33,695<span></span></td>
        <td class="nump">11<span></span></td>
        <td class="nump">33,684<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares Issued in Underwritten Offering (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
        <td class="nump">2,342<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,342<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (Loss) Gain on Marketable Securities</a></td>
        <td class="num">(90)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(90)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
        <td class="num">(44,799)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(44,799)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 68,722<span></span></td>
        <td class="nump">$ 44<span></span></td>
        <td class="nump">$ 271,032<span></span></td>
        <td class="nump">$ 2,652<span></span></td>
        <td class="num">$ (205,006)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="nump">44,210,636<span></span></td>
        <td class="nump">44,210,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569643-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(4) FAIR VALUE MEASUREMENTS </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth the Company's financial assets subject to fair value measurements: </font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="114"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="36"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>As of<br />
December&#160;31, 2011 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;1 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;2 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;3 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Money market funds and cash equivalents</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,038</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,038</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">41,413</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">41,413</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">52,451</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">11,038</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">41,413</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;<br /></font></p>
<div style="PADDING-RIGHT: 0pt; PADDING-LEFT: 0pt; PADDING-BOTTOM: 0pt; MARGIN-LEFT: 10%; WIDTH: 80%; PADDING-TOP: 0pt; POSITION: relative">
<p style="FONT-FAMILY: times"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: times" align="left"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="88"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="45"></td>
<td style="FONT-FAMILY: times" width="12"></td>
<td style="FONT-FAMILY: times" align="right" width="7"></td>
<td style="FONT-FAMILY: times" width="36"></td>
<td style="FONT-FAMILY: times" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>As of<br />
December&#160;31, 2010 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;1 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;2 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" align="center" colspan="2"><font size="1"><b>Level&#160;3 </b></font></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="bottom">
<th style="FONT-FAMILY: times" align="left"><font size="1">&#160;</font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th>
<th style="FONT-FAMILY: times" align="center" colspan="11"><font size="1"><b>(In thousands)</b></font><br /></th>
<th style="FONT-FAMILY: times"><font size="1">&#160;</font></th></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Money market funds and cash equivalents</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,975</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,975</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="white">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times"><font size="2">Marketable securities</font></p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">39,811</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">39,811</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr>
<tr style="HEIGHT: 0px" valign="top" bgcolor="#CCEEFF">
<td style="FONT-FAMILY: times" valign="bottom">
<p style="MARGIN-LEFT: 10pt; TEXT-INDENT: -10pt; FONT-FAMILY: times">&#160;</p></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">50,786</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">10,975</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">$</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">39,811</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: times" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: times" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="FONT-SIZE: 1.5pt; HEIGHT: 0px" valign="top">
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2.25pt double; FONT-FAMILY: times" valign="bottom" align="right" colspan="2">&#160;</td>
<td style="FONT-FAMILY: times" valign="bottom">&#160;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents, marketable securities, short-term accounts receivable, accounts payable and debt obligations. The Company values its marketable securities utilizing independent pricing services which normally drive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable are reflected in the accompanying consolidated financial statements at cost, which approximates fair value due to the short-term nature of these instruments. Based on current market interest rates available to the Company for long-term liabilities with similar terms and maturities, the Company believes the fair value approximates the carrying value of the principal portion of the Term Loan and note payable at December&#160;31, 2011. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>37</ContextCount>
  <ElementCount>128</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/BalanceSheet</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/BalanceSheetParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/CashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1010 - Disclosure - NATURE OF BUSINESS AND OVERVIEW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview</Role>
      <ShortName>NATURE OF BUSINESS AND OVERVIEW</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1030 - Disclosure - BUSINESS COMBINATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureBusinessCombinations</Role>
      <ShortName>BUSINESS COMBINATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1040 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1050 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1060 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1070 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1080 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1090 - Disclosure - OTHER LONG-TERM LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities</Role>
      <ShortName>OTHER LONG-TERM LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1100 - Disclosure - TERM LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureTermLoan</Role>
      <ShortName>TERM LOAN</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1110 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1120 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1130 - Disclosure - SIGNIFICANT REVENUE ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSignificantRevenueArrangements</Role>
      <ShortName>SIGNIFICANT REVENUE ARRANGEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1140 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1150 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1160 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1170 - Disclosure - RETIREMENT SAVINGS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan</Role>
      <ShortName>RETIREMENT SAVINGS PLAN</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1180 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0010 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 0040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>cldx-20111231.xml</File>
    <File>cldx-20111231.xsd</File>
    <File>cldx-20111231_cal.xml</File>
    <File>cldx-20111231_def.xml</File>
    <File>cldx-20111231_lab.xml</File>
    <File>cldx-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementDisclosureAbstract', window );"><strong>COLLABORATION AGREEMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times"><font size="2"><b>(14) COLLABORATION AGREEMENTS </b></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense was $1.4&#160;million, $1.0&#160;million and $0.7&#160;million for the years ended December&#160;31, 2011, 2010 and 2009, respectively. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Medarex,&#160;Inc., a subsidiary of Bristol-Myers Squibb (Medarex) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Medarex, a former related party, and the Company have entered into the following agreements, each of which was approved by a majority of its independent directors who did not have an interest in the transaction. These agreements include:</font></p>
<ul>
<li style="list-style: none">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">An Assignment and License Agreement, as amended, (Assignment and License Agreement) that provides for the assignment of certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#8482; and an anti-mannose receptor product; and </font><font size="2"><br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"><font size="2">&#8226;</font> </dt>
<dd style="FONT-FAMILY: times"><font size="2">A Research and Commercialization Agreement, as amended, (Research and Commercialization Agreement) that provides the Company with certain rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform for generating antibodies. </font></dd></dl></li></ul>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Under the terms of the Assignment and License Agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of (i)&#160;the expiration of the last to expire applicable patent and (ii)&#160;the tenth anniversary of the first commercial sale of such licensed product. Under the terms of the Research and Commercialization Agreement, the Company may be required to pay milestones of up to $7.0&#160;million upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low- to mid-single digits on any net product sales to Medarex with respect to the development of any products containing such licensed antibodies until the later of (i)&#160;the expiration of the last to expire applicable patent and (ii)&#160;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, the Company exercised an option under the Research and Commercialization Agreement, whereby it licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including CDX-1127. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Rockefeller University (Rockefeller) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205 receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for educational and research purposes. The Company may be required to pay milestones of up to $3.9&#160;million upon obtaining first approval for commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low- to mid-single digits on any net product sales to Rockefeller with respect to development and commercialization of the human DEC-205 receptor. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Duke University Brain Tumor Cancer Center (Duke) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to rindopepimut. The Company may be required to pay milestone of up to $1.0&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Duke with respect to development and commercialization of rindopepimut. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Ludwig Institute for Cancer Research (Ludwig) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in combination with the Company's APC Targeting Technology. The term of the agreement is for ten years. The Company may be required to pay milestones of up to $1.0&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Ludwig with respect to development and commercialization of the technology licensed from Ludwig. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Alteris Therapeutics,&#160;Inc. (Alteris) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be required to pay Alteris up to $5.0&#160;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including rindopepimut. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Thomas Jefferson University (TJU) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with our acquisition of the assets of Alteris, the Company obtained the rights to two exclusive license agreements with TJU dated February 2003 related to the EGFRvIII tumor antigen. Under Under these licenses, the Company may be required to pay milestones of up to $3.0&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to TJU with respect to development and commercialization of rindopepimut. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>3M Company </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In June 2008, the Company and 3M Company entered into a license agreement for the exclusive worldwide rights to access 3M Company's proprietary Immune Response Modifier, Resiquimod&#8482;, (and additional Toll-Like Receptor 7/8 agonists (TLR)) for clinical study with the Company's proprietary APC Targeting Technology, for use as vaccine adjuvants, with the right to sublicense the technology. The Company may be required to pay milestones of up to $3.8&#160;million upon obtaining first approval for commercial sale of each product using this vaccine adjuvant and royalty payments in the low-single digits on any net product sales to 3M Company with respect to development and commercialization of the technology licensed from 3M Company. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>University of Southampton, UK (Southampton) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. The Company may be required to pay milestones of up to approximately $1.4&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Southampton with respect to development and commercialization of CDX-1127 </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Amgen&#160;Inc. (Amgen) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In March 2009, the Company entered into a license agreement with Amgen to expand its Precision Targeted Immunotherapy Platform by acquiring exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. The Company may be required to pay milestones of up to $1.3&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Amgen with respect to development and commercialization of the technology licensed from Amgen, including CDX-301. </font></p>
<p style="FONT-FAMILY: times"><font size="2"><i>Seattle Genetics,&#160;Inc. (Seattle Genetics) </i></font></p>
<p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the CuraGen acquisition, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may be required to pay milestones of up to $7.5&#160;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales to Seattle Genetics with respect to development and commercialization of the ADC technology, including CDX-011. </font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_CollaborativeArrangementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cldx_CollaborativeArrangementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cldx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-1<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
